ccomp||bacillus-16/VBZ||legionnaires-1/VBZ	nsubj||process-8/NN||disease-3/NN	cop||process-8/NN||is-4/VBZ	advmod||process-8/NN||primarily-5/RB	det||process-8/NN||a-6/DT	amod||process-8/NN||pneumonic-7/JJ	ccomp||legionnaires-1/VBZ||process-8/NN	vmod||process-8/NN||caused-9/VBN	agent||caused-9/VBN||legionellapneumophilia-11/NN	det||aerobic-15/NN||a-13/DT	amod||aerobic-15/NN||gram-negative-14/JJ	nsubj||bacillus-16/VBZ||aerobic-15/NN	nsubj||has-19/VBZ||aerobic-15/NN	root||ROOT-0/null||bacillus-16/VBZ	advmod||has-19/VBZ||also-18/RB	conj_but||bacillus-16/VBZ||has-19/VBZ	amod||involvement-22/NN||multiple-20/JJ	nn||involvement-22/NN||system-21/NN	dobj||has-19/VBZ||involvement-22/NN	legionnaires'disease--1||legionellapneumophilia-11||no||legionnaires'disease is primarily a pneumonic process caused by legionellapneumophilia , a gram-negative aerobic bacillus but also has multiple system involvement.
prep||undertaken-7/VBN||given-1/VBN	det||scenario-3/NN||these-2/DT	pobj||given-1/VBN||scenario-3/NN	det||study-5/NN||the-4/DT	nsubjpass||undertaken-7/VBN||study-5/NN	nsubj||examine-9/VB||study-5/NN	nsubj||aids-14/VBZ||study-5/NN	nsubj||identify-18/VB||study-5/NN	auxpass||undertaken-7/VBN||was-6/VBD	root||ROOT-0/null||undertaken-7/VBN	aux||examine-9/VB||to-8/TO	xcomp||undertaken-7/VBN||examine-9/VB	dobj||examine-9/VB||trends-10/NNS	prep_in||examine-9/VB||hiv-12/NN	xcomp||undertaken-7/VBN||aids-14/VBZ	conj_and||examine-9/VB||aids-14/VBZ	amod||knowledge-16/NN||comprehensive-15/JJ	dobj||aids-14/VBZ||knowledge-16/NN	xcomp||undertaken-7/VBN||identify-18/VB	conj_and||examine-9/VB||identify-18/VB	det||correlates-21/NNS||the-19/DT	amod||correlates-21/NNS||main-20/JJ	dobj||identify-18/VB||correlates-21/NNS	amod||hiv-24/NN||comprehensive-23/JJ	prep_of||correlates-21/NNS||hiv-24/NN	nn||knowledge-27/NN||aids-26/NNS	prep_of||correlates-21/NNS||knowledge-27/NN	conj_and||hiv-24/NN||knowledge-27/NN	amod||women-32/NNS||kenyan-29/JJ	amod||women-32/NNS||urban-30/JJ	amod||women-32/NNS||young-31/JJ	prep_among||identify-18/VB||women-32/NNS	aids-26||hiv-24||no||given these scenario the study was undertaken to examine trends in hiv and aids comprehensive knowledge and identify the main correlates of comprehensive hiv and aids knowledge among kenyan urban young women.
det||earliest-3/JJS||the-2/DT	prep_among||imposition-16/NN||earliest-3/JJS	det||responses-8/NNS||the-5/DT	amod||responses-8/NNS||most-6/JJS	amod||responses-8/NNS||enduring-7/VBG	conj_and||earliest-3/JJS||responses-8/NNS	prep_among||imposition-16/NN||responses-8/NNS	det||hiv/aids-11/NNS||the-10/DT	prep_to||responses-8/NNS||hiv/aids-11/NNS	nsubj||imposition-16/NN||epidemic-12/NN	aux||imposition-16/NN||has-13/VBZ	cop||imposition-16/NN||been-14/VBN	det||imposition-16/NN||the-15/DT	root||ROOT-0/null||imposition-16/NN	prep_by||imposition-16/NN||governments-18/NNS	nn||stay-22/NN||entry-20/NN	prep_of||governments-18/NNS||stay-22/NN	nn||restrictions-26/NNS||residence-25/NN	prep_of||governments-18/NNS||restrictions-26/NNS	conj_and||stay-22/NN||restrictions-26/NNS	prep_for||imposition-16/NN||non-nationals-28/NNS	vmod||non-nationals-28/NNS||living-29/VBG	prep_with||living-29/VBG||hiv-31/NN	prep_with||living-29/VBG||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||among the earliest and the most enduring responses to the hiv/aids epidemic has been the imposition by governments of entry, stay, and residence restrictions for non-nationals living with hiv and aids.
nsubj||explore-2/VB||we-1/PRP	root||ROOT-0/null||explore-2/VB	dobj||explore-2/VB||reasons-3/NNS	prep_for||reasons-3/NNS||this-5/DT	amod||doubts-10/NNS||prevailing-9/VBG	prep_such_as||this-5/DT||doubts-10/NNS	det||efficacy-13/NN||the-12/DT	prep_about||doubts-10/NNS||efficacy-13/NN	prep_of||doubts-10/NNS||fondaparinux-15/NN	det||setting-18/NN||the-17/DT	prep_in||doubts-10/NNS||setting-18/NN	prep_of||setting-18/NN||angioplasty-20/NN	det||problem-23/NN||the-22/DT	prep_such_as||this-5/DT||problem-23/NN	conj_and||doubts-10/NNS||problem-23/NN	nn||thrombosis-26/NNS||catheter-25/NN	prep_of||problem-23/NN||thrombosis-26/NNS	det||lack-30/NN||the-29/DT	prep_such_as||this-5/DT||lack-30/NN	conj_and||doubts-10/NNS||lack-30/NN	prep_of||lack-30/NN||antidote-32/NN	amod||complications-37/NNS||bleeding-36/VBG	prep_in_case_of||antidote-32/NN||complications-37/NNS	fondaparinux-15||thrombosis-26||no_rel||we explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications.
nsubj||extracted-2/VBD||we-1/PRP	nsubj||compared-4/VBD||we-1/PRP	root||ROOT-0/null||extracted-2/VBD	conj_and||extracted-2/VBD||compared-4/VBD	det||markers-9/NN||the-5/DT	amod||markers-9/NN||following-6/VBG	amod||markers-9/NN||parameters-7/JJ	nn||markers-9/NN||biochemical-8/NN	dobj||extracted-2/VBD||markers-9/NN	nn||markers-12/NNS||hbv-11/NN	dobj||extracted-2/VBD||markers-12/NNS	conj_and||markers-9/NN||markers-12/NNS	nn||antigen-15/NN||surface-14/NN	dep||markers-12/NNS||antigen-15/NN	amod||antibody-18/NN||core-17/JJ	dep||antigen-15/NN||antibody-18/NN	nn||antibody-21/NN||surface-20/NN	dep||antigen-15/NN||antibody-21/NN	conj_and||antibody-18/NN||antibody-21/NN	nn||antibody-25/NN||hcv-24/NN	dobj||extracted-2/VBD||antibody-25/NN	conj_and||markers-9/NN||antibody-25/NN	amod||studies-28/NNS||radiological-27/JJ	dobj||extracted-2/VBD||studies-28/NNS	conj_and||markers-9/NN||studies-28/NNS	dobj||extracted-2/VBD||length-31/NN	conj_and||markers-9/NN||length-31/NN	prep_of||length-31/NN||stay-33/NN	appos||stay-33/NN||los-35/NN	hbv-11||antibody-25||no_rel||we extracted and compared the following parameters biochemical markers, hbv markers (surface antigen, core antibody and surface antibody), hcv antibody, radiological studies, and length of stay (los).
amod||polyol-2/NN||petroleum-based-1/JJ	nsubjpass||replaced-4/VBN||polyol-2/NN	auxpass||replaced-4/VBN||was-3/VBD	root||ROOT-0/null||replaced-4/VBN	nn||lignin-9/NN||hardwood-6/NN	nn||lignin-9/NN||ethanol-7/NN	nn||lignin-9/NN||organosolv-8/NN	prep_with||replaced-4/VBN||lignin-9/NN	appos||lignin-9/NN||hel-11/NN	nn||lignin-16/NN||hardwood-14/NN	nn||lignin-16/NN||kraft-15/NN	prep_with||replaced-4/VBN||lignin-16/NN	conj_or||lignin-9/NN||lignin-16/NN	appos||lignin-9/NN||hkl-18/NN	number||%-25/NN||25-21/CD	dep||%-25/NN||%-22/NN	dep||%-25/NN||to-23/TO	number||%-25/NN||70-24/CD	prep_from||replaced-4/VBN||%-25/NN	nn||percentage-28/NN||molar-27/NN	appos||%-25/NN||percentage-28/NN	prepc_in||replaced-4/VBN||preparing-31/VBG	amod||foam-34/NN||rigid-32/JJ	nn||foam-34/NN||polyurethane-33/NN	dobj||preparing-31/VBG||foam-34/NN	ethanol-7||rigid-32||no_rel||petroleum-based polyol was replaced with hardwood ethanol organosolv lignin (hel) or hardwood kraft lignin (hkl) from 25% to 70% (molar percentage) in preparing rigid polyurethane foam.
amod||men-2/NNS||fifty-nine-1/JJ	nsubjpass||studied-14/VBN||men-2/NNS	advmod||controlled-5/VBN||well-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||men-2/NNS||type2diabetes-6/NNS	num||men-12/NNS||18-8/CD	amod||men-12/NNS||age-matched-9/JJ	amod||men-12/NNS||healthy-10/JJ	amod||men-12/NNS||normoglycemic-11/JJ	prep_with||men-2/NNS||men-12/NNS	conj_and||type2diabetes-6/NNS||men-12/NNS	auxpass||studied-14/VBN||were-13/VBD	root||ROOT-0/null||studied-14/VBN	xcomp||studied-14/VBN||using-15/VBG	amod||tomography-18/NN||positron-16/JJ	nn||tomography-18/NN||emission-17/NN	dobj||using-15/VBG||tomography-18/NN	aux||assess-20/VB||to-19/TO	vmod||using-15/VBG||assess-20/VB	amod||perfusion-23/NN||hepatic-21/JJ	nn||perfusion-23/NN||tissue-22/NN	dobj||assess-20/VB||perfusion-23/NN	amod||glucose-26/NN||insulin-stimulated-25/JJ	dobj||assess-20/VB||glucose-26/NN	amod||metabolism-31/NN||fasting-29/JJ	amod||metabolism-31/NN||fattyacid-30/JJ	dobj||assess-20/VB||metabolism-31/NN	conj_and||glucose-26/NN||metabolism-31/NN	dobj||assess-20/VB||respectively-33/RB	advmod||glucose-26/NN||respectively-33/RB	conj_and||glucose-26/NN||respectively-33/RB	prep_in||assess-20/VB||relation-36/NN	amod||content-40/NN||hepatic-38/JJ	nn||content-40/NN||triglyceride-39/NN	prep_to||relation-36/NN||content-40/NN	vmod||content-40/NN||quantified-42/VBN	amod||spectroscopy-47/NN||proton-44/JJ	amod||spectroscopy-47/NN||magnetic-45/JJ	nn||spectroscopy-47/NN||resonance-46/NN	agent||quantified-42/VBN||spectroscopy-47/NN	type2diabetes-6||fattyacid-30||no_rel||fifty-nine men with well controlled type2diabetes and 18 age-matched healthy normoglycemic men were studied using positron emission tomography to assess hepatic tissue perfusion, insulin-stimulated glucose, and fasting fattyacid metabolism, respectively, in relation to hepatic triglyceride content, quantified by proton magnetic resonance spectroscopy.
advmod||observed-32/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-32/VBN||correlation-11/NN	prep_between||correlation-11/NN||hepatitisbsurfaceantigen-13/NN	appos||hepatitisbsurfaceantigen-13/NN||hbsag-15/NN	vmod||correlation-11/NN||stimulated-17/VBN	amod||expression-20/NN||il-2-18/JJ	nn||expression-20/NN||gene-19/NN	dobj||stimulated-17/VBN||expression-20/NN	advmod||detectable-23/JJ||as-22/RB	dobj||stimulated-17/VBN||detectable-23/JJ	amod||expression-20/NN||detectable-23/JJ	conj_and||expression-20/NN||detectable-23/JJ	prep_in||detectable-23/JJ||wb-25/NN	amod||titers-30/NNS||specific-28/JJ	nn||titers-30/NNS||antibody-29/NN	dobj||stimulated-17/VBN||titers-30/NNS	conj_and||expression-20/NN||titers-30/NNS	auxpass||observed-32/VBN||was-31/VBD	root||ROOT-0/null||observed-32/VBN	prep_in||observed-32/VBN||donors-34/NNS	vmod||donors-34/NNS||vaccinated-35/VBN	amod||virus-38/NN||hepatitisb-37/JJ	prep_against||vaccinated-35/VBN||virus-38/NN	appos||virus-38/NN||hbv-40/NN	num||months-44/NNS||six-43/CD	prep_between||virus-38/NN||months-44/NNS	num||years-47/NNS||twenty-46/CD	prep_between||virus-38/NN||years-47/NNS	conj_and||months-44/NNS||years-47/NNS	det||tests-50/NNS||the-49/DT	prep_before||vaccinated-35/VBN||tests-50/NNS	hbv-40||hepatitisbsurfaceantigen-13||yes||importantly, a highly significant (p = 0.000009) correlation between hepatitisbsurfaceantigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisb virus (hbv) between six months and twenty years before the tests.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||work-5/NN||this-4/DT	prep_of||aim-2/NN||work-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||potential-10/NN||the-9/DT	dobj||evaluate-8/VB||potential-10/NN	prep_of||potential-10/NN||proteoliposomes-12/NNS	appos||proteoliposomes-12/NNS||pl-14/NN	vmod||proteoliposomes-12/NNS||extracted-16/VBN	prep_from||extracted-16/VBN||bordetellapertussis-18/NNS	det||candidate-22/NN||a-20/DT	nn||candidate-22/NN||vaccine-21/NN	prep_as||bordetellapertussis-18/NNS||candidate-22/NN	prep_against||candidate-22/NN||whoopingcough-24/NN	whoopingcough-24||bordetellapertussis-18||no||the aim of this work was to evaluate the potential of proteoliposomes (pl) extracted from bordetellapertussis as a vaccine candidate against whoopingcough.
ccomp||causes-10/VBZ||similar-1/JJ	nn||propofol-5/NN||lipid-3/NN	nn||propofol-5/NN||emulsion-4/NN	prep_to||similar-1/JJ||propofol-5/NN	nn||propofol-8/NN||microemulsion-7/NN	nsubj||causes-10/VBZ||propofol-8/NN	advmod||causes-10/VBZ||also-9/RB	root||ROOT-0/null||causes-10/VBZ	det||incidence-13/NN||a-11/DT	amod||incidence-13/NN||high-12/JJ	dobj||causes-10/VBZ||incidence-13/NN	prep_of||incidence-13/NN||pain-15/NN	amod||injection-18/NN||intravenous-17/JJ	prep_during||causes-10/VBZ||injection-18/NN	pain-15||propofol-8||yes||similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain during intravenous injection.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||enrichment-4/NN||natural-3/JJ	nsubj||is-2/VBZ||enrichment-4/NN	nn||cells-7/NNS||nk-6/NN	prep_of||enrichment-4/NN||cells-7/NNS	det||liver-11/NN||the-9/DT	amod||liver-11/NN||human-10/JJ	prep_in||cells-7/NNS||liver-11/NN	det||predominance-15/NN||this-13/DT	amod||predominance-15/NN||intrahepatic-14/JJ	nsubj||underscores-16/VBZ||predominance-15/NN	conj_and||is-2/VBZ||underscores-16/VBZ	poss||importance-19/NN||their-17/PRP$	amod||importance-19/NN||potential-18/JJ	dobj||underscores-16/VBZ||importance-19/NN	det||control-22/NN||the-21/DT	prep_in||underscores-16/VBZ||control-22/NN	prep_of||control-22/NN||infections-24/NNS	amod||viruses-27/NNS||hepatotropic-26/JJ	prep_with||infections-24/NNS||viruses-27/NNS	amod||virus-31/NN||hepatitisb-30/JJ	prep_such_as||viruses-27/NNS||virus-31/NN	appos||virus-31/NN||hbv-33/NN	hbv-33||viruses-27||no||there is natural enrichment of nk cells in the human liver and this intrahepatic predominance underscores their potential importance in the control of infections with hepatotropic viruses such as hepatitisb virus (hbv).
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||records-4/NNS||medical-3/JJ	dobj||collected-2/VBD||records-4/NNS	num||men-8/NNS||170-6/CD	amod||men-8/NNS||adult-7/JJ	prep_of||records-4/NNS||men-8/NNS	dep||men-8/NNS||diagnosed-9/VBN	prep_with||diagnosed-9/VBN||chronichepatitisc-11/NN	nsubj||started-13/VBD||chronichepatitisc-11/NN	rcmod||chronichepatitisc-11/NN||started-13/VBD	dobj||started-13/VBD||treatment-14/NN	det||combination-17/NN||a-16/DT	prep_with||started-13/VBD||combination-17/NN	amod||interferon-alpha-20/NN||pegylated-19/JJ	prep_of||combination-17/NN||interferon-alpha-20/NN	prep_with||started-13/VBD||ribavirin-22/NNP	conj_and||combination-17/NN||ribavirin-22/NNP	prep_between||ribavirin-22/NNP||january-24/NNP	num||january-24/NNP||2003-25/CD	dep||men-8/NNS||june-27/NNP	conj_and||diagnosed-9/VBN||june-27/NNP	num||june-27/NNP||2009-28/CD	det||centre-33/NN||the-30/DT	amod||centre-33/NN||croatian-31/JJ	nn||centre-33/NN||reference-32/NN	prep_at||june-27/NNP||centre-33/NN	prep_for||centre-33/NN||viralhepatitis-35/NNS	ribavirin-22||viralhepatitis-35||no_rel||we collected medical records of 170 adult men diagnosed with chronichepatitisc who started treatment with a combination of pegylated interferon-alpha and ribavirin between january 2003 and june 2009 at the croatian reference centre for viralhepatitis.
nn||samples-4/NNS||naf-1/NN	conj_and||naf-1/NN||plasma-3/NN	nn||samples-4/NNS||plasma-3/NN	nsubjpass||collected-6/VBN||samples-4/NNS	nsubjpass||collected-6/VBN||samples-4/NNS	auxpass||collected-6/VBN||were-5/VBD	root||ROOT-0/null||collected-6/VBN	conj_and||collected-6/VBN||collected-6/VBN	prep_in||collected-6/VBN||women-8/NNS	amod||risk-13/NN||increased-10/VBN	nn||risk-13/NN||breast-11/NN	nn||risk-13/NN||cancer-12/NN	prep_at||collected-6/VBN||risk-13/NN	advmod||risk-13/NN||before-14/IN	num||weeks-17/NNS||2-16/CD	npadvmod||collected-6/VBN||weeks-17/NNS	prepc_after||collected-6/VBN||taking-19/VBG	num||200-21/CD||celecoxib-20/CD	num||daily-26/RB||200-21/CD	num||mg-24/CD||400-23/CD	conj_or||200-21/CD||mg-24/CD	num||daily-26/RB||mg-24/CD	advmod||daily-26/RB||twice-25/RB	dobj||taking-19/VBG||daily-26/RB	appos||daily-26/RB||bid-28/NN	celecoxib-20||cancer-12||no_rel||naf and plasma samples were collected in women at increased breast cancer risk before and 2 weeks after taking celecoxib 200 or 400 mg twice daily (bid).
aux||compare-2/VB||to-1/TO	csubj||doublet-12/VBP||compare-2/VB	det||activity-4/NN||the-3/DT	dobj||compare-2/VB||activity-4/NN	dobj||compare-2/VB||toxicity-6/NN	conj_and||activity-4/NN||toxicity-6/NN	prep_of||activity-4/NN||docetaxel/carboplatin-8/NN	appos||docetaxel/carboplatin-8/NN||dc-10/NN	root||ROOT-0/null||doublet-12/VBP	amod||agent-15/NN||vs-13/JJ	amod||agent-15/NN||single-14/JJ	nsubj||docetaxel-16/VB||agent-15/NN	ccomp||doublet-12/VBP||docetaxel-16/VB	dep||treatment-22/NN||d-18/LS	amod||treatment-22/NN||as-20/IN	amod||treatment-22/NN||second-line-21/JJ	dobj||docetaxel-16/VB||treatment-22/NN	prep_in||treatment-22/NN||patients-24/NNS	amod||non-smallcelllungcancer-27/NN||advanced-26/VBN	prep_with||patients-24/NNS||non-smallcelllungcancer-27/NN	dep||treatment-22/NN||nsclc-29/JJ	non-smallcelllungcancer-27||docetaxel-16||yes||to compare the activity and toxicity of docetaxel/carboplatin (dc) doublet vs single agent docetaxel (d) as second-line treatment in patients with advanced non-smallcelllungcancer (nsclc).
amod||control-3/NN||tight-1/JJ	nn||control-3/NN||glucose-2/NN	nsubjpass||advocated-18/VBN||control-3/NN	det||care-7/NN||the-5/DT	amod||care-7/NN||acute-6/JJ	prep_during||control-3/NN||care-7/NN	prep_of||care-7/NN||patients-9/NNS	amod||injury-14/NN||severe-11/JJ	amod||injury-14/NN||traumatic-12/JJ	nn||injury-14/NN||brain-13/NN	prep_with||patients-9/NNS||injury-14/NN	aux||advocated-18/VBN||has-15/VBZ	advmod||advocated-18/VBN||recently-16/RB	auxpass||advocated-18/VBN||been-17/VBN	ccomp||is-40/VBZ||advocated-18/VBN	prepc_based_on||advocated-18/VBN||on-20/IN	amod||concerns-22/NNS||experimental-21/JJ	pobj||advocated-18/VBN||concerns-22/NNS	amod||effects-25/NNS||deleterious-24/JJ	prep_about||concerns-22/NNS||effects-25/NNS	prepc_of||effects-25/NNS||presenting-27/VBG	det||brain-30/NN||the-28/DT	amod||brain-30/NN||injured-29/JJ	dobj||presenting-27/VBG||brain-30/NN	det||load-35/NN||a-32/DT	amod||load-35/NN||high-33/JJ	nn||load-35/NN||glucose-34/NN	prep_with||presenting-27/VBG||load-35/NN	advmod||presenting-27/VBG||however-37/RB	expl||is-40/VBZ||there-39/EX	root||ROOT-0/null||is-40/VBZ	dep||worsens-48/VBZ||little-41/JJ	neg||evidence-45/NN||no-43/DT	amod||evidence-45/NN||clinical-44/JJ	conj_or||little-41/JJ||evidence-45/NN	dep||worsens-48/VBZ||evidence-45/NN	mark||worsens-48/VBZ||that-46/IN	nsubj||worsens-48/VBZ||hyperglycemia-47/NN	ccomp||is-40/VBZ||worsens-48/VBZ	amod||injury-50/NN||neurologic-49/JJ	dobj||worsens-48/VBZ||injury-50/NN	hyperglycemia-47||glucose-34||no||tight glucose control during the acute care of patients with severe traumatic brain injury has recently been advocated based on experimental concerns about deleterious effects of presenting the injured brain with a high glucose load, however, there is little or no clinical evidence that hyperglycemia worsens neurologic injury.
advmod||dependent-19/JJ||however-1/RB	amod||sepsis-5/NN||monocyte-driven-4/JJ	prep_unlike||dependent-19/JJ||sepsis-5/NN	vmod||sepsis-5/NN||caused-6/VBN	agent||caused-6/VBN||endotoxin-8/NN	nsubj||dependent-19/JJ||translocation-10/NN	nsubj||monocytes-29/VBZ||translocation-10/NN	conj_and||translocation-10/NN||secretion-12/NN	nsubj||dependent-19/JJ||secretion-12/NN	amod||mediated-15/NN||hmgb-1-14/JJ	prep_of||translocation-10/NN||mediated-15/NN	prep_by||mediated-15/NN||tsst-1-17/CD	cop||dependent-19/JJ||was-18/VBD	root||ROOT-0/null||dependent-19/JJ	det||presence-22/NN||the-21/DT	prep_on||dependent-19/JJ||presence-22/NN	det||cells-27/NNS||both-24/DT	amod||cells-27/NNS||activated-25/VBN	nn||cells-27/NNS||t-26/NN	prep_of||presence-22/NN||cells-27/NNS	conj_and||dependent-19/JJ||monocytes-29/VBZ	sepsis-5||endotoxin-8||no_rel||however, unlike monocyte-driven sepsis caused by endotoxin, translocation and secretion of hmgb-1 mediated by tsst-1 was dependent on the presence of both activated t cells and monocytes.
prep_in||involved-16/VBN||addition-2/NN	nsubjpass||involved-16/VBN||transport-4/NN	conj_and||transport-4/NN||diffusion-6/NN	nsubjpass||involved-16/VBN||diffusion-6/NN	prep_of||transport-4/NN||ions-8/NNS	det||epithelium-14/NN||the-10/DT	nn||epithelium-14/NN||bbb-11/NN	conj_and||bbb-11/NN||cp-13/NN	nn||epithelium-14/NN||cp-13/NN	prep_by||ions-8/NNS||epithelium-14/NN	auxpass||involved-16/VBN||are-15/VBP	root||ROOT-0/null||involved-16/VBN	det||formation-19/NN||the-18/DT	prep_in||involved-16/VBN||formation-19/NN	prep_of||formation-19/NN||fluid-21/NN	det||isf-24/NN||the-23/DT	prep_of||formation-19/NN||isf-24/NN	conj_and||fluid-21/NN||isf-24/NN	prep_of||formation-19/NN||csf-26/NN	conj_and||fluid-21/NN||csf-26/NN	advmod||involved-16/VBN||respectively-28/RB	dep||involved-16/VBN||so-30/IN	det||part-33/NN||the-31/DT	amod||part-33/NN||last-32/JJ	nsubj||discusses-37/VBZ||part-33/NN	nsubj||cp-51/VBP||part-33/NN	det||review-36/NN||this-35/DT	prep_of||part-33/NN||review-36/NN	parataxis||involved-16/VBN||discusses-37/VBZ	amod||biology-39/NN||molecular-38/JJ	dobj||discusses-37/VBZ||biology-39/NN	nn||transporters/exchangers-42/NNS||ion-41/NN	prep_of||biology-39/NN||transporters/exchangers-42/NNS	nn||channels-45/NNS||ion-44/NN	prep_of||biology-39/NN||channels-45/NNS	conj_and||transporters/exchangers-42/NNS||channels-45/NNS	det||endothelial-49/NN||the-47/DT	nn||endothelial-49/NN||brain-48/NN	prep_in||discusses-37/VBZ||endothelial-49/NN	parataxis||involved-16/VBN||cp-51/VBP	conj_and||discusses-37/VBZ||cp-51/VBP	amod||cells-53/NNS||epithelial-52/JJ	dobj||cp-51/VBP||cells-53/NNS	ion-44||cp-51||no_rel||in addition, transport and diffusion of ions by the bbb and cp epithelium are involved in the formation of fluid, the isf and csf, respectively, so the last part of this review discusses molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and cp epithelial cells.
poss||results-2/NNS||its-1/PRP$	nsubj||lead-4/VB||results-2/NNS	nsubj||lead-4/VB||results-2/NNS	aux||lead-4/VB||will-3/MD	root||ROOT-0/null||lead-4/VB	conj_and||lead-4/VB||lead-4/VB	det||understanding-8/NN||a-6/DT	amod||understanding-8/NN||new-7/JJ	prep_to||lead-4/VB||understanding-8/NN	det||role-11/NN||the-10/DT	prep_of||understanding-8/NN||role-11/NN	prep_of||role-11/NN||heparins-13/NNS	det||prevention-16/NN||the-15/DT	prep_in||heparins-13/NNS||prevention-16/NN	amod||thromboembolism-19/NN||venous-18/JJ	prep_of||prevention-16/NN||thromboembolism-19/NN	poss||effect-23/NN||their-22/PRP$	prep_of||lead-4/VB||effect-23/NN	nn||rates-28/NNS||survival-25/NN	prep_on||lead-4/VB||remission-27/NN	conj_and||rates-28/NNS||remission-27/NN	prep_on||lead-4/VB||rates-28/NNS	prep_on||lead-4/VB||toxicity-30/NN	conj_and||rates-28/NNS||toxicity-30/NN	amod||regimens-33/NNS||chemotherapeutic-32/JJ	prep_of||rates-28/NNS||regimens-33/NNS	thromboembolism-19||heparins-13||yes||its results will lead to a new understanding of the role of heparins in the prevention of venous thromboembolism and of their effect on survival, remission rates and toxicity of chemotherapeutic regimens.
nsubj||d-5/VBD||immunoglobulin-1/NN	nsubjpass||reported-21/VBN||immunoglobulin-1/NN	nsubjpass||associated-24/VBN||immunoglobulin-1/NN	appos||immunoglobulin-1/NN||ig-3/NN	root||ROOT-0/null||d-5/VBD	amod||accounts-10/NNS||multiplemyeloma-6/JJ	appos||accounts-10/NNS||mm-8/NN	dobj||d-5/VBD||accounts-10/NNS	num||%-13/NN||2-12/CD	prep_for||d-5/VBD||%-13/NN	det||cases-17/NNS||all-15/DT	nn||cases-17/NNS||mm-16/NN	prep_of||%-13/NN||cases-17/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||d-5/VBD||reported-21/VBN	aux||associated-24/VBN||to-22/TO	auxpass||associated-24/VBN||be-23/VB	xcomp||reported-21/VBN||associated-24/VBN	amod||prognosis-27/NN||poor-26/JJ	prep_with||associated-24/VBN||prognosis-27/NN	prepc_compared_with||associated-24/VBN||with-29/IN	amod||subtypes-32/NNS||other-30/JJ	nn||subtypes-32/NNS||mm-31/NN	pobj||associated-24/VBN||subtypes-32/NNS	multiplemyeloma-6||immunoglobulin-1||no_rel||immunoglobulin (ig) d multiplemyeloma (mm) accounts for 2% of all mm cases and has been reported to be associated with poor prognosis compared with other mm subtypes.
nsubjpass||up-regulated-3/VBN||htr2a-1/NNS	auxpass||up-regulated-3/VBN||was-2/VBD	root||ROOT-0/null||up-regulated-3/VBN	prep_in||up-regulated-3/VBN||cfs-5/NN	amod||expression-8/NN||allele-specific-7/JJ	prep_through||up-regulated-3/VBN||expression-8/NN	vmod||expression-8/NN||modulated-9/VBN	nn||factors-12/NNS||transcription-11/NN	agent||modulated-9/VBN||factors-12/NNS	amod||sites-15/NNS||critical-14/JJ	prep_at||factors-12/NNS||sites-15/NNS	poss||promoter-18/NN||its-17/PRP$	prep_in||sites-15/NNS||promoter-18/NN	det||site-22/NN||an-19/DT	amod||site-22/NN||e47-20/JJ	amod||site-22/NN||binding-21/JJ	dobj||modulated-9/VBN||site-22/NN	nn||âˆ-25/NN||position-24/NN	prep_at||site-22/NN||âˆ-25/NN	num||âˆ-25/NN||1,438-27/CD	dep||site-22/NN||created-30/VBN	det||a-allele-33/NN||the-32/DT	prep_by||created-30/VBN||a-allele-33/NN	amod||polymorphism-36/NN||rs6311-35/JJ	prep_of||a-allele-33/NN||polymorphism-36/NN	det||site-46/NN||a-39/DT	amod||site-46/NN||glucocorticoid-40/JJ	nn||site-46/NN||receptor-41/NN	nn||site-46/NN||gr-43/NN	amod||site-46/NN||binding-45/JJ	prep_through||up-regulated-3/VBN||site-46/NN	conj_and||expression-8/NN||site-46/NN	vmod||site-46/NN||encompassing-47/VBG	det||cpg-49/NN||a-48/DT	dobj||encompassing-47/VBG||cpg-49/NN	nn||âˆ-52/NN||position-51/NN	prep_at||encompassing-47/VBG||âˆ-52/NN	num||âˆ-52/NN||1,420-54/CD	amod||1,224-65/NN||sp1-57/JJ	amod||1,224-65/NN||binding-58/JJ	nn||methylation-61/NN||cpg-60/NN	prep_at||binding-58/JJ||methylation-61/NN	nn||1,224-65/NN||site-62/NN	nn||1,224-65/NN||âˆ-63/NN	prep_through||up-regulated-3/VBN||1,224-65/NN	conj_and||expression-8/NN||1,224-65/NN	cfs-5||glucocorticoid-40||no_rel||htr2a was up-regulated in cfs through allele-specific expression modulated by transcription factors at critical sites in its promoter an e47 binding site at position âˆ’1,438, (created by the a-allele of rs6311 polymorphism), a glucocorticoid receptor (gr) binding site encompassing a cpg at position âˆ’1,420, and sp1 binding at cpg methylation site âˆ’1,224.
num||trials-3/NNS||three-1/CD	amod||trials-3/NNS||quasi-experimental-2/JJ	nsubj||matched-4/VBD||trials-3/NNS	root||ROOT-0/null||matched-4/VBD	det||criteria-7/NNS||the-5/DT	nn||criteria-7/NNS||inclusion-6/NN	nsubj||found-10/VBD||criteria-7/NNS	num||trials-9/NNS||two-8/CD	dep||criteria-7/NNS||trials-9/NNS	ccomp||matched-4/VBD||found-10/VBD	det||reduction-12/NN||a-11/DT	dobj||found-10/VBD||reduction-12/NN	prep_in||found-10/VBD||pain-14/NN	det||use-17/NN||the-16/DT	prep_for||found-10/VBD||use-17/NN	nn||needling-22/NN||trigger-19/NN	nn||needling-22/NN||point-20/NN	amod||needling-22/NN||dry-21/JJ	prep_of||use-17/NN||needling-22/NN	advmod||found-30/VBD||when-23/WRB	csubj||found-30/VBD||combined-24/VBN	prep_with||combined-24/VBN||acupuncture-26/NN	det||third-29/JJ||the-28/DT	prep_with||combined-24/VBN||third-29/JJ	conj_and||acupuncture-26/NN||third-29/JJ	advcl||found-10/VBD||found-30/VBD	det||reduction-32/NN||a-31/DT	dobj||found-30/VBD||reduction-32/NN	prep_in||found-30/VBD||pain-34/NN	xcomp||found-30/VBD||using-35/VBG	number||%-37/NN||1-36/CD	amod||injections-39/NNS||%-37/NN	amod||injections-39/NNS||lidocaine-38/JJ	dobj||using-35/VBG||injections-39/NNS	advmod||combined-41/VBN||when-40/WRB	advcl||using-35/VBG||combined-41/VBN	amod||therapy-44/NN||physical-43/JJ	prep_with||combined-41/VBN||therapy-44/NN	pain-34||lidocaine-38||yes||three quasi-experimental trials matched the inclusion criteria  two trials found a reduction in pain for the use of trigger point dry needling when combined with acupuncture and the third found a reduction in pain using 1% lidocaine injections when combined with physical therapy.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||paper-5/NN||this-4/DT	prep_of||aim-2/NN||paper-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	prep_of||effect-10/NN||antipsychotics-12/NNS	det||treatment-15/NN||the-14/DT	prep_for||antipsychotics-12/NNS||treatment-15/NN	prep_of||treatment-15/NN||schizophrenia-17/NN	det||community-20/NN||a-19/DT	prep_in||evaluate-8/VB||community-20/NN	vmod||community-20/NN||based-21/VBN	dobj||based-21/VBN||study-22/NN	amod||function-25/NN||sexual-24/JJ	prep_on||based-21/VBN||function-25/NN	nn||levels-28/NNS||prolactin-27/NN	prep_on||based-21/VBN||levels-28/NNS	conj_and||function-25/NN||levels-28/NNS	vmod||function-25/NN||comparing-29/VBG	det||use-31/NN||the-30/DT	dobj||comparing-29/VBG||use-31/NN	prep_of||use-31/NN||aripiprazole-33/NN	prep_of||use-31/NN||standard-35/NN	conj_and||aripiprazole-33/NN||standard-35/NN	prep_of||use-31/NN||care-37/NN	nsubj||choice-46/NN||care-37/NN	appos||care-37/NN||soc-39/NN	cop||choice-46/NN||was-43/VBD	det||choice-46/NN||a-44/DT	amod||choice-46/NN||limited-45/JJ	rcmod||care-37/NN||choice-46/NN	num||antipsychotics-53/NNS||three-48/CD	advmod||used-50/JJ||widely-49/RB	amod||antipsychotics-53/NNS||used-50/JJ	conj_and||used-50/JJ||available-52/JJ	amod||antipsychotics-53/NNS||available-52/JJ	prep_of||choice-46/NN||antipsychotics-53/NNS	dep||antipsychotics-53/NNS||olanzapine-55/NN	dep||olanzapine-55/NN||quetiapine-57/JJ	dep||olanzapine-55/NN||risperidone-59/JJ	conj_or||quetiapine-57/JJ||risperidone-59/JJ	det||trial-64/NN||the-62/DT	nn||trial-64/NN||schizophrenia-63/NN	dep||antipsychotics-53/NNS||trial-64/NN	amod||-RSB--73/NNS||aripiprazole-66/JJ	nn||-RSB--73/NNS||-LSB--67/NNP	nn||-RSB--73/NNS||star-68/NN	nn||-RSB--73/NNS||-RSB--69/NN	nn||-RSB--73/NNS||study-70/NN	nn||-RSB--73/NNS||-LSB--71/NN	amod||-RSB--73/NNS||nct00237913-72/JJ	prep_of||trial-64/NN||-RSB--73/NNS	schizophrenia-63||risperidone-59||yes||the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]).
det||study-2/NN||this-1/DT	nsubj||revealed-3/VBD||study-2/NN	root||ROOT-0/null||revealed-3/VBD	mark||was-6/VBD||that-4/IN	expl||was-6/VBD||there-5/EX	ccomp||revealed-3/VBD||was-6/VBD	det||difference-9/NN||a-7/DT	amod||difference-9/NN||significant-8/JJ	nsubj||was-6/VBD||difference-9/NN	nn||grade-13/NN||hbeag-11/NN	prep_between||difference-9/NN||grade-13/NN	nn||mutation-17/NN||ymdd-16/NN	prep_between||difference-9/NN||mutation-17/NN	conj_and||grade-13/NN||mutation-17/NN	mark||observed-23/VBN||whereas-18/IN	neg||different-21/JJ||no-19/DT	amod||different-21/JJ||significant-20/JJ	nsubjpass||observed-23/VBN||different-21/JJ	auxpass||observed-23/VBN||was-22/VBD	advcl||was-6/VBD||observed-23/VBN	nn||pcr-29/NN||hbsag-25/NN	conj_and||hbsag-25/NN||hbv-27/NN	nn||pcr-29/NN||hbv-27/NN	nn||pcr-29/NN||dna-28/NN	prep_between||observed-23/VBN||pcr-29/NN	hbv-27||hbsag-25||yes||this study revealed that there was a significant difference between hbeag, grade, and ymdd mutation whereas no significant different was observed between hbsag and hbv dna pcr.
nsubj||identified-21/VBD||comparison-1/NN	prep_of||comparison-1/NN||mirnas-3/NNS	vmod||mirnas-3/NNS||affected-4/VBN	amod||deficiency-7/NN||ago2-6/JJ	agent||affected-4/VBN||deficiency-7/NN	prep_with||affected-4/VBN||mirnas-9/NNS	nsubjpass||enriched-12/VBN||mirnas-9/NNS	nsubjpass||up-regulated-14/VBN||mirnas-9/NNS	auxpass||enriched-12/VBN||are-11/VBP	rcmod||mirnas-9/NNS||enriched-12/VBN	rcmod||mirnas-9/NNS||up-regulated-14/VBN	conj_and/or||enriched-12/VBN||up-regulated-14/VBN	prep_in||up-regulated-14/VBN||drd2-neurons-16/JJ	prep_in||drd2-neurons-16/JJ||response-18/NN	prep_to||up-regulated-14/VBN||cocaine-20/NN	root||ROOT-0/null||identified-21/VBD	det||set-23/NN||a-22/DT	dobj||identified-21/VBD||set-23/NN	prep_of||set-23/NN||mirnas-25/NNS	nsubj||likely-28/JJ||mirnas-25/NNS	nsubj||play-30/VB||mirnas-25/NNS	cop||likely-28/JJ||are-27/VBP	rcmod||mirnas-25/NNS||likely-28/JJ	aux||play-30/VB||to-29/TO	xcomp||likely-28/JJ||play-30/VB	det||role-32/NN||a-31/DT	dobj||play-30/VB||role-32/NN	prep_in||role-32/NN||cocaineaddiction-34/NN	cocaineaddiction-34||cocaine-20||no||comparison of mirnas affected by ago2 deficiency with mirnas that are enriched and/or up-regulated in drd2-neurons in response to cocaine identified a set of mirnas that are likely to play a role in cocaineaddiction.
nsubj||possess-2/VBP||clinicians-1/NNS	ccomp||developed-45/VBN||possess-2/VBP	det||arsenal-4/NN||an-3/DT	dobj||possess-2/VBP||arsenal-4/NN	nsubj||combat-9/VB||arsenal-4/NN	amod||measures-7/NNS||supportive-6/JJ	prep_of||arsenal-4/NN||measures-7/NNS	aux||combat-9/VB||to-8/TO	xcomp||possess-2/VBP||combat-9/VB	amod||sepsis-11/NN||severe-10/JJ	dobj||combat-9/VB||sepsis-11/NN	dobj||combat-9/VB||septicshock-13/NN	conj_and||sepsis-11/NN||septicshock-13/NN	det||success-17/NN||some-16/DT	nsubjpass||achieved-24/VBN||success-17/NN	advmod||controversial-20/JJ||albeit-19/IN	amod||success-17/NN||controversial-20/JJ	aux||achieved-24/VBN||has-22/VBZ	auxpass||achieved-24/VBN||been-23/VBN	conj_and||possess-2/VBP||achieved-24/VBN	ccomp||developed-45/VBN||achieved-24/VBN	agent||achieved-24/VBN||using-26/VBG	amod||doses-28/NNS||low-27/JJ	dobj||using-26/VBG||doses-28/NNS	prep_of||doses-28/NNS||corticosteroids-30/NNS	prep_of||doses-28/NNS||recombinanthumanactivatedproteinc-32/NNP	conj_or||corticosteroids-30/NNS||recombinanthumanactivatedproteinc-32/NNP	advmod||using-26/VBG||however-34/RB	det||treatment-41/NN||a-36/DT	advmod||effective-38/JJ||truly-37/RB	amod||treatment-41/NN||effective-38/JJ	amod||treatment-41/NN||mediator-directed-39/JJ	amod||treatment-41/NN||specific-40/JJ	nsubjpass||developed-45/VBN||treatment-41/NN	aux||developed-45/VBN||has-42/VBZ	neg||developed-45/VBN||not-43/RB	auxpass||developed-45/VBN||been-44/VBN	root||ROOT-0/null||developed-45/VBN	advmod||developed-45/VBN||yet-46/RB	septicshock-13||recombinanthumanactivatedproteinc-32||yes||clinicians possess an arsenal of supportive measures to combat severe sepsis and septicshock , and some success , albeit controversial , has been achieved by using low doses of corticosteroids or recombinanthumanactivatedproteinc. however , a truly effective mediator-directed specific treatment has not been developed yet .
det||strychnine-4/NN||the-1/DT	amod||strychnine-4/NN||glycine-2/JJ	nn||strychnine-4/NN||antagonist-3/NN	nsubj||alter-7/VB||strychnine-4/NN	aux||alter-7/VB||did-5/VBD	neg||alter-7/VB||not-6/RB	root||ROOT-0/null||alter-7/VB	nn||bradycardia-11/NN||hr-8/NN	conj_or||hr-8/NN||baroreflex-10/NN	nn||bradycardia-11/NN||baroreflex-10/NN	dobj||alter-7/VB||bradycardia-11/NN	glycine-2||bradycardia-11||no_rel||the glycine antagonist strychnine did not alter hr or baroreflex bradycardia.
det||consensus-2/NN||some-1/DT	nsubjpass||reached-4/VBN||consensus-2/NN	auxpass||reached-4/VBN||was-3/VBD	root||ROOT-0/null||reached-4/VBN	det||probability-7/NN||the-6/DT	prep_around||reached-4/VBN||probability-7/NN	mark||progress-18/VB||that-8/IN	nsubj||progress-18/VB||patients-9/NNS	amod||settings-13/NNS||higher-11/JJR	nn||settings-13/NNS||transmission-12/NN	prep_from||patients-9/NNS||settings-13/NNS	amod||malaria-16/NN||untreated-15/JJ	prep_with||settings-13/NNS||malaria-16/NN	aux||progress-18/VB||would-17/MD	ccomp||reached-4/VBN||progress-18/VB	amod||disease-21/NN||severe-20/JJ	prep_to||progress-18/VB||disease-21/NN	dep||disease-21/NN||median-23/NN	num||%-25/NN||3-24/CD	dep||median-23/NN||%-25/NN	amod||1â-32/NNS||inter-quartile-27/JJ	nn||1â-32/NNS||range-28/NN	discourse||1â-32/NNS||iqr-30/UH	appos||%-25/NN||1â-32/NNS	dep||%-36/NN||$-33/$	num||$-33/$||5-35/CD	amod||1â-32/NNS||%-36/NN	det||probability-41/NN||the-40/DT	prep_to||progress-18/VB||probability-41/NN	conj_and||disease-21/NN||probability-41/NN	mark||required-46/VBD||that-42/IN	det||illness-45/NN||a-43/DT	amod||illness-45/NN||non-malaria-44/JJ	nsubj||required-46/VBD||illness-45/NN	ccomp||progress-18/VB||required-46/VBD	dobj||required-46/VBD||antibiotics-47/NNS	prep_in||required-46/VBD||areas-49/NNS	amod||prevalence-53/NN||low-51/JJ	nn||prevalence-53/NN||hiv-52/NN	prep_of||areas-49/NNS||prevalence-53/NN	number||20-56/CD||median-55/CD	num||%-57/NN||20-56/CD	appos||prevalence-53/NN||%-57/NN	malaria-16||antibiotics-47||no_rel||some consensus was reached around the probability that patients from higher transmission settings with untreated malaria would progress to severe disease (median 3%, inter-quartile range (iqr) 1â€“5%), and the probability that a non-malaria illness required antibiotics in areas of low hiv prevalence (median 20%).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	nsubj||prednisone-22/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||pharmacokinetics-14/VBZ||whether-9/IN	nsubj||pharmacokinetics-14/VBZ||mycophenolatemofetil-10/NN	appos||mycophenolatemofetil-10/NN||mmf-12/NN	ccomp||determine-8/VB||pharmacokinetics-14/VBZ	dep||pharmacokinetics-14/VBZ||pk-16/NN	amod||mmf-20/NN||combined-19/VBN	prep_under||pharmacokinetics-14/VBZ||mmf-20/NN	xcomp||was-6/VBD||prednisone-22/VB	conj_and||determine-8/VB||prednisone-22/VB	amod||therapy-24/NN||remission-maintenance-23/JJ	nsubj||predict-26/VB||therapy-24/NN	aux||predict-26/VB||can-25/MD	ccomp||prednisone-22/VB||predict-26/VB	amod||lupuserythematosus-28/NNS||systemic-27/JJ	dobj||predict-26/VB||lupuserythematosus-28/NNS	appos||lupuserythematosus-28/NNS||sle-30/NN	amod||flares-33/NNS||clinical-32/JJ	dobj||determine-8/VB||flares-33/NNS	mycophenolatemofetil-10||sle-30||no_rel||the aim of this study was to determine whether mycophenolatemofetil (mmf) pharmacokinetics (pk) under combined mmf and prednisone remission-maintenance therapy can predict systemic lupuserythematosus (sle) clinical flares.
prepc_according_to||-lrb--9/VBD||to-2/TO	nn||diffusion-4/NN||disc-3/NN	pobj||-lrb--9/VBD||diffusion-4/NN	nn||s.aureus-8/NNS||methicillin-6/NN	nn||s.aureus-8/NNS||resistance-7/NN	nsubj||-lrb--9/VBD||s.aureus-8/NNS	root||ROOT-0/null||-lrb--9/VBD	nn||-rrb--11/NNP||mrsa-10/NNP	nsubj||%-14/NN||-rrb--11/NNP	cop||%-14/NN||was-12/VBD	num||%-14/NN||75-13/CD	ccomp||-lrb--9/VBD||%-14/NN	amod||aurous-19/NNS||vancomycin-16/JJ	nn||aurous-19/NNS||resistance-17/NN	nn||aurous-19/NNS||s.-18/NN	nsubj||-lrb--20/VBD||aurous-19/NNS	nsubj||based-27/VBN||aurous-19/NNS	conj_and||-lrb--9/VBD||-lrb--20/VBD	nn||-rrb--22/NNP||vrsa-21/NNP	nsubj||%-25/NN||-rrb--22/NNP	cop||%-25/NN||was-23/VBD	num||%-25/NN||0-24/CD	ccomp||-lrb--20/VBD||%-25/NN	conj_and||-lrb--9/VBD||based-27/VBN	conj_and||-lrb--20/VBD||based-27/VBN	prep_on||based-27/VBN||mic-29/NN	nsubj||%-34/NN||mrsa-31/NN	cop||%-34/NN||was-32/VBD	num||%-34/NN||68.5-33/CD	dep||-lrb--9/VBD||%-34/NN	nsubj||%-39/NN||vrsa-36/NN	cop||%-39/NN||was-37/VBD	num||%-39/NN||0-38/CD	conj_and||-lrb--9/VBD||%-39/NN	mrsa-31||s.aureus-8||no||according to disc diffusion , methicillin resistance s.aureus -lrb- mrsa -rrb- was 75 % and vancomycin resistance s. aurous -lrb- vrsa -rrb- was 0 % and based on mic , mrsa was 68.5 % and vrsa was 0 % .
nsubj||disease-9/NN||systemiclupuserythematosus-1/NNS	appos||systemiclupuserythematosus-1/NNS||sle-3/NN	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||a-6/DT	amod||disease-9/NN||systemic-7/JJ	amod||disease-9/NN||autoimmune-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||characterized-10/VBN	amod||interferons-15/NNS||increased-12/VBN	nn||interferons-15/NNS||type-13/NN	amod||interferons-15/NNS||i-14/VBG	agent||characterized-10/VBN||interferons-15/NNS	dep||disease-9/NN||ifns-17/NNS	nn||inflammation-21/NN||multiorgan-20/NN	conj_and||disease-9/NN||inflammation-21/NN	advmod||targeting-23/VBG||frequently-22/RB	vmod||inflammation-21/NN||targeting-23/VBG	det||skin-25/NN||the-24/DT	dobj||targeting-23/VBG||skin-25/NN	interferons-15||systemiclupuserythematosus-1||no_rel||systemiclupuserythematosus (sle) is a systemic autoimmune disease characterized by increased type i interferons (ifns) and multiorgan inflammation frequently targeting the skin.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
mark||used-12/VBN||although-1/IN	det||vaccine-5/NN||an-2/DT	amod||vaccine-5/NN||attenuated-3/JJ	nn||vaccine-5/NN||vzv-4/NN	nsubjpass||used-12/VBN||vaccine-5/NN	appos||vaccine-5/NN||v-oka-7/NNP	aux||used-12/VBN||has-9/VBZ	auxpass||used-12/VBN||been-10/VBN	advmod||used-12/VBN||widely-11/RB	advcl||seen-24/VBN||used-12/VBN	prep_in||used-12/VBN||children-14/NNS	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||children-14/NNS||states-18/NNS	nn||outbreaks-21/NNS||chickenpox-20/NN	nsubjpass||seen-24/VBN||outbreaks-21/NNS	auxpass||seen-24/VBN||are-22/VBP	advmod||seen-24/VBN||still-23/RB	root||ROOT-0/null||seen-24/VBN	det||vaccine-29/NN||the-27/DT	nn||vaccine-29/NN||shingles-28/NNS	nsubj||reduces-31/VBZ||vaccine-29/NN	advmod||reduces-31/VBZ||only-30/RB	conj_and||seen-24/VBN||reduces-31/VBZ	det||risk-33/NN||the-32/DT	dobj||reduces-31/VBZ||risk-33/NN	prep_of||risk-33/NN||shingles-35/NNS	num||%-38/NN||50-37/CD	prep_by||reduces-31/VBZ||%-38/NN	chickenpox-20||vzv-4||no||although an attenuated vzv vaccine (v-oka) has been widely used in children in the united states, chickenpox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%.
num||%-2/NN||19.99-1/CD	nsubj||had-3/VBD||%-2/NN	ccomp||impaired-9/VBN||had-3/VBD	dobj||had-3/VBD||hyperglycemia-4/NN	num||%-7/NN||9.47-6/CD	nsubj||impaired-9/VBN||%-7/NN	aux||impaired-9/VBN||had-8/VBD	root||ROOT-0/null||impaired-9/VBN	amod||glucose-11/NN||fasting-10/VBG	dobj||impaired-9/VBN||glucose-11/NN	appos||glucose-11/NN||ifg-13/NN	num||%-17/NN||10.52-16/CD	dobj||impaired-9/VBN||%-17/NN	conj_and||glucose-11/NN||%-17/NN	vmod||%-17/NN||had-18/VBD	dobj||had-18/VBD||diabetes-19/NN	hyperglycemia-4||glucose-11||no||19.99% had hyperglycemia, 9.47% had impaired fasting glucose (ifg) and 10.52% had diabetes.
det||study-3/NN||this-2/DT	prep_in||evaluated-30/VBN||study-3/NN	det||response-8/NN||the-5/DT	amod||response-8/NN||humoral-6/JJ	amod||response-8/NN||immune-7/JJ	nsubjpass||evaluated-30/VBN||response-8/NN	nn||reactivity-11/NN||cross-10/NN	conj_and||response-8/NN||reactivity-11/NN	nsubjpass||evaluated-30/VBN||reactivity-11/NN	prep_against||response-8/NN||mtb-13/NN	prep_of||mtb-13/NN||liposomes-16/NNS	vmod||liposomes-16/NNS||containing-17/VBG	det||mixture-19/NN||a-18/DT	dobj||containing-17/VBG||mixture-19/NN	nn||glycolipids-23/NNS||cell-21/NN	nn||glycolipids-23/NNS||wall-22/NN	prep_of||mixture-19/NN||glycolipids-23/NNS	nn||lipids-28/NNS||ms-25/NN	conj_and||ms-25/NN||commercial-27/JJ	nn||lipids-28/NNS||commercial-27/JJ	prep_of||glycolipids-23/NNS||lipids-28/NNS	auxpass||evaluated-30/VBN||was-29/VBD	root||ROOT-0/null||evaluated-30/VBN	mark||study-35/VB||in-32/IN	dep||study-35/VB||order-33/NN	aux||study-35/VB||to-34/TO	advcl||evaluated-30/VBN||study-35/VB	poss||use-38/NN||its-36/PRP$	amod||use-38/NN||possible-37/JJ	dobj||study-35/VB||use-38/NN	det||component-41/NN||a-40/DT	prep_as||study-35/VB||component-41/NN	det||candidate-45/NN||a-43/DT	nn||candidate-45/NN||vaccine-44/NN	prep_of||component-41/NN||candidate-45/NN	prep_against||candidate-45/NN||tuberculosis-47/NNP	tuberculosis-47||mtb-13||no||in this study, the humoral immune response and cross reactivity against mtb, of liposomes containing a mixture of cell wall glycolipids of ms and commercial lipids was evaluated, in order to study its possible use as a component of a vaccine candidate against tuberculosis.
nsubj||pathogen-7/NN||cryptococcusneoformans-1/NNS	cop||pathogen-7/NN||is-2/VBZ	det||pathogen-7/NN||a-3/DT	amod||pathogen-7/NN||human-4/JJ	amod||pathogen-7/NN||opportunistic-5/JJ	amod||pathogen-7/NN||fungal-6/JJ	root||ROOT-0/null||pathogen-7/NN	amod||pathogen-7/NN||responsible-8/JJ	prepc_for||responsible-8/JJ||âˆ-10/VBG	number||1/3-12/CD||1/4-11/CD	dobj||âˆ-10/VBG||1/3-12/CD	amod||deaths-15/NNS||hiv/aids-14/JJ	prep_of||1/3-12/CD||deaths-15/NNS	advmod||âˆ-10/VBG||worldwide-16/RB	aids--1||hiv--1||no||cryptococcusneoformans is a human opportunistic fungal pathogen responsible for âˆ¼1/3 of hiv/aids deaths worldwide.
advmod||identified-6/VBD||similarly-1/RB	amod||analyses-5/NNS||mass-3/JJ	amod||analyses-5/NNS||spectrometric-4/JJ	nsubj||identified-6/VBD||analyses-5/NNS	root||ROOT-0/null||identified-6/VBD	nn||²-8/NNS||î-7/NN	dobj||identified-6/VBD||²-8/NNS	nn||b2-11/NNS||crystallin-10/NN	dep||²-8/NNS||b2-11/NNS	det||cross-reacting-16/NN||the-13/DT	amod||cross-reacting-16/NN||retinal-14/JJ	nn||cross-reacting-16/NN||protein-15/NN	prep_as||b2-11/NNS||cross-reacting-16/NN	prep_with||identified-6/VBD||lrub-antiserum-18/NN	cross--1||antiserum--1||no_rel||similarly, mass spectrometric analyses identified î²-crystallin b2 as the retinal protein cross-reacting with lrub-antiserum.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||outcomes-5/NNS||the-4/DT	prep_on||report-2/VBP||outcomes-5/NNS	num||patients-11/NNS||21-7/CD	amod||patients-11/NNS||consecutive-8/JJ	amod||patients-11/NNS||gastric-9/JJ	nn||patients-11/NNS||cancer-10/NN	prep_of||outcomes-5/NNS||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_off||treated-12/VBN||protocol-14/NN	amod||carboplatin-17/NNS||adjuvant-16/JJ	prep_with||treated-12/VBN||carboplatin-17/NNS	dep||carboplatin-17/NNS||area-19/NN	det||ã-25/NN||the-21/DT	nn||ã-25/NN||curve-22/NN	num||ã-25/NN||5-23/CD	nn||ã-25/NN||mg/ml-24/NN	prep_under||area-19/NN||ã-25/NN	dep||ã-25/NN||min-27/NN	prep_with||treated-12/VBN||paclitaxel-30/NN	conj_and||carboplatin-17/NNS||paclitaxel-30/NN	quantmod||$-33/$||175â-32/RB	num||mg/m2-36/NNS||$-33/$	num||$-33/$||200-35/CD	dep||paclitaxel-30/NN||mg/m2-36/NNS	det||weeks-40/NNS||every-38/DT	num||weeks-40/NNS||3-39/CD	tmod||treated-12/VBN||weeks-40/NNS	prepc_followed_by||treated-12/VBN||by-43/IN	amod||analogs-46/NNS||concurrent-44/JJ	nn||analogs-46/NNS||pyrimidine-45/NN	pobj||treated-12/VBN||analogs-46/NNS	dep||â-51/FW||either-48/DT	nn||â-51/FW||capecitabine-49/FW	nn||â-51/FW||1,600-50/FW	dep||analogs-46/NNS||â-51/FW	num||mg/m2/day-55/NNS||$-52/$	num||$-52/$||2,000-54/CD	dep||â-51/FW||mg/m2/day-55/NNS	num||patients-58/NNS||17-57/CD	prep_in||mg/m2/day-55/NNS||patients-58/NNS	number||200-62/CD||5fu-61/CD	num||mg/m2/day-63/NNS||200-62/CD	dep||â-51/FW||mg/m2/day-63/NNS	conj_or||mg/m2/day-55/NNS||mg/m2/day-63/NNS	num||patients-66/NNS||4-65/CD	prep_in||mg/m2/day-63/NNS||patients-66/NNS	pobj||treated-12/VBN||radiation-69/NN	conj_and||analogs-46/NNS||radiation-69/NN	dep||analogs-46/NNS||45â-71/NNS	dep||45â-71/NNS||$-72/$	num||$-72/$||50.4-74/CD	dep||$-72/$||gy-75/NN	cancer-10||paclitaxel-30||no_rel||we report on the outcomes of 21 consecutive gastric cancer patients treated off protocol with adjuvant carboplatin (area under the curve 5 mg/ml ã— min) and paclitaxel (175â€“200 mg/m2) every 3 weeks, followed by concurrent pyrimidine analogs (either capecitabine 1,600â€“2,000 mg/m2/day in 17 patients, or 5fu 200 mg/m2/day in 4 patients) and radiation (45â€“50.4 gy).
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubj||had-7/VBD||plus-5/NN	advmod||had-7/VBD||assay-6/RB	root||ROOT-0/null||had-7/VBD	det||sensitivity-9/NN||a-8/DT	dobj||had-7/VBD||sensitivity-9/NN	num||%-12/NN||95.3-11/CD	prep_of||sensitivity-9/NN||%-12/NN	num||%-15/NN||100-14/CD	prep_of||sensitivity-9/NN||%-15/NN	conj_and||%-12/NN||%-15/NN	num||%-19/NN||94.4-18/CD	prep_of||sensitivity-9/NN||%-19/NN	conj_and||%-12/NN||%-19/NN	nn||resistance-22/NN||inh-21/NN	prep_for||had-7/VBD||resistance-22/NN	nn||resistance-25/NN||rif-24/NN	prep_for||had-7/VBD||resistance-25/NN	conj_and||resistance-22/NN||resistance-25/NN	prep_for||had-7/VBD||mdr-tb-28/NN	conj_and||resistance-22/NN||mdr-tb-28/NN	advmod||had-7/VBD||respectively-30/RB	tb--1||rif-24||yes||the genotypeâ® mtbdr plus assay had a sensitivity of 95.3%, 100%, and 94.4% for inh resistance, rif resistance, and mdr-tb, respectively.
det||palivizumab-9/NN||the-1/DT	amod||palivizumab-9/NN||f-2/JJ	amod||palivizumab-9/NN||protein-directed-3/JJ	amod||palivizumab-9/NN||monoclonal-4/JJ	nn||palivizumab-9/NN||antibody-5/NN	appos||palivizumab-9/NN||mab-7/NN	nsubjpass||shown-12/VBN||palivizumab-9/NN	nsubj||prevent-14/VB||palivizumab-9/NN	aux||shown-12/VBN||has-10/VBZ	auxpass||shown-12/VBN||been-11/VBN	root||ROOT-0/null||shown-12/VBN	aux||prevent-14/VB||to-13/TO	xcomp||shown-12/VBN||prevent-14/VB	amod||rsvinfection-19/NN||severe-15/JJ	dep||severe-15/JJ||lower-16/JJR	amod||rsvinfection-19/NN||respiratory-17/JJ	nn||rsvinfection-19/NN||tract-18/NN	dobj||prevent-14/VB||rsvinfection-19/NN	prep_in||prevent-14/VB||animals-21/NNS	prep_in||prevent-14/VB||humans-23/NNS	conj_and||animals-21/NNS||humans-23/NNS	rsvinfection-19||palivizumab-9||yes||the f protein-directed monoclonal antibody (mab) palivizumab has been shown to prevent severe lower respiratory tract rsvinfection in animals and humans.
nsubjpass||comprised-32/VBN||prions-1/NNS	amod||agents-4/NNS||infectious-3/JJ	appos||prions-1/NNS||agents-4/NNS	vmod||agents-4/NNS||associated-5/VBN	prep_with||associated-5/VBN||priondiseases-7/NNS	prep_such_as||priondiseases-7/NNS||creutzfeldt-jakobdisease-10/NN	prep_in||creutzfeldt-jakobdisease-10/NN||humans-12/NNS	amod||encephalopathy-16/NN||bovine-14/JJ	nn||encephalopathy-16/NN||spongiform-15/NN	prep_such_as||priondiseases-7/NNS||encephalopathy-16/NN	conj_and||creutzfeldt-jakobdisease-10/NN||encephalopathy-16/NN	appos||encephalopathy-16/NN||bse-18/NN	prep_in||encephalopathy-16/NN||cattle-21/NNS	prep_such_as||priondiseases-7/NNS||scrapie-24/NN	conj_and||creutzfeldt-jakobdisease-10/NN||scrapie-24/NN	prep_in||scrapie-24/NN||sheep-26/NN	prep_in||scrapie-24/NN||goats-28/NNS	conj_and||sheep-26/NN||goats-28/NNS	auxpass||comprised-32/VBN||are-30/VBP	advmod||comprised-32/VBN||primarily-31/RB	root||ROOT-0/null||comprised-32/VBN	prep_of||comprised-32/VBN||prpsc-34/NN	det||isoform-39/NN||a-36/DT	amod||isoform-39/NN||protease-resistant-37/JJ	amod||isoform-39/NN||misfolded-38/JJ	appos||prpsc-34/NN||isoform-39/NN	det||prpc-44/NN||the-41/DT	amod||prpc-44/NN||cellular-42/JJ	nn||prpc-44/NN||prionprotein-43/NN	prep_of||isoform-39/NN||prpc-44/NN	priondiseases-7||prions-1||no||prions, infectious agents associated with priondiseases such as creutzfeldt-jakobdisease in humans, bovine spongiform encephalopathy (bse) in cattle, and scrapie in sheep and goats, are primarily comprised of prpsc, a protease-resistant misfolded isoform of the cellular prionprotein prpc.
det||plurality-2/NN||a-1/DT	nsubjpass||treated-8/VBN||plurality-2/NN	prep_of||plurality-2/NN||patients-4/NNS	prep_with||patients-4/NNS||schizophrenia-6/NN	auxpass||treated-8/VBN||was-7/VBD	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||clozapine-10/NN	num||%-13/NN||39-12/CD	appos||clozapine-10/NN||%-13/NN	nsubjpass||followed-18/VBN||this-16/DT	auxpass||followed-18/VBN||was-17/VBD	parataxis||treated-8/VBN||followed-18/VBN	agent||followed-18/VBN||risperidone-20/JJ	agent||followed-18/VBN||sulpride-22/JJ	conj_and||risperidone-20/JJ||sulpride-22/JJ	agent||followed-18/VBN||chlorpromazine-24/JJ	conj_and||risperidone-20/JJ||chlorpromazine-24/JJ	agent||followed-18/VBN||perphenazine-26/JJ	conj_and||risperidone-20/JJ||perphenazine-26/JJ	agent||followed-18/VBN||haloperidol-29/JJ	conj_and||risperidone-20/JJ||haloperidol-29/JJ	schizophrenia-6||clozapine-10||yes||a plurality of patients with schizophrenia was treated with clozapine (39%); this was followed by risperidone, sulpride, chlorpromazine, perphenazine, and haloperidol.
det||sample-6/NN||any-1/DT	amod||sample-6/NN||patient-2/JJ	prep_with||patient-2/JJ||one-4/CD	nn||sample-6/NN||blood-5/NN	nsubj||received-15/VBD||sample-6/NN	vmod||sample-6/NN||containing-7/VBG	quantmod||than-9/IN||more-8/JJR	num||genomes-12/NNS||than-9/IN	num||cytomegalovirus-11/NNS||3000-10/CD	dep||than-9/IN||cytomegalovirus-11/NNS	dobj||containing-7/VBG||genomes-12/NNS	prep_per||genomes-12/NNS||ml-14/NN	root||ROOT-0/null||received-15/VBD	dobj||received-15/VBD||ganciclovir-16/NN	num||measurements-23/NNS||two-18/CD	amod||measurements-23/NNS||consecutive-19/JJ	amod||measurements-23/NNS||undetectable-20/JJ	nn||measurements-23/NNS||cytomegalovirus-21/NN	nn||measurements-23/NNS||dna-22/NN	prep_until||received-15/VBD||measurements-23/NNS	cytomegalovirus-21||ganciclovir-16||yes||any patient with one blood sample containing more than 3000 cytomegalovirus genomes per ml received ganciclovir until two consecutive undetectable cytomegalovirus dna measurements.
det||therapy-4/NN||the-1/DT	amod||therapy-4/NN||hyperbaric-2/JJ	nn||therapy-4/NN||oxygen-3/NN	nsubj||trial-24/NN||therapy-4/NN	prep_in||therapy-4/NN||diabetics-6/NNS	amod||footulcers-9/NNS||chronic-8/JJ	prep_with||diabetics-6/NNS||footulcers-9/NNS	dep||therapy-4/NN||hodfu-11/VBN	dep||therapy-4/NN||study-13/NN	cop||trial-24/NN||was-14/VBD	det||trial-24/NN||a-15/DT	amod||trial-24/NN||randomized-16/JJ	amod||trial-24/NN||single-center-18/JJ	amod||trial-24/NN||double-blinded-20/JJ	amod||trial-24/NN||placebo-controlled-22/JJ	amod||trial-24/NN||clinical-23/JJ	root||ROOT-0/null||trial-24/NN	footulcers-9||oxygen-3||no_rel||the hyperbaric oxygen therapy in diabetics with chronic footulcers (hodfu) study was a randomized, single-center, double-blinded, placebo-controlled clinical trial.
nn||treatment-2/NN||calcitonin-1/NN	nsubj||increased-3/VBD||treatment-2/NN	root||ROOT-0/null||increased-3/VBD	nn||synthesis-7/NN||proteoglycan-4/NN	conj_and||proteoglycan-4/NN||collagen-6/NN	nn||synthesis-7/NN||collagen-6/NN	dobj||increased-3/VBD||synthesis-7/NN	amod||cartilage-11/NN||human-9/JJ	nn||cartilage-11/NN||oa-10/NN	prep_in||increased-3/VBD||cartilage-11/NN	oa-10||collagen-6||no_rel||calcitonin treatment increased proteoglycan and collagen synthesis in human oa cartilage.
det||study-2/NN||this-1/DT	nsubj||adopted-3/VBD||study-2/NN	root||ROOT-0/null||adopted-3/VBD	det||model-6/NN||an-4/DT	nn||model-6/NN||fe-5/NN	dobj||adopted-3/VBD||model-6/NN	vmod||adopted-3/VBD||taking-8/VBG	prep_into||taking-8/VBG||account-10/NN	det||asymmetry-13/NN||the-11/DT	amod||asymmetry-13/NN||possible-12/JJ	dobj||taking-8/VBG||asymmetry-13/NN	advmod||existing-15/VBG||inherently-14/RB	amod||asymmetry-13/NN||existing-15/VBG	det||spine-18/NN||the-17/DT	prep_in||existing-15/VBG||spine-18/NN	prep_with||spine-18/NN||respect-20/NN	det||plane-24/NN||the-22/DT	amod||plane-24/NN||sagittal-23/JJ	prep_to||existing-15/VBG||plane-24/NN	det||outline-31/NN||a-27/DT	advmod||geometrically-29/JJ||more-28/RBR	amod||outline-31/NN||geometrically-29/JJ	amod||outline-31/NN||realistic-30/JJ	prep_with||adopted-3/VBD||outline-31/NN	aux||analyze-33/VB||to-32/TO	vmod||outline-31/NN||analyze-33/VB	vmod||outline-31/NN||compare-35/VB	conj_and||analyze-33/VB||compare-35/VB	det||behaviour-38/NN||the-36/DT	amod||behaviour-38/NN||biomechanical-37/JJ	dobj||analyze-33/VB||behaviour-38/NN	det||spine-42/NN||the-40/DT	nn||spine-42/NN||lumbar-41/NN	prep_of||behaviour-38/NN||spine-42/NN	prep_with||analyze-33/VB||regard-44/NN	det||force-48/NN||the-46/DT	amod||force-48/NN||facet-47/JJ	prep_to||adopted-3/VBD||force-48/NN	nsubjpass||associated-55/VBN||force-48/NN	nn||pressure-51/NN||intradiscal-50/NN	prep_to||adopted-3/VBD||pressure-51/NN	conj_and||force-48/NN||pressure-51/NN	nsubjpass||associated-55/VBN||pressure-51/NN	auxpass||associated-55/VBN||are-54/VBP	rcmod||force-48/NN||associated-55/VBN	amod||painsymptoms-59/NNS||low-57/JJ	amod||painsymptoms-59/NNS||back-58/JJ	prep_with||associated-55/VBN||painsymptoms-59/NNS	amod||disorders-63/NNS||other-61/JJ	amod||disorders-63/NNS||spinal-62/JJ	prep_with||associated-55/VBN||disorders-63/NNS	conj_and||painsymptoms-59/NNS||disorders-63/NNS	painsymptoms-59||fe-5||no_rel||this study adopted an fe model, taking into account the possible asymmetry inherently existing in the spine with respect to the sagittal plane, with a more geometrically realistic outline to analyze and compare the biomechanical behaviour of the lumbar spine with regard to the facet force and intradiscal pressure, which are associated with low back painsymptoms and other spinal disorders.
nsubj||have-9/VBP||patients-1/NNS	amod||levels-4/NNS||higher-3/JJR	prep_with||patients-1/NNS||levels-4/NNS	amod||glucose-8/NN||fasting-6/JJ	nn||glucose-8/NN||serum-7/NN	prep_of||levels-4/NNS||glucose-8/NN	root||ROOT-0/null||have-9/VBP	amod||rates-12/NNS||higher-10/JJR	nn||rates-12/NNS||death-11/NN	dobj||have-9/VBP||rates-12/NNS	amod||cancer-15/NN||pancreatic-14/JJ	prep_from||rates-12/NNS||cancer-15/NN	prepc_compared_to||have-9/VBP||to-17/TO	pobj||have-9/VBP||patients-18/NNS	amod||levels-21/NNS||lower-20/JJR	prep_with||patients-18/NNS||levels-21/NNS	amod||glucose-25/NN||fasting-23/VBG	nn||glucose-25/NN||serum-24/NN	prep_of||levels-21/NNS||glucose-25/NN	glucose-25||cancer-15||no_rel||patients with higher levels of fasting serum glucose have higher death rates from pancreatic cancer compared to patients with lower levels of fasting serum glucose.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||‰-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	hypertension-21||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â€“11.0 mmol/l), diabetes (dm; p-glucose â‰¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||âˆ-14/VB	num||±-17/NN||’14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||âˆ-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||âˆ-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||âˆ-37/NN	num||±-40/NN||’14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||âˆ-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||âˆ-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||âˆ-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	insulin-82||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (âˆ’14 â± 3 pg/ml [âˆ’4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (âˆ’14 â± 2 pg/ml [âˆ’4.0 â± 0.6 pmol/l]) but increased to âˆ’3 â± 3 pg/ml (âˆ’0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||sb-56||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
nsubj||causes-7/VBZ||aquafol-1/NN	det||propofol-5/NN||a-3/DT	nn||propofol-5/NN||microemulsion-4/NN	appos||aquafol-1/NN||propofol-5/NN	root||ROOT-0/null||causes-7/VBZ	advmod||severe-9/JJ||more-8/RBR	amod||pain-12/NN||severe-9/JJ	conj_and||severe-9/JJ||frequent-11/JJ	amod||pain-12/NN||frequent-11/JJ	dobj||causes-7/VBZ||pain-12/NN	prep_on||causes-7/VBZ||injection-14/NN	prep_than||injection-14/NN||propofol-16/NN	pain-12||propofol-16||yes||aquafol, a microemulsion propofol, causes more severe and frequent pain on injection than propofol.
nsubj||some-11/DT||smoking-1/NN	nn||carcinogens-4/NNS||chemical-3/NN	appos||smoking-1/NN||carcinogens-4/NNS	nn||solvents-9/NNS||asbestos-6/NN	conj_or||asbestos-6/NN||organic-8/JJ	nn||solvents-9/NNS||organic-8/JJ	prep_like||carcinogens-4/NNS||solvents-9/NNS	cop||some-11/DT||are-10/VBP	root||ROOT-0/null||some-11/DT	det||factors-14/NNS||these-13/DT	prep_of||some-11/DT||factors-14/NNS	nsubj||increase-16/VBP||factors-14/NNS	rcmod||factors-14/NNS||increase-16/VBP	det||risk-18/NN||the-17/DT	dobj||increase-16/VBP||risk-18/NN	det||rcc-21/NN||the-20/DT	prep_of||risk-18/NN||rcc-21/NN	rcc-21||carcinogens-4||no_rel||smoking, chemical carcinogens like asbestos or organic solvents are some of these factors that increase the risk of the rcc.
det||study-3/NN||the-1/DT	nn||study-3/NN||action-2/NN	nsubj||trial-21/NN||study-3/NN	amod||investigation-8/NN||attentiondeficithyperactivitydisorder-5/JJ	amod||investigation-8/NN||controlled-6/VBN	nn||investigation-8/NN||trial-7/NN	dep||study-3/NN||investigation-8/NN	det||non-stimulant-11/NN||a-10/DT	prep_of||investigation-8/NN||non-stimulant-11/NN	cop||trial-21/NN||is-13/VBZ	det||trial-21/NN||a-14/DT	amod||trial-21/NN||multi-center-15/JJ	amod||trial-21/NN||double-blind-17/JJ	amod||trial-21/NN||randomized-19/JJ	amod||trial-21/NN||cross-over-20/JJ	root||ROOT-0/null||trial-21/NN	det||medication-25/NN||the-23/DT	amod||medication-25/NN||non-stimulant-24/JJ	prep_of||trial-21/NN||medication-25/NN	appos||medication-25/NN||atomoxetine-27/NN	prep_in||medication-25/NN||children-30/NNS	prep_in||medication-25/NN||adolescents-32/NNS	conj_and||children-30/NNS||adolescents-32/NNS	prep_with||children-30/NNS||attentiondeficithyperactivitydisorder-34/NN	dep||medication-25/NN||adhd-36/VBN	attentiondeficithyperactivitydisorder-34||atomoxetine-27||yes||the action study ( attentiondeficithyperactivitydisorder controlled trial investigation of a non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, atomoxetine, in children and adolescents with attentiondeficithyperactivitydisorder (adhd).
amod||clinics-2/NNS||hiv/aids-1/JJ	nsubj||face-9/VBP||clinics-2/NNS	nn||countries-8/NNS||uganda-4/NN	conj_and||uganda-4/NN||other-6/JJ	nn||countries-8/NNS||other-6/JJ	amod||countries-8/NNS||low-income-7/JJ	prep_in||clinics-2/NNS||countries-8/NNS	root||ROOT-0/null||face-9/VBP	amod||numbers-11/NNS||increasing-10/VBG	dobj||face-9/VBP||numbers-11/NNS	prep_of||numbers-11/NNS||patients-13/NNS	nn||shortages-16/NNS||workforce-15/NN	prep_of||numbers-11/NNS||shortages-16/NNS	conj_and||patients-13/NNS||shortages-16/NNS	aids--1||hiv--1||no||hiv/aids clinics in uganda and other low-income countries face increasing numbers of patients and workforce shortages.
num||weeks-3/NNS||two-2/CD	prep_after||hivpositive-16/JJ||weeks-3/NNS	prep_of||weeks-3/NNS||treatment-5/NN	det||rate-8/NN||the-6/DT	nn||rate-8/NN||conversion-7/NN	nsubj||hivpositive-16/JJ||rate-8/NN	nsubj||hivpositive-16/JJ||rate-8/NN	amod||microscopy-12/NN||standard-10/JJ	nn||microscopy-12/NN||sputum-11/NN	prep_by||rate-8/NN||microscopy-12/NN	cop||hivpositive-16/JJ||was-13/VBD	dep||in-15/IN||higher-14/JJR	advmod||hivpositive-16/JJ||in-15/IN	root||ROOT-0/null||hivpositive-16/JJ	conj_negcc||hivpositive-16/JJ||hivpositive-16/JJ	num||%-19/NN||72.8-18/CD	dep||hivpositive-16/JJ||%-19/NN	advmod||negative-23/JJ||hiv-22/RB	amod||patients-28/NNS||negative-23/JJ	num||%-26/NN||63.3-25/CD	appos||patients-28/NNS||%-26/NN	prep_than||hivpositive-16/JJ||patients-28/NNS	amod||analysis-31/NN||univariate-30/JJ	prep_by||hivpositive-16/JJ||analysis-31/NN	dep||analysis-31/NN||p-33/VBN	dep||0.046-35/CD||=-34/SYM	ccomp||p-33/VBN||0.046-35/CD	amod||analysis-42/NN||multivariate-41/JJ	prep_in||hivpositive-16/JJ||analysis-42/NN	hivpositive-16||hiv-22||no||after two weeks of treatment the conversion rate by standard sputum microscopy was higher in hivpositive(72.8%) than hiv negative(63.3%) patients by univariate analysis(p = 0.046), but not in multivariate analysis.
nsubj||explore-2/VB||we-1/PRP	root||ROOT-0/null||explore-2/VB	dobj||explore-2/VB||reasons-3/NNS	prep_for||reasons-3/NNS||this-5/DT	amod||doubts-10/NNS||prevailing-9/VBG	prep_such_as||this-5/DT||doubts-10/NNS	det||efficacy-13/NN||the-12/DT	prep_about||doubts-10/NNS||efficacy-13/NN	prep_of||doubts-10/NNS||fondaparinux-15/NN	det||setting-18/NN||the-17/DT	prep_in||doubts-10/NNS||setting-18/NN	prep_of||setting-18/NN||angioplasty-20/NN	det||problem-23/NN||the-22/DT	prep_such_as||this-5/DT||problem-23/NN	conj_and||doubts-10/NNS||problem-23/NN	nn||thrombosis-26/NNS||catheter-25/NN	prep_of||problem-23/NN||thrombosis-26/NNS	det||lack-30/NN||the-29/DT	prep_such_as||this-5/DT||lack-30/NN	conj_and||doubts-10/NNS||lack-30/NN	prep_of||lack-30/NN||antidote-32/NN	amod||complications-37/NNS||bleeding-36/VBG	prep_in_case_of||antidote-32/NN||complications-37/NNS	bleeding-36||antidote-32||no_rel||we explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications.
amod||activity-2/NN||sympathetic-1/JJ	nsubjpass||measured-4/VBN||activity-2/NN	auxpass||measured-4/VBN||was-3/VBD	root||ROOT-0/null||measured-4/VBN	num||patients-7/NNS||eight-6/CD	prep_in||measured-4/VBN||patients-7/NNS	nn||patients-10/NNS||chf-9/NN	prep_with||patients-7/NNS||patients-10/NNS	amod||weeks-13/NNS||8â-12/JJ	prep_during||measured-4/VBN||weeks-13/NNS	nn||weeks-18/NNS||discontinuation-15/NN	conj_and||discontinuation-15/NN||4â-17/JJ	nn||weeks-18/NNS||4â-17/JJ	prep_after||weeks-13/NNS||weeks-18/NNS	prep_after||measured-4/VBN||restart-20/NNP	nn||therapy-23/NN||statin-22/NN	prep_of||restart-20/NNP||therapy-23/NN	agent||measured-4/VBN||microneurography-25/NN	amod||muscle-28/NN||direct-27/JJ	prep_for||microneurography-25/NN||muscle-28/NN	amod||recording-31/NN||sympathetic-29/JJ	nn||recording-31/NN||nerve-30/NN	dep||muscle-28/NN||recording-31/NN	appos||recording-31/NN||msna-33/NNP	prep_for||microneurography-25/NN||measurement-36/NN	conj_and||muscle-28/NN||measurement-36/NN	amod||concentrations-41/NNS||arterial-38/JJ	nn||concentrations-41/NNS||plasma-39/NN	nn||concentrations-41/NNS||norepinephrine-40/NN	prep_of||measurement-36/NN||concentrations-41/NNS	chf-9||statin-22||no_rel||sympathetic activity was measured in eight patients with chf patients during 8â weeks after discontinuation and 4â weeks after restart of statin therapy by microneurography for direct muscle sympathetic nerve recording (msna) and measurement of arterial plasma norepinephrine concentrations.
amod||virus-2/NN||chronichepatitisc-1/JJ	nsubj||remains-7/VBZ||virus-2/NN	appos||virus-2/NN||hcv-4/NN	advmod||remains-7/VBZ||infection-6/RB	root||ROOT-0/null||remains-7/VBZ	det||burden-10/NN||a-8/DT	amod||burden-10/NN||serious-9/JJ	xcomp||remains-7/VBZ||burden-10/NN	amod||health-13/NN||public-12/JJ	prep_to||burden-10/NN||health-13/NN	advmod||remains-7/VBZ||worldwide-14/RB	chronichepatitisc-1||hcv-4||no||chronichepatitisc virus (hcv) infection remains a serious burden to public health worldwide.
prep_in||found-11/VBD||comparison-2/NN	nn||data-5/NNS||registration-4/NN	prep_with||comparison-2/NN||data-5/NNS	det||sample-8/NN||the-7/DT	prep_for||data-5/NNS||sample-8/NN	nsubj||found-11/VBD||we-10/PRP	root||ROOT-0/null||found-11/VBD	det||increase-13/NN||an-12/DT	dobj||found-11/VBD||increase-13/NN	det||proportion-17/NN||the-15/DT	amod||proportion-17/NN||relative-16/JJ	prep_in||found-11/VBD||proportion-17/NN	prep_of||proportion-17/NN||deaths-19/NNS	prep_in||deaths-19/NNS||hospitals-21/NNS	prep_due_to||found-11/VBD||stroke-24/NN	amod||heartdisease-27/NN||ischemic-26/JJ	prep_due_to||found-11/VBD||heartdisease-27/NN	conj_and||stroke-24/NN||heartdisease-27/NN	nn||accidents-30/NNS||transport-29/NN	prep_due_to||found-11/VBD||accidents-30/NNS	conj_and||stroke-24/NN||accidents-30/NNS	prep_due_to||found-11/VBD||hiv/aids-32/NNS	conj_and||stroke-24/NN||hiv/aids-32/NNS	prep_due_to||found-11/VBD||diabetes-34/NN	conj_and||stroke-24/NN||diabetes-34/NN	prep_due_to||found-11/VBD||liverdiseases-36/NNS	conj_and||stroke-24/NN||liverdiseases-36/NNS	amod||obstructivepulmonarydisease-40/NN||chronic-39/JJ	prep_due_to||found-11/VBD||obstructivepulmonarydisease-40/NN	conj_and||stroke-24/NN||obstructivepulmonarydisease-40/NN	aids--1||hiv--1||no||in comparison with registration data for the sample, we found an increase in the relative proportion of deaths in hospitals due to stroke, ischemic heartdisease, transport accidents, hiv/aids, diabetes, liverdiseases, and chronic obstructivepulmonarydisease.
nsubj||are-11/VBP||studies-1/NNS	aux||explore-3/VB||to-2/TO	vmod||studies-1/NNS||explore-3/VB	det||effect-5/NN||the-4/DT	dobj||explore-3/VB||effect-5/NN	prep_of||effect-5/NN||anticoagulants-7/NNS	nn||survival-10/NN||cancer-9/NN	prep_on||anticoagulants-7/NNS||survival-10/NN	root||ROOT-0/null||are-11/VBP	advmod||are-11/VBP||underway-12/RB	amod||malignancies-15/NNS||other-14/JJ	prep_in||are-11/VBP||malignancies-15/NNS	nn||breast-24/NN||lung-18/NN	dep||breast-24/NN||pancreas-20/NN	dep||breast-24/NN||ovary-22/NN	prep_such_as||malignancies-15/NNS||breast-24/NN	nn||cancer-28/NN||stomach-27/NN	prep_such_as||malignancies-15/NNS||cancer-28/NN	conj_and||breast-24/NN||cancer-28/NN	cancer-28||anticoagulants-7||no_rel||studies to explore the effect of anticoagulants on cancer survival are underway in other malignancies such as lung, pancreas, ovary, breast, and stomach cancer.
nsubjpass||associated-3/VBN||fecv-1/NNP	auxpass||associated-3/VBN||is-2/VBZ	root||ROOT-0/null||associated-3/VBN	amod||infections-8/NNS||asymptomatic-5/JJ	amod||infections-8/NNS||persistent-6/JJ	amod||infections-8/NNS||enteric-7/JJ	prep_with||associated-3/VBN||infections-8/NNS	mark||causes-12/VBZ||while-10/IN	nsubj||causes-12/VBZ||fipv-11/NNP	dep||infections-8/NNS||causes-12/VBZ	dobj||causes-12/VBZ||felineinfectiousperitonitis-13/NNS	appos||felineinfectiousperitonitis-13/NNS||fip-15/NN	det||disease-22/NN||a-18/DT	advmod||fatal-20/JJ||usually-19/RB	amod||disease-22/NN||fatal-20/JJ	amod||disease-22/NN||systemic-21/JJ	dobj||causes-12/VBZ||disease-22/NN	conj_and||felineinfectiousperitonitis-13/NNS||disease-22/NN	amod||cats-25/NNS||domestic-24/JJ	prep_in||disease-22/NN||cats-25/NNS	det||felidae-29/NN||some-27/DT	amod||felidae-29/NN||wild-28/JJ	dobj||causes-12/VBZ||felidae-29/NN	conj_and||felineinfectiousperitonitis-13/NNS||felidae-29/NN	fip-15||fipv-11||no||fecv is associated with asymptomatic persistent enteric infections, while fipv causes felineinfectiousperitonitis (fip), a usually fatal systemic disease in domestic cats and some wild felidae.
amod||infections-2/NNS||human-1/JJ	nsubjpass||confirmed-11/VBN||infections-2/NNS	advmod||pathogenic-5/JJ||highly-4/RB	amod||avianinfluenzaviruses-7/NNS||pathogenic-5/JJ	amod||avianinfluenzaviruses-7/NNS||h5n1-6/JJ	prep_with||infections-2/NNS||avianinfluenzaviruses-7/NNS	aux||confirmed-11/VBN||have-8/VBP	advmod||confirmed-11/VBN||generally-9/RB	auxpass||confirmed-11/VBN||been-10/VBN	root||ROOT-0/null||confirmed-11/VBN	amod||amplification-14/NN||molecular-13/JJ	agent||confirmed-11/VBN||amplification-14/NN	amod||methods-17/NNS||culture-based-16/JJ	agent||confirmed-11/VBN||methods-17/NNS	conj_or||amplification-14/NN||methods-17/NNS	h5n1-6||influenzaviruses--1||no||human infections with highly pathogenic h5n1 avianinfluenzaviruses have generally been confirmed by molecular amplification or culture-based methods.
det||enterotoxin-3/NN||the-1/DT	nn||enterotoxin-3/NN||cholera-2/NN	nsubj||-lrb--4/VBD||enterotoxin-3/NN	root||ROOT-0/null||-lrb--4/VBD	nn||-rrb--6/NNS||ct-5/NN	nsubj||factor-11/NN||-rrb--6/NNS	cop||factor-11/NN||is-7/VBZ	det||factor-11/NN||a-8/DT	amod||factor-11/NN||major-9/JJ	nn||factor-11/NN||virulence-10/NN	ccomp||-lrb--4/VBD||factor-11/NN	prep_of||factor-11/NN||v.cholerae-13/NN	cholera-2||v.cholerae-13||no||the cholera enterotoxin -lrb- ct -rrb- is a major virulence factor of v.cholerae .
advmod||shown-8/VBN||recently-1/RB	amod||waves-5/NNS||astrocyte-2/JJ	nn||waves-5/NNS||intercellular-3/NN	nn||waves-5/NNS||calcium-4/NN	nsubjpass||shown-8/VBN||waves-5/NNS	nsubj||underlie-10/VB||waves-5/NNS	aux||shown-8/VBN||have-6/VBP	auxpass||shown-8/VBN||been-7/VBN	root||ROOT-0/null||shown-8/VBN	aux||underlie-10/VB||to-9/TO	xcomp||shown-8/VBN||underlie-10/VB	dobj||underlie-10/VB||seizures-11/NNS	amod||drugs-16/NNS||conventional-14/JJ	amod||drugs-16/NNS||antiepileptic-15/JJ	nsubjpass||shown-19/VBN||drugs-16/NNS	nsubj||attenuate-21/VB||drugs-16/NNS	aux||shown-19/VBN||have-17/VBP	auxpass||shown-19/VBN||been-18/VBN	conj_and||shown-8/VBN||shown-19/VBN	aux||attenuate-21/VB||to-20/TO	xcomp||shown-19/VBN||attenuate-21/VB	det||waves-24/NNS||these-22/DT	nn||waves-24/NNS||calcium-23/NN	dobj||attenuate-21/VB||waves-24/NNS	calcium-23||seizures-11||no_rel||recently astrocyte intercellular calcium waves have been shown to underlie seizures, and conventional antiepileptic drugs have been shown to attenuate these calcium waves.
nn||proteins-2/NNS||gluten-1/NN	nsubj||induce-6/VB||proteins-2/NNS	prep_from||proteins-2/NNS||wheat-4/NN	aux||induce-6/VB||can-5/MD	root||ROOT-0/null||induce-6/VB	dobj||induce-6/VB||celiacdisease-7/NN	appos||celiacdisease-7/NN||cd-9/NN	advmod||susceptible-13/JJ||genetically-12/RB	amod||individuals-14/NNS||susceptible-13/JJ	prep_in||celiacdisease-7/NN||individuals-14/NNS	cd-9||celiacdisease-7||no_rel||gluten proteins from wheat can induce celiacdisease (cd) in genetically susceptible individuals.
nsubj||decreased-2/VBD||melatonin-1/NN	root||ROOT-0/null||decreased-2/VBD	det||hyperglycemia-5/NN||the-3/DT	amod||hyperglycemia-5/NN||abnormal-4/JJ	dobj||decreased-2/VBD||hyperglycemia-5/NN	vmod||hyperglycemia-5/NN||seen-6/VBN	det||load-10/NN||a-8/DT	nn||load-10/NN||glucose-9/NN	prep_after||seen-6/VBN||load-10/NN	number||%-13/NN||10-12/CD	amod||rats-15/NNS||%-13/NN	amod||rats-15/NNS||fructose-treated-14/JJ	prep_in||load-10/NN||rats-15/NNS	nsubj||modify-20/VB||it-17/PRP	aux||modify-20/VB||did-18/VBD	neg||modify-20/VB||not-19/RB	conj_but||decreased-2/VBD||modify-20/VB	det||tolerance-23/NN||the-21/DT	amod||tolerance-23/NN||greater-22/JJR	dobj||modify-20/VB||tolerance-23/NN	prep_to||modify-20/VB||glucose-25/NN	vmod||glucose-25/NN||observed-26/VBN	prep_in||observed-26/VBN||animals-28/NNS	vmod||animals-28/NNS||drinking-29/VBG	number||%-31/NN||5-30/CD	amod||fructose-32/NN||%-31/NN	dobj||drinking-29/VBG||fructose-32/NN	hyperglycemia-5||glucose-25||no||melatonin decreased the abnormal hyperglycemia seen after a glucose load in 10% fructose-treated rats but it did not modify the greater tolerance to glucose observed in animals drinking 5% fructose.
det||species-2/NN||the-1/DT	nsubj||consists-18/VBZ||species-2/NN	prep_of||species-2/NN||listeriamonocytogenes-4/NNS	det||pathogen-9/NN||a-6/DT	amod||pathogen-9/NN||facultative-7/JJ	nn||pathogen-9/NN||intracellular-8/NN	appos||species-2/NN||pathogen-9/NN	det||agent-13/NN||the-11/DT	amod||agent-13/NN||causative-12/JJ	appos||species-2/NN||agent-13/NN	conj_and||pathogen-9/NN||agent-13/NN	amod||listeriosis-16/NNS||human-15/JJ	prep_of||agent-13/NN||listeriosis-16/NNS	root||ROOT-0/null||consists-18/VBZ	quantmod||three-22/CD||at-20/IN	mwe||at-20/IN||least-21/JJS	pobj||at-20/IN||least-21/JJS	num||lineages-25/NNS||three-22/CD	amod||lineages-25/NNS||distinct-23/JJ	amod||lineages-25/NNS||genetic-24/JJ	prep_of||consists-18/VBZ||lineages-25/NNS	listeriosis-16||listeriamonocytogenes-4||no||the species of listeriamonocytogenes , a facultative intracellular pathogen and the causative agent of human listeriosis, consists of at least three distinct genetic lineages.
nsubj||important-3/JJ||it-1/PRP	nsubj||assess-10/VB||it-1/PRP	cop||important-3/JJ||is-2/VBZ	root||ROOT-0/null||important-3/JJ	det||control-6/NN||the-5/DT	prep_for||important-3/JJ||control-6/NN	prep_of||control-6/NN||ai-8/NNP	aux||assess-10/VB||to-9/TO	xcomp||important-3/JJ||assess-10/VB	mark||acquires-15/VBZ||whether-11/IN	det||virus-14/NN||the-12/DT	amod||virus-14/NN||h9n2-13/JJ	nsubj||acquires-15/VBZ||virus-14/NN	ccomp||assess-10/VB||acquires-15/VBZ	advmod||acquires-15/VBZ||pathogenicity-16/RB	amod||viruses-21/NNS||h5-18/JJ	conj_and||h5-18/JJ||h7-20/JJ	amod||viruses-21/NNS||h7-20/JJ	prep_as||acquires-15/VBZ||viruses-21/NNS	virus-14||viruses-21||no||it is important for the control of ai to assess whether the h9n2 virus acquires pathogenicity as h5 and h7 viruses.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||measure-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||measure-8/VB||to-7/TO	xcomp||was-6/VBD||measure-8/VB	det||impact-10/NN||the-9/DT	dobj||measure-8/VB||impact-10/NN	det||intervention-14/NN||an-12/DT	amod||intervention-14/NN||educational-13/JJ	prep_of||impact-10/NN||intervention-14/NN	prep_on||measure-8/VB||parents-16/NNS	prep_of||parents-16/NNS||children-18/NNS	vmod||children-18/NNS||taking-19/VBG	dobj||taking-19/VBG||methotrexate-20/NN	appos||methotrexate-20/NN||mtx-22/NN	prep_for||methotrexate-20/NN||juvenileidiopathicarthritis-25/NNS	appos||juvenileidiopathicarthritis-25/NNS||jia-27/NN	juvenileidiopathicarthritis-25||mtx-22||yes||the purpose of this study was to measure the impact of an educational intervention on parents of children taking methotrexate (mtx) for juvenileidiopathicarthritis (jia).
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
nsubj||component-8/NN||rifampicin-1/NN	appos||rifampicin-1/NN||rif-3/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||a-6/DT	amod||component-8/NN||major-7/JJ	root||ROOT-0/null||component-8/NN	amod||therapy-13/NN||fixed-10/VBN	nn||therapy-13/NN||dose-11/NN	nn||therapy-13/NN||combination-12/NN	prep_in||component-8/NN||therapy-13/NN	det||treatment-16/NN||the-15/DT	prep_for||therapy-13/NN||treatment-16/NN	prep_of||treatment-16/NN||tuberculosis-18/NNP	tuberculosis-18||rifampicin-1||yes||rifampicin (rif) is a major component in fixed dose combination therapy for the treatment of tuberculosis.
amod||investigations-3/NNS||basic-1/JJ	nn||investigations-3/NNS||science-2/NN	nsubj||spawned-5/VBN||investigations-3/NNS	aux||spawned-5/VBN||have-4/VBP	root||ROOT-0/null||spawned-5/VBN	amod||questions-8/NNS||clinical-7/JJ	prep_from||spawned-5/VBN||questions-8/NNS	det||biology-13/NN||the-11/DT	amod||biology-13/NN||molecular-12/JJ	prep_such_as||questions-8/NNS||biology-13/NN	amod||cancer-16/NN||colorectal-15/JJ	prep_of||biology-13/NN||cancer-16/NN	prep_such_as||questions-8/NNS||use-18/NN	conj_and||biology-13/NN||use-18/NN	amod||inhibitors-21/NNS||cyclooxygenase-20/JJ	prep_of||use-18/NN||inhibitors-21/NNS	nn||regression-24/NN||polyp-23/NN	prep_of||use-18/NN||regression-24/NN	conj_and||inhibitors-21/NNS||regression-24/NN	nn||antagonists-29/NNS||novel-27/NN	nn||antagonists-29/NNS||cytokine-28/NN	prep_such_as||questions-8/NNS||antagonists-29/NNS	conj_and||biology-13/NN||antagonists-29/NNS	prep_in||antagonists-29/NNS||inflammatoryboweldisease-31/NN	cancer-16||basic-1||no_rel||basic science investigations have spawned from clinical questions such as the molecular biology of colorectal cancer, use of cyclooxygenase inhibitors and polyp regression, and novel cytokine antagonists in inflammatoryboweldisease.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||recently-3/RB	root||ROOT-0/null||shown-4/VBN	mark||induces-13/VBZ||that-5/IN	det||meal-12/NN||a-6/DT	amod||meal-12/NN||high-fat-7/JJ	nn||meal-12/NN||high-carbohydrate-8/NN	dep||meal-12/NN||hfhc-10/JJ	nsubj||induces-13/VBZ||meal-12/NN	ccomp||shown-4/VBN||induces-13/VBZ	det||increase-15/NN||an-14/DT	dobj||induces-13/VBZ||increase-15/NN	nn||concentrations-18/NNS||plasma-17/NN	prep_in||increase-15/NN||concentrations-18/NNS	prep_of||concentrations-18/NNS||endotoxin-20/NN	amod||-RSB--25/NNP||lipopolysaccharide-22/JJ	nn||-RSB--25/NNP||-LSB--23/NNP	nn||-RSB--25/NNP||lps-24/NN	appos||endotoxin-20/NN||-RSB--25/NNP	det||expression-29/NN||the-28/DT	prep_in||increase-15/NN||expression-29/NN	conj_and||concentrations-18/NNS||expression-29/NN	amod||receptor-4-32/NN||toll-like-31/JJ	prep_of||expression-29/NN||receptor-4-32/NN	dep||receptor-4-32/NN||tlr-4-34/JJ	dobj||induces-13/VBZ||suppresser-37/NN	conj_and||increase-15/NN||suppresser-37/NN	amod||socs3-42/NNS||cytokine-39/JJ	amod||socs3-42/NNS||signaling-3-40/JJ	prep_of||suppresser-37/NN||socs3-42/NNS	nn||cells-46/NNS||mononuclear-45/NN	prep_in||socs3-42/NNS||cells-46/NNS	appos||cells-46/NNS||mncs-48/NNS	prep_in||cells-46/NNS||addition-51/NN	amod||stress-54/NN||oxidative-53/JJ	prep_to||induces-13/VBZ||stress-54/NN	amod||inflammation-57/NN||cellular-56/JJ	prep_to||induces-13/VBZ||inflammation-57/NN	conj_and||stress-54/NN||inflammation-57/NN	endotoxin-20||inflammation-57||no_rel||we have recently shown that a high-fat high-carbohydrate (hfhc) meal induces an increase in plasma concentrations of endotoxin (lipopolysaccharide [lps]) and the expression of toll-like receptor-4 (tlr-4) and suppresser of cytokine signaling-3 (socs3) in mononuclear cells (mncs) in addition to oxidative stress and cellular inflammation.
det||understanding-2/NN||an-1/DT	nsubj||evolving-24/VBG||understanding-2/NN	nsubj||become-55/VBN||understanding-2/NN	det||risks-5/NNS||the-4/DT	prep_of||understanding-2/NN||risks-5/NNS	prep_of||understanding-2/NN||benefits-7/NNS	conj_and||risks-5/NNS||benefits-7/NNS	amod||value-11/NN||relative-10/JJ	prep_of||understanding-2/NN||value-11/NN	conj_and||risks-5/NNS||value-11/NN	prep_of||value-11/NN||glatirameracetate-13/NN	appos||glatirameracetate-13/NN||ga-15/NN	prep_in||glatirameracetate-13/NN||multiplesclerosis-18/NNS	appos||multiplesclerosis-18/NNS||ms-20/NN	aux||evolving-24/VBG||has-22/VBZ	aux||evolving-24/VBG||been-23/VBN	root||ROOT-0/null||evolving-24/VBG	prepc_based_on||evolving-24/VBG||on-26/IN	advmod||completed-28/VBN||recently-27/RB	amod||studies-30/NNS||completed-28/VBN	amod||studies-30/NNS||head-to-head-29/JJ	pobj||evolving-24/VBG||studies-30/NNS	dep||studies-30/NNS||regard-31/VBP	parataxis||regard-31/VBP||rebif-33/VB	nn||glatirameracetate-35/NN||vs-34/NN	dobj||rebif-33/VB||glatirameracetate-35/NN	prepc_in||rebif-33/VB||relapsing-37/VBG	nn||disease-39/NN||ms-38/NN	dobj||relapsing-37/VBG||disease-39/NN	prep||evolving-24/VBG||beyond-42/IN	amod||outcomes-47/NNS||betaseron-44/JJ	advmod||yielding-46/JJ||efficacy-45/RB	amod||outcomes-47/NNS||yielding-46/JJ	dep||evolving-24/VBG||outcomes-47/NNS	det||dose-51/NN||a-49/DT	amod||dose-51/NN||new-50/JJ	prep_of||outcomes-47/NNS||dose-51/NN	conj_and||evolving-24/VBG||become-55/VBN	nn||copaxone-59/NN||betaseron-57/NN	nn||copaxone-59/NN||vs-58/NN	dep||become-55/VBN||copaxone-59/NN	prep_in||copaxone-59/NN||multiplesclerosis-61/NNS	amod||gadolinium-64/NN||triple-dose-63/JJ	prep_with||multiplesclerosis-61/NNS||gadolinium-64/NN	amod||endpoints-68/NNS||3-tesla-66/JJ	nn||endpoints-68/NNS||mri-67/NN	prep_with||multiplesclerosis-61/NNS||endpoints-68/NNS	conj_and||gadolinium-64/NN||endpoints-68/NNS	glatirameracetate-35||multiplesclerosis-61||no_rel||an understanding of the risks, benefits, and relative value of glatirameracetate (ga) in multiplesclerosis (ms) has been evolving based on recently completed head-to-head studies regard (rebif vs glatirameracetate in relapsing ms disease); beyond (betaseron efficacy yielding outcomes of a new dose); and become (betaseron vs copaxone in multiplesclerosis with triple-dose gadolinium and 3-tesla mri endpoints).
num||measurements-4/NNS||77-1/CD	amod||measurements-4/NNS||different-2/JJ	nn||measurements-4/NNS||alp-3/NN	nsubjpass||included-28/VBN||measurements-4/NNS	number||nutritional-7/JJ||38-6/CD	amod||rickets-8/NNS||nutritional-7/JJ	prep_from||measurements-4/NNS||rickets-8/NNS	appos||rickets-8/NNS||nr-10/NN	num||rickets-15/NNS||7-13/CD	amod||rickets-15/NNS||vitamind-dependent-14/JJ	prep_from||measurements-4/NNS||rickets-15/NNS	conj_and||rickets-8/NNS||rickets-15/NNS	appos||rickets-15/NNS||vddr-17/NN	num||patients-26/NNS||8-20/CD	amod||patients-26/NNS||hypophosphatemic-21/JJ	nn||patients-26/NNS||rickets-22/NN	appos||patients-26/NNS||hr-24/NN	prep_from||measurements-4/NNS||patients-26/NNS	conj_and||rickets-8/NNS||patients-26/NNS	auxpass||included-28/VBN||were-27/VBD	root||ROOT-0/null||included-28/VBN	rickets-22||vitamind--1||yes||77 different alp measurements from 38 nutritional rickets (nr), 7 vitamind-dependent rickets (vddr) and 8 hypophosphatemic rickets (hr) patients were included.
det||total-2/NN||a-1/DT	nsubjpass||assigned-27/VBN||total-2/NN	nsubjpass||assigned-27/VBN||total-2/NN	num||men-5/NNS||83-4/CD	prep_of||total-2/NN||men-5/NNS	prep_of||total-2/NN||women-7/NNS	conj_and||men-5/NNS||women-7/NNS	prep_with||men-5/NNS||type2diabetes-9/CD	dep||total-2/NN||aged-11/VBN	number||â-13/CD||56.1-12/CD	num||±-14/NNS||â-13/CD	dobj||aged-11/VBN||±-14/NNS	number||years-16/NNS||7.5-15/CD	amod||±-14/NNS||years-16/NNS	number||35.4-19/CD||bmi-18/CD	num||â-20/NN||35.4-19/CD	npadvmod||±-21/JJ||â-20/NN	dep||years-16/NNS||±-21/JJ	num||kg/m2-23/NNS||4.6-22/CD	dep||years-16/NNS||kg/m2-23/NNS	auxpass||assigned-27/VBN||were-25/VBD	advmod||assigned-27/VBN||randomly-26/RB	root||ROOT-0/null||assigned-27/VBN	conj_or||assigned-27/VBN||assigned-27/VBN	det||diet-33/NN||an-29/DT	amod||diet-33/NN||isocaloric-30/JJ	amod||diet-33/NN||energy-restricted-32/JJ	prep_to||assigned-27/VBN||diet-33/NN	amod||subjects-36/NNS||female-35/JJ	dep||diet-33/NN||subjects-36/NNS	num||subjects-41/NNS||6-37/CD	amod||subjects-41/NNS||mj/day-38/JJ	amod||subjects-41/NNS||male-40/JJ	dep||subjects-36/NNS||subjects-41/NNS	number||mj/day-43/JJ||7-42/CD	amod||subjects-41/NNS||mj/day-43/JJ	det||carbohydrate-48/NN||either-46/DT	amod||carbohydrate-48/NN||standard-47/JJ	prep_of||diet-33/NN||carbohydrate-48/NN	dep||carbohydrate-48/NN||con-50/NN	dep||con-50/NN||carbohydrateproteinfat-52/NN	num||carbohydrateproteinfat-52/NN||531926-53/CD	amod||protein-57/NN||high-56/JJ	prep_of||diet-33/NN||protein-57/NN	conj_or||carbohydrate-48/NN||protein-57/NN	dep||carbohydrate-48/NN||hp-59/NN	dep||hp-59/NN||433322-61/CD	amod||rt-68/NN||supervised-67/JJ	prep_with||assigned-27/VBN||rt-68/NN	prep_without||assigned-27/VBN||rt-68/NN	num||days/week-71/NN||3-70/CD	appos||rt-68/NN||days/week-71/NN	num||weeks-75/NNS||16-74/CD	prep_for||assigned-27/VBN||weeks-75/NNS	carbohydrate-48||type2diabetes-9||no_rel||a total of 83 men and women with type2diabetes (aged 56.1 â± 7.5 years, bmi 35.4 â± 4.6 kg/m2) were randomly assigned to an isocaloric, energy-restricted diet (female subjects 6 mj/day, male subjects 7 mj/day) of either standard carbohydrate (con; carbohydrateproteinfat 531926) or high protein (hp; 433322), with or without supervised rt (3 days/week) for 16 weeks.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
det||pigs-3/NNS||all-1/DT	nn||pigs-3/NNS||guinea-2/NN	nsubj||underwent-4/VBD||pigs-3/NNS	nsubj||test-7/VB||pigs-3/NNS	root||ROOT-0/null||underwent-4/VBD	advmod||underwent-4/VBD||autopsy-5/RB	aux||test-7/VB||to-6/TO	xcomp||underwent-4/VBD||test-7/VB	dep||test-7/VB||for-8/IN	nn||disease-10/NN||tb-9/NN	pobj||for-8/IN||disease-10/NN	dep||test-7/VB||defined-12/VBN	conj_or||for-8/IN||defined-12/VBN	amod||changes-16/NNS||characteristic-14/JJ	nn||changes-16/NNS||autopsy-15/NN	prep_by||defined-12/VBN||changes-16/NNS	dep||test-7/VB||by-18/IN	conj_or||for-8/IN||by-18/IN	det||culture-20/NN||the-19/DT	pobj||by-18/IN||culture-20/NN	prep_of||culture-20/NN||mycobacteriumtuberculosis-22/NNS	prep_from||mycobacteriumtuberculosis-22/NNS||organs-24/NNS	tb-9||mycobacteriumtuberculosis-22||no||all guinea pigs underwent autopsy to test for tb disease, defined by characteristic autopsy changes or by the culture of mycobacteriumtuberculosis from organs.
amod||hctz-3/NN||aml/val-1/JJ	amod||hctz-3/NN||+-2/JJ	nsubj||provided-4/VBD||hctz-3/NN	root||ROOT-0/null||provided-4/VBD	advmod||greater-6/JJR||significantly-5/RB	amod||reductions-8/NNS||greater-6/JJR	nn||reductions-8/NNS||bp-7/NN	dobj||provided-4/VBD||reductions-8/NNS	nn||hctz-12/NN||aml-10/NN	nn||hctz-12/NN||+-11/NN	prep_than||provided-4/VBD||hctz-12/NN	prep_in||hctz-12/NN||patients-14/NNS	nn||hypertension-18/NN||stage-16/NN	num||hypertension-18/NN||2-17/CD	prep_with||provided-4/VBD||hypertension-18/NN	hypertension-18||hctz-12||yes||aml/val+hctz provided significantly greater bp reductions than aml+hctz in patients with stage 2 hypertension.
root||ROOT-0/null||study-1/VB	det||effects-3/NNS||the-2/DT	dobj||study-1/VB||effects-3/NNS	iobj||study-1/VB||effects-3/NNS	prep_of||effects-3/NNS||exenatide-5/NN	appos||exenatide-5/NN||exe-7/NN	amod||effects-3/NNS||plus-9/IN	amod||rosi-12/NNS||rosiglitazone-10/JJ	dep||effects-3/NNS||rosi-12/NNS	nn||²-16/NNS||î-15/NN	prep_on||rosi-12/NNS||²-16/NNS	nn||function-19/NN||cell-18/NN	dep||rosi-12/NNS||function-19/NN	nn||sensitivity-22/NN||insulin-21/NN	dep||rosi-12/NNS||sensitivity-22/NN	conj_and||function-19/NN||sensitivity-22/NN	vmod||function-19/NN||using-23/VBG	amod||techniques-29/NNS||hyperglycemic-24/JJ	conj_and||hyperglycemic-24/JJ||euglycemic-26/JJ	amod||techniques-29/NNS||euglycemic-26/JJ	nn||techniques-29/NNS||insulin-27/NN	nn||techniques-29/NNS||clamp-28/NN	dobj||using-23/VBG||techniques-29/NNS	prep_in||techniques-29/NNS||participants-31/NNS	prep_with||participants-31/NNS||type2diabetes-33/NNS	prep_on||type2diabetes-33/NNS||metformin-35/NN	metformin-35||type2diabetes-33||no_rel||study the effects of exenatide (exe) plus rosiglitazone (rosi) on î²-cell function and insulin sensitivity using hyperglycemic and euglycemic insulin clamp techniques in participants with type2diabetes on metformin.
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	bcg-1||tuberculosis-22||no_rel||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
det||earliest-3/JJS||the-2/DT	prep_among||imposition-16/NN||earliest-3/JJS	det||responses-8/NNS||the-5/DT	amod||responses-8/NNS||most-6/JJS	amod||responses-8/NNS||enduring-7/VBG	conj_and||earliest-3/JJS||responses-8/NNS	prep_among||imposition-16/NN||responses-8/NNS	det||hiv/aids-11/NNS||the-10/DT	prep_to||responses-8/NNS||hiv/aids-11/NNS	nsubj||imposition-16/NN||epidemic-12/NN	aux||imposition-16/NN||has-13/VBZ	cop||imposition-16/NN||been-14/VBN	det||imposition-16/NN||the-15/DT	root||ROOT-0/null||imposition-16/NN	prep_by||imposition-16/NN||governments-18/NNS	nn||stay-22/NN||entry-20/NN	prep_of||governments-18/NNS||stay-22/NN	nn||restrictions-26/NNS||residence-25/NN	prep_of||governments-18/NNS||restrictions-26/NNS	conj_and||stay-22/NN||restrictions-26/NNS	prep_for||imposition-16/NN||non-nationals-28/NNS	vmod||non-nationals-28/NNS||living-29/VBG	prep_with||living-29/VBG||hiv-31/NN	prep_with||living-29/VBG||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||among the earliest and the most enduring responses to the hiv/aids epidemic has been the imposition by governments of entry, stay, and residence restrictions for non-nationals living with hiv and aids.
mark||have-3/VBP||as-1/IN	nsubj||have-3/VBP||children-2/NNS	nsubj||are-11/VBP||children-2/NNS	advcl||was-24/VBD||have-3/VBP	det||incidence-6/NN||the-4/DT	amod||incidence-6/NN||highest-5/JJS	dobj||have-3/VBP||incidence-6/NN	nn||infection-9/NN||influenza-8/NN	prep_of||incidence-6/NN||infection-9/NN	conj_and||have-3/VBP||are-11/VBP	advcl||was-24/VBD||are-11/VBP	amod||risk-14/NN||high-13/JJ	prep_at||are-11/VBP||risk-14/NN	amod||disease-17/NN||severe-16/JJ	prep_of||risk-14/NN||disease-17/NN	det||aim-20/NN||the-19/DT	nsubj||was-24/VBD||aim-20/NN	nsubj||evaluate-26/VB||aim-20/NN	det||study-23/NN||this-22/DT	prep_of||aim-20/NN||study-23/NN	root||ROOT-0/null||was-24/VBD	aux||evaluate-26/VB||to-25/TO	xcomp||was-24/VBD||evaluate-26/VB	det||importance-29/NN||the-27/DT	amod||importance-29/NN||clinical-28/JJ	dobj||evaluate-26/VB||importance-29/NN	det||impact-32/NN||the-31/DT	dobj||evaluate-26/VB||impact-32/NN	conj_and||importance-29/NN||impact-32/NN	det||households-35/NNS||the-34/DT	prep_on||evaluate-26/VB||households-35/NNS	amod||influenzavirus-40/NNS||oseltamivir-resistant-37/JJ	amod||influenzavirus-40/NNS||seasonal-38/JJ	amod||influenzavirus-40/NNS||a/h1n1-39/JJ	prep_of||households-35/NNS||influenzavirus-40/NNS	det||population-46/NN||an-42/DT	advmod||healthy-44/JJ||otherwise-43/RB	amod||population-46/NN||healthy-44/JJ	amod||population-46/NN||pediatric-45/JJ	prep_in||influenzavirus-40/NNS||population-46/NN	influenza-8||influenzavirus-40||no||as children have the highest incidence of influenza infection and are at high risk of severe disease, the aim of this study was to evaluate the clinical importance and the impact on the households of oseltamivir-resistant seasonal a/h1n1 influenzavirus in an otherwise healthy pediatric population.
nsubjpass||revealed-4/VBN||it-1/PRP	auxpass||revealed-4/VBN||was-2/VBD	advmod||revealed-4/VBN||also-3/RB	root||ROOT-0/null||revealed-4/VBN	mark||decreases-10/VBZ||that-5/IN	amod||sufficiently-9/NNS||regular-6/JJ	amod||sufficiently-9/NNS||colchicine-7/JJ	nn||sufficiently-9/NNS||treatment-8/NN	nsubj||decreases-10/VBZ||sufficiently-9/NNS	ccomp||revealed-4/VBN||decreases-10/VBZ	det||rate-12/NN||the-11/DT	dobj||decreases-10/VBZ||rate-12/NN	prep_of||rate-12/NN||apoptosis-14/NNS	nn||patients-17/NNS||familialmediterraneanfever-16/NN	prep_in||apoptosis-14/NNS||patients-17/NNS	prepc_by||decreases-10/VBZ||affecting-19/VBG	det||intensity-21/NN||the-20/DT	dobj||affecting-19/VBG||intensity-21/NN	amod||reactions-24/NNS||autoinflammatory-23/JJ	prep_of||intensity-21/NN||reactions-24/NNS	familialmediterraneanfever-16||colchicine-7||yes||it was also revealed that regular colchicine treatment sufficiently decreases the rate of apoptosis in familialmediterraneanfever patients by affecting the intensity of autoinflammatory reactions.
mark||associated-10/VBN||although-1/IN	amod||factors-3/NNS||proinflammatory-2/JJ	nsubjpass||associated-10/VBN||factors-3/NNS	prep_including||factors-3/NNS||nitricoxide-5/NN	discourse||nitricoxide-5/NN||no-7/UH	auxpass||associated-10/VBN||are-9/VBP	advcl||is-15/VBZ||associated-10/VBN	prep_with||associated-10/VBN||oa-12/NN	expl||is-15/VBZ||there-14/EX	root||ROOT-0/null||is-15/VBZ	amod||evidence-17/NN||recent-16/JJ	nsubj||is-15/VBZ||evidence-17/NN	vmod||evidence-17/NN||suggesting-18/VBG	advmod||suggesting-18/VBG||that-19/IN	dep||that-19/IN||no-20/DT	poss||derivatives-24/NNS||its-22/PRP$	nn||derivatives-24/NNS||redox-23/NN	nsubj||play-27/VB||derivatives-24/NNS	aux||play-27/VB||may-25/MD	advmod||play-27/VB||also-26/RB	conj_and||is-15/VBZ||play-27/VB	amod||roles-29/NNS||protective-28/JJ	dobj||play-27/VB||roles-29/NNS	det||joint-32/NN||the-31/DT	prep_in||play-27/VB||joint-32/NN	oa-12||nitricoxide-5||no_rel||although proinflammatory factors including nitricoxide (no) are associated with oa, there is recent evidence suggesting that no and its redox derivatives may also play protective roles in the joint.
prep_for||show-5/VBP||instance-2/NN	nsubj||show-5/VBP||we-4/PRP	root||ROOT-0/null||show-5/VBP	mark||surges-35/VBZ||that-6/IN	advmod||restored-10/VBN||when-7/WRB	nsubjpass||restored-10/VBN||normoglycemia-8/NN	auxpass||restored-10/VBN||is-9/VBZ	advcl||surges-35/VBZ||restored-10/VBN	amod||insulin-13/NN||exogenous-12/JJ	agent||restored-10/VBN||insulin-13/NN	nn||transplantation-16/NN||islet-15/NN	agent||restored-10/VBN||transplantation-16/NN	conj_or||insulin-13/NN||transplantation-16/NN	det||²-20/NN||the-18/DT	nn||²-20/NN||î-19/NN	nsubj||surges-35/VBZ||²-20/NN	nn||returns-25/NNS||cell-22/NN	nn||returns-25/NNS||proliferation-23/NN	nn||returns-25/NNS||rate-24/NN	dep||²-20/NN||returns-25/NNS	amod||levels-28/NNS||low-27/JJ	prep_towards||returns-25/NNS||levels-28/NNS	vmod||returns-25/NNS||found-29/VBN	nn||animals-32/NNS||control-31/NN	prep_in||found-29/VBN||animals-32/NNS	dep||returns-25/NNS||yet-34/RB	ccomp||show-5/VBP||surges-35/VBZ	advmod||recurs-38/VBZ||when-36/WRB	nsubj||recurs-38/VBZ||hyperglycemia-37/NN	advcl||surges-35/VBZ||recurs-38/VBZ	hyperglycemia-37||insulin-13||yes||for instance, we show that when normoglycemia is restored by exogenous insulin or islet transplantation, the î²-cell proliferation rate returns towards low levels found in control animals, yet surges when hyperglycemia recurs.
amod||hyperglycemia-2/NN||intermittent-1/JJ	nsubj||induced-3/VBZ||hyperglycemia-2/NN	nsubj||decreased-10/VBD||hyperglycemia-2/NN	root||ROOT-0/null||induced-3/VBZ	det||degree-6/NN||a-4/DT	amod||degree-6/NN||higher-5/JJR	dobj||induced-3/VBZ||degree-6/NN	prep_of||degree-6/NN||apoptosis-8/NNS	conj_and||induced-3/VBZ||decreased-10/VBD	det||insulin-12/NN||the-11/DT	dobj||decreased-10/VBD||insulin-12/NN	amod||capacity-14/NN||secretory-13/JJ	npadvmod||more-15/RBR||capacity-14/NN	advmod||decreased-10/VBD||more-15/RBR	amod||cells-19/NNS||pancreatic-17/JJ	nn||cells-19/NNS||beta-18/NN	prep_in||decreased-10/VBD||cells-19/NNS	amod||hyperglycemia-22/NN||chronic-21/JJ	prep_than||decreased-10/VBD||hyperglycemia-22/NN	hyperglycemia-22||insulin-12||yes||intermittent hyperglycemia induced a higher degree of apoptosis and decreased the insulin secretory capacity more in pancreatic beta cells than chronic hyperglycemia.
prep_after||observed-17/VBD||adjustment-2/NN	nn||sex-6/NN||age-4/NN	prep_for||adjustment-2/NN||sex-6/NN	nn||circumference-10/NN||waist-9/NN	prep_for||adjustment-2/NN||circumference-10/NN	conj_and||sex-6/NN||circumference-10/NN	det||ors-14/NN||the-12/DT	amod||ors-14/NN||standardized-13/JJ	nsubj||observed-17/VBD||ors-14/NN	prep_for||ors-14/NN||incident-16/NN	root||ROOT-0/null||observed-17/VBD	nsubj||identical-20/JJ||apnea-18/NN	cop||identical-20/JJ||were-19/VBD	ccomp||observed-17/VBD||identical-20/JJ	prepc_for||identical-20/JJ||fasting-22/VBG	dobj||fasting-22/VBG||insulin-23/NN	det||assessment-28/NN||the-25/DT	amod||assessment-28/NN||homeostasis-26/JJ	nn||assessment-28/NN||model-27/NN	dobj||fasting-22/VBG||assessment-28/NN	conj_and||insulin-23/NN||assessment-28/NN	prep_of||assessment-28/NN||insulinresistance-30/NN	num||insulinresistance-30/NN||1.31-31/CD	npadvmod||â-34/RB||1.13-33/CD	dep||$-35/$||â-34/RB	dep||insulinresistance-30/NN||$-35/$	num||$-35/$||1.51-37/CD	prep_of||assessment-28/NN||1.24-40/CD	conj_and||insulinresistance-30/NN||1.24-40/CD	npadvmod||â-43/RB||1.09-42/CD	dep||$-44/$||â-43/RB	dep||insulinresistance-30/NN||$-44/$	num||$-44/$||1.41-46/CD	prep_for||fasting-22/VBG||triglycerides-49/CD	prep_for||fasting-22/VBG||1.52-51/CD	conj_and||triglycerides-49/CD||1.52-51/CD	dep||triglycerides-49/CD||1.12-53/CD	dep||triglycerides-49/CD||$-55/$	conj_â||1.12-53/CD||$-55/$	num||$-55/$||2.05-57/CD	prep_for||fasting-22/VBG||smoking-60/NN	triglycerides-49||insulinresistance-30||no_rel||after adjustment for age, sex, and waist circumference, the standardized ors for incident observed apnea were identical for fasting insulin and the homeostasis model assessment of insulinresistance 1.31 (1.13â€“1.51) and 1.24 (1.09â€“1.41) for triglycerides and 1.52 (1.12â€“2.05) for smoking.
prep_in||causes-5/VBZ||humans-2/NNS	nsubj||causes-5/VBZ||c.neoformans-4/NNS	root||ROOT-0/null||causes-5/VBZ	num||types-7/NNS||three-6/CD	dobj||causes-5/VBZ||types-7/NNS	amod||cryptococcalmeningitis-12/NNS||infections-9/JJ	nn||cryptococcalmeningitis-12/NNS||pulmonarycryptococcosis-10/NNS	prep_of||types-7/NNS||cryptococcalmeningitis-12/NNS	prep_of||types-7/NNS||wound-14/NN	conj_and||cryptococcalmeningitis-12/NNS||wound-14/NN	nn||cryptococcosis-17/NNS||cutaneous-16/NN	prep_of||types-7/NNS||cryptococcosis-17/NNS	conj_or||cryptococcalmeningitis-12/NNS||cryptococcosis-17/NNS	cryptococcalmeningitis-12||c.neoformans-4||no||in humans , c.neoformans causes three types of infections pulmonarycryptococcosis , cryptococcalmeningitis and wound or cutaneous cryptococcosis .
det||results-2/NNS||the-1/DT	nsubj||show-6/VBP||results-2/NNS	det||study-5/NN||this-4/DT	prep_of||results-2/NNS||study-5/NN	root||ROOT-0/null||show-6/VBP	mark||added-9/VBD||that-7/IN	nsubj||added-9/VBD||remifentanil-8/NN	nsubj||propofol-11/VB||remifentanil-8/NN	ccomp||show-6/VBP||added-9/VBD	aux||propofol-11/VB||to-10/TO	xcomp||added-9/VBD||propofol-11/VB	nn||sensitization-15/NN||anesthesia-12/NN	nn||sensitization-15/NN||causes-13/NNS	nn||sensitization-15/NN||pain-14/NN	dobj||propofol-11/VB||sensitization-15/NN	det||period-20/NN||the-17/DT	amod||period-20/NN||immediate-18/JJ	nn||period-20/NN||postoperative-19/NN	prep_in||sensitization-15/NN||period-20/NN	pain-14||remifentanil-8||yes||the results of this study show that remifentanil added to propofol anesthesia causes pain sensitization in the immediate postoperative period.
nsubjpass||diagnosed-3/VBN||he-1/PRP	nsubjpass||treated-11/VBN||he-1/PRP	auxpass||diagnosed-3/VBN||was-2/VBD	root||ROOT-0/null||diagnosed-3/VBN	amod||sinusitis-6/NNS||odontogenic-5/JJ	prep_with||diagnosed-3/VBN||sinusitis-6/NNS	prep_with||diagnosed-3/VBN||orbitalcellulitis-8/NNS	conj_and||sinusitis-6/NNS||orbitalcellulitis-8/NNS	conj_and||diagnosed-3/VBN||treated-11/VBN	prep_with||treated-11/VBN||antibiotics-13/NNS	antibiotics-13||orbitalcellulitis-8||no_rel||he was diagnosed with odontogenic sinusitis and orbitalcellulitis, and treated with antibiotics.
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	poliomyelitis-9||polioviruses-31||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
amod||studies-2/NNS||more-1/JJR	nsubjpass||suggested-4/VBN||studies-2/NNS	auxpass||suggested-4/VBN||are-3/VBP	root||ROOT-0/null||suggested-4/VBN	aux||evaluate-6/VB||to-5/TO	ccomp||suggested-4/VBN||evaluate-6/VB	det||efficacy-8/NN||the-7/DT	dobj||evaluate-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||clozapine-10/NN	conj_and||in-11/IN||in-11/IN	prep_in||evaluate-6/VB||patients-12/NNS	prep_with||patients-12/NNS||bpd-14/NN	preconj||in-11/IN||both-16/DT	amod||features-21/NNS||psychotic-20/JJ	prep_with||in-11/IN||features-21/NNS	prep_without||in-11/IN||features-21/NNS	aux||find-24/VB||to-23/TO	ccomp||suggested-4/VBN||find-24/VB	conj_and||evaluate-6/VB||find-24/VB	prt||find-24/VB||out-25/RP	det||dose-28/NN||the-26/DT	amod||dose-28/NN||optimum-27/JJ	dobj||find-24/VB||dose-28/NN	aux||weigh-31/VB||to-30/TO	ccomp||suggested-4/VBN||weigh-31/VB	conj_and||evaluate-6/VB||weigh-31/VB	det||risk-33/NN||the-32/DT	dobj||weigh-31/VB||risk-33/NN	dobj||weigh-31/VB||benefits-35/NNS	conj_and||risk-33/NN||benefits-35/NNS	prep_of||risk-33/NN||clozapine-37/NN	psychotic-20||clozapine-37||yes||more studies are suggested to evaluate the efficacy of clozapine in patients with bpd, both with and without psychotic features, to find out the optimum dose and to weigh the risk and benefits of clozapine.
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||‰-10/NNS||â-9/NN	dobj||aged-8/VBN||‰-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||‰-24/NNS||â-23/NN	prep_of||thickness-21/NN||‰-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||‰-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	obesity-50||albumin-32||no_rel||asymptomatic patients ( n = 485) aged â‰¥50 years with either a maximal carotid artery intima-media thickness of â‰¥1.1 mm, or a urinary albumin â‰¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
det||paper-3/NN||this-2/DT	prep_in||compile-6/VB||paper-3/NN	nsubj||compile-6/VB||we-5/PRP	root||ROOT-0/null||compile-6/VB	det||data-10/NNS||the-7/DT	advmod||data-10/NNS||most-8/RBS	amod||data-10/NNS||significant-9/JJ	nsubj||available-11/JJ||data-10/NNS	xcomp||compile-6/VB||available-11/JJ	amod||properties-16/NNS||biochemical-13/JJ	conj_and||biochemical-13/JJ||biological-15/JJ	amod||properties-16/NNS||biological-15/JJ	prep_about||available-11/JJ||properties-16/NNS	nn||transporters-19/NNS||sugar-18/NN	prep_of||properties-16/NNS||transporters-19/NNS	amod||tissues-22/NNS||normal-21/JJ	prep_in||transporters-19/NNS||tissues-22/NNS	nsubj||review-25/VBP||we-24/PRP	conj_and||compile-6/VB||review-25/VBP	det||information-28/NN||the-26/DT	amod||information-28/NN||available-27/JJ	dobj||review-25/VBP||information-28/NN	nn||expression-32/NN||sugar-30/NN	nn||expression-32/NN||carrier-31/NN	prep_about||review-25/VBP||expression-32/NN	amod||types-35/NNS||different-34/JJ	prep_in||expression-32/NN||types-35/NNS	prep_of||types-35/NNS||cancer-37/NN	sugar-30||cancer-37||no_rel||in this paper, we compile the most significant data available about biochemical and biological properties of sugar transporters in normal tissues and we review the available information about sugar carrier expression in different types of cancer.
aux||describe-2/VB||to-1/TO	csubj||implemented-12/VBD||describe-2/VB	det||program-11/NN||an-3/DT	amod||program-11/NN||innovative-4/JJ	amod||program-11/NN||2-year-5/JJ	amod||program-11/NN||long-term-7/JJ	nn||program-11/NN||apprenticeship-8/NN	nn||program-11/NN||fellowship-9/NN	nn||program-11/NN||training-10/NN	dobj||describe-2/VB||program-11/NN	root||ROOT-0/null||implemented-12/VBD	amod||school-16/NN||makerere-14/JJ	nn||school-16/NN||university-15/NN	prep_by||implemented-12/VBD||school-16/NN	amod||health-19/NN||public-18/JJ	prep_of||school-16/NN||health-19/NN	appos||health-19/NN||maksph-21/NN	aux||strengthen-24/VB||to-23/TO	xcomp||implemented-12/VBD||strengthen-24/VB	dobj||strengthen-24/VB||capacity-25/NN	prep_for||strengthen-24/VB||leadership-27/NN	prep_for||strengthen-24/VB||management-29/NN	conj_and||leadership-27/NN||management-29/NN	amod||programs-32/NNS||hiv/aids-31/JJ	prep_of||leadership-27/NN||programs-32/NNS	prep_in||programs-32/NNS||uganda-34/NN	aids--1||hiv--1||no||to describe an innovative 2-year, long-term apprenticeship fellowship training program implemented by makerere university school of public health (maksph) to strengthen capacity for leadership and management of hiv/aids programs in uganda.
mark||affects-6/VBZ||although-1/IN	nsubj||affects-6/VBZ||chronichepatitisb-2/NN	appos||chronichepatitisb-2/NN||chb-4/NN	advcl||is-15/VBZ||affects-6/VBZ	quantmod||million-9/CD||approximately-7/RB	number||million-9/CD||2-8/CD	dobj||affects-6/VBZ||million-9/CD	vmod||million-9/CD||united-10/VBN	nn||residents-12/NNS||states-11/NNS	dobj||united-10/VBN||residents-12/NNS	expl||is-15/VBZ||there-14/EX	root||ROOT-0/null||is-15/VBZ	neg||screening-18/NN||no-16/DT	amod||screening-18/NN||systematic-17/JJ	nsubj||is-15/VBZ||screening-18/NN	amod||individuals-21/NNS||at-risk-20/JJ	prep_of||screening-18/NN||individuals-21/NNS	nsubj||remain-25/VBP||most-24/JJS	conj_and||is-15/VBZ||remain-25/VBP	acomp||remain-25/VBP||unaware-26/JJ	poss||infection-33/NN||their-28/PRP$	amod||infection-33/NN||hepatitisbvirus-29/JJ	appos||infection-33/NN||hbv-31/NN	prep_of||remain-25/VBP||infection-33/NN	hbv-31||hepatitisbvirus-29||no||although chronichepatitisb (chb) affects approximately 2 million united states residents, there is no systematic screening of at-risk individuals, and most remain unaware of their hepatitisbvirus (hbv) infection.
det||woman-3/NN||a-1/DT	amod||woman-3/NN||43-year-old-2/JJ	nsubj||found-8/VBD||woman-3/NN	amod||pain-7/NN||chronic-5/JJ	amod||pain-7/NN||back-6/JJ	prep_with||woman-3/NN||pain-7/NN	root||ROOT-0/null||found-8/VBD	dobj||found-8/VBD||relief-9/NN	prepc_by||found-8/VBD||taking-11/VBG	dobj||taking-11/VBG||carisoprodol-12/NN	det||relaxant-19/NN||a-14/DT	advmod||acting-16/JJ||centrally-15/RB	amod||relaxant-19/NN||acting-16/JJ	amod||relaxant-19/NN||skeletal-17/JJ	nn||relaxant-19/NN||muscle-18/NN	appos||carisoprodol-12/NN||relaxant-19/NN	pain-7||carisoprodol-12||yes||a 43-year-old woman with chronic back pain found relief by taking carisoprodol, a centrally acting skeletal muscle relaxant.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||uncertain-3/JJ	mark||increases-8/VBZ||whether-4/IN	nsubj||increases-8/VBZ||use-5/NN	nsubj||decreases-21/VBZ||use-5/NN	prep_of||use-5/NN||insulin-7/NN	ccomp||remains-2/VBZ||increases-8/VBZ	nn||risk-10/NN||cancer-9/NN	dobj||increases-8/VBZ||risk-10/NN	poss||effect-14/NN||its-13/PRP$	prep_because_of||risk-10/NN||effect-14/NN	nn||growth-17/NN||cell-16/NN	prep_on||increases-8/VBZ||growth-17/NN	prep_on||increases-8/VBZ||proliferation-19/NN	conj_and||growth-17/NN||proliferation-19/NN	ccomp||remains-2/VBZ||decreases-21/VBZ	conj_or||increases-8/VBZ||decreases-21/VBZ	nn||risk-23/NN||cancer-22/NN	dobj||decreases-21/VBZ||risk-23/NN	poss||effect-28/NN||its-26/PRP$	amod||effect-28/NN||glucose-lowering-27/JJ	prep_because_of||risk-23/NN||effect-28/NN	cancer-22||insulin-7||no_rel||it remains uncertain whether use of insulin increases cancer risk because of its effect on cell growth and proliferation or decreases cancer risk because of its glucose-lowering effect.
det||subsystems-3/NNS||these-1/DT	num||subsystems-3/NNS||eight-2/CD	nsubj||cover-4/VBP||subsystems-3/NNS	root||ROOT-0/null||cover-4/VBP	nsubj||hiv/aids-8/VBZ||i-6/FW	ccomp||cover-4/VBP||hiv/aids-8/VBZ	nn||reporting-10/NN||case-9/NN	dobj||hiv/aids-8/VBZ||reporting-10/NN	appos||testing-16/NN||ii-13/NN	amod||testing-16/NN||hiv-15/JJ	dep||reporting-10/NN||testing-16/NN	dep||reporting-10/NN||counselling-18/NN	conj_and||testing-16/NN||counselling-18/NN	appos||treatment-24/NN||iii-21/NN	amod||treatment-24/NN||antiretroviral-23/JJ	dep||reporting-10/NN||treatment-24/NN	conj_and||testing-16/NN||treatment-24/NN	appos||treatment-24/NN||art-26/NN	prep_for||treatment-24/NN||adults-29/NNS	amod||art-34/NN||iv-32/JJ	dep||reporting-10/NN||art-34/NN	conj_and||testing-16/NN||art-34/NN	prep_for||art-34/NN||children-36/NNS	appos||interventions-42/NN||v-39/NN	amod||interventions-42/NN||behavioural-41/JJ	dep||reporting-10/NN||interventions-42/NN	conj_and||testing-16/NN||interventions-42/NN	amod||groups-45/NNS||high-risk-44/JJ	prep_for||interventions-42/NN||groups-45/NNS	appos||maintenance-51/NN||vi-48/NN	amod||maintenance-51/NN||methadone-50/JJ	dep||reporting-10/NN||maintenance-51/NN	conj_and||testing-16/NN||maintenance-51/NN	dep||maintenance-51/NN||treatment-52/NN	dep||reporting-10/NN||vii-55/NN	conj_and||testing-16/NN||vii-55/NN	amod||surveillance-60/NN||sentinel-57/JJ	conj_and||sentinel-57/JJ||behavioural-59/JJ	amod||surveillance-60/NN||behavioural-59/JJ	dep||vii-55/NN||surveillance-60/NN	appos||county-67/NN||viii-64/NNP	amod||county-67/NN||local-66/JJ	dep||reporting-10/NN||county-67/NN	conj_and||testing-16/NN||county-67/NN	nn||information-69/NN||background-68/NN	dep||county-67/NN||information-69/NN	aids--1||hiv-15||no||these eight subsystems cover (i) hiv/aids case reporting; (ii) hiv testing and counselling; (iii) antiretroviral treatment (art) for adults; (iv) art for children; (v) behavioural interventions for high-risk groups; (vi) methadone maintenance treatment; (vii) sentinel and behavioural surveillance; and (viii) local county background information.
advmod||recognized-16/VBN||currently-1/RB	amod||5-fluorouracil-3/NN||definitive-2/JJ	nsubjpass||recognized-16/VBN||5-fluorouracil-3/NN	dep||5-fluorouracil-3/NN||5-fu-5/JJ	punct||cisplatin-8/NN||/-7/:	dep||5-fluorouracil-3/NN||cisplatin-8/NN	appos||cisplatin-8/NN||cddp-10/NN	vmod||5-fluorouracil-3/NN||based-13/VBN	advmod||recognized-16/VBN||chemotherapy-14/RB	auxpass||recognized-16/VBN||is-15/VBZ	root||ROOT-0/null||recognized-16/VBN	prep_as||recognized-16/VBN||one-18/CD	det||treatments-23/NNS||the-20/DT	advmod||treatments-23/NNS||most-21/RBS	amod||treatments-23/NNS||promising-22/JJ	prep_of||one-18/CD||treatments-23/NNS	prep_for||treatments-23/NNS||esophagealcancer-25/NN	esophagealcancer-25||cddp-10||yes||currently definitive 5-fluorouracil (5-fu)/cisplatin (cddp) -based chemotherapy is recognized as one of the most promising treatments for esophagealcancer.
det||rates-3/NNS||the-1/DT	nn||rates-3/NNS||incidence-2/NN	nsubj||30.8-12/CD||rates-3/NNS	amod||thromboembolism-6/NN||venous-5/JJ	prep_for||rates-3/NNS||thromboembolism-6/NN	det||population-10/NN||the-8/DT	nn||population-10/NN||study-9/NN	prep_in||thromboembolism-6/NN||population-10/NN	cop||30.8-12/CD||were-11/VBD	root||ROOT-0/null||30.8-12/CD	num||%-15/NN||95-14/CD	dep||30.8-12/CD||%-15/NN	nn||interval-17/NN||confidence-16/NN	dep||%-15/NN||interval-17/NN	number||36.8-20/CD||25.6-18/CD	dep||36.8-20/CD||to-19/TO	dep||interval-17/NN||36.8-20/CD	prep_per||30.8-12/CD||100â-23/CD	num||years-28/NNS||$-24/$	number||000-26/CD||‰-25/CD	num||$-24/$||000-26/CD	nn||years-28/NNS||woman-27/NN	npadvmod||30.8-12/CD||years-28/NNS	prep_among||30.8-12/CD||users-30/NNS	prep_of||users-30/NNS||oralcontraceptives-32/NNS	vmod||oralcontraceptives-32/NNS||containing-33/VBG	dobj||containing-33/VBG||drospirenone-34/NN	dobj||containing-33/VBG||12.5-36/CD	conj_and||drospirenone-34/NN||12.5-36/CD	number||15.9-40/CD||9.61-38/CD	dep||15.9-40/CD||to-39/TO	dep||12.5-36/CD||15.9-40/CD	prep_per||12.5-36/CD||100â-43/CD	num||years-48/NNS||$-44/$	number||000-46/CD||‰-45/CD	num||$-44/$||000-46/CD	nn||years-48/NNS||woman-47/NN	npadvmod||containing-33/VBG||years-48/NNS	prep_among||containing-33/VBG||users-50/NNS	prep_of||users-50/NNS||oralcontraceptives-52/NNS	vmod||oralcontraceptives-52/NNS||containing-53/VBG	acomp||containing-53/VBG||levonorgestrel-54/JJ	thromboembolism-6||drospirenone-34||no||the incidence rates for venous thromboembolism in the study population were 30.8 (95% confidence interval 25.6 to 36.8) per 100â€‰000 woman years among users of oralcontraceptives containing drospirenone and 12.5 (9.61 to 15.9) per 100â€‰000 woman years among users of oralcontraceptives containing levonorgestrel.
det||children-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||children-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	prep_for||treated-4/VBN||malaria-6/NN	nn||artemether-9/NN||intramuscular-8/NN	prep_with||treated-4/VBN||artemether-9/NN	malaria-6||artemether-9||yes||all children were treated for malaria with intramuscular artemether.
nsubj||agent-8/NN||5-fluorouracil-1/NN	dep||5-fluorouracil-1/NN||5-fu-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||chemotherapeutic-7/JJ	root||ROOT-0/null||agent-8/NN	amod||choice-11/NN||first-10/JJ	prep_of||agent-8/NN||choice-11/NN	amod||cancer-14/NN||colorectal-13/JJ	prep_in||choice-11/NN||cancer-14/NN	amod||cases-19/NNS||most-18/JJS	prep_in||develops-24/VBZ||cases-19/NNS	nsubj||develops-24/VBZ||resistance-21/NN	prep_to||resistance-21/NN||5-fu-23/CD	conj_but||agent-8/NN||develops-24/VBZ	amod||mechanisms-27/NNS||various-26/JJ	prep_through||develops-24/VBZ||mechanisms-27/NNS	cancer-14||5-fluorouracil-1||no_rel||5-fluorouracil (5-fu) is the chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-fu develops through various mechanisms.
det||authorities-2/NNS||some-1/DT	nsubj||suggest-3/VBP||authorities-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||association-9/NN||that-4/IN	expl||association-9/NN||there-5/EX	aux||association-9/NN||may-6/MD	cop||association-9/NN||be-7/VB	det||association-9/NN||an-8/DT	ccomp||suggest-3/VBP||association-9/NN	prep_between||association-9/NN||eczema-11/NN	prep_between||association-9/NN||asthma-13/NN	conj_and||eczema-11/NN||asthma-13/NN	ccomp||suggest-3/VBP||antibiotics-15/NNS	conj_and||association-9/NN||antibiotics-15/NNS	vmod||antibiotics-15/NNS||prescribed-16/VBN	prep_in||prescribed-16/VBN||childhood-18/NN	advmod||disagree-23/VBP||however-20/RB	nsubj||disagree-23/VBP||others-22/NNS	parataxis||suggest-3/VBP||disagree-23/VBP	asthma-13||antibiotics-15||no_rel||some authorities suggest that there may be an association between eczema and asthma and antibiotics prescribed in childhood; however, others disagree.
num||studies-3/NNS||two-1/CD	amod||studies-3/NNS||pivotal-2/JJ	nsubj||demonstrated-5/VBN||studies-3/NNS	aux||demonstrated-5/VBN||have-4/VBP	root||ROOT-0/null||demonstrated-5/VBN	det||efficacy-7/NN||the-6/DT	dobj||demonstrated-5/VBN||efficacy-7/NN	prep_of||efficacy-7/NN||fondaparinux-9/NN	det||myocardialinfarction-31/NN||an-11/DT	amod||myocardialinfarction-31/NN||anticoagulant-12/JJ	det||setting-15/NN||the-14/DT	prep_in||anticoagulant-12/JJ||setting-15/NN	prep_of||setting-15/NN||acs-17/NN	advmod||oasis-5-20/JJ||namely-19/RB	conj_and||anticoagulant-12/JJ||oasis-5-20/JJ	amod||myocardialinfarction-31/NN||oasis-5-20/JJ	amod||acs-24/NN||non-st-22/JJ	nn||acs-24/NN||elevation-23/NN	prep_in||oasis-5-20/JJ||acs-24/NN	conj_and||anticoagulant-12/JJ||oasis-6-27/JJ	amod||myocardialinfarction-31/NN||oasis-6-27/JJ	nn||elevation-30/NN||st-29/NN	prep_in||oasis-6-27/JJ||elevation-30/NN	prep_as||demonstrated-5/VBN||myocardialinfarction-31/NN	appos||myocardialinfarction-31/NN||mi-33/NN	myocardialinfarction-31||fondaparinux-9||no_rel||two pivotal studies have demonstrated the efficacy of fondaparinux as an anticoagulant in the setting of acs, namely oasis-5 in non-st elevation acs, and oasis-6 in st elevation myocardialinfarction (mi).
amod||array-2/NN||bac-based-1/JJ	nsubj||identified-3/VBD||array-2/NN	nsubj||tumors-18/VB||array-2/NN	root||ROOT-0/null||identified-3/VBD	num||regions-6/NNS||27-4/CD	amod||regions-6/NNS||chromosomal-5/JJ	dobj||identified-3/VBD||regions-6/NNS	advmod||different-9/JJ||significantly-8/RB	amod||changes-12/NNS||different-9/JJ	nn||changes-12/NNS||copy-10/NN	nn||changes-12/NNS||number-11/NN	prep_with||identified-3/VBD||changes-12/NNS	det||aa-15/NN||the-14/DT	prep_between||changes-12/NNS||aa-15/NN	aux||tumors-18/VB||ca-17/MD	conj_and||identified-3/VBD||tumors-18/VB	det||cohort-22/NN||the-20/DT	amod||cohort-22/NN||first-21/JJ	prep_in||tumors-18/VB||cohort-22/NN	poss||test-27/NN||fisher-24/NN	amod||test-27/NN||exact-26/JJ	dep||cohort-22/NN||test-27/NN	nn||0.05-31/NNP||p-29/NNP	nn||0.05-31/NNP||<-30/NNP	appos||test-27/NN||0.05-31/NNP	ca-17||tumors-18||no_rel||bac-based array identified 27 chromosomal regions with significantly different copy number changes between the aa and ca tumors in the first cohort (fisher's exact test, p < 0.05).
det||study-3/NN||this-2/DT	prep_in||combined-6/VBD||study-3/NN	nsubj||combined-6/VBD||we-5/PRP	root||ROOT-0/null||combined-6/VBD	acomp||combined-6/VBD||gm-csf-7/JJ	nn||±-10/NNP||ifn-î-9/NNP	prep_with||gm-csf-7/JJ||±-10/NNP	mark||improve-14/VB||in-11/IN	dep||improve-14/VB||order-12/NN	aux||improve-14/VB||to-13/TO	advcl||combined-6/VBD||improve-14/VB	nn||tolerance-16/NN||ifn-15/NN	dobj||improve-14/VB||tolerance-16/NN	amod||patients-20/NNS||post-asct-18/JJ	nn||patients-20/NNS||myeloma-19/NN	prep_in||improve-14/VB||patients-20/NNS	myeloma-19||ifn-15||yes||in this study, we combined gm-csf with ifn-î± in order to improve ifn tolerance in post-asct myeloma patients.
det||adhesion-2/NN||the-1/DT	nsubj||observed-16/JJ||adhesion-2/NN	conj_and||adhesion-2/NN||spreading-4/NN	nsubj||observed-16/JJ||spreading-4/NN	amod||cells-9/NNS||rmg-i-6/JJ	conj_and||rmg-i-6/JJ||rmg-i-h-8/JJ	amod||cells-9/NNS||rmg-i-h-8/JJ	prep_of||adhesion-2/NN||cells-9/NNS	prep_on||adhesion-2/NN||hyaluronicacid-11/NN	appos||adhesion-2/NN||ha-13/NN	cop||observed-16/JJ||were-15/VBD	root||ROOT-0/null||observed-16/JJ	hyaluronicacid-11||adhesion-2||no_rel||the adhesion and spreading of rmg-i and rmg-i-h cells on hyaluronicacid (ha) were observed.
nsubj||improve-15/VB||addition-1/NN	amod||diet-9/NN||ezetimibe-3/JJ	det||loss-8/NN||a-5/DT	amod||loss-8/NN||moderate-6/JJ	nn||loss-8/NN||weight-7/NN	prep_to||ezetimibe-3/JJ||loss-8/NN	prep_of||addition-1/NN||diet-9/NN	amod||subjects-12/NNS||obese-11/JJ	prep_in||diet-9/NN||subjects-12/NNS	aux||improve-15/VB||can-13/MD	advmod||improve-15/VB||significantly-14/RB	root||ROOT-0/null||improve-15/VB	amod||steatosis-17/NNS||hepatic-16/JJ	dobj||improve-15/VB||steatosis-17/NNS	dobj||improve-15/VB||inflammation-19/NNS	conj_and||steatosis-17/NNS||inflammation-19/NNS	amod||metabolism-26/NN||ldlâ-22/JJ	amod||metabolism-26/NN||$-23/$	amod||metabolism-26/NN||apob-100-25/JJ	dobj||improve-15/VB||metabolism-26/NN	conj_and||steatosis-17/NNS||metabolism-26/NN	ezetimibe-3||obese-11||no_rel||addition of ezetimibe to a moderate weight loss diet in obese subjects can significantly improve hepatic steatosis, inflammation, and ldlâ€“apob-100 metabolism.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||amphotericinb-16||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
nsubjpass||measured-3/VBN||glucose-1/NN	auxpass||measured-3/VBN||was-2/VBD	root||ROOT-0/null||measured-3/VBN	quantmod||times-7/NNS||at-4/IN	mwe||at-4/IN||least-5/JJS	pobj||at-4/IN||least-5/JJS	number||times-7/NNS||two-6/CD	dobj||measured-3/VBN||times-7/NNS	det||day-9/NN||a-8/DT	dep||times-7/NNS||day-9/NN	nsubjpass||divided-14/VBN||patients-12/NNS	auxpass||divided-14/VBN||were-13/VBD	conj_and||measured-3/VBN||divided-14/VBN	det||group-18/NN||the-16/DT	nn||group-18/NN||hyperglycaemia-17/NN	prep_into||divided-14/VBN||group-18/NN	nn||¥-23/NNP||glucose-20/NN	nn||¥-23/NNP||â-21/NN	nn||¥-23/NNP||‰-22/NNP	dep||mmol/l-25/JJ||¥-23/NNP	number||mmol/l-25/JJ||7.8-24/CD	dep||group-18/NN||mmol/l-25/JJ	nn||group-29/NN||normoglycaemia-28/NN	prep_into||divided-14/VBN||group-29/NN	conj_and||group-18/NN||group-29/NN	hyperglycaemia-17||glucose-20||no||glucose was measured at least two times a day, and patients were divided into the hyperglycaemia group (glucose â‰¥7.8 mmol/l) and normoglycaemia group.
det||individuals-2/NNS||the-1/DT	nsubj||have-16/VBP||individuals-2/NNS	nsubj||identified-4/VBD||we-3/PRP	rcmod||individuals-2/NNS||identified-4/VBD	prepc_as||identified-4/VBD||having-6/VBG	amod||influence-10/NN||regional-7/JJ	conj_or||regional-7/JJ||international-9/JJ	amod||influence-10/NN||international-9/JJ	dobj||having-6/VBG||influence-10/NN	det||field-13/NN||the-12/DT	prep_in||influence-10/NN||field-13/NN	prep_of||field-13/NN||hiv/aids-15/NNS	root||ROOT-0/null||have-16/VBP	det||ability-18/NN||the-17/DT	dobj||have-16/VBP||ability-18/NN	prep_to||ability-18/NN||leverage-20/NN	det||environment-25/NN||an-21/DT	advmod||conducive-23/JJ||increasingly-22/RB	amod||environment-25/NN||conducive-23/JJ	nn||environment-25/NN||funding-24/NN	dep||leverage-20/NN||environment-25/NN	det||base-30/NN||a-27/DT	amod||base-30/NN||growing-28/VBG	nn||base-30/NN||evidence-29/NN	prep_to||ability-18/NN||base-30/NN	conj_and||leverage-20/NN||base-30/NN	aux||address-32/VB||to-31/TO	vmod||have-16/VBP||address-32/VB	det||challenges-39/NNS||the-33/DT	amod||challenges-39/NNS||policy-34/NN	conj_and||policy-34/NN||programmatic-36/JJ	amod||challenges-39/NNS||programmatic-36/JJ	conj_and||policy-34/NN||operational-38/JJ	amod||challenges-39/NNS||operational-38/JJ	dobj||address-32/VB||challenges-39/NNS	prepc_to||address-32/VB||integrating-41/VBG	nn||planning-43/NN||family-42/NN	dobj||integrating-41/VBG||planning-43/NN	prep_with||integrating-41/VBG||hiv/aids-45/NNS	aids--1||hiv--1||no||the individuals we identified as having regional or international influence in the field of hiv/aids have the ability to leverage an increasingly conducive funding environment and a growing evidence base to address the policy, programmatic and operational challenges to integrating family planning with hiv/aids.
det||route-4/NN||the-1/DT	amod||route-4/NN||main-2/JJ	nn||route-4/NN||transmission-3/NN	nsubj||mother-12/NN||route-4/NN	nsubj||contributes-17/VBZ||route-4/NN	det||hepatitisbvirus-7/NNS||the-6/DT	prep_of||route-4/NN||hepatitisbvirus-7/NNS	appos||hepatitisbvirus-7/NNS||hbv-9/NN	cop||mother-12/NN||is-11/VBZ	root||ROOT-0/null||mother-12/NN	nn||transmission-15/NN||child-14/NN	prep_to||mother-12/NN||transmission-15/NN	conj_and||mother-12/NN||contributes-17/VBZ	advmod||contributes-17/VBZ||significantly-18/RB	amod||infection-22/NN||chronic-20/JJ	nn||infection-22/NN||hbv-21/NN	prep_to||contributes-17/VBZ||infection-22/NN	hbv-21||hepatitisbvirus-7||no||the main transmission route of the hepatitisbvirus (hbv) is mother to child transmission and contributes significantly to chronic hbv infection.
advmod||glucose-4/NN||chronically-1/RB	nn||glucose-4/NN||elevated-2/NN	nn||glucose-4/NN||blood-3/NN	nsubj||indicator-11/NN||glucose-4/NN	appos||glucose-4/NN||hyperglycaemia-6/NNP	cop||indicator-11/NN||is-8/VBZ	det||indicator-11/NN||the-9/DT	amod||indicator-11/NN||primary-10/JJ	root||ROOT-0/null||indicator-11/NN	prep_of||indicator-11/NN||type2diabetes-13/NNS	nsubj||has-16/VBZ||type2diabetes-13/NNS	rcmod||type2diabetes-13/NNS||has-16/VBZ	det||prevalence-18/NN||a-17/DT	dobj||has-16/VBZ||prevalence-18/NN	nsubj||varies-20/VBZ||prevalence-18/NN	rcmod||prevalence-18/NN||varies-20/VBZ	advmod||varies-20/VBZ||considerably-21/RB	prep_by||varies-20/VBZ||ethnicity-23/NN	det||usa-26/NN||the-25/DT	prep_in||ethnicity-23/NN||usa-26/NN	prep_with||varies-20/VBZ||african-americans-29/NNS	advmod||affected-31/VBN||disproportionately-30/RB	vmod||african-americans-29/NNS||affected-31/VBN	hyperglycaemia-6||glucose-4||no||chronically elevated blood glucose (hyperglycaemia) is the primary indicator of type2diabetes, which has a prevalence that varies considerably by ethnicity in the usa, with african-americans disproportionately affected.
nsubj||decreased-11/VBD||sir-1/NN	amod||sarcoma-4/NN||kaposi-3/JJ	prep_for||sir-1/NN||sarcoma-4/NN	discourse||sarcoma-4/NN||ks-6/UH	prep_for||sir-1/NN||non-hodgkinlymphoma-9/NN	conj_and||sarcoma-4/NN||non-hodgkinlymphoma-9/NN	advmod||decreased-11/VBD||greatly-10/RB	root||ROOT-0/null||decreased-11/VBD	prep_in||decreased-11/VBD||1997â-13/CD	dobj||decreased-11/VBD||$-14/$	num||$-14/$||2004-16/CD	prepc_compared_with||$-14/$||with-18/IN	amod||$-20/NNS||1986â-19/JJ	pobj||$-14/$||$-20/NNS	dep||$-20/NNS||1996-22/CD	amod||sirs-26/NNS||high-25/JJ	nsubj||persisted-29/VBD||sirs-26/NNS	prep_for||sirs-26/NNS||ks-28/NN	conj_but||decreased-11/VBD||persisted-29/VBD	det||fraction-34/NN||the-31/DT	advmod||large-33/JJ||increasingly-32/RB	amod||fraction-34/NN||large-33/JJ	prep_in||persisted-29/VBD||fraction-34/NN	prep_of||fraction-34/NN||pwha-36/NN	nsubj||had-38/VBD||pwha-36/NN	nsubj||aids-50/VBZ||pwha-36/NN	rcmod||pwha-36/NN||had-38/VBD	det||interval-40/NN||an-39/DT	dobj||had-38/VBD||interval-40/NN	punct||year-44/NN||<-42/``	num||year-44/NN||1-43/CD	prep_of||interval-40/NN||year-44/NN	amod||test-48/NN||first-46/JJ	amod||test-48/NN||hiv-positive-47/JJ	prep_between||year-44/NN||test-48/NN	rcmod||pwha-36/NN||aids-50/VBZ	conj_and||had-38/VBD||aids-50/VBZ	dobj||aids-50/VBZ||diagnosis-51/NN	aids-50||hiv--1||no||sir for kaposi sarcoma (ks) and non-hodgkinlymphoma greatly decreased in 1997â€“2004 compared with 1986â€“1996, but high sirs for ks persisted in the increasingly large fraction of pwha who had an interval of <1 year between first hiv-positive test and aids diagnosis.
det||agents-4/NNS||some-1/DT	amod||agents-4/NNS||newer-2/JJR	amod||agents-4/NNS||antipsychotic-3/JJ	nsubj||have-13/VB||agents-4/NNS	prep_such_as||agents-4/NNS||olanzapine-8/NN	prep_such_as||agents-4/NNS||aripiprazole-10/NN	conj_and||olanzapine-8/NN||aripiprazole-10/NN	aux||have-13/VB||may-12/MD	root||ROOT-0/null||have-13/VB	amod||efficacy-15/NN||adequate-14/JJ	dobj||have-13/VB||efficacy-15/NN	det||profile-21/NN||a-17/DT	advmod||favorable-19/JJ||more-18/RBR	amod||profile-21/NN||favorable-19/JJ	amod||profile-21/NN||adverse-effect-20/JJ	prep_with||have-13/VB||profile-21/NN	amod||agents-25/NNS||older-23/JJR	amod||agents-25/NNS||antipsychotic-24/JJ	prep_than||profile-21/NN||agents-25/NNS	prepc_for||agents-25/NNS||treating-27/VBG	dobj||treating-27/VBG||chorea-28/NN	dobj||treating-27/VBG||psychosis-30/NNS	conj_and||chorea-28/NN||psychosis-30/NNS	psychosis-30||olanzapine-8||yes||some newer antipsychotic agents, such as olanzapine and aripiprazole, may have adequate efficacy with a more favorable adverse-effect profile than older antipsychotic agents for treating chorea and psychosis.
amod||results-2/NNS||satisfactory-1/JJ	nsubjpass||obtained-4/VBN||results-2/NNS	auxpass||obtained-4/VBN||were-3/VBD	root||ROOT-0/null||obtained-4/VBN	advmod||subjected-6/VBN||when-5/WRB	advcl||obtained-4/VBN||subjected-6/VBN	amod||tests-9/NNS||physico-chemical-8/JJ	prep_to||subjected-6/VBN||tests-9/NNS	prep_such_as||tests-9/NNS||uniformity-12/NN	nn||ph-19/NN||weight-14/NN	dep||ph-19/NN||thickness-16/NN	dep||ph-19/NN||surface-18/NN	prep_of||uniformity-12/NN||ph-19/NN	amod||endurance-22/NNS||folding-21/JJ	appos||tests-9/NNS||endurance-22/NNS	appos||tests-9/NNS||uniformity-24/NN	conj_and||endurance-22/NNS||uniformity-24/NN	nn||content-27/NN||drug-26/NN	prep_of||uniformity-24/NN||content-27/NN	amod||index-30/NN||swelling-29/VBG	appos||tests-9/NNS||index-30/NN	conj_and||endurance-22/NNS||index-30/NN	amod||strength-33/NN||bioadhesive-32/JJ	appos||index-30/NN||strength-33/NN	amod||strength-37/NN||tensile-36/JJ	appos||tests-9/NNS||strength-37/NN	conj_and||endurance-22/NNS||strength-37/NN	swelling-29||chemical--1||no_rel||satisfactory results were obtained when subjected to physico-chemical tests such as uniformity of weight, thickness, surface ph, folding endurance, uniformity of drug content, swelling index, bioadhesive strength, and tensile strength.
nsubjpass||injected-4/VBN||animals-1/NNS	nsubj||showed-20/VBD||animals-1/NNS	auxpass||injected-4/VBN||were-3/VBD	rcmod||animals-1/NNS||injected-4/VBN	det||dose-8/NN||a-6/DT	amod||dose-8/NN||low-7/JJ	prep_with||injected-4/VBN||dose-8/NN	num||î-11/NN||10-10/CD	dep||dose-8/NN||î-11/NN	num||g-13/NN||1/4-12/CD	dep||î-11/NN||g-13/NN	nn||transposon-18/NN||statin-16/NN	nn||transposon-18/NN||ae-17/NN	prep_of||dose-8/NN||transposon-18/NN	vmod||transposon-18/NN||plasmid-19/VBN	root||ROOT-0/null||showed-20/VBD	det||decrease-23/NN||a-21/DT	amod||decrease-23/NN||significant-22/JJ	dobj||showed-20/VBD||decrease-23/NN	nn||formation-26/NN||tumor-25/NN	prep_in||showed-20/VBD||formation-26/NN	advmod||plasmid-33/VBD||only-27/RB	advmod||plasmid-33/VBD||when-28/WRB	nsubj||plasmid-33/VBD||co-injected-29/JJ	nn||transposase-encoding-32/NN||sb-31/NN	prep_with||co-injected-29/JJ||transposase-encoding-32/NN	advcl||showed-20/VBD||plasmid-33/VBD	mark||affect-62/VB||while-35/IN	prep_for||affect-62/VB||animals-37/NNS	vmod||animals-37/NNS||injected-38/VBN	det||dose-42/NN||a-40/DT	amod||dose-42/NN||higher-41/JJR	prep_with||injected-38/VBN||dose-42/NN	num||î-45/NN||25-44/CD	dep||dose-42/NN||î-45/NN	num||g-47/NN||1/4-46/CD	dep||î-45/NN||g-47/NN	amod||transposon-52/NN||statin-50/JJ	nn||transposon-52/NN||ae-51/NN	prep_of||dose-42/NN||transposon-52/NN	nsubj||affect-62/VB||co-injection-54/NN	amod||plasmid-58/NN||sb-56/JJ	amod||plasmid-58/NN||transposase-encoding-57/JJ	prep_of||co-injection-54/NN||plasmid-58/NN	aux||affect-62/VB||did-59/VBD	neg||affect-62/VB||not-60/RB	advmod||affect-62/VB||significantly-61/RB	dep||plasmid-33/VBD||affect-62/VB	nn||load-64/NN||tumor-63/NN	dobj||affect-62/VB||load-64/NN	tumor-63||statin-50||no_rel||animals that were injected with a low dose (10 î¼g) of statin ae transposon plasmid showed a significant decrease in tumor formation only when co-injected with sb transposase-encoding plasmid, while for animals injected with a higher dose (25 î¼g) of statin ae transposon, co-injection of sb transposase-encoding plasmid did not significantly affect tumor load.
nsubjpass||allocated-17/VBN||patients-1/NNS	nsubj||receive-19/VB||patients-1/NNS	conj_and||patients-1/NNS||methods-3/NNS	nsubjpass||allocated-17/VBN||methods-3/NNS	nsubj||receive-19/VB||methods-3/NNS	number||hundred-5/CD||two-4/CD	dep||patients-1/NNS||hundred-5/CD	amod||patients-9/NNS||thirty-six-7/JJ	amod||patients-9/NNS||chemotherapy-naive-8/JJ	conj_and||patients-1/NNS||patients-9/NNS	nsubjpass||allocated-17/VBN||patients-9/NNS	nsubj||receive-19/VB||patients-9/NNS	amod||cancer-14/NN||inoperable-11/JJ	amod||cancer-14/NN||non-small-cell-12/JJ	nn||cancer-14/NN||lung-13/NN	prep_with||patients-9/NNS||cancer-14/NN	auxpass||allocated-17/VBN||were-15/VBD	advmod||allocated-17/VBN||randomly-16/RB	root||ROOT-0/null||allocated-17/VBN	aux||receive-19/VB||to-18/TO	xcomp||allocated-17/VBN||receive-19/VB	preconj||mg/m2-22/NNS||either-20/CC	num||mg/m2-22/NNS||200-21/CD	dobj||receive-19/VB||mg/m2-22/NNS	amod||cisplatin-25/NN||liposomal-24/JJ	prep_of||mg/m2-22/NNS||cisplatin-25/NN	num||paclitaxel-29/NN||135-27/CD	amod||paclitaxel-29/NN||mg/m2-28/JJ	prep_of||mg/m2-22/NNS||paclitaxel-29/NN	conj_and||cisplatin-25/NN||paclitaxel-29/NN	dep||paclitaxel-29/NN||arm-31/NN	dep||arm-31/NN||a-32/DT	num||cisplatin-37/NN||75-35/CD	amod||cisplatin-37/NN||mg/m2-36/JJ	dobj||receive-19/VB||cisplatin-37/NN	conj_or||mg/m2-22/NNS||cisplatin-37/NN	num||paclitaxel-41/NN||135-39/CD	amod||paclitaxel-41/NN||mg/m2-40/JJ	conj_or||mg/m2-22/NNS||paclitaxel-41/NN	conj_and||cisplatin-37/NN||paclitaxel-41/NN	appos||paclitaxel-41/NN||arm-43/NN	num||arm-43/NN||b-44/CD	advmod||mg/m2-22/NNS||once-47/RB	det||weeks-50/NNS||every-48/DT	num||weeks-50/NNS||2-49/CD	tmod||receive-19/VB||weeks-50/NNS	det||basis-54/NN||an-52/DT	nn||basis-54/NN||outpatient-53/NN	prep_on||receive-19/VB||basis-54/NN	cancer-14||cisplatin-37||no_rel||patients and methods two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m2 of liposomal cisplatin and 135 mg/m2 paclitaxel (arm a) or 75 mg/m2 cisplatin and 135 mg/m2 paclitaxel (arm b), once every 2 weeks on an outpatient basis.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	priondisease-12||prion-23||no||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
amod||infusion-3/NN||continuous-1/JJ	amod||infusion-3/NN||remifentanil-2/JJ	nsubj||had-15/VBD||infusion-3/NN	num||kg/min-8/NNS||0.05-5/CD	nn||kg/min-8/NNS||âµg-6/NNP	nn||kg/min-8/NNS||/-7/NN	appos||infusion-3/NN||kg/min-8/NNS	advmod||postoperatively-11/RB||immediately-10/RB	amod||infusion-3/NN||postoperatively-11/RB	amod||pca-14/NN||alfentanil-based-13/JJ	prep_with||postoperatively-11/RB||pca-14/NN	root||ROOT-0/null||had-15/VBD	det||effect-18/NN||a-16/DT	amod||effect-18/NN||similar-17/JJ	dobj||had-15/VBD||effect-18/NN	det||infusion-25/NN||a-20/DT	number||/-23/NN||0.1-21/CD	dep||/-23/NN||âµg-22/JJ	amod||infusion-25/NN||/-23/NN	nn||infusion-25/NN||kg/min-24/NN	prep_as||effect-18/NN||infusion-25/NN	prep_with||had-15/VBD||respect-27/NN	nn||control-30/NN||pain-29/NN	prep_to||had-15/VBD||control-30/NN	nn||effects-33/NNS||side-32/NN	prep_without||had-15/VBD||effects-33/NNS	pain-29||alfentanil--1||yes||continuous remifentanil infusion (0.05 âµg/kg/min) immediately postoperatively with alfentanil-based pca had a similar effect as a 0.1 âµg/kg/min infusion with respect to pain control without side effects.
amod||minimus-3/NNS||purified-1/JJ	nn||minimus-3/NNS||a.-2/NN	nsubj||cypor-4/VBP||minimus-3/NNS	root||ROOT-0/null||cypor-4/VBP	amod||-rrb--8/NNS||enzyme-5/JJ	amod||-rrb--8/NNS||-lrb--6/JJ	nn||-rrb--8/NNS||ancypor-7/NN	nsubj||partner-14/NN||-rrb--8/NNS	nsubj||loses-19/VBZ||-rrb--8/NNS	cop||partner-14/NN||is-11/VBZ	det||partner-14/NN||the-12/DT	nn||partner-14/NN||redox-13/NN	rcmod||-rrb--8/NNS||partner-14/NN	amod||p450s-17/NNS||cytochrome-16/JJ	prep_of||partner-14/NN||p450s-17/NNS	ccomp||cypor-4/VBP||loses-19/VBZ	amod||-rrb--24/NNS||flavin-adenosine-20/JJ	amod||-rrb--24/NNS||di-nucleotide-21/JJ	amod||-rrb--24/NNS||-lrb--22/JJ	nn||-rrb--24/NNS||fad-23/NN	dobj||loses-19/VBZ||-rrb--24/NNS	amod||cofactors-31/NNS||flavin-26/JJ	amod||cofactors-31/NNS||mono-nucleotide-27/JJ	amod||cofactors-31/NNS||-lrb--28/JJ	nn||cofactors-31/NNS||fmn-29/NN	nn||cofactors-31/NNS||-rrb--30/NN	dobj||loses-19/VBZ||cofactors-31/NNS	conj_and||-rrb--24/NNS||cofactors-31/NNS	nsubj||affect-33/VBP||cofactors-31/NNS	rcmod||cofactors-31/NNS||affect-33/VBP	poss||activity-36/NN||its-34/PRP$	amod||activity-36/NN||enzyme-35/JJ	dobj||affect-33/VBP||activity-36/NN	enzyme-35||mono--1||no_rel||purified a. minimus cypor enzyme -lrb- ancypor -rrb- , which is the redox partner of cytochrome p450s , loses flavin-adenosine di-nucleotide -lrb- fad -rrb- and flavin mono-nucleotide -lrb- fmn -rrb- cofactors that affect its enzyme activity .
det||search-4/NN||a-1/DT	amod||search-4/NN||comprehensive-2/JJ	nn||search-4/NN||literature-3/NN	nsubjpass||carried-6/VBN||search-4/NN	nsubj||identify-9/VB||search-4/NN	auxpass||carried-6/VBN||was-5/VBD	root||ROOT-0/null||carried-6/VBN	prt||carried-6/VBN||out-7/RP	aux||identify-9/VB||to-8/TO	xcomp||carried-6/VBN||identify-9/VB	amod||trials-12/NNS||randomised-10/JJ	amod||trials-12/NNS||controlled-11/JJ	dobj||identify-9/VB||trials-12/NNS	prep_of||trials-12/NNS||polyethyleneglycol-14/NN	appos||polyethyleneglycol-14/NN||peg-16/NNP	prep||identify-9/VB||versus-18/FW	det||placebo-20/NN||either-19/DT	pobj||versus-18/FW||placebo-20/NN	amod||comparator-23/NN||active-22/JJ	pobj||versus-18/FW||comparator-23/NN	conj_or||placebo-20/NN||comparator-23/NN	prep_in||carried-6/VBN||patients-26/NNS	vmod||patients-26/NNS||aged-27/VBN	number||18-29/CD||<-28/CD	num||years-30/NNS||18-29/CD	npadvmod||aged-27/VBN||years-30/NNS	amod||constipation-34/NN||primary-32/JJ	amod||constipation-34/NN||chronic-33/JJ	prep_with||aged-27/VBN||constipation-34/NN	constipation-34||polyethyleneglycol-14||yes||a comprehensive literature search was carried out to identify randomised controlled trials of polyethyleneglycol (peg) versus either placebo or active comparator, in patients aged <18 years with primary chronic constipation.
det||observations-2/NNS||these-1/DT	nsubj||suggest-3/VBP||observations-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||have-10/VB||that-4/IN	amod||administration-6/NN||oral-5/JJ	nsubj||have-10/VB||administration-6/NN	prep_of||administration-6/NN||egcg-8/NN	aux||have-10/VB||may-9/MD	ccomp||suggest-3/VBP||have-10/VB	amod||effects-13/NNS||significant-11/JJ	amod||effects-13/NNS||beneficial-12/JJ	dobj||have-10/VB||effects-13/NNS	poss||patients-17/NNS||parkinson-15/NN	prep_in||effects-13/NNS||patients-17/NNS	vmod||patients-17/NNS||treated-18/VBN	prep_with||treated-18/VBN||l-dopa-20/NN	prep_with||treated-18/VBN||carbidopa-22/NN	conj_and||l-dopa-20/NN||carbidopa-22/NN	agent||treated-18/VBN||exerting-24/VBG	det||inhibition-27/NN||a-25/DT	amod||inhibition-27/NN||modest-26/JJ	dobj||exerting-24/VBG||inhibition-27/NN	amod||methylation-30/NN||l-dopa-29/JJ	prep_of||inhibition-27/NN||methylation-30/NN	det||neuroprotection-34/NN||a-32/DT	amod||neuroprotection-34/NN||strong-33/JJ	dobj||exerting-24/VBG||neuroprotection-34/NN	conj_plus||inhibition-27/NN||neuroprotection-34/NN	amod||damage-37/NN||oxidative-36/JJ	prep_against||neuroprotection-34/NN||damage-37/NN	prep_against||neuroprotection-34/NN||degeneration-39/NN	conj_and||damage-37/NN||degeneration-39/NN	parkinson's--1||l-dopa-29||yes||these observations suggest that oral administration of egcg may have significant beneficial effects in parkinson's patients treated with l-dopa and carbidopa by exerting a modest inhibition of l-dopa methylation plus a strong neuroprotection against oxidative damage and degeneration.
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	hypertension-36||hormone-22||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
det||study-3/NN||this-1/DT	amod||study-3/NN||open-label-2/JJ	nsubj||compared-4/VBD||study-3/NN	ccomp||used-17/VBD||compared-4/VBD	det||efficacy-6/NN||the-5/DT	dobj||compared-4/VBD||efficacy-6/NN	dobj||compared-4/VBD||tolerability-8/NN	conj_and||efficacy-6/NN||tolerability-8/NN	prep_of||efficacy-6/NN||aripiprazole-10/NN	prep_with||compared-4/VBD||haloperidol-12/NN	det||typicalantipsychotic-15/NN||a-14/DT	nsubj||used-17/VBD||typicalantipsychotic-15/NN	nsubj||treat-19/VB||typicalantipsychotic-15/NN	advmod||used-17/VBD||widely-16/RB	root||ROOT-0/null||used-17/VBD	aux||treat-19/VB||to-18/TO	xcomp||used-17/VBD||treat-19/VB	dobj||treat-19/VB||patients-20/NNS	prep_with||treat-19/VB||ticdisorders-22/NNS	typicalantipsychotic-15||ticdisorders-22||no_rel||this open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typicalantipsychotic widely used to treat patients with ticdisorders.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||pyrazinamide-48||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubjpass||proven-4/VBN||ranolazine-1/NN	aux||proven-4/VBN||has-2/VBZ	auxpass||proven-4/VBN||been-3/VBN	root||ROOT-0/null||proven-4/VBN	amod||trials-8/NNS||multiple-6/JJ	amod||trials-8/NNS||clinical-7/JJ	prep_in||proven-4/VBN||trials-8/NNS	aux||reduce-10/VB||to-9/TO	ccomp||proven-4/VBN||reduce-10/VB	det||symptoms-12/NNS||the-11/DT	dobj||reduce-10/VB||symptoms-12/NNS	prep_of||symptoms-12/NNS||angina-14/NN	advmod||reduce-10/VB||safely-15/RB	advmod||reduce-10/VB||effectively-17/RB	conj_and||safely-15/RB||effectively-17/RB	aux||improve-20/VB||to-19/TO	ccomp||proven-4/VBN||improve-20/VB	conj_and||reduce-10/VB||improve-20/VB	nn||tolerance-22/NN||exercise-21/NN	dobj||improve-20/VB||tolerance-22/NN	prep_in||improve-20/VB||patients-24/NNS	amod||coronaryheartdisease-27/NN||symptomatic-26/JJ	prep_with||patients-24/NNS||coronaryheartdisease-27/NN	ranolazine-1||coronaryheartdisease-27||no_rel||ranolazine has been proven in multiple clinical trials to reduce the symptoms of angina safely and effectively and to improve exercise tolerance in patients with symptomatic coronaryheartdisease.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||enhanced-20/VBD||that-5/IN	det||model-12/NN||a-7/DT	nn||model-12/NN||chemically-8/NNP	nn||model-12/NN||induced-9/NNP	nn||model-12/NN||skin-10/NN	nn||model-12/NN||carcinoma-11/NN	prep_in||enhanced-20/VBD||model-12/NN	amod||drainage-16/NN||increased-14/VBN	amod||drainage-16/NN||vegf-c-15/JJ	nsubj||enhanced-20/VBD||drainage-16/NN	nsubj||facilitated-28/VBD||drainage-16/NN	det||tumor-19/NN||the-18/DT	prep_from||drainage-16/NN||tumor-19/NN	ccomp||found-4/VBD||enhanced-20/VBD	dobj||enhanced-20/VBD||lymphangiogenesis-21/NNS	det||node-26/NN||the-23/DT	amod||node-26/NN||sentinel-24/JJ	nn||node-26/NN||lymph-25/NN	prep_in||enhanced-20/VBD||node-26/NN	ccomp||found-4/VBD||facilitated-28/VBD	conj_and||enhanced-20/VBD||facilitated-28/VBD	amod||spread-30/NN||metastatic-29/JJ	dobj||facilitated-28/VBD||spread-30/NN	nn||cells-33/NNS||cancer-32/NN	prep_of||spread-30/NN||cells-33/NNS	det||lymphatics-36/NNS||the-35/DT	prep_via||cells-33/NNS||lymphatics-36/NNS	tumor-19||chemically-8||no_rel||recently, we found that in a chemically induced skin carcinoma model, increased vegf-c drainage from the tumor enhanced lymphangiogenesis in the sentinel lymph node and facilitated metastatic spread of cancer cells via the lymphatics.
det||mainstay-2/NN||the-1/DT	nsubj||represents-5/VBZ||mainstay-2/NN	prep_of||mainstay-2/NN||management-4/NN	root||ROOT-0/null||represents-5/VBZ	dep||represents-5/VBZ||directed-6/VBN	amod||therapy-8/NN||antiviral-7/JJ	dobj||directed-6/VBN||therapy-8/NN	prep_after||directed-6/VBN||evidence-10/NN	prep_of||evidence-10/NN||recurrence-12/NN	prep_of||recurrence-12/NN||chronichepatitisc-14/NNP	vmod||chronichepatitisc-14/NNP||combined-16/VBN	amod||interferon-18/NN||pegylated-17/JJ	dobj||combined-16/VBN||interferon-18/NN	nn||therapy-21/NN||ribavirin-20/NNP	nsubj||treatment-26/NN||therapy-21/NN	cop||treatment-26/NN||is-22/VBZ	det||treatment-26/NN||the-23/DT	amod||treatment-26/NN||current-24/JJ	amod||treatment-26/NN||standard-25/JJ	conj_and||represents-5/VBZ||treatment-26/NN	amod||rates-31/NNS||sustained-28/VBN	amod||rates-31/NNS||viral-29/JJ	nn||rates-31/NNS||response-30/NN	prep_with||treatment-26/NN||rates-31/NNS	number||%-37/NN||25-33/CD	dep||%-37/NN||%-34/NN	dep||%-37/NN||to-35/TO	number||%-37/NN||45-36/CD	prep_of||rates-31/NNS||%-37/NN	chronichepatitisc-14||ribavirin-20||yes||the mainstay of management represents directed antiviral therapy after evidence of recurrence of chronichepatitisc. combined pegylated interferon and ribavirin therapy is the current standard treatment with sustained viral response rates of 25 % to 45 % .
nsubj||trial-7/NN||e1684-1/NNS	cop||trial-7/NN||was-2/VBD	det||trial-7/NN||the-3/DT	amod||trial-7/NN||pivotal-4/JJ	amod||trial-7/NN||adjuvant-5/JJ	nn||trial-7/NN||melanoma-6/NN	root||ROOT-0/null||trial-7/NN	prep_for||trial-7/NN||establishment-9/NN	amod||interferon-12/NN||high-dose-11/JJ	prep_of||establishment-9/NN||interferon-12/NN	appos||trial-7/NN||ifn-14/NN	amod||therapy-18/NN||effective-17/JJ	prep_as||trial-7/NN||therapy-18/NN	amod||patients-22/NNS||high-risk-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_of||therapy-18/NN||patients-22/NNS	melanoma-21||interferon-12||yes||e1684 was the pivotal adjuvant melanoma trial for establishment of high-dose interferon (ifn) as effective therapy of high-risk melanoma patients.
det||report-3/NN||this-1/DT	nn||report-3/NN||case-2/NN	nsubj||demonstrates-4/VBZ||report-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||response-7/NN||a-5/DT	amod||response-7/NN||satisfying-6/JJ	nsubj||had-24/VBD||response-7/NN	nsubjpass||discontinued-27/VBN||response-7/NN	aux||topiramate-9/VB||to-8/TO	vmod||response-7/NN||topiramate-9/VB	det||patient-13/NN||a-11/DT	amod||patient-13/NN||79-year-old-12/JJ	prep_in||topiramate-9/VB||patient-13/NN	amod||essentialtremor-16/NN||disabling-15/VBG	prep_with||topiramate-9/VB||essentialtremor-16/NN	nsubj||propranolol-19/VBP||whom-18/WP	nsubj||primidone-23/VBP||whom-18/WP	prepc_in||essentialtremor-16/NN||propranolol-19/VBP	prepc_in||essentialtremor-16/NN||primidone-23/VBP	conj_and||propranolol-19/VBP||primidone-23/VBP	ccomp||demonstrates-4/VBZ||had-24/VBD	aux||discontinued-27/VBN||to-25/TO	auxpass||discontinued-27/VBN||be-26/VB	xcomp||had-24/VBD||discontinued-27/VBN	xcomp||discontinued-27/VBN||due-28/JJ	amod||effects-32/NNS||severe-30/JJ	nn||effects-32/NNS||side-31/NN	prep_to||due-28/JJ||effects-32/NNS	primidone-23||essentialtremor-16||no_rel||this case report demonstrates a satisfying response to topiramate in a 79-year-old patient with disabling essentialtremor in whom propranolol as well as primidone had to be discontinued due to severe side effects.
mark||changed-19/VBN||although-1/IN	det||$-7/NN||the-2/DT	number||available-4/JJ||3-3/CD	amod||$-7/NN||available-4/JJ	amod||$-7/NN||therapeutic-5/JJ	nn||$-7/NN||agentsâ-6/NN	nsubj||changed-19/VBN||$-7/NN	dep||$-15/JJ||docetaxel-9/JJ	amod||$-7/NN||erlotinib-11/JJ	conj_and||$-15/JJ||erlotinib-11/JJ	amod||$-7/NN||pemetrexedâ-14/NN	conj_and||$-15/JJ||pemetrexedâ-14/NN	amod||$-7/NN||$-15/JJ	aux||changed-19/VBN||have-17/VBP	advmod||changed-19/VBN||significantly-18/RB	advcl||established-39/VBN||changed-19/VBN	det||landscape-22/NN||the-20/DT	nn||landscape-22/NN||treatment-21/NN	dobj||changed-19/VBN||landscape-22/NN	amod||nsclc-25/NN||recurrent-24/JJ	prep_for||landscape-22/NN||nsclc-25/NN	det||selection-29/NN||the-27/DT	amod||selection-29/NN||optimal-28/JJ	nsubjpass||established-39/VBN||selection-29/NN	amod||therapy-35/NN||second-31/JJ	conj_and||second-31/JJ||third-line-34/NN	amod||therapy-35/NN||third-line-34/NN	prep_of||selection-29/NN||therapy-35/NN	aux||established-39/VBN||has-36/VBZ	neg||established-39/VBN||not-37/RB	auxpass||established-39/VBN||been-38/VBN	root||ROOT-0/null||established-39/VBN	nsclc-25||docetaxel-9||yes||although the 3 available therapeutic agentsâ€”docetaxel, erlotinib, and pemetrexedâ€”have significantly changed the treatment landscape for recurrent nsclc , the optimal selection of second- and third-line therapy has not been established.
amod||history-2/NN||parental-1/JJ	nsubjpass||associated-7/VBN||history-2/NN	prep_of||history-2/NN||type2diabetes-4/CD	auxpass||associated-7/VBN||was-5/VBD	advmod||associated-7/VBN||independently-6/RB	root||ROOT-0/null||associated-7/VBN	prep_with||associated-7/VBN||age-9/NN	prep_at||associated-7/VBN||onset-11/NN	prep_of||onset-11/NN||type1diabetes-13/NNS	nn||ratio-16/NN||odds-15/NNS	dep||type1diabetes-13/NNS||ratio-16/NN	num||-LSB--18/NNS||1.02-17/CD	dep||ratio-16/NN||-LSB--18/NNS	number||%-20/NN||95-19/CD	amod||-LSB--18/NNS||%-20/NN	advmod||-LSB--18/NNS||ci-21/RB	num||â-23/NN||1.01-22/CD	pobj||ci-21/RB||â-23/NN	num||-RSB--27/NNS||$-24/$	num||$-24/$||1.03-26/CD	dep||-LSB--18/NNS||-RSB--27/NNS	prep_of||onset-11/NN||bmi-30/NN	conj_and||type1diabetes-13/NNS||bmi-30/NN	num||-LSB--33/NNS||1.07-32/CD	dep||bmi-30/NN||-LSB--33/NNS	num||â-35/NN||1.02-34/CD	dep||-LSB--33/NNS||â-35/NN	num||-RSB--39/NNS||$-36/$	num||$-36/$||1.12-38/CD	dep||â-35/NN||-RSB--39/NNS	prep_of||onset-11/NN||triglycerides-42/NNPS	conj_and||type1diabetes-13/NNS||triglycerides-42/NNPS	num||-LSB--45/NNS||1.18-44/CD	dep||triglycerides-42/NNPS||-LSB--45/NNS	num||â-47/NN||1.03-46/CD	dep||-LSB--45/NNS||â-47/NN	num||-RSB--51/NNS||$-48/$	num||$-48/$||1.35-50/CD	dep||â-47/NN||-RSB--51/NNS	nn||dose-56/NN||insulin-55/NN	prep_of||onset-11/NN||dose-56/NN	conj_and||type1diabetes-13/NNS||dose-56/NN	prep_per||dose-56/NN||kilogram-58/NN	num||-LSB--61/NNS||1.63-60/CD	dep||type1diabetes-13/NNS||-LSB--61/NNS	num||â-63/NN||1.04-62/CD	dep||-LSB--61/NNS||â-63/NN	num||-RSB--67/NNS||$-64/$	num||$-64/$||2.54-66/CD	dep||â-63/NN||-RSB--67/NNS	type2diabetes-4||insulin-55||yes||parental history of type2diabetes was independently associated with age at onset of type1diabetes (odds ratio 1.02 [95% ci 1.01â€“1.03]), bmi (1.07 [1.02â€“1.12]), triglycerides (1.18 [1.03â€“1.35]), and insulin dose per kilogram (1.63 [1.04â€“2.54]).
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||lidocaine-21||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
aux||study-2/VB||to-1/TO	advcl||analyzed-18/VBD||study-2/VB	det||effects-4/NNS||the-3/DT	dobj||study-2/VB||effects-4/NNS	amod||growth-7/NN||insulin-like-6/JJ	nn||level-13/NN||growth-7/NN	amod||level-13/NN||factor-1-8/JJ	dep||factor-1-8/JJ||igf-1-10/JJ	nn||level-13/NN||plasma-12/NN	prep_of||effects-4/NNS||level-13/NN	prep_on||study-2/VB||ovaries-15/NNS	nsubj||analyzed-18/VBD||we-17/PRP	root||ROOT-0/null||analyzed-18/VBD	nsubj||isolated-20/VBD||ovaries-19/NNS	ccomp||analyzed-18/VBD||isolated-20/VBD	amod||knockout-25/NN||2-year-old-22/JJ	amod||knockout-25/NN||growthhormone-23/JJ	nn||knockout-25/NN||receptor-24/NN	prep_from||isolated-20/VBD||knockout-25/NN	appos||knockout-25/NN||ghr-ko-27/NNP	amod||mice-31/NNS||laron-29/JJ	nn||mice-31/NNS||dwarf-30/NN	dobj||isolated-20/VBD||mice-31/NNS	advmod||circulating-35/VBG||low-34/JJ	prepc_with||isolated-20/VBD||circulating-35/VBG	nn||levels-37/NNS||plasma-36/NN	dobj||circulating-35/VBG||levels-37/NNS	dep||bovine-43/JJ||igf-1-39/JJ	conj_and||bovine-43/JJ||6-month-old-42/JJ	amod||mice-49/NNS||6-month-old-42/JJ	amod||mice-49/NNS||bovine-43/JJ	amod||mice-49/NNS||growthhormone-44/JJ	amod||mice-49/NNS||transgenic-45/JJ	appos||mice-49/NNS||bghtg-47/NN	prep_of||levels-37/NNS||mice-49/NNS	advmod||circulating-53/VBG||high-52/RB	prepc_with||isolated-20/VBD||circulating-53/VBG	nn||levels-55/NNS||plasma-54/NN	dobj||circulating-53/VBG||levels-55/NNS	prep_of||levels-55/NNS||igf-1-57/CD	dwarf-30||growthhormone-44||yes||to study the effects of insulin-like growth factor-1 (igf-1) plasma level on ovaries, we analyzed ovaries isolated from 2-year-old growthhormone receptor knockout (ghr-ko) laron dwarf mice, with low circulating plasma levels of igf-1, and 6-month-old bovine growthhormone transgenic (bghtg) mice, with high circulating plasma levels of igf-1.
mark||skin-9/NN||although-1/IN	det||majority-3/NN||the-2/DT	nsubj||skin-9/NN||majority-3/NN	amod||infections-6/NNS||ca-mrsa-5/JJ	prep_of||majority-3/NN||infections-6/NNS	cop||skin-9/NN||are-7/VBP	amod||skin-9/NN||mild-8/JJ	advcl||reported-18/VBN||skin-9/NN	conj_and||skin-9/NN||softtissueinfections-11/NNS	advcl||reported-18/VBN||softtissueinfections-11/NNS	amod||life-threatening-14/JJ||severe-13/JJ	amod||cases-15/NNS||life-threatening-14/JJ	nsubjpass||reported-18/VBN||cases-15/NNS	aux||reported-18/VBN||have-16/VBP	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	mrsa--1||ca--1||no_rel||although the majority of ca-mrsa infections are mild skin and softtissueinfections, severe life-threatening cases have been reported.
det||2003-3/CD||the-2/DT	prep_during||randomised-26/VBN||2003-3/CD	num||seasons-8/NNS||2004-5/CD	nn||seasons-8/NNS||malaria-6/NN	nn||seasons-8/NNS||transmission-7/NN	conj_and||2003-3/CD||seasons-8/NNS	prep_during||randomised-26/VBN||seasons-8/NNS	num||children-12/NNS||1200-10/CD	nn||children-12/NNS||gambian-11/NN	nsubjpass||randomised-26/VBN||children-12/NNS	nsubj||receive-28/VB||children-12/NNS	amod||anaemia-17/NN||moderate-14/JJ	conj_or||moderate-14/JJ||severe-16/JJ	amod||anaemia-17/NN||severe-16/JJ	prep_with||children-12/NNS||anaemia-17/NN	nn||<-21/NNS||hb-19/NN	nn||<-21/NNS||concentration-20/NN	dep||g/dl-23/JJ||<-21/NNS	number||g/dl-23/JJ||7-22/CD	dep||anaemia-17/NN||g/dl-23/JJ	auxpass||randomised-26/VBN||were-25/VBD	root||ROOT-0/null||randomised-26/VBN	aux||receive-28/VB||to-27/TO	xcomp||randomised-26/VBN||receive-28/VB	det||sulfadoxine-pyrimethamine-31/NN||either-29/DT	amod||sulfadoxine-pyrimethamine-31/NN||monthly-30/JJ	dobj||receive-28/VB||sulfadoxine-pyrimethamine-31/NN	appos||sulfadoxine-pyrimethamine-31/NN||sp-33/NN	dobj||receive-28/VB||placebo-36/NN	conj_or||sulfadoxine-pyrimethamine-31/NN||placebo-36/NN	det||end-39/NN||the-38/DT	prep_until||receive-28/VB||end-39/NN	det||season-44/NN||the-41/DT	nn||season-44/NN||malaria-42/NN	nn||season-44/NN||transmission-43/NN	prep_of||end-39/NN||season-44/NN	prep_in||enrolled-49/VBN||season-44/NN	nsubjpass||enrolled-49/VBN||they-47/PRP	auxpass||enrolled-49/VBN||were-48/VBD	rcmod||season-44/NN||enrolled-49/VBN	det||trial-54/NN||a-52/DT	amod||trial-54/NN||double-blind-53/JJ	prep_in||enrolled-49/VBN||trial-54/NN	malaria-42||pyrimethamine--1||no||during the 2003 and 2004 malaria transmission seasons, 1200 gambian children with moderate or severe anaemia (hb concentration <7 g/dl) were randomised to receive either monthly sulfadoxine-pyrimethamine (sp) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial.
nsubj||affect-7/VB||use-1/NN	det||drugs-4/NNS||both-3/DT	prep_of||use-1/NN||drugs-4/NNS	aux||affect-7/VB||will-5/MD	advmod||affect-7/VB||positively-6/RB	root||ROOT-0/null||affect-7/VB	dobj||affect-7/VB||many-8/JJ	det||abnormalities-13/NNS||the-10/DT	amod||abnormalities-13/NNS||underlying-11/JJ	amod||abnormalities-13/NNS||metabolic-12/JJ	prep_of||many-8/JJ||abnormalities-13/NNS	vmod||abnormalities-13/NNS||associated-14/VBN	prep_with||associated-14/VBN||type2diabetes-16/CD	det||secretion-21/NN||the-19/DT	amod||secretion-21/NN||disordered-20/JJ	prep_including||abnormalities-13/NNS||secretion-21/NN	prep_of||secretion-21/NN||insulin-23/NN	prep_of||secretion-21/NN||glucagon-25/NN	conj_and||insulin-23/NN||glucagon-25/NN	amod||sensitivity-30/NN||impaired-29/VBN	dobj||affect-7/VB||sensitivity-30/NN	conj_and||many-8/JJ||sensitivity-30/NN	nsubjpass||known-35/VBN||sensitivity-30/NN	nsubj||accompany-37/VB||sensitivity-30/NN	prep_to||sensitivity-30/NN||insulin-32/NN	auxpass||known-35/VBN||are-34/VBP	rcmod||sensitivity-30/NN||known-35/VBN	aux||accompany-37/VB||to-36/TO	xcomp||known-35/VBN||accompany-37/VB	det||disease-39/NN||this-38/DT	dobj||accompany-37/VB||disease-39/NN	type2diabetes-16||insulin-32||yes||use of both drugs will positively affect many of the underlying metabolic abnormalities associated with type2diabetes, including the disordered secretion of insulin and glucagon as well as impaired sensitivity to insulin which are known to accompany this disease.
prep_in||shown-24/VBN||patients-2/NNS	amod||asthma-5/NN||persistent-4/JJ	prep_with||patients-2/NNS||asthma-5/NN	advmod||treated-7/VBN||previously-6/RB	vmod||asthma-5/NN||treated-7/VBN	preconj||treated-7/VBN||either-8/CC	amod||beta-agonists-11/NNS||short-acting-10/JJ	prep_with||treated-7/VBN||beta-agonists-11/NNS	advmod||treated-7/VBN||alone-12/RB	amod||therapy-16/NN||twice-daily-14/JJ	nn||therapy-16/NN||maintenance-15/NN	npadvmod||treated-7/VBN||therapy-16/NN	prep_with||treated-7/VBN||ics-18/NN	conj_or||beta-agonists-11/NNS||ics-18/NN	amod||mf-21/NN||once-daily-20/JJ	nsubjpass||shown-24/VBN||mf-21/NN	nsubj||superior-27/JJ||mf-21/NN	nsubj||placebo-29/VB||mf-21/NN	nsubjpass||shown-45/VBN||mf-21/NN	aux||shown-24/VBN||has-22/VBZ	auxpass||shown-24/VBN||been-23/VBN	root||ROOT-0/null||shown-24/VBN	aux||superior-27/JJ||to-25/TO	cop||superior-27/JJ||be-26/VB	xcomp||shown-24/VBN||superior-27/JJ	aux||placebo-29/VB||to-28/TO	xcomp||superior-27/JJ||placebo-29/VB	prepc_in||placebo-29/VB||improving-31/VBG	nn||function-33/NN||lung-32/NN	dobj||improving-31/VBG||function-33/NN	nn||control-36/NN||symptom-35/NN	dobj||improving-31/VBG||control-36/NN	conj_and||function-33/NN||control-36/NN	dobj||improving-31/VBG||quality-39/NN	conj_and||function-33/NN||quality-39/NN	prep_of||quality-39/NN||life-41/NN	aux||shown-45/VBN||has-44/VBZ	conj_and||shown-24/VBN||shown-45/VBN	amod||efficacy-47/NN||comparable-46/JJ	dobj||shown-45/VBN||efficacy-47/NN	prepc_compared_with||shown-45/VBN||with-49/IN	pobj||shown-45/VBN||budesonide-50/JJ	pobj||shown-45/VBN||beclomethasone-52/JJ	conj_and||budesonide-50/JJ||beclomethasone-52/JJ	pobj||shown-45/VBN||fluticasone-55/JJ	conj_and||budesonide-50/JJ||fluticasone-55/JJ	asthma-5||fluticasone-55||yes||in patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ics, once-daily mf has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone.
nsubj||disease-7/NN||melioidosis-1/NNS	cop||disease-7/NN||is-2/VBZ	det||disease-7/NN||a-3/DT	amod||disease-7/NN||serious-4/JJ	amod||disease-7/NN||community-acquired-5/JJ	amod||disease-7/NN||infectious-6/JJ	root||ROOT-0/null||disease-7/NN	vmod||disease-7/NN||caused-8/VBN	det||burkholderiapseudomallei-14/NN||the-10/DT	amod||burkholderiapseudomallei-14/NN||gram-negative-11/JJ	amod||burkholderiapseudomallei-14/NN||environmental-12/JJ	nn||burkholderiapseudomallei-14/NN||bacterium-13/NN	agent||caused-8/VBN||burkholderiapseudomallei-14/NN	melioidosis-1||burkholderiapseudomallei-14||no||melioidosis is a serious community-acquired infectious disease caused by the gram-negative environmental bacterium burkholderiapseudomallei .
amod||basic-2/JJ||htlv-1-1/JJ	amod||gene-9/NN||basic-2/JJ	amod||gene-9/NN||leucine-3/JJ	nn||gene-9/NN||zipper-4/NN	nn||gene-9/NN||factor-5/NN	appos||gene-9/NN||hbz-7/NN	nsubj||has-10/VBZ||gene-9/NN	root||ROOT-0/null||has-10/VBZ	det||role-13/NN||a-11/DT	amod||role-13/NN||critical-12/JJ	dobj||has-10/VBZ||role-13/NN	amod||infectivity-16/NN||htlv-1-15/JJ	prep_in||role-13/NN||infectivity-16/NN	det||development-19/NN||the-18/DT	dobj||has-10/VBZ||development-19/NN	conj_and||role-13/NN||development-19/NN	prep_of||development-19/NN||atl-21/NN	prep_of||development-19/NN||ham/tsp-23/NN	conj_and||atl-21/NN||ham/tsp-23/NN	ham--1||htlv-1-15||no||htlv-1 basic leucine zipper factor (hbz) gene has a critical role in htlv-1 infectivity and the development of atl and ham/tsp.
amod||infections-6/NNS||community-acquired-1/JJ	amod||infections-6/NNS||methicillin-resistantstaphylococcusaureus-2/JJ	amod||infections-6/NNS||ca-mrsa-4/JJ	nsubj||emerged-15/VBN||infections-6/NNS	amod||people-9/NNS||young-8/JJ	prep_among||infections-6/NNS||people-9/NNS	amod||factors-13/NNS||healthcare-associated-11/JJ	nn||factors-13/NNS||risk-12/NN	prep_without||people-9/NNS||factors-13/NNS	aux||emerged-15/VBN||have-14/VBP	root||ROOT-0/null||emerged-15/VBN	det||decade-19/NN||the-17/DT	amod||decade-19/NN||past-18/JJ	prep_during||emerged-15/VBN||decade-19/NN	ca--1||methicillin-resistantstaphylococcusaureus-2||no_rel||community-acquired methicillin-resistantstaphylococcusaureus (ca-mrsa) infections among young people without healthcare-associated risk factors have emerged during the past decade.
nsubj||concluded-2/VBD||we-1/PRP	root||ROOT-0/null||concluded-2/VBD	det||stimulation-5/NN||that-3/DT	nn||stimulation-5/NN||insulin-4/NN	dobj||concluded-2/VBD||stimulation-5/NN	amod||day-7/NN||-lrb--6/JJ	tmod||concluded-2/VBD||day-7/NN	num||-rrb--9/NNS||4-8/CD	nsubj||contribute-17/VBP||-rrb--9/NNS	nn||inhibition-12/NN||glucagon-11/NN	conj_and||-rrb--9/NNS||inhibition-12/NN	nsubj||contribute-17/VBP||inhibition-12/NN	amod||day-14/NN||-lrb--13/JJ	tmod||contribute-17/VBP||day-14/NN	num||-rrb--16/NNS||3-15/CD	nsubj||contribute-17/VBP||-rrb--16/NNS	dep||concluded-2/VBD||contribute-17/VBP	advmod||contribute-17/VBP||equally-18/RB	det||effect-21/NN||the-20/DT	prep_to||contribute-17/VBP||effect-21/NN	amod||turnover-26/NN||glp-1-23/JJ	prep_on||glp-1-23/JJ||glucose-25/NN	prep_of||effect-21/NN||turnover-26/NN	prep_in||turnover-26/NN||patients-28/NNS	prep_with||patients-28/NNS||type2diabetes-30/CD	det||changes-34/NNS||these-33/DT	nsubj||explain-35/VBP||changes-34/NNS	conj_and||concluded-2/VBD||explain-35/VBP	det||effect-38/NN||the-36/DT	amod||effect-38/NN||glucose-lowering-37/JJ	dobj||explain-35/VBP||effect-38/NN	amod||day-42/NN||glp-1-40/JJ	amod||day-42/NN||-lrb--41/JJ	prep_of||effect-38/NN||day-42/NN	num||day-42/NN||5-43/CD	nn||-rrb--47/NN||day-45/NN	num||-rrb--47/NN||1-46/CD	prep_vs.||day-42/NN||-rrb--47/NN	type2diabetes-30||insulin-4||yes||we concluded that insulin stimulation -lrb- day 4 -rrb- and glucagon inhibition -lrb- day 3 -rrb- contribute equally to the effect of glp-1 on glucose turnover in patients with type2diabetes , and these changes explain the glucose-lowering effect of glp-1 -lrb- day 5 vs. day 1 -rrb- .
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	type2diabetes-21||fat--1||no_rel||research design and methodsâ€” to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||itraconazole-20||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
amod||years-3/NNS||recent-2/JJ	prep_in||advances-8/NNS||years-3/NNS	expl||advances-8/NNS||there-4/EX	aux||advances-8/NNS||have-5/VBP	cop||advances-8/NNS||been-6/VBN	amod||advances-8/NNS||major-7/JJ	root||ROOT-0/null||advances-8/NNS	nsubj||had-20/VBN||advances-8/NNS	poss||knowledge-11/NN||our-10/PRP$	prep_in||advances-8/NNS||knowledge-11/NN	det||regulation-14/NN||the-13/DT	prep_of||knowledge-11/NN||regulation-14/NN	nn||metabolism-17/NN||iron-16/NN	prep_of||regulation-14/NN||metabolism-17/NN	aux||had-20/VBN||have-19/VBP	rcmod||advances-8/NNS||had-20/VBN	dobj||had-20/VBN||implications-21/NNS	prepc_for||had-20/VBN||understanding-23/VBG	det||pathophysiology-25/NN||the-24/DT	dobj||understanding-23/VBG||pathophysiology-25/NN	det||disorders-29/NNS||some-27/DT	amod||disorders-29/NNS||human-28/JJ	prep_of||pathophysiology-25/NN||disorders-29/NNS	nn||diseases-35/NNS||beta-thalassemia-31/NN	conj_and||beta-thalassemia-31/NN||other-33/JJ	nn||diseases-35/NNS||other-33/JJ	nn||diseases-35/NNS||ironoverload-34/NN	prep_like||had-20/VBN||diseases-35/NNS	ironoverload-34||iron-16||no||in recent years there have been major advances in our knowledge of the regulation of iron metabolism that have had implications for understanding the pathophysiology of some human disorders like beta-thalassemia and other ironoverload diseases.
nsubj||plays-11/VBZ||detection-1/NN	nn||dna-4/NN||hbv-3/NN	prep_of||detection-1/NN||dna-4/NN	prepc_in||dna-4/NN||hbsag-6/VBG	amod||patients-10/NNS||negative-7/JJ	amod||patients-10/NNS||chronic-8/JJ	nn||patients-10/NNS||hcv-9/NN	dobj||hbsag-6/VBG||patients-10/NNS	root||ROOT-0/null||plays-11/VBZ	det||role-15/NN||a-12/DT	amod||role-15/NN||non-13/JJ	amod||role-15/NN||significant-14/JJ	dobj||plays-11/VBZ||role-15/NN	prep_in||role-15/NN||non-response-17/NN	nn||patients-20/NNS||egyptian-19/NN	prep_of||non-response-17/NN||patients-20/NNS	amod||therapy-24/NN||pegylated-22/JJ	nn||therapy-24/NN||interferon/ribavirin-23/NN	prep_to||plays-11/VBZ||therapy-24/NN	hbv-3||hbsag-6||yes||detection of hbv dna in hbsag negative chronic hcv patients plays a non significant role in non-response of egyptian patients to pegylated interferon/ribavirin therapy.
nsubj||show-2/VBP||findings-1/NNS	root||ROOT-0/null||show-2/VBP	mark||face-14/VBP||that-3/IN	nsubj||face-14/VBP||children-4/NNS	vmod||children-4/NNS||affected-5/VBN	agent||affected-5/VBN||hiv-7/NN	agent||affected-5/VBN||aids-9/NNS	conj_and||hiv-7/NN||aids-9/NNS	amod||settings-13/NNS||low-11/JJ	nn||settings-13/NNS||prevalence-12/NN	prep_in||affected-5/VBN||settings-13/NNS	ccomp||show-2/VBP||face-14/VBP	amod||vulnerabilities-16/NNS||increased-15/VBN	dobj||face-14/VBP||vulnerabilities-16/NNS	amod||vulnerabilities-16/NNS||similar-17/JJ	prep_to||similar-17/JJ||those-19/DT	amod||settings-23/NNS||high-21/JJ	nn||settings-23/NNS||prevalence-22/NN	prep_in||those-19/DT||settings-23/NNS	aids-9||hiv-7||no||findings show that children affected by hiv and aids in low prevalence settings face increased vulnerabilities similar to those in high prevalence settings.
amod||information-2/NN||extensive-1/JJ	nsubj||available-6/JJ||information-2/NN	prep_on||information-2/NN||safety-4/NN	cop||available-6/JJ||is-5/VBZ	root||ROOT-0/null||available-6/JJ	mark||used-11/VBN||as-7/IN	nsubjpass||used-11/VBN||etanercept-8/NN	nsubj||first-26/JJ||etanercept-8/NN	aux||used-11/VBN||has-9/VBZ	auxpass||used-11/VBN||been-10/VBN	advcl||available-6/JJ||used-11/VBN	amod||years-14/NNS||many-13/JJ	prep_for||used-11/VBN||years-14/NNS	amod||indications-17/NNS||other-16/JJ	prep_for||years-14/NNS||indications-17/NNS	prep_such_as||indications-17/NNS||rheumatoidarthritis-20/NNS	prep_such_as||indications-17/NNS||psoriaticarthritis-22/NNS	conj_and||rheumatoidarthritis-20/NNS||psoriaticarthritis-22/NNS	cop||first-26/JJ||is-24/VBZ	det||first-26/JJ||the-25/DT	advcl||available-6/JJ||first-26/JJ	conj_and||used-11/VBN||first-26/JJ	det||tumor-29/NN||the-28/DT	prep_of||first-26/JJ||tumor-29/NN	rcmod||tumor-29/NN||necrosis-30/VBZ	nn||antagonists-32/NNS||factor-31/NN	dobj||necrosis-30/VBZ||antagonists-32/NNS	nsubj||gain-34/VB||antagonists-32/NNS	aux||gain-34/VB||to-33/TO	xcomp||necrosis-30/VBZ||gain-34/VB	dobj||gain-34/VB||approval-35/NN	prep_in||gain-34/VB||psoriasis-37/NNS	psoriaticarthritis-22||etanercept-8||yes||extensive information on safety is available as etanercept has been used for many years for other indications such as rheumatoidarthritis and psoriaticarthritis and is the first of the tumor necrosis factor antagonists to gain approval in psoriasis.
advmod||associated-9/VBN||even-1/RB	mark||associated-9/VBN||though-2/IN	nsubjpass||associated-9/VBN||coronavirusinfection-3/NN	prep_of||coronavirusinfection-3/NN||humans-5/NNS	auxpass||associated-9/VBN||is-6/VBZ	neg||associated-9/VBN||not-7/RB	advmod||associated-9/VBN||normally-8/RB	advcl||showed-25/VBD||associated-9/VBN	amod||diseases-12/NNS||severe-11/JJ	prep_with||associated-9/VBN||diseases-12/NNS	det||identification-15/NN||the-14/DT	nsubj||showed-25/VBD||identification-15/NN	det||coronavirus-18/NNS||the-17/DT	prep_of||identification-15/NN||coronavirus-18/NNS	amod||coronavirus-18/NNS||responsible-19/JJ	det||outbreak-22/NN||the-21/DT	prep_for||responsible-19/JJ||outbreak-22/NN	prep_of||outbreak-22/NN||severeacuterespiratorysyndrome-24/NN	root||ROOT-0/null||showed-25/VBD	mark||enter-31/VB||that-26/IN	advmod||pathogenic-28/JJ||highly-27/RB	amod||coronaviruses-29/NNS||pathogenic-28/JJ	nsubj||enter-31/VB||coronaviruses-29/NNS	aux||enter-31/VB||can-30/MD	ccomp||showed-25/VBD||enter-31/VB	det||population-34/NN||the-32/DT	amod||population-34/NN||human-33/JJ	dobj||enter-31/VB||population-34/NN	severeacuterespiratorysyndrome-24||coronaviruses-29||no||even though coronavirusinfection of humans is not normally associated with severe diseases, the identification of the coronavirus responsible for the outbreak of severeacuterespiratorysyndrome showed that highly pathogenic coronaviruses can enter the human population.
nsubj||interviewed-2/VBD||we-1/PRP	root||ROOT-0/null||interviewed-2/VBD	num||parents-5/NNS||33-3/CD	amod||parents-5/NNS||hiv-infected-4/JJ	dobj||interviewed-2/VBD||parents-5/NNS	det||cost-9/NN||the-7/DT	nn||cost-9/NN||hiv-8/NN	prep_from||interviewed-2/VBD||cost-9/NN	nn||study-13/NN||services-11/NNS	nn||study-13/NN||utilization-12/NN	prep_from||interviewed-2/VBD||study-13/NN	conj_and||cost-9/NN||study-13/NN	appos||cost-9/NN||hcsus-15/NNS	prep_from||interviewed-2/VBD||27-18/CD	conj_and||cost-9/NN||27-18/CD	poss||children-22/NNS||their-20/PRP$	amod||children-22/NNS||minor-21/JJ	prep_of||27-18/CD||children-22/NNS	num||children-26/NNS||19-24/CD	amod||children-26/NNS||adult-25/JJ	prep_from||interviewed-2/VBD||children-26/NNS	conj_and||cost-9/NN||children-26/NNS	num||caregivers-30/NNS||15-29/CD	prep_from||interviewed-2/VBD||caregivers-30/NNS	conj_and||cost-9/NN||caregivers-30/NNS	det||process-33/NN||the-32/DT	prep_about||interviewed-2/VBD||process-33/NN	prep_of||process-33/NN||children-35/NNS	vmod||children-35/NNS||learning-36/VBG	mark||hivpositive-41/JJ||that-37/IN	poss||parents-39/NNS||their-38/PRP$	nsubj||hivpositive-41/JJ||parents-39/NNS	cop||hivpositive-41/JJ||were-40/VBD	ccomp||learning-36/VBG||hivpositive-41/JJ	hivpositive-41||hiv-8||no||we interviewed 33 hiv-infected parents from the hiv cost and services utilization study (hcsus), 27 of their minor children, 19 adult children, and 15 caregivers about the process of children learning that their parents were hivpositive.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	type2diabetes-34||leucine-22||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||monophosphate-151/NN||a-148/DT	amod||monophosphate-151/NN||cyclic-149/JJ	nn||monophosphate-151/NN||adenosine-150/NN	prep_in||agonists-146/NNS||monophosphate-151/NN	appos||monophosphate-151/NN||camp-153/NN	amod||assay-156/JJ||functional-155/JJ	amod||monophosphate-151/NN||assay-156/JJ	amod||cells-164/NNS||chinese-158/JJ	nn||cells-164/NNS||hamster-159/NN	nn||cells-164/NNS||ovary-160/NN	appos||cells-164/NNS||cho-162/NN	prep_in||agonists-146/NNS||cells-164/NNS	vmod||cells-164/NNS||expressing-165/VBG	amod||ar-167/NN||ha2b-166/JJ	dobj||expressing-165/VBG||ar-167/NN	nm-122||ar-167||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosine monophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	insulin-24||type1diabetes-9||no_rel||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||cloned-12/VBN||study-4/NN	amod||rv1985c-8/NNS||recombinant-6/JJ	nn||rv1985c-8/NNS||protein-7/NN	nsubjpass||cloned-12/VBN||rv1985c-8/NNS	nsubjpass||expressed-14/VBN||rv1985c-8/NNS	nsubjpass||purified-16/VBN||rv1985c-8/NNS	nsubjpass||characterized-19/VBN||rv1985c-8/NNS	nsubjpass||investigated-21/VBN||rv1985c-8/NNS	prep_from||rv1985c-8/NNS||rd2-10/CD	auxpass||cloned-12/VBN||was-11/VBD	root||ROOT-0/null||cloned-12/VBN	conj_and||cloned-12/VBN||expressed-14/VBN	conj_and||cloned-12/VBN||purified-16/VBN	advmod||characterized-19/VBN||immunologically-18/RB	conj_and||cloned-12/VBN||characterized-19/VBN	conj_and||cloned-12/VBN||investigated-21/VBN	poss||value-26/NN||its-23/PRP$	advmod||diagnostic-25/JJ||potentially-24/RB	amod||value-26/NN||diagnostic-25/JJ	prep_for||investigated-21/VBN||value-26/NN	nn||infection-32/NN||tuberculosis-28/NNP	appos||infection-32/NN||tb-30/NN	prep_for||value-26/NN||infection-32/NN	amod||individuals-35/NNS||bcg-vaccinated-34/JJ	prep_among||investigated-21/VBN||individuals-35/NNS	tuberculosis-28||bcg--1||no||in the present study, recombinant protein rv1985c from rd2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (tb) infection among bcg-vaccinated individuals.
det||literature-3/NN||the-1/DT	amod||literature-3/NN||available-2/JJ	nsubjpass||reviewed-5/VBN||literature-3/NN	nsubj||examine-7/VB||literature-3/NN	auxpass||reviewed-5/VBN||was-4/VBD	root||ROOT-0/null||reviewed-5/VBN	aux||examine-7/VB||to-6/TO	xcomp||reviewed-5/VBN||examine-7/VB	det||links-9/NNS||the-8/DT	dobj||examine-7/VB||links-9/NNS	amod||antibiotics-12/NNS||prescribed-11/JJ	prep_between||links-9/NNS||antibiotics-12/NNS	nn||eczema-15/NN||childhood-14/NN	prep_between||links-9/NNS||eczema-15/NN	conj_and||antibiotics-12/NNS||eczema-15/NN	conj_and||antibiotics-12/NNS||asthma-17/NN	conj_and||eczema-15/NN||asthma-17/NN	asthma-17||antibiotics-12||no_rel||the available literature was reviewed to examine the links between prescribed antibiotics and childhood eczema and asthma.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatic-37||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
poss||disposal-7/NN||results-1/NNS	amod||disposal-7/NN||$-3/$	amod||disposal-7/NN||insulin-stimulated-5/JJ	nn||disposal-7/NN||glucose-6/NN	nsubj||lower-10/JJR||disposal-7/NN	cop||lower-10/JJR||was-8/VBD	advmod||lower-10/JJR||significantly-9/RB	root||ROOT-0/null||lower-10/JJR	prep_in||lower-10/JJR||subjects-12/NNS	prep_with||subjects-12/NNS||type2diabetes-14/CD	prepc_compared_with||lower-10/JJR||with-16/IN	pobj||lower-10/JJR||subjects-17/NNS	prep_with||subjects-17/NNS||ngt-19/FW	prep_with||subjects-17/NNS||igt-21/FW	conj_and||ngt-19/FW||igt-21/FW	neg||difference-25/NN||no-24/DT	prep_with||lower-10/JJR||difference-25/NN	det||two-29/CD||the-27/DT	amod||two-29/CD||latter-28/JJ	prep_between||difference-25/NN||two-29/CD	type2diabetes-14||insulin--1||yes||results â€”insulin-stimulated glucose disposal was significantly lower in subjects with type2diabetes compared with subjects with ngt and igt, with no difference between the latter two.
prep_in||needed-7/VBN||conclusion-2/NN	amod||monitoring-5/NN||careful-4/JJ	nsubjpass||needed-7/VBN||monitoring-5/NN	auxpass||needed-7/VBN||is-6/VBZ	root||ROOT-0/null||needed-7/VBN	advmod||treating-9/VBG||when-8/WRB	advcl||needed-7/VBN||treating-9/VBG	dobj||treating-9/VBG||patients-10/NNS	prep_with||treating-9/VBG||venlafaxine-12/NN	mark||similar-19/JJ||because-14/IN	poss||syndrome-17/NN||its-15/PRP$	nn||syndrome-17/NN||discontinuation-16/NN	nsubj||similar-19/JJ||syndrome-17/NN	cop||similar-19/JJ||is-18/VBZ	advcl||treating-9/VBG||similar-19/JJ	prep_to||similar-19/JJ||symptoms-21/NNS	amod||depressivedisorder-24/NN||major-23/JJ	prep_of||symptoms-21/NNS||depressivedisorder-24/NN	advmod||result-29/VB||suicidality-27/RB	aux||result-29/VB||may-28/MD	advcl||needed-7/VBN||result-29/VB	conj_and||treating-9/VBG||result-29/VB	det||overdose-32/NN||an-31/DT	prep_from||result-29/VB||overdose-32/NN	depressivedisorder-24||venlafaxine-12||yes||in conclusion, careful monitoring is needed when treating patients with venlafaxine, because its discontinuation syndrome is similar to symptoms of major depressivedisorder, and suicidality may result from an overdose.
det||study-2/NN||the-1/DT	nsubj||suggests-3/VBZ||study-2/NN	ccomp||interpreted-29/VBN||suggests-3/VBZ	det||utility-5/NN||the-4/DT	dobj||suggests-3/VBZ||utility-5/NN	nn||mannan-8/NN||candida-7/NN	prep_of||utility-5/NN||mannan-8/NN	nn||dna-11/NN||candida-10/NN	prep_of||utility-5/NN||dna-11/NN	conj_or||mannan-8/NN||dna-11/NN	det||diagnosis-14/NN||the-13/DT	prep_in||mannan-8/NN||diagnosis-14/NN	prep_of||diagnosis-14/NN||invasivecandidiasis-16/NNS	advmod||suggests-3/VBZ||however-18/RB	det||levels-22/NNS||the-20/DT	nn||levels-22/NNS||bdg-21/NN	nsubjpass||interpreted-29/VBN||levels-22/NNS	amod||subjects-26/NNS||pediatric-24/JJ	nn||subjects-26/NNS||cancer-25/NN	prep_in||levels-22/NNS||subjects-26/NNS	aux||interpreted-29/VBN||should-27/MD	auxpass||interpreted-29/VBN||be-28/VB	root||ROOT-0/null||interpreted-29/VBN	prep_with||interpreted-29/VBN||caution-31/NN	invasivecandidiasis-16||candida-10||no||the study suggests the utility of candida mannan or candida dna in the diagnosis of invasivecandidiasis, however, the bdg levels in pediatric cancer subjects should be interpreted with caution.
det||preponderance-2/NN||the-1/DT	nsubjpass||explained-20/VBN||preponderance-2/NN	num||deaths-5/NNS||rabies-4/CD	dep||connected-6/VBN||deaths-5/NNS	amod||rabiesviruses-17/NNS||connected-6/VBN	det||noctivagans-12/NNS||the-8/DT	num||noctivagans-12/NNS||two-9/CD	amod||noctivagans-12/NNS||uncommon-10/JJ	nn||noctivagans-12/NNS||l.-11/NN	prep_with||connected-6/VBN||noctivagans-12/NNS	nn||subflavus-15/NNS||p.-14/NN	prep_with||connected-6/VBN||subflavus-15/NNS	conj_and||noctivagans-12/NNS||subflavus-15/NNS	nn||rabiesviruses-17/NNS||bat-16/NN	prep_of||preponderance-2/NN||rabiesviruses-17/NNS	auxpass||explained-20/VBN||is-18/VBZ	advmod||explained-20/VBN||best-19/RBS	root||ROOT-0/null||explained-20/VBN	poss||evolution-23/NN||their-22/PRP$	agent||explained-20/VBN||evolution-23/NN	amod||infectivity-27/NN||increased-25/JJ	amod||infectivity-27/NN||viral-26/JJ	prep_of||evolution-23/NN||infectivity-27/NN	rabies-4||rabiesviruses-17||no||the preponderance of rabies deaths connected with the two uncommon l. noctivagans and p. subflavus bat rabiesviruses is best explained by their evolution of increased viral infectivity .
nsubj||consisted-2/VBD||treatment-1/NN	root||ROOT-0/null||consisted-2/VBD	amod||treatment-11/NN||antibiotics-4/JJ	conj_and||antibiotics-4/JJ||corticosteroids-6/JJ	amod||treatment-11/NN||corticosteroids-6/JJ	conj_and||antibiotics-4/JJ||immunoglobulin-8/JJ	amod||treatment-11/NN||immunoglobulin-8/JJ	conj_and||antibiotics-4/JJ||supportive-10/JJ	amod||treatment-11/NN||supportive-10/JJ	prep_of||consisted-2/VBD||treatment-11/NN	prep_for||consisted-2/VBD||haemodynamic-13/JJ	prep_for||consisted-2/VBD||respiratory-15/JJ	conj_and||haemodynamic-13/JJ||respiratory-15/JJ	prep_for||consisted-2/VBD||renalfailure-17/JJ	conj_and||haemodynamic-13/JJ||renalfailure-17/JJ	immunoglobulin-8||renalfailure-17||no_rel||treatment consisted of antibiotics, corticosteroids, immunoglobulin and supportive treatment for haemodynamic, respiratory and renalfailure.
nsubj||results-7/VBZ||infection-1/NN	prep_with||infection-1/NN||mycobacteriumtuberculosis-3/NNS	appos||mycobacteriumtuberculosis-3/NNS||mtb-5/NN	root||ROOT-0/null||results-7/VBZ	amod||outcomes-11/NNS||different-9/JJ	amod||outcomes-11/NNS||clinical-10/JJ	prep_in||results-7/VBZ||outcomes-11/NNS	vmod||outcomes-11/NNS||ranging-12/VBG	amod||containment-15/NN||asymptomatic-14/JJ	prep_from||ranging-12/VBG||containment-15/NN	advmod||progressing-18/VBG||rapidly-17/RB	prepc_to||ranging-12/VBG||progressing-18/VBG	dobj||progressing-18/VBG||tuberculosis-19/NNP	appos||tuberculosis-19/NNP||tb-21/NN	tb-21||mycobacteriumtuberculosis-3||no||infection with mycobacteriumtuberculosis ( mtb ) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (tb).
amod||skinmanifestations-2/NNS||limited-1/JJ	nsubjpass||tackled-6/VBN||skinmanifestations-2/NNS	aux||tackled-6/VBN||may-3/MD	auxpass||tackled-6/VBN||be-4/VB	advmod||tackled-6/VBN||amply-5/RB	root||ROOT-0/null||tackled-6/VBN	amod||therapy-9/NN||topical-8/JJ	agent||tackled-6/VBN||therapy-9/NN	advmod||far-12/RB||so-11/RB	advmod||tackled-6/VBN||far-12/RB	advmod||relying-15/VBG||mainly-14/RB	ccomp||tackled-6/VBN||relying-15/VBG	xcomp||tackled-6/VBN||relying-15/VBG	prep_on||relying-15/VBG||corticosteroids-17/NNS	corticosteroids-17||skinmanifestations-2||no_rel||limited skinmanifestations may be amply tackled by topical therapy, so far, mainly relying on corticosteroids.
nsubj||discovered-3/VBD||we-1/PRP	advmod||discovered-3/VBD||previously-2/RB	root||ROOT-0/null||discovered-3/VBD	det||facet-7/NN||an-4/DT	amod||facet-7/NN||addictive-5/JJ	amod||facet-7/NN||molecular-6/JJ	dobj||discovered-3/VBD||facet-7/NN	prep_of||facet-7/NN||anorexia-9/NNP	vmod||discovered-3/VBD||involving-11/VBG	dobj||involving-11/VBG||production-12/NN	det||accumbens-17/NNS||the-15/DT	nn||accumbens-17/NNS||nucleus-16/NN	prep_in||discovered-3/VBD||accumbens-17/NNS	appos||accumbens-17/NNS||nac-19/NN	det||transcripts-25/NNS||the-23/DT	amod||transcripts-25/NNS||same-24/JJ	prep_of||accumbens-17/NNS||transcripts-25/NNS	vmod||transcripts-25/NNS||stimulated-26/VBN	prep_in||stimulated-26/VBN||response-28/NN	prep_to||stimulated-26/VBN||cocaine-30/NN	prep_to||stimulated-26/VBN||amphetamine-32/NN	conj_and||cocaine-30/NN||amphetamine-32/NN	appos||cocaine-30/NN||cart-34/NN	prep_upon||stimulated-26/VBN||stimulation-37/NN	det||receptors-41/NNS||the-39/DT	amod||receptors-41/NNS||5-ht4-40/JJ	prep_of||stimulation-37/NN||receptors-41/NNS	dep||receptors-41/NNS||5-htr4-43/JJ	prep_of||stimulation-37/NN||mdma-46/NN	conj_or||receptors-41/NNS||mdma-46/NN	appos||receptors-41/NNS||ecstasy-48/NN	amphetamine-32||anorexia-9||no_rel||we previously discovered an addictive molecular facet of anorexia, involving production, in the nucleus accumbens (nac), of the same transcripts stimulated in response to cocaine and amphetamine (cart) upon stimulation of the 5-ht4 receptors (5-htr4) or mdma (ecstasy).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||prevalence-8/NN||the-7/DT	dobj||investigated-6/VBD||prevalence-8/NN	amod||mutations-11/NNS||hnf4a-10/JJ	prep_of||prevalence-8/NN||mutations-11/NNS	det||cohort-15/NN||a-13/DT	amod||cohort-15/NN||large-14/JJ	prep_in||investigated-6/VBD||cohort-15/NN	prep_of||cohort-15/NN||patients-17/NNS	amod||responsive-20/JJ||diazoxide-19/JJ	amod||hypoglycemia-22/NN||responsive-20/JJ	amod||hypoglycemia-22/NN||hyperinsulinemic-21/JJ	prep_with||patients-17/NNS||hypoglycemia-22/NN	appos||hypoglycemia-22/NN||hh-24/NN	hypoglycemia-22||diazoxide-19||no||in this study, we investigated the prevalence of hnf4a mutations in a large cohort of patients with diazoxide responsive hyperinsulinemic hypoglycemia (hh).
advmod||assessed-17/VBN||here-1/RB	det||significance-5/NN||the-3/DT	amod||significance-5/NN||prognostic-4/JJ	nsubjpass||assessed-17/VBN||significance-5/NN	det||marker-9/NN||this-7/DT	amod||marker-9/NN||epigenetic-8/JJ	prep_of||significance-5/NN||marker-9/NN	amod||toxicity-15/NN||severe-13/JJ	amod||toxicity-15/NN||5-fu-14/JJ	prep_with_respect_to||marker-9/NN||toxicity-15/NN	auxpass||assessed-17/VBN||was-16/VBD	root||ROOT-0/null||assessed-17/VBN	num||patients-21/NNS||27-19/CD	nn||patients-21/NNS||cancer-20/NN	prep_in||assessed-17/VBN||patients-21/NNS	vmod||patients-21/NNS||receiving-22/VBG	dobj||receiving-22/VBG||5-fu-23/JJ	vmod||5-fu-23/JJ||based-24/VBN	advmod||based-24/VBN||chemotherapy-25/RB	num||patients-29/NNS||17-28/CD	prep_including||based-24/VBN||patients-29/NNS	vmod||patients-29/NNS||experiencing-30/VBG	amod||effects-34/NNS||severe-31/JJ	amod||effects-34/NNS||toxic-32/JJ	nn||effects-34/NNS||side-33/NN	dobj||experiencing-30/VBG||effects-34/NNS	nn||administration-37/NN||drug-36/NN	prep_following||effects-34/NNS||administration-37/NN	prep_of||none-39/NN||administration-37/NN	nsubj||carriers-43/NNS||none-39/NN	cop||carriers-43/NNS||were-42/VBD	rcmod||administration-37/NN||carriers-43/NNS	det||mutation-49/NN||a-45/DT	amod||mutation-49/NN||known-46/JJ	amod||mutation-49/NN||deleterious-47/JJ	amod||mutation-49/NN||dpyd-48/JJ	prep_of||carriers-43/NNS||mutation-49/NN	num||patients-54/NNS||ten-52/CD	nn||patients-54/NNS||control-53/NN	dobj||receiving-22/VBG||patients-54/NNS	conj_and||5-fu-23/JJ||patients-54/NNS	5-fu-23||cancer-20||no_rel||here, the prognostic significance of this epigenetic marker with respect to severe 5-fu toxicity was assessed in 27 cancer patients receiving 5-fu based chemotherapy, including 17 patients experiencing severe toxic side effects following drug administration, none of which were carriers of a known deleterious dpyd mutation, and ten control patients.
nsubjpass||shown-12/VBN||reduction-1/NN	amod||layer-6/NN||retinal-3/JJ	nn||layer-6/NN||nerve-4/NN	nn||layer-6/NN||fibre-5/NN	prep_of||reduction-1/NN||layer-6/NN	dep||reduction-1/NN||rnfl-8/JJ	advmod||shown-12/VBN||thickness-10/RB	auxpass||shown-12/VBN||was-11/VBD	root||ROOT-0/null||shown-12/VBN	prep_as||shown-12/VBN||part-14/NN	det||process-18/NN||the-16/DT	amod||process-18/NN||neurodegenerative-17/JJ	prep_of||part-14/NN||process-18/NN	det||range-21/NN||a-20/DT	prep_in||shown-12/VBN||range-21/NN	amod||pathologies-25/NNS||different-23/JJ	nn||pathologies-25/NNS||neurodegenerative-24/NN	prep_of||range-21/NN||pathologies-25/NNS	amod||disease-31/NN||alzheimerâ-27/JJ	dep||alzheimerâ-27/JJ||$-28/$	number||s-30/CD||²-29/CD	num||$-28/$||s-30/CD	prep_including||pathologies-25/NNS||disease-31/NN	appos||disease-31/NN||ad-33/NN	amod||parkinsonâ-37/NNS||idiopathic-36/JJ	prep_including||pathologies-25/NNS||parkinsonâ-37/NNS	conj_and||disease-31/NN||parkinsonâ-37/NNS	num||disease-41/NN||$-38/$	number||s-40/CD||™-39/CD	num||$-38/$||s-40/CD	dep||parkinsonâ-37/NNS||disease-41/NN	appos||disease-41/NN||pd-43/NN	nn||ataxia-47/NN||spinocerebellar-46/NN	prep_including||pathologies-25/NNS||ataxia-47/NN	conj_and||disease-31/NN||ataxia-47/NN	appos||ataxia-47/NN||sca-49/NN	amod||atrophy-54/NN||multiple-52/JJ	nn||atrophy-54/NN||system-53/NN	prep_including||pathologies-25/NNS||atrophy-54/NN	conj_and||disease-31/NN||atrophy-54/NN	appos||atrophy-54/NN||msa-56/NN	alzheimer--1||fibre-5||no_rel||reduction of retinal nerve fibre layer (rnfl) thickness was shown as part of the neurodegenerative process in a range of different neurodegenerative pathologies including alzheimerâ€²s disease (ad), idiopathic parkinsonâ€™s disease (pd), spinocerebellar ataxia (sca) and multiple system atrophy (msa).
prep_conclusionsâ||demonstrated-7/VBN||$-2/$	det||study-5/NN||this-4/DT	nsubj||demonstrated-7/VBN||study-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||amplify-16/VB||that-8/IN	amod||administration-10/NN||6-week-9/JJ	nsubj||amplify-16/VB||administration-10/NN	det||fluoxetine-14/NN||the-12/DT	amod||fluoxetine-14/NN||ssri-13/JJ	prep_of||administration-10/NN||fluoxetine-14/NN	aux||amplify-16/VB||can-15/MD	ccomp||demonstrated-7/VBN||amplify-16/VB	nn||mechanisms-21/NNS||ans-17/NN	conj_and||ans-17/NN||metabolic-19/JJ	nn||mechanisms-21/NNS||metabolic-19/JJ	nn||mechanisms-21/NNS||counterregulatory-20/NN	dobj||amplify-16/VB||mechanisms-21/NNS	amod||hypoglycemia-24/NN||moderate-23/JJ	prep_during||amplify-16/VB||hypoglycemia-24/NN	prep_in||hypoglycemia-24/NN||patients-26/NNS	prep_with||patients-26/NNS||type1diabetes-28/CD	hypoglycemia-24||fluoxetine-14||no_rel||conclusionsâ€” this study has demonstrated that 6-week administration of the ssri fluoxetine can amplify ans and metabolic counterregulatory mechanisms during moderate hypoglycemia in patients with type1diabetes.
det||stents-3/NNS||the-1/DT	amod||stents-3/NNS||carvedilol-loaded-2/JJ	nsubj||tended-4/VBD||stents-3/NNS	nsubj||inhibit-6/VB||stents-3/NNS	root||ROOT-0/null||tended-4/VBD	aux||inhibit-6/VB||to-5/TO	xcomp||tended-4/VBD||inhibit-6/VB	amod||hyperplasia-8/NN||neointimal-7/JJ	dobj||inhibit-6/VB||hyperplasia-8/NN	det||occurrence-11/NN||the-10/DT	prep_without||inhibit-6/VB||occurrence-11/NN	amod||myocardialinfarction-16/NN||cardiac-13/JJ	nn||myocardialinfarction-16/NN||death-14/NN	prep_of||occurrence-11/NN||myocardialinfarction-16/NN	nn||thrombosis-20/NNS||stent-19/NN	prep_of||occurrence-11/NN||thrombosis-20/NNS	conj_or||myocardialinfarction-16/NN||thrombosis-20/NNS	amod||follow-up-23/NN||2-year-22/JJ	prep_at||inhibit-6/VB||follow-up-23/NN	myocardialinfarction-16||carvedilol--1||yes||the carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardialinfarction, or stent thrombosis at 2-year follow-up.
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-30/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||pain-18/NN||chronic-15/JJ	amod||pain-18/NN||low-16/JJ	nn||pain-18/NN||back-17/NN	prep_in||activity-13/NN||pain-18/NN	appos||pain-18/NN||cbp-20/NN	nn||osteoarthritis-25/NNS||knee-24/NN	prep_in||treatment-6/NN||osteoarthritis-25/NNS	appos||effects-2/NNS||oa-27/NN	auxpass||investigated-30/VBN||were-29/VBD	root||ROOT-0/null||investigated-30/VBN	xcomp||investigated-30/VBN||using-31/VBG	amod||fmri-33/NNS||serial-32/JJ	dobj||using-31/VBG||fmri-33/NNS	dep||fmri-33/NNS||contrasting-35/VBG	dobj||contrasting-35/VBG||fmri-36/NNS	advmod||weeks-42/NNS||before-38/RB	conj_and||before-38/RB||after-40/IN	advmod||weeks-42/NNS||after-40/IN	pobj||after-40/IN||two-41/CD	prep_between||fmri-36/NNS||weeks-42/NNS	prep_of||fmri-36/NNS||treatment-44/NN	lidocaine-8||osteoarthritis-25||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic low back pain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
det||kits-5/NNS||the-1/DT	num||kits-5/NNS||70-2/CD	amod||kits-5/NNS||hbsag-3/JJ	nn||kits-5/NNS||test-4/NN	nsubjpass||evaluated-11/VBN||kits-5/NNS	advmod||world-9/NN||around-7/RB	det||world-9/NN||the-8/DT	prep_from||kits-5/NNS||world-9/NN	auxpass||evaluated-11/VBN||were-10/VBD	root||ROOT-0/null||evaluated-11/VBN	amod||a-f-56/NNS||comparatively-12/RB	poss||sensitivity-16/NN||their-14/PRP$	amod||sensitivity-16/NN||clinical-15/JJ	prep_for||comparatively-12/RB||sensitivity-16/NN	amod||sensitivity-19/NN||analytical-18/JJ	prep_for||comparatively-12/RB||sensitivity-19/NN	conj_and||sensitivity-16/NN||sensitivity-19/NN	prep_for||comparatively-12/RB||sensitivity-21/NN	conj_and||sensitivity-16/NN||sensitivity-21/NN	nn||genotypes-24/NNS||hbv-23/NN	prep_to||sensitivity-21/NN||genotypes-24/NNS	nn||subtypes-27/NNS||hbsag-26/NN	prep_to||sensitivity-21/NN||subtypes-27/NNS	conj_and||genotypes-24/NNS||subtypes-27/NNS	prep_for||comparatively-12/RB||specificity-30/NN	conj_and||sensitivity-16/NN||specificity-30/NN	vmod||specificity-30/NN||using-31/VBG	amod||icbs-43/NNS||394-32/JJ	num||clinical-35/NNS||146-34/CD	dep||icbs-43/NNS||clinical-35/NNS	num||analytical-38/NNS||48-37/CD	conj_and||clinical-35/NNS||analytical-38/NNS	dep||icbs-43/NNS||analytical-38/NNS	num||negative-41/NN||200-40/CD	conj_and||clinical-35/NNS||negative-41/NN	dep||icbs-43/NNS||negative-41/NN	dobj||using-31/VBG||icbs-43/NNS	nn||members-46/NNS||master-44/NN	nn||members-46/NNS||panel-45/NN	dep||specificity-30/NN||members-46/NNS	amod||origin-50/NN||diverse-48/JJ	amod||origin-50/NN||geographical-49/JJ	prep_of||members-46/NNS||origin-50/NN	vmod||origin-50/NN||comprising-51/VBG	det||genotypes-55/NNS||the-52/DT	amod||genotypes-55/NNS||major-53/JJ	nn||genotypes-55/NNS||hbv-54/NN	dobj||comprising-51/VBG||genotypes-55/NNS	dobj||evaluated-11/VBN||a-f-56/NNS	det||subtypes-60/NNS||the-58/DT	amod||subtypes-60/NNS||hbsag-59/VBG	dobj||evaluated-11/VBN||subtypes-60/NNS	conj_and||a-f-56/NNS||subtypes-60/NNS	amod||subtypes-60/NNS||adw2-61/JJ	dep||adw2-61/JJ||,4-62/CD	num||,4-62/CD||adr-64/CD	dep||adw2-61/JJ||ayw1-4-66/CD	conj_and||,4-62/CD||ayw1-4-66/CD	hbv-54||hbsag-59||yes||the 70 hbsag test kits from around the world were evaluated comparatively for their clinical sensitivity, analytical sensitivity, sensitivity to hbv genotypes and hbsag subtypes, and specificity using 394 (146 clinical, 48 analytical and 200 negative) icbs master panel members of diverse geographical origin comprising the major hbv genotypes a-f and the hbsag subtypes adw2,4 , adr and ayw1-4 .
amod||models-2/NNS||prognostic-1/JJ	nsubj||used-3/VBD||models-2/NNS	root||ROOT-0/null||used-3/VBD	amod||analysis-7/NN||multivariate-4/JJ	nn||analysis-7/NN||cox-5/NN	nn||analysis-7/NN||regression-6/NN	dobj||used-3/VBD||analysis-7/NN	amod||analyses-10/NNS||multivariate-9/JJ	prep_for||analysis-7/NN||analyses-10/NNS	prep_of||analyses-10/NNS||survival-12/NN	poss||study-15/NN||our-14/PRP$	nsubj||showed-16/VBD||study-15/NN	parataxis||used-3/VBD||showed-16/VBD	nsubj||p-lvd-18/JJ||that-17/DT	nsubj||i-lvd-22/JJ||that-17/DT	nsubjpass||correlated-26/VBN||that-17/DT	xcomp||showed-16/VBD||p-lvd-18/JJ	xcomp||showed-16/VBD||i-lvd-22/JJ	conj_negcc||p-lvd-18/JJ||i-lvd-22/JJ	auxpass||correlated-26/VBN||was-24/VBD	advmod||correlated-26/VBN||significantly-25/RB	xcomp||showed-16/VBD||correlated-26/VBN	ccomp||p-lvd-18/JJ||correlated-26/VBN	conj_negcc||p-lvd-18/JJ||correlated-26/VBN	nn||invasion-31/NN||lymph-28/NN	nn||invasion-31/NN||vascular-29/NN	nn||invasion-31/NN||space-30/NN	prep_with||correlated-26/VBN||invasion-31/NN	appos||invasion-31/NN||lvsi-33/NNP	nn||metastasis-38/NNS||lymph-36/NN	nn||metastasis-38/NNS||node-37/NN	prep_with||correlated-26/VBN||metastasis-38/NNS	conj_and||invasion-31/NN||metastasis-38/NNS	nn||stage-41/NN||tumor-40/NN	prep_with||correlated-26/VBN||stage-41/NN	conj_and||invasion-31/NN||stage-41/NN	amod||expression-45/NN||cd44-44/JJ	prep_with||correlated-26/VBN||expression-45/NN	conj_and||invasion-31/NN||expression-45/NN	amod||carcinoma-48/NN||endometrial-47/JJ	prep_in||correlated-26/VBN||carcinoma-48/NN	i---1||metastasis-38||no_rel||prognostic models used multivariate cox regression analysis for multivariate analyses of survival; our study showed that p-lvd, but not i-lvd, was significantly correlated with lymph vascular space invasion (lvsi), lymph node metastasis, tumor stage, and cd44 expression in endometrial carcinoma.
nsubj||observed-2/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	det||increase-5/NN||a-3/DT	amod||increase-5/NN||significant-4/JJ	dobj||observed-2/VBD||increase-5/NN	nn||uti-9/NN||e.-7/NN	nn||uti-9/NN||coli-8/NNS	prep_in||observed-2/VBD||uti-9/NN	amod||infants-12/NNS||fwls-11/JJ	prep_among||uti-9/NN||infants-12/NNS	amod||rates-15/NNS||high-14/JJ	prep_with||observed-2/VBD||rates-15/NNS	nn||resistance-18/NN||ampicillin-17/NN	prep_of||rates-15/NNS||resistance-18/NN	uti-9||ampicillin-17||yes||we observed a significant increase in e. coli uti among fwls infants with high rates of ampicillin resistance .
nsubj||dependent-3/JJ||liverinflammation-1/NN	cop||dependent-3/JJ||was-2/VBD	root||ROOT-0/null||dependent-3/JJ	prep_on||dependent-3/JJ||genotype-5/NN	amod||type-10/NN||apoe2ki-7/JJ	amod||type-10/NN||>-8/JJ	amod||type-10/NN||wild-9/JJ	dep||genotype-5/NN||type-10/NN	prep_on||dependent-3/JJ||gender-13/NN	conj_and||genotype-5/NN||gender-13/NN	amod||male-17/NN||female-15/JJ	amod||male-17/NN||>-16/JJ	appos||gender-13/NN||male-17/NN	nn||content-22/NN||cholesterol-21/NN	prep_on||dependent-3/JJ||content-22/NN	conj_and||genotype-5/NN||content-22/NN	amod||low-26/NN||high-24/JJ	amod||low-26/NN||>-25/JJ	appos||content-22/NN||low-26/NN	det||diet-30/NN||the-29/DT	prep_of||content-22/NN||diet-30/NN	neg||dependent-3/JJ||not-33/RB	advmod||fat-36/JJ||dietary-35/RB	amod||composition-37/NN||fat-36/JJ	prep_on||dependent-3/JJ||composition-37/NN	conj_but||genotype-5/NN||composition-37/NN	cholesterol-21||liverinflammation-1||no_rel||liverinflammation was dependent on genotype (apoe2ki > wild type), gender (female > male), and cholesterol content (high > low) of the diet, but not on dietary fat composition.
amod||alters-4/NNS||adjunctive-1/JJ	amod||alters-4/NNS||quetiapine-2/JJ	nn||alters-4/NNS||treatment-3/NN	nsubj||sleep-5/VBP||alters-4/NNS	root||ROOT-0/null||sleep-5/VBP	dobj||sleep-5/VBP||architecture-6/NN	prep_in||sleep-5/VBP||patients-8/NNS	nsubj||explain-18/VB||patients-8/NNS	amod||depressivedisorder-11/NN||major-10/JJ	prep_with||patients-8/NNS||depressivedisorder-11/NN	prep_with||patients-8/NNS||bipolardisorder-13/NN	conj_or||depressivedisorder-11/NN||bipolardisorder-13/NN	aux||explain-18/VB||may-16/MD	advmod||explain-18/VB||partially-17/RB	rcmod||patients-8/NNS||explain-18/VB	poss||properties-22/NNS||its-19/PRP$	amod||properties-22/NNS||early-20/JJ	nn||properties-22/NNS||antidepressant-21/NN	dobj||explain-18/VB||properties-22/NNS	bipolardisorder-13||quetiapine-2||yes||adjunctive quetiapine treatment alters sleep architecture in patients with major depressivedisorder or bipolardisorder, which may partially explain its early antidepressant properties.
amod||transcription-3/NN||herv-w-1/JJ	nn||transcription-3/NN||env-2/NN	nsubjpass||found-5/VBN||transcription-3/NN	nsubjpass||elevated-8/VBN||transcription-3/NN	auxpass||found-5/VBN||was-4/VBD	root||ROOT-0/null||found-5/VBN	aux||elevated-8/VBN||to-6/TO	auxpass||elevated-8/VBN||be-7/VB	xcomp||found-5/VBN||elevated-8/VBN	prep_in||elevated-8/VBN||bd-10/NN	nsubj||<-13/VBP||p-12/PRP	dep||elevated-8/VBN||<-13/VBP	amod||$-15/$||10â-14/VBD	dobj||<-13/VBP||$-15/$	num||$-15/$||4-17/CD	prep_in||elevated-8/VBN||sz-21/NN	conj_and||bd-10/NN||sz-21/NN	dep||sz-21/NN||p-23/VBN	dep||0.012-25/CD||=-24/SYM	ccomp||p-23/VBN||0.012-25/CD	advmod||elevated-8/VBN||as-27/RB	prepc_compared_with||elevated-8/VBN||with-29/IN	pobj||elevated-8/VBN||hc-30/NN	xcomp||found-5/VBN||with-33/IN	conj_but||elevated-8/VBN||with-33/IN	amod||values-35/NNS||higher-34/JJR	pobj||with-33/IN||values-35/NNS	prep_in||values-35/NNS||bd-37/NN	prep||bd-37/NN||than-38/IN	pcomp||than-38/IN||in-39/IN	nn||group-41/NN||sz-40/NN	pobj||in-39/IN||group-41/NN	dep||values-35/NNS||p-43/VBN	dep||0.01-45/CD||<-44/SYM	ccomp||p-43/VBN||0.01-45/CD	hc-30||sz-40||no_rel||herv-w env transcription was found to be elevated in bd ( p <10â€“4) and in sz ( p =0.012) as compared with hc, but with higher values in bd than in sz group ( p <0.01).
det||study-3/NN||a-1/DT	amod||study-3/NN||cross-sectional-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	num||patients-9/NNS||1143-7/CD	nn||patients-9/NNS||hiv-8/NN	prep_among||conducted-5/VBN||patients-9/NNS	prep_under||conducted-5/VBN||follow-up-11/NN	det||center-17/NN||a-13/DT	amod||center-17/NN||hiv/aids-14/JJ	nn||center-17/NN||outpatient-15/NN	nn||center-17/NN||reference-16/NN	prep_in||follow-up-11/NN||center-17/NN	det||system-23/NN||the-19/DT	amod||system-23/NN||brazilian-20/JJ	amod||system-23/NN||public-21/JJ	nn||system-23/NN||health-22/NN	prep_of||center-17/NN||system-23/NN	aids--1||hiv-8||no||a cross-sectional study was conducted among 1143 hiv patients under follow-up in a hiv/aids outpatient reference center of the brazilian public health system.
root||ROOT-0/null||herein-1/VB	nsubj||document-4/VB||we-3/PRP	ccomp||herein-1/VB||document-4/VB	mark||provides-14/VBZ||that-5/IN	det||signature-8/NN||the-6/DT	amod||signature-8/NN||bioenergetic-7/JJ	nsubj||provides-14/VBZ||signature-8/NN	amod||cells-13/NNS||isogenic-10/JJ	nn||cells-13/NNS||colon-11/NN	nn||cells-13/NNS||cancer-12/NN	prep_of||signature-8/NN||cells-13/NNS	ccomp||document-4/VB||provides-14/VBZ	det||gauge-16/NN||a-15/DT	dobj||provides-14/VBZ||gauge-16/NN	aux||predict-18/VB||to-17/TO	vmod||gauge-16/NN||predict-18/VB	det||response-21/NN||the-19/DT	amod||response-21/NN||cell-death-20/JJ	dobj||predict-18/VB||response-21/NN	det||inhibitors-25/NNS||the-23/DT	amod||inhibitors-25/NNS||metabolic-24/JJ	prep_to||predict-18/VB||inhibitors-25/NNS	amod||3brp-29/NNS||3-bromopyruvate-27/JJ	prep_to||predict-18/VB||3brp-29/NNS	conj_and||inhibitors-25/NNS||3brp-29/NNS	amod||ia-34/NN||iodoacetate-32/JJ	prep_to||predict-18/VB||ia-34/NN	conj_and||inhibitors-25/NNS||ia-34/NN	det||anti-metabolite-39/NN||the-38/DT	prep_to||predict-18/VB||anti-metabolite-39/NN	conj_and||inhibitors-25/NNS||anti-metabolite-39/NN	prep_to||predict-18/VB||5-fluorouracil-41/NN	conj_and||inhibitors-25/NNS||5-fluorouracil-41/NN	dep||inhibitors-25/NNS||5-fu-43/JJ	cancer-12||5-fluorouracil-41||no_rel||herein, we document that the bioenergetic signature of isogenic colon cancer cells provides a gauge to predict the cell-death response to the metabolic inhibitors, 3-bromopyruvate (3brp) and iodoacetate (ia), and the anti-metabolite, 5-fluorouracil (5-fu).
amod||myotubes-2/NNS||c2c12-1/JJ	nsubjpass||used-11/VBN||myotubes-2/NNS	nsubj||evaluate-13/VB||myotubes-2/NNS	det||model-7/NN||the-4/DT	amod||model-7/NN||kk-ay-5/JJ	nn||model-7/NN||murine-6/NN	conj_and||myotubes-2/NNS||model-7/NN	nsubjpass||used-11/VBN||model-7/NN	nsubj||evaluate-13/VB||model-7/NN	prep_of||model-7/NN||type2diabetes-9/CD	auxpass||used-11/VBN||were-10/VBD	root||ROOT-0/null||used-11/VBN	aux||evaluate-13/VB||to-12/TO	xcomp||used-11/VBN||evaluate-13/VB	det||effect-15/NN||the-14/DT	dobj||evaluate-13/VB||effect-15/NN	nsubjpass||upregulated-38/VBN||effect-15/NN	prep_of||effect-15/NN||pmi5011-17/NNS	amod||levels-20/NNS||steady-state-19/JJ	prep_on||pmi5011-17/NNS||levels-20/NNS	amod||activity-25/NN||ubiquitylation-22/JJ	prep_of||levels-20/NNS||proteasome-24/JJ	amod||activity-25/NN||proteasome-24/JJ	conj_and||activity-25/NN||proteasome-24/JJ	prep_of||levels-20/NNS||activity-25/NN	prep_of||levels-20/NNS||expression-27/NN	conj_and||activity-25/NN||expression-27/NN	dep||muscle-specific-33/JJ||atrogin-1-29/JJ	conj_and||muscle-specific-33/JJ||murf-1-31/JJ	amod||ligases-35/NNS||murf-1-31/JJ	amod||ligases-35/NNS||muscle-specific-33/JJ	nn||ligases-35/NNS||ubiquitin-34/NN	prep_of||levels-20/NNS||ligases-35/NNS	auxpass||upregulated-38/VBN||are-37/VBP	rcmod||effect-15/NN||upregulated-38/VBN	amod||insulin-41/NN||impaired-40/VBN	prep_with||upregulated-38/VBN||insulin-41/NN	vmod||insulin-41/NN||signaling-42/VBG	type2diabetes-9||insulin-41||yes||c2c12 myotubes and the kk-ay murine model of type2diabetes were used to evaluate the effect of pmi5011 on steady-state levels of ubiquitylation, proteasome activity and expression of atrogin-1 and murf-1, muscle-specific ubiquitin ligases that are upregulated with impaired insulin signaling.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||compare-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||compare-4/VB||to-3/TO	xcomp||aimed-2/VBD||compare-4/VB	det||effects-6/NNS||the-5/DT	dobj||compare-4/VB||effects-6/NNS	prep_of||effects-6/NNS||sufentanil-8/NN	amod||doses-11/NNS||analgesic-10/JJ	prep_in||sufentanil-8/NN||doses-11/NNS	prepc_for||compare-4/VB||reducing-13/VBG	det||pain-16/NN||the-14/DT	nn||pain-16/NN||injection-15/NN	dobj||reducing-13/VBG||pain-16/NN	nn||propofol-19/NN||microemulsion-18/NN	prep_of||pain-16/NN||propofol-19/NN	pain-16||sufentanil-8||yes||we aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain of microemulsion propofol.
advmod||show-4/VBP||here-1/RB	nsubj||show-4/VBP||we-3/PRP	root||ROOT-0/null||show-4/VBP	mark||promotes-32/VBZ||that-5/IN	amod||expression-7/NN||ectopic-6/JJ	nsubj||promotes-32/VBZ||expression-7/NN	det||isoform-13/NN||a-9/DT	advmod||important-11/JJ||clinically-10/RB	amod||isoform-13/NN||important-11/JJ	amod||isoform-13/NN||oncogenic-12/JJ	prep_of||expression-7/NN||isoform-13/NN	prep_of||isoform-13/NN||her2-15/NNS	appos||her2-15/NNS||her2î-17/NNS	dep||expression-7/NN||16-19/CD	nsubjpass||expressed-23/VBN||16-19/CD	auxpass||expressed-23/VBN||is-22/VBZ	rcmod||16-19/CD||expressed-23/VBN	num||%-27/NN||>-25/CD	num||%-27/NN||30-26/CD	prep_in||expressed-23/VBN||%-27/NN	amod||breasttumors-30/NNS||er-positive-29/JJ	prep_of||%-27/NN||breasttumors-30/NNS	ccomp||show-4/VBP||promotes-32/VBZ	nn||resistance-34/NN||tamoxifen-33/NN	dobj||promotes-32/VBZ||resistance-34/NN	nn||independence-37/NN||estrogen-36/NN	dobj||promotes-32/VBZ||independence-37/NN	conj_and||resistance-34/NN||independence-37/NN	amod||xenografts-40/NNS||mcf-7-39/JJ	prep_of||resistance-34/NN||xenografts-40/NNS	breasttumors-30||estrogen-36||no||here, we show that ectopic expression of a clinically important oncogenic isoform of her2, her2î”16, which is expressed in >30% of er-positive breasttumors, promotes tamoxifen resistance and estrogen independence of mcf-7 xenografts.
nsubjpass||included-30/VBN||patients-1/NNS	advmod||hypertension-5/NN||previously-3/RB	amod||hypertension-5/NN||uncontrolled-4/JJ	prep_with||patients-1/NNS||hypertension-5/NN	quantmod||one-9/CD||at-7/IN	mwe||at-7/IN||least-8/JJS	pobj||at-7/IN||least-8/JJS	num||factor-12/NN||one-9/CD	amod||factor-12/NN||further-10/JJ	nn||factor-12/NN||risk-11/NN	prep_with||hypertension-5/NN||factor-12/NN	prep_in||deemed-16/VBD||factor-12/NN	nsubj||deemed-16/VBD||physicians-15/NNS	rcmod||factor-12/NN||deemed-16/VBD	det||treatment-18/NN||a-17/DT	dobj||deemed-16/VBD||treatment-18/NN	num||hctz-25/NNS||16-20/CD	amod||hctz-25/NNS||mg-21/JJ	amod||hctz-25/NNS||candesartan/12-22/JJ	num||hctz-25/NNS||.5-23/CD	nn||hctz-25/NNS||mg-24/NN	prep_with||deemed-16/VBD||hctz-25/NNS	aux||necessary-28/JJ||to-26/TO	cop||necessary-28/JJ||be-27/VB	vmod||deemed-16/VBD||necessary-28/JJ	auxpass||included-30/VBN||were-29/VBD	root||ROOT-0/null||included-30/VBN	hypertension-5||candesartan--1||yes||patients with previously uncontrolled hypertension with at least one further risk factor in which physicians deemed a treatment with 16 mg candesartan/12.5 mg hctz to be necessary were included.
det||potency-2/NN||the-1/DT	nsubj||comparable-18/JJ||potency-2/NN	prepc_of||potency-2/NN||pgg-ptx-4/VBG	advmod||tested-6/VBN||when-5/WRB	advcl||pgg-ptx-4/VBG||tested-6/VBN	amod||line-16/NN||vitro-8/NN	det||cancer-13/NN||the-10/DT	amod||cancer-13/NN||human-11/JJ	nn||cancer-13/NN||lung-12/NN	prep_against||vitro-8/NN||cancer-13/NN	amod||line-16/NN||h460-14/JJ	nn||line-16/NN||cell-15/NN	prep_in||tested-6/VBN||line-16/NN	cop||comparable-18/JJ||was-17/VBD	root||ROOT-0/null||comparable-18/JJ	amod||conjugates-23/NNS||other-20/JJ	amod||conjugates-23/NNS||known-21/VBN	amod||conjugates-23/NNS||polymer-ptx-22/JJ	prep_to||comparable-18/JJ||conjugates-23/NNS	ptx--1||cancer-13||no_rel||the potency of pgg-ptx when tested in vitro against the human lung cancer h460 cell line was comparable to other known polymer-ptx conjugates.
nn||ifn-2/NNP||alpha-1/NNP	nsubj||studied-6/NN||ifn-2/NNP	cop||studied-6/NN||is-3/VBZ	det||studied-6/NN||the-4/DT	amod||studied-6/NN||best-5/JJS	root||ROOT-0/null||studied-6/NN	nn||activity-9/NN||displays-8/NNS	conj_and||studied-6/NN||activity-9/NN	amod||diseases-13/NNS||many-11/JJ	amod||diseases-13/NNS||neoplastic-12/JJ	prep_in||studied-6/NN||diseases-13/NNS	nsubj||shown-17/VBN||it-15/PRP	aux||shown-17/VBN||has-16/VBZ	parataxis||studied-6/NN||shown-17/VBN	det||promise-20/NN||the-18/DT	amod||promise-20/NN||most-19/JJS	dobj||shown-17/VBN||promise-20/NN	det||cancers-24/NNS||the-22/DT	amod||cancers-24/NNS||hematological-23/JJ	prep_in||promise-20/NN||cancers-24/NNS	mark||respond-41/VB||although-25/IN	amod||tumors-28/NNS||several-26/JJ	amod||tumors-28/NNS||solid-27/JJ	nsubj||respond-41/VB||tumors-28/NNS	nn||kaposi-32/NNS||epidemic-31/NN	poss||sarcoma-34/NN||kaposi-32/NNS	prep_including||tumors-28/NNS||sarcoma-34/NN	prep_including||tumors-28/NNS||renalcellcarcinoma-36/NN	conj_and||sarcoma-34/NN||renalcellcarcinoma-36/NN	prep_including||tumors-28/NNS||melanoma-39/NN	conj_and||sarcoma-34/NN||melanoma-39/NN	advcl||shown-17/VBN||respond-41/VB	melanoma-39||ifn-2||yes||alpha ifn is the best studied and displays activity in many neoplastic diseases; it has shown the most promise in the hematological cancers although several solid tumors, including epidemic kaposi's sarcoma, renalcellcarcinoma, and melanoma, respond.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubj||had-7/VBD||plus-5/NN	advmod||had-7/VBD||assay-6/RB	root||ROOT-0/null||had-7/VBD	det||sensitivity-9/NN||a-8/DT	dobj||had-7/VBD||sensitivity-9/NN	num||%-12/NN||95.3-11/CD	prep_of||sensitivity-9/NN||%-12/NN	num||%-15/NN||100-14/CD	prep_of||sensitivity-9/NN||%-15/NN	conj_and||%-12/NN||%-15/NN	num||%-19/NN||94.4-18/CD	prep_of||sensitivity-9/NN||%-19/NN	conj_and||%-12/NN||%-19/NN	nn||resistance-22/NN||inh-21/NN	prep_for||had-7/VBD||resistance-22/NN	nn||resistance-25/NN||rif-24/NN	prep_for||had-7/VBD||resistance-25/NN	conj_and||resistance-22/NN||resistance-25/NN	prep_for||had-7/VBD||mdr-tb-28/NN	conj_and||resistance-22/NN||mdr-tb-28/NN	advmod||had-7/VBD||respectively-30/RB	tb--1||inh-21||yes||the genotypeâ® mtbdr plus assay had a sensitivity of 95.3%, 100%, and 94.4% for inh resistance, rif resistance, and mdr-tb, respectively.
amod||patients-4/NNS||intensive-1/JJ	nn||patients-4/NNS||care-2/NN	nn||patients-4/NNS||unit-3/NN	nsubj||have-6/VBP||patients-4/NNS	advmod||have-6/VBP||usually-5/RB	root||ROOT-0/null||have-6/VBP	det||glucose-9/NN||a-7/DT	amod||glucose-9/NN||deregulated-8/VBN	dobj||have-6/VBP||glucose-9/NN	amod||glucose-9/NN||homeostasis-10/JJ	amod||glucose-9/NN||present-12/JJ	conj_and||homeostasis-10/JJ||present-12/JJ	prep_with||glucose-9/NN||hyperglycemia-14/NN	prep_with||glucose-9/NN||hyperinsulinemia-16/NN	conj_and||hyperglycemia-14/NN||hyperinsulinemia-16/NN	vmod||glucose-9/NN||suggesting-18/VBG	amod||insulinresistance-20/NN||overall-19/JJ	dobj||suggesting-18/VBG||insulinresistance-20/NN	hyperglycemia-14||glucose-9||no||intensive care unit patients usually have a deregulated glucose homeostasis and present with hyperglycemia and hyperinsulinemia, suggesting overall insulinresistance.
nsubj||produced-2/VBD||we-1/PRP	root||ROOT-0/null||produced-2/VBD	det||vaccine-5/NN||a-3/DT	amod||vaccine-5/NN||conjugate-4/JJ	nsubj||expressed-11/VBD||vaccine-5/NN	prep_against||vaccine-5/NN||wnv-7/NN	vmod||wnv-7/NN||consisting-8/VBG	prep_of||consisting-8/VBG||recombinantly-10/NN	ccomp||produced-2/VBD||expressed-11/VBD	nn||iii-13/NN||domain-12/NN	dobj||expressed-11/VBD||iii-13/NN	appos||iii-13/NN||diii-15/NNP	det||glycoprotein-20/NN||the-18/DT	amod||glycoprotein-20/NN||e-19/JJ	prep_of||iii-13/NN||glycoprotein-20/NN	advmod||cross-linked-22/VBN||chemically-21/RB	vmod||glycoprotein-20/NN||cross-linked-22/VBN	amod||particles-25/NNS||virus-like-24/JJ	prep_to||cross-linked-22/VBN||particles-25/NNS	vmod||particles-25/NNS||derived-26/VBN	det||ap205-32/NN||the-28/DT	advmod||discovered-30/VBN||recently-29/RB	amod||ap205-32/NN||discovered-30/VBN	nn||ap205-32/NN||bacteriophage-31/NN	prep_from||derived-26/VBN||ap205-32/NN	cross--1||chemically-21||no_rel||we produced a conjugate vaccine against wnv consisting of recombinantly expressed domain iii (diii) of the e glycoprotein chemically cross-linked to virus-like particles derived from the recently discovered bacteriophage ap205.
nsubjpass||discussed-6/VBN||treatment-1/NN	amod||malaria-4/NN||chloroquine-resistant-3/JJ	prep_of||treatment-1/NN||malaria-4/NN	auxpass||discussed-6/VBN||is-5/VBZ	root||ROOT-0/null||discussed-6/VBN	malaria-4||chloroquine--1||yes||treatment of chloroquine-resistant malaria is discussed.
det||protection-3/NN||the-1/DT	amod||protection-3/NN||acute-2/JJ	nsubj||supports-19/VBZ||protection-3/NN	amod||stimuli-7/NNS||subsequent-5/JJ	nn||stimuli-7/NNS||bronchoconstrictor-6/NN	prep_against||protection-3/NN||stimuli-7/NNS	amod||amp-11/NN||inhaled-10/JJ	prep_such_as||stimuli-7/NNS||amp-11/NN	det||reversal-15/NN||the-13/DT	amod||reversal-15/NN||rapid-14/JJ	prep_such_as||stimuli-7/NNS||reversal-15/NN	conj_and||amp-11/NN||reversal-15/NN	amod||obstruction-18/NN||airway-17/JJ	prep_of||reversal-15/NN||obstruction-18/NN	root||ROOT-0/null||supports-19/VBZ	det||use-21/NN||the-20/DT	dobj||supports-19/VBZ||use-21/NN	prep_of||use-21/NN||budesonide/formoterol-23/NN	preconj||relief-26/NN||both-25/DT	prep_for||supports-19/VBZ||relief-26/NN	prep_for||supports-19/VBZ||prevention-28/NN	conj_and||relief-26/NN||prevention-28/NN	det||treatment-31/NN||the-30/DT	prep_in||relief-26/NN||treatment-31/NN	prep_of||treatment-31/NN||asthma-33/NN	asthma-33||budesonide--1||no||the acute protection against subsequent bronchoconstrictor stimuli such as inhaled amp and the rapid reversal of airway obstruction supports the use of budesonide/formoterol for both relief and prevention in the treatment of asthma.
nsubj||indicate-2/VBP||studies-1/NNS	root||ROOT-0/null||indicate-2/VBP	mark||induced-7/VBN||that-3/IN	nsubjpass||induced-7/VBN||insulinresistance-4/NN	aux||induced-7/VBN||can-5/MD	auxpass||induced-7/VBN||be-6/VB	ccomp||indicate-2/VBP||induced-7/VBN	agent||induced-7/VBN||stimulating-9/VBG	det||degradation-11/NN||the-10/DT	dobj||stimulating-9/VBG||degradation-11/NN	amod||molecules-14/NNS||important-13/JJ	prep_of||degradation-11/NN||molecules-14/NNS	det||insulin-17/NN||the-16/DT	prep_in||stimulating-9/VBG||insulin-17/NN	vmod||insulin-17/NN||signaling-18/VBG	advmod||signaling-18/VBG||pathway-19/RB	amod||akt1-34/NNS||particular-22/JJ	det||irs1-28/NNS||the-23/DT	nn||irs1-28/NNS||insulin-24/NN	nn||irs1-28/NNS||receptor-25/NN	nn||irs1-28/NNS||substrate-26/NN	nn||irs1-28/NNS||proteins-27/NNS	dep||particular-22/JJ||irs1-28/NNS	dep||particular-22/JJ||irs2-30/NNS	conj_and||irs1-28/NNS||irs2-30/NNS	det||kinase-33/NN||the-32/DT	dep||particular-22/JJ||kinase-33/NN	conj_and||irs1-28/NNS||kinase-33/NN	prep_in||signaling-18/VBG||akt1-34/NNS	appos||akt1-34/NNS||akt-36/NN	insulin-24||insulinresistance-4||no_rel||studies indicate that insulinresistance can be induced by stimulating the degradation of important molecules in the insulin signaling pathway, in particular the insulin receptor substrate proteins irs1, irs2 and the kinase akt1 (akt).
det||rationale-2/NN||the-1/DT	nsubj||starts-12/VBZ||rationale-2/NN	amod||humanpapillomavirus-6/NNS||current-4/JJ	amod||humanpapillomavirus-6/NNS||worldwide-5/JJ	prep_behind||rationale-2/NN||humanpapillomavirus-6/NNS	dep||rationale-2/NN||hpv-8/VBN	nn||programs-11/NNS||vaccination-10/NN	dep||rationale-2/NN||programs-11/NNS	root||ROOT-0/null||starts-12/VBZ	num||premises-16/NNS||two-14/CD	amod||premises-16/NNS||basic-15/JJ	prep_from||starts-12/VBZ||premises-16/NNS	dep||have-33/VBP||1-18/LS	mark||prevent-23/VB||that-20/IN	nsubj||prevent-23/VB||hpvvaccines-21/NNS	nsubj||save-27/VB||hpvvaccines-21/NNS	aux||prevent-23/VB||will-22/MD	advcl||have-33/VBP||prevent-23/VB	amod||cancers-25/NNS||cervical-24/JJ	dobj||prevent-23/VB||cancers-25/NNS	conj_and||prevent-23/VB||save-27/VB	advcl||have-33/VBP||save-27/VB	iobj||save-27/VB||lives-28/NNS	dobj||save-27/VB||and-29/NNP	nsubj||have-33/VBP||2-31/CD	parataxis||starts-12/VBZ||have-33/VBP	neg||risk-35/NN||no-34/DT	dobj||have-33/VBP||risk-35/NN	amod||effects-39/NNS||serious-37/JJ	nn||effects-39/NNS||side-38/NN	prep_of||risk-35/NN||effects-39/NNS	cancers-25||basic-15||no_rel||the rationale behind current worldwide humanpapillomavirus (hpv) vaccination programs starts from two basic premises, 1) that hpvvaccines will prevent cervical cancers and save lives and, 2) have no risk of serious side effects.
advmod||consisted-5/VBD||histologically-1/RB	det||tumor-4/NN||the-3/DT	nsubj||consisted-5/VBD||tumor-4/NN	root||ROOT-0/null||consisted-5/VBD	amod||nests-8/NNS||organoid-7/JJ	prep_of||consisted-5/VBD||nests-8/NNS	amod||cells-12/NNS||large-10/JJ	amod||cells-12/NNS||polygonal-11/JJ	prep_of||nests-8/NNS||cells-12/NNS	prep_of||cytoplasm-15/NN||cells-12/NNS	det||cytoplasm-15/NN||the-14/DT	nsubj||had-18/VBD||cytoplasm-15/NN	rcmod||cells-12/NNS||had-18/VBD	amod||granules-23/NNS||eosinophilic-19/JJ	conj_and||eosinophilic-19/JJ||d-pas-21/JJ	amod||granules-23/NNS||d-pas-21/JJ	amod||granules-23/NNS||positive-22/JJ	dobj||had-18/VBD||granules-23/NNS	pas--1||tumor-4||no_rel||histologically, the tumor consisted of organoid nests of large polygonal cells, the cytoplasm of which had eosinophilic and d-pas positive granules.
nsubj||shown-3/VBN||we-1/PRP	aux||shown-3/VBN||have-2/VBP	root||ROOT-0/null||shown-3/VBN	mark||reduced-19/VBD||that-4/IN	nsubj||reduced-19/VBD||rgcs-5/NNS	vmod||rgcs-5/NNS||exposed-6/VBN	prep_to||exposed-6/VBN||hypoxia-8/NN	num||%-11/NN||1-10/CD	appos||hypoxia-8/NN||%-11/NN	nn||display-18/NN||hypoxia-14/NN	amod||display-18/NN||mimetic-15/JJ	amod||display-18/NN||cobalt-16/JJ	nn||display-18/NN||chloride-17/NN	prep_to||exposed-6/VBN||display-18/NN	conj_or||hypoxia-8/NN||display-18/NN	ccomp||shown-3/VBN||reduced-19/VBD	dobj||reduced-19/VBD||expression-20/NN	prep_of||expression-20/NN||prdx6-22/CD	amod||expression-26/NN||higher-24/JJR	nn||expression-26/NN||ros-25/NN	prep_with||reduced-19/VBD||expression-26/NN	prep_with||reduced-19/VBD||activation-28/NN	conj_and||expression-26/NN||activation-28/NN	prep_of||activation-28/NN||nf-îºb-30/NN	cobalt-16||hypoxia-14||no_rel||we have shown that rgcs exposed to hypoxia (1%) or hypoxia mimetic cobalt chloride display reduced expression of prdx6 with higher ros expression and activation of nf-îºb.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||formoterol--1||no||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||reported-2/JJ	nsubj||growing-10/VBG||incidence-3/NN	amod||isolates-6/NNS||drug-resistant-5/JJ	prep_of||incidence-3/NN||isolates-6/NNS	prep_of||isolates-6/NNS||m.tuberculosis-8/NNS	aux||growing-10/VBG||is-9/VBZ	root||ROOT-0/null||growing-10/VBG	advmod||growing-10/VBG||steadily-11/RB	advmod||reported-52/VBN||however-13/RB	nsubjpass||reported-52/VBN||data-15/NNS	det||variation-19/NN||the-17/DT	amod||variation-19/NN||genetic-18/JJ	prep_on||data-15/NNS||variation-19/NN	prep_of||variation-19/NN||isolates-21/NNP	prep_of||isolates-21/NNP||m.tuberculosis-23/NNS	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	vmod||m.tuberculosis-23/NNS||circulating-24/VBG	conj_and||circulating-24/VBG||circulating-24/VBG	amod||ukraine-27/NN||northern-26/JJ	prep_in||circulating-24/VBG||ukraine-27/NN	det||spectrum-31/NN||the-30/DT	prep_on||circulating-24/VBG||spectrum-31/NN	prep_on||circulating-24/VBG||frequency-33/NN	conj_and||spectrum-31/NN||frequency-33/NN	prep_of||spectrum-31/NN||occurrence-35/NN	prep_of||occurrence-35/NN||mutations-37/NNS	vmod||mutations-37/NNS||determining-38/VBG	dobj||determining-38/VBG||resistance-39/NN	det||drugs-44/NNS||the-41/DT	amod||drugs-44/NNS||principal-42/JJ	amod||drugs-44/NNS||anti-tuberculosis-43/JJ	prep_to||determining-38/VBG||drugs-44/NNS	amod||drugs-44/NNS||isoniazid-45/JJ	amod||drugs-44/NNS||rifampicin-47/JJ	conj_and||isoniazid-45/JJ||rifampicin-47/JJ	aux||reported-52/VBN||have-48/VBP	neg||reported-52/VBN||not-49/RB	advmod||reported-52/VBN||yet-50/RB	auxpass||reported-52/VBN||been-51/VBN	parataxis||growing-10/VBG||reported-52/VBN	tuberculosis--1||isoniazid-45||yes||the reported incidence of drug-resistant isolates of m.tuberculosis is growing steadily ; however , data on the genetic variation of isolates of m.tuberculosis circulating in northern ukraine and on the spectrum and frequency of occurrence of mutations determining resistance to the principal anti-tuberculosis drugs isoniazid and rifampicin have not yet been reported .
det||paper-2/NN||this-1/DT	nsubj||presents-3/VBZ||paper-2/NN	root||ROOT-0/null||presents-3/VBZ	det||findings-5/NNS||the-4/DT	dobj||presents-3/VBZ||findings-5/NNS	nsubj||investigate-11/VB||findings-5/NNS	det||study-9/NN||an-7/DT	amod||study-9/NN||exploratory-8/JJ	prep_of||findings-5/NNS||study-9/NN	aux||investigate-11/VB||to-10/TO	xcomp||presents-3/VBZ||investigate-11/VB	det||challenges-13/NNS||the-12/DT	dobj||investigate-11/VB||challenges-13/NNS	vmod||challenges-13/NNS||faced-14/VBN	agent||faced-14/VBN||people-16/NNS	vmod||people-16/NNS||living-17/VBG	prep_with||living-17/VBG||hiv/aids-19/NNS	appos||hiv/aids-19/NNS||plwha-21/NNP	prep_in||hiv/aids-19/NNS||communities-24/NNS	amod||town-27/NN||cape-26/JJ	prep_in||communities-24/NNS||town-27/NN	amod||africa-30/NN||south-29/JJ	appos||town-27/NN||africa-30/NN	aids--1||hiv--1||no||this paper presents the findings of an exploratory study to investigate the challenges faced by people living with hiv/aids (plwha) in communities in cape town, south africa.
det||findings-2/NNS||these-1/DT	nsubj||provide-3/VBP||findings-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||support-5/NN||further-4/JJ	dobj||provide-3/VBP||support-5/NN	det||hypothesis-8/NNS||the-7/DT	prep_for||provide-3/VBP||hypothesis-8/NNS	nsubj||increased-10/VBN||hypothesis-8/NNS	rcmod||hypothesis-8/NNS||increased-10/VBN	nn||metabolism-12/NN||drug-11/NN	nsubj||mediate-15/VB||metabolism-12/NN	nsubj||highlight-24/VB||metabolism-12/NN	conj_and||metabolism-12/NN||efflux-14/NN	nsubj||mediate-15/VB||efflux-14/NN	ccomp||increased-10/VBN||mediate-15/VB	nn||resistance-19/NN||permethrin-16/NN	conj_and||permethrin-16/NN||ivermectin-18/NN	nn||resistance-19/NN||ivermectin-18/NN	dobj||mediate-15/VB||resistance-19/NN	amod||mites-22/NNS||scabies-21/JJ	prep_in||mediate-15/VB||mites-22/NNS	ccomp||increased-10/VBN||highlight-24/VB	conj_and||mediate-15/VB||highlight-24/VB	det||threat-26/NN||the-25/DT	dobj||highlight-24/VB||threat-26/NN	amod||resistance-30/NN||emerging-28/VBG	amod||resistance-30/NN||acaricide-29/JJ	prep_of||threat-26/NN||resistance-30/NN	det||treatment-33/NN||the-32/DT	prep_to||increased-10/VBN||treatment-33/NN	prep_of||treatment-33/NN||scabies-35/NNS	advmod||increased-10/VBN||worldwide-36/RB	scabies-35||permethrin-16||yes||these findings provide further support for the hypothesis that increased drug metabolism and efflux mediate permethrin and ivermectin resistance in scabies mites and highlight the threat of emerging acaricide resistance to the treatment of scabies worldwide.
amod||infection-2/NN||human-1/JJ	nsubj||lead-6/VB||infection-2/NN	prep_with||infection-2/NN||parvovirusb19-4/CD	aux||lead-6/VB||may-5/MD	root||ROOT-0/null||lead-6/VB	det||spectrum-10/NN||a-8/DT	amod||spectrum-10/NN||diverse-9/JJ	prep_to||lead-6/VB||spectrum-10/NN	amod||manifestations-13/NNS||clinical-12/JJ	prep_of||spectrum-10/NN||manifestations-13/NNS	amod||erythemainfectiosum-17/NN||benign-16/JJ	prep_including||spectrum-10/NN||erythemainfectiosum-17/NN	prep_in||erythemainfectiosum-17/NN||children-19/NNS	amod||crisis-23/NN||transient-21/JJ	amod||crisis-23/NN||aplastic-22/JJ	appos||children-19/NNS||crisis-23/NN	prep_in||crisis-23/NN||patients-25/NNS	amod||anaemia-28/NN||haemolytic-27/JJ	prep_with||patients-25/NNS||anaemia-28/NN	amod||hydrops-32/NNS||congenital-31/JJ	nsubj||foetalis-33/VBZ||hydrops-32/NNS	conj_and||lead-6/VB||foetalis-33/VBZ	erythemainfectiosum-17||parvovirusb19-4||no||human infection with parvovirusb19 may lead to a diverse spectrum of clinical manifestations, including benign erythemainfectiosum in children, transient aplastic crisis in patients with haemolytic anaemia, and congenital hydrops foetalis.
det||treatment-2/NN||the-1/DT	nsubj||requires-11/VBZ||treatment-2/NN	amod||hypertension-7/NN||moderate-4/JJ	conj_or||moderate-4/JJ||severe-6/JJ	amod||hypertension-7/NN||severe-6/JJ	prep_of||treatment-2/NN||hypertension-7/NN	amod||cases-10/NNS||most-9/JJS	prep_in||hypertension-7/NN||cases-10/NNS	root||ROOT-0/null||requires-11/VBZ	det||use-14/NN||the-12/DT	amod||use-14/NN||contemporaneous-13/JJ	dobj||requires-11/VBZ||use-14/NN	amod||antihypertensiveagents-17/NNS||multiple-16/JJ	prep_of||use-14/NN||antihypertensiveagents-17/NNS	antihypertensiveagents-17||hypertension-7||no_rel||the treatment of moderate or severe hypertension in most cases requires the contemporaneous use of multiple antihypertensiveagents.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||elucidate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||elucidate-8/VB||to-7/TO	xcomp||was-6/VBD||elucidate-8/VB	det||pathophysiology-10/NN||the-9/DT	dobj||elucidate-8/VB||pathophysiology-10/NN	amod||osteoporosis-13/NNS||as-related-12/JJ	prep_of||pathophysiology-10/NN||osteoporosis-13/NNS	prepc_by||elucidate-8/VB||investigating-15/VBG	det||relation-17/NN||the-16/DT	dobj||investigating-15/VBG||relation-17/NN	nn||density-21/NN||bone-19/NN	nn||density-21/NN||mineral-20/NN	prep_between||relation-17/NN||density-21/NN	dep||density-21/NN||bmd-23/VBN	prep_between||relation-17/NN||btm-26/NN	conj_and||density-21/NN||btm-26/NN	vmod||btm-26/NN||vitamind-28/VBN	amod||assessments-32/NNS||clinical-31/JJ	prep_between||relation-17/NN||assessments-32/NNS	conj_and||density-21/NN||assessments-32/NNS	nn||activity-35/NN||disease-34/NN	prep_of||assessments-32/NNS||activity-35/NN	amod||function-38/NN||physical-37/JJ	prep_of||assessments-32/NNS||function-38/NN	conj_and||activity-35/NN||function-38/NN	aux||identify-44/VB||to-43/TO	prep_between||relation-17/NN||identify-44/VB	conj_and||density-21/NN||identify-44/VB	vmod||density-21/NN||identify-44/VB	dobj||identify-44/VB||parameters-45/NNS	nsubjpass||related-48/VBN||parameters-45/NNS	auxpass||related-48/VBN||are-47/VBP	rcmod||parameters-45/NNS||related-48/VBN	amod||bmd-51/NN||low-50/JJ	prep_to||related-48/VBN||bmd-51/NN	appos||bmd-51/NN||osteopenia-53/NN	appos||bmd-51/NN||osteoporosis-55/NNS	conj_or||osteopenia-53/NN||osteoporosis-55/NNS	dep||related-48/VBN||in-57/IN	prep_as||related-48/VBN||patients-59/NNS	amod||disease-62/NN||active-61/JJ	prep_with||patients-59/NNS||disease-62/NN	osteoporosis-55||vitamind-28||yes||the aim of this study was to elucidate the pathophysiology of as-related osteoporosis by investigating the relation between bone mineral density (bmd), btm, vitamind, and clinical assessments of disease activity and physical function, as well as to identify parameters that are related to low bmd (osteopenia or osteoporosis) in as patients with active disease.
nsubj||illness-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||illness-9/NN||is-5/VBZ	det||illness-9/NN||a-6/DT	amod||illness-9/NN||severe-7/JJ	nn||illness-9/NN||respiratory-8/NN	root||ROOT-0/null||illness-9/NN	vmod||illness-9/NN||caused-10/VBN	det||virus-14/NN||a-12/DT	nn||virus-14/NN||novel-13/NN	agent||caused-10/VBN||virus-14/NN	det||sarscoronavirus-17/NNS||the-16/DT	appos||virus-14/NN||sarscoronavirus-17/NNS	appos||sarscoronavirus-17/NNS||sars-cov-19/NNP	severeacuterespiratorysyndrome-1||sars-cov-19||no||severeacuterespiratorysyndrome (sars) is a severe respiratory illness caused by a novel virus, the sarscoronavirus (sars-cov).
advmod||used-7/VBN||paradoxically-1/RB	nsubjpass||used-7/VBN||arsenictrioxide-3/NN	nsubj||induce-9/VB||arsenictrioxide-3/NN	aux||used-7/VBN||can-4/MD	advmod||used-7/VBN||also-5/RB	auxpass||used-7/VBN||be-6/VB	root||ROOT-0/null||used-7/VBN	aux||induce-9/VB||to-8/TO	xcomp||used-7/VBN||induce-9/VB	dobj||induce-9/VB||remission-10/NN	prep_in||induce-9/VB||patients-12/NNS	prep_with||patients-12/NNS||acutepromyelocyticleukemia-14/NN	appos||acutepromyelocyticleukemia-14/NN||apl-16/NN	det||rate-21/NN||a-19/DT	nn||rate-21/NN||success-20/NN	prep_with||induce-9/VB||rate-21/NN	quantmod||80-24/CD||approximately-23/RB	num||%-25/NN||80-24/CD	prep_of||rate-21/NN||%-25/NN	apl-16||arsenictrioxide-3||yes||paradoxically, arsenictrioxide can also be used to induce remission in patients with acutepromyelocyticleukemia (apl) with a success rate of approximately 80%.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
nsubj||report-5/NN||this-1/DT	nsubj||provided-15/VBN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	xcomp||report-5/NN||describing-6/VBG	det||technique-9/NN||this-7/DT	nn||technique-9/NN||multiplex-8/NN	dobj||describing-6/VBG||technique-9/NN	nn||fibrosis-12/NN||liver-11/NN	prep_for||describing-6/VBG||fibrosis-12/NN	aux||provided-15/VBN||has-14/VBZ	conj_and||report-5/NN||provided-15/VBN	det||proof-17/NN||the-16/DT	dobj||provided-15/VBN||proof-17/NN	prep_of||proof-17/NN||concept-19/NN	det||suitability-22/NN||the-21/DT	prep_of||concept-19/NN||suitability-22/NN	prep_of||suitability-22/NN||rna-24/NN	vmod||rna-24/NN||extracted-25/VBN	nn||sections-28/NNS||paraffin-27/NN	prep_from||extracted-25/VBN||sections-28/NNS	prepc_for||extracted-25/VBN||investigating-30/VBG	det||modulation-32/NN||the-31/DT	dobj||investigating-30/VBG||modulation-32/NN	det||panel-35/NN||a-34/DT	prep_of||modulation-32/NN||panel-35/NN	amod||genes-40/NNS||proinflammatory-37/JJ	conj_and||proinflammatory-37/JJ||profibrogenic-39/JJ	amod||genes-40/NNS||profibrogenic-39/JJ	prep_of||panel-35/NN||genes-40/NNS	paraffin-27||fibrosis-12||no_rel||this is the first report describing this multiplex technique for liver fibrosis and has provided the proof of concept of the suitability of rna extracted from paraffin sections for investigating the modulation of a panel of proinflammatory and profibrogenic genes.
amod||insulinresistance-2/NN||peripheral-1/JJ	nsubjpass||linked-4/VBN||insulinresistance-2/NN	auxpass||linked-4/VBN||is-3/VBZ	root||ROOT-0/null||linked-4/VBN	det||increase-7/NN||an-6/DT	prep_to||linked-4/VBN||increase-7/NN	amod||species-11/NNS||reactive-9/JJ	nn||species-11/NNS||oxygen-10/NN	prep_in||increase-7/NN||species-11/NNS	appos||species-11/NNS||ros-13/NN	vmod||increase-7/NN||leading-16/VBG	prep_in||leading-16/VBG||part-18/NN	det||production-21/NN||the-20/DT	prep_to||part-18/NN||production-21/NN	amod||aldehydes-25/NNS||reactive-23/JJ	nn||aldehydes-25/NNS||lipid-24/NN	prep_of||production-21/NN||aldehydes-25/NNS	mark||termed-37/VBD||that-26/IN	csubj||termed-37/VBD||modify-27/VB	det||chains-30/NNS||the-28/DT	nn||chains-30/NNS||side-29/NN	dobj||modify-27/VB||chains-30/NNS	nn||aminoacids-33/NNS||protein-32/NN	prep_of||chains-30/NNS||aminoacids-33/NNS	det||reaction-36/NN||a-35/DT	prep_in||aminoacids-33/NNS||reaction-36/NN	ccomp||leading-16/VBG||termed-37/VBD	nn||carbonylation-39/NN||protein-38/NN	dobj||termed-37/VBD||carbonylation-39/NN	aldehydes-25||insulinresistance-2||no_rel||peripheral insulinresistance is linked to an increase in reactive oxygen species (ros), leading in part to the production of reactive lipid aldehydes that modify the side chains of protein aminoacids in a reaction termed protein carbonylation.
amod||glucose/hyperglycemia-2/NN||high-1/JJ	nsubj||regulate-3/VB||glucose/hyperglycemia-2/NN	root||ROOT-0/null||regulate-3/VB	nn||expression-6/NN||vascular-4/NN	amod||expression-6/NN||a20-5/JJ	dobj||regulate-3/VB||expression-6/NN	amod||ubiquitination-9/NN||o-glcnacylation-dependent-8/JJ	prep_via||expression-6/NN||ubiquitination-9/NN	nn||degradation-12/NN||proteasomal-11/NN	prep_via||expression-6/NN||degradation-12/NN	conj_and||ubiquitination-9/NN||degradation-12/NN	hyperglycemia--1||glucose--1||no||high glucose/hyperglycemia regulate vascular a20 expression via o-glcnacylation-dependent ubiquitination and proteasomal degradation.
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	tb--1||inh-27||yes||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	melanoma-22||ifn--1||yes||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
nsubjpass||caused-12/VBN||buruliulcer-1/NN	det||mycobacterialdisease-5/NN||the-3/DT	amod||mycobacterialdisease-5/NN||third-4/JJ	appos||buruliulcer-1/NN||mycobacterialdisease-5/NN	prep_after||mycobacterialdisease-5/NN||tuberculosis-7/NNP	prep_after||mycobacterialdisease-5/NN||leprosy-9/NNP	conj_and||tuberculosis-7/NNP||leprosy-9/NNP	auxpass||caused-12/VBN||is-11/VBZ	root||ROOT-0/null||caused-12/VBN	det||ulcerans-18/NNS||the-14/DT	amod||ulcerans-18/NNS||environmental-15/JJ	nn||ulcerans-18/NNS||mycobacterium-16/NN	nn||ulcerans-18/NNS||m.-17/NN	agent||caused-12/VBN||ulcerans-18/NNS	mycobacterialdisease-5||mycobacterium-16||no||buruliulcer , the third mycobacterialdisease after tuberculosis and leprosy , is caused by the environmental mycobacterium m. ulcerans .
nsubj||factor-6/NN||it-1/PRP	cop||factor-6/NN||is-2/VBZ	advmod||factor-6/NN||also-3/RB	det||factor-6/NN||an-4/DT	amod||factor-6/NN||important-5/JJ	root||ROOT-0/null||factor-6/NN	amod||prognosis-9/NN||poor-8/JJ	prep_in||factor-6/NN||prognosis-9/NN	nn||users-12/NNS||drug-11/NN	prep_among||prognosis-9/NN||users-12/NNS	amod||virus-15/NN||hepatitisc-14/JJ	prep_with||users-12/NNS||virus-15/NN	appos||virus-15/NN||hcv-17/NN	mark||impacts-21/VBZ||as-19/IN	nsubj||impacts-21/VBZ||it-20/PRP	advcl||factor-6/NN||impacts-21/VBZ	dobj||impacts-21/VBZ||progression-22/NN	prep_to||impacts-21/VBZ||hepaticcirrhosis-24/NNS	nn||overdose-27/NN||opiate-26/NN	prep_to||impacts-21/VBZ||overdose-27/NN	conj_or||hepaticcirrhosis-24/NNS||overdose-27/NN	amod||users-30/NNS||opioid-29/JJ	prep_in||impacts-21/VBZ||users-30/NNS	opioid-29||hepaticcirrhosis-24||no_rel||it is also an important factor in poor prognosis among drug users with hepatitisc virus (hcv) as it impacts progression to hepaticcirrhosis or opiate overdose in opioid users.
det||pain-3/NN||the-1/DT	nn||pain-3/NN||injection-2/NN	nsubj||frequent-8/JJ||pain-3/NN	nsubj||difficult-10/JJ||pain-3/NN	nsubj||prevent-12/VB||pain-3/NN	nn||propofol-6/NN||microemulsion-5/NN	prep_of||pain-3/NN||propofol-6/NN	cop||frequent-8/JJ||is-7/VBZ	root||ROOT-0/null||frequent-8/JJ	conj_and||frequent-8/JJ||difficult-10/JJ	aux||prevent-12/VB||to-11/TO	xcomp||frequent-8/JJ||prevent-12/VB	pain-3||propofol-6||yes||the injection pain of microemulsion propofol is frequent and difficult to prevent.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthma-15||ibuprofen-42||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||expressed-8/VBN||that-4/IN	nn||proteins-6/NNS||socs-5/NNS	nsubjpass||expressed-8/VBN||proteins-6/NNS	auxpass||expressed-8/VBN||are-7/VBP	ccomp||demonstrate-3/VBP||expressed-8/VBN	amod||lines-13/NNS||human-10/JJ	nn||lines-13/NNS||melanoma-11/NN	nn||lines-13/NNS||cell-12/NN	prep_in||expressed-8/VBN||lines-13/NNS	poss||modulation-16/NN||their-15/PRP$	nsubj||influence-18/VB||modulation-16/NN	aux||influence-18/VB||can-17/MD	conj_and||demonstrate-3/VBP||influence-18/VB	det||responsiveness-20/NNS||the-19/DT	dobj||influence-18/VB||responsiveness-20/NNS	nn||cells-23/NNS||melanoma-22/NN	prep_of||responsiveness-20/NNS||cells-23/NNS	nn||±-26/NNP||ifn-î-25/NNP	prep_to||influence-18/VB||±-26/NNP	nn||³-29/NNP||ifn-î-28/NNP	prep_to||influence-18/VB||³-29/NNP	conj_and||±-26/NNP||³-29/NNP	melanoma-22||ifn--1||yes||these data demonstrate that socs proteins are expressed in human melanoma cell lines and their modulation can influence the responsiveness of melanoma cells to ifn-î± and ifn-î³.
det||thomson-2/NN||the-1/DT	nsubj||reuters-3/VBZ||thomson-2/NN	root||ROOT-0/null||reuters-3/VBZ	nn||databases-6/NNS||marketscanâ-4/NNP	nn||databases-6/NNS||®-5/NNP	nsubjpass||used-8/VBN||databases-6/NNS	nsubj||analyze-11/VB||databases-6/NNS	auxpass||used-8/VBN||were-7/VBD	ccomp||reuters-3/VBZ||used-8/VBN	aux||analyze-11/VB||to-9/TO	advmod||analyze-11/VB||retrospectively-10/RB	xcomp||used-8/VBN||analyze-11/VB	amod||patients-15/NNS||insulin-naã-12/JJ	amod||patients-15/NNS||¯-13/JJ	nn||patients-15/NNS||ve-14/NN	dobj||analyze-11/VB||patients-15/NNS	prep_with||analyze-11/VB||type2diabetes-17/CD	prepc_by||analyze-11/VB||initiating-19/VBG	nn||therapy-21/NN||insulin-20/NN	dobj||initiating-19/VBG||therapy-21/NN	type2diabetes-17||insulin-20||yes||the thomson reuters marketscanâ® databases were used to retrospectively analyze insulin-naã¯ve patients with type2diabetes by initiating insulin therapy.
aux||select-2/VB||to-1/TO	advcl||matched-16/VBD||select-2/VB	amod||compartments-4/NNS||cellular-3/JJ	dobj||select-2/VB||compartments-4/NNS	advmod||likely-6/JJ||most-5/RBS	amod||compartments-4/NNS||likely-6/JJ	aux||give-8/VB||to-7/TO	xcomp||likely-6/JJ||give-8/VB	dobj||give-8/VB||rise-9/NN	prep_to||give-8/VB||subgroups-11/NNS	prep_of||subgroups-11/NNS||ependymoma-13/NN	nsubj||matched-16/VBD||we-15/PRP	root||ROOT-0/null||matched-16/VBD	det||transcriptomes-18/NNS||the-17/DT	nsubj||stem-27/VBP||transcriptomes-18/NNS	amod||tumors-21/NNS||human-20/JJ	prep_of||transcriptomes-18/NNS||tumors-21/NNS	prep_to||tumors-21/NNS||those-23/DT	nn||neural-26/NN||mouse-25/NN	prep_of||those-23/DT||neural-26/NN	ccomp||matched-16/VBD||stem-27/VBP	dobj||stem-27/VBP||cells-28/NNS	appos||cells-28/NNS||nscs-30/NNS	vmod||cells-28/NNS||isolated-33/VBN	amod||regions-36/NNS||different-35/JJ	prep_from||isolated-33/VBN||regions-36/NNS	det||cns-39/NN||the-38/DT	prep_of||regions-36/NNS||cns-39/NN	amod||stages-43/NNS||different-41/JJ	amod||stages-43/NNS||developmental-42/JJ	prep_at||cns-39/NN||stages-43/NNS	det||locus-51/NNS||an-46/DT	amod||locus-51/NNS||intact-47/JJ	conj_or||intact-47/JJ||deleted-49/JJ	amod||locus-51/NNS||deleted-49/JJ	amod||locus-51/NNS||ink4a/arf-50/JJ	prep_with||cells-28/NNS||locus-51/NNS	rise-9||arf--1||no_rel||to select cellular compartments most likely to give rise to subgroups of ependymoma, we matched the transcriptomes of human tumors to those of mouse neural stem cells (nscs), isolated from different regions of the cns at different developmental stages, with an intact or deleted ink4a/arf locus.
aux||study-2/VB||to-1/TO	root||ROOT-0/null||study-2/VB	det||effect-4/NN||the-3/DT	dobj||study-2/VB||effect-4/NN	amod||versus-11/NNS||nebivolol-6/JJ	num||mg-8/NNS||5-7/CD	npadvmod||once-9/RB||mg-8/NNS	amod||versus-11/NNS||once-9/RB	amod||versus-11/NNS||daily-10/JJ	prep_of||effect-4/NN||versus-11/NNS	dep||versus-11/NNS||s-13/PRP	dep||study-2/VB||atenolol-16/NN	num||atenolol-16/NN||25-17/CD	vmod||atenolol-16/NN||mg-18/VBN	advmod||daily-20/RB||once-19/RB	advmod||mg-18/VBN||daily-20/RB	prep_in||mg-18/VBN||patients-22/NNS	amod||hypertension-25/NN||essential-24/JJ	prep_with||patients-22/NNS||hypertension-25/NN	hypertension-25||atenolol-16||yes||to study the effect of nebivolol 5 mg once daily versus (s)-atenolol 25 mg once daily in patients with essential hypertension.
nsubj||investigated-15/VBD||aims-1/NNS	det||trial-14/NN||this-2/DT	amod||trial-14/NN||52-week-3/JJ	amod||trial-14/NN||randomized-5/JJ	amod||trial-14/NN||multinational-7/JJ	amod||trial-14/NN||open-label-9/JJ	amod||trial-14/NN||parallel-group-11/JJ	amod||trial-14/NN||non-inferiority-13/JJ	dep||aims-1/NNS||trial-14/NN	root||ROOT-0/null||investigated-15/VBD	det||efficacy-17/NN||the-16/DT	nsubj||bolus-24/VBZ||efficacy-17/NN	conj_and||efficacy-17/NN||safety-19/NN	nsubj||bolus-24/VBZ||safety-19/NN	nn||$-22/NNP||basalâ-21/NNP	prep_of||efficacy-17/NN||$-22/NNP	ccomp||investigated-15/VBD||bolus-24/VBZ	dobj||bolus-24/VBZ||treatment-25/NN	prep_with||bolus-24/VBZ||insulin-27/NN	nn||insulin-27/NN||detemir-28/FW	nn||insulin-27/NN||vs.-29/FW	nn||insulin-27/NN||nph-30/FW	nn||insulin-27/NN||-lrb--31/FW	nn||insulin-27/NN||neutral-32/FW	nn||insulin-27/NN||protamine-33/FW	nn||insulin-27/NN||hagedorn-34/FW	nn||insulin-27/NN||-rrb--35/FW	dep||insulin-27/NN||insulin-36/FW	prep_in||insulin-27/NN||combination-39/NN	prep_with||combination-39/NN||insulinaspart-41/NN	prep_in||combination-39/NN||subjects-44/NNS	vmod||subjects-44/NNS||aged-45/VBN	dobj||aged-45/VBN||2â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||16-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_with||aged-45/VBN||type1diabetesmellitus-52/CD	type1diabetesmellitus-52||insulin-36||yes||aims this 52-week , randomized , multinational , open-label , parallel-group , non-inferiority trial investigated the efficacy and safety of basalâ $ `` bolus treatment with insulin detemir vs. nph -lrb- neutral protamine hagedorn -rrb- insulin , in combination with insulinaspart , in subjects aged 2â $ `` 16 years with type1diabetesmellitus .
amod||mutations-2/NNS||loss-of-function-1/JJ	nsubj||cause-8/VBP||mutations-2/NNS	prep_in||mutations-2/NNS||progranulin-4/NN	appos||mutations-2/NNS||grn-6/NN	root||ROOT-0/null||cause-8/VBP	amod||frontotemporaldementia-21/NN||ubiquitin-9/JJ	advmod||dna-binding-13/JJ||tar-12/RB	conj_and||ubiquitin-9/JJ||dna-binding-13/JJ	amod||frontotemporaldementia-21/NN||dna-binding-13/JJ	dep||dna-binding-13/JJ||protein-14/NN	num||protein-14/NN||43-15/CD	dep||dna-binding-13/JJ||tdp-43-17/JJ	amod||frontotemporaldementia-21/NN||positive-20/JJ	dobj||cause-8/VBP||frontotemporaldementia-21/NN	appos||frontotemporaldementia-21/NN||ftld-u-23/NNP	det||disease-29/NN||a-26/DT	amod||disease-29/NN||progressive-27/JJ	nn||disease-29/NN||neurodegenerative-28/NN	appos||frontotemporaldementia-21/NN||disease-29/NN	vmod||disease-29/NN||affecting-30/VBG	ccomp||affecting-30/VBG||âˆ-31/VB	number||10-33/CD||1/4-32/CD	num||%-34/NN||10-33/CD	dobj||âˆ-31/VB||%-34/NN	amod||patients-38/NNS||early-onset-36/JJ	nn||patients-38/NNS||dementia-37/NN	prep_of||%-34/NN||patients-38/NNS	tar-12||frontotemporaldementia-21||no_rel||loss-of-function mutations in progranulin ( grn ) cause ubiquitin- and tar dna-binding protein 43 (tdp-43)-positive frontotemporaldementia (ftld-u), a progressive neurodegenerative disease affecting âˆ¼10% of early-onset dementia patients.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||compare-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||compare-6/VB||to-5/TO	xcomp||conducted-4/VBN||compare-6/VB	det||effect-8/NN||the-7/DT	dobj||compare-6/VB||effect-8/NN	advmod||administered-11/VBN||rectally-10/RB	amod||paracetamol-12/NNP||administered-11/VBN	prep_of||effect-8/NN||paracetamol-12/NNP	amod||method-25/NN||diclofenac-14/JJ	prep||diclofenac-14/JJ||combined-15/VBN	pcomp||combined-15/VBN||with-16/IN	amod||block-19/NN||regional-17/JJ	nn||block-19/NN||nerve-18/NN	pobj||with-16/IN||block-19/NN	det||control-24/NN||the-21/DT	amod||control-24/NN||traditional-22/JJ	nn||control-24/NN||pain-23/NN	prep_with||block-19/NN||control-24/NN	prep_of||effect-8/NN||method-25/NN	conj_or||paracetamol-12/NNP||method-25/NN	pain-23||paracetamol-12||yes||this study was conducted to compare the effect of rectally administered paracetamol or diclofenac combined with regional nerve block with the traditional pain control method.
nsubj||cutaneous-5/NNS||eumycetoma-1/NN	cop||cutaneous-5/NNS||is-2/VBZ	det||cutaneous-5/NNS||a-3/DT	amod||cutaneous-5/NNS||chronic-4/JJ	root||ROOT-0/null||cutaneous-5/NNS	nn||infection-8/NN||subcutaneous-7/NNS	conj_and||cutaneous-5/NNS||infection-8/NN	vmod||cutaneous-5/NNS||caused-9/VBN	amod||genera-12/NN||various-11/JJ	agent||caused-9/VBN||genera-12/NN	num||granules-18/NNS||fungi-14/CD	amod||granules-18/NNS||producing-15/VBG	amod||granules-18/NNS||specific-16/JJ	amod||granules-18/NNS||colored-17/VBN	prep_of||genera-12/NN||granules-18/NNS	vmod||granules-18/NNS||known-19/VBN	prep_as||known-19/VBN||grains-21/NNS	eumycetoma-1||fungi-14||no||eumycetoma is a chronic cutaneous and subcutaneous infection caused by various genera of fungi producing specific colored granules known as grains.
aux||develop-2/VB||to-1/TO	root||ROOT-0/null||develop-2/VB	det||formulation-5/NN||an-3/DT	amod||formulation-5/NN||oral-4/JJ	dobj||develop-2/VB||formulation-5/NN	nsubj||stable-13/JJ||formulation-5/NN	prep_of||formulation-5/NN||amphotericinb-7/NN	appos||formulation-5/NN||amb-9/NN	cop||stable-13/JJ||is-12/VBZ	rcmod||formulation-5/NN||stable-13/JJ	det||temperatures-16/NNS||the-15/DT	prep_at||stable-13/JJ||temperatures-16/NNS	nsubj||climatic-19/VBZ||who-18/WP	prepc_of||temperatures-16/NNS||climatic-19/VBZ	dobj||climatic-19/VBZ||zones-20/NNS	num||zones-20/NNS||3-21/CD	dobj||climatic-19/VBZ||4-23/CD	conj_and||zones-20/NNS||4-23/CD	dep||zones-20/NNS||30â-25/NNS	dep||30â-25/NNS||$-26/$	num||c-30/NN||43â-28/CD	amod||c-30/NN||°-29/JJ	npadvmod||of-41/RB||c-30/NN	cc||c-30/NN||and-32/CC	nn||efficacy-36/NN||evaluate-34/NN	poss||efficacy-36/NN||its-35/PRP$	prep_to||c-30/NN||efficacy-36/NN	det||model-40/NN||a-38/DT	amod||model-40/NN||murine-39/JJ	prep_in||efficacy-36/NN||model-40/NN	dep||visceralleishmaniasis-42/CD||of-41/RB	num||$-26/$||visceralleishmaniasis-42/CD	appos||zones-20/NNS||vl-44/NN	visceralleishmaniasis-42||amphotericinb-7||yes||to develop an oral formulation of amphotericinb (amb) that is stable at the temperatures of who climatic zones 3 and 4 (30â€“43â°c) and to evaluate its efficacy in a murine model of visceralleishmaniasis (vl).
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	det||safety-4/NN||the-3/DT	dobj||assessed-2/VBD||safety-4/NN	amod||therapy-7/NN||cabergoline-6/JJ	prep_of||safety-4/NN||therapy-7/NN	prep_during||assessed-2/VBD||pregnancy-9/NN	det||lady-12/NN||a-11/DT	prep_in||assessed-2/VBD||lady-12/NN	nn||intolerant-15/NN||hyperprolactinemia-14/NN	prep_with||lady-12/NN||intolerant-15/NN	aux||bromocriptine-17/VB||to-16/TO	vmod||assessed-2/VBD||bromocriptine-17/VB	hyperprolactinemia-14||cabergoline-6||yes||we assessed the safety of cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to bromocriptine.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||association-4/NN||no-3/DT	nsubj||was-2/VBD||association-4/NN	amod||alleles-10/NNS||functional-6/JJ	dep||functional-6/JJ||cyp2c19-7/CD	dep||functional-6/JJ||cyp2d6-9/CD	conj_and||cyp2c19-7/CD||cyp2d6-9/CD	prep_between||association-4/NN||alleles-10/NNS	nn||outcome-13/NN||treatment-12/NN	nsubj||was-2/VBD||outcome-13/NN	conj_and||association-4/NN||outcome-13/NN	nn||patients-16/NNS||multiplemyeloma-15/NN	prep_in||outcome-13/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	prep_with||treated-17/VBN||cyclophosphamide-19/NN	prep_with||treated-17/VBN||thalidomide-21/NN	conj_or||cyclophosphamide-19/NN||thalidomide-21/NN	prep_with||treated-17/VBN||bortezomib-23/NN	conj_or||cyclophosphamide-19/NN||bortezomib-23/NN	multiplemyeloma-15||thalidomide-21||yes||there was no association between functional cyp2c19 and cyp2d6 alleles and treatment outcome in multiplemyeloma patients treated with cyclophosphamide, thalidomide or bortezomib.
advmod||report-3/VBP||here-1/RB	nsubj||report-3/VBP||we-2/PRP	root||ROOT-0/null||report-3/VBP	advmod||report-3/VBP||yet-4/RB	det||reovirus-7/NNS||another-5/DT	amod||reovirus-7/NNS||melaka-like-6/JJ	dobj||report-3/VBP||reovirus-7/NNS	dep||reovirus-7/NNS||named-9/VBN	nn||virus-11/NN||kampar-10/NN	dobj||named-9/VBN||virus-11/NN	amod||reovirus-7/NNS||isolated-13/VBN	det||swab-17/NN||the-15/DT	nn||swab-17/NN||throat-16/NN	prep_from||isolated-13/VBN||swab-17/NN	nsubj||suffering-33/VBG||swab-17/NN	det||patient-24/NN||a-19/DT	number||old-22/JJ||54-20/CD	npadvmod||old-22/JJ||year-21/NN	amod||patient-24/NN||old-22/JJ	amod||patient-24/NN||male-23/JJ	prep_of||swab-17/NN||patient-24/NN	nn||malaysia-30/NN||kampar-26/NN	dep||malaysia-30/NN||perak-28/NN	prep_in||patient-24/NN||malaysia-30/NN	aux||suffering-33/VBG||was-32/VBD	rcmod||swab-17/NN||suffering-33/VBG	amod||fever-36/NN||high-35/JJ	prep_from||suffering-33/VBG||fever-36/NN	amod||disease-40/NN||acute-38/JJ	nn||disease-40/NN||respiratory-39/NN	prep_from||suffering-33/VBG||disease-40/NN	conj_and||fever-36/NN||disease-40/NN	prep_from||suffering-33/VBG||vomiting-42/NN	conj_and||fever-36/NN||vomiting-42/NN	det||time-45/NN||the-44/DT	prep_at||suffering-33/VBG||time-45/NN	prep_of||time-45/NN||virusisolation-47/NN	virusisolation-47||vomiting-42||no_rel||here we report yet another melaka-like reovirus (named kampar virus) isolated from the throat swab of a 54 year old male patient in kampar, perak, malaysia who was suffering from high fever, acute respiratory disease and vomiting at the time of virusisolation.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||artemether--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
amod||viruses-2/NNS||several-1/JJ	nsubjpass||associated-5/VBN||viruses-2/NNS	aux||associated-5/VBN||have-3/VBP	auxpass||associated-5/VBN||been-4/VBN	root||ROOT-0/null||associated-5/VBN	det||development-8/NN||the-7/DT	prep_with||associated-5/VBN||development-8/NN	amod||arthritis-11/NN||inflammatory-10/JJ	prep_of||development-8/NN||arthritis-11/NN	det||viruses-16/NNS||the-14/DT	nn||viruses-16/NNS||hepatitis-15/NN	prep_including||development-8/NN||viruses-16/NNS	amod||virus-19/NN||hepatitisb-18/JJ	dep||viruses-16/NNS||virus-19/NN	nn||virus-22/NN||hepatitisc-21/NN	dep||viruses-16/NNS||virus-22/NN	conj_and||virus-19/NN||virus-22/NN	prep_including||development-8/NN||hiv-25/NN	conj_and||viruses-16/NNS||hiv-25/NN	det||parvovirusb19-28/NN||the-27/DT	prep_including||development-8/NN||parvovirusb19-28/NN	conj_and||viruses-16/NNS||parvovirusb19-28/NN	det||virus-i-34/NN||the-30/DT	amod||virus-i-34/NN||human-31/JJ	amod||virus-i-34/NN||t-cell-32/JJ	amod||virus-i-34/NN||lymphotropic-33/JJ	prep_including||development-8/NN||virus-i-34/NN	conj_and||viruses-16/NNS||virus-i-34/NN	det||alphaviruses-38/NNS||the-37/DT	prep_including||development-8/NN||alphaviruses-38/NNS	conj_and||viruses-16/NNS||alphaviruses-38/NNS	virus-22||viruses-16||no||several viruses have been associated with the development of inflammatory arthritis, including the hepatitis viruses (hepatitisb virus and hepatitisc virus), hiv, the parvovirusb19, the human t-cell lymphotropic virus-i, and the alphaviruses.
nsubj||thromboembolism-9/VBP||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||risk-5/NN||the-4/DT	dobj||compare-3/VB||risk-5/NN	amod||venous-8/NNS||non-fatal-7/JJ	prep_of||risk-5/NN||venous-8/NNS	root||ROOT-0/null||thromboembolism-9/VBP	prep_in||thromboembolism-9/VBP||women-11/NNS	vmod||women-11/NNS||receiving-12/VBG	dobj||receiving-12/VBG||oralcontraceptives-13/NNS	vmod||oralcontraceptives-13/NNS||containing-14/VBG	dobj||containing-14/VBG||drospirenone-15/NN	prep_with||containing-14/VBG||that-17/DT	prep_in||that-17/DT||women-19/NNS	vmod||women-19/NNS||receiving-20/VBG	dobj||receiving-20/VBG||oralcontraceptives-21/NNS	vmod||oralcontraceptives-21/NNS||containing-22/VBG	acomp||containing-22/VBG||levonorgestrel-23/JJ	thromboembolism-9||drospirenone-15||no||objective to compare the risk of non-fatal venous thromboembolism in women receiving oralcontraceptives containing drospirenone with that in women receiving oralcontraceptives containing levonorgestrel.
amod||renalcellcarcinoma-4/NN||clear-2/JJ	nn||renalcellcarcinoma-4/NN||cell-3/NN	prep_in||described-12/VBN||renalcellcarcinoma-4/NN	amod||disturbances-6/NNS||many-5/JJ	nsubjpass||described-12/VBN||disturbances-6/NNS	amod||pathway-10/NN||t3-8/JJ	amod||pathway-10/NN||signaling-9/JJ	prep_in||disturbances-6/NNS||pathway-10/NN	auxpass||described-12/VBN||was-11/VBD	root||ROOT-0/null||described-12/VBN	det||type-16/NN||that-15/WDT	prep_in||shown-31/VBN||type-16/NN	prep_of||type-16/NN||cancer-18/NN	advmod||shown-31/VBN||also-19/RB	nsubjpass||shown-31/VBN||expression-20/NN	det||g1-24/NN||some-22/DT	amod||g1-24/NN||key-23/JJ	prep_of||expression-20/NN||g1-24/NN	amod||regulators-29/NNS||s-26/JJ	nn||regulators-29/NNS||phase-27/NN	nn||regulators-29/NNS||progression-28/NN	prep_to||g1-24/NN||regulators-29/NNS	auxpass||shown-31/VBN||was-30/VBD	ccomp||described-12/VBN||shown-31/VBN	cancer-18||t3-8||no_rel||in clear cell renalcellcarcinoma many disturbances in t3 signaling pathway was described, in that type of cancer also expression of some key g1 to s phase progression regulators was shown.
poss||findings-2/NNS||its-1/PRP$	nsubj||contribute-4/VB||findings-2/NNS	aux||contribute-4/VB||may-3/MD	root||ROOT-0/null||contribute-4/VB	det||identification-7/NN||the-6/DT	prep_in||contribute-4/VB||identification-7/NN	amod||individuals-11/NNS||higher-9/JJR	nn||individuals-11/NNS||risk-10/NN	prep_of||identification-7/NN||individuals-11/NNS	prep_for||individuals-11/NNS||diabetes-13/NN	prep_for||individuals-11/NNS||cardiovasculardisease-15/NN	conj_and||diabetes-13/NN||cardiovasculardisease-15/NN	det||comprehension-19/NN||a-17/DT	amod||comprehension-19/NN||better-18/JJR	prep_with||contribute-4/VB||comprehension-19/NN	det||intercorrelation-23/NN||the-21/DT	amod||intercorrelation-23/NN||complex-22/JJ	prep_about||comprehension-19/NN||intercorrelation-23/NN	nn||metabolism-28/NN||adiposity-25/NN	prep_between||intercorrelation-23/NN||glucose-27/NN	conj_and||metabolism-28/NN||glucose-27/NN	prep_between||intercorrelation-23/NN||metabolism-28/NN	prep_between||intercorrelation-23/NN||vasculardisease-30/NN	conj_and||metabolism-28/NN||vasculardisease-30/NN	vasculardisease-30||glucose-27||no_rel||its findings may contribute in the identification of higher risk individuals for diabetes and cardiovasculardisease with a better comprehension about the complex intercorrelation between adiposity, glucose metabolism and vasculardisease.
nn||methylation-2/NN||dna-1/NN	nsubjpass||recognized-6/VBN||methylation-2/NN	nsubj||play-8/VB||methylation-2/NN	aux||recognized-6/VBN||is-3/VBZ	auxpass||recognized-6/VBN||being-4/VBG	advmod||recognized-6/VBN||increasingly-5/RB	root||ROOT-0/null||recognized-6/VBN	aux||play-8/VB||to-7/TO	xcomp||recognized-6/VBN||play-8/VB	det||role-10/NN||a-9/DT	dobj||play-8/VB||role-10/NN	prep_in||play-8/VB||regulation-12/NN	amod||expression-19/NN||hepatitisbvirus-14/JJ	dep||hepatitisbvirus-14/JJ||hbv-16/NN	nn||expression-19/NN||gene-18/NN	prep_of||regulation-12/NN||expression-19/NN	hbv-16||hepatitisbvirus-14||no||dna methylation is being increasingly recognized to play a role in regulation of hepatitisbvirus (hbv) gene expression.
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	insulin--1||type2diabetes-12||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
det||combination-2/NN||a-1/DT	nsubj||treatment-14/NN||combination-2/NN	prep_of||combination-2/NN||levodopa-4/NN	appos||levodopa-4/NN||l-dopa-6/NNP	prep_of||combination-2/NN||carbidopa-9/NN	conj_and||levodopa-4/NN||carbidopa-9/NN	cop||treatment-14/NN||is-10/VBZ	det||treatment-14/NN||the-11/DT	advmod||commonly-used-13/JJ||most-12/RBS	amod||treatment-14/NN||commonly-used-13/JJ	root||ROOT-0/null||treatment-14/NN	nn||management-17/NN||symptom-16/NN	prep_for||treatment-14/NN||management-17/NN	nn||sdisease-21/NN||parkinson-19/NN	prep_in||management-17/NN||sdisease-21/NN	parkinson'sdisease--1||carbidopa-9||yes||a combination of levodopa (l-dopa) and carbidopa is the most commonly-used treatment for symptom management in parkinson'sdisease.
nsubj||demonstrate-2/VBP||we-1/PRP	root||ROOT-0/null||demonstrate-2/VBP	mark||infect-6/VB||that-3/IN	amod||humaninfluenzaviruses-5/NNS||original-4/JJ	nsubj||infect-6/VB||humaninfluenzaviruses-5/NNS	ccomp||demonstrate-2/VBP||infect-6/VB	amod||cells-11/NNS||primary-7/JJ	amod||cells-11/NNS||human-8/JJ	amod||cells-11/NNS||nasal-9/JJ	amod||cells-11/NNS||epithelial-10/JJ	dobj||infect-6/VB||cells-11/NNS	amod||ph-14/NN||acidic-13/JJ	prep_at||cells-11/NNS||ph-14/NN	dep||5.4-18/CD||down-16/RP	dep||5.4-18/CD||to-17/TO	dep||ph-14/NN||5.4-18/CD	mark||lose-24/VBP||whereas-21/IN	amod||hpaivs-23/NNS||h5n1-22/JJ	nsubj||lose-24/VBP||hpaivs-23/NNS	advcl||infect-6/VB||lose-24/VBP	advmod||lose-24/VBP||infectivity-25/RB	nn||‰-28/NNS||phâ-27/NN	prep_at||lose-24/VBP||‰-28/NNS	amod||‰-28/NNS||$-29/$	number||$-29/$||5.6-30/CD	h5n1-22||influenzaviruses--1||no||we demonstrate that original humaninfluenzaviruses infect primary human nasal epithelial cells at acidic ph (down to 5.4), whereas h5n1 hpaivs lose infectivity at phâ‰¤5.6.
prepc_compared_with||had-11/VBD||with-2/IN	nn||subjects-4/NNS||control-3/NN	pobj||had-11/VBD||subjects-4/NNS	amod||patients-7/NNS||type2diabetes-low-6/JJ	conj_and||subjects-4/NNS||patients-7/NNS	pobj||had-11/VBD||patients-7/NNS	amod||patients-10/NNS||type2diabetes-high-9/JJ	nsubj||had-11/VBD||patients-10/NNS	root||ROOT-0/null||had-11/VBD	det||perfusion-16/NN||the-12/DT	amod||perfusion-16/NN||lowest-13/JJS	amod||perfusion-16/NN||hepatic-14/JJ	amod||perfusion-16/NN||parenchymal-15/JJ	dobj||had-11/VBD||perfusion-16/NN	dep||perfusion-16/NN||p-18/VBN	dep||0.004-20/CD||=-19/SYM	ccomp||p-18/VBN||0.004-20/CD	amod||uptake-26/NN||insulin-stimulated-23/JJ	amod||uptake-26/NN||hepatic-24/JJ	nn||uptake-26/NN||glucose-25/NN	dobj||had-11/VBD||uptake-26/NN	conj_and||perfusion-16/NN||uptake-26/NN	dep||uptake-26/NN||p-28/VBN	dep||0.013-30/CD||=-29/SYM	ccomp||p-28/VBN||0.013-30/CD	type2diabetes--1||insulin--1||yes||compared with control subjects and type2diabetes-low patients, type2diabetes-high patients had the lowest hepatic parenchymal perfusion ( p = 0.004) and insulin-stimulated hepatic glucose uptake ( p = 0.013).
det||emergence-2/NN||the-1/DT	nsubj||become-10/VBN||emergence-2/NN	amod||resistance-5/NN||pyrethroid-4/JJ	prep_of||emergence-2/NN||resistance-5/NN	amod||gambiae-8/NN||anopheles-7/JJ	prep_in||resistance-5/NN||gambiae-8/NN	aux||become-10/VBN||has-9/VBZ	root||ROOT-0/null||become-10/VBN	det||concern-13/NN||a-11/DT	amod||concern-13/NN||serious-12/JJ	xcomp||become-10/VBN||concern-13/NN	det||success-17/NN||the-15/DT	amod||success-17/NN||future-16/JJ	prep_to||become-10/VBN||success-17/NN	nn||control-20/NN||malaria-19/NN	prep_of||success-17/NN||control-20/NN	malaria-19||pyrethroid-4||no_rel||the emergence of pyrethroid resistance in anopheles gambiae has become a serious concern to the future success of malaria control.
nsubjpass||used-30/VBN||time-1/NN	vmod||time-1/NN||spent-2/VBN	det||range-9/NN||the-4/DT	amod||range-9/NN||predefined-5/JJ	nn||range-9/NN||blood-6/NN	nn||range-9/NN||glucose-7/NN	nn||range-9/NN||level-8/NN	prep_in||spent-2/VBN||range-9/NN	appos||range-9/NN||time-11/NN	vmod||time-11/NN||needed-12/VBN	aux||reach-14/VB||to-13/TO	xcomp||needed-12/VBN||reach-14/VB	det||target-20/NN||the-15/DT	amod||target-20/NN||defined-16/JJ	nn||target-20/NN||blood-17/NN	nn||target-20/NN||glucose-18/NN	nn||target-20/NN||level-19/NN	dobj||reach-14/VB||target-20/NN	amod||indicators-23/NNS||hyperglycaemia-related-22/JJ	dobj||reach-14/VB||indicators-23/NNS	conj_and||target-20/NN||indicators-23/NNS	amod||indicators-26/NNS||protocol-related-25/JJ	dobj||reach-14/VB||indicators-26/NNS	conj_and||target-20/NN||indicators-26/NNS	auxpass||used-30/VBN||were-27/VBD	advmod||used-30/VBN||other-28/JJ	advmod||used-30/VBN||frequently-29/RB	root||ROOT-0/null||used-30/VBN	dobj||used-30/VBN||indicators-31/NNS	hyperglycaemia--1||glucose-18||no||time spent in the predefined blood glucose level range, time needed to reach the defined blood glucose level target, hyperglycaemia-related indicators and protocol-related indicators were other frequently used indicators.
amod||-rrb--7/NNP||methicillin-resistantstaphylococcusaureus-1/JJ	nn||-rrb--7/NNP||-lrb--2/NN	nn||-rrb--7/NNP||s.aureus-3/NNS	nn||-rrb--7/NNP||-rrb--4/NNP	nn||-rrb--7/NNP||-lrb--5/NNP	nn||-rrb--7/NNP||mrsa-6/NNP	nsubjpass||reported-18/VBN||-rrb--7/NNP	amod||-rrb--7/NNP||resistant-9/JJ	det||antibiotics-12/NNS||all-11/DT	prep_to||resistant-9/JJ||antibiotics-12/NNS	prep_including||antibiotics-12/NNS||vancomycin-14/NN	aux||reported-18/VBN||has-16/VBZ	auxpass||reported-18/VBN||been-17/VBN	root||ROOT-0/null||reported-18/VBN	prep_in||reported-18/VBN||japan-20/NN	prep_in||reported-18/VBN||usa-22/NN	conj_and||japan-20/NN||usa-22/NN	prep_in||reported-18/VBN||canada-24/NN	conj_and||japan-20/NN||canada-24/NN	prep_in||reported-18/VBN||brazil-26/NN	conj_and||japan-20/NN||brazil-26/NN	mrsa-6||s.aureus-3||no||methicillin-resistantstaphylococcusaureus -lrb- s.aureus -rrb- -lrb- mrsa -rrb- , resistant to all antibiotics including vancomycin , has been reported in japan , usa , canada and brazil .
nsubj||one-20/CD||insulinresistance-1/NN	appos||insulinresistance-1/NN||ir-3/NN	det||response-9/NN||a-6/DT	amod||response-9/NN||reduced-7/VBN	amod||response-9/NN||physiological-8/JJ	appos||insulinresistance-1/NN||response-9/NN	amod||tissues-12/NNS||peripheral-11/JJ	prep_of||response-9/NN||tissues-12/NNS	det||action-15/NN||the-14/DT	prep_to||response-9/NN||action-15/NN	prep_of||response-9/NN||insulin-17/NN	cop||one-20/CD||is-19/VBZ	root||ROOT-0/null||one-20/CD	det||causes-24/NNS||the-22/DT	amod||causes-24/NNS||major-23/JJ	prep_of||one-20/CD||causes-24/NNS	prep_of||causes-24/NNS||type2diabetes-26/CD	type2diabetes-26||insulin-17||yes||insulinresistance (ir), a reduced physiological response of peripheral tissues to the action of insulin, is one of the major causes of type2diabetes.
nn||stover-2/NN||corn-1/NN	nsubj||pretreated-7/VBN||stover-2/NN	nsubj||digested-11/VBN||stover-2/NN	conj_and||stover-2/NN||switchgrass-4/NNS	nsubj||pretreated-7/VBN||switchgrass-4/NNS	conj_and||stover-2/NN||ddgs-6/NNS	nsubj||pretreated-7/VBN||ddgs-6/NNS	root||ROOT-0/null||pretreated-7/VBN	prep_with||pretreated-7/VBN||afex-9/NN	conj_and||pretreated-7/VBN||digested-11/VBN	det||set-15/NN||the-13/DT	amod||set-15/NN||core-14/JJ	prep_with||digested-11/VBN||set-15/NN	vmod||set-15/NN||required-16/VBN	det||proportion-19/NN||a-17/DT	amod||proportion-19/NN||higher-18/JJR	dobj||required-16/VBN||proportion-19/NN	num||ex3-25/NNS||endo-î-21/CD	nn||ex3-25/NNS||²-22/NNP	amod||ex3-25/NNS||1,4-xylanase-23/JJ	prep_of||proportion-19/NN||ex3-25/NNS	det||proportion-30/NN||a-28/DT	amod||proportion-30/NN||lower-29/JJR	prep_of||proportion-19/NN||proportion-30/NN	conj_and||ex3-25/NNS||proportion-30/NN	num||eg1-36/NNS||endo-î-32/CD	nn||eg1-36/NNS||²-33/NNP	amod||eg1-36/NNS||1,4-glucanase-34/JJ	prep_of||proportion-30/NN||eg1-36/NNS	prepc_compared_to||eg1-36/NNS||to-39/TO	det||materials-42/NNS||the-40/DT	amod||materials-42/NNS||same-41/JJ	pobj||eg1-36/NNS||materials-42/NNS	vmod||materials-42/NNS||pretreated-43/VBN	amod||base-46/NN||dilute-45/JJ	prep_with||pretreated-43/VBN||base-46/NN	prep_with||pretreated-43/VBN||ap-48/NN	conj_or||base-46/NN||ap-48/NN	base-46||endo--1||no_rel||corn stover, switchgrass and ddgs pretreated with afex and digested with the core set required a higher proportion of endo-î²1,4-xylanase (ex3) and a lower proportion of endo-î²1,4-glucanase (eg1) compared to the same materials pretreated with dilute base or ap.
nsubj||herpesvirus-12/NNS||marek-1/NN	amod||virus-4/NN||sdisease-3/JJ	dep||marek-1/NN||virus-4/NN	appos||marek-1/NN||mdv-6/NN	cop||herpesvirus-12/NNS||is-8/VBZ	det||herpesvirus-12/NNS||a-9/DT	advmod||contagious-11/JJ||highly-10/RB	amod||herpesvirus-12/NNS||contagious-11/JJ	root||ROOT-0/null||herpesvirus-12/NNS	nsubj||causes-14/VBZ||herpesvirus-12/NNS	rcmod||herpesvirus-12/NNS||causes-14/VBZ	det||condition-17/NN||a-15/DT	amod||condition-17/NN||neoplastic-16/JJ	dobj||causes-14/VBZ||condition-17/NN	nn||populations-20/NNS||chicken-19/NN	prep_in||condition-17/NN||populations-20/NNS	marek'sdisease--1||herpesvirus-12||no||marek'sdisease virus (mdv) is a highly contagious herpesvirus which causes a neoplastic condition in chicken populations.
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||inhibitory-2/JJ	nsubj||similar-9/JJ||effects-3/NNS	det||antibodies-7/NNS||these-5/DT	num||antibodies-7/NNS||five-6/CD	prep_of||effects-3/NNS||antibodies-7/NNS	cop||similar-9/JJ||were-8/VBD	root||ROOT-0/null||similar-9/JJ	det||specific-19/NN||those-11/DT	amod||specific-19/NN||observed-12/JJ	det||antibody-18/NN||a-14/DT	advmod||described-16/JJ||previously-15/RB	amod||antibody-18/NN||described-16/JJ	nn||antibody-18/NN||neutralizing-17/NN	prep_with||observed-12/JJ||antibody-18/NN	prep_to||similar-9/JJ||specific-19/NN	det||loop-24/NN||the-21/DT	amod||loop-24/NN||140s-22/JJ	amod||loop-24/NN||antigenic-23/JJ	prep_for||specific-19/NN||loop-24/NN	ccomp||similar-9/JJ||present-25/VB	prep_within||present-25/VB||ha1-27/CD	ccomp||similar-9/JJ||highlight-29/VB	conj_and||present-25/VB||highlight-29/VB	det||possibility-32/NN||the-30/DT	amod||possibility-32/NN||exciting-31/JJ	dobj||highlight-29/VB||possibility-32/NN	mark||efficacious-38/NNS||that-33/IN	det||antibodies-35/NNS||these-34/DT	nsubj||efficacious-38/NNS||antibodies-35/NNS	aux||efficacious-38/NNS||may-36/MD	cop||efficacious-38/NNS||be-37/VB	ccomp||similar-9/JJ||efficacious-38/NNS	amod||strains-42/NNS||multiple-40/JJ	amod||strains-42/NNS||h5n1-41/JJ	prep_against||efficacious-38/NNS||strains-42/NNS	h5n1-41||antibodies-35||no_rel||the inhibitory effects of these five antibodies were similar to those observed with a previously described neutralizing antibody specific for the 140s antigenic loop present within ha1 and highlight the exciting possibility that these antibodies may be efficacious against multiple h5n1 strains.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||outcomes-10/NNS||the-9/DT	dobj||compare-8/VB||outcomes-10/NNS	amod||concomitant-14/NN||postoperative-12/JJ	nn||concomitant-14/NN||adjuvant-13/NN	prep_of||outcomes-10/NNS||concomitant-14/NN	advmod||using-16/VBG||chemoradiotherapy-15/RB	vmod||concomitant-14/NN||using-16/VBG	num||schedules-19/NNS||two-17/CD	amod||schedules-19/NNS||different-18/JJ	dobj||using-16/VBG||schedules-19/NNS	prep_of||schedules-19/NNS||cisplatin-21/NN	prep_for||cisplatin-21/NN||patients-23/NNS	amod||squamouscellcarcinoma-27/NN||high-risk-25/JJ	amod||squamouscellcarcinoma-27/NN||oral-26/JJ	prep_with||patients-23/NNS||squamouscellcarcinoma-27/NN	dep||squamouscellcarcinoma-27/NN||oscc-29/JJ	squamouscellcarcinoma-27||adjuvant-13||no_rel||the aim of this study was to compare the outcomes of postoperative adjuvant concomitant chemoradiotherapy using two different schedules of cisplatin for patients with high-risk oral squamouscellcarcinoma (oscc).
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||efficacy-4/NN||the-3/DT	dobj||assess-2/VB||efficacy-4/NN	dobj||assess-2/VB||tolerability-6/NN	conj_and||efficacy-4/NN||tolerability-6/NN	det||association-9/NN||the-8/DT	prep_of||efficacy-4/NN||association-9/NN	dep||association-9/NN||sibutramine-10/NN	dep||sibutramine-10/NN||10â-12/NNS	dep||10â-12/NNS||$-13/$	amod||orlistat-21/NNS||20â-15/JJ	dep||20â-15/JJ||$-16/$	num||$-16/$||‰-17/CD	dep||$-16/$||mg/day-18/NN	nn||orlistat-21/NNS||and-20/NNP	npadvmod||treatment-34/JJR||orlistat-21/NNS	dep||orlistat-21/NNS||120â-23/NNS	num||times-28/NNS||$-24/$	number||mg-26/CD||‰-25/CD	num||$-24/$||mg-26/CD	num||times-28/NNS||2-3-27/CD	dep||120â-23/NNS||times-28/NNS	det||day-30/NN||a-29/DT	dep||times-28/NNS||day-30/NN	prep_in||orlistat-21/NNS||the-33/DT	amod||obesity-36/NNS||treatment-34/JJR	prep||treatment-34/JJR||of-35/IN	npadvmod||in-37/IN||obesity-36/NNS	dep||trial-41/CD||in-37/IN	dep||in-37/IN||a-38/NNP	prep_six-month||in-37/IN||open-40/JJ	num||$-13/$||trial-41/CD	obesity-36||sibutramine-10||yes||to assess the efficacy and tolerability of the association sibutramine (10â€“20â€‰mg/day) and orlistat (120â€‰mg 2-3 times a day) in the treatment of obesity in a six-month open trial.
num||patients-5/NNS||42-3/CD	amod||patients-5/NNS||hiv/aids-4/JJ	prep_out_of||infected-13/VBN||patients-5/NNS	num||%-8/NN||59.5-7/CD	nsubjpass||infected-13/VBN||%-8/NN	appos||%-8/NN||25/42-10/CD	auxpass||infected-13/VBN||were-12/VBD	root||ROOT-0/null||infected-13/VBN	amod||parasites-16/NNS||intestinal-15/JJ	prep_with||infected-13/VBN||parasites-16/NNS	mark||infected-31/VBN||while-18/IN	advmod||%-21/NN||only-19/RB	num||%-21/NN||9.32-20/CD	nsubjpass||infected-31/VBN||%-21/NN	appos||%-21/NN||33/354-23/CD	det||patients-29/NNS||the-26/DT	amod||patients-29/NNS||hiv-27/JJ	amod||patients-29/NNS||negative-28/JJ	prep_of||%-21/NN||patients-29/NNS	auxpass||infected-31/VBN||were-30/VBD	advcl||infected-13/VBN||infected-31/VBN	amod||parasites-34/NNS||intestinal-33/JJ	prep_with||infected-31/VBN||parasites-34/NNS	aids--1||hiv-27||no||out of 42 hiv/aids patients, 59.5% (25/42) were infected with intestinal parasites, while only 9.32% (33/354) of the hiv negative patients were infected with intestinal parasites.
mark||improve-4/VB||in-1/IN	dep||improve-4/VB||order-2/NN	aux||improve-4/VB||to-3/TO	advcl||treating-15/VBG||improve-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||systemic-6/JJ	dobj||improve-4/VB||effects-7/NNS	amod||therapy-10/NN||adjuvant-9/JJ	prep_of||effects-7/NNS||therapy-10/NN	nsubj||treating-15/VBG||we-12/PRP	aux||treating-15/VBG||have-13/VBP	aux||treating-15/VBG||been-14/VBN	root||ROOT-0/null||treating-15/VBG	dobj||treating-15/VBG||patients-16/NNS	amod||cancer-20/NN||resected-18/JJ	amod||cancer-20/NN||gastric-19/JJ	prep_with||patients-16/NNS||cancer-20/NN	prep_with||treating-15/VBG||carboplatin-22/NN	prep_with||treating-15/VBG||paclitaxel-24/NN	conj_and||carboplatin-22/NN||paclitaxel-24/NN	vmod||carboplatin-22/NN||followed-25/VBN	amod||analogue-28/NN||fluoropyrimidine-27/JJ	agent||followed-25/VBN||analogue-28/NN	agent||followed-25/VBN||radiation-30/NN	conj_and||analogue-28/NN||radiation-30/NN	cancer-20||carboplatin-22||no_rel||in order to improve the systemic effects of adjuvant therapy, we have been treating patients with resected gastric cancer with carboplatin and paclitaxel followed by fluoropyrimidine analogue and radiation.
amod||chemotherapeutics-2/NNS||first-line-1/JJ	nsubj||dacarbazine-11/NN||chemotherapeutics-2/NNS	vmod||chemotherapeutics-2/NNS||used-3/VBN	nn||therapy-6/NN||melanoma-5/NN	prep_in||used-3/VBN||therapy-6/NN	cop||dacarbazine-11/NN||are-7/VBP	det||dacarbazine-11/NN||the-8/DT	amod||dacarbazine-11/NN||methylating-9/VBG	nn||dacarbazine-11/NN||agents-10/NNS	root||ROOT-0/null||dacarbazine-11/NN	dep||dacarbazine-11/NN||dtic-13/JJ	conj_and||dacarbazine-11/NN||temozolomide-16/NN	appos||temozolomide-16/NN||tmz-18/NN	det||agents-23/NNS||the-21/DT	amod||agents-23/NNS||chloroethylating-22/VBG	conj_and||dacarbazine-11/NN||agents-23/NNS	conj_and||temozolomide-16/NN||agents-23/NNS	amod||agents-23/NNS||bcnu-24/JJ	amod||agents-23/NNS||fotemustine-26/JJ	conj_and||bcnu-24/JJ||fotemustine-26/JJ	melanoma-5||bcnu-24||yes||first-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (dtic) and temozolomide (tmz) and the chloroethylating agents bcnu and fotemustine.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	ifn--1||melanoma-54||no_rel||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||analysis-3/NN||the-1/DT	amod||analysis-3/NN||multivariate-2/JJ	nsubj||showed-4/VBD||analysis-3/NN	root||ROOT-0/null||showed-4/VBD	mark||tended-9/VBD||that-5/IN	nsubj||tended-9/VBD||patients-6/NNS	nsubj||have-11/VB||patients-6/NNS	prep_at||patients-6/NNS||risk-8/NN	ccomp||showed-4/VBD||tended-9/VBD	aux||have-11/VB||to-10/TO	xcomp||tended-9/VBD||have-11/VB	det||characteristics-14/NNS||the-12/DT	amod||characteristics-14/NNS||following-13/JJ	dobj||have-11/VB||characteristics-14/NNS	vmod||characteristics-14/NNS||recruited-15/VBN	det||clinic-20/NN||the-17/DT	nn||clinic-20/NN||hiv-18/NN	nn||clinic-20/NN||testing-19/NN	prep_from||recruited-15/VBN||clinic-20/NN	dep||tended-9/VBD||lived-22/VBD	advmod||lived-22/VBD||alone-23/RB	dep||tended-9/VBD||declared-25/VBD	neg||religion-27/NN||no-26/DT	dobj||declared-25/VBD||religion-27/NN	dep||tended-9/VBD||had-29/VBD	det||level-32/NN||a-30/DT	amod||level-32/NN||low-31/JJ	dobj||had-29/VBD||level-32/NN	prep_of||level-32/NN||education-34/NN	dep||tended-9/VBD||felt-36/VBD	acomp||felt-36/VBD||uninformed-37/JJ	prep_about||felt-36/VBD||hiv/aids-39/NNS	cop||younger-42/JJR||were-41/VBD	dep||tended-9/VBD||younger-42/JJR	aux||had-45/VBN||had-44/VBD	dep||tended-9/VBD||had-45/VBN	amod||partners-48/NNS||concurrent-46/JJ	amod||partners-48/NNS||sexual-47/JJ	dobj||had-45/VBN||partners-48/NNS	det||months-53/NNS||the-50/DT	amod||months-53/NNS||last-51/JJ	num||months-53/NNS||12-52/CD	prep_in||partners-48/NNS||months-53/NNS	aids--1||hiv-18||no||the multivariate analysis showed that patients at risk tended to have the following characteristics recruited from the hiv testing clinic, lived alone, declared no religion, had a low level of education, felt uninformed about hiv/aids, were younger, had had concurrent sexual partners in the last 12 months.
poss||results-2/NNS||our-1/PRP$	nsubj||indicate-3/VBP||results-2/NNS	ccomp||found-27/VBN||indicate-3/VBP	mark||cause-12/VB||that-4/IN	nsubj||cause-12/VB||ammonia-5/NN	det||mixture-8/NN||a-7/DT	conj_and||ammonia-5/NN||mixture-8/NN	nsubj||cause-12/VB||mixture-8/NN	prep_of||mixture-8/NN||cytokines-10/NNS	dep||cytokines-10/NNS||each-11/DT	ccomp||indicate-3/VBP||cause-12/VB	dobj||cause-12/VB||astrocyte-13/NN	amod||astrocyte-13/NN||swelling-14/VBG	advmod||added-20/VBN||when-16/WRB	det||agents-18/NNS||these-17/DT	nsubjpass||added-20/VBN||agents-18/NNS	auxpass||added-20/VBN||are-19/VBP	ccomp||indicate-3/VBP||added-20/VBN	conj_but||cause-12/VB||added-20/VBN	advmod||added-20/VBN||simultaneously-21/RB	neg||effects-25/NNS||no-23/DT	amod||effects-25/NNS||additive-24/JJ	nsubjpass||found-27/VBN||effects-25/NNS	auxpass||found-27/VBN||were-26/VBD	root||ROOT-0/null||found-27/VBN	ammonia-5||swelling-14||no_rel||our results indicate that ammonia and a mixture of cytokines each cause astrocyte swelling but when these agents are added simultaneously, no additive effects were found.
advmod||administrated-13/VBN||even-1/RB	mark||administrated-13/VBN||though-2/IN	nsubjpass||administrated-13/VBN||immunoprophylaxis-3/NNS	amod||immunoglobulin-6/NN||hepatitisb-5/JJ	prep_with||immunoprophylaxis-3/NNS||immunoglobulin-6/NN	appos||immunoglobulin-6/NN||hbig-8/NN	prep_with||immunoprophylaxis-3/NNS||hepatitisbvaccine-11/NN	conj_and||immunoglobulin-6/NN||hepatitisbvaccine-11/NN	auxpass||administrated-13/VBN||is-12/VBZ	advcl||suffer-33/VBP||administrated-13/VBN	prep_to||administrated-13/VBN||neonates-15/NNS	poss||mothers-17/NNS||neonates-15/NNS	nsubj||antigen-21/NN||mothers-17/NNS	cop||antigen-21/NN||are-18/VBP	amod||antigen-21/NN||hepatitisb-19/JJ	nn||antigen-21/NN||surface-20/NN	rcmod||neonates-15/NNS||antigen-21/NN	appos||antigen-21/NN||hbsag-23/NN	amod||antigen-21/NN||positive-25/JJ	quantmod||10-28/CD||about-27/RB	num||%-29/NN||10-28/CD	nsubj||suffer-33/VBP||%-29/NN	det||neonates-32/NNS||the-31/DT	prep_of||%-29/NN||neonates-32/NNS	root||ROOT-0/null||suffer-33/VBP	nn||infection-36/NN||hbv-35/NN	prep_from||suffer-33/VBP||infection-36/NN	poss||life-40/NN||their-38/PRP$	amod||life-40/NN||early-39/JJ	prep_in||infection-36/NN||life-40/NN	hbv-35||hepatitisbvaccine-11||yes||even though immunoprophylaxis with hepatitisb immunoglobulin (hbig) and hepatitisbvaccine is administrated to neonates whose mothers are hepatitisb surface antigen (hbsag) positive, about 10% of the neonates suffer from hbv infection in their early life.
prep_after||improve-32/VB||admission-2/NN	nsubjpass||treated-6/VBN||she-4/PRP	nsubjpass||discovered-13/VBN||she-4/PRP	nsubj||heterozygous-16/JJ||she-4/PRP	auxpass||treated-6/VBN||was-5/VBD	parataxis||improve-32/VB||treated-6/VBN	amod||infection-10/NN||culture-proven-8/JJ	amod||infection-10/NN||salmonellatyphi-associated-9/JJ	prep_for||treated-6/VBN||infection-10/NN	auxpass||discovered-13/VBN||was-12/VBD	conj_and||treated-6/VBN||discovered-13/VBN	parataxis||improve-32/VB||discovered-13/VBN	aux||heterozygous-16/JJ||to-14/TO	cop||heterozygous-16/JJ||be-15/VB	xcomp||discovered-13/VBN||heterozygous-16/JJ	nn||e.-19/NN||haemoglobin-18/NN	prep_for||heterozygous-16/JJ||e.-19/NN	prep_despite||heterozygous-16/JJ||treatment-21/NN	amod||antibiotics-24/NNS||appropriate-23/JJ	prep_with||heterozygous-16/JJ||antibiotics-24/NNS	det||patient-27/NN||the-26/DT	poss||condition-29/NN||patient-27/NN	nsubj||improve-32/VB||condition-29/NN	aux||improve-32/VB||did-30/VBD	neg||improve-32/VB||not-31/RB	root||ROOT-0/null||improve-32/VB	xcomp||improve-32/VB||prompting-34/VBG	amod||investigation-36/NN||further-35/JJ	dobj||prompting-34/VBG||investigation-36/NN	nsubj||revealed-39/VBD||investigation-36/NN	rcmod||investigation-36/NN||revealed-39/VBD	dobj||revealed-39/VBD||malariaduetoplasmodiumfalciparum-40/NN	antibiotics-24||malariaduetoplasmodiumfalciparum-40||no_rel||after admission , she was treated for culture-proven salmonellatyphi-associated infection and was discovered to be heterozygous for haemoglobin e. despite treatment with appropriate antibiotics , the patient 's condition did not improve , prompting further investigation , which revealed malariaduetoplasmodiumfalciparum .
amod||pruritus-2/NNS||chloroquine-induced-1/JJ	nsubj||remains-3/VBZ||pruritus-2/NNS	root||ROOT-0/null||remains-3/VBZ	xcomp||remains-3/VBZ||one-4/CD	det||side-effects-9/NNS||the-6/DT	advmod||side-effects-9/NNS||most-7/RBS	amod||side-effects-9/NNS||common-8/JJ	prep_of||one-4/CD||side-effects-9/NNS	det||use-12/NN||the-11/DT	prep_in||side-effects-9/NNS||use-12/NN	prep_of||use-12/NN||chloroquine-14/NN	det||prophylaxis-17/NN||the-16/DT	prep_in||chloroquine-14/NN||prophylaxis-17/NN	prep_in||chloroquine-14/NN||treatment-19/NN	conj_and||prophylaxis-17/NN||treatment-19/NN	amod||malaria-22/NN||uncomplicated-21/JJ	prep_of||prophylaxis-17/NN||malaria-22/NN	det||advent-25/NN||the-24/DT	prep_before||remains-3/VBZ||advent-25/NN	amod||therapies-29/NNS||artemisinin-based-27/JJ	nn||therapies-29/NNS||combination-28/NN	prep_of||advent-25/NN||therapies-29/NNS	malaria-22||chloroquine-14||yes||chloroquine-induced pruritus remains one of the most common side-effects in the use of chloroquine in the prophylaxis and treatment of uncomplicated malaria before the advent of artemisinin-based combination therapies.
amod||--3/NNS||compounds-1/JJ	amod||--3/NNS||1-deoxy-1-2/JJ	dep||--3/NNS||6-5/CD	amod||â-9/NN||-LSB--7/JJ	nn||â-9/NN||n-8/NN	dep||--3/NNS||â-9/NN	dep||â-9/NN||$-10/$	num||$-10/$||²-11/CD	dep||â-9/NN||furan-2-carbonyl-14/NN	nn||-RSB--18/NNS||hydrazino-17/NN	dep||furan-2-carbonyl-14/NN||-RSB--18/NNS	num||h-20/NN||-9-19/CD	dep||-RSB--18/NNS||h-20/NN	dep||furan-2-carbonyl-14/NN||purin-9-yl-22/JJ	amod||d-ribofuranuronamide-30/NN||n-ethyl-25/JJ	nn||²-28/NNP||î-27/NNP	dep||d-ribofuranuronamide-30/NN||²-28/NNP	dep||--3/NNS||d-ribofuranuronamide-30/NN	dep||d-ribofuranuronamide-30/NN||19-32/CD	amod||k-35/JJ||ha1-34/JJ	amod||iâ-71/NN||k-35/JJ	amod||iâ-71/NN||iâ-36/JJ	amod||iâ-71/NN||$-37/$	number||=-39/CD||‰-38/CD	num||$-37/$||=-39/CD	amod||iâ-71/NN||â-40/JJ	amod||iâ-71/NN||$-41/$	number||1050â-43/CD||‰-42/CD	num||$-41/$||1050â-43/CD	amod||iâ-71/NN||nm-44/JJ	amod||iâ-71/NN||ha2a-46/JJ	amod||iâ-71/NN||k-47/JJ	amod||iâ-71/NN||iâ-48/JJ	amod||iâ-71/NN||$-49/$	number||=-51/CD||‰-50/CD	num||$-49/$||=-51/CD	amod||iâ-71/NN||â-52/JJ	amod||iâ-71/NN||$-53/$	number||1550â-55/CD||‰-54/CD	num||$-53/$||1550â-55/CD	amod||iâ-71/NN||nm-56/JJ	amod||iâ-71/NN||ha2b-58/JJ	amod||iâ-71/NN||ec50â-59/JJ	amod||iâ-71/NN||$-60/$	number||=-62/CD||‰-61/CD	num||$-60/$||=-62/CD	amod||iâ-71/NN||â-63/JJ	amod||iâ-71/NN||$-64/$	number||82â-66/CD||‰-65/CD	num||$-64/$||82â-66/CD	amod||iâ-71/NN||nm-67/JJ	amod||iâ-71/NN||ha3-69/JJ	nn||iâ-71/NN||k-70/NN	appos||19-32/CD||iâ-71/NN	dep||iâ-71/NN||$-72/$	number||>-74/CD||‰-73/CD	num||$-72/$||>-74/CD	vmod||$-72/$||â-75/VBN	dep||m-81/NN||$-76/$	num||m-81/NN||‰-77/CD	num||m-81/NN||5â-78/CD	nn||m-81/NN||î-79/NN	num||m-81/NN||1/4-80/CD	dobj||â-75/VBN||m-81/NN	poss||analogue-86/NN||its-84/PRP$	amod||analogue-86/NN||2-chloro-85/JJ	dep||--3/NNS||analogue-86/NN	conj_and||d-ribofuranuronamide-30/NN||analogue-86/NN	nsubjpass||confirmed-139/VBN||23-87/CD	nsubj||agonists-146/NNS||23-87/CD	amod||iâ-91/NN||ha1-89/JJ	nn||iâ-91/NN||k-90/NN	dep||23-87/CD||iâ-91/NN	num||â-95/NN||$-92/$	number||=-94/CD||‰-93/CD	num||$-92/$||=-94/CD	prep||iâ-91/NN||â-95/NN	amod||î-134/NN||$-96/$	dep||$-96/$||‰-97/JJ	amod||î-134/NN||3500â-98/JJ	amod||î-134/NN||nm-99/JJ	amod||î-134/NN||ha2a-101/JJ	amod||î-134/NN||k-102/JJ	amod||î-134/NN||iâ-103/JJ	amod||î-134/NN||$-104/$	number||=-106/CD||‰-105/CD	num||$-104/$||=-106/CD	amod||î-134/NN||â-107/JJ	amod||î-134/NN||$-108/$	number||4950â-110/CD||‰-109/CD	num||$-108/$||4950â-110/CD	amod||î-134/NN||nm-111/JJ	amod||î-134/NN||ha2b-113/JJ	amod||î-134/NN||ec50â-114/JJ	amod||î-134/NN||$-115/$	number||=-117/CD||‰-116/CD	num||$-115/$||=-117/CD	amod||î-134/NN||â-118/JJ	amod||î-134/NN||$-119/$	number||210â-121/CD||‰-120/CD	num||$-119/$||210â-121/CD	amod||î-134/NN||nm-122/JJ	amod||î-134/NN||ha3-124/JJ	amod||î-134/NN||k-125/JJ	amod||î-134/NN||iâ-126/JJ	amod||î-134/NN||$-127/$	number||>-129/CD||‰-128/CD	num||$-127/$||>-129/CD	amod||î-134/NN||â-130/JJ	amod||î-134/NN||$-131/$	num||$-131/$||‰-132/CD	amod||î-134/NN||5â-133/JJ	dep||â-95/NN||î-134/NN	number||m-136/JJ||1/4-135/CD	amod||î-134/NN||m-136/JJ	auxpass||confirmed-139/VBN||were-138/VBD	rcmod||analogue-86/NN||confirmed-139/VBN	aux||agonists-146/NNS||to-140/TO	cop||agonists-146/NNS||be-141/VB	amod||agonists-146/NNS||potent-142/JJ	conj_and||potent-142/JJ||selective-144/JJ	amod||agonists-146/NNS||selective-144/JJ	amod||agonists-146/NNS||full-145/JJ	xcomp||confirmed-139/VBN||agonists-146/NNS	det||monophosphate-151/NN||a-148/DT	amod||monophosphate-151/NN||cyclic-149/JJ	nn||monophosphate-151/NN||adenosine-150/NN	prep_in||agonists-146/NNS||monophosphate-151/NN	appos||monophosphate-151/NN||camp-153/NN	amod||assay-156/JJ||functional-155/JJ	amod||monophosphate-151/NN||assay-156/JJ	amod||cells-164/NNS||chinese-158/JJ	nn||cells-164/NNS||hamster-159/NN	nn||cells-164/NNS||ovary-160/NN	appos||cells-164/NNS||cho-162/NN	prep_in||agonists-146/NNS||cells-164/NNS	vmod||cells-164/NNS||expressing-165/VBG	amod||ar-167/NN||ha2b-166/JJ	dobj||expressing-165/VBG||ar-167/NN	nm-122||ar-167||no_rel||compounds 1-deoxy-1-{6-[ n â€²-(furan-2-carbonyl)-hydrazino]-9 h -purin-9-yl}-n-ethyl- î² -d-ribofuranuronamide ( 19 , ha1 k iâ€‰=â€‰1050â nm, ha2a k iâ€‰=â€‰1550â nm, ha2b ec50â€‰=â€‰82â nm, ha3 k iâ€‰>â€‰5â î¼m) and its 2-chloro analogue 23 (ha1 k iâ€‰=â€‰3500â nm, ha2a k iâ€‰=â€‰4950â nm, ha2b ec50â€‰=â€‰210â nm, ha3 k iâ€‰>â€‰5â î¼m) were confirmed to be potent and selective full agonists in a cyclic adenosine monophosphate (camp) functional assay in chinese hamster ovary (cho) cells expressing ha2b ar.
advmod||greater-2/JJR||significantly-1/RB	amod||reductions-3/NNS||greater-2/JJR	nsubjpass||observed-9/VBN||reductions-3/NNS	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||bp-7/NN||seated-5/JJ	amod||bp-7/NN||diastolic-6/JJ	prep_in||reductions-3/NNS||bp-7/NN	auxpass||observed-9/VBN||were-8/VBD	root||ROOT-0/null||observed-9/VBN	conj_and||observed-9/VBN||observed-9/VBN	prep_between||observed-9/VBN||baseline-11/NN	num||weeks-15/NNS||eight-14/CD	prep_after||observed-9/VBN||weeks-15/NNS	prep_of||weeks-15/NNS||treatment-17/NN	prep_with||observed-9/VBN||olmesartan/amlodipine-19/NN	prepc_compared_with||observed-9/VBN||with-22/IN	nn||doses-24/NNS||equivalent-23/NN	pobj||observed-9/VBN||doses-24/NNS	amod||monotherapy-29/NN||olmesartan-26/JJ	conj_or||olmesartan-26/JJ||amolodipine-28/JJ	amod||monotherapy-29/NN||amolodipine-28/JJ	prep_of||doses-24/NNS||monotherapy-29/NN	appos||monotherapy-29/NN||p-31/NNP	number||0.001-33/CD||<-32/CD	num||p-31/NNP||0.001-33/CD	det||combination-39/NN||the-37/DT	amod||combination-39/NN||factorial-38/JJ	prep_in||doses-24/NNS||combination-39/NN	amod||trial-51/NN||olmesartanmedoxomil-41/JJ	conj_and||olmesartanmedoxomil-41/JJ||amlodipine-43/JJ	amod||trial-51/NN||amlodipine-43/JJ	amod||trial-51/NN||besylate-44/JJ	amod||highbloodpressure-47/NN||controlling-46/JJ	prep_in||besylate-44/JJ||highbloodpressure-47/NN	appos||highbloodpressure-47/NN||coach-49/NN	prep_of||combination-39/NN||trial-51/NN	highbloodpressure-47||olmesartan-26||yes||significantly greater reductions in seated diastolic bp were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy ( p < 0.001), in the factorial combination of olmesartanmedoxomil and amlodipine besylate in controlling highbloodpressure (coach) trial.
poss||results-2/NNS||our-1/PRP$	nsubj||have-3/VBP||results-2/NNS	root||ROOT-0/null||have-3/VBP	dobj||have-3/VBP||implications-4/NNS	nsubj||have-17/VB||implications-4/NNS	amod||patients-13/NNS||uninsured-6/JJ	amod||hiv/aids-12/NNS||insured-11/JJ	conj_and||uninsured-6/JJ||hiv/aids-12/NNS	amod||patients-13/NNS||hiv/aids-12/NNS	prep_for||implications-4/NNS||patients-13/NNS	aux||have-17/VB||do-15/VBP	neg||have-17/VB||not-16/RB	rcmod||implications-4/NNS||have-17/VB	det||plan-20/NN||a-18/DT	amod||plan-20/NN||medical-19/JJ	dobj||have-17/VB||plan-20/NN	nsubj||covers-22/VBZ||plan-20/NN	rcmod||plan-20/NN||covers-22/VBZ	poss||sufficiently-25/NN||their-23/PRP$	nn||sufficiently-25/NN||charges-24/NNS	dobj||covers-22/VBZ||sufficiently-25/NN	aids--1||hiv--1||no||our results have implications for uninsured, as well as insured hiv/aids patients who do not have a medical plan that covers their charges sufficiently.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	hivinfections-27||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||caspofungin-25||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
nsubj||atypicalantipsychoticdrug-4/NN||aripiprazole-1/NN	cop||atypicalantipsychoticdrug-4/NN||is-2/VBZ	det||atypicalantipsychoticdrug-4/NN||an-3/DT	root||ROOT-0/null||atypicalantipsychoticdrug-4/NN	vmod||atypicalantipsychoticdrug-4/NN||approved-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||approved-5/VBN||treatment-8/NN	amod||disorders-11/NNS||psychiatric-10/JJ	prep_of||treatment-8/NN||disorders-11/NNS	nn||depressivedisorder-19/NN||schizophrenia-14/NN	prep_such_as||disorders-11/NNS||bipolardisorder-16/NN	conj_and||depressivedisorder-19/NN||bipolardisorder-16/NN	prep_such_as||disorders-11/NNS||major-18/JJ	amod||depressivedisorder-19/NN||major-18/JJ	conj_and||depressivedisorder-19/NN||major-18/JJ	prep_such_as||disorders-11/NNS||depressivedisorder-19/NN	prep_such_as||disorders-11/NNS||autism-21/NN	conj_and||depressivedisorder-19/NN||autism-21/NN	schizophrenia-14||aripiprazole-1||yes||aripiprazole is an atypicalantipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
nsubj||showed-19/VBD||mining-1/NN	dep||transcriptomic-4/JJ||available-3/JJ	amod||data-7/NNS||transcriptomic-4/JJ	conj_and||transcriptomic-4/JJ||proteomic-6/JJ	amod||data-7/NNS||proteomic-6/JJ	prep_of||mining-1/NN||data-7/NNS	vmod||data-7/NNS||pertaining-8/VBG	amod||models-12/NNS||established-10/VBN	nn||models-12/NNS||rodent-11/NN	prep_to||pertaining-8/VBG||models-12/NNS	nn||patients-18/NNS||epilepsy-14/NN	conj_and||epilepsy-14/NN||human-16/JJ	nn||patients-18/NNS||human-16/JJ	amod||patients-18/NNS||epileptic-17/JJ	prep_of||models-12/NNS||patients-18/NNS	root||ROOT-0/null||showed-19/VBD	dobj||showed-19/VBD||overrepresentation-20/NN	prep_of||overrepresentation-20/NN||epilepsy-22/NN	vmod||epilepsy-22/NN||associated-23/VBN	dobj||associated-23/VBN||genes-24/NNS	poss||set-29/NN||our-26/PRP$	amod||set-29/NN||ptz-27/JJ	amod||set-29/NN||regulated-28/JJ	prep_in||genes-24/NNS||set-29/NN	epileptic-17||ptz-27||no||mining of available transcriptomic and proteomic data pertaining to established rodent models of epilepsy and human epileptic patients showed overrepresentation of epilepsy associated genes in our ptz regulated set.
nsubj||taking-3/VBG||he-1/PRP	aux||taking-3/VBG||was-2/VBD	root||ROOT-0/null||taking-3/VBG	amod||mg-6/NN||atenolol-4/JJ	dep||atenolol-4/JJ||100-5/CD	dobj||taking-3/VBG||mg-6/NN	punct||day-8/NN||/-7/:	dep||mg-6/NN||day-8/NN	appos||day-8/NN||amlodipine-10/NN	num||amlodipine-10/NN||10-11/CD	advmod||taking-3/VBG||mg/day-12/RB	det||combination-16/NN||a-15/DT	nsubj||mg/hydrochlorothiazide-20/VBP||combination-16/NN	nsubj||experienced-25/VBD||combination-16/NN	amod||20-19/CD||lisinopril-18/JJ	prep_of||combination-16/NN||20-19/CD	conj_and||taking-3/VBG||mg/hydrochlorothiazide-20/VBP	num||mg-22/NN||12.5-21/CD	dobj||mg/hydrochlorothiazide-20/VBP||mg-22/NN	advmod||mg/hydrochlorothiazide-20/VBP||daily-23/RB	conj_and||taking-3/VBG||experienced-25/VBD	conj_but||mg/hydrochlorothiazide-20/VBP||experienced-25/VBD	amod||peaks-28/NNS||several-26/JJ	nn||peaks-28/NNS||hypertension-27/NN	dobj||experienced-25/VBD||peaks-28/NNS	dobj||experienced-25/VBD||hypotension-30/NN	conj_and||peaks-28/NNS||hypotension-30/NN	hypertension-27||lisinopril-18||yes||he was taking atenolol 100 mg /day, amlodipine 10 mg/day, and a combination of lisinopril 20 mg/hydrochlorothiazide 12.5 mg daily but experienced several hypertension peaks and hypotension.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||screened-115/VBN||study-4/NN	num||alkaloids-8/NNS||13-6/CD	amod||alkaloids-8/NNS||bromopyrrole-7/JJ	appos||study-4/NN||alkaloids-8/NNS	det||oroidin-12/NN||the-11/DT	prep_including||study-4/NN||oroidin-12/NN	rcmod||oroidin-12/NN||analogs-13/VBZ	dep||analogs-13/VBZ||hymenidin-14/VB	number||2-16/CD||-lrb--15/CD	num||-rrb--17/NNS||2-16/CD	dobj||hymenidin-14/VB||-rrb--17/NNS	dep||analogs-13/VBZ||dispacamide-19/VB	conj_and||hymenidin-14/VB||dispacamide-19/VB	dobj||dispacamide-19/VB||b-20/SYM	vmod||b-20/SYM||-lrb--21/VBG	number||-rrb--23/CD||3-22/CD	dobj||-lrb--21/VBG||-rrb--23/CD	dep||analogs-13/VBZ||dispacamide-25/VB	conj_and||hymenidin-14/VB||dispacamide-25/VB	dobj||dispacamide-25/VB||d-26/SYM	vmod||d-26/SYM||-lrb--27/VBG	num||-rrb--29/NNS||4-28/CD	dobj||-lrb--27/VBG||-rrb--29/NNS	dep||analogs-13/VBZ||stevensine-31/VB	conj_and||hymenidin-14/VB||stevensine-31/VB	number||5-33/CD||-lrb--32/CD	num||-rrb--34/NNS||5-33/CD	dobj||stevensine-31/VB||-rrb--34/NNS	dep||analogs-13/VBZ||spongiacidin-36/VB	conj_and||hymenidin-14/VB||spongiacidin-36/VB	dobj||spongiacidin-36/VB||b-37/SYM	number||6-39/CD||-lrb--38/CD	num||-rrb--40/NNS||6-39/CD	dep||b-37/SYM||-rrb--40/NNS	poss||derivatives-43/NNS||their-42/PRP$	appos||b-37/SYM||derivatives-43/NNS	vmod||derivatives-43/NNS||lacking-44/VBG	det||bromoaldisin-48/NN||the-45/DT	amod||bromoaldisin-48/NN||imidazole-46/JJ	nn||bromoaldisin-48/NN||ring-47/NN	dobj||lacking-44/VBG||bromoaldisin-48/NN	vmod||lacking-44/VBG||-lrb--49/VBG	num||-rrb--51/NNS||7-50/CD	dobj||-lrb--49/VBG||-rrb--51/NNS	dep||analogs-13/VBZ||longamide-53/VB	conj_and||hymenidin-14/VB||longamide-53/VB	dobj||longamide-53/VB||b-54/SYM	vmod||b-54/SYM||-lrb--55/VBG	number||-rrb--57/CD||8-56/CD	dobj||-lrb--55/VBG||-rrb--57/CD	dep||analogs-13/VBZ||longamide-59/VB	conj_and||hymenidin-14/VB||longamide-59/VB	det||-rrb--63/NN||a-60/DT	number||9-62/CD||-lrb--61/CD	num||-rrb--63/NN||9-62/CD	dobj||longamide-59/VB||-rrb--63/NN	det||-rrb--72/NNS||the-65/DT	amod||-rrb--72/NNS||dimeric-66/JJ	nn||-rrb--72/NNS||oroidin-67/NN	nn||-rrb--72/NNS||derivatives-68/NNS	nn||-rrb--72/NNS||sceptrin-69/NN	amod||-rrb--72/NNS||-lrb--70/JJ	num||-rrb--72/NNS||10-71/CD	dobj||longamide-59/VB||-rrb--72/NNS	conj_and||-rrb--63/NN||-rrb--72/NNS	num||-rrb--80/NNS||dibromopalauâ-74/CD	amod||-rrb--80/NNS||$-75/$	num||$-75/$||™-76/CD	amod||-rrb--80/NNS||amine-77/JJ	number||11-79/CD||-lrb--78/CD	num||-rrb--80/NNS||11-79/CD	dobj||longamide-59/VB||-rrb--80/NNS	conj_and||-rrb--63/NN||-rrb--80/NNS	det||bromopyrrolohomoarginin-85/NN||the-83/DT	amod||bromopyrrolohomoarginin-85/NN||non-oroidin-84/JJ	dobj||longamide-59/VB||bromopyrrolohomoarginin-85/NN	conj_and||-rrb--63/NN||bromopyrrolohomoarginin-85/NN	number||12-87/CD||-lrb--86/CD	num||-rrb--88/NNS||12-87/CD	dep||bromopyrrolohomoarginin-85/NN||-rrb--88/NNS	dep||analogs-13/VBZ||manzacidin-90/VB	conj_and||hymenidin-14/VB||manzacidin-90/VB	det||-rrb--94/NNS||a-91/DT	amod||-rrb--94/NNS||-lrb--92/JJ	num||-rrb--94/NNS||13-93/CD	dobj||manzacidin-90/VB||-rrb--94/NNS	dep||analogs-13/VBZ||agelongine-97/VB	conj_and||hymenidin-14/VB||agelongine-97/VB	number||14-99/CD||-lrb--98/CD	num||-rrb--100/NNS||14-99/CD	dobj||agelongine-97/VB||-rrb--100/NNS	csubjpass||screened-115/VBN||obtained-102/VBN	amod||sponges-105/NNS||marine-104/JJ	prep_from||obtained-102/VBN||sponges-105/NNS	vmod||sponges-105/NNS||belonging-106/VBG	prep_to||belonging-106/VBG||axinella-108/NN	det||genera-112/NN||a-110/DT	amod||genera-112/NN||gelas-111/JJ	prep_to||belonging-106/VBG||genera-112/NN	conj_and||axinella-108/NN||genera-112/NN	aux||screened-115/VBN||have-113/VBP	auxpass||screened-115/VBN||been-114/VBN	dep||rhodesiense-131/VBP||screened-115/VBN	amod||brucei-130/NNS||vitro-117/NN	num||-lrb--128/NNS||four-119/CD	amod||-lrb--128/NNS||parasitic-120/JJ	nn||-lrb--128/NNS||protozoa-121/NN	dep||-lrb--128/NNS||i.e.-123/NNS	num||-lrb--128/NNS||two-125/CD	nn||-lrb--128/NNS||trypanosoma-126/NN	nn||-lrb--128/NNS||species-127/NNS	prep_against||vitro-117/NN||-lrb--128/NNS	nn||brucei-130/NNS||t.-129/NN	prep_in||screened-115/VBN||brucei-130/NNS	root||ROOT-0/null||rhodesiense-131/VBP	conj_and||rhodesiense-131/VBP||t.-133/VBP	amod||-rrb--135/NNS||cruzi-134/JJ	dobj||rhodesiense-131/VBP||-rrb--135/NNS	nn||donovani-138/NNS||leishmania-137/NN	dobj||rhodesiense-131/VBP||donovani-138/NNS	conj_and||-rrb--135/NNS||donovani-138/NNS	nn||falciparum-141/NN||plasmodium-140/NN	dobj||rhodesiense-131/VBP||falciparum-141/NN	conj_and||-rrb--135/NNS||falciparum-141/NN	amod||strain-144/NN||-lrb--142/JJ	amod||strain-144/NN||k1-143/JJ	nsubj||rhodesiense-131/VBP||strain-144/NN	nsubj||t.-133/VBP||strain-144/NN	det||mortality-168/NN||a-146/DT	amod||resistant-148/JJ||chloroquine-147/JJ	amod||mortality-168/NN||resistant-148/JJ	nn||mortality-168/NN||strain-149/NN	nn||mortality-168/NN||-rrb--150/NN	amod||mortality-168/NN||responsible-152/JJ	amod||diseases-155/NNS||human-154/JJ	prep_of||responsible-152/JJ||diseases-155/NNS	amod||morbidity-158/NN||high-157/JJ	prep_with||diseases-155/NNS||morbidity-158/NN	dep||responsible-152/JJ||in-161/IN	det||case-163/NN||the-162/DT	pobj||in-161/IN||case-163/NN	prep_of||case-163/NN||malaria-165/NN	conj_and||responsible-152/JJ||high-167/JJ	amod||mortality-168/NN||high-167/JJ	appos||strain-144/NN||mortality-168/NN	malaria-165||chloroquine-147||yes||in the present study , 13 bromopyrrole alkaloids , including the oroidin analogs hymenidin -lrb- 2 -rrb- , dispacamide b -lrb- 3 -rrb- and dispacamide d -lrb- 4 -rrb- , stevensine -lrb- 5 -rrb- and spongiacidin b -lrb- 6 -rrb- , their derivatives lacking the imidazole ring bromoaldisin -lrb- 7 -rrb- , longamide b -lrb- 8 -rrb- and longamide a -lrb- 9 -rrb- , the dimeric oroidin derivatives sceptrin -lrb- 10 -rrb- and dibromopalauâ $ ™ amine -lrb- 11 -rrb- , and the non-oroidin bromopyrrolohomoarginin -lrb- 12 -rrb- , manzacidin a -lrb- 13 -rrb- , and agelongine -lrb- 14 -rrb- , obtained from marine sponges belonging to axinella and a gelas genera have been screened in vitro against four parasitic protozoa , i.e. , two trypanosoma species -lrb- t. brucei rhodesiense and t. cruzi -rrb- , leishmania donovani and plasmodium falciparum -lrb- k1 strain , a chloroquine resistant strain -rrb- , responsible of human diseases with high morbidity and , in the case of malaria , high mortality .
advmod||demonstrated-11/VBN||posaconazole-1/RB	det||member-5/NN||a-3/DT	amod||member-5/NN||new-4/JJ	nsubj||demonstrated-11/VBN||member-5/NN	det||class-9/NN||the-7/DT	amod||class-9/NN||triazole-8/JJ	prep_of||member-5/NN||class-9/NN	aux||demonstrated-11/VBN||has-10/VBZ	root||ROOT-0/null||demonstrated-11/VBN	amod||activity-14/NN||vitro-13/JJ	prep_in||demonstrated-11/VBN||activity-14/NN	det||spectrum-18/NN||a-16/DT	amod||spectrum-18/NN||broad-17/JJ	prep_against||demonstrated-11/VBN||spectrum-18/NN	prep_of||spectrum-18/NN||fungi-20/NNS	amod||activity-23/NN||clinical-22/JJ	prep_against||demonstrated-11/VBN||activity-23/NN	conj_and||spectrum-18/NN||activity-23/NN	amod||pathogens-27/NNS||various-25/JJ	amod||pathogens-27/NNS||fungal-26/JJ	prep_against||activity-23/NN||pathogens-27/NNS	amod||spp.-31/NN||aspergillus-30/JJ	prep_including||demonstrated-11/VBN||spp.-31/NN	nn||spp.-34/NN||candida-33/NN	prep_including||demonstrated-11/VBN||spp.-34/NN	conj_and||spp.-31/NN||spp.-34/NN	prep_including||demonstrated-11/VBN||zygomycetes-36/NNS	conj_and||spp.-31/NN||zygomycetes-36/NNS	nn||spp-40/NN||fusarium-39/NN	prep_including||demonstrated-11/VBN||spp-40/NN	conj_and||spp.-31/NN||spp-40/NN	zygomycetes-36||fungi-20||no||posaconazole, a new member of the triazole class has demonstrated in vitro activity against a broad spectrum of fungi and clinical activity against various fungal pathogens, including aspergillus spp., candida spp., zygomycetes, and fusarium spp.
num||patients-2/NNS||twelve-1/CD	nsubj||received-6/VBD||patients-2/NNS	amod||cancers-5/NNS||gynecological-4/JJ	prep_with||patients-2/NNS||cancers-5/NNS	root||ROOT-0/null||received-6/VBD	amod||pegfilgrastim-11/NN||carboplatin/paclitaxel-7/JJ	amod||pegfilgrastim-11/NN||chemotherapy-8/JJ	conj_and||chemotherapy-8/JJ||single-dose-10/JJ	amod||pegfilgrastim-11/NN||single-dose-10/JJ	dobj||received-6/VBD||pegfilgrastim-11/NN	prep_as||received-6/VBD||prophylaxis-13/NNS	amod||neutropenia-16/NN||febrile-15/JJ	prep_of||prophylaxis-13/NNS||neutropenia-16/NN	neutropenia-16||pegfilgrastim-11||yes||twelve patients with gynecological cancers received carboplatin/paclitaxel chemotherapy and single-dose pegfilgrastim as prophylaxis of febrile neutropenia.
vmod||produced-10/VBD||resultsâ-1/VBG	dobj||resultsâ-1/VBG||$-2/$	prep_with||resultsâ-1/VBG||hyperinsulinemia-5/FW	prep_with||resultsâ-1/VBG||hyperglycemia-7/FW	conj_and||hyperinsulinemia-5/FW||hyperglycemia-7/FW	nsubj||produced-10/VBD||exenatide-9/NN	root||ROOT-0/null||produced-10/VBD	det||increase-13/NN||a-11/DT	amod||increase-13/NN||significant-12/JJ	dobj||produced-10/VBD||increase-13/NN	amod||turnover-17/NN||total-15/JJ	nn||turnover-17/NN||glucose-16/NN	prep_in||produced-10/VBD||turnover-17/NN	quantmod||30-21/CD||âˆ-19/RB	number||30-21/CD||1/4-20/CD	num||%-22/NN||30-21/CD	prep_by||produced-10/VBD||%-22/NN	mark||indicated-25/VBD||as-24/IN	advcl||produced-10/VBD||indicated-25/VBD	amod||infusion-29/NN||portal-27/JJ	nn||infusion-29/NN||glucose-28/NN	prep_by||indicated-25/VBD||infusion-29/NN	dobj||indicated-25/VBD||rate-30/NN	nn||rate-30/NN||-lrb--31/FW	nn||rate-30/NN||saline-32/FW	nn||rate-30/NN||15.9-33/FW	nn||rate-30/NN||â-34/FW	nn||rate-30/NN||±-35/FW	nn||rate-30/NN||1.6-36/FW	nn||rate-30/NN||vs.-37/FW	nn||rate-30/NN||exenatide-38/FW	nn||rate-30/NN||20.4-39/FW	nn||rate-30/NN||â-40/FW	nn||rate-30/NN||±-41/FW	nn||rate-30/NN||2.1-42/FW	nn||rate-30/NN||mg-43/FW	nn||rate-30/NN||â-44/FW	nn||rate-30/NN||·-45/FW	nn||rate-30/NN||kgâˆ-46/FW	nn||rate-30/NN||1-48/FW	nn||rate-30/NN||â-49/FW	nn||rate-30/NN||·-50/FW	dep||rate-30/NN||minâˆ-51/FW	nsubj||âˆ-70/VBP||1-53/CD	nsubj||increased-76/VBD||1-53/CD	vmod||1-53/CD||p-55/VBN	dep||-rrb--58/NNS||<-56/SYM	num||-rrb--58/NNS||0.001-57/CD	ccomp||p-55/VBN||-rrb--58/NNS	xcomp||p-55/VBN||resulting-60/VBG	amod||d-68/NNP||increased-62/VBN	amod||d-68/NNP||whole-body-63/JJ	nn||d-68/NNP||glucose-64/NN	nn||d-68/NNP||disposal-65/NN	nn||d-68/NNP||-lrb--66/NN	nn||d-68/NNP||r-67/NNP	prep_from||resulting-60/VBG||d-68/NNP	rcmod||rate-30/NN||âˆ-70/VBP	number||20-72/CD||1/4-71/CD	num||%-73/NN||20-72/CD	nsubj||-rrb--74/NN||%-73/NN	xcomp||âˆ-70/VBP||-rrb--74/NN	rcmod||rate-30/NN||increased-76/VBD	conj_and||âˆ-70/VBP||increased-76/VBD	amod||uptake-79/NN||net-77/JJ	amod||uptake-79/NN||hepatic-78/JJ	nsubj||-rrb--88/NN||uptake-79/NN	nn||âˆ-84/FW||exogenous-81/FW	nn||âˆ-84/FW||glucose-82/FW	nn||âˆ-84/FW||-lrb--83/FW	prep_of||uptake-79/NN||âˆ-84/FW	number||%-87/NN||1/4-85/CD	number||%-87/NN||80-86/CD	amod||âˆ-84/FW||%-87/NN	xcomp||increased-76/VBD||-rrb--88/NN	hyperglycemia-7||glucose-82||no||resultsâ $ '' with hyperinsulinemia and hyperglycemia , exenatide produced a significant increase in total glucose turnover by âˆ 1/4 30 % , as indicated by portal glucose infusion rate -lrb- saline 15.9 â ± 1.6 vs. exenatide 20.4 â ± 2.1 mg â · kgâˆ ' 1 â · minâˆ ' 1 , p < 0.001 -rrb- , resulting from increased whole-body glucose disposal -lrb- r d , âˆ 1/4 20 % -rrb- and increased net hepatic uptake of exogenous glucose -lrb- âˆ 1/4 80 % -rrb- .
nsubjpass||approved-14/VBN||levofloxacin-1/NN	det||fluoroquinolone-4/NN||a-3/DT	appos||levofloxacin-1/NN||fluoroquinolone-4/NN	appos||levofloxacin-1/NN||l-isomer-6/NN	conj_and||fluoroquinolone-4/NN||l-isomer-6/NN	det||ofloxacin-10/NN||the-8/DT	amod||ofloxacin-10/NN||racemate-9/JJ	prep_of||fluoroquinolone-4/NN||ofloxacin-10/NN	aux||approved-14/VBN||has-12/VBZ	auxpass||approved-14/VBN||been-13/VBN	root||ROOT-0/null||approved-14/VBN	det||treatment-17/NN||the-16/DT	prep_for||approved-14/VBN||treatment-17/NN	amod||bacterialinfections-22/NNS||acute-19/JJ	conj_and||acute-19/JJ||chronic-21/JJ	amod||bacterialinfections-22/NNS||chronic-21/JJ	prep_of||treatment-17/NN||bacterialinfections-22/NNS	bacterialinfections-22||levofloxacin-1||yes||levofloxacin, a fluoroquinolone and l-isomer of the racemate ofloxacin, has been approved for the treatment of acute and chronic bacterialinfections.
nsubj||bacillus-5/NNS||mycobacteriumtuberculosis-1/NNS	cop||bacillus-5/NNS||is-2/VBZ	det||bacillus-5/NNS||a-3/DT	amod||bacillus-5/NNS||virulent-4/JJ	root||ROOT-0/null||bacillus-5/NNS	vmod||bacillus-5/NNS||causing-6/VBG	dobj||causing-6/VBG||tuberculosis-7/NNP	det||disease-10/NN||a-9/DT	appos||tuberculosis-7/NNP||disease-10/NN	amod||disease-10/NN||responsible-11/JJ	num||deaths-14/NNS||million-13/CD	prep_for||responsible-11/JJ||deaths-14/NNS	det||year-16/NN||each-15/DT	dep||deaths-14/NNS||year-16/NN	advmod||causing-6/VBG||worldwide-17/RB	tuberculosis-7||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis is a virulent bacillus causing tuberculosis, a disease responsible for million deaths each year worldwide.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâ€”irondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâ€”both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
nn||manifestations-2/NNS||ocular-1/NN	nsubj||occur-4/VB||manifestations-2/NNS	aux||occur-4/VB||can-3/MD	root||ROOT-0/null||occur-4/VB	quantmod||50-8/CD||up-6/IN	dep||50-8/CD||to-7/TO	num||%-9/NN||50-8/CD	prep_in||occur-4/VB||%-9/NN	amod||patients-20/NNS||humanimmunodeficiencyvirus-11/JJ	appos||patients-20/NNS||hiv-13/NN	amod||patients-20/NNS||/-15/JJ	amod||patients-20/NNS||acquiredimmunedeficiencysyndrome-16/JJ	dep||acquiredimmunedeficiencysyndrome-16/JJ||aids-18/NNS	prep_of||%-9/NN||patients-20/NNS	nn||involvement-24/NN||posterior-22/NN	nn||involvement-24/NN||segment-23/NN	nsubj||presentation-29/NN||involvement-24/NN	cop||presentation-29/NN||is-25/VBZ	det||presentation-29/NN||the-26/DT	advmod||common-28/JJ||most-27/RBS	amod||presentation-29/NN||common-28/JJ	conj_and||occur-4/VB||presentation-29/NN	acquiredimmunedeficiencysyndrome-16||hiv-13||no||ocular manifestations can occur in up to 50% of humanimmunodeficiencyvirus (hiv)/acquiredimmunedeficiencysyndrome (aids) patients and posterior segment involvement is the most common presentation.
nsubj||undertook-2/VBD||we-1/PRP	root||ROOT-0/null||undertook-2/VBD	det||analysis-5/NN||a-3/DT	nn||analysis-5/NN||retrospective-4/NN	dobj||undertook-2/VBD||analysis-5/NN	det||prevalence-8/NN||the-7/DT	prep_of||analysis-5/NN||prevalence-8/NN	prep_of||prevalence-8/NN||mdr-tb-10/NN	prep_in||undertook-2/VBD||children-12/NNS	prep_with||children-12/NNS||mycobacteriumtuberculosis-14/NNS	appos||mycobacteriumtuberculosis-14/NNS||mtb-16/NN	num||hospitals-20/NNS||two-19/CD	prep_at||undertook-2/VBD||hospitals-20/NNS	amod||africa-25/NN||johannesburg-22/JJ	amod||africa-25/NN||south-24/JJ	prep_in||hospitals-20/NNS||africa-25/NN	tb--1||mycobacteriumtuberculosis-14||no||we undertook a retrospective analysis of the prevalence of mdr-tb in children with mycobacteriumtuberculosis (mtb) at two hospitals in johannesburg, south africa.
amod||attachments-5/NNS||multipoint-1/JJ	conj_and||multipoint-1/JJ||multisubunit-3/JJ	amod||attachments-5/NNS||multisubunit-3/JJ	nn||attachments-5/NNS||covalent-4/NN	nsubj||provide-14/VBP||attachments-5/NNS	prep_of||attachments-5/NNS||enzymes-7/NNS	advmod||functionalized-10/JJ||appropriately-9/RB	amod||supports-11/NNS||functionalized-10/JJ	prep_on||enzymes-7/NNS||supports-11/NNS	prep_via||supports-11/NNS||linkers-13/NNS	root||ROOT-0/null||provide-14/VBP	acomp||provide-14/VBP||rigidity-15/JJ	det||structure-20/NN||the-17/DT	amod||structure-20/NN||immobilized-18/JJ	nn||structure-20/NN||enzyme-19/NN	prep_to||rigidity-15/JJ||structure-20/NN	advmod||resulting-23/VBG||ultimately-22/RB	xcomp||provide-14/VBP||resulting-23/VBG	amod||stability-27/NN||improved-25/VBN	nn||stability-27/NN||enzyme-26/NN	prep_in||resulting-23/VBG||stability-27/NN	enzyme-26||rigidity-15||no_rel||multipoint and multisubunit covalent attachments of enzymes on appropriately functionalized supports via linkers provide rigidity to the immobilized enzyme structure, ultimately resulting in improved enzyme stability.
nsubj||prevented-9/VBD||loperamide-1/NN	det||drug-6/NN||a-3/DT	amod||drug-6/NN||standard-4/JJ	amod||drug-6/NN||antidiarrheal-5/JJ	appos||loperamide-1/NN||drug-6/NN	advmod||prevented-9/VBD||similarly-8/RB	root||ROOT-0/null||prevented-9/VBD	det||diarrhea-11/NN||the-10/DT	dobj||prevented-9/VBD||diarrhea-11/NN	diarrhea-11||loperamide-1||no||loperamide, a standard antidiarrheal drug, similarly prevented the diarrhea.
det||filoviruses-2/NNS||the-1/DT	nsubj||viruses-12/NNS||filoviruses-2/NNS	amod||filoviruses-2/NNS||marburg-4/JJ	amod||filoviruses-2/NNS||ebola-6/JJ	conj_and||marburg-4/JJ||ebola-6/JJ	cop||viruses-12/NNS||are-8/VBP	amod||viruses-12/NNS||non-segmented-9/JJ	amod||viruses-12/NNS||negative-strand-10/JJ	nn||viruses-12/NNS||rna-11/NN	root||ROOT-0/null||viruses-12/NNS	vmod||viruses-12/NNS||causing-13/VBG	amod||hemorrhagicfever-15/NN||severe-14/JJ	dobj||causing-13/VBG||hemorrhagicfever-15/NN	amod||rates-19/NNS||high-17/JJ	nn||rates-19/NNS||mortality-18/NN	prep_with||causing-13/VBG||rates-19/NNS	prep_in||rates-19/NNS||humans-21/NNS	nn||primates-24/NNS||nonhuman-23/NN	prep_in||rates-19/NNS||primates-24/NNS	conj_and||humans-21/NNS||primates-24/NNS	hemorrhagicfever-15||viruses-12||no||the filoviruses, marburg and ebola, are non-segmented negative-strand rna viruses causing severe hemorrhagicfever with high mortality rates in humans and nonhuman primates.
advmod||known-5/VBN||additionally-1/RB	nsubjpass||known-5/VBN||tam-3/NN	nsubj||promote-7/VB||tam-3/NN	auxpass||known-5/VBN||are-4/VBP	root||ROOT-0/null||known-5/VBN	aux||promote-7/VB||to-6/TO	xcomp||known-5/VBN||promote-7/VB	nn||progression-9/NN||tumor-8/NN	dobj||promote-7/VB||progression-9/NN	amod||types-13/NNS||most-11/JJS	nn||types-13/NNS||cancer-12/NN	prep_for||progression-9/NN||types-13/NNS	prep_including||progression-9/NN||lymphomas-16/NNS	tam-3||cancer-12||no_rel||additionally, tam are known to promote tumor progression for most cancer types, including lymphomas.
amod||infections-6/NNS||community-acquired-1/JJ	amod||infections-6/NNS||methicillin-resistantstaphylococcusaureus-2/JJ	amod||infections-6/NNS||ca-mrsa-4/JJ	nsubj||emerged-15/VBN||infections-6/NNS	amod||people-9/NNS||young-8/JJ	prep_among||infections-6/NNS||people-9/NNS	amod||factors-13/NNS||healthcare-associated-11/JJ	nn||factors-13/NNS||risk-12/NN	prep_without||people-9/NNS||factors-13/NNS	aux||emerged-15/VBN||have-14/VBP	root||ROOT-0/null||emerged-15/VBN	det||decade-19/NN||the-17/DT	amod||decade-19/NN||past-18/JJ	prep_during||emerged-15/VBN||decade-19/NN	mrsa--1||ca--1||no_rel||community-acquired methicillin-resistantstaphylococcusaureus (ca-mrsa) infections among young people without healthcare-associated risk factors have emerged during the past decade.
nsubj||live-3/VB||plha-1/NN	nsubjpass||associated-165/VBN||plha-1/NN	rcmod||plha-1/NN||live-3/VB	poss||-LSB--7/NN||their-5/PRP$	nn||-LSB--7/NN||families-6/NNS	prep_with||live-3/VB||-LSB--7/NN	prep_with||live-3/VB||=-9/NNP	conj_or||-LSB--7/NN||=-9/NNP	num||=-9/NNP||3.29-10/CD	num||%-13/NN||95-12/CD	dobj||live-3/VB||%-13/NN	vmod||%-13/NN||ci-14/VBN	num||-RSB--18/NNS||1.28-8-15/CD	nn||-RSB--18/NNS||.45-16/CD	dobj||ci-14/VBN||-RSB--18/NNS	dobj||ci-14/VBN||lived-20/VBN	conj_or||-RSB--18/NNS||lived-20/VBN	vmod||-RSB--18/NNS||lived-20/VBN	det||-LSB--25/NN||a-22/DT	amod||-LSB--25/NN||rented-23/VBN	nn||-LSB--25/NN||house-24/NN	prep_in||lived-20/VBN||-LSB--25/NN	number||2.52-28/CD||=-27/CD	num||-RSB--35/NN||2.52-28/CD	number||%-31/NN||95-30/CD	amod||-RSB--35/NN||%-31/NN	amod||-RSB--35/NN||ci-32/JJ	nn||-RSB--35/NN||1.09-5-33/NN	num||-RSB--35/NN||.79-34/CD	prep_in||lived-20/VBN||-RSB--35/NN	conj_or||-LSB--25/NN||-RSB--35/NN	dobj||have-54/VBP||-RSB--35/NN	amod||women-38/NNS||non-pregnant-37/JJ	appos||-RSB--35/NN||women-38/NNS	num||women-38/NNS||-LSB--39/CD	num||9.3-42/CD||=-41/CD	num||women-38/NNS||9.3-42/CD	conj_or||-LSB--39/CD||9.3-42/CD	number||%-45/NN||95-44/CD	amod||ci-46/NN||%-45/NN	appos||-RSB--35/NN||ci-46/NN	num||-RSB--49/NNS||1.93-44-47/CD	num||-RSB--49/NNS||.82-48/CD	dep||ci-46/NN||-RSB--49/NNS	amod||art-53/NN||perceived-52/VBN	nsubj||have-54/VBP||art-53/NN	rcmod||-RSB--35/NN||have-54/VBP	amod||effects-57/NNS||many-55/JJ	nn||effects-57/NNS||side-56/NN	dobj||have-54/VBP||effects-57/NNS	vmod||effects-57/NNS||-LSB--58/VBN	dep||6.23-61/CD||=-60/SYM	dobj||have-54/VBP||6.23-61/CD	conj_or||effects-57/NNS||6.23-61/CD	num||%-64/NN||95-63/CD	prep_in||lived-20/VBN||%-64/NN	conj_or||-LSB--25/NN||%-64/NN	num||-RSB--68/NNS||ci1-65/CD	nn||-RSB--68/NNS||.63,23.82-66/CD	dep||%-64/NN||-RSB--68/NNS	nsubj||perceived-71/VBD||who-70/WP	prep_in||lived-20/VBN||perceived-71/VBD	conj_or||-LSB--25/NN||perceived-71/VBD	amod||-LSB--92/NNS||hiv-72/JJ	prepc_as||hiv-72/JJ||stigmatizing-74/VBG	nn||-LSB--76/NNS||disease-75/NN	iobj||stigmatizing-74/VBG||-LSB--76/NNS	number||3.1-79/CD||=-78/CD	num||ci-83/NN||3.1-79/CD	number||%-82/NN||95-81/CD	amod||ci-83/NN||%-82/NN	iobj||stigmatizing-74/VBG||ci-83/NN	conj_or||-LSB--76/NNS||ci-83/NN	num||-RSB--86/NNS||1.09-8-84/CD	num||-RSB--86/NNS||.76-85/CD	dobj||stigmatizing-74/VBG||-RSB--86/NNS	nsubj||tested-89/VBN||-RSB--86/NNS	rcmod||-RSB--86/NNS||tested-89/VBN	prep_with||tested-89/VBN||sickness/symptoms-91/NNS	dobj||perceived-71/VBD||-LSB--92/NNS	dep||2.62-95/CD||=-94/SYM	dobj||perceived-71/VBD||2.62-95/CD	conj_or||-LSB--92/NNS||2.62-95/CD	number||%-98/NN||95-97/CD	amod||-RSB--102/NNS||%-98/NN	nn||-RSB--102/NNS||ci-99/NN	amod||-RSB--102/NNS||1.26-5-100/JJ	num||-RSB--102/NNS||.44-101/CD	dobj||ci-14/VBN||-RSB--102/NNS	conj_or||-RSB--18/NNS||-RSB--102/NNS	nsubj||disclose-107/VB||-RSB--102/NNS	aux||disclose-107/VB||did-105/VBD	neg||disclose-107/VB||not-106/RB	rcmod||-RSB--102/NNS||disclose-107/VB	poss||status-110/NN||their-108/PRP$	nn||status-110/NN||hiv-109/NN	dobj||disclose-107/VB||status-110/NN	poss||-LSB--114/NN||their-112/PRP$	nn||-LSB--114/NN||partner-113/NN	prep_for||disclose-107/VB||-LSB--114/NN	number||2.78-117/CD||=-116/CD	num||ci-121/NN||2.78-117/CD	number||%-120/NN||95-119/CD	amod||ci-121/NN||%-120/NN	dobj||ci-14/VBN||ci-121/NN	conj_or||-RSB--18/NNS||ci-121/NN	num||-LSB--129/NNS||1.02-7-122/CD	num||-LSB--129/NNS||.56-123/CD	nn||-LSB--129/NNS||-RSB--124/NNP	amod||-LSB--129/NNS||frequent-126/JJ	nn||-LSB--129/NNS||alcohol-127/NN	nn||-LSB--129/NNS||users-128/NNS	dep||ci-121/NN||-LSB--129/NNS	dep||3.55-132/CD||=-131/SYM	dobj||live-3/VB||3.55-132/CD	conj_or||%-13/NN||3.55-132/CD	number||%-135/NN||95-134/CD	amod||-LSB--152/NN||%-135/NN	amod||-LSB--152/NN||ci-136/JJ	amod||-LSB--152/NN||1.63-7-137/JJ	num||-RSB--139/NNS||.71-138/CD	nn||-LSB--152/NN||-RSB--139/NNS	nsubj||spent-142/VBD||who-141/WP	conj_and||-RSB--139/NNS||spent-142/VBD	nn||-LSB--152/NN||spent-142/VBD	mwe||than-144/IN||more-143/JJR	quantmod||120-145/CD||than-144/IN	num||months-146/NNS||120-145/CD	tmod||spent-142/VBD||months-146/NNS	prep_with||spent-142/VBD||partner-148/NN	nn||diagnosis-151/NN||hiv-150/NN	prep_at||spent-142/VBD||diagnosis-151/NN	dobj||live-3/VB||-LSB--152/NN	dep||5.86-155/CD||=-154/SYM	dobj||live-3/VB||5.86-155/CD	conj_or||-LSB--152/NN||5.86-155/CD	number||%-158/NN||95-157/CD	amod||-RSB--162/NNS||%-158/NN	amod||-RSB--162/NNS||ci-159/JJ	number||.41-161/CD||1.35-25-160/CD	num||-RSB--162/NNS||.41-161/CD	dobj||live-3/VB||-RSB--162/NNS	auxpass||associated-165/VBN||were-163/VBD	advmod||associated-165/VBN||significantly-164/RB	root||ROOT-0/null||associated-165/VBN	amod||presentation-168/NN||late-167/JJ	prep_with||associated-165/VBN||presentation-168/NN	amod||care-171/NN||hiv/aids-170/JJ	prep_to||associated-165/VBN||care-171/NN	aids--1||hiv-150||no||plha who live with their families [or = 3.29, 95%ci 1.28-8.45)], lived in a rented house [or = 2.52, 95%ci 1.09-5.79], non-pregnant women [or = 9.3, 95% ci 1.93-44.82], who perceived art have many side effects [or = 6.23, 95%ci1.63,23.82)], who perceived hiv as stigmatizing disease [or = 3.1, 95% ci 1.09-8.76], who tested with sickness/symptoms [or = 2.62, 95% ci 1.26-5.44], who did not disclose their hiv status for their partner [or = 2.78, 95% ci 1.02-7.56], frequent alcohol users [or = 3.55, 95% ci 1.63-7.71] and who spent more than 120 months with partner at hiv diagnosis[or = 5.86, 95% ci 1.35-25.41] were significantly associated with late presentation to hiv/aids care.
amod||cholesterol-2/NN||dietary-1/JJ	nsubj||plays-3/VBZ||cholesterol-2/NN	root||ROOT-0/null||plays-3/VBZ	det||role-8/NN||a-4/DT	amod||role-8/NN||determining-5/JJ	amod||role-8/NN||independent-7/JJ	dobj||plays-3/VBZ||role-8/NN	prep_in||plays-3/VBZ||inflammation-10/NN	dep||plays-3/VBZ||especially-12/RB	amod||mice-15/NNS||female-14/JJ	prep_in||plays-3/VBZ||mice-15/NNS	cholesterol-2||inflammation-10||no_rel||dietary cholesterol plays a determining, independent role in inflammation, especially in female mice.
dep||generalized-21/VBD||using-1/VBG	dobj||using-1/VBG||data-2/NNS	det||vancouver-5/NN||the-4/DT	prep_from||using-1/VBG||vancouver-5/NN	nn||study-9/NN||injection-6/NN	nn||study-9/NN||drug-7/NN	nn||study-9/NN||users-8/NNS	nsubj||generalized-21/VBD||study-9/NN	appos||study-9/NN||vidus-11/NNS	det||study-17/NN||an-14/DT	amod||study-17/NN||observational-15/JJ	nn||study-17/NN||cohort-16/NN	appos||study-9/NN||study-17/NN	prep_of||study-17/NN||idu-19/NN	root||ROOT-0/null||generalized-21/VBD	nn||equations-23/NNS||estimating-22/NN	nsubjpass||performed-28/VBN||equations-23/NNS	nsubj||examine-30/VB||equations-23/NNS	appos||equations-23/NNS||gee-25/NN	auxpass||performed-28/VBN||were-27/VBD	ccomp||generalized-21/VBD||performed-28/VBN	aux||examine-30/VB||to-29/TO	xcomp||performed-28/VBN||examine-30/VB	amod||factors-34/NNS||socio-demographic-31/JJ	conj_and||socio-demographic-31/JJ||behavioural-33/JJ	amod||factors-34/NNS||behavioural-33/JJ	dobj||examine-30/VB||factors-34/NNS	vmod||factors-34/NNS||associated-35/VBN	prep_with||associated-35/VBN||reports-37/NNS	prepc_of||reports-37/NNS||receiving-39/VBG	dobj||receiving-39/VBG||assistance-40/NN	prepc_with||receiving-39/VBG||injecting-42/VBG	amod||settings-45/NNS||outdoor-44/JJ	prep_in||injecting-42/VBG||settings-45/NNS	idu-19||gee-25||no_rel||using data from the vancouver injection drug users study (vidus), an observational cohort study of idu, generalized estimating equations (gee) were performed to examine socio-demographic and behavioural factors associated with reports of receiving assistance with injecting in outdoor settings.
amod||t2d-3/NNS||type2diabetesmellitus-1/JJ	nsubj||disease-20/NN||t2d-3/NNS	det||disorder-8/NN||a-6/DT	amod||disorder-8/NN||metabolic-7/JJ	appos||t2d-3/NNS||disorder-8/NN	vmod||disorder-8/NN||characterized-9/VBN	amod||deficiency-15/NN||insulinresistance-11/JJ	conj_and||insulinresistance-11/JJ||relative-13/JJ	amod||deficiency-15/NN||relative-13/JJ	nn||deficiency-15/NN||insulin-14/NN	agent||characterized-9/VBN||deficiency-15/NN	cop||disease-20/NN||is-17/VBZ	det||disease-20/NN||a-18/DT	amod||disease-20/NN||complex-19/JJ	root||ROOT-0/null||disease-20/NN	amod||importance-25/NN||major-22/JJ	amod||importance-25/NN||public-23/JJ	nn||importance-25/NN||health-24/NN	prep_of||disease-20/NN||importance-25/NN	t2d-3||insulin-14||yes||type2diabetesmellitus (t2d), a metabolic disorder characterized by insulinresistance and relative insulin deficiency, is a complex disease of major public health importance.
amod||women-3/NNS||hiv-infected-1/JJ	nn||women-3/NNS||childbearing-2/NN	nsubjpass||enrolled-12/VBN||women-3/NNS	vmod||women-3/NNS||diagnosed-5/VBN	vmod||women-3/NNS||diagnosed-5/VBN	conj_or||diagnosed-5/VBN||diagnosed-5/VBN	prep_before||diagnosed-5/VBN||pregnancy-9/NN	prep_during||diagnosed-5/VBN||pregnancy-9/NN	auxpass||enrolled-12/VBN||were-11/VBD	root||ROOT-0/null||enrolled-12/VBN	advmod||enrolled-12/VBN||prospectively-13/RB	det||study-18/NN||a-15/DT	amod||study-18/NN||post-natal-16/JJ	nn||study-18/NN||cohort-17/NN	prep_in||enrolled-12/VBN||study-18/NN	num||centres-23/NNS||four-20/CD	amod||centres-23/NNS||regional-21/JJ	nn||centres-23/NNS||hiv/aids-22/NN	prep_in||study-18/NN||centres-23/NNS	prep_in||centres-23/NNS||ukraine-25/NN	prep_from||enrolled-12/VBN||december-27/NNP	num||december-27/NNP||2007-28/CD	aids--1||hiv--1||no||hiv-infected childbearing women, diagnosed before or during pregnancy, were enrolled prospectively in a post-natal cohort study in four regional hiv/aids centres in ukraine from december 2007.
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	virusinfection-29||ketoconazole-10||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
csubj||raises-24/VBZ||encouraging-1/VBG	dobj||encouraging-1/VBG||data-2/NNS	amod||efficacy-6/NN||potential-4/JJ	nn||efficacy-6/NN||equivalent-5/NN	prep_of||data-2/NNS||efficacy-6/NN	amod||administration-9/NN||easier-8/JJR	prep_of||data-2/NNS||administration-9/NN	conj_and||efficacy-6/NN||administration-9/NN	amod||grade-13/NN||fewer-12/JJR	prep_of||data-2/NNS||grade-13/NN	conj_and||efficacy-6/NN||grade-13/NN	num||reactions-18/NNS||3-14/CD	conj_and||3-14/CD||4-16/CD	num||reactions-18/NNS||4-16/CD	amod||reactions-18/NNS||adverse-17/JJ	dep||grade-13/NN||reactions-18/NNS	prepc_compared_with||encouraging-1/VBG||with-20/IN	amod||interferon-23/NN||high-dose-21/JJ	amod||interferon-23/NN||intravenous-22/JJ	pobj||encouraging-1/VBG||interferon-23/NN	root||ROOT-0/null||raises-24/VBZ	det||question-26/NN||the-25/DT	dobj||raises-24/VBZ||question-26/NN	poss||role-30/NN||its-28/PRP$	amod||role-30/NN||potential-29/JJ	prep_of||question-26/NN||role-30/NN	nn||melanoma-34/NN||stage-32/NN	nn||melanoma-34/NN||iii-33/NN	prep_in||role-30/NN||melanoma-34/NN	det||setting-38/NN||the-36/DT	amod||setting-38/NN||adjuvant-37/JJ	prep_in||melanoma-34/NN||setting-38/NN	melanoma-34||adjuvant-37||no_rel||encouraging data of potential equivalent efficacy, easier administration, and fewer grade 3 and 4 adverse reactions compared with high-dose intravenous interferon raises the question of its potential role in stage iii melanoma in the adjuvant setting.
nsubj||disease-5/NN||type1diabetesmellitus-1/NNS	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||an-3/DT	amod||disease-5/NN||autoimmune-4/JJ	root||ROOT-0/null||disease-5/NN	dep||disease-5/NN||caused-6/VBN	prep_by||caused-6/VBN||destruction-8/NN	amod||cells-12/NNS||pancreatic-10/JJ	nn||cells-12/NNS||beta-11/NN	prep_of||destruction-8/NN||cells-12/NNS	dep||disease-5/NN||characterized-14/VBN	conj_and||caused-6/VBN||characterized-14/VBN	prep_by||characterized-14/VBN||defect-16/NN	nn||secretion-19/NN||insulin-18/NN	prep_in||defect-16/NN||secretion-19/NN	mark||and/or-28/VBZ||while-20/IN	amod||results-22/NNS||type2diabetesmellitus-21/JJ	nsubj||and/or-28/VBZ||results-22/NNS	prep_from||results-22/NNS||abnormalities-24/NNS	nn||secretion-27/NN||insulin-26/NN	prep_in||abnormalities-24/NNS||secretion-27/NN	advcl||characterized-14/VBN||and/or-28/VBZ	nn||action-30/NN||insulin-29/NN	dobj||and/or-28/VBZ||action-30/NN	dobj||and/or-28/VBZ||both-32/DT	conj_or||action-30/NN||both-32/DT	type1diabetesmellitus-1||insulin-29||yes||type1diabetesmellitus is an autoimmune disease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
amod||therapy-2/NN||antiretroviral-1/JJ	nsubj||lifesaving-7/VBG||therapy-2/NN	appos||therapy-2/NN||art-4/NN	aux||lifesaving-7/VBG||is-6/VBZ	root||ROOT-0/null||lifesaving-7/VBG	prep_in||lifesaving-7/VBG||patients-9/NNS	amod||hivinfection-12/NN||advanced-11/JJ	prep_with||patients-9/NNS||hivinfection-12/NN	det||magnitude-16/NN||the-15/DT	nsubj||remains-28/VBZ||magnitude-16/NN	prep_of||magnitude-16/NN||benefit-18/NN	amod||treatment-27/NN||hiv-infected-20/JJ	nn||treatment-27/NN||patients-21/NNS	nn||treatment-27/NN||receiving-22/NN	nn||treatment-27/NN||tuberculosis-23/NNP	appos||treatment-27/NN||tb-25/NN	prep_in||benefit-18/NN||treatment-27/NN	conj_but||lifesaving-7/VBG||remains-28/VBZ	acomp||remains-28/VBZ||uncertain-29/JJ	amod||data-33/NNS||population-based-32/JJ	nsubj||limited-38/JJ||data-33/NNS	amod||countries-36/NNS||developing-35/VBG	prep_from||data-33/NNS||countries-36/NNS	cop||limited-38/JJ||are-37/VBP	conj_but||lifesaving-7/VBG||limited-38/JJ	conj_and||remains-28/VBZ||limited-38/JJ	hivinfection-12||hiv--1||no||antiretroviral therapy (art) is lifesaving in patients with advanced hivinfection, but the magnitude of benefit in hiv-infected patients receiving tuberculosis (tb) treatment remains uncertain, and population-based data from developing countries are limited.
mark||defined-8/VBN||while-1/IN	det||neuropathology-3/NN||the-2/DT	nsubjpass||defined-8/VBN||neuropathology-3/NN	prep_of||neuropathology-3/NN||kuru-5/NN	auxpass||defined-8/VBN||is-6/VBZ	advmod||defined-8/VBN||well-7/RB	advcl||are-11/VBP||defined-8/VBN	expl||are-11/VBP||there-10/EX	root||ROOT-0/null||are-11/VBP	amod||data-13/NNS||few-12/JJ	nsubj||are-11/VBP||data-13/NNS	det||distribution-16/NN||the-15/DT	prep_concerning||data-13/NNS||distribution-16/NN	amod||prionprotein-19/NN||disease-related-18/JJ	prep_of||distribution-16/NN||prionprotein-19/NN	amod||tissues-22/NNS||peripheral-21/JJ	prep_in||prionprotein-19/NN||tissues-22/NNS	prionprotein-19||kuru-5||no_rel||while the neuropathology of kuru is well defined, there are few data concerning the distribution of disease-related prionprotein in peripheral tissues.
prep_in||contribute-6/VB||owat-2/NN	nsubj||contribute-6/VB||fibrosis-4/NN	nsubj||limit-8/VB||fibrosis-4/NN	nsubjpass||associated-13/VBN||fibrosis-4/NN	aux||contribute-6/VB||could-5/MD	root||ROOT-0/null||contribute-6/VB	aux||limit-8/VB||to-7/TO	xcomp||contribute-6/VB||limit-8/VB	amod||hypertrophy-10/NN||adipocyte-9/JJ	dobj||limit-8/VB||hypertrophy-10/NN	auxpass||associated-13/VBN||is-12/VBZ	conj_and||contribute-6/VB||associated-13/VBN	det||profile-18/NN||a-15/DT	amod||profile-18/NN||better-16/JJR	nn||profile-18/NN||lipid-17/NN	prep_with||associated-13/VBN||profile-18/NN	mark||hamper-24/VB||whereas-20/IN	nn||fibrosis-22/NN||scwat-21/NN	nsubj||hamper-24/VB||fibrosis-22/NN	aux||hamper-24/VB||may-23/MD	dep||profile-18/NN||hamper-24/VB	amod||loss-27/NN||fat-25/JJ	amod||loss-27/NN||mass-26/JJ	dobj||hamper-24/VB||loss-27/NN	vmod||loss-27/NN||induced-28/VBN	agent||induced-28/VBN||surgery-30/NN	lipid-17||fibrosis-22||no_rel||in owat, fibrosis could contribute to limit adipocyte hypertrophy and is associated with a better lipid profile, whereas scwat fibrosis may hamper fat mass loss induced by surgery.
agent||reported-56/VBN||employing-2/VBG	det||approach-6/NN||an-3/DT	amod||approach-6/NN||unbiased-4/JJ	amod||approach-6/NN||metagenomic-5/JJ	dobj||employing-2/VBG||approach-6/NN	nsubj||allows-9/VBZ||approach-6/NN	rcmod||approach-6/NN||allows-9/VBZ	det||detection-11/NN||the-10/DT	dobj||allows-9/VBZ||detection-11/NN	preconj||unexpected-14/JJ||both-13/DT	amod||agents-19/NNS||unexpected-14/JJ	advmod||unknown-17/JJ||previously-16/RB	conj_and||unexpected-14/JJ||unknown-17/JJ	amod||agents-19/NNS||unknown-17/JJ	amod||agents-19/NNS||infectious-18/JJ	prep_of||detection-11/NN||agents-19/NNS	det||detection-22/NN||the-21/DT	nsubjpass||reported-56/VBN||detection-22/NN	num||viruses-25/NNS||three-24/CD	prep_of||detection-22/NN||viruses-25/NNS	amod||virus-30/NN||aphid-27/JJ	amod||virus-30/NN||lethal-28/JJ	nn||virus-30/NN||paralysis-29/NN	appos||viruses-25/NNS||virus-30/NN	appos||virus-30/NN||alpv-32/NNP	amod||virus-38/NN||israel-35/JJ	amod||virus-38/NN||acute-36/JJ	nn||virus-38/NN||paralysis-37/NN	appos||viruses-25/NNS||virus-38/NN	conj_and||virus-30/NN||virus-38/NN	appos||virus-38/NN||iapv-40/NNP	nn||virus-46/NN||lake-44/NN	nn||virus-46/NN||sinai-45/NN	appos||viruses-25/NNS||virus-46/NN	conj_and||virus-30/NN||virus-46/NN	appos||virus-46/NN||lsv-48/NN	prep_in||viruses-25/NNS||honeybees-52/NNS	prep_from||honeybees-52/NNS||spain-54/NN	auxpass||reported-56/VBN||is-55/VBZ	root||ROOT-0/null||reported-56/VBN	det||article-59/NN||this-58/DT	prep_in||reported-56/VBN||article-59/NN	virus-46||viruses-25||no||by employing an unbiased metagenomic approach, which allows the detection of both unexpected and previously unknown infectious agents, the detection of three viruses, aphid lethal paralysis virus (alpv), israel acute paralysis virus (iapv), and lake sinai virus (lsv), in honeybees from spain is reported in this article.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	il-2-23||renalcellcarcinoma-6||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	amod||methylcellulose-18/NN||hydroxypropyl-17/JJ	appos||consumption-8/NN||methylcellulose-18/NN	dep||methylcellulose-18/NN||hpmc-20/JJ	nn||lipids-30/NNS||glucose-24/NN	nn||lipids-30/NNS||control-25/NN	conj_and||control-25/NN||insulinresistance-27/NN	nn||lipids-30/NNS||insulinresistance-27/NN	conj_and||control-25/NN||liver-29/NN	nn||lipids-30/NNS||liver-29/NN	prep_on||examined-3/VBD||lipids-30/NNS	det||model-36/NN||an-32/DT	amod||model-36/NN||obese-33/JJ	amod||model-36/NN||diabetic-34/JJ	nn||model-36/NN||rat-35/NN	prep_in||lipids-30/NNS||model-36/NN	insulinresistance-27||glucose-24||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropyl methylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
nsubj||endocrinedisease-6/NN||endogenous-1/NNS	vmod||endogenous-1/NNS||cushing-2/VBG	dobj||cushing-2/VBG||syndrome-3/NN	cop||endocrinedisease-6/NN||is-4/VBZ	det||endocrinedisease-6/NN||an-5/DT	root||ROOT-0/null||endocrinedisease-6/NN	vmod||endocrinedisease-6/NN||caused-7/VBN	amod||secretion-10/NN||excessive-9/JJ	agent||caused-7/VBN||secretion-10/NN	nn||hormone-13/NN||adrenocorticotropin-12/NN	prep_of||secretion-10/NN||hormone-13/NN	quantmod||80-16/CD||approximately-15/RB	num||%-17/NN||80-16/CD	prep_in||caused-7/VBN||%-17/NN	prep_of||%-17/NN||cases-19/NNS	advmod||caused-7/VBN||usually-21/RB	det||adenoma-26/NN||a-23/DT	advmod||corticotroph-25/JJ||pituitary-24/RB	amod||adenoma-26/NN||corticotroph-25/JJ	agent||caused-7/VBN||adenoma-26/NN	amod||-RSB--31/NNP||cushingdisease-28/JJ	nn||-RSB--31/NNP||-LSB--29/NNP	nn||-RSB--31/NNP||cd-30/NN	appos||adenoma-26/NN||-RSB--31/NNP	cd-30||adenoma-26||no_rel||endogenous cushing syndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||‰-10/NNS||â-9/NN	dobj||aged-8/VBN||‰-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||‰-24/NNS||â-23/NN	prep_of||thickness-21/NN||‰-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||‰-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	hypertension-61||triglyceride-57||no_rel||asymptomatic patients ( n = 485) aged â‰¥50 years with either a maximal carotid artery intima-media thickness of â‰¥1.1 mm, or a urinary albumin â‰¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
poss||model-5/NN||our-2/PRP$	amod||model-5/NN||experimental-3/JJ	nn||model-5/NN||vili-4/NN	prep_in||attenuated-11/VBD||model-5/NN	det||acidosis-8/NNS||both-6/DT	amod||acidosis-8/NNS||metabolic-7/JJ	nsubj||attenuated-11/VBD||acidosis-8/NNS	conj_and||acidosis-8/NNS||hypercapnicacidosis-10/NNS	nsubj||attenuated-11/VBD||hypercapnicacidosis-10/NNS	root||ROOT-0/null||attenuated-11/VBD	amod||edema-14/NN||vili-induced-12/JJ	amod||edema-14/NN||pulmonary-13/JJ	dobj||attenuated-11/VBD||edema-14/NN	xcomp||attenuated-11/VBD||implying-15/VBG	det||mechanism-17/NN||a-16/DT	dobj||implying-15/VBG||mechanism-17/NN	dep||mechanism-17/NN||other-18/JJ	amod||effects-22/NNS||possible-20/JJ	amod||effects-22/NNS||synergistic-21/JJ	prep_than||mechanism-17/NN||effects-22/NNS	prep_of||effects-22/NNS||acidosis-24/NNS	prep_with||implying-15/VBG||co2-26/NNS	amod||attenuation-29/NN||vili-28/JJ	prep_for||co2-26/NNS||attenuation-29/NN	hypercapnicacidosis-10||co2-26||no||in our experimental vili model both metabolic acidosis and hypercapnicacidosis attenuated vili-induced pulmonary edema implying a mechanism other than possible synergistic effects of acidosis with co2 for vili attenuation.
nn||virulence-2/NN||hiv-1/NN	nsubj||varies-12/VBZ||virulence-2/NN	vmod||virulence-2/NN||i.e.-4/VBN	det||time-6/NN||the-5/DT	dobj||i.e.-4/VBN||time-6/NN	prep_of||time-6/NN||progression-8/NN	prep_to||i.e.-4/VBN||aids-10/NNS	root||ROOT-0/null||varies-12/VBZ	advmod||varies-12/VBZ||greatly-13/RB	prep_among||varies-12/VBZ||patients-15/NNS	aids-10||hiv-1||no||hiv virulence , i.e. the time of progression to aids , varies greatly among patients .
amod||o1-2/NNS||vibriocholerae-1/JJ	nsubj||causing-9/VBG||o1-2/NNS	amod||humans-7/NNS||v.cholerae-4/JJ	amod||humans-7/NNS||o139-5/JJ	amod||humans-7/NNS||infect-6/JJ	conj_and||o1-2/NNS||humans-7/NNS	nsubj||causing-9/VBG||humans-7/NNS	root||ROOT-0/null||causing-9/VBG	det||cholera-15/NN||the-10/DT	amod||cholera-15/NN||diarrheal-11/JJ	conj_and||diarrheal-11/JJ||waterborne-13/JJ	amod||cholera-15/NN||waterborne-13/JJ	nn||cholera-15/NN||disease-14/NN	dobj||causing-9/VBG||cholera-15/NN	nsubj||problem-22/NN||cholera-15/NN	cop||problem-22/NN||is-18/VBZ	det||problem-22/NN||a-19/DT	amod||problem-22/NN||worldwide-20/JJ	nn||problem-22/NN||health-21/NN	rcmod||cholera-15/NN||problem-22/NN	cholera-15||v.cholerae-4||no||vibriocholerae o1 and v.cholerae o139 infect humans , causing the diarrheal and waterborne disease cholera , which is a worldwide health problem .
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
amod||feâˆ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâˆ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâˆ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâˆ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	ironoverload-37||iron-31||no||defective feâˆ’s cluster synthesis not only affects activities of many ironâˆ’sulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
nsubj||characterize-5/VBP||perturbations-1/NNS	nn||metabolism-4/NN||lipid-3/NN	prep_in||perturbations-1/NNS||metabolism-4/NN	root||ROOT-0/null||characterize-5/VBP	dobj||characterize-5/VBP||many-6/JJ	det||chronicdiseases-9/NNS||the-8/DT	prep_of||many-6/JJ||chronicdiseases-9/NNS	advmod||plaguing-11/VBG||currently-10/RB	vmod||chronicdiseases-9/NNS||plaguing-11/VBG	poss||society-13/NN||our-12/PRP$	dobj||plaguing-11/VBG||society-13/NN	prep_such_as||many-6/JJ||obesity-17/NN	prep_such_as||many-6/JJ||diabetes-19/NN	conj_and||obesity-17/NN||diabetes-19/NN	prep_such_as||many-6/JJ||cardiovasculardisease-22/NN	conj_and||obesity-17/NN||cardiovasculardisease-22/NN	cardiovasculardisease-22||lipid-3||no_rel||perturbations in lipid metabolism characterize many of the chronicdiseases currently plaguing our society, such as obesity, diabetes, and cardiovasculardisease.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||study-3/NN||this-2/DT	prep_in||applied-21/VBN||study-3/NN	det||approach-8/NN||a-5/DT	nn||approach-8/NN||landscape-6/NN	amod||approach-8/NN||epidemiologic-7/JJ	nsubjpass||applied-21/VBN||approach-8/NN	nsubj||increase-23/VB||approach-8/NN	vmod||approach-8/NN||combined-10/VBN	amod||system-14/NN||geographic-12/JJ	nn||system-14/NN||information-13/NN	prep_with||combined-10/VBN||system-14/NN	amod||techniques-18/NNS||remote-16/JJ	nn||techniques-18/NNS||sensing-17/NN	prep_with||combined-10/VBN||techniques-18/NNS	conj_and||system-14/NN||techniques-18/NNS	auxpass||applied-21/VBN||was-20/VBD	root||ROOT-0/null||applied-21/VBN	aux||increase-23/VB||to-22/TO	xcomp||applied-21/VBN||increase-23/VB	poss||understanding-25/NN||our-24/PRP$	dobj||increase-23/VB||understanding-25/NN	prep_of||understanding-25/NN||hfrs-27/NNS	prep_due_to||increase-23/VB||hantaanvirus-30/NNS	poss||relationship-33/NN||its-32/PRP$	prep_due_to||increase-23/VB||relationship-33/NN	conj_and||hantaanvirus-30/NNS||relationship-33/NN	nn||elements-36/NNS||landscape-35/NN	prep_with||increase-23/VB||elements-36/NNS	prep_in||elements-36/NNS||china-38/NN	hfrs-27||hantaanvirus-30||no||in this study, a landscape epidemiologic approach, combined with geographic information system and remote sensing techniques, was applied to increase our understanding of hfrs due to hantaanvirus and its relationship with landscape elements in china.
nsubj||invasion-8/NN||cutaneoustuberculosis-1/NNS	appos||cutaneoustuberculosis-1/NNS||tb-3/NN	cop||invasion-8/NN||is-5/VBZ	advmod||invasion-8/NN||essentially-6/RB	det||invasion-8/NN||an-7/DT	root||ROOT-0/null||invasion-8/NN	det||skin-11/NN||the-10/DT	prep_of||invasion-8/NN||skin-11/NN	prep_by||skin-11/NN||mycobacteriumtuberculosis-13/NNS	det||bacteria-17/NNS||the-15/DT	amod||bacteria-17/NNS||same-16/JJ	appos||mycobacteriumtuberculosis-13/NNS||bacteria-17/NNS	nsubj||causes-19/VBZ||bacteria-17/NNS	rcmod||bacteria-17/NNS||causes-19/VBZ	dobj||causes-19/VBZ||pulmonarytuberculosis-20/NNS	pulmonarytuberculosis-20||mycobacteriumtuberculosis-13||no||cutaneoustuberculosis (tb) is essentially an invasion of the skin by mycobacteriumtuberculosis , the same bacteria that causes pulmonarytuberculosis.
nsubj||received-15/VBN||janumettm-1/NN	nsubj||received-15/VBN||janumettm-1/NN	nsubj||received-15/VBN||janumettm-1/NN	det||combination-6/NN||a-3/DT	amod||combination-6/NN||fixed-4/VBN	nn||combination-6/NN||dose-5/NN	appos||janumettm-1/NN||combination-6/NN	prep_of||combination-6/NN||sitagliptin/metforminhcl-8/NN	vmod||combination-6/NN||manufactured-9/VBN	nn||pharmaceuticals-12/NNS||merck-11/NN	agent||manufactured-9/VBN||pharmaceuticals-12/NNS	aux||received-15/VBN||has-14/VBZ	root||ROOT-0/null||received-15/VBN	conj_or||received-15/VBN||received-15/VBN	conj_or||received-15/VBN||received-15/VBN	nsubj||approval-21/NN||us-16/PRP	nn||approval-21/NN||food-17/NN	conj_and||food-17/NN||drug-19/NN	nn||approval-21/NN||drug-19/NN	nn||approval-21/NN||administration-20/NN	xcomp||received-15/VBN||approval-21/NN	prep_for||approval-21/NN||treatment-23/NN	prep_of||treatment-23/NN||patients-25/NNS	prep_with||received-15/VBN||type2diabetes-27/NNS	nsubjpass||controlled-32/VBN||type2diabetes-27/NNS	auxpass||controlled-32/VBN||are-30/VBP	advmod||controlled-32/VBN||inadequately-31/RB	rcmod||type2diabetes-27/NNS||controlled-32/VBN	preconj||received-15/VBN||either-34/CC	prep_by||received-15/VBN||sitagliptin-36/NN	prep_by||received-15/VBN||metformin-38/NN	conj_or||sitagliptin-36/NN||metformin-38/NN	advmod||received-15/VBN||alone-39/RB	advmod||received-15/VBN||together-41/RB	amod||form-45/NN||free-dose-43/JJ	nn||form-45/NN||combination-44/NN	prep_in||received-15/VBN||form-45/NN	type2diabetes-27||sitagliptin-36||yes||janumettm, a fixed dose combination of sitagliptin/metforminhcl manufactured by merck pharmaceuticals, has received us food and drug administration approval for treatment of patients with type2diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form.
amod||cases-4/NNS||histopathologically-2/JJ	amod||cases-4/NNS||ambiguous-3/JJ	prep_in||marker-17/NN||cases-4/NNS	amod||expression-9/NN||lower-6/JJR	nn||expression-9/NN||cyclin-7/NN	nn||expression-9/NN||d3-8/NN	nsubj||marker-17/NN||expression-9/NN	amod||nevi-12/NNS||dysplastic-11/JJ	prep_in||expression-9/NN||nevi-12/NNS	aux||marker-17/NN||can-13/MD	cop||marker-17/NN||be-14/VB	det||marker-17/NN||a-15/DT	amod||marker-17/NN||diagnostic-16/JJ	root||ROOT-0/null||marker-17/NN	det||type-21/NN||that-19/DT	nn||type-21/NN||lesion-20/NN	prep_for||marker-17/NN||type-21/NN	nevi-12||d3-8||no_rel||in histopathologically ambiguous cases, lower cyclin d3 expression in dysplastic nevi can be a diagnostic marker for that lesion type.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tb-21||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
det||hallmarks-2/NNS||the-1/DT	nsubj||include-6/VBP||hallmarks-2/NNS	amod||hyperglycaemia-5/NN||stress-induced-4/JJ	prep_of||hallmarks-2/NNS||hyperglycaemia-5/NN	root||ROOT-0/null||include-6/VBP	acomp||include-6/VBP||insulinresistance-8/JJ	ccomp||insulinresistance-8/JJ||associated-10/VBN	det||increase-13/NN||an-12/DT	prep_with||associated-10/VBN||increase-13/NN	amod||output-17/NN||hepatic-15/JJ	nn||output-17/NN||glucose-16/NN	prep_in||increase-13/NN||output-17/NN	amod||release-20/NN||insufficient-19/JJ	prep_with||associated-10/VBN||release-20/NN	conj_and||increase-13/NN||release-20/NN	prep_of||release-20/NN||insulin-22/NN	prep_with||associated-10/VBN||regard-24/NN	prep_to||associated-10/VBN||glycaemia-26/NN	hyperglycaemia-5||insulin-22||yes||the hallmarks of stress-induced hyperglycaemia include 'insulinresistance' associated with an increase in hepatic glucose output and insufficient release of insulin with regard to glycaemia.
nsubj||hypothesize-2/VBP||we-1/PRP	dep||gsls-19/VBZ||hypothesize-2/VBP	mark||reflect-6/VB||that-3/IN	nsubj||reflect-6/VB||these-4/DT	aux||reflect-6/VB||might-5/MD	ccomp||hypothesize-2/VBP||reflect-6/VB	amod||compartmentation-8/NN||preexisting-7/JJ	dobj||reflect-6/VB||compartmentation-8/NN	amod||lipids-12/NNS||endogenous-10/JJ	nn||lipids-12/NNS||pm-11/NN	prep_of||compartmentation-8/NN||lipids-12/NNS	amod||domains-15/NNS||non-overlapping-14/JJ	prep_into||reflect-6/VB||domains-15/NNS	nn||order-18/NN||differential-17/NN	prep_of||domains-15/NNS||order-18/NN	root||ROOT-0/null||gsls-19/VBZ	num||pc-23/NN||>-20/CD	nn||pc-23/NN||sm-21/NN	nn||pc-23/NN||>-22/NN	nsubj||gsls-19/VBZ||pc-23/NN	vmod||gsls-19/VBZ||resulting-25/VBG	nn||self-adhesion-28/NN||differential-27/NN	prep_into||resulting-25/VBG||self-adhesion-28/NN	det||former-32/NN||the-30/DT	num||former-32/NN||two-31/CD	prep_of||self-adhesion-28/NN||former-32/NN	prep_with||resulting-25/VBG||exclusion-35/NN	det||latter-38/NN||the-37/DT	prep_of||exclusion-35/NN||latter-38/NN	lipids-12||adhesion--1||no_rel||we hypothesize that these might reflect preexisting compartmentation of endogenous pm lipids into non-overlapping domains of differential order gsls > sm > pc, resulting into differential self-adhesion of the two former, with exclusion of the latter.
det||applicability-2/NN||the-1/DT	nsubjpass||demonstrated-10/VBN||applicability-2/NN	det||sensor-5/NN||the-4/DT	prep_of||applicability-2/NN||sensor-5/NN	nn||purposes-8/NNS||screening-7/NN	prep_for||sensor-5/NN||purposes-8/NNS	auxpass||demonstrated-10/VBN||is-9/VBZ	root||ROOT-0/null||demonstrated-10/VBN	det||comparison-14/NN||the-12/DT	amod||comparison-14/NN||functional-13/JJ	agent||demonstrated-10/VBN||comparison-14/NN	amod||analogues-18/NNS||potent-16/JJ	amod||analogues-18/NNS||synthetic-17/JJ	prep_of||comparison-14/NN||analogues-18/NNS	prep_of||analogues-18/NNS||vitamind3-20/NNS	vmod||vitamind3-20/NNS||designed-21/VBN	det||treatment-24/NN||the-23/DT	prep_for||designed-21/VBN||treatment-24/NN	prep_of||treatment-24/NN||psoriasis-26/NNS	prep_of||treatment-24/NN||cancer-28/NN	conj_and||psoriasis-26/NNS||cancer-28/NN	psoriasis-26||vitamind3-20||yes||the applicability of the sensor for screening purposes is demonstrated by the functional comparison of potent synthetic analogues of vitamind3 designed for the treatment of psoriasis and cancer.
nsubj||secretes-2/VBZ||bacillusanthracis-1/NNS	root||ROOT-0/null||secretes-2/VBZ	amod||factors-5/NNS||several-3/JJ	nn||factors-5/NNS||virulence-4/NN	dobj||secretes-2/VBZ||factors-5/NNS	xcomp||secretes-2/VBZ||targeting-6/VBG	amod||organs-9/NNS||different-7/JJ	nn||organs-9/NNS||host-8/NN	dobj||targeting-6/VBG||organs-9/NNS	nn||types-12/NNS||cell-11/NN	dobj||targeting-6/VBG||types-12/NNS	conj_and||organs-9/NNS||types-12/NNS	nn||infection-15/NN||inhalationalanthrax-14/NN	prep_during||targeting-6/VBG||infection-15/NN	inhalationalanthrax-14||bacillusanthracis-1||no||bacillusanthracis secretes several virulence factors targeting different host organs and cell types during inhalationalanthrax infection.
nsubj||reduced-9/VBD||prevention-1/NN	amod||reabsorption-5/NN||renal-3/JJ	nn||reabsorption-5/NN||glucose-4/NN	prep_of||prevention-1/NN||reabsorption-5/NN	amod||deletion-8/NN||sglt2-7/JJ	prep_by||reabsorption-5/NN||deletion-8/NN	root||ROOT-0/null||reduced-9/VBD	dobj||reduced-9/VBD||hfd-10/NN	amod||hyperglycemia-14/NN||obesity-associated-13/JJ	dobj||reduced-9/VBD||hyperglycemia-14/NN	conj_and||hfd-10/NN||hyperglycemia-14/NN	amod||glucoseintolerance-17/NN||improved-16/VBN	conj_and||hfd-10/NN||glucoseintolerance-17/NN	conj_and||hyperglycemia-14/NN||glucoseintolerance-17/NN	amod||secretion-23/NN||increased-20/VBN	amod||secretion-23/NN||glucose-stimulated-21/JJ	nn||secretion-23/NN||insulin-22/NN	conj_and||hfd-10/NN||secretion-23/NN	conj_and||hyperglycemia-14/NN||secretion-23/NN	prep_in||secretion-23/NN||vivo-25/NN	hyperglycemia-14||glucose-4||no||prevention of renal glucose reabsorption by sglt2 deletion reduced hfd- and obesity-associated hyperglycemia, improved glucoseintolerance, and increased glucose-stimulated insulin secretion in vivo.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||domain-29/NN||a-3/DT	amod||domain-29/NN||methodology-4/JJ	prepc_for||methodology-4/JJ||automating-6/VBG	nn||assignments-9/NNS||protein-7/NN	nn||assignments-9/NNS||resonance-8/NN	dobj||automating-6/VBG||assignments-9/NNS	nn||data-14/NNS||mas-11/NN	nn||data-14/NNS||ssnmr-12/NN	nn||data-14/NNS||spectral-13/NN	prep_of||assignments-9/NNS||data-14/NNS	poss||application-17/NN||its-16/PRP$	prep_of||assignments-9/NNS||application-17/NN	conj_and||data-14/NNS||application-17/NN	amod||lists-21/NNS||experimental-19/JJ	nn||lists-21/NNS||peak-20/NN	prep_to||automating-6/VBG||lists-21/NNS	det||î-24/NN||the-23/DT	prep_of||lists-21/NNS||î-24/NN	number||1-26/CD||²-25/CD	num||î-24/NN||1-26/CD	nn||domain-29/NN||immunoglobulin-27/NN	amod||domain-29/NN||binding-28/VBG	dobj||present-2/VBP||domain-29/NN	nn||g-32/NN||protein-31/NN	prep_of||domain-29/NN||g-32/NN	appos||g-32/NN||gb1-34/NNP	vmod||g-32/NN||derived-36/VBN	det||sample-44/NN||a-38/DT	amod||sample-44/NN||uniformly-39/JJ	amod||sample-44/NN||13c-40/JJ	conj_and||13c-40/JJ||15n-labeled-43/JJ	amod||sample-44/NN||15n-labeled-43/JJ	prep_from||derived-36/VBN||sample-44/NN	mas-11||immunoglobulin-27||no_rel||we present a methodology for automating protein resonance assignments of mas ssnmr spectral data and its application to experimental peak lists of the î²1 immunoglobulin binding domain of protein g (gb1) derived from a uniformly 13c- and 15n-labeled sample.
advmod||associated-20/VBN||even-1/RB	prep_in||associated-20/VBN||offspring-3/NN	prep_of||offspring-3/NN||mothers-5/NNS	det||test-12/NN||a-7/DT	amod||test-12/NN||normal-8/JJ	amod||test-12/NN||oral-9/JJ	nn||test-12/NN||glucose-10/NN	nn||test-12/NN||tolerance-11/NN	prep_with||mothers-5/NNS||test-12/NN	prep_during||test-12/NN||pregnancy-14/NN	amod||overweight-18/NN||maternal-16/JJ	nn||overweight-18/NN||prepregnancy-17/NN	nsubjpass||associated-20/VBN||overweight-18/NN	auxpass||associated-20/VBN||is-19/VBZ	root||ROOT-0/null||associated-20/VBN	amod||risk-23/NN||increased-22/VBN	prep_with||associated-20/VBN||risk-23/NN	det||outcomes-26/NNS||these-25/DT	prep_for||risk-23/NN||outcomes-26/NNS	amod||prevalence-29/NN||overweight-28/JJ	dep||outcomes-26/NNS||prevalence-29/NN	num||%-31/NN||27.9-30/CD	dep||prevalence-29/NN||%-31/NN	number||2.56-33/CD||-LSB--32/CD	num||-RSB--43/NN||2.56-33/CD	nn||-RSB--43/NN||-RSB--34/NNP	amod||-RSB--43/NN||abdominal-36/JJ	amod||-RSB--43/NN||obesity-37/JJ	amod||-RSB--43/NN||prevalence-38/JJ	number||%-40/NN||19.5-39/CD	amod||-RSB--43/NN||%-40/NN	number||2.60-42/CD||-LSB--41/CD	num||-RSB--43/NN||2.60-42/CD	dep||%-31/NN||-RSB--43/NN	obesity-37||glucose-10||no_rel||even in offspring of mothers with a normal oral glucose tolerance test during pregnancy, maternal prepregnancy overweight is associated with increased risk for these outcomes (overweight prevalence 27.9% [2.56], abdominal obesity prevalence 19.5% [2.60]).
det||result-2/NN||the-1/DT	nsubj||showed-3/VBD||result-2/NN	root||ROOT-0/null||showed-3/VBD	mark||weaker-9/JJR||that-4/IN	det||pressure-7/NN||the-5/DT	nn||pressure-7/NN||selection-6/NN	nsubj||weaker-9/JJR||pressure-7/NN	cop||weaker-9/JJR||was-8/VBD	ccomp||showed-3/VBD||weaker-9/JJR	prep||weaker-9/JJR||in-10/IN	det||2000s-12/NN||the-11/DT	npadvmod||than-13/IN||2000s-12/NN	pcomp||in-10/IN||than-13/IN	det||1980s-16/NNS||the-15/DT	prep_in||weaker-9/JJR||1980s-16/NNS	xcomp||weaker-9/JJR||indicating-18/VBG	mark||become-23/VBN||that-19/IN	nsubj||become-23/VBN||it-20/PRP	aux||become-23/VBN||might-21/MD	aux||become-23/VBN||have-22/VB	ccomp||indicating-18/VBG||become-23/VBN	dep||become-23/VBN||easier-24/RBR	det||hiv-27/NN||the-26/DT	prep_for||become-23/VBN||hiv-27/NN	aux||infect-29/VB||to-28/TO	dep||hiv-27/NN||infect-29/VB	det||host-32/NN||a-30/DT	amod||host-32/NN||new-31/JJ	dobj||infect-29/VB||host-32/NN	aux||develop-35/VB||to-34/TO	dep||hiv-27/NN||develop-35/VB	conj_and||infect-29/VB||develop-35/VB	prep_into||develop-35/VB||aids-37/NNS	advmod||develop-35/VB||now-38/RB	prep||now-38/RB||than-39/IN	num||years-41/NNS||20-40/CD	npadvmod||ago-42/RB||years-41/NNS	pcomp||than-39/IN||ago-42/RB	mark||becoming-49/VBG||that-44/IN	det||hiv-46/NN||the-45/DT	nsubj||becoming-49/VBG||hiv-46/NN	aux||becoming-49/VBG||may-47/MD	aux||becoming-49/VBG||be-48/VB	ccomp||indicating-18/VBG||becoming-49/VBG	conj_and||become-23/VBN||becoming-49/VBG	amod||virulent-51/NN||more-50/JJR	xcomp||becoming-49/VBG||virulent-51/NN	det||population-55/NN||the-53/DT	amod||population-55/NN||japanese-54/JJ	prep_in||becoming-49/VBG||population-55/NN	aids-37||hiv-46||no||the result showed that the selection pressure was weaker in the 2000s than in the 1980s, indicating that it might have become easier for the hiv to infect a new host and to develop into aids now than 20 years ago and that the hiv may be becoming more virulent in the japanese population.
amod||therapies-2/NNS||targeted-1/JJ	nsubjpass||licensed-17/VBN||therapies-2/NNS	nsubjpass||demonstrated-20/VBN||therapies-2/NNS	prep_such_as||therapies-2/NNS||bevacizumab-5/NN	amod||therapies-2/NNS||erlotinib-7/JJ	amod||therapies-2/NNS||gefitinib-9/JJ	conj_and||erlotinib-7/JJ||gefitinib-9/JJ	amod||therapies-2/NNS||sunitinib-11/JJ	conj_and||erlotinib-7/JJ||sunitinib-11/JJ	amod||therapies-2/NNS||sorafenib-13/JJ	conj_and||erlotinib-7/JJ||sorafenib-13/JJ	auxpass||licensed-17/VBN||are-15/VBP	advmod||licensed-17/VBN||all-16/RB	root||ROOT-0/null||licensed-17/VBN	aux||demonstrated-20/VBN||have-19/VBP	conj_and||licensed-17/VBN||demonstrated-20/VBN	amod||survival-22/NN||improved-21/VBN	dobj||demonstrated-20/VBN||survival-22/NN	prep_in||survival-22/NN||patients-24/NNS	prep_with||patients-24/NNS||metastaticdisease-26/NN	gefitinib-9||metastaticdisease-26||no_rel||targeted therapies such as bevacizumab, erlotinib, gefitinib, sunitinib and sorafenib, are all licensed and have demonstrated improved survival in patients with metastaticdisease.
nsubj||aim-2/VBP||we-1/PRP	nsubj||highlight-4/VB||we-1/PRP	root||ROOT-0/null||aim-2/VBP	aux||highlight-4/VB||to-3/TO	xcomp||aim-2/VBP||highlight-4/VB	det||resistance-7/NN||the-5/DT	amod||resistance-7/NN||increasing-6/VBG	dobj||highlight-4/VB||resistance-7/NN	prep_of||resistance-7/NN||cmv-9/NN	amod||agents-14/NNS||conventional-11/JJ	amod||agents-14/NNS||first-line-12/JJ	amod||agents-14/NNS||antiviral-13/JJ	prep_to||highlight-4/VB||agents-14/NNS	prep_such_as||agents-14/NNS||foscarnet-17/NN	cmv-9||foscarnet-17||yes||we aim to highlight the increasing resistance of cmv to conventional first-line antiviral agents such as foscarnet.
det||correlation-3/NN||a-1/DT	amod||correlation-3/NN||significant-2/JJ	nsubj||observed-13/JJ||correlation-3/NN	nn||signals-6/NNS||lipid-5/NN	prep_between||correlation-3/NN||signals-6/NNS	prep_between||correlation-3/NN||necrosis-8/NNS	conj_and||signals-6/NNS||necrosis-8/NNS	nn||metastases-11/NNS||brain-10/NN	prep_in||signals-6/NNS||metastases-11/NNS	cop||observed-13/JJ||was-12/VBD	root||ROOT-0/null||observed-13/JJ	dep||<-16/JJ||p-15/RB	dep||observed-13/JJ||<-16/JJ	dep||<-16/JJ||0.01-17/CD	poss||origin-24/NN||their-22/PRP$	amod||origin-24/NN||primary-23/JJ	prep_irrespective_of||observed-13/JJ||origin-24/NN	metastases-11||lipid-5||no_rel||a significant correlation between lipid signals and necrosis in brain metastases was observed ( p < 0.01), irrespective of their primary origin.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||‰-20/NNS||kd-18/NN	nn||‰-20/NNS||â-19/NN	dobj||log-17/VB||‰-20/NNS	amod||‰-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||‰-38/VBG	number||4-40/CD||¥-39/CD	dobj||‰-38/VBG||4-40/CD	kd-36||sertraline-33||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â‰¤ 2), but higher sorption behavior can be expected for sertraline (log kd â‰¥ 4).
nsubj||lower-15/JJR||results-1/NNS	det||intention-4/NN||an-3/DT	prep_in||results-1/NNS||intention-4/NN	aux||treat-6/VB||to-5/TO	vmod||intention-4/NN||treat-6/VB	dobj||treat-6/VB||analysis-7/NN	det||risk-10/NN||the-9/DT	appos||analysis-7/NN||risk-10/NN	prep_of||risk-10/NN||death-12/NN	cop||lower-15/JJR||was-13/VBD	advmod||lower-15/JJR||significantly-14/RB	root||ROOT-0/null||lower-15/JJR	det||arm-20/NN||the-17/DT	amod||arm-20/NN||titrated-18/JJ	nn||arm-20/NN||oxygen-19/NN	prep_in||lower-15/JJR||arm-20/NN	prepc_compared_with||lower-15/JJR||with-22/IN	det||arm-27/NN||the-23/DT	amod||arm-27/NN||high-24/JJ	nn||arm-27/NN||flow-25/NN	nn||arm-27/NN||oxygen-26/NN	pobj||lower-15/JJR||arm-27/NN	det||patients-30/NNS||all-29/DT	prep_for||arm-27/NN||patients-30/NNS	amod||oxygen-34/NN||high-32/JJ	nn||oxygen-34/NN||flow-33/NN	nsubj||n-35/VBP||oxygen-34/NN	dep||arm-27/NN||n-35/VBP	number||226-37/CD||=-36/CD	dobj||n-35/VBP||226-37/CD	amod||n-41/NN||titrated-39/JJ	nn||n-41/NN||oxygen-40/NN	dep||226-37/CD||n-41/NN	number||179-43/CD||=-42/CD	dep||n-41/NN||179-43/CD	det||subgroup-48/NN||the-47/DT	prep_for||arm-27/NN||subgroup-48/NN	conj_and||patients-30/NNS||subgroup-48/NN	prep_of||subgroup-48/NN||patients-50/NNS	amod||obstructivepulmonarydisease-54/NN||confirmed-52/JJ	amod||obstructivepulmonarydisease-54/NN||chronic-53/JJ	prep_with||patients-50/NNS||obstructivepulmonarydisease-54/NN	amod||n-58/NN||high-56/JJ	nn||n-58/NN||flow-57/NN	nsubj||titrated-62/VBD||n-58/NN	number||117-60/CD||=-59/CD	dep||n-58/NN||117-60/CD	dep||subgroup-48/NN||titrated-62/VBD	nsubj||97-65/CD||n-63/NN	dep||97-65/CD||=-64/SYM	ccomp||titrated-62/VBD||97-65/CD	obstructivepulmonarydisease-54||oxygen-40||yes||results in an intention to treat analysis, the risk of death was significantly lower in the titrated oxygen arm compared with the high flow oxygen arm for all patients (high flow oxygen n=226; titrated oxygen n=179) and for the subgroup of patients with confirmed chronic obstructivepulmonarydisease (high flow n=117; titrated n=97).
det||protein-3/NN||the-1/DT	nn||protein-3/NN||fusion-2/NN	nsubjpass||analyzed-5/VBN||protein-3/NN	auxpass||analyzed-5/VBN||was-4/VBD	root||ROOT-0/null||analyzed-5/VBN	prep_for||analyzed-5/VBN||reactivity-7/NN	nn||patients-10/NNS||sars-9/NNS	poss||sera-12/NN||patients-10/NNS	prep_with||analyzed-5/VBN||sera-12/NN	prep_with||analyzed-5/VBN||anti-sera-15/NN	conj_and||sera-12/NN||anti-sera-15/NN	det||coronaviruses-20/NNS||the-17/DT	num||coronaviruses-20/NNS||two-18/CD	amod||coronaviruses-20/NNS||human-19/JJ	prep_against||anti-sera-15/NN||coronaviruses-20/NNS	vmod||coronaviruses-20/NNS||hcov-21/VBG	amod||oc43-25/NNS||229e-22/JJ	conj_and||229e-22/JJ||hcov-24/JJ	amod||oc43-25/NNS||hcov-24/JJ	dobj||hcov-21/VBG||oc43-25/NNS	nn||assays-32/NNS||elisa-27/NN	conj_and||elisa-27/NN||ifa-29/NN	nn||assays-32/NNS||ifa-29/NN	conj_and||elisa-27/NN||immunoblot-31/NN	nn||assays-32/NNS||immunoblot-31/NN	agent||hcov-21/VBG||assays-32/NNS	sars-9||coronaviruses-20||no||the fusion protein was analyzed for reactivity with sars patients' sera and with anti-sera against the two human coronaviruses hcov 229e and hcov oc43 by elisa, ifa and immunoblot assays.
nsubj||anthropozoonoticdisease-5/NN||brucellosis-1/NNS	cop||anthropozoonoticdisease-5/NN||is-2/VBZ	det||anthropozoonoticdisease-5/NN||a-3/DT	amod||anthropozoonoticdisease-5/NN||worldwide-4/JJ	root||ROOT-0/null||anthropozoonoticdisease-5/NN	vmod||anthropozoonoticdisease-5/NN||caused-6/VBN	det||pathogen-12/NN||an-8/DT	advmod||pathogen-12/NN||in-9/RB	amod||pathogen-12/NN||vivo-10/JJ	nn||pathogen-12/NN||intracellular-11/NN	agent||caused-6/VBN||pathogen-12/NN	vmod||pathogen-12/NN||belonging-13/VBG	prep_to||belonging-13/VBG||genusbrucella-15/NN	brucellosis-1||genusbrucella-15||no||brucellosis is a worldwide anthropozoonoticdisease caused by an in vivo intracellular pathogen belonging to genusbrucella .
det||rate-6/NN||the-1/DT	amod||rate-6/NN||minimum-2/JJ	amod||rate-6/NN||estimated-3/JJ	nn||rate-6/NN||population-4/NN	nn||rate-6/NN||mortality-5/NN	nsubj||8.63-12/CD||rate-6/NN	prep_from||rate-6/NN||melioidosis-8/NNS	prep_in||melioidosis-8/NNS||2006-10/CD	cop||8.63-12/CD||was-11/VBD	root||ROOT-0/null||8.63-12/CD	num||people-15/NNS||100,000-14/CD	prep_per||8.63-12/CD||people-15/NNS	num||%-18/NN||95-17/CD	dep||people-15/NNS||%-18/NN	nn||â-22/FW||ci-19/FW	nn||â-22/FW||=-20/FW	nn||â-22/FW||7.33-21/FW	dep||%-18/NN||â-22/FW	dep||â-22/FW||$-23/$	num||$-23/$||10.11-25/CD	det||cause-32/NN||the-28/DT	amod||cause-32/NN||third-29/JJ	advmod||common-31/JJ||most-30/RBS	amod||cause-32/NN||common-31/JJ	appos||people-15/NNS||cause-32/NN	prep_of||cause-32/NN||death-34/NN	amod||diseases-37/NNS||infectious-36/JJ	prep_from||death-34/NN||diseases-37/NNS	prep_in||diseases-37/NNS||northeast-39/NN	vmod||northeast-39/NN||thailand-40/VBN	prep_after||thailand-40/VBN||humanimmunodeficiencyvirus-42/NNS	discourse||humanimmunodeficiencyvirus-42/NNS||hiv-44/UH	punct||aids-49/NNS||/-46/:	amod||aids-49/NNS||acquiredimmunodeficiencysyndrome-47/JJ	dep||humanimmunodeficiencyvirus-42/NNS||aids-49/NNS	dep||humanimmunodeficiencyvirus-42/NNS||tuberculosis-52/NNP	conj_and||aids-49/NNS||tuberculosis-52/NNP	acquiredimmunodeficiencysyndrome-47||hiv-44||no||the minimum estimated population mortality rate from melioidosis in 2006 was 8.63 per 100,000 people (95% ci = 7.33â€“10.11), the third most common cause of death from infectious diseases in northeast thailand after humanimmunodeficiencyvirus (hiv)/acquiredimmunodeficiencysyndrome (aids) and tuberculosis.
mark||noticed-8/VBN||although-1/IN	amod||non-adherence-3/NN||high-2/JJ	nsubjpass||noticed-8/VBN||non-adherence-3/NN	prep_to||non-adherence-3/NN||medication-5/NN	aux||noticed-8/VBN||has-6/VBZ	auxpass||noticed-8/VBN||been-7/VBN	advcl||known-17/VBN||noticed-8/VBN	prep_for||noticed-8/VBN||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	nsubjpass||known-17/VBN||little-15/RB	nsubj||mesalamine-21/VB||little-15/RB	auxpass||known-17/VBN||is-16/VBZ	root||ROOT-0/null||known-17/VBN	prep_about||known-17/VBN||adherence-19/NN	aux||mesalamine-21/VB||to-20/TO	xcomp||known-17/VBN||mesalamine-21/VB	dobj||mesalamine-21/VB||treatments-22/NNS	nsubj||predict-27/VB||treatments-22/NNS	dobj||mesalamine-21/VB||determinants-24/NNS	conj_and||treatments-22/NNS||determinants-24/NNS	nsubj||predict-27/VB||determinants-24/NNS	aux||predict-27/VB||can-26/MD	rcmod||treatments-22/NNS||predict-27/VB	dobj||predict-27/VB||adherence-28/NN	uc-12||mesalamine-21||yes||although high non-adherence to medication has been noticed for ulcerativecolitis (uc), little is known about adherence to mesalamine treatments and determinants that can predict adherence.
amod||variables-3/NNS||various-2/JJ	prep_among||related-30/VBN||variables-3/NNS	nn||inhalation-6/NN||opium-5/NN	appos||variables-3/NNS||inhalation-6/NN	parataxis||related-30/VBN||p-8/VB	dep||0.01-10/CD||=-9/SYM	ccomp||p-8/VB||0.01-10/CD	csubjpass||related-30/VBN||having-13/VBG	amod||cough-15/NN||productive-14/JJ	dobj||having-13/VBG||cough-15/NN	dobj||having-13/VBG||hemoptysis-17/NNS	conj_and||cough-15/NN||hemoptysis-17/NNS	nn||pain-20/NN||chest-19/NN	dobj||having-13/VBG||pain-20/NN	conj_and||cough-15/NN||pain-20/NN	dobj||having-13/VBG||confusion-22/NN	conj_and||cough-15/NN||confusion-22/NN	dobj||having-13/VBG||loss-25/NN	conj_and||cough-15/NN||loss-25/NN	prep_of||loss-25/NN||consciousness-27/NN	auxpass||related-30/VBN||were-28/VBD	advmod||related-30/VBN||significantly-29/RB	root||ROOT-0/null||related-30/VBN	aux||icu-32/VB||to-31/TO	xcomp||related-30/VBN||icu-32/VB	dobj||icu-32/VB||admission-33/NN	dep||<-36/JJ||p-35/RB	dep||icu-32/VB||<-36/JJ	dep||<-36/JJ||0.05-37/CD	pain-20||opium-5||yes||among various variables, opium inhalation ( p = 0.01), having productive cough, hemoptysis, chest pain, confusion, and loss of consciousness were significantly related to icu admission ( p < 0.05).
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||‰-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||‰-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||‰-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||‰-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||‰-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||‰-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9â€‰mmâ€‰hg and bedtime hbp was 129.7â±13.8/74.7â±10.1â€‰mmâ€‰hg, whereas cbp was 135.6â±15.4/77.6â±10.9â€‰mmâ€‰hg.
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	aza--1||tumors-12||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
amod||ablation-3/NN||radioiodine-1/JJ	nn||ablation-3/NN||remnant-2/NN	nsubj||increase-11/VB||ablation-3/NN	amod||cancer-7/NN||differentiated-5/JJ	nn||cancer-7/NN||thyroid-6/NN	prep_of||ablation-3/NN||cancer-7/NN	aux||increase-11/VB||does-8/VBZ	neg||increase-11/VB||not-9/RB	advmod||increase-11/VB||further-10/RBR	root||ROOT-0/null||increase-11/VB	amod||damage-13/NN||oxidative-12/JJ	dobj||increase-11/VB||damage-13/NN	amod||lipids-16/NNS||membrane-15/JJ	prep_to||increase-11/VB||lipids-16/NNS	advmod||increase-11/VB||at-18/IN	pobj||at-18/IN||least-19/JJS	advmod||at-18/IN||early-20/JJ	prep_after||increase-11/VB||therapy-23/NN	cancer-7||lipids-16||no_rel||radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids, at least early, after therapy.
nsubj||appears-6/VBZ||alogliptin-1/NN	nsubj||option-13/NN||alogliptin-1/NN	prep||alogliptin-1/NN||plus-2/CC	amod||treatment-5/NN||pioglitazone-3/JJ	nn||treatment-5/NN||combination-4/NN	pobj||plus-2/CC||treatment-5/NN	root||ROOT-0/null||appears-6/VBZ	aux||option-13/NN||to-7/TO	cop||option-13/NN||be-8/VB	det||option-13/NN||an-9/DT	amod||option-13/NN||efficacious-10/JJ	amod||option-13/NN||initial-11/JJ	amod||option-13/NN||therapeutic-12/JJ	xcomp||appears-6/VBZ||option-13/NN	prep_for||option-13/NN||type2diabetes-15/CD	pioglitazone-3||type2diabetes-15||no_rel||alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type2diabetes.
det||number-5/NN||the-1/DT	amod||number-5/NN||corresponding-2/JJ	nn||number-5/NN||dna-3/NN	nn||number-5/NN||copy-4/NN	nsubj||lower-8/JJR||number-5/NN	nsubj||sz-22/JJ||number-5/NN	cop||lower-8/JJR||was-6/VBD	advmod||lower-8/JJR||paradoxically-7/RB	root||ROOT-0/null||lower-8/JJR	det||genome-11/NN||the-10/DT	prep_in||lower-8/JJR||genome-11/NN	prep_of||genome-11/NN||patients-13/NNS	prep_with||patients-13/NNS||bd-15/NN	dep||lower-8/JJR||p-17/VBN	dep||0.0016-19/CD||=-18/SYM	ccomp||p-17/VBN||0.0016-19/CD	conj_or||lower-8/JJR||sz-22/JJ	dep||lower-8/JJR||p-24/VB	number||0.0003-26/CD||<-25/CD	dobj||p-24/VB||0.0003-26/CD	prep||lower-8/JJR||than-28/IN	pcomp||than-28/IN||in-29/IN	pobj||in-29/IN||hc-30/NN	hc-30||sz-22||no_rel||the corresponding dna copy number was paradoxically lower in the genome of patients with bd ( p =0.0016) or sz ( p <0.0003) than in hc.
det||score-3/NN||the-1/DT	nn||score-3/NN||pain-2/NN	nsubjpass||assessed-5/VBN||score-3/NN	nsubjpass||assessed-5/VBN||score-3/NN	auxpass||assessed-5/VBN||was-4/VBD	root||ROOT-0/null||assessed-5/VBN	conj_and||assessed-5/VBN||assessed-5/VBN	det||scale-11/NN||a-7/DT	amod||scale-11/NN||4-point-8/JJ	amod||scale-11/NN||verbal-9/JJ	nn||scale-11/NN||rating-10/NN	agent||assessed-5/VBN||scale-11/NN	appos||scale-11/NN||vrs-13/NN	num||seconds-17/NNS||10-16/CD	prep_at||scale-11/NN||seconds-17/NNS	prep_after||assessed-5/VBN||injection-19/NN	amod||mg-24/NN||microemulsion-21/JJ	nn||mg-24/NN||propofol-22/NN	num||mg-24/NN||30-23/CD	prep_of||injection-19/NN||mg-24/NN	det||injection-28/NN||the-27/DT	prep_during||assessed-5/VBN||injection-28/NN	det||dose-33/NN||the-30/DT	amod||dose-33/NN||remaining-31/VBG	nn||dose-33/NN||total-32/NN	prep_of||injection-28/NN||dose-33/NN	pain-2||propofol-22||yes||the pain score was assessed by a 4-point verbal rating scale (vrs) at 10 seconds after injection of microemulsion propofol 30 mg and during the injection of the remaining total dose.
nn||profiles-4/NNS||antigen-1/NN	nn||profiles-4/NNS||recognition-2/NN	nn||profiles-4/NNS||pattern-3/NN	nsubj||showed-18/VBD||profiles-4/NNS	prep_in||profiles-4/NNS||serum-6/NN	nn||patients-10/NNS||tb-8/NN	nn||patients-10/NNS||+-9/NN	prep_from||serum-6/NN||patients-10/NNS	prep_from||patients-10/NNS||armenia-12/NN	prep_vs.||armenia-12/NN||patients-14/NNS	vmod||patients-14/NNS||recruited-15/VBN	prep_in||recruited-15/VBN||sweden-17/NN	root||ROOT-0/null||showed-18/VBD	mark||similar-25/JJ||that-19/IN	amod||epitopes-22/NNS||igg-defined-20/JJ	nn||epitopes-22/NNS||mtb-21/NN	nsubj||similar-25/JJ||epitopes-22/NNS	cop||similar-25/JJ||are-23/VBP	advmod||similar-25/JJ||very-24/RB	ccomp||showed-18/VBD||similar-25/JJ	prep_in||similar-25/JJ||individuals-27/NNS	amod||background-31/NN||different-29/JJ	amod||background-31/NN||genetic-30/JJ	prep_with||individuals-27/NNS||background-31/NN	tb-8||mtb-21||no||antigen recognition pattern profiles in serum from tb + patients from armenia vs. patients recruited in sweden showed that igg-defined mtb epitopes are very similar in individuals with different genetic background .
det||contribution-3/NN||the-1/DT	amod||contribution-3/NN||relative-2/JJ	nsubj||unclear-16/JJ||contribution-3/NN	det||components-9/NNS||the-5/DT	amod||components-9/NNS||budesonide-6/JJ	conj_and||budesonide-6/JJ||formoterol-8/JJ	amod||components-9/NNS||formoterol-8/JJ	prep_of||contribution-3/NN||components-9/NNS	det||control-14/NN||the-11/DT	amod||control-14/NN||improved-12/JJ	nn||control-14/NN||asthma-13/NN	prep_to||components-9/NNS||control-14/NN	cop||unclear-16/JJ||is-15/VBZ	root||ROOT-0/null||unclear-16/JJ	asthma-13||formoterol-8||yes||the relative contribution of the budesonide and formoterol components to the improved asthma control is unclear.
nsubj||treatment-9/NN||bacilluscalmette-guerin-1/NN	appos||bacilluscalmette-guerin-1/NN||bcg-3/NN	cop||treatment-9/NN||is-5/VBZ	det||treatment-9/NN||the-6/DT	advmod||effective-8/JJ||most-7/RBS	amod||treatment-9/NN||effective-8/JJ	root||ROOT-0/null||treatment-9/NN	amod||cancer-14/NN||non-muscle-11/JJ	nn||cancer-14/NN||invasive-12/NN	nn||cancer-14/NN||bladder-13/NN	prep_for||treatment-9/NN||cancer-14/NN	bacilluscalmette-guerin-1||cancer-14||no_rel||bacilluscalmette-guerin (bcg) is the most effective treatment for non-muscle invasive bladder cancer.
nsubjpass||collected-3/VBN||sera-1/NN	auxpass||collected-3/VBN||were-2/VBD	root||ROOT-0/null||collected-3/VBN	prep_at||collected-3/VBN||weeks-5/NNS	num||weeks-5/NNS||0-6/CD	prep_at||collected-3/VBN||4-8/CD	conj_and||weeks-5/NNS||4-8/CD	det||total-11/NN||a-10/DT	prep_from||collected-3/VBN||total-11/NN	num||patients-14/NNS||336-13/CD	prep_of||total-11/NN||patients-14/NNS	nn||dataset-17/NN||training-16/NN	dep||patients-14/NNS||dataset-17/NN	appos||dataset-17/NN||n-19/NN	dep||100-21/CD||=-20/SYM	rcmod||n-19/NN||100-21/CD	nn||dataset-24/NN||test-23/NN	dep||n-19/NN||dataset-24/NN	vmod||dataset-24/NN||n-26/VBN	dep||236-28/CD||=-27/SYM	ccomp||n-26/VBN||236-28/CD	det||study-33/NN||the-31/DT	amod||study-33/NN||go-forward-32/JJ	prep_from||collected-3/VBN||study-33/NN	prep_of||study-33/NN||patients-35/NNS	amod||rheumatoidarthritis-38/NNS||active-37/JJ	prep_with||collected-3/VBN||rheumatoidarthritis-38/NNS	prep_despite||collected-3/VBN||mtx-40/NN	rheumatoidarthritis-38||mtx-40||yes||sera were collected at weeks 0 and 4 from a total of 336 patients (training dataset, n = 100; test dataset, n = 236) from the go-forward study of patients with active rheumatoidarthritis despite mtx.
dep||assess-4/VB||a-1/LS	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||suitability-6/NN||the-5/DT	dobj||assess-4/VB||suitability-6/NN	det||content-10/NN||the-8/DT	nn||content-10/NN||curriculum-9/NN	prep_of||suitability-6/NN||content-10/NN	amod||quality-13/NN||didactical-12/JJ	nsubj||delivered-16/VBD||quality-13/NN	nsubj||educate-18/VB||quality-13/NN	prep_of||quality-13/NN||information-15/NN	conj_and||assess-4/VB||delivered-16/VBD	aux||educate-18/VB||to-17/TO	xcomp||delivered-16/VBD||educate-18/VB	dobj||educate-18/VB||journalists-19/NNS	det||program-23/NN||the-21/DT	amod||program-23/NN||j2j-22/JJ	prep_in||journalists-19/NNS||program-23/NN	prep_in||journalists-19/NNS||hiv/aids-25/NNS	nn||evaluation-28/NN||process-27/NN	appos||hiv/aids-25/NNS||evaluation-28/NN	prep_in||journalists-19/NNS||b-31/SYM	conj_and||hiv/aids-25/NNS||b-31/SYM	aux||explore-34/VB||to-33/TO	vmod||educate-18/VB||explore-34/VB	det||effects-36/NNS||the-35/DT	dobj||explore-34/VB||effects-36/NNS	amod||programs-39/NNS||such-38/JJ	prep_of||effects-36/NNS||programs-39/NNS	poss||reporting-43/NN||journalists-41/NNS	prep_on||explore-34/VB||reporting-43/NN	amod||related-46/JJ||hiv/aids-45/JJ	amod||information-47/NN||related-46/JJ	prep_of||reporting-43/NN||information-47/NN	nn||evaluation-50/NN||outcome-49/NN	appos||information-47/NN||evaluation-50/NN	aids--1||hiv--1||no||a) to assess the suitability of the curriculum content and didactical quality of information delivered to educate journalists in the j2j program in hiv/aids (process evaluation) and b) to explore the effects of such programs on journalists' reporting of hiv/aids related information (outcome evaluation).
det||age-2/NN||the-1/DT	nsubj||2.8-23/CD||age-2/NN	vmod||age-2/NN||adjusted-3/VBN	nn||ratio-6/NN||incidence-4/NN	nn||ratio-6/NN||rate-5/NN	dobj||adjusted-3/VBN||ratio-6/NN	amod||thromboembolism-9/NN||venous-8/JJ	prep_for||ratio-6/NN||thromboembolism-9/NN	amod||use-12/NN||current-11/JJ	prep_for||adjusted-3/VBN||use-12/NN	prep_of||use-12/NN||oralcontraceptives-14/NNS	vmod||oralcontraceptives-14/NNS||containing-15/VBG	dobj||containing-15/VBG||drospirenone-16/NN	prepc_compared_with||containing-15/VBG||with-18/IN	pobj||containing-15/VBG||those-19/DT	vmod||those-19/DT||containing-20/VBG	acomp||containing-20/VBG||levonorgestrel-21/JJ	cop||2.8-23/CD||was-22/VBD	root||ROOT-0/null||2.8-23/CD	number||3.8-27/CD||2.1-25/CD	dep||3.8-27/CD||to-26/TO	dep||2.8-23/CD||3.8-27/CD	thromboembolism-9||levonorgestrel-21||no||the age adjusted incidence rate ratio for venous thromboembolism for current use of oralcontraceptives containing drospirenone compared with those containing levonorgestrel was 2.8 (2.1 to 3.8).
det||essence-2/NN||the-1/DT	nsubj||is-6/VBZ||essence-2/NN	poss||research-5/NN||our-4/PRP$	prep_of||essence-2/NN||research-5/NN	root||ROOT-0/null||is-6/VBZ	mark||characterized-28/VBN||that-7/IN	nsubjpass||characterized-28/VBN||patients-8/NNS	nsubjpass||characterized-28/VBN||patients-8/NNS	prep_with||patients-8/NNS||t1dm-10/NN	prep_with||patients-8/NNS||ht-12/NN	conj_and||t1dm-10/NN||ht-12/NN	prep_with||patients-8/NNS||microalbuminuria-15/NN	conj_and||t1dm-10/NN||microalbuminuria-15/NN	discourse||microalbuminuria-15/NN||ma-17/UH	conj_and||t1dm-10/NN||diabeticretinopathy-20/NN	conj_and||microalbuminuria-15/NN||diabeticretinopathy-20/NN	discourse||microalbuminuria-15/NN||dr-22/UH	appos||patients-8/NNS||ma/dr-25/NN	auxpass||characterized-28/VBN||are-27/VBP	ccomp||is-6/VBZ||characterized-28/VBN	ccomp||is-6/VBZ||characterized-28/VBN	conj_and||characterized-28/VBN||characterized-28/VBN	det||level-33/NN||a-30/DT	advmod||higher-32/JJR||significantly-31/RB	amod||level-33/NN||higher-32/JJR	agent||characterized-28/VBN||level-33/NN	prep_of||level-33/NN||vegf-35/NN	num||â-38/NN||340.23-37/CD	dep||vegf-35/NN||â-38/NN	punct||â-38/NN||±-39/:	npadvmod||â-41/RB||93.22-40/CD	prep||â-38/NN||â-41/RB	pobj||â-41/RB||$-42/$	num||$-42/$||‰-43/CD	advmod||â-41/RB||pgâ-44/RB	num||$-48/$||$-45/$	number||mlâ-47/CD||‰-46/CD	num||$-45/$||mlâ-47/CD	pobj||â-41/RB||$-48/$	num||$-48/$||1-50/CD	nn||serum-54/NN||blood-53/NN	prep_in||characterized-28/VBN||serum-54/NN	prep_in||serum-54/NN||comparison-56/NN	det||group-59/NN||the-58/DT	prep_with||characterized-28/VBN||group-59/NN	amod||patients-62/NNS||t1dm-61/JJ	prep_of||group-59/NN||patients-62/NNS	prep_without||characterized-28/VBN||ht-64/FW	prep_without||characterized-28/VBN||ma/dr-66/FW	conj_and||ht-64/FW||ma/dr-66/FW	num||â-69/NN||183.6-68/CD	dep||characterized-28/VBN||â-69/NN	punct||â-69/NN||±-70/:	num||â-72/NN||96.6-71/CD	dep||â-69/NN||â-72/NN	num||$-76/NNS||$-73/$	number||pgâ-75/CD||‰-74/CD	num||$-73/$||pgâ-75/CD	dep||â-72/NN||$-76/NNS	punct||â-69/NN||‰-77/:	dep||â-69/NN||mlâ-78/VBN	dobj||mlâ-78/VBN||$-79/$	num||$-79/$||1-81/CD	amod||controls-86/NNS||healthy-85/JJ	prep_with||characterized-28/VBN||controls-86/NNS	num||â-89/NN||145.32-88/CD	dep||controls-86/NNS||â-89/NN	punct||â-89/NN||±-90/:	npadvmod||â-92/RB||75.58-91/CD	prep||â-89/NN||â-92/RB	pobj||â-92/RB||$-93/$	num||$-93/$||‰-94/CD	advmod||â-92/RB||pgâ-95/RB	num||$-99/$||$-96/$	number||mlâ-98/CD||‰-97/CD	num||$-96/$||mlâ-98/CD	pobj||â-92/RB||$-99/$	num||$-99/$||1-101/CD	dr-22||essence-2||no_rel||the essence of our research is that patients with t1dm and ht and with microalbuminuria (ma) and diabeticretinopathy (dr) (ma/dr) are characterized by a significantly higher level of vegf (340.23â±93.22â€‰pgâ€‰mlâ€“1) in blood serum in comparison with the group of t1dm patients without ht and ma/dr (183.6â±96.6â€‰pgâ€‰mlâ€“1) and with healthy controls (145.32â±75.58â€‰pgâ€‰mlâ€“1).
mark||used-12/VBN||although-1/IN	det||vaccine-5/NN||an-2/DT	amod||vaccine-5/NN||attenuated-3/JJ	nn||vaccine-5/NN||vzv-4/NN	nsubjpass||used-12/VBN||vaccine-5/NN	appos||vaccine-5/NN||v-oka-7/NNP	aux||used-12/VBN||has-9/VBZ	auxpass||used-12/VBN||been-10/VBN	advmod||used-12/VBN||widely-11/RB	advcl||seen-24/VBN||used-12/VBN	prep_in||used-12/VBN||children-14/NNS	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||children-14/NNS||states-18/NNS	nn||outbreaks-21/NNS||chickenpox-20/NN	nsubjpass||seen-24/VBN||outbreaks-21/NNS	auxpass||seen-24/VBN||are-22/VBP	advmod||seen-24/VBN||still-23/RB	root||ROOT-0/null||seen-24/VBN	det||vaccine-29/NN||the-27/DT	nn||vaccine-29/NN||shingles-28/NNS	nsubj||reduces-31/VBZ||vaccine-29/NN	advmod||reduces-31/VBZ||only-30/RB	conj_and||seen-24/VBN||reduces-31/VBZ	det||risk-33/NN||the-32/DT	dobj||reduces-31/VBZ||risk-33/NN	prep_of||risk-33/NN||shingles-35/NNS	num||%-38/NN||50-37/CD	prep_by||reduces-31/VBZ||%-38/NN	chickenpox-20||vzv-4||yes||although an attenuated vzv vaccine (v-oka) has been widely used in children in the united states, chickenpox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%.
det||part-4/NN||this-1/DT	nn||part-4/NN||paper-2/NN	nn||part-4/NN||forms-3/NNS	nsubj||â-21/VBP||part-4/NN	nsubj||changing-38/VBG||part-4/NN	det||review-7/NN||a-6/DT	prep_of||part-4/NN||review-7/NN	advmod||commissioned-11/VBN||â-8/RB	pobj||â-8/RB||$-9/$	vmod||review-7/NN||commissioned-11/VBN	det||initiative-16/NN||the-13/DT	amod||initiative-16/NN||joint-14/JJ	nn||initiative-16/NN||learning-15/NN	agent||commissioned-11/VBN||initiative-16/NN	prep_on||initiative-16/NN||children-18/NNS	prep_on||initiative-16/NN||hiv/aids-20/NNS	conj_and||children-18/NNS||hiv/aids-20/NNS	root||ROOT-0/null||â-21/VBP	dobj||â-21/VBP||$-22/$	amod||studies-26/NNS||qualitative-25/JJ	prep_of||$-22/$||studies-26/NNS	advmod||changed-34/VBN||how-28/WRB	nsubj||changed-34/VBN||families-29/NNS	amod||africa-32/NN||southern-31/JJ	prep_in||families-29/NNS||africa-32/NN	aux||changed-34/VBN||have-33/VBP	prepc_of||studies-26/NNS||changed-34/VBN	aux||changing-38/VBG||are-37/VBP	conj_and||â-21/VBP||changing-38/VBG	det||result-42/NN||a-41/DT	prep_as||changing-38/VBG||result-42/NN	det||impact-45/NN||the-44/DT	prep_of||result-42/NN||impact-45/NN	prep_of||impact-45/NN||hiv-47/NN	prep_of||impact-45/NN||aids-49/NNS	conj_and||hiv-47/NN||aids-49/NNS	aids-49||hiv-47||no||this paper forms part of a review â€” commissioned by the joint learning initiative on children and hiv/aids â€” of qualitative studies of how families in southern africa have changed, and are changing, as a result of the impact of hiv and aids.
amod||determinants-2/NNS||relevant-1/JJ	nsubjpass||discussed-12/VBN||determinants-2/NNS	det||spread-6/NN||the-4/DT	amod||spread-6/NN||future-5/JJ	prep_of||determinants-2/NNS||spread-6/NN	prep_of||spread-6/NN||hiv-8/NN	prep_among||hiv-8/NN||ivdu-10/NN	auxpass||discussed-12/VBN||are-11/VBP	root||ROOT-0/null||discussed-12/VBN	det||factors-18/NNS||the-15/DT	amod||factors-18/NNS||major-16/JJ	nn||factors-18/NNS||risk-17/NN	prep_including||discussed-12/VBN||factors-18/NNS	prep_for||factors-18/NNS||hivseropositivity-20/NN	det||modes-23/NNS||the-22/DT	prep_including||discussed-12/VBN||modes-23/NNS	conj_and||factors-18/NNS||modes-23/NNS	nn||transmission-26/NN||hiv-25/NN	prep_of||modes-23/NNS||transmission-26/NN	prep_including||discussed-12/VBN||aspects-29/NNS	conj_and||factors-18/NNS||aspects-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||aspects-29/NNS||history-33/NN	prep_of||history-33/NN||hivinfection-35/NN	prep_in||hivinfection-35/NN||ivdu-37/NN	hivseropositivity-20||hiv-25||no||relevant determinants of the future spread of hiv among ivdu are discussed, including the major risk factors for hivseropositivity, the modes of hiv transmission, and aspects of the natural history of hivinfection in ivdu.
prep_in||found-6/VBN||fact-2/NN	nsubjpass||found-6/VBN||it-3/PRP	aux||found-6/VBN||has-4/VBZ	auxpass||found-6/VBN||been-5/VBN	root||ROOT-0/null||found-6/VBN	amod||studies-9/NNS||recent-8/JJ	prep_in||found-6/VBN||studies-9/NNS	mark||low-19/JJ||that-10/IN	det||prevalence-12/NN||the-11/DT	nsubj||low-19/JJ||prevalence-12/NN	amod||sensitization-15/NN||atopic-14/JJ	prep_of||prevalence-12/NN||sensitization-15/NN	prep_of||prevalence-12/NN||atopicasthma-17/NN	conj_and||sensitization-15/NN||atopicasthma-17/NN	cop||low-19/JJ||is-18/VBZ	ccomp||found-6/VBN||low-19/JJ	prep_among||low-19/JJ||farmers-21/NNS	prepc_compared_with||farmers-21/NNS||with-23/IN	amod||populations-25/NNS||other-24/JJ	pobj||farmers-21/NNS||populations-25/NNS	atopicasthma-17||atopic-14||no||in fact it has been found in recent studies that the prevalence of atopic sensitization and atopicasthma is low among farmers compared with other populations.
prep||undertaken-7/VBN||given-1/VBN	det||scenario-3/NN||these-2/DT	pobj||given-1/VBN||scenario-3/NN	det||study-5/NN||the-4/DT	nsubjpass||undertaken-7/VBN||study-5/NN	nsubj||examine-9/VB||study-5/NN	nsubj||aids-14/VBZ||study-5/NN	nsubj||identify-18/VB||study-5/NN	auxpass||undertaken-7/VBN||was-6/VBD	root||ROOT-0/null||undertaken-7/VBN	aux||examine-9/VB||to-8/TO	xcomp||undertaken-7/VBN||examine-9/VB	dobj||examine-9/VB||trends-10/NNS	prep_in||examine-9/VB||hiv-12/NN	xcomp||undertaken-7/VBN||aids-14/VBZ	conj_and||examine-9/VB||aids-14/VBZ	amod||knowledge-16/NN||comprehensive-15/JJ	dobj||aids-14/VBZ||knowledge-16/NN	xcomp||undertaken-7/VBN||identify-18/VB	conj_and||examine-9/VB||identify-18/VB	det||correlates-21/NNS||the-19/DT	amod||correlates-21/NNS||main-20/JJ	dobj||identify-18/VB||correlates-21/NNS	amod||hiv-24/NN||comprehensive-23/JJ	prep_of||correlates-21/NNS||hiv-24/NN	nn||knowledge-27/NN||aids-26/NNS	prep_of||correlates-21/NNS||knowledge-27/NN	conj_and||hiv-24/NN||knowledge-27/NN	amod||women-32/NNS||kenyan-29/JJ	amod||women-32/NNS||urban-30/JJ	amod||women-32/NNS||young-31/JJ	prep_among||identify-18/VB||women-32/NNS	aids-26||hiv-24||no||given these scenario the study was undertaken to examine trends in hiv and aids comprehensive knowledge and identify the main correlates of comprehensive hiv and aids knowledge among kenyan urban young women.
nsubjpass||collected-22/VBN||information-1/NN	prep_on||information-1/NN||gender-3/NN	prep_on||information-1/NN||age-5/NN	conj_and||gender-3/NN||age-5/NN	prep_on||information-1/NN||workplace-7/NN	conj_and||gender-3/NN||workplace-7/NN	nn||title-10/NN||job-9/NN	prep_on||information-1/NN||title-10/NN	conj_and||gender-3/NN||title-10/NN	nn||vaccination-13/NN||bcg-12/NN	prep_on||information-1/NN||vaccination-13/NN	conj_and||gender-3/NN||vaccination-13/NN	prep_on||information-1/NN||history-15/NN	conj_and||gender-3/NN||history-15/NN	preconj||tb-18/NN||both-17/DT	prep_of||history-15/NN||tb-18/NN	prep_of||history-15/NN||tst-20/NN	conj_and||tb-18/NN||tst-20/NN	auxpass||collected-22/VBN||were-21/VBD	root||ROOT-0/null||collected-22/VBN	xcomp||collected-22/VBN||using-23/VBG	det||questionnaire-26/NN||a-24/DT	amod||questionnaire-26/NN||standardised-25/JJ	dobj||using-23/VBG||questionnaire-26/NN	tb-18||bcg-12||yes||information on gender, age, workplace, job title, bcg vaccination and history of both tb and tst were collected using a standardised questionnaire.
nn||inhibition-2/NN||microglia-1/NN	nsubj||abolished-4/VBD||inhibition-2/NN	advmod||abolished-4/VBD||also-3/RB	root||ROOT-0/null||abolished-4/VBD	amod||hyperalgesia-6/NN||thermal-5/JJ	dobj||abolished-4/VBD||hyperalgesia-6/NN	det||allodynia-10/NN||the-8/DT	amod||allodynia-10/NN||enhanced-9/JJ	dobj||abolished-4/VBD||allodynia-10/NN	conj_and||hyperalgesia-6/NN||allodynia-10/NN	vmod||allodynia-10/NN||induced-11/VBN	amod||des-arg9-bk-14/NN||intrathecal-13/JJ	agent||induced-11/VBN||des-arg9-bk-14/NN	prepc_without||induced-11/VBN||affecting-16/VBG	dobj||affecting-16/VBG||hyperglycemia-17/NN	nn||rats-20/NNS||stz-19/NN	prep_in||affecting-16/VBG||rats-20/NNS	des--1||hyperglycemia-17||no_rel||microglia inhibition also abolished thermal hyperalgesia and the enhanced allodynia induced by intrathecal des-arg9-bk without affecting hyperglycemia in stz rats.
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	carbohydrate--1||type2diabetes-44||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
amod||proteins-4/NNS||other-1/JJ	amod||proteins-4/NNS||disease-related-2/JJ	amod||proteins-4/NNS||amyloidogenic-3/JJ	root||ROOT-0/null||proteins-4/NNS	prep_such_as||proteins-4/NNS||prionprotein-8/NN	prep_in||prionprotein-8/NN||priondiseases-10/NNS	nn||±-13/NNS||î-12/NN	prep_in||prionprotein-8/NN||±-13/NNS	conj_or||priondiseases-10/NNS||±-13/NNS	dep||proteins-4/NNS||synuclein-15/NN	prep_in||synuclein-15/NN||dementia-17/NN	amod||bodies-20/NNS||lewy-19/JJ	prep_with||dementia-17/NN||bodies-20/NNS	nn||similarities-23/NNS||exhibit-22/NN	prep_in||synuclein-15/NN||similarities-23/NNS	conj_and||dementia-17/NN||similarities-23/NNS	det||incorporation-26/NN||the-25/DT	prep_in||similarities-23/NNS||incorporation-26/NN	prep_into||incorporation-26/NN||membranes-28/NNS	det||formation-31/NN||the-30/DT	prep_in||synuclein-15/NN||formation-31/NN	conj_and||dementia-17/NN||formation-31/NN	amod||channels-34/NNS||calcium-permeable-33/JJ	prep_of||formation-31/NN||channels-34/NNS	priondiseases-10||prionprotein-8||no||other disease-related amyloidogenic proteins, such as prionprotein in priondiseases or î± -synuclein in dementia with lewy bodies, exhibit similarities in the incorporation into membranes and the formation of calcium-permeable channels.
det||review-2/NN||this-1/DT	nsubj||highlights-3/VBZ||review-2/NN	nsubj||summarises-25/VBZ||review-2/NN	root||ROOT-0/null||highlights-3/VBZ	det||developments-6/NNS||the-4/DT	amod||developments-6/NNS||recent-5/JJ	dobj||highlights-3/VBZ||developments-6/NNS	prep_in||highlights-3/VBZ||relation-8/NN	amod||effects-12/NNS||proposed-10/VBN	amod||effects-12/NNS||anti-tumour-11/JJ	prep_to||highlights-3/VBZ||effects-12/NNS	prep_of||effects-12/NNS||bisphosphonates-14/NNS	vmod||bisphosphonates-14/NNS||reported-15/VBN	prep||reported-15/VBN||from-16/IN	pcomp||from-16/IN||in-17/IN	amod||models-22/NNS||vitro-18/NN	conj_and||vitro-18/NN||in-20/IN	amod||models-22/NNS||in-20/IN	pobj||in-20/IN||vivo-21/NN	pobj||in-17/IN||models-22/NNS	conj_and||highlights-3/VBZ||summarises-25/VBZ	det||data-27/NNS||the-26/DT	dobj||summarises-25/VBZ||data-27/NNS	amod||studies-32/NNS||key-29/JJ	nn||studies-32/NNS||breast-30/NN	nn||studies-32/NNS||cancer-31/NN	prep_from||summarises-25/VBZ||studies-32/NNS	tumour--1||bisphosphonates-14||no_rel||this review highlights the recent developments in relation to proposed anti-tumour effects of bisphosphonates reported from in vitro and in vivo models, and summarises the data from key breast cancer studies.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||investigate-9/VB||purpose-2/NN	det||study-6/NN||this-4/DT	amod||study-6/NN||subsequent-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||investigate-9/VB||to-8/TO	xcomp||was-7/VBD||investigate-9/VB	mark||had-24/VBD||whether-10/IN	conj_or||muc5b-11/NNS||muc5b-11/NNS	nsubj||had-24/VBD||muc5b-11/NNS	nsubj||had-24/VBD||muc5b-11/NNS	conj_and||muc5b-11/NNS||muc7-13/NNS	nsubj||had-24/VBD||muc7-13/NNS	prep_from||muc5b-11/NNS||saliva-15/NN	nn||patients-18/NNS||hiv-17/NN	prep_of||saliva-15/NN||patients-18/NNS	amod||aids-23/NNS||full-21/JJ	amod||aids-23/NNS||blown-22/JJ	prep_with||muc5b-11/NNS||aids-23/NNS	ccomp||investigate-9/VB||had-24/VBD	det||activity-28/NN||a-25/DT	amod||activity-28/NN||similar-26/JJ	nn||activity-28/NN||inhibitory-27/NN	dobj||had-24/VBD||activity-28/NN	det||virus-31/NN||the-30/DT	prep_against||activity-28/NN||virus-31/NN	aids-23||hiv-17||no||the purpose of this subsequent study was to investigate whether muc5b and muc7 from saliva of hiv patients or with full blown aids had a similar inhibitory activity against the virus.
det||aims-2/NNS||the-1/DT	nsubj||were-9/VBD||aims-2/NNS	nsubj||investigate-11/VB||aims-2/NNS	det||study-5/NN||this-4/DT	prep_of||aims-2/NNS||study-5/NN	advmod||were-9/VBD||therefore-7/RB	root||ROOT-0/null||were-9/VBD	aux||investigate-11/VB||to-10/TO	xcomp||were-9/VBD||investigate-11/VB	det||association-13/NN||the-12/DT	dobj||investigate-11/VB||association-13/NN	prep_between||association-13/NN||differences-15/NNS	prep_in||investigate-11/VB||genes-17/NNS	vmod||genes-17/NNS||associated-18/VBN	det||metabolism-21/NN||the-20/DT	prep_with||associated-18/VBN||metabolism-21/NN	prep_with||associated-18/VBN||clearance-23/NN	conj_and||metabolism-21/NN||clearance-23/NN	prep_with||associated-18/VBN||efficacy-25/NN	conj_and||metabolism-21/NN||efficacy-25/NN	prep_of||metabolism-21/NN||leflunomide-27/NN	poss||cessation-30/NN||its-29/PRP$	prep_with||associated-18/VBN||cessation-30/NN	nsubjpass||treated-39/VBN||cessation-30/NN	det||group-33/NN||a-32/DT	prep_in||cessation-30/NN||group-33/NN	amod||patients-36/NNS||rheumatoidarthritis-35/JJ	prep_of||group-33/NN||patients-36/NNS	auxpass||treated-39/VBN||were-38/VBD	rcmod||cessation-30/NN||treated-39/VBN	det||approach-46/NN||an-41/DT	amod||approach-46/NN||intensive-42/JJ	amod||approach-46/NN||contemporary-43/JJ	amod||approach-46/NN||treat-to-target-45/JJ	prep_with||treated-39/VBN||approach-46/NN	rheumatoidarthritis-35||leflunomide-27||yes||the aims of this study, therefore, were to investigate the association between differences in genes associated with the metabolism, clearance and efficacy of leflunomide with its cessation in a group of rheumatoidarthritis patients who were treated with an intensive contemporary, treat-to-target approach.
det||increase-5/NN||the-1/DT	amod||increase-5/NN||phloridzin-hypoglycemia-2/JJ	amod||increase-5/NN||induced-3/JJ	nn||increase-5/NN||glucagon-4/NN	nsubjpass||attenuated-7/VBN||increase-5/NN	auxpass||attenuated-7/VBN||was-6/VBD	root||ROOT-0/null||attenuated-7/VBN	num||%-10/NN||40-9/CD	dobj||attenuated-7/VBN||%-10/NN	nn||microinjection-15/NN||vmh-13/NN	nn||microinjection-15/NN||insulin-14/NN	agent||attenuated-7/VBN||microinjection-15/NN	hypoglycemia--1||glucagon-4||yes||the phloridzin-hypoglycemia induced glucagon increase was attenuated (40%) by vmh insulin microinjection.
nsubj||drives-2/VBZ||bcgvaccine-1/NN	root||ROOT-0/null||drives-2/VBZ	det||immunity-9/NN||a-3/DT	amod||immunity-9/NN||strong-4/JJ	nn||immunity-9/NN||t-5/NN	nn||immunity-9/NN||helper-6/NN	num||immunity-9/NN||1-7/CD	amod||immunity-9/NN||cellular-8/JJ	dobj||drives-2/VBZ||immunity-9/NN	nsubj||essential-12/JJ||immunity-9/NN	cop||essential-12/JJ||is-11/VBZ	rcmod||immunity-9/NN||essential-12/JJ	det||protection-15/NN||the-14/DT	prep_for||essential-12/JJ||protection-15/NN	prep_against||protection-15/NN||mycobacteria-17/NN	advmod||suggest-22/VBP||however-19/RB	amod||studies-21/NNS||recent-20/JJ	nsubj||suggest-22/VBP||studies-21/NNS	parataxis||drives-2/VBZ||suggest-22/VBP	mark||have-27/VB||that-23/IN	nn||vaccination-25/NN||bcg-24/NN	nsubj||have-27/VB||vaccination-25/NN	aux||have-27/VB||can-26/MD	ccomp||suggest-22/VBP||have-27/VB	amod||effects-30/NNS||non-specific-28/JJ	amod||effects-30/NNS||beneficial-29/JJ	nsubj||unrelated-31/JJ||effects-30/NNS	xcomp||have-27/VB||unrelated-31/JJ	prep_to||have-27/VB||tuberculosis-33/NNP	tuberculosis-33||bcg-24||yes||bcgvaccine drives a strong t helper 1 cellular immunity which is essential for the protection against mycobacteria, however recent studies suggest that bcg vaccination can have non-specific beneficial effects unrelated to tuberculosis.
amod||techniques-3/NNS||conventional-1/JJ	amod||techniques-3/NNS||microbiological-2/JJ	nsubjpass||performed-14/VBN||techniques-3/NNS	nn||rt-pcr-6/NN||m-5/NN	conj_and||techniques-3/NNS||rt-pcr-6/NN	nsubjpass||performed-14/VBN||rt-pcr-6/NN	amod||complex-9/NN||m.tuberculosis-8/JJ	prep_for||rt-pcr-6/NN||complex-9/NN	nn||spp-12/NN||brucella-11/NN	prep_for||rt-pcr-6/NN||spp-12/NN	conj_and||complex-9/NN||spp-12/NN	auxpass||performed-14/VBN||were-13/VBD	root||ROOT-0/null||performed-14/VBN	num||specimens-18/NNS||45-16/CD	amod||specimens-18/NNS||clinical-17/JJ	prep_on||performed-14/VBN||specimens-18/NNS	prep_from||specimens-18/NNS||patients-20/NNS	amod||complications-23/NNS||focal-22/JJ	prep_with||performed-14/VBN||complications-23/NNS	prep_of||complications-23/NNS||brucellosis-25/NNS	prep_of||complications-23/NNS||extrapulmonarytuberculosis-27/NNS	conj_or||brucellosis-25/NNS||extrapulmonarytuberculosis-27/NNS	num||samples-31/NNS||26-29/CD	nn||samples-31/NNS||control-30/NN	prep_of||complications-23/NNS||samples-31/NNS	conj_and||brucellosis-25/NNS||samples-31/NNS	brucellosis-25||brucella-11||no||conventional microbiological techniques and m rt-pcr for m.tuberculosis complex and brucella spp were performed on 45 clinical specimens from patients with focal complications of brucellosis or extrapulmonarytuberculosis and 26 control samples .
amod||assessment-2/NN||manual-1/JJ	nsubj||limits-9/VBZ||assessment-2/NN	amod||tissue-5/NN||stained-4/JJ	prep_of||assessment-2/NN||tissue-5/NN	det||biopsies-8/NNS||all-7/DT	prep_of||tissue-5/NN||biopsies-8/NNS	root||ROOT-0/null||limits-9/VBZ	dobj||limits-9/VBZ||speed-10/NN	dobj||limits-9/VBZ||accuracy-12/NN	conj_and||speed-10/NN||accuracy-12/NN	amod||practice-15/NN||clinical-14/JJ	prep_in||speed-10/NN||practice-15/NN	prep_in||speed-10/NN||research-17/NN	conj_and||practice-15/NN||research-17/NN	nn||diagnosis-21/NN||prostate-19/NN	nn||diagnosis-21/NN||cancer-20/NN	prep_of||speed-10/NN||diagnosis-21/NN	speed-10||cancer-20||no_rel||manual assessment of stained tissue of all biopsies limits speed and accuracy in clinical practice and research of prostate cancer diagnosis.
advmod||awaiting-2/VBG||eagerly-1/RB	vmod||become-42/VBN||awaiting-2/VBG	det||results-4/NNS||the-3/DT	dobj||awaiting-2/VBG||results-4/NNS	det||management-7/NN||the-6/DT	prep_of||results-4/NNS||management-7/NN	amod||study-10/NN||myelomeningocele-9/JJ	prep_of||management-7/NN||study-10/NN	dep||management-7/NN||moms-12/VBZ	prep_of||results-4/NNS||with-15/IN	conj_and||management-7/NN||with-15/IN	det||interest-18/NN||an-16/DT	amod||interest-18/NN||increasing-17/VBG	pobj||with-15/IN||interest-18/NN	prepc_in||interest-18/NN||setting-20/VBG	prt||setting-20/VBG||up-21/RP	amod||repair-24/NN||intrauterine-22/JJ	nn||repair-24/NN||myelomeningocele-23/NN	dobj||setting-20/VBG||repair-24/NN	appos||repair-24/NN||iumr-26/NN	det||management-31/NN||the-29/DT	amod||management-31/NN||optimal-30/JJ	nsubj||become-42/VBN||management-31/NN	prep_of||management-31/NN||patients-33/NNS	vmod||patients-33/NNS||suffering-34/VBG	amod||myelomeningocele-37/NN||congenital-36/JJ	prep_from||suffering-34/VBG||myelomeningocele-37/NN	appos||myelomeningocele-37/NN||mmc-39/NN	aux||become-42/VBN||has-41/VBZ	root||ROOT-0/null||become-42/VBN	det||matter-44/NN||a-43/DT	xcomp||become-42/VBN||matter-44/NN	prep_of||matter-44/NN||debate-46/NN	advmod||become-42/VBN||again-47/RB	myelomeningocele-37||mmc-39||no_rel||eagerly awaiting the results of the management of myelomeningocele study (moms) and with an increasing interest in setting up intrauterine myelomeningocele repair (iumr), the optimal management of patients suffering from congenital myelomeningocele (mmc) has become a matter of debate again.
nsubjpass||controlled-6/VBN||constipation-1/NN	aux||controlled-6/VBN||can-2/MD	advmod||controlled-6/VBN||generally-3/RB	auxpass||controlled-6/VBN||be-4/VB	advmod||controlled-6/VBN||well-5/RB	root||ROOT-0/null||controlled-6/VBN	amod||treatment-10/NN||polyethyleneglycol-8/JJ	nn||treatment-10/NN||maintenance-9/NN	prep_with||controlled-6/VBN||treatment-10/NN	constipation-1||polyethyleneglycol-8||yes||constipation can generally be well controlled with polyethyleneglycol maintenance treatment.
nsubjpass||increased-11/VBN||hepcidin-1/NN	det||regulator-5/NN||a-3/DT	amod||regulator-5/NN||key-4/JJ	appos||hepcidin-1/NN||regulator-5/NN	nn||homeostasis-8/NNS||iron-7/NN	prep_of||regulator-5/NN||homeostasis-8/NNS	auxpass||increased-11/VBN||is-10/VBZ	root||ROOT-0/null||increased-11/VBN	prep_in||increased-11/VBN||response-13/NN	prep_to||increased-11/VBN||inflammation-15/NN	det||infections-18/NNS||some-17/DT	prep_to||increased-11/VBN||infections-18/NNS	conj_and||inflammation-15/NN||infections-18/NNS	nsubj||unclear-37/JJ||the-21/DT	prep_in||role-24/NN||vivo-23/NN	rcmod||the-21/DT||role-24/NN	prep_of||role-24/NN||hepcidin-26/NN	advmod||role-24/NN||particularly-28/RB	prep_in||role-24/NN||children-30/NNS	prep_with||children-30/NNS||irondeficiencyanemia-32/NN	appos||the-21/DT||ida-34/NN	cop||unclear-37/JJ||is-36/VBZ	conj_but||increased-11/VBN||unclear-37/JJ	irondeficiencyanemia-32||iron-7||yes||hepcidin, a key regulator of iron homeostasis, is increased in response to inflammation and some infections, but the in vivo role of hepcidin, particularly in children with irondeficiencyanemia (ida) is unclear.
amod||vitamind-2/NN||adequate-1/JJ	nsubj||reduce-9/VB||vitamind-2/NN	nn||nutrition-5/NN||calcium-4/NN	conj_and||vitamind-2/NN||nutrition-5/NN	nsubj||reduce-9/VB||nutrition-5/NN	prep_throughout||vitamind-2/NN||life-7/NN	aux||reduce-9/VB||may-8/MD	root||ROOT-0/null||reduce-9/VB	det||risk-11/NN||the-10/DT	dobj||reduce-9/VB||risk-11/NN	prep_of||risk-11/NN||osteoporosis-13/NN	nn||supplementation-17/NN||calcium-16/NN	nsubj||reduce-21/VB||supplementation-17/NN	prep_during||supplementation-17/NN||pregnancy-19/NN	aux||reduce-21/VB||may-20/MD	conj_and||reduce-9/VB||reduce-21/VB	amod||weight-26/NN||preeclampsia-22/JJ	conj_and||preeclampsia-22/JJ||low-24/JJ	amod||weight-26/NN||low-24/JJ	nn||weight-26/NN||birth-25/NN	dobj||reduce-21/VB||weight-26/NN	osteoporosis-13||vitamind-2||yes||adequate vitamind and calcium nutrition throughout life may reduce the risk of osteoporosis, and calcium supplementation during pregnancy may reduce preeclampsia and low birth weight.
det||results-2/NNS||the-1/DT	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||provide-8/VBP||that-4/IN	det||r5-7/NNS||the-5/DT	nn||r5-7/NNS||group-6/NN	nsubj||provide-8/VBP||r5-7/NNS	nsubj||showed-21/VBD||r5-7/NNS	ccomp||suggest-3/VBP||provide-8/VBP	amod||relief-10/NN||more-9/JJR	dobj||provide-8/VBP||relief-10/NN	amod||pain-14/NN||propofol-12/JJ	amod||pain-14/NN||induced-13/JJ	prep_in||provide-8/VBP||pain-14/NN	det||r3-18/NN||the-16/DT	nn||r3-18/NN||group-17/NN	prep_than||pain-14/NN||r3-18/NN	ccomp||suggest-3/VBP||showed-21/VBD	conj_but||provide-8/VBP||showed-21/VBD	amod||possibility-23/NN||great-22/JJ	dobj||showed-21/VBD||possibility-23/NN	prep_of||possibility-23/NN||hypotension-25/NN	prep_of||possibility-23/NN||bradycardia-27/NN	conj_and||hypotension-25/NN||bradycardia-27/NN	det||groups-30/NNS||both-29/DT	prep_in||showed-21/VBD||groups-30/NNS	nsubj||means-33/VBZ||groups-30/NNS	rcmod||groups-30/NNS||means-33/VBZ	nsubjpass||used-37/VBN||it-34/PRP	aux||used-37/VBN||should-35/MD	auxpass||used-37/VBN||be-36/VB	ccomp||means-33/VBZ||used-37/VBN	prep_with||used-37/VBN||cautions-39/NNP	det||patients-43/NNS||the-41/DT	amod||patients-43/NNS||elderly-42/JJ	prep_in||used-37/VBN||patients-43/NNS	pain-14||propofol-12||yes||the results suggest that the group r5 provide more relief in propofol induced pain than the group r3, but showed great possibility of hypotension and bradycardia in both groups, which means it should be used with cautions in the elderly patients.
nsubj||drug-5/NN||mesalamine-1/NN	cop||drug-5/NN||is-2/VBZ	det||drug-5/NN||the-3/DT	amod||drug-5/NN||first-line-4/JJ	root||ROOT-0/null||drug-5/NN	det||treatment-8/NN||the-7/DT	prep_for||drug-5/NN||treatment-8/NN	prep_of||treatment-8/NN||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	uc-12||mesalamine-1||yes||mesalamine is the first-line drug for the treatment of ulcerativecolitis (uc).
det||combination-3/NN||the-1/DT	amod||combination-3/NN||olmesartan/amlodipine-2/JJ	nsubj||demonstrated-5/VBN||combination-3/NN	aux||demonstrated-5/VBN||has-4/VBZ	root||ROOT-0/null||demonstrated-5/VBN	amod||efficacy-7/NN||greater-6/JJR	dobj||demonstrated-5/VBN||efficacy-7/NN	poss||monotherapies-11/NNS||its-9/PRP$	nn||monotherapies-11/NNS||component-10/NN	prep_than||demonstrated-5/VBN||monotherapies-11/NNS	prepc_in||demonstrated-5/VBN||reducing-13/VBG	dobj||reducing-13/VBG||bp-14/NN	prep_in||reducing-13/VBG||patients-16/NNS	amod||hypertension-19/NN||mild-to-severe-18/JJ	prep_with||patients-16/NNS||hypertension-19/NN	hypertension-19||olmesartan--1||yes||the olmesartan/amlodipine combination has demonstrated greater efficacy than its component monotherapies in reducing bp in patients with mild-to-severe hypertension.
amod||explants-4/NNS||human-1/JJ	nn||explants-4/NNS||oa-2/NN	nn||explants-4/NNS||cartilage-3/NN	nsubjpass||cultured-6/VBN||explants-4/NNS	auxpass||cultured-6/VBN||were-5/VBD	root||ROOT-0/null||cultured-6/VBN	prep_with||cultured-6/VBN||salmoncalcitonin-8/NN	xcomp||cultured-6/VBN||-LSB--9/VBG	num||-RSB--13/NNS||100-10/CD	amod||-RSB--13/NNS||pm-100-11/JJ	nn||-RSB--13/NNS||nm-12/NN	dobj||-LSB--9/VBG||-RSB--13/NNS	oa-2||salmoncalcitonin-8||no_rel||human oa cartilage explants were cultured with salmoncalcitonin [100 pm-100 nm].
nsubj||reduced-2/VBD||bumetanide-1/NN	root||ROOT-0/null||reduced-2/VBD	advmod||reduced-2/VBD||significantly-3/RB	det||scale-7/NN||the-4/DT	nn||scale-7/NN||childhoodautism-5/NN	nn||scale-7/NN||rating-6/NN	dobj||reduced-2/VBD||scale-7/NN	appos||scale-7/NN||cars-9/NNS	num||'d-13/NNP||d90âˆ-12/CD	dep||scale-7/NN||'d-13/NNP	num||'d-13/NNP||0-14/CD	nn||<-17/NNS||p-16/NN	dep||'d-13/NNP||<-17/NNS	num||placebo-21/NN||0.004-18/CD	amod||placebo-21/NN||treated-19/JJ	nn||placebo-21/NN||vs-20/NN	dep||<-17/NNS||placebo-21/NN	amod||impressions-26/NNS||clinical-24/JJ	amod||impressions-26/NNS||global-25/JJ	dobj||reduced-2/VBD||impressions-26/NNS	dep||impressions-26/NNS||p-28/VBN	number||0.017-30/CD||<-29/CD	dobj||p-28/VBN||0.017-30/CD	vmod||0.017-30/CD||treated-31/VBN	nn||placebo-33/NN||vs-32/NN	dobj||treated-31/VBN||placebo-33/NN	num||values-40/NNS||autism-36/CD	amod||values-40/NNS||diagnostic-37/JJ	nn||values-40/NNS||observation-38/NN	nn||values-40/NNS||schedule-39/NN	dobj||reduced-2/VBD||values-40/NNS	conj_and||impressions-26/NNS||values-40/NNS	tmod||removed-60/VBN||values-40/NNS	advmod||removed-60/VBN||when-41/WRB	det||cases-45/NNS||the-42/DT	advmod||severe-44/JJ||most-43/RBS	amod||cases-45/NNS||severe-44/JJ	nsubjpass||removed-60/VBN||cases-45/NNS	dep||cases-45/NNS||cars-47/NNS	dep||cars-47/NNS||values-48/NNS	det||s.d.-53/NNP||the-50/DT	nn||s.d.-53/NNP||meanâ-51/NNP	nn||s.d.-53/NNP||±-52/NNP	prep_above||values-48/NNS||s.d.-53/NNP	dep||values-48/NNS||n-55/NN	dep||9-57/CD||=-56/SYM	rcmod||n-55/NN||9-57/CD	auxpass||removed-60/VBN||were-59/VBD	rcmod||values-40/NNS||removed-60/VBN	nn||p-64/NN||wilcoxon-62/NN	nn||p-64/NN||test-63/NN	dep||values-40/NNS||p-64/NN	dep||p-64/NN||value-66/NN	dep||0.031-68/CD||=-67/SYM	rcmod||value-66/NN||0.031-68/CD	poss||t-72/NN||student-70/NN	dep||value-66/NN||t-72/NN	dep||t-72/NN||test-74/NN	dep||test-74/NN||p-75/NN	dep||value-66/NN||value-77/NN	dep||0.017-79/CD||=-78/SYM	rcmod||value-77/NN||0.017-79/CD	bumetanide-1||childhoodautism-5||no_rel||bumetanide reduced significantly the childhoodautism rating scale (cars) (d90âˆ’d0; p <0.004 treated vs placebo), clinical global impressions ( p <0.017 treated vs placebo) and autism diagnostic observation schedule values when the most severe cases (cars values above the meanâ±s.d.; n =9) were removed (wilcoxon test p -value=0.031; student's t -test p -value=0.017).
det||test-6/NN||the-2/DT	amod||test-6/NN||castoroil-3/JJ	amod||test-6/NN||induced-4/JJ	nn||test-6/NN||diarrhoea-5/NN	prep_in||showed-11/VBD||test-6/NN	predet||doses-10/NNS||all-8/PDT	det||doses-10/NNS||the-9/DT	nsubj||showed-11/VBD||doses-10/NNS	root||ROOT-0/null||showed-11/VBD	amod||effects-13/NNS||anti-spasmodic-12/JJ	dobj||showed-11/VBD||effects-13/NNS	diarrhoea-5||castoroil-3||no||in the castoroil induced diarrhoea test, all the doses showed anti-spasmodic effects.
nsubj||vlmâ-2/VBZ||abbreviations-1/NNS	root||ROOT-0/null||vlmâ-2/VBZ	ccomp||vlmâ-2/VBZ||$-3/VBG	amod||migrans-7/NNS||visceral-5/JJ	nn||migrans-7/NNS||larva-6/NN	dobj||$-3/VBG||migrans-7/NNS	dep||$-3/VBG||olmâ-9/VBG	dobj||olmâ-9/VBG||$-10/$	nn||$-17/FW||ocular-12/FW	nn||$-17/FW||larva-13/FW	nn||$-17/FW||migrans-14/FW	dep||$-17/FW||esrâ-16/FW	dep||$-10/$||$-17/FW	amod||$-30/NN||erythrocyte-19/JJ	nn||$-30/NN||sedimentation-20/NN	nn||$-30/NN||rate-21/NN	dep||$-30/NN||hbvâ-23/NNP	num||$-30/NN||$-24/CD	nn||$-30/NN||hepatitisb-26/NN	nn||$-30/NN||virus-27/NN	amod||$-30/NN||hcvâ-29/JJ	nsubj||hepatits-32/VBZ||$-30/NN	rcmod||$-17/FW||hepatits-32/VBZ	dep||virus-34/NN||c-33/SYM	dep||$-17/FW||virus-34/NN	vmod||virus-34/NN||ebvâ-36/VBN	num||$-40/NNS||$-37/$	num||$-37/$||epsteinâ-39/CD	dobj||ebvâ-36/VBN||$-40/NNS	amod||virus-43/NN||barr-42/JJR	dobj||ebvâ-36/VBN||virus-43/NN	dep||$-3/VBG||cmvâ-45/VBG	dobj||cmvâ-45/VBG||$-46/$	dep||$-46/$||cytomegalovirusinfection-48/NN	dep||$-3/VBG||hivâ-50/VBG	amod||tomography-59/NN||$-51/JJ	dep||tomography-59/NN||humanimmunodeficiencyvirus-53/NNS	amod||tomography-59/NN||ctâ-55/JJ	amod||tomography-59/NN||$-56/$	amod||tomography-59/NN||computed-58/JJ	dobj||hivâ-50/VBG||tomography-59/NN	dep||$-3/VBG||elisaâ-61/VBG	num||$-65/NNS||$-62/$	num||$-62/$||enzymeâ-64/CD	dobj||elisaâ-61/VBG||$-65/NNS	amod||assay-69/NN||linked-67/VBN	nn||assay-69/NN||immunosorbent-68/NN	dep||elisaâ-61/VBG||assay-69/NN	dep||$-3/VBG||cbcâ-71/VBG	dobj||cbcâ-71/VBG||$-72/$	amod||count-76/NN||complete-74/JJ	nn||count-76/NN||blood-75/NN	dobj||$-3/VBG||count-76/NN	infection--1||hiv--1||no||abbreviations vlmâ€“visceral larva migrans, olmâ€“ocular larva migrans, esrâ€“erythrocyte sedimentation rate, hbvâ€“ hepatitisb virus, hcvâ€“hepatits c virus, ebvâ€“epsteinâ€“barr virus, cmvâ€“ cytomegalovirusinfection, hivâ€“humanimmunodeficiencyvirus, ctâ€“ computed tomography, elisaâ€“enzymeâ€“linked immunosorbent assay, cbcâ€“complete blood count.
prep_in||shown-24/VBN||patients-2/NNS	amod||asthma-5/NN||persistent-4/JJ	prep_with||patients-2/NNS||asthma-5/NN	advmod||treated-7/VBN||previously-6/RB	vmod||asthma-5/NN||treated-7/VBN	preconj||treated-7/VBN||either-8/CC	amod||beta-agonists-11/NNS||short-acting-10/JJ	prep_with||treated-7/VBN||beta-agonists-11/NNS	advmod||treated-7/VBN||alone-12/RB	amod||therapy-16/NN||twice-daily-14/JJ	nn||therapy-16/NN||maintenance-15/NN	npadvmod||treated-7/VBN||therapy-16/NN	prep_with||treated-7/VBN||ics-18/NN	conj_or||beta-agonists-11/NNS||ics-18/NN	amod||mf-21/NN||once-daily-20/JJ	nsubjpass||shown-24/VBN||mf-21/NN	nsubj||superior-27/JJ||mf-21/NN	nsubj||placebo-29/VB||mf-21/NN	nsubjpass||shown-45/VBN||mf-21/NN	aux||shown-24/VBN||has-22/VBZ	auxpass||shown-24/VBN||been-23/VBN	root||ROOT-0/null||shown-24/VBN	aux||superior-27/JJ||to-25/TO	cop||superior-27/JJ||be-26/VB	xcomp||shown-24/VBN||superior-27/JJ	aux||placebo-29/VB||to-28/TO	xcomp||superior-27/JJ||placebo-29/VB	prepc_in||placebo-29/VB||improving-31/VBG	nn||function-33/NN||lung-32/NN	dobj||improving-31/VBG||function-33/NN	nn||control-36/NN||symptom-35/NN	dobj||improving-31/VBG||control-36/NN	conj_and||function-33/NN||control-36/NN	dobj||improving-31/VBG||quality-39/NN	conj_and||function-33/NN||quality-39/NN	prep_of||quality-39/NN||life-41/NN	aux||shown-45/VBN||has-44/VBZ	conj_and||shown-24/VBN||shown-45/VBN	amod||efficacy-47/NN||comparable-46/JJ	dobj||shown-45/VBN||efficacy-47/NN	prepc_compared_with||shown-45/VBN||with-49/IN	pobj||shown-45/VBN||budesonide-50/JJ	pobj||shown-45/VBN||beclomethasone-52/JJ	conj_and||budesonide-50/JJ||beclomethasone-52/JJ	pobj||shown-45/VBN||fluticasone-55/JJ	conj_and||budesonide-50/JJ||fluticasone-55/JJ	asthma-5||budesonide-50||no||in patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ics, once-daily mf has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable efficacy compared with budesonide, beclomethasone, and fluticasone.
num||patients-2/NNS||four-1/CD	nsubj||had-3/VBD||patients-2/NNS	root||ROOT-0/null||had-3/VBD	dobj||had-3/VBD||murinetyphus-4/NNS	num||patients-7/NNS||three-6/CD	nsubj||had-8/VBD||patients-7/NNS	dep||had-3/VBD||had-8/VBD	dobj||had-8/VBD||scrubtyphus-9/NNS	num||patients-13/NNS||eight-12/CD	nsubj||had-14/VBD||patients-13/NNS	conj_and||had-3/VBD||had-14/VBD	nn||rickettsioses-17/NNS||spottedfever-15/NN	nn||rickettsioses-17/NNS||group-16/NN	dobj||had-14/VBD||rickettsioses-17/NNS	det||case-22/NN||the-20/DT	amod||case-22/NN||first-21/JJ	prep_including||had-14/VBD||case-22/NN	amod||infection-25/NN||rickettsiafelis-24/JJ	prep_of||case-22/NN||infection-25/NN	vmod||infection-25/NN||reported-26/VBN	prep_in||reported-26/VBN||asia-28/NN	murinetyphus-4||rickettsiafelis-24||no||four patients had murinetyphus, three patients had scrubtyphus, and eight patients had spottedfever group rickettsioses, including the first case of rickettsiafelis infection reported in asia.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	nephrocalcinosis-7||crystal-4||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
nsubjpass||diagnosed-3/VBN||he-1/PRP	nsubjpass||treated-11/VBN||he-1/PRP	auxpass||diagnosed-3/VBN||was-2/VBD	root||ROOT-0/null||diagnosed-3/VBN	amod||sinusitis-6/NNS||odontogenic-5/JJ	prep_with||diagnosed-3/VBN||sinusitis-6/NNS	prep_with||diagnosed-3/VBN||orbitalcellulitis-8/NNS	conj_and||sinusitis-6/NNS||orbitalcellulitis-8/NNS	conj_and||diagnosed-3/VBN||treated-11/VBN	prep_with||treated-11/VBN||antibiotics-13/NNS	sinusitis-6||antibiotics-13||no_rel||he was diagnosed with odontogenic sinusitis and orbitalcellulitis, and treated with antibiotics.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
nsubj||present-3/JJ||psychosis-1/NNS	cop||present-3/JJ||was-2/VBD	root||ROOT-0/null||present-3/JJ	num||percent-6/NN||29-5/CD	prep_in||present-3/JJ||percent-6/NN	amod||patients-9/NNS||cocaine-disordered-8/JJ	prep_of||percent-6/NN||patients-9/NNS	vmod||patients-9/NNS||hospitalized-10/VBN	prep_in||hospitalized-10/VBN||1985-12/CD	det||epidemic-15/NN||an-14/DT	prep_during||hospitalized-10/VBN||epidemic-15/NN	amod||cocaineabuse-18/NN||freebase-17/JJ	prep_of||epidemic-15/NN||cocaineabuse-18/NN	det||bahamas-21/NNS||the-20/DT	prep_in||cocaineabuse-18/NN||bahamas-21/NNS	cocaineabuse-18||cocaine--1||no||psychosis was present in 29 percent of cocaine-disordered patients hospitalized in 1985 during an epidemic of freebase cocaineabuse in the bahamas.
nsubj||showed-7/VBD||none-1/NN	det||swine-4/NNS||the-3/DT	prep_of||none-1/NN||swine-4/NNS	prep_of||none-1/NN||avianinfluenzaviruses-6/NNS	conj_and||swine-4/NNS||avianinfluenzaviruses-6/NNS	root||ROOT-0/null||showed-7/VBD	advmod||showed-7/VBD||transmissibility-8/RB	nn||pigs-11/NNS||guinea-10/NN	prep_among||showed-7/VBD||pigs-11/NNS	prep_in||transmit-36/VB||contrast-14/NN	amod||h1n1-18/NNS||pandemic-16/JJ	nsubj||transmit-36/VB||h1n1-18/NNS	num||virus-21/NN||2009-20/CD	nsubj||transmitted-22/VBD||virus-21/NN	rcmod||h1n1-18/NNS||transmitted-22/VBD	amod||pigs-26/NNS||infected-24/JJ	nn||pigs-26/NNS||guinea-25/NN	prep_from||transmitted-22/VBD||pigs-26/NNS	det||animals-29/NNS||all-28/DT	prep_to||transmitted-22/VBD||animals-29/NNS	amod||humaninfluenzaviruses-32/NNS||seasonal-31/JJ	prep_to||transmitted-22/VBD||humaninfluenzaviruses-32/NNS	conj_and||animals-29/NNS||humaninfluenzaviruses-32/NNS	aux||transmit-36/VB||could-33/MD	advmod||transmit-36/VB||also-34/RB	advmod||transmit-36/VB||horizontally-35/RB	parataxis||showed-7/VBD||transmit-36/VB	nn||pigs-39/NNS||guinea-38/NN	prep_in||transmit-36/VB||pigs-39/NNS	avianinfluenza--1||influenzaviruses--1||no||none of the swine and avianinfluenzaviruses showed transmissibility among guinea pigs; in contrast, pandemic (h1n1) 2009 virus transmitted from infected guinea pigs to all animals and seasonal humaninfluenzaviruses could also horizontally transmit in guinea pigs.
nsubj||results-7/VBZ||infection-1/NN	prep_with||infection-1/NN||mycobacteriumtuberculosis-3/NNS	appos||mycobacteriumtuberculosis-3/NNS||mtb-5/NN	root||ROOT-0/null||results-7/VBZ	amod||outcomes-11/NNS||different-9/JJ	amod||outcomes-11/NNS||clinical-10/JJ	prep_in||results-7/VBZ||outcomes-11/NNS	vmod||outcomes-11/NNS||ranging-12/VBG	amod||containment-15/NN||asymptomatic-14/JJ	prep_from||ranging-12/VBG||containment-15/NN	advmod||progressing-18/VBG||rapidly-17/RB	prepc_to||ranging-12/VBG||progressing-18/VBG	dobj||progressing-18/VBG||tuberculosis-19/NNP	appos||tuberculosis-19/NNP||tb-21/NN	tb-21||mtb-5||no||infection with mycobacteriumtuberculosis ( mtb ) results in different clinical outcomes ranging from asymptomatic containment to rapidly progressing tuberculosis (tb).
advmod||discuss-4/VB||here-1/RB	nsubj||discuss-4/VB||we-3/PRP	nsubj||explore-21/VB||we-3/PRP	root||ROOT-0/null||discuss-4/VB	det||pathways-8/NNS||the-5/DT	amod||pathways-8/NNS||potential-6/JJ	amod||pathways-8/NNS||regulatory-7/JJ	dobj||discuss-4/VB||pathways-8/NNS	vmod||pathways-8/NNS||involved-9/VBN	det||downregulation-12/NN||the-11/DT	prep_in||involved-9/VBN||downregulation-12/NN	amod||inflammation-15/NN||pathogenic-14/JJ	prep_of||downregulation-12/NN||inflammation-15/NN	det||gut-18/NN||the-17/DT	prep_in||inflammation-15/NN||gut-18/NN	conj_and||discuss-4/VB||explore-21/VB	dobj||explore-21/VB||questions-22/NNS	det||responses-26/NNS||the-24/DT	amod||responses-26/NNS||immune-25/JJ	prep_regarding||questions-22/NNS||responses-26/NNS	nsubj||require-32/VBP||responses-26/NNS	amod||acidophilus-30/NNS||lta-deficient-28/JJ	nn||acidophilus-30/NNS||l.-29/NN	prep_to||responses-26/NNS||acidophilus-30/NNS	rcmod||responses-26/NNS||require-32/VBP	amod||studies-34/NNS||future-33/JJ	dobj||require-32/VBP||studies-34/NNS	acidophilus-30||inflammation-15||no_rel||here , we discuss the potential regulatory pathways involved in the downregulation of pathogenic inflammation in the gut , and explore questions regarding the immune responses to lta-deficient l. acidophilus that require future studies .
amod||administration-2/NN||single-1/JJ	nsubj||elicited-5/VBD||administration-2/NN	prep_of||administration-2/NN||indomethacin-4/NN	root||ROOT-0/null||elicited-5/VBD	amod||area-8/NN||increased-6/VBN	amod||area-8/NN||ulcerative-7/JJ	dobj||elicited-5/VBD||area-8/NN	nn||activity-11/NN||mpo-10/NN	dobj||elicited-5/VBD||activity-11/NN	conj_and||area-8/NN||activity-11/NN	det||intestine-15/NN||the-13/DT	amod||intestine-15/NN||small-14/JJ	prep_in||elicited-5/VBD||intestine-15/NN	indomethacin-4||ulcerative-7||no_rel||single administration of indomethacin elicited increased ulcerative area and mpo activity in the small intestine.
nsubjpass||caused-4/VBN||type1diabetes-1/NNS	auxpass||caused-4/VBN||is-2/VBZ	advmod||caused-4/VBN||generally-3/RB	root||ROOT-0/null||caused-4/VBN	nn||deficiency-7/NN||insulin-6/NN	agent||caused-4/VBN||deficiency-7/NN	vmod||deficiency-7/NN||accompanied-8/VBN	det||destruction-11/NN||the-10/DT	agent||accompanied-8/VBN||destruction-11/NN	amod||²-15/NNS||islet-13/JJ	nn||²-15/NNS||î-14/NN	prep_of||destruction-11/NN||²-15/NNS	dep||destruction-11/NN||cells-17/NNS	type1diabetes-1||insulin-6||yes||type1diabetes is generally caused by insulin deficiency accompanied by the destruction of islet î²-cells.
det||cases-2/NNS||the-1/DT	nsubjpass||divided-4/VBN||cases-2/NNS	auxpass||divided-4/VBN||were-3/VBD	root||ROOT-0/null||divided-4/VBN	prep_into||divided-4/VBN||those-6/DT	vmod||those-6/DT||suspected-7/VBN	prepc_of||suspected-7/VBN||having-9/VBG	amod||wear-11/NN||high-10/JJ	nsubj||suspected-14/VBN||wear-11/NN	conj_and||wear-11/NN||those-13/DT	nsubj||suspected-14/VBN||those-13/DT	ccomp||having-9/VBG||suspected-14/VBN	aux||based-19/VBN||having-16/VBG	dobj||based-19/VBN||metal-17/NN	advmod||based-19/VBN||hypersensitivity-18/RB	prepc_of||suspected-14/VBN||based-19/VBN	amod||findings-26/NNS||clinical-21/JJ	conj_and||clinical-21/JJ||radiographic-23/JJ	amod||findings-26/NNS||radiographic-23/JJ	conj_and||clinical-21/JJ||retrieval-25/NN	amod||findings-26/NNS||retrieval-25/NN	prep_on||based-19/VBN||findings-26/NNS	metal-17||hypersensitivity-18||no_rel||the cases were divided into those suspected of having high wear and those suspected of having metal hypersensitivity based on clinical, radiographic and retrieval findings.
nsubjpass||overexpressed-4/VBN||hsp70-1/NNS	nsubjpass||localization-19/VBN||hsp70-1/NNS	auxpass||overexpressed-4/VBN||was-2/VBD	advmod||overexpressed-4/VBN||generally-3/RB	root||ROOT-0/null||overexpressed-4/VBN	det||tissues-8/NNS||the-6/DT	amod||tissues-8/NNS||myocardial-7/JJ	prep_in||overexpressed-4/VBN||tissues-8/NNS	amod||cells-11/NNS||inflammatory-10/JJ	prep_in||overexpressed-4/VBN||cells-11/NNS	conj_and||tissues-8/NNS||cells-11/NNS	amod||myocarditis-14/NNS||fmdv-induced-13/JJ	prep_of||cells-11/NNS||myocarditis-14/NNS	nn||accumulation-17/NN||differential-16/NN	prep_with||overexpressed-4/VBN||accumulation-17/NN	conj_and||overexpressed-4/VBN||localization-19/VBN	amod||hearts-22/NNS||same-21/JJ	prep_in||localization-19/VBN||hearts-22/NNS	dep||localization-19/VBN||when-23/WRB	prepc_compared_to||overexpressed-4/VBN||to-25/TO	amod||hearts-28/NNS||non-foot-and-mouthdisease-26/JJ	nn||hearts-28/NNS||control-27/NN	pobj||overexpressed-4/VBN||hearts-28/NNS	foot-and-mouthdisease--1||fmdv--1||no||hsp70 was generally overexpressed in the myocardial tissues and inflammatory cells of fmdv-induced myocarditis with differential accumulation and localization in same hearts when compared to non-foot-and-mouthdisease control hearts.
nsubjpass||reported-14/VBN||bisphosphonates-1/NNS	nsubj||have-16/VB||bisphosphonates-1/NNS	det||drug-4/NN||the-3/DT	appos||bisphosphonates-1/NNS||drug-4/NN	prep_of||drug-4/NN||choice-6/NN	aux||treat-8/VB||to-7/TO	vmod||drug-4/NN||treat-8/VB	dobj||treat-8/VB||osteoporosis-9/NNS	aux||reported-14/VBN||have-11/VBP	auxpass||reported-14/VBN||been-12/VBN	advmod||reported-14/VBN||recently-13/RB	root||ROOT-0/null||reported-14/VBN	aux||have-16/VB||to-15/TO	xcomp||reported-14/VBN||have-16/VB	amod||effects-18/NNS||anti-angiogenic-17/JJ	dobj||have-16/VB||effects-18/NNS	osteoporosis-9||bisphosphonates-1||no_rel||bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects.
poss||activity-3/NN||her-1/PRP$	amod||activity-3/NN||rheumatoidarthritis-2/JJ	nsubj||mild-6/JJ||activity-3/NN	nsubj||controlled-9/VBN||activity-3/NN	aux||mild-6/JJ||had-4/VBD	cop||mild-6/JJ||been-5/VBN	root||ROOT-0/null||mild-6/JJ	advmod||controlled-9/VBN||well-8/RB	conj_and||mild-6/JJ||controlled-9/VBN	amod||prednisone-15/NN||hydroxychloroquine-11/JJ	conj_and||hydroxychloroquine-11/JJ||low-13/JJ	amod||prednisone-15/NN||low-13/JJ	nn||prednisone-15/NN||dose-14/NN	prep_with||controlled-9/VBN||prednisone-15/NN	rheumatoidarthritis-2||hydroxychloroquine-11||yes||her rheumatoidarthritis activity had been mild and well controlled with hydroxychloroquine and low dose prednisone.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||explored-4/VBD||study-3/NN	root||ROOT-0/null||explored-4/VBD	det||growth-24/NN||the-5/DT	nn||effect-9/NN||vivo-7/NN	nn||effect-9/NN||immunomodulatory-8/NN	prep_in||interleukin-17-17/JJ||effect-9/NN	prep_on||effect-9/NN||interferon-gamma-11/NN	nn||³-14/NNP||ifn-î-13/NNP	appos||interferon-gamma-11/NN||³-14/NNP	amod||growth-24/NN||interleukin-17-17/JJ	dep||interleukin-17-17/JJ||il-17-19/JJ	conj_and||interleukin-17-17/JJ||transforming-23/JJ	amod||growth-24/NN||transforming-23/JJ	nsubj||evoked-32/VBD||growth-24/NN	number||1-26/CD||factor-beta-25/CD	amod||growth-24/NN||1-26/CD	dep||1-26/CD||tgf-î-28/NNP	number||1-30/CD||²-29/CD	num||tgf-î-28/NNP||1-30/CD	ccomp||explored-4/VBD||evoked-32/VBD	num||water-extracts-35/NNS||two-34/CD	prep_by||evoked-32/VBD||water-extracts-35/NNS	vmod||water-extracts-35/NNS||prepared-36/VBN	nn||leaves-39/NNS||ej-38/NN	prep_from||prepared-36/VBN||leaves-39/NNS	det||tissues-42/NNS||the-41/DT	prep_in||leaves-39/NNS||tissues-42/NNS	amod||mice-48/NNS||normal-44/JJ	conj_and||normal-44/JJ||meth-a-fibrosarcoma-46/JJ	amod||mice-48/NNS||meth-a-fibrosarcoma-46/JJ	nn||mice-48/NNS||bearing-47/NN	prep_of||tissues-42/NNS||mice-48/NNS	meth--1||fibrosarcoma--1||no_rel||the present study explored the in vivo immunomodulatory effect on interferon-gamma (ifn-î³), interleukin-17 (il-17), and transforming growth factor-beta 1 (tgf-î²1) evoked by two water-extracts prepared from ej leaves in the tissues of normal and meth-a-fibrosarcoma bearing mice.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||artemether--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
det||sensitivity-2/NN||the-1/DT	nsubjpass||evaluated-12/VBN||sensitivity-2/NN	conj_and||sensitivity-2/NN||specificity-4/NN	nsubjpass||evaluated-12/VBN||specificity-4/NN	det||elisa-8/NN||the-6/DT	amod||elisa-8/NN||epitope-blocking-7/JJ	prep_of||sensitivity-2/NN||elisa-8/NN	prep_for||elisa-8/NN||h5n1-10/CD	auxpass||evaluated-12/VBN||were-11/VBD	root||ROOT-0/null||evaluated-12/VBN	xcomp||evaluated-12/VBN||using-13/VBG	nn||antisera-15/NN||chicken-14/NN	dobj||using-13/VBG||antisera-15/NN	amod||clades-19/NNS||multiple-17/JJ	nn||clades-19/NNS||virus-18/NN	prep_to||using-13/VBG||clades-19/NNS	amod||subtypes-23/NNS||other-21/JJ	nn||subtypes-23/NNS||influenza-22/NN	prep_to||using-13/VBG||subtypes-23/NNS	conj_and||clades-19/NNS||subtypes-23/NNS	nn||samples-28/NNS||serum-27/NN	prep_to||using-13/VBG||samples-28/NNS	conj_and||clades-19/NNS||samples-28/NNS	prep_from||samples-28/NNS||individuals-30/NNS	advmod||infected-32/VBN||naturally-31/RB	vmod||individuals-30/NNS||infected-32/VBN	amod||influenzaviruses-37/NNS||h5n1-34/JJ	conj_or||h5n1-34/JJ||seasonal-36/JJ	amod||influenzaviruses-37/NNS||seasonal-36/JJ	prep_with||infected-32/VBN||influenzaviruses-37/NNS	h5n1-34||influenzaviruses-37||no||the sensitivity and specificity of the epitope-blocking elisa for h5n1 were evaluated using chicken antisera to multiple virus clades and other influenza subtypes as well as serum samples from individuals naturally infected with h5n1 or seasonal influenzaviruses.
nsubj||mimetic-12/NN||exenatide-1/NN	advmod||known-4/VBN||also-3/RB	dep||exenatide-1/NN||known-4/VBN	advmod||exendin-4-6/JJ||as-5/RB	acomp||known-4/VBN||exendin-4-6/JJ	cop||mimetic-12/NN||is-8/VBZ	det||mimetic-12/NN||a-9/DT	amod||mimetic-12/NN||glucagon-like-10/JJ	amod||mimetic-12/NN||peptide-1-11/JJ	root||ROOT-0/null||mimetic-12/NN	nsubjpass||indicated-16/VBN||mimetic-12/NN	auxpass||indicated-16/VBN||is-15/VBZ	rcmod||mimetic-12/NN||indicated-16/VBN	det||treatment-19/NN||the-18/DT	prep_for||indicated-16/VBN||treatment-19/NN	prep_of||treatment-19/NN||type2diabetesmellitus-21/CD	type2diabetesmellitus-21||exenatide-1||yes||exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type2diabetesmellitus.
nsubj||infection-13/NN||rabbitpox-1/NN	dep||rabbitpox-1/NN||rabbitpoxvirusinfection-3/VBN	prep_in||rabbitpoxvirusinfection-3/VBN||rabbits-5/NNS	cop||infection-13/NN||is-7/VBZ	det||infection-13/NN||a-8/DT	amod||infection-13/NN||severe-9/JJ	advmod||lethal-12/JJ||often-11/RB	conj_and||severe-9/JJ||lethal-12/JJ	amod||infection-13/NN||lethal-12/JJ	root||ROOT-0/null||infection-13/NN	nsubjpass||identified-17/VBN||infection-13/NN	aux||identified-17/VBN||has-15/VBZ	auxpass||identified-17/VBN||been-16/VBN	rcmod||infection-13/NN||identified-17/VBN	det||model-22/NN||an-19/DT	amod||model-22/NN||ideal-20/JJ	nn||model-22/NN||disease-21/NN	prep_as||identified-17/VBN||model-22/NN	det||study-25/NN||the-24/DT	prep_for||model-22/NN||study-25/NN	prep_of||study-25/NN||poxviruses-27/NNS	det||species-31/NN||a-29/DT	amod||species-31/NN||non-rodent-30/JJ	prep_in||poxviruses-27/NNS||species-31/NN	rabbitpox-1||rabbitpoxvirus--1||no||rabbitpox (rabbitpoxvirusinfection in rabbits) is a severe and often lethal infection that has been identified as an ideal disease model for the study of poxviruses in a non-rodent species.
aux||determine-2/VB||to-1/TO	advcl||isolated-32/VBD||determine-2/VB	det||characteristics-5/NNS||the-3/DT	nn||characteristics-5/NNS||transmission-4/NN	dobj||determine-2/VB||characteristics-5/NNS	amod||strains-8/NNS||m.tuberculosis-7/JJ	prep_of||characteristics-5/NNS||strains-8/NNS	vmod||strains-8/NNS||isolated-9/VBN	prep_in||isolated-9/VBN||beijing-11/NN	prep_in||isolated-9/VBN||china-13/NN	conj_and||beijing-11/NN||china-13/NN	poss||relationships-18/NNS||their-16/PRP$	amod||relationships-18/NNS||genetic-17/JJ	prep_in||isolated-9/VBN||relationships-18/NNS	conj_and||beijing-11/NN||relationships-18/NNS	advmod||characteristics-5/NNS||especially-20/RB	dep||characteristics-5/NNS||those-21/DT	amod||strains-25/NNS||beijing-23/VBG	nn||strains-25/NNS||family-24/NN	prep_among||those-21/DT||strains-25/NNS	amod||strains-31/NNS||260â-27/JJ	amod||strains-31/NNS||$-28/$	dep||$-28/$||‰-29/JJ	nn||strains-31/NNS||m.tuberculosis-30/NN	nsubj||isolated-32/VBD||strains-31/NNS	root||ROOT-0/null||isolated-32/VBD	prep_from||isolated-32/VBD||patients-34/NNS	xcomp||isolated-32/VBD||presenting-35/VBG	nsubjpass||analyzed-38/VBN||pulmonarytuberculosis-36/NNS	auxpass||analyzed-38/VBN||were-37/VBD	dep||presenting-35/VBG||analyzed-38/VBN	agent||analyzed-38/VBN||spoligotyping-40/VBG	agent||analyzed-38/VBN||examining-44/VBG	conj_and||spoligotyping-40/VBG||examining-44/VBG	num||loci-47/NNS||22-45/CD	nn||loci-47/NNS||vntr-46/NN	dobj||examining-44/VBG||loci-47/NNS	det||presence/absence-50/NN||the-49/DT	nsubj||6110-53/CD||presence/absence-50/NN	prep||presence/absence-50/NN||of-51/IN	cop||6110-53/CD||is-52/VBZ	dep||presenting-35/VBG||6110-53/CD	conj_and||analyzed-38/VBN||6110-53/CD	det||region-57/NN||the-55/DT	nn||region-57/NN||ntf-56/NN	prep_in||6110-53/CD||region-57/NN	prep_in||6110-53/CD||rd105-59/NNS	conj_and||region-57/NN||rd105-59/NNS	prep_in||6110-53/CD||rd181-61/NNS	conj_and||region-57/NN||rd181-61/NNS	pulmonarytuberculosis-36||m.tuberculosis-30||no||to determine the transmission characteristics of m.tuberculosis strains isolated in beijing , china , and their genetic relationships , especially those among beijing family strains , 260â $ ‰ m.tuberculosis strains isolated from patients presenting pulmonarytuberculosis were analyzed by spoligotyping , and by examining 22 vntr loci and the presence/absence of is 6110 in the ntf region , rd105 and rd181 .
det||risk-3/NN||an-1/DT	amod||risk-3/NN||increased-2/VBN	nsubjpass||forecast-10/VBN||risk-3/NN	prep_for||risk-3/NN||hemorrhagicfeverwithrenalsyndrome-5/NN	vmod||hemorrhagicfeverwithrenalsyndrome-5/NN||caused-6/VBN	agent||caused-6/VBN||puumalahantavirus-8/NNS	auxpass||forecast-10/VBN||was-9/VBD	root||ROOT-0/null||forecast-10/VBN	prep_for||forecast-10/VBN||sweden-12/NN	prep_in||sweden-12/NN||2007-14/CD	hemorrhagicfeverwithrenalsyndrome-5||puumalahantavirus-8||no||an increased risk for hemorrhagicfeverwithrenalsyndrome caused by puumalahantavirus was forecast for sweden in 2007.
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||propofol-28||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
nn||proteins-2/NNS||gluten-1/NN	nsubj||induce-6/VB||proteins-2/NNS	prep_from||proteins-2/NNS||wheat-4/NN	aux||induce-6/VB||can-5/MD	root||ROOT-0/null||induce-6/VB	dobj||induce-6/VB||celiacdisease-7/NN	appos||celiacdisease-7/NN||cd-9/NN	advmod||susceptible-13/JJ||genetically-12/RB	amod||individuals-14/NNS||susceptible-13/JJ	prep_in||celiacdisease-7/NN||individuals-14/NNS	celiacdisease-7||gluten-1||no||gluten proteins from wheat can induce celiacdisease (cd) in genetically susceptible individuals.
poss||studies-2/NNS||our-1/PRP$	nsubj||contribute-3/VBP||studies-2/NNS	root||ROOT-0/null||contribute-3/VBP	det||understanding-7/NN||a-5/DT	amod||understanding-7/NN||deeper-6/JJR	prep_to||contribute-3/VBP||understanding-7/NN	amod||responses-10/NNS||hematologic-9/JJ	prep_of||understanding-7/NN||responses-10/NNS	prep_in||contribute-3/VBP||patients-12/NNS	amod||infections-15/NNS||chronic-14/JJ	prep_with||patients-12/NNS||infections-15/NNS	prep_such_as||infections-15/NNS||hiv/aids-18/NNS	prep_such_as||infections-15/NNS||tuberculosis-20/NNP	conj_or||hiv/aids-18/NNS||tuberculosis-20/NNP	num||tuberculosis-20/NNP||3-21/CD	dobj||contribute-3/VBP||5-23/CD	parataxis||contribute-3/VBP||5-23/CD	aids--1||hiv--1||no||our studies contribute to a deeper understanding of hematologic responses in patients with chronic infections such as hiv/aids or tuberculosis 3 - 5 .
amod||insulin-3/NN||total-1/JJ	amod||insulin-3/NN||mean-2/JJ	nsubj||use-4/VBP||insulin-3/NN	root||ROOT-0/null||use-4/VBP	dep||use-4/VBP||increased-5/VBN	amod||patients-8/NNS||type2diabetes-7/JJ	prep_in||increased-5/VBN||patients-8/NNS	dep||increased-5/VBN||from-10/IN	number||â-12/CD||0.67-11/CD	num||â-18/NN||â-12/CD	nn||â-18/NN||±-13/NNP	num||â-18/NN||1.35-14/CD	amod||â-18/NN||u/kg-15/JJ	prep_to||u/kg-15/JJ||0.88-17/CD	pobj||from-10/IN||â-18/NN	dep||u/kg-21/JJ||±-19/NNP	num||±-19/NNP||1.33-20/CD	amod||â-18/NN||u/kg-21/JJ	vmod||â-18/NN||p-23/VBN	num||0.001-25/CD||<-24/CD	dobj||p-23/VBN||0.001-25/CD	det||decrease-30/NN||a-28/DT	amod||decrease-30/NN||slight-29/JJ	prep_with||increased-5/VBN||decrease-30/NN	amod||patients-33/NNS||type1diabetes-32/JJ	prep_in||decrease-30/NN||patients-33/NNS	number||â-37/CD||1.04-36/CD	num||â-43/NN||â-37/CD	nn||â-43/NN||±-38/NNP	num||â-43/NN||2.51-39/CD	amod||â-43/NN||u/kg-40/JJ	prep_to||u/kg-40/JJ||0.98-42/CD	prep_from||decrease-30/NN||â-43/NN	number||2.58-45/CD||±-44/CD	dep||u/kg-46/JJ||2.58-45/CD	dep||â-43/NN||u/kg-46/JJ	vmod||â-43/NN||p-48/VBN	num||0.001-50/CD||<-49/CD	dobj||p-48/VBN||0.001-50/CD	type2diabetes-7||insulin-3||yes||total mean insulin use increased in type2diabetes patients (from 0.67 â± 1.35 u/kg to 0.88 â± 1.33 u/kg, p < 0.001) with a slight decrease in type1diabetes patients (from 1.04 â± 2.51 u/kg to 0.98 â± 2.58 u/kg, p < 0.001).
nsubj||resulted-13/VBD||phagocytosis-1/NNS	prep_of||phagocytosis-1/NNS||cvb3-infected-3/JJ	amod||islets-12/NNS||mock-infected-7/JJ	conj_and||mock-infected-7/JJ||human-9/JJ	amod||islets-12/NNS||human-9/JJ	conj_and||mock-infected-7/JJ||porcine-11/JJ	amod||islets-12/NNS||porcine-11/JJ	prep_of||phagocytosis-1/NNS||islets-12/NNS	conj_negcc||cvb3-infected-3/JJ||islets-12/NNS	root||ROOT-0/null||resulted-13/VBD	prep_in||resulted-13/VBD||induction-15/NN	prep_of||induction-15/NN||isgs-17/NNS	prep_in||resulted-13/VBD||dcs-19/NN	det||rig-29/NN||the-22/DT	nn||rig-29/NN||retinoicacidâ-23/NNP	nn||rig-29/NN||$-24/NNP	nn||rig-29/NN||inducible-26/NN	nn||rig-29/NN||gene-27/NN	prep_including||resulted-13/VBD||rig-29/NN	prep_including||resulted-13/VBD||iâ-32/RB	advmod||rig-29/NN||iâ-32/RB	conj_and||rig-29/NN||iâ-32/RB	pobj||iâ-32/RB||$-33/$	prep_like||iâ-32/RB||helicases-36/NNS	dep||helicases-36/NNS||rlhs-38/NNS	prep_including||resulted-13/VBD||rig-i-41/NN	conj_and||rig-29/NN||rig-i-41/NN	nn||mda5-52/NN||melanoma-44/NNP	nn||mda5-52/NN||differentiationâ-45/NNP	nn||mda5-52/NN||$-46/NNP	amod||mda5-52/NN||associated-48/JJ	nn||mda5-52/NN||gene-49/NN	num||mda5-52/NN||5-50/CD	prep_including||resulted-13/VBD||mda5-52/NN	conj_and||rig-29/NN||mda5-52/NN	melanoma-44||rig-29||no_rel||phagocytosis of cvb3-infected, but not mock-infected, human and porcine islets resulted in induction of isgs in dcs, including the retinoicacidâ€“inducible gene (rig)-iâ€“like helicases (rlhs), rig-i, and melanoma differentiationâ€“associated gene 5 (mda5).
det||study-3/NN||this-1/DT	nn||study-3/NN||pilot-2/NN	nsubjpass||set-5/VBN||study-3/NN	auxpass||set-5/VBN||was-4/VBD	root||ROOT-0/null||set-5/VBN	amod||1-7/CD||out-6/IN	nsubj||make-10/VB||1-7/CD	aux||make-10/VB||to-9/TO	ccomp||set-5/VBN||make-10/VB	xcomp||set-5/VBN||make-10/VB	det||estimate-13/NN||a-11/DT	amod||estimate-13/NN||rough-12/JJ	dobj||make-10/VB||estimate-13/NN	det||equivalence-16/NN||the-15/DT	prep_of||estimate-13/NN||equivalence-16/NN	prep_of||equivalence-16/NN||ibuprofen-18/NN	prep_of||equivalence-16/NN||ciprofloxacin-20/NN	conj_and||ibuprofen-18/NN||ciprofloxacin-20/NN	amod||urinarytractinfection-23/NN||uncomplicated-22/JJ	prep_for||make-10/VB||urinarytractinfection-23/NN	nn||resolution-28/NN||symptom-27/NN	prep_with_regard_to||make-10/VB||resolution-28/NN	ccomp||set-5/VBN||2-31/CD	xcomp||set-5/VBN||2-31/CD	conj_and||make-10/VB||2-31/CD	aux||demonstrate-34/VB||to-33/TO	vmod||make-10/VB||demonstrate-34/VB	det||feasibility-36/NN||the-35/DT	dobj||demonstrate-34/VB||feasibility-36/NN	det||trial-44/NN||a-38/DT	amod||trial-44/NN||double-blind-39/JJ	amod||trial-44/NN||randomized-41/JJ	amod||trial-44/NN||controlled-42/JJ	nn||trial-44/NN||drug-43/NN	prep_of||feasibility-36/NN||trial-44/NN	amod||practices-48/NNS||german-46/JJ	amod||practices-48/NNS||general-47/JJ	prep_in||trial-44/NN||practices-48/NNS	urinarytractinfection-23||ciprofloxacin-20||yes||this pilot study was set out 1) to make a rough estimate of the equivalence of ibuprofen and ciprofloxacin for uncomplicated urinarytractinfection with regard to symptom resolution, and 2) to demonstrate the feasibility of a double-blind, randomized controlled drug trial in german general practices.
advmod||added-2/VBD||when-1/WRB	advcl||improved-28/VBD||added-2/VBD	amod||drugs-6/NNS||oral-4/JJ	nn||drugs-6/NNS||antidiabetes-5/NNS	prep_to||added-2/VBD||drugs-6/NNS	det||trial-11/NN||a-8/DT	amod||randomized-10/JJ||26-week-9/JJ	amod||trial-11/NN||randomized-10/JJ	prep_in||added-2/VBD||trial-11/NN	amod||effect-14/NN||liraglutide-13/JJ	dep||trial-11/NN||effect-14/NN	dep||trial-11/NN||action-16/NN	conj_and||effect-14/NN||action-16/NN	nn||-6-22/NNP||diabetes-18/NNP	nn||-6-22/NNP||-LSB--19/NNP	nn||-6-22/NNP||lead-20/NN	nn||-6-22/NNP||-RSB--21/NNP	prep_in||effect-14/NN||-6-22/NNP	nsubj||improved-28/VBD||liraglutide-25/NN	advmod||effectively-27/RB||more-26/RBR	advmod||improved-28/VBD||effectively-27/RB	root||ROOT-0/null||improved-28/VBD	dobj||improved-28/VBD||a1c-29/NNS	vmod||improved-28/VBD||fasting-31/VBG	number||glucose-33/CD||plasma-32/CD	dobj||fasting-31/VBG||glucose-33/CD	det||model-38/NN||the-36/DT	amod||model-38/NN||homeostasis-37/JJ	dobj||fasting-31/VBG||model-38/NN	conj_and||glucose-33/CD||model-38/NN	nn||²-41/NNS||î-40/NN	prep_of||model-38/NN||²-41/NNS	nn||function-44/NN||cell-43/NN	dep||model-38/NN||function-44/NN	appos||function-44/NN||homa-b-46/NNP	prep_than||function-44/NN||exenatide-49/NN	advmod||persistent-53/JJ||less-52/RBR	amod||nausea-54/NN||persistent-53/JJ	prep_with||fasting-31/VBG||nausea-54/NN	prep_with||fasting-31/VBG||hypoglycemia-56/NN	conj_and||nausea-54/NN||hypoglycemia-56/NN	hypoglycemia-56||glucose-33||yes||when added to oral antidiabetes drugs in a 26-week randomized trial (liraglutide effect and action in diabetes [lead]-6), liraglutide more effectively improved a1c, fasting plasma glucose, and the homeostasis model of î²-cell function (homa-b) than exenatide, with less persistent nausea and hypoglycemia.
det||number-2/NN||the-1/DT	nsubj||%-18/NN||number-2/NN	amod||persons-6/NNS||hiv-4/JJ	amod||persons-6/NNS||infected-5/JJ	prep_of||number-2/NN||persons-6/NNS	vmod||persons-6/NNS||reported-7/VBN	aux||screened-11/VBN||to-8/TO	aux||screened-11/VBN||have-9/VB	auxpass||screened-11/VBN||been-10/VBN	xcomp||reported-7/VBN||screened-11/VBN	prep_for||screened-11/VBN||tb-13/NN	cop||%-18/NN||was-14/VBD	mwe||than-16/IN||less-15/JJR	quantmod||1-17/CD||than-16/IN	num||%-18/NN||1-17/CD	root||ROOT-0/null||%-18/NN	mark||reported-24/VBN||while-19/IN	amod||therapy-22/NN||isoniazid-20/JJ	nn||therapy-22/NN||preventive-21/NN	nsubjpass||reported-24/VBN||therapy-22/NN	nsubjpass||provided-28/VBN||therapy-22/NN	auxpass||reported-24/VBN||was-23/VBD	dep||%-18/NN||reported-24/VBN	aux||provided-28/VBN||to-25/TO	aux||provided-28/VBN||have-26/VB	auxpass||provided-28/VBN||been-27/VBN	xcomp||reported-24/VBN||provided-28/VBN	mwe||than-31/IN||less-30/JJR	quantmod||0.1-32/CD||than-31/IN	num||%-33/NN||0.1-32/CD	prep_to||provided-28/VBN||%-33/NN	amod||persons-36/NNS||eligible-35/JJ	prep_of||%-33/NN||persons-36/NNS	prep_in||persons-36/NNS||2006-38/CD	tb-13||isoniazid-20||yes||the number of hiv infected persons reported to have been screened for tb was less than 1% while isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006.
nsubjpass||associated-10/VBN||exposure-1/NN	amod||silica-4/NN||crystalline-3/JJ	prep_to||exposure-1/NN||silica-4/NN	amod||workers-8/NNS||vermont-6/JJ	nn||workers-8/NNS||granite-7/NN	prep_in||silica-4/NN||workers-8/NNS	auxpass||associated-10/VBN||was-9/VBD	root||ROOT-0/null||associated-10/VBN	amod||mortality-13/NN||increased-12/VBN	prep_with||associated-10/VBN||mortality-13/NN	prep_from||mortality-13/NN||silicosis-15/NNS	amod||disease-20/NN||other-17/JJ	amod||disease-20/NN||non-malignant-18/JJ	nn||disease-20/NN||respiratory-19/NN	prep_from||mortality-13/NN||disease-20/NN	conj_and||silicosis-15/NNS||disease-20/NN	expl||was-24/VBD||there-23/EX	conj_but||associated-10/VBN||was-24/VBD	neg||evidence-26/NN||no-25/DT	nsubj||was-24/VBD||evidence-26/NN	nsubj||increased-28/VBD||evidence-26/NN	rcmod||evidence-26/NN||increased-28/VBD	nn||mortality-31/NN||lung-29/NN	nn||mortality-31/NN||cancer-30/NN	nsubj||due-36/JJ||mortality-31/NN	det||cohort-34/NN||the-33/DT	prep_in||mortality-31/NN||cohort-34/NN	cop||due-36/JJ||was-35/VBD	ccomp||increased-28/VBD||due-36/JJ	prep_to||due-36/JJ||exposure-38/NN	silicosis-15||silica-4||no||exposure to crystalline silica in vermont granite workers was associated with increased mortality from silicosis and other non-malignant respiratory disease, but there was no evidence that increased lung cancer mortality in the cohort was due to exposure.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||cloned-12/VBN||study-4/NN	amod||rv1985c-8/NNS||recombinant-6/JJ	nn||rv1985c-8/NNS||protein-7/NN	nsubjpass||cloned-12/VBN||rv1985c-8/NNS	nsubjpass||expressed-14/VBN||rv1985c-8/NNS	nsubjpass||purified-16/VBN||rv1985c-8/NNS	nsubjpass||characterized-19/VBN||rv1985c-8/NNS	nsubjpass||investigated-21/VBN||rv1985c-8/NNS	prep_from||rv1985c-8/NNS||rd2-10/CD	auxpass||cloned-12/VBN||was-11/VBD	root||ROOT-0/null||cloned-12/VBN	conj_and||cloned-12/VBN||expressed-14/VBN	conj_and||cloned-12/VBN||purified-16/VBN	advmod||characterized-19/VBN||immunologically-18/RB	conj_and||cloned-12/VBN||characterized-19/VBN	conj_and||cloned-12/VBN||investigated-21/VBN	poss||value-26/NN||its-23/PRP$	advmod||diagnostic-25/JJ||potentially-24/RB	amod||value-26/NN||diagnostic-25/JJ	prep_for||investigated-21/VBN||value-26/NN	nn||infection-32/NN||tuberculosis-28/NNP	appos||infection-32/NN||tb-30/NN	prep_for||value-26/NN||infection-32/NN	amod||individuals-35/NNS||bcg-vaccinated-34/JJ	prep_among||investigated-21/VBN||individuals-35/NNS	tb-30||bcg--1||no||in the present study, recombinant protein rv1985c from rd2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic value for tuberculosis (tb) infection among bcg-vaccinated individuals.
amod||restriction-2/NN||calorie-1/JJ	nsubjpass||known-10/VBN||restriction-2/NN	nsubj||attenuate-12/VB||restriction-2/NN	nsubj||improve-15/VB||restriction-2/NN	appos||restriction-2/NN||cr-4/NN	amod||exercise-8/NN||endurance-7/JJ	conj_and||restriction-2/NN||exercise-8/NN	nsubjpass||known-10/VBN||exercise-8/NN	nsubj||attenuate-12/VB||exercise-8/NN	auxpass||known-10/VBN||are-9/VBP	root||ROOT-0/null||known-10/VBN	aux||attenuate-12/VB||to-11/TO	xcomp||known-10/VBN||attenuate-12/VB	advmod||attenuate-12/VB||obesity-13/RB	xcomp||known-10/VBN||improve-15/VB	conj_and||attenuate-12/VB||improve-15/VB	det||syndrome-18/NN||the-16/DT	amod||syndrome-18/NN||metabolic-17/JJ	dobj||improve-15/VB||syndrome-18/NN	cr-4||obesity-13||no_rel||calorie restriction (cr) and endurance exercise are known to attenuate obesity and improve the metabolic syndrome.
prep_in||undergoing-22/VBG||addition-2/NN	amod||inhibitors-7/NNS||promising-4/JJ	nn||inhibitors-7/NNS||novel-5/NN	nn||inhibitors-7/NNS||proteasome-6/NN	nsubj||distinct-11/JJ||inhibitors-7/NNS	nsubj||undergoing-22/VBG||inhibitors-7/NNS	cop||distinct-11/JJ||are-10/VBP	rcmod||inhibitors-7/NNS||distinct-11/JJ	prep_from||distinct-11/JJ||bortezomib-13/NN	nn||activities-19/NNS||exhibit-16/NN	nn||activities-19/NNS||equipotent-17/NN	amod||activities-19/NNS||anti-multiplemyeloma-18/JJ	rcmod||inhibitors-7/NNS||activities-19/NNS	conj_and||distinct-11/JJ||activities-19/NNS	aux||undergoing-22/VBG||are-21/VBP	root||ROOT-0/null||undergoing-22/VBG	amod||evaluation-24/NN||clinical-23/JJ	dobj||undergoing-22/VBG||evaluation-24/NN	mark||improve-28/VB||in-25/IN	dep||improve-28/VB||order-26/NN	aux||improve-28/VB||to-27/TO	advcl||undergoing-22/VBG||improve-28/VB	amod||outcome-30/NN||patient-29/JJ	dobj||improve-28/VB||outcome-30/NN	prep_in||improve-28/VB||multiplemyeloma-32/NN	multiplemyeloma-32||bortezomib-13||yes||in addition, promising novel proteasome inhibitors, which are distinct from bortezomib, and exhibit equipotent anti-multiplemyeloma activities, are undergoing clinical evaluation in order to improve patient outcome in multiplemyeloma.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||outcomes-13/NNS||the-9/DT	amod||outcomes-13/NNS||functional-10/JJ	conj_and||functional-10/JJ||anatomic-12/JJ	amod||outcomes-13/NNS||anatomic-12/JJ	dobj||evaluate-8/VB||outcomes-13/NNS	amod||ranibizumab-16/NN||intravitreal-15/JJ	prep_of||outcomes-13/NNS||ranibizumab-16/NN	det||treatment-19/NN||the-18/DT	prep_for||outcomes-13/NNS||treatment-19/NN	amod||pigment-23/NN||symptomatic-21/JJ	amod||pigment-23/NN||drusenoid-22/JJ	prep_of||treatment-19/NN||pigment-23/NN	amod||detachment-25/JJ||epithelial-24/JJ	amod||outcomes-13/NNS||detachment-25/JJ	amod||neovascularization-28/NN||choroidal-27/JJ	prep_without||evaluate-8/VB||neovascularization-28/NN	prep_in||evaluate-8/VB||age-relatedmaculardegeneration-30/NN	ranibizumab-16||age-relatedmaculardegeneration-30||no_rel||the aim of our study was to evaluate the functional and anatomic outcomes of intravitreal ranibizumab for the treatment of symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-relatedmaculardegeneration.
nsubj||one-6/CD||isoniazid-1/NN	appos||isoniazid-1/NN||inh-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||drugs-12/NNS||the-8/DT	amod||drugs-12/NNS||main-9/JJ	amod||drugs-12/NNS||first-10/JJ	nn||drugs-12/NNS||line-11/NN	prep_of||one-6/CD||drugs-12/NNS	vmod||drugs-12/NNS||used-13/VBN	prep_in||used-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||tuberculosis-17/NNP	nsubj||result-26/VB||development-19/NN	prep_of||development-19/NN||resistance-21/NN	det||compound-24/NN||this-23/DT	prep_against||resistance-21/NN||compound-24/NN	aux||result-26/VB||can-25/MD	conj_and||one-6/CD||result-26/VB	amod||problems-29/NNS||serious-28/JJ	prep_in||result-26/VB||problems-29/NNS	nn||procedures-32/NNS||treatment-31/NN	prep_in||problems-29/NNS||procedures-32/NNS	tuberculosis-17||isoniazid-1||yes||isoniazid (inh) is one of the main first line drugs used in treatment of tuberculosis and development of resistance against this compound can result in serious problems in treatment procedures.
det||combination-2/NN||the-1/DT	nsubjpass||introduced-8/VBN||combination-2/NN	prep_of||combination-2/NN||artesunate-4/NN	prep_of||combination-2/NN||mefloquine-6/NN	conj_and||artesunate-4/NN||mefloquine-6/NN	auxpass||introduced-8/VBN||was-7/VBD	root||ROOT-0/null||introduced-8/VBN	det||treatment-13/NN||the-10/DT	amod||treatment-13/NN||national-11/JJ	amod||treatment-13/NN||first-line-12/JJ	prep_as||introduced-8/VBN||treatment-13/NN	prep_for||treatment-13/NN||plasmodiumfalciparummalaria-15/NN	prep_in||introduced-8/VBN||cambodia-17/NN	prep_in||cambodia-17/NN||2000-19/CD	plasmodiumfalciparummalaria-15||mefloquine-6||yes||the combination of artesunate and mefloquine was introduced as the national first-line treatment for plasmodiumfalciparummalaria in cambodia in 2000.
nsubj||metalloid-5/NN||arsenic-1/NN	cop||metalloid-5/NN||is-2/VBZ	det||metalloid-5/NN||a-3/DT	amod||metalloid-5/NN||toxic-4/JJ	root||ROOT-0/null||metalloid-5/NN	nsubj||causes-7/VBZ||metalloid-5/NN	nsubj||binds-11/VBZ||metalloid-5/NN	nsubj||cysteine-13/VB||metalloid-5/NN	rcmod||metalloid-5/NN||causes-7/VBZ	nn||cancer-9/NN||skin-8/NN	dobj||causes-7/VBZ||cancer-9/NN	rcmod||metalloid-5/NN||binds-11/VBZ	conj_and||causes-7/VBZ||binds-11/VBZ	aux||cysteine-13/VB||to-12/TO	xcomp||binds-11/VBZ||cysteine-13/VB	discourse||cysteine-13/VB||residuesâ-14/UH	dep||residuesâ-14/UH||$-15/UH	det||property-18/NN||a-17/DT	dobj||cysteine-13/VB||property-18/NN	nsubjpass||used-22/VBN||property-18/NN	nsubj||infer-24/VB||property-18/NN	aux||used-22/VBN||could-20/MD	auxpass||used-22/VBN||be-21/VB	rcmod||property-18/NN||used-22/VBN	aux||infer-24/VB||to-23/TO	xcomp||used-22/VBN||infer-24/VB	nn||responsiveness-26/NNS||arsenic-25/NN	dobj||infer-24/VB||responsiveness-26/NNS	det||protein-30/NN||a-28/DT	nn||protein-30/NN||target-29/NN	prep_of||responsiveness-26/NNS||protein-30/NN	cancer-9||arsenic-25||no_rel||arsenic is a toxic metalloid that causes skin cancer and binds to cysteine residuesâ€”a property that could be used to infer arsenic responsiveness of a target protein.
amod||workers-3/NNS||exposed-2/VBN	prep_among||lowered-13/VBD||workers-3/NNS	det||presence-6/NN||the-5/DT	nsubj||lowered-13/VBD||presence-6/NN	amod||evidence-9/NN||radiographic-8/JJ	prep_of||presence-6/NN||evidence-9/NN	prep_of||evidence-9/NN||asbestosis-11/NNS	advmod||lowered-13/VBD||further-12/RB	root||ROOT-0/null||lowered-13/VBD	dobj||lowered-13/VBD||fvc-14/NN	dobj||lowered-13/VBD||dlco-16/NN	conj_and||fvc-14/NN||dlco-16/NN	dobj||lowered-13/VBD||fev1/fvc-19/NNS	conj_negcc||fvc-14/NN||fev1/fvc-19/NNS	prepc_compared_to||lowered-13/VBD||to-21/TO	nn||exposure-23/NN||asbestos-22/NN	pobj||lowered-13/VBD||exposure-23/NN	amod||asbestosis-26/NNS||radiographic-25/JJ	prep_without||exposure-23/NN||asbestosis-26/NNS	asbestosis-26||asbestos-22||no||among exposed workers, the presence of radiographic evidence of asbestosis further lowered fvc and dlco but not fev1/fvc compared to asbestos exposure without radiographic asbestosis.
advmod||known-5/VBN||however-1/RB	nsubjpass||known-5/VBN||little-3/RB	auxpass||known-5/VBN||is-4/VBZ	root||ROOT-0/null||known-5/VBN	amod||use-8/NN||timh-7/JJ	prep_about||known-5/VBN||use-8/NN	prep_about||known-5/VBN||safety-10/NN	conj_or||use-8/NN||safety-10/NN	prep_about||known-5/VBN||efficacy-12/NN	conj_or||use-8/NN||efficacy-12/NN	amod||management-15/NN||hiv/aids-14/JJ	prep_in||known-5/VBN||management-15/NN	prep_in||management-15/NN||india-17/NN	nsubj||has-20/VBZ||india-17/NN	rcmod||india-17/NN||has-20/VBZ	dobj||has-20/VBZ||one-21/CD	det||systems-27/NNS||the-23/DT	amod||systems-27/NNS||largest-24/JJS	nn||systems-27/NNS||indigenous-25/NNS	amod||systems-27/NNS||medical-26/JJ	prep_of||one-21/CD||systems-27/NNS	det||world-30/NN||the-29/DT	prep_in||systems-27/NNS||world-30/NN	aids--1||hiv--1||no||however, little is known about timh use, safety or efficacy in hiv/aids management in india, which has one of the largest indigenous medical systems in the world.
nsubj||relied-11/VBN||treatment-1/NN	prep_of||treatment-1/NN||attention-deficit/hyperactivitydisorder-3/NN	dep||treatment-1/NN||adhd-5/VBN	aux||relied-11/VBN||has-7/VBZ	amod||years-10/NNS||many-9/JJ	prep_for||relied-11/VBN||years-10/NNS	root||ROOT-0/null||relied-11/VBN	nn||formulations-17/NNS||psychostimulants-13/NNS	advmod||formulations-17/NNS||particularly-15/RB	amod||formulations-17/NNS||various-16/JJ	prep_on||relied-11/VBN||formulations-17/NNS	prep_of||formulations-17/NNS||amphetamines-19/NNS	prep_of||formulations-17/NNS||methylphenidate-21/NN	conj_and||amphetamines-19/NNS||methylphenidate-21/NN	hyperactivitydisorder--1||methylphenidate-21||yes||treatment of attention-deficit/hyperactivitydisorder (adhd) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate.
det||rate-2/NN||the-1/DT	nsubj||ranged-9/VBD||rate-2/NN	prep_of||rate-2/NN||response-4/NN	aux||levofloxacin-6/VB||to-5/TO	vmod||response-4/NN||levofloxacin-6/VB	prep_by||levofloxacin-6/VB||bacterialdisease-8/NN	root||ROOT-0/null||ranged-9/VBD	num||%-12/NN||97.4-11/CD	prep_from||ranged-9/VBD||%-12/NN	prep_in||%-12/NN||keratitis-14/NNS	num||%-17/NN||88.3-16/CD	prep_to||ranged-9/VBD||%-17/NN	prep_in||%-17/NN||dacryocystitis-19/NNS	bacterialdisease-8||levofloxacin-6||yes||the rate of response to levofloxacin by bacterialdisease ranged from 97.4% in keratitis to 88.3% in dacryocystitis.
nn||migration-3/NN||metal-1/NN	nn||migration-3/NN||clip-2/NN	nsubjpass||associated-5/VBN||migration-3/NN	auxpass||associated-5/VBN||was-4/VBD	root||ROOT-0/null||associated-5/VBN	prep_with||associated-5/VBN||2-7/CD	num||%-10/NN||8-9/CD	appos||2-7/CD||%-10/NN	det||cases-16/NNS||the-13/DT	num||cases-16/NNS||25-14/CD	nn||cases-16/NNS||rrp-15/NN	prep_of||2-7/CD||cases-16/NNS	nn||neckcontracture-19/NN||bladder-18/NN	prep_of||cases-16/NNS||neckcontracture-19/NN	prep_with||associated-5/VBN||both-21/DT	conj_and||2-7/CD||both-21/DT	num||%-24/NN||100-23/CD	appos||both-21/DT||%-24/NN	det||cases-29/NNS||the-27/DT	nn||cases-29/NNS||rrp-28/NN	prep_of||both-21/DT||cases-29/NNS	nn||stone-32/NN||bladder-31/NN	prep_of||cases-29/NNS||stone-32/NN	neckcontracture-19||metal-1||no_rel||metal clip migration was associated with 2 (8%) of the 25 rrp cases of bladder neckcontracture and both (100%) of the rrp cases of bladder stone.
amod||reports-2/NNS||previous-1/JJ	nsubj||shown-4/VBN||reports-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||recruits-7/VBZ||that-5/IN	nsubj||recruits-7/VBZ||adenovirus-6/NNS	ccomp||shown-4/VBN||recruits-7/VBZ	nn||factor-11/NN||nucleolar-8/NN	nn||factor-11/NN||protein-9/NN	nn||factor-11/NN||upstream-binding-10/NN	dobj||recruits-7/VBZ||factor-11/NN	dep||recruits-7/VBZ||ubf-13/NN	nn||centres-18/NNS||adenovirusdna-16/NN	nn||centres-18/NNS||replication-17/NN	prep_into||recruits-7/VBZ||centres-18/NNS	adenovirusdna-16||adenovirus-6||no||previous reports have shown that adenovirus recruits nucleolar protein upstream-binding factor (ubf) into adenovirusdna replication centres.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	det||therapy-9/NN||a-6/DT	amod||therapy-9/NN||4-week-7/JJ	nn||therapy-9/NN||adjunctive-8/NN	prep_of||effect-4/NN||therapy-9/NN	amod||exe-13/NN||exenatide-11/JJ	prep_of||therapy-9/NN||exe-13/NN	dep||exe-13/NN||5â-16/NNS	nn||metformin-57/NN||$-17/$	num||î-20/NN||10-19/CD	npadvmod||response-37/RB||î-20/NN	num||b.i.d.-23/NNP||1/4-21/CD	nn||b.i.d.-23/NNP||g-22/NNP	npadvmod||in-36/IN||b.i.d.-23/NNP	conj_or||b.i.d.-23/NNP||sitagliptin-26/NN	npadvmod||in-36/IN||sitagliptin-26/NN	appos||sitagliptin-26/NN||sita-28/NNP	num||mg-32/NN||100-31/CD	npadvmod||once-33/RB||mg-32/NN	dep||sitagliptin-26/NN||once-33/RB	dep||once-33/RB||daily-34/RB	advmod||î-20/NN||in-36/IN	dep||+-56/CD||response-37/RB	det||challenge-43/NN||a-39/DT	amod||challenge-43/NN||standardized-40/JJ	nn||challenge-43/NN||breakfast-41/NN	nn||challenge-43/NN||meal-42/NN	prep_to||response-37/RB||challenge-43/NN	num||men-46/NNS||48-45/CD	prep_in||response-37/RB||men-46/NNS	prep_in||response-37/RB||women-48/NNS	conj_or||men-46/NNS||women-48/NNS	amod||insulinglargine-52/NN||type2diabetes-50/JJ	nn||insulinglargine-52/NN||receiving-51/NN	prep_with||men-46/NNS||insulinglargine-52/NN	appos||insulinglargine-52/NN||glar-54/NN	num||$-17/$||+-56/CD	dep||5â-16/NNS||metformin-57/NN	dep||exe-13/NN||met-59/VBN	type2diabetes-50||insulinglargine-52||yes||to assess the effect of a 4-week adjunctive therapy of exenatide (exe) (5â€“10 î¼g b.i.d.) or sitagliptin (sita) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type2diabetes receiving insulinglargine (glar) + metformin (met).
det||relationship-2/NN||the-1/DT	nsubjpass||supported-8/VBN||relationship-2/NN	prep_between||relationship-2/NN||ngf-4/NN	prep_between||relationship-2/NN||pain-6/NN	conj_and||ngf-4/NN||pain-6/NN	auxpass||supported-8/VBN||is-7/VBZ	root||ROOT-0/null||supported-8/VBN	amod||mutations-12/NNS||genetic-10/JJ	nn||mutations-12/NNS||evidence-11/NN	agent||supported-8/VBN||mutations-12/NNS	det||receptor-17/NN||the-14/DT	nn||receptor-17/NN||ngf-15/NN	nn||receptor-17/NN||trka-16/NN	prep_in||mutations-12/NNS||receptor-17/NN	prep_in||supported-8/VBN||patients-19/NNS	vmod||patients-19/NNS||affected-20/VBN	det||disease-25/NN||an-22/DT	advmod||rare-24/JJ||hereditary-23/RB	amod||disease-25/NN||rare-24/JJ	agent||affected-20/VBN||disease-25/NN	number||sensory-28/JJ||hereditary-27/CD	dep||disease-25/NN||sensory-28/JJ	amod||iv-33/NN||autonomic-30/JJ	nn||iv-33/NN||neuropathy-31/NNP	nn||iv-33/NN||type-32/NN	dep||disease-25/NN||iv-33/NN	conj_and||sensory-28/JJ||iv-33/NN	nn||iv-36/NN||hsan-35/NN	appos||sensory-28/JJ||iv-36/NN	ccomp||affected-20/VBN||determine-38/VB	det||form-41/NN||a-39/DT	amod||form-41/NN||congenital-40/JJ	dobj||determine-38/VB||form-41/NN	amod||pain-44/NN||severe-43/JJ	prep_of||form-41/NN||pain-44/NN	advmod||determine-38/VB||insensitivity-45/RB	amod||retardation-49/NN||mental-48/JJ	prep_with||determine-38/VB||retardation-49/NN	mark||determines-68/VBZ||while-51/IN	det||mutation-53/NN||a-52/DT	nsubj||determines-68/VBZ||mutation-53/NN	amod||gene-56/NN||ngfb-55/JJ	prep_in||mutation-53/NN||gene-56/NN	vmod||determines-68/VBZ||leading-58/VBG	det||r100w-63/NN||the-60/DT	amod||r100w-63/NN||aminoacid-61/JJ	nn||r100w-63/NN||substitution-62/NN	prep_to||leading-58/VBG||r100w-63/NN	amod||ngf-66/NN||mature-65/JJ	prep_in||r100w-63/NN||ngf-66/NN	dep||retardation-49/NN||determines-68/VBZ	det||loss-71/NN||a-69/DT	amod||loss-71/NN||similar-70/JJ	dobj||determines-68/VBZ||loss-71/NN	nn||perception-74/NN||pain-73/NN	prep_of||loss-71/NN||perception-74/NN	amod||cognitive-78/JJ||overt-77/JJ	amod||defects-80/NNS||cognitive-78/JJ	amod||defects-80/NNS||neurological-79/JJ	prep_without||determines-68/VBZ||defects-80/NNS	nn||v-83/NN||hsan-82/NN	appos||defects-80/NNS||v-83/NN	pain-73||aminoacid-61||no_rel||the relationship between ngf and pain is supported by genetic evidence mutations in the ngf trka receptor in patients affected by an hereditary rare disease (hereditary sensory and autonomic neuropathy type iv, hsan iv) determine a congenital form of severe pain insensitivity, with mental retardation, while a mutation in ngfb gene, leading to the aminoacid substitution r100w in mature ngf, determines a similar loss of pain perception, without overt cognitive neurological defects (hsan v).
nsubj||epitopes-5/VBZ||recognition-1/NN	amod||pres1-4/NNS||several-3/JJ	prep_of||recognition-1/NN||pres1-4/NNS	root||ROOT-0/null||epitopes-5/VBZ	prep_in||accompanied-35/VBN||particular-9/JJ	det||epitope-12/NN||the-11/DT	nsubjpass||accompanied-35/VBN||epitope-12/NN	vmod||epitope-12/NN||contained-13/VBN	det||half-17/NN||the-15/DT	amod||half-17/NN||second-16/JJ	prep_within||contained-13/VBN||half-17/NN	det||site-22/NN||the-19/DT	amod||binding-21/JJ||hepatocyte-20/JJ	amod||site-22/NN||binding-21/JJ	prep_of||half-17/NN||site-22/NN	amod||site-22/NN||localised-23/JJ	det||protein-28/NN||the-25/DT	amod||protein-28/NN||hepatitisb-26/JJ	nn||protein-28/NN||surface-27/NN	prep_in||localised-23/JJ||protein-28/NN	det||vaccine-33/NN||the-30/DT	amod||vaccine-33/NN||third-generation-31/JJ	nn||vaccine-33/NN||hepatitisb-32/NN	prep_of||protein-28/NN||vaccine-33/NN	auxpass||accompanied-35/VBN||is-34/VBZ	conj_and||epitopes-5/VBZ||accompanied-35/VBN	det||response-41/NN||a-37/DT	advmod||pronounced-39/JJ||more-38/RBR	amod||response-41/NN||pronounced-39/JJ	nn||response-41/NN||antibody-40/NN	agent||accompanied-35/VBN||response-41/NN	det||protein-45/NN||the-43/DT	amod||protein-45/NN||s-gene-derived-44/JJ	prep_to||accompanied-35/VBN||protein-45/NN	amod||newborns-48/NNS||healthy-47/JJ	prep_in||protein-45/NN||newborns-48/NNS	hepatitisb-32||hepatitisbvaccine--1||yes||recognition of several pres1 epitopes, and in particular, the epitope contained within the second half of the hepatocyte binding site localised in the hepatitisb surface protein of the third-generation hepatitisb vaccine is accompanied by a more pronounced antibody response to the s-gene-derived protein in healthy newborns.
nsubj||tool-5/NN||mdct-1/NN	cop||tool-5/NN||is-2/VBZ	det||tool-5/NN||a-3/DT	amod||tool-5/NN||useful-4/JJ	root||ROOT-0/null||tool-5/NN	prepc_in||tool-5/NN||detecting-7/VBG	dobj||detecting-7/VBG||findings-8/NNS	prep_of||findings-8/NNS||silicosis-10/NNS	prep_in||silicosis-10/NNS||workers-12/NNS	nsubj||has-14/VBZ||workers-12/NNS	rcmod||workers-12/NNS||has-14/VBZ	nn||exposure-16/NN||silica-15/NN	dobj||has-14/VBZ||exposure-16/NN	silicosis-10||silica-15||no||mdct is a useful tool in detecting findings of silicosis in workers who has silica exposure.
amod||evidence-3/NN||available-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||favours-11/VBZ||evidence-3/NN	vmod||evidence-3/NN||supported-5/VBN	amod||guidelines-8/NNS||current-7/JJ	agent||supported-5/VBN||guidelines-8/NNS	advmod||favours-11/VBZ||strongly-10/RB	root||ROOT-0/null||favours-11/VBZ	det||initiation-13/NN||the-12/DT	dobj||favours-11/VBZ||initiation-13/NN	amod||therapy-16/NN||antidiabetic-15/JJ	prep_of||initiation-13/NN||therapy-16/NN	prep_with||favours-11/VBZ||metformin-18/NN	amod||patients-23/NNS||middle-20/JJ	amod||patients-23/NNS||eastern-21/JJ	amod||patients-23/NNS||type2diabetes-22/JJ	prep_in||metformin-18/NN||patients-23/NNS	advmod||exist-28/VBP||where-25/WRB	neg||contraindications-27/NNS||no-26/DT	nsubj||exist-28/VBP||contraindications-27/NNS	rcmod||patients-23/NNS||exist-28/VBP	type2diabetes-22||metformin-18||yes||available clinical evidence, supported by current guidelines, strongly favours the initiation of antidiabetic therapy with metformin in middle eastern type2diabetes patients, where no contraindications exist.
nsubj||agent-5/NN||bartonellabacilliformis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiological-4/JJ	root||ROOT-0/null||agent-5/NN	amod||bartonellosis-8/NNS||human-7/JJ	prep_of||agent-5/NN||bartonellosis-8/NNS	nsubj||endemic-13/JJ||bartonellosis-8/NNS	cop||endemic-13/JJ||is-11/VBZ	advmod||endemic-13/JJ||highly-12/RB	rcmod||bartonellosis-8/NNS||endemic-13/JJ	prep_to||endemic-13/JJ||peru-15/JJ	bartonellosis-8||bartonellabacilliformis-1||no||bartonellabacilliformis is the etiological agent of human bartonellosis, which is highly endemic to peru.
root||ROOT-0/null||objective-1/NN	aux||determine-3/VB||to-2/TO	dep||objective-1/NN||determine-3/VB	det||efficacy-5/NN||the-4/DT	dobj||determine-3/VB||efficacy-5/NN	nn||treatment-8/NN||statin-7/NN	prep_of||efficacy-5/NN||treatment-8/NN	prep_on||determine-3/VB||risk-10/NN	prep_of||risk-10/NN||coronaryheartdisease-12/NN	prep_in||determine-3/VB||patients-14/NNS	amod||hypercholesterolaemia-17/NN||familial-16/JJ	prep_with||patients-14/NNS||hypercholesterolaemia-17/NN	coronaryheartdisease-12||statin-7||no_rel||objective to determine the efficacy of statin treatment on risk of coronaryheartdisease in patients with familial hypercholesterolaemia.
amod||regimens-2/NNS||efavirenz-based-1/JJ	nsubjpass||associated-11/VBN||regimens-2/NNS	neg||aids-6/NNS||no-4/DT	amod||aids-6/NNS||clinical-5/JJ	conj_and||regimens-2/NNS||aids-6/NNS	nsubjpass||associated-11/VBN||aids-6/NNS	amod||initiation-9/NN||haart-8/JJ	prep_at||aids-6/NNS||initiation-9/NN	auxpass||associated-11/VBN||were-10/VBD	root||ROOT-0/null||associated-11/VBN	amod||risk-14/NN||lower-13/JJR	prep_with||associated-11/VBN||risk-14/NN	prep_of||risk-14/NN||change-16/NN	nn||ratio-19/NN||hazard-18/NN	dep||risk-14/NN||ratio-19/NN	discourse||ratio-19/NN||hr-21/UH	rcmod||ratio-19/NN||â-23/VBP	num||â-27/NN||$-24/$	number||=-26/CD||š-25/CD	num||$-24/$||=-26/CD	dobj||â-23/VBP||â-27/NN	amod||â-27/NN||$-28/$	number||.7-30/CD||š1-29/CD	num||$-28/$||.7-30/CD	num||%-33/NN||95-32/CD	dep||$-28/$||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||1.1-35/FW	dep||%-33/NN||â-36/FW	dep||â-36/FW||$-37/$	num||$-37/$||2.6-39/CD	dobj||â-23/VBP||2.1-42/CD	conj_and||â-27/NN||2.1-42/CD	num||%-45/NN||95-44/CD	dep||2.1-42/CD||%-45/NN	vmod||%-45/NN||ci-46/VBN	num||â-48/NNS||1.7-47/CD	dobj||ci-46/VBN||â-48/NNS	num||â-48/NNS||$-49/$	num||$-49/$||2.5-51/CD	vmod||2.1-42/CD||comparing-53/VBG	amod||regimens-55/NNS||neverapine-based-54/JJ	dobj||comparing-53/VBG||regimens-55/NNS	amod||regimens-58/NNS||other-57/JJ	dobj||comparing-53/VBG||regimens-58/NNS	conj_and||regimens-55/NNS||regimens-58/NNS	prep_to||comparing-53/VBG||efavirenz-60/NN	advmod||comparing-53/VBG||respectively-62/RB	nn||â-68/FW||hrâ-64/FW	nn||â-68/FW||$-65/FW	nn||â-68/FW||š-66/FW	nn||â-68/FW||=-67/FW	dobj||â-23/VBP||â-68/FW	conj_and||â-27/NN||â-68/FW	dep||â-68/FW||$-69/$	number||.3-71/CD||š1-70/CD	num||$-69/$||.3-71/CD	num||%-74/NN||95-73/CD	dep||â-27/NN||%-74/NN	vmod||%-74/NN||ci-75/VBN	num||â-77/NNS||1.1-76/CD	dobj||ci-75/VBN||â-77/NNS	num||â-77/NNS||$-78/$	num||$-78/$||1.5-80/CD	amod||aids-84/NNS||clinical-83/JJ	prep_for||ratio-19/NN||aids-84/NNS	amod||initiation-87/NN||haart-86/JJ	prep_at||aids-84/NNS||initiation-87/NN	aids-84||efavirenz-60||yes||efavirenz-based regimens and no clinical aids at haart initiation were associated with lower risk of change (hazard ratio (hr)â€š=â€š1.7 (95% ci 1.1â€“2.6) and 2.1 (95% ci 1.7â€“2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; hrâ€š=â€š1.3 (95% ci 1.1â€“1.5) for clinical aids at haart initiation).
amod||studies-2/NNS||autopsy-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	nsubj||dysregulation-36/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||infect-14/VB||that-5/IN	amod||avianinfluenzavirus-9/NNS||human-6/JJ	advmod||pathogenic-8/JJ||highly-7/RB	amod||avianinfluenzavirus-9/NNS||pathogenic-8/JJ	nsubj||infect-14/VB||avianinfluenzavirus-9/NNS	appos||avianinfluenzavirus-9/NNS||h5n1-11/NNP	aux||infect-14/VB||can-13/MD	ccomp||shown-4/VBN||infect-14/VB	amod||organs-17/NNS||multiple-15/JJ	amod||organs-17/NNS||human-16/JJ	dobj||infect-14/VB||organs-17/NNS	amod||organs-17/NNS||other-18/JJ	advmod||lungs-22/NNS||just-20/RB	det||lungs-22/NNS||the-21/DT	prep_than||infect-14/VB||lungs-22/NNS	mark||replication-34/NN||that-25/IN	amod||causes-27/NNS||possible-26/JJ	nsubj||replication-34/NN||causes-27/NNS	nn||damage-30/NN||organ-29/NN	prep_of||causes-27/NNS||damage-30/NN	cop||replication-34/NN||are-31/VBP	det||replication-34/NN||either-32/DT	amod||replication-34/NN||viral-33/JJ	ccomp||shown-4/VBN||replication-34/NN	conj_and||infect-14/VB||replication-34/NN	conj_and/or||shown-4/VBN||dysregulation-36/VBN	prep_of||dysregulation-36/VBN||cytokines-38/NNS	prep_of||dysregulation-36/VBN||chemokines-40/NNS	conj_and||cytokines-38/NNS||chemokines-40/NNS	h5n1-11||avianinfluenzavirus-9||no||autopsy studies have shown that human highly pathogenic avianinfluenzavirus (h5n1) can infect multiple human organs other than just the lungs, and that possible causes of organ damage are either viral replication and/or dysregulation of cytokines and chemokines.
det||combination-2/NN||the-1/DT	nsubjpass||introduced-8/VBN||combination-2/NN	prep_of||combination-2/NN||artesunate-4/NN	prep_of||combination-2/NN||mefloquine-6/NN	conj_and||artesunate-4/NN||mefloquine-6/NN	auxpass||introduced-8/VBN||was-7/VBD	root||ROOT-0/null||introduced-8/VBN	det||treatment-13/NN||the-10/DT	amod||treatment-13/NN||national-11/JJ	amod||treatment-13/NN||first-line-12/JJ	prep_as||introduced-8/VBN||treatment-13/NN	prep_for||treatment-13/NN||plasmodiumfalciparummalaria-15/NN	prep_in||introduced-8/VBN||cambodia-17/NN	prep_in||cambodia-17/NN||2000-19/CD	plasmodiumfalciparummalaria-15||mefloquine-6||yes||the combination of artesunate and mefloquine was introduced as the national first-line treatment for plasmodiumfalciparummalaria in cambodia in 2000.
det||total-2/NN||a-1/DT	nsubjpass||studied-13/VBN||total-2/NN	nsubjpass||analyzed-28/VBD||total-2/NN	nsubj||identify-30/VB||total-2/NN	num||patients-5/NNS||170-4/CD	prep_of||total-2/NN||patients-5/NNS	amod||allergies-8/NNS||various-7/JJ	prep_with||patients-5/NNS||allergies-8/NNS	amod||conditions-11/NNS||asthmatic-10/JJ	prep_with||patients-5/NNS||conditions-11/NNS	conj_and||allergies-8/NNS||conditions-11/NNS	auxpass||studied-13/VBN||were-12/VBD	root||ROOT-0/null||studied-13/VBN	nsubj||using-22/VBG||cytokines-16/NNS	det||serum-19/NN||the-18/DT	prep_in||cytokines-16/NNS||serum-19/NN	prep_by||serum-19/NN||elisa-21/NN	prepc_for||studied-13/VBN||using-22/VBG	dobj||using-22/VBG||kits-23/NNS	prep_from||using-22/VBG||immunotech-25/NN	conj_and||studied-13/VBN||analyzed-28/VBD	aux||identify-30/VB||to-29/TO	xcomp||analyzed-28/VBD||identify-30/VB	det||factors-33/NNS||the-31/DT	amod||factors-33/NNS||triggering-32/VBG	dobj||identify-30/VB||factors-33/NNS	amod||contributors-36/NNS||main-35/JJ	dobj||identify-30/VB||contributors-36/NNS	conj_or||factors-33/NNS||contributors-36/NNS	prep_towards||contributors-36/NNS||allergy-38/NN	prep_towards||contributors-36/NNS||asthma-40/NN	conj_and||allergy-38/NN||asthma-40/NN	allergies-8||allergy-38||no||a total of 170 patients with various allergies and asthmatic conditions were studied, for cytokines in the serum by elisa using kits from immunotech, and analyzed to identify the triggering factors or main contributors towards allergy and asthma.
advmod||shown-12/VBN||additionally-1/RB	det||capacity-5/NN||the-3/DT	amod||capacity-5/NN||immunosuppressive-4/JJ	nsubjpass||shown-12/VBN||capacity-5/NN	nsubjpass||increased-15/VBN||capacity-5/NN	amod||cells-9/NNS||feline-7/JJ	nn||cells-9/NNS||treg-8/NN	prep_of||capacity-5/NN||cells-9/NNS	aux||shown-12/VBN||has-10/VBZ	auxpass||shown-12/VBN||been-11/VBN	root||ROOT-0/null||shown-12/VBN	aux||increased-15/VBN||to-13/TO	auxpass||increased-15/VBN||be-14/VB	xcomp||shown-12/VBN||increased-15/VBN	prep_during||increased-15/VBN||fivinfection-17/NN	fivinfection-17||immunosuppressive-4||no_rel||additionally, the immunosuppressive capacity of feline treg cells has been shown to be increased during fivinfection.
amod||levels-4/NNS||mean-1/JJ	nn||levels-4/NNS||serum-2/NN	nn||levels-4/NNS||vldl-tg-3/NN	nsubj||tended-5/VBD||levels-4/NNS	nsubj||decrease-7/VB||levels-4/NNS	root||ROOT-0/null||tended-5/VBD	aux||decrease-7/VB||to-6/TO	xcomp||tended-5/VBD||decrease-7/VB	nn||progression-10/NN||disease-9/NN	prep_with||decrease-7/VB||progression-10/NN	prep_from||progression-10/NN||f1-12/CD	prep_to||decrease-7/VB||f4-14/NNS	appos||f4-14/NNS||cirrhosis-16/NNS	tg--1||cirrhosis-16||no_rel||mean serum vldl-tg levels tended to decrease with disease progression from f1 to f4 (cirrhosis).
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||efficacy-13/NN||urate-lowering-9/JJ	appos||efficacy-13/NN||ul-11/NN	dobj||compare-8/VB||efficacy-13/NN	dobj||compare-8/VB||safety-15/NN	conj_and||efficacy-13/NN||safety-15/NN	amod||febuxostat-18/NN||daily-17/JJ	prep_of||safety-15/NN||febuxostat-18/NN	amod||mg/dl-35/NNS||allopurinol-20/JJ	prep_in||allopurinol-20/JJ||subjects-22/NNS	prep_with||subjects-22/NNS||gout-24/NN	prep_with||subjects-22/NNS||serum-26/NN	conj_and||gout-24/NN||serum-26/NN	amod||mg/dl-35/NNS||urate-27/JJ	appos||mg/dl-35/NNS||sua-29/NN	nn||mg/dl-35/NNS||â-31/NN	nn||mg/dl-35/NNS||‰-32/NNP	nn||mg/dl-35/NNS||¥-33/NNP	num||mg/dl-35/NNS||8.0-34/CD	dobj||compare-8/VB||mg/dl-35/NNS	conj_and||efficacy-13/NN||mg/dl-35/NNS	det||trial-39/NN||a-37/DT	amod||trial-39/NN||six-month-38/JJ	prep_in||mg/dl-35/NNS||trial-39/NN	gout-24||allopurinol-20||yes||the purpose of this study was to compare urate-lowering (ul) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sua) â‰¥ 8.0 mg/dl in a six-month trial.
nn||bovis-2/NNS||m.-1/NN	nsubj||bacille-3/VBP||bovis-2/NNS	root||ROOT-0/null||bacille-3/VBP	nn||-rrb--9/NNP||calmette-guã-4/NNP	nn||-rrb--9/NNP||©-5/NNP	nn||-rrb--9/NNP||rin-6/NNP	nn||-rrb--9/NNP||-lrb--7/NNP	nn||-rrb--9/NNP||bcg-8/NNP	nsubj||fails-22/VBZ||-rrb--9/NNP	nsubj||protect-25/VB||-rrb--9/NNP	advmod||vaccine-15/NN||currently-11/RB	det||vaccine-15/NN||the-12/DT	advmod||available-14/JJ||only-13/RB	amod||vaccine-15/NN||available-14/JJ	appos||-rrb--9/NNP||vaccine-15/NN	nn||-rrb--20/NNP||tuberculosis-17/NNP	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||tb-19/NNP	prep_against||vaccine-15/NN||-rrb--20/NNP	ccomp||bacille-3/VBP||fails-22/VBZ	aux||protect-25/VB||to-23/TO	advmod||protect-25/VB||adequately-24/RB	xcomp||fails-22/VBZ||protect-25/VB	dobj||protect-25/VB||individuals-26/NNS	amod||infection-32/NN||active-28/JJ	conj_and||active-28/JJ||latent-30/JJ	amod||infection-32/NN||latent-30/JJ	nn||infection-32/NN||tb-31/NN	prep_from||protect-25/VB||infection-32/NN	tb-31||bcg-8||no||m. bovis bacille calmette-guã © rin -lrb- bcg -rrb- , currently the only available vaccine against tuberculosis -lrb- tb -rrb- , fails to adequately protect individuals from active and latent tb infection .
det||exception-3/NN||the-2/DT	prep_with||effective-11/JJ||exception-3/NN	amod||angioplasty-6/NN||primary-5/JJ	prep_of||exception-3/NN||angioplasty-6/NN	nsubj||effective-11/JJ||fondaparinux-8/NN	nsubjpass||associated-20/VBN||fondaparinux-8/NN	cop||effective-11/JJ||is-9/VBZ	advmod||effective-11/JJ||as-10/RB	root||ROOT-0/null||effective-11/JJ	prep_as||effective-11/JJ||enoxaparin-13/NN	prep_as||effective-11/JJ||ufh-15/NN	conj_or||enoxaparin-13/NN||ufh-15/NN	auxpass||associated-20/VBN||is-18/VBZ	advmod||associated-20/VBN||also-19/RB	conj_but||effective-11/JJ||associated-20/VBN	det||reduction-24/NN||a-22/DT	amod||reduction-24/NN||considerable-23/JJ	prep_with||associated-20/VBN||reduction-24/NN	amod||complications-27/NNS||bleeding-26/VBG	prep_in||reduction-24/NN||complications-27/NNS	advmod||effective-11/JJ||thus-30/RB	conj_and||effective-11/JJ||thus-30/RB	det||benefit-36/NN||an-32/DT	amod||benefit-36/NN||undeniable-33/JJ	amod||benefit-36/NN||net-34/JJ	amod||benefit-36/NN||clinical-35/JJ	conj_and||effective-11/JJ||benefit-36/NN	dobj||effective-11/JJ||benefit-36/NN	enoxaparin-13||bleeding-26||no_rel||with the exception of primary angioplasty, fondaparinux is as effective as enoxaparin or ufh, but is also associated with a considerable reduction in bleeding complications, and thus, an undeniable net clinical benefit.
nsubj||osteoporosis-13/NNS||one-1/CD	poss||effects-10/NNS||their-3/PRP$	advmod||common-5/JJ||most-4/RBS	amod||effects-10/NNS||common-5/JJ	advmod||significant-8/JJ||clinically-7/RB	conj_and||common-5/JJ||significant-8/JJ	amod||effects-10/NNS||significant-8/JJ	nn||effects-10/NNS||side-9/NN	prep_of||one-1/CD||effects-10/NNS	cop||osteoporosis-13/NNS||is-11/VBZ	amod||osteoporosis-13/NNS||glucocorticoid-induced-12/JJ	root||ROOT-0/null||osteoporosis-13/NNS	appos||osteoporosis-13/NNS||giop-15/NN	osteoporosis-13||glucocorticoid--1||no_rel||one of their most common and clinically significant side effects is glucocorticoid-induced osteoporosis (giop).
nn||vaccination-2/NN||bcg-1/NN	nsubj||represents-9/VBZ||vaccination-2/NN	vmod||vaccination-2/NN||combined-4/VBN	amod||boosts-7/NNS||adenoviral-delivered-6/JJ	prep_with||combined-4/VBN||boosts-7/NNS	root||ROOT-0/null||represents-9/VBZ	det||strategy-12/NN||a-10/DT	amod||strategy-12/NN||reasonable-11/JJ	dobj||represents-9/VBZ||strategy-12/NN	aux||augment-14/VB||to-13/TO	vmod||strategy-12/NN||augment-14/VB	vmod||strategy-12/NN||broaden-16/VB	conj_and||augment-14/VB||broaden-16/VB	vmod||strategy-12/NN||prolong-18/VB	conj_and||augment-14/VB||prolong-18/VB	amod||protection-20/NN||immune-19/JJ	dobj||augment-14/VB||protection-20/NN	prep_against||augment-14/VB||tuberculosis-22/NNP	appos||tuberculosis-22/NNP||tb-24/NN	tuberculosis-22||bcg-1||no||bcg vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (tb).
nsubj||stress-2/NN||we-1/PRP	root||ROOT-0/null||stress-2/NN	det||importance-4/NN||the-3/DT	dobj||stress-2/NN||importance-4/NN	amod||diagnosis-7/NN||early-6/JJ	prep_of||importance-4/NN||diagnosis-7/NN	prep_of||diagnosis-7/NN||csvt-9/NN	xcomp||stress-2/NN||using-10/VBG	dobj||using-10/VBG||ct-11/NN	dobj||using-10/VBG||mri-13/NN	conj_and||ct-11/NN||mri-13/NN	prep_in||ct-11/NN||children-15/NNS	prep_with||using-10/VBG||leukemia-17/NN	auxpass||treated-19/VBN||being-18/VBG	vmod||leukemia-17/NN||treated-19/VBN	prep_with||treated-19/VBN||l-asparaginase-21/NN	nsubj||permit-25/VB||this-23/DT	aux||permit-25/VB||will-24/MD	parataxis||stress-2/NN||permit-25/VB	amod||treatment-27/NN||timely-26/JJ	dobj||permit-25/VB||treatment-27/NN	l-asparaginase-21||leukemia-17||no_rel||we stress the importance of early diagnosis of csvt using ct and mri in children with leukemia being treated with l-asparaginase; this will permit timely treatment.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	det||ã-7/NN||a-5/DT	num||ã-7/NN||3.0-6/CD	dobj||report-4/VBP||ã-7/NN	nn||structure-10/NN||crystal-9/NN	dep||ã-7/NN||structure-10/NN	det||ferritin-13/NN||a-12/DT	prep_of||structure-10/NN||ferritin-13/NN	appos||ã-7/NN||annotated-15/JJ	prep_as||annotated-15/JJ||bacterioferritin-17/NN	dep||annotated-15/JJ||b-18/SYM	appos||annotated-15/JJ||bfrb-20/NN	prep_from||annotated-15/JJ||mycobacteriumtuberculosis-24/NNS	dep||ã-7/NN||mtb-26/VBN	det||agent-31/NN||the-29/DT	amod||agent-31/NN||causative-30/JJ	appos||ã-7/NN||agent-31/NN	nsubj||continues-35/VBZ||agent-31/NN	nsubj||one-38/CD||agent-31/NN	prep_of||agent-31/NN||tuberculosis-33/NNP	rcmod||agent-31/NN||continues-35/VBZ	aux||one-38/CD||to-36/TO	cop||one-38/CD||be-37/VB	xcomp||continues-35/VBZ||one-38/CD	det||world-41/NN||the-40/DT	poss||diseases-44/NNS||world-41/NN	amod||diseases-44/NNS||deadliest-43/JJS	prep_of||one-38/CD||diseases-44/NNS	tuberculosis-33||mycobacteriumtuberculosis-24||no||here, we report a 3.0 ã… crystal structure of a ferritin, annotated as bacterioferritin b (bfrb), from mycobacteriumtuberculosis (mtb), the causative agent of tuberculosis that continues to be one of the world's deadliest diseases.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||no||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
amod||antigen-3/NN||hepatitisb-1/JJ	nn||antigen-3/NN||surface-2/NN	nsubjpass||done-23/VBN||antigen-3/NN	appos||antigen-3/NN||hbsag-5/NN	amod||antigen-10/NN||hepatitisb-8/JJ	nn||antigen-10/NN||envelope-9/NN	appos||antigen-3/NN||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	conj_and||antigen-3/NN||hbv-dna-15/NN	nsubjpass||done-23/VBN||hbv-dna-15/NN	nn||biopsy-19/NN||liver-18/NN	conj_and||antigen-3/NN||biopsy-19/NN	nsubjpass||done-23/VBN||biopsy-19/NN	prep_before||biopsy-19/NN||rt-21/NN	auxpass||done-23/VBN||were-22/VBD	root||ROOT-0/null||done-23/VBN	det||patients-26/NNS||all-25/DT	prep_in||done-23/VBN||patients-26/NNS	hepatitisb-8||hepatitisbsurfaceantigen--1||yes||hepatitisb surface antigen (hbsag), hepatitisb envelope antigen (hbeag), hbv-dna, and liver biopsy before rt were done in all patients.
nsubj||reduced-8/VBD||pretreatment-1/NN	nn||kg-7/NN||sufentanil-3/NN	num||kg-7/NN||0.3-4/CD	nn||kg-7/NN||âµg-5/NN	nn||kg-7/NN||/-6/NN	prep_with||pretreatment-1/NN||kg-7/NN	root||ROOT-0/null||reduced-8/VBD	det||severity-10/NN||the-9/DT	dobj||reduced-8/VBD||severity-10/NN	amod||pain-15/NN||microemulsion-12/JJ	amod||pain-15/NN||propofol-13/JJ	nn||pain-15/NN||injection-14/NN	prep_of||severity-10/NN||pain-15/NN	prepc_without||reduced-8/VBD||increasing-17/VBG	amod||pressure-20/NN||arterial-18/JJ	nn||pressure-20/NN||blood-19/NN	dobj||increasing-17/VBG||pressure-20/NN	nn||rate-23/NN||heart-22/NN	dobj||increasing-17/VBG||rate-23/NN	conj_and||pressure-20/NN||rate-23/NN	amod||intubation-26/NN||endotracheal-25/JJ	prep_after||increasing-17/VBG||intubation-26/NN	pain-15||propofol-13||yes||pretreatment with sufentanil 0.3 âµg/kg reduced the severity of microemulsion propofol injection pain without increasing arterial blood pressure and heart rate after endotracheal intubation.
nn||sodium-2/NN||enoxaparin-1/NN	nsubj||heparin-8/NN||sodium-2/NN	cop||heparin-8/NN||is-3/VBZ	det||heparin-8/NN||a-4/DT	amod||heparin-8/NN||low-5/JJ	amod||heparin-8/NN||molecular-6/JJ	nn||heparin-8/NN||weight-7/NN	root||ROOT-0/null||heparin-8/NN	appos||heparin-8/NN||lmwh-10/NN	prep_for||heparin-8/NN||use-13/NN	prepc_in||use-13/NN||preventing-15/VBG	amod||venousthrombosis-17/NNS||deep-16/JJ	dobj||preventing-15/VBG||venousthrombosis-17/NNS	prep_in||preventing-15/VBG||patients-19/NNS	vmod||patients-19/NNS||undergoing-20/VBG	amod||arthroplasty-23/NN||total-21/JJ	nn||arthroplasty-23/NN||hip-22/NN	dobj||undergoing-20/VBG||arthroplasty-23/NN	amod||arthroplasty-27/NN||total-25/JJ	nn||arthroplasty-27/NN||knee-26/NN	dobj||undergoing-20/VBG||arthroplasty-27/NN	conj_and||arthroplasty-23/NN||arthroplasty-27/NN	venousthrombosis-17||heparin-8||yes||enoxaparin sodium is a low molecular weight heparin (lmwh) for use in preventing deep venousthrombosis in patients undergoing total hip arthroplasty and total knee arthroplasty.
nsubj||reach-6/VB||mice-2/NNS	prep_in||correlate-16/VB||mice-2/NNS	aux||reach-6/VB||did-4/VBD	neg||reach-6/VB||not-5/RB	rcmod||mice-2/NNS||reach-6/VB	nn||stage-8/NN||terminal-7/NN	dobj||reach-6/VB||stage-8/NN	prep_of||stage-8/NN||infection-10/NN	nn||progression-13/NN||tb-12/NN	nsubj||correlate-16/VB||progression-13/NN	aux||correlate-16/VB||did-14/VBD	neg||correlate-16/VB||not-15/RB	root||ROOT-0/null||correlate-16/VB	nn||loads-20/NNS||lung-18/NN	nn||loads-20/NNS||mtb-19/NN	prep_with||correlate-16/VB||loads-20/NNS	tb-12||mtb-19||no||in mice that did not reach terminal stage of infection, tb progression did not correlate with lung mtb loads.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||inhibitory-2/JJ	nsubj||strong-13/JJ||effect-3/NN	nsubj||equivalent-17/JJ||effect-3/NN	det||ligands-6/NNS||these-5/DT	prep_of||effect-3/NN||ligands-6/NNS	amod||production-10/NN||cysteinyl-8/JJ	nn||production-10/NN||leukotriene-9/NN	prep_on||ligands-6/NNS||production-10/NN	cop||strong-13/JJ||is-11/VBZ	advmod||strong-13/JJ||quite-12/RB	root||ROOT-0/null||strong-13/JJ	cop||equivalent-17/JJ||is-15/VBZ	advmod||equivalent-17/JJ||almost-16/RB	conj_and||strong-13/JJ||equivalent-17/JJ	prep_to||equivalent-17/JJ||that-19/DT	det||zileuton-24/NN||the-21/DT	amod||zileuton-24/NN||anti-asthma-22/JJ	nn||zileuton-24/NN||compound-23/NN	prep_of||that-19/DT||zileuton-24/NN	asthma--1||zileuton-24||yes||the inhibitory effect of these ligands on cysteinyl leukotriene production is quite strong and is almost equivalent to that of the anti-asthma compound zileuton.
mark||dependent-9/JJ||although-1/IN	det||response-3/NN||the-2/DT	nsubj||dependent-9/JJ||response-3/NN	nn||treatment-6/NN||interferon-5/NN	prep_to||response-3/NN||treatment-6/NN	cop||dependent-9/JJ||is-7/VBZ	advmod||dependent-9/JJ||largely-8/RB	advcl||remains-31/VBZ||dependent-9/JJ	csubj||remains-31/VBZ||dependent-9/JJ	nn||genotypes-12/NNS||hcv-11/NN	prep_on||dependent-9/JJ||genotypes-12/NNS	mark||exists-19/VBZ||whether-14/IN	ccomp||dependent-9/JJ||not-16/RB	conj_or||exists-19/VBZ||not-16/RB	det||relationship-18/NN||a-17/DT	nsubj||exists-19/VBZ||relationship-18/NN	ccomp||dependent-9/JJ||exists-19/VBZ	nn||variability-23/NN||hcv-21/NN	nn||variability-23/NN||genome-22/NN	prep_between||exists-19/VBZ||variability-23/NN	amod||course-26/NN||clinical-25/JJ	prep_between||exists-19/VBZ||course-26/NN	conj_and||variability-23/NN||course-26/NN	amod||disease-29/NN||hepatitisc-28/JJ	prep_of||variability-23/NN||disease-29/NN	advmod||remains-31/VBZ||still-30/RB	root||ROOT-0/null||remains-31/VBZ	acomp||remains-31/VBZ||unknown-32/JJ	hepatitisc-28||hcv-21||no||although the response to interferon treatment is largely dependent on hcv genotypes, whether or not a relationship exists between hcv genome variability and clinical course of hepatitisc disease still remains unknown.
amod||supplementation-2/NN||leucine-1/JJ	nsubjpass||carried-4/VBN||supplementation-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	prep_in||carried-4/VBN||noncnzo10/ltj-7/NNS	appos||noncnzo10/ltj-7/NNS||rcs10-9/NNP	det||model-14/NN||a-12/DT	amod||model-14/NN||polygenic-13/JJ	prep_in||carried-4/VBN||model-14/NN	conj_and||noncnzo10/ltj-7/NNS||model-14/NN	vmod||model-14/NN||predisposed-15/VBN	amod||failure-19/NN||beta-17/JJ	nn||failure-19/NN||cell-18/NN	prep_to||predisposed-15/VBN||failure-19/NN	prep_in||carried-4/VBN||type2diabetes-21/NNS	conj_and||noncnzo10/ltj-7/NNS||type2diabetes-21/NNS	amod||j-27/NN||b6.cg-ay-25/JJ	amod||j-27/NN||/-26/JJ	prep_in||carried-4/VBN||j-27/NN	conj_and||noncnzo10/ltj-7/NNS||j-27/NN	det||y-30/NN||a-29/DT	appos||j-27/NN||y-30/NN	det||model-35/NN||a-33/DT	amod||model-35/NN||monogenic-34/JJ	conj_and||noncnzo10/ltj-7/NNS||model-35/NN	conj_and||j-27/NN||model-35/NN	amod||receptor-40/NN||impaired-37/VBN	amod||receptor-40/NN||central-38/JJ	nn||receptor-40/NN||melanocortin-39/NN	prep_for||model-35/NN||receptor-40/NN	vmod||receptor-40/NN||signaling-41/VBG	advmod||signaling-41/VBG||obesity-43/RB	amod||insulinresistance-47/NN||severe-46/JJ	conj_and||noncnzo10/ltj-7/NNS||insulinresistance-47/NN	conj_and||j-27/NN||insulinresistance-47/NN	leucine-1||insulinresistance-47||no_rel||leucine supplementation was carried out in noncnzo10/ltj (rcs10) - a polygenic model predisposed to beta cell failure and type2diabetes, and in b6.cg-ay/j ( a y ) - a monogenic model for impaired central melanocortin receptor signaling, obesity, and severe insulinresistance.
nsubj||pathogen-14/NN||staphylococcusaureus-1/NNS	amod||s.aureus-5/NNS||methicillin-resistant-4/JJ	prep_including||staphylococcusaureus-1/NNS||s.aureus-5/NNS	vmod||s.aureus-5/NNS||-lrb--6/VBG	nn||-rrb--8/NNS||mrsa-7/NN	dobj||-lrb--6/VBG||-rrb--8/NNS	cop||pathogen-14/NN||is-10/VBZ	det||pathogen-14/NN||an-11/DT	amod||pathogen-14/NN||important-12/JJ	amod||pathogen-14/NN||human-13/JJ	root||ROOT-0/null||pathogen-14/NN	nsubj||produces-16/VBZ||pathogen-14/NN	nsubj||causes-22/VBZ||pathogen-14/NN	rcmod||pathogen-14/NN||produces-16/VBZ	det||variety-18/NN||a-17/DT	dobj||produces-16/VBZ||variety-18/NN	prep_of||variety-18/NN||toxins-20/NNS	rcmod||pathogen-14/NN||causes-22/VBZ	conj_and||produces-16/VBZ||causes-22/VBZ	det||range-25/NN||a-23/DT	amod||range-25/NN||wide-24/JJ	dobj||causes-22/VBZ||range-25/NN	prep_of||range-25/NN||infections-27/NNS	amod||infections-31/NNS||soft-tissue-30/JJ	prep_including||produces-16/VBZ||infections-31/NNS	prep_including||produces-16/VBZ||bacteremia-33/NN	conj_and||infections-31/NNS||bacteremia-33/NN	amod||poisoning-38/NN||staphylococcal-36/JJ	nn||poisoning-38/NN||food-37/NN	prep_including||produces-16/VBZ||poisoning-38/NN	conj_and||infections-31/NNS||poisoning-38/NN	mrsa-7||staphylococcusaureus-1||no||staphylococcusaureus , including methicillin-resistant s.aureus -lrb- mrsa -rrb- , is an important human pathogen that produces a variety of toxins and causes a wide range of infections , including soft-tissue infections , bacteremia , and staphylococcal food poisoning .
nsubj||important-8/JJ||adherence-1/NN	det||regimen-6/NN||the-3/DT	amod||regimen-6/NN||14-day-4/JJ	nn||regimen-6/NN||primaquine-5/NN	prep_to||adherence-1/NN||regimen-6/NN	cop||important-8/JJ||is-7/VBZ	root||ROOT-0/null||important-8/JJ	det||cure-12/NN||the-10/DT	amod||cure-12/NN||radical-11/JJ	prep_for||important-8/JJ||cure-12/NN	nn||infection-16/NN||p.-14/NN	nn||infection-16/NN||vivaxmalaria-15/NN	prep_of||cure-12/NN||infection-16/NN	vivaxmalaria-15||primaquine-5||yes||adherence to the 14-day primaquine regimen is important for the radical cure of p. vivaxmalaria infection .
nsubjpass||evaluated-3/VBN||subjects-1/NNS	auxpass||evaluated-3/VBN||were-2/VBD	root||ROOT-0/null||evaluated-3/VBN	prep_for||evaluated-3/VBN||diabeticnephropathy-5/NN	amod||rate-11/NN||24-h-7/JJ	nn||rate-11/NN||urinary-8/NN	nn||rate-11/NN||albumin-9/NN	nn||rate-11/NN||excretion-10/NN	dep||diabeticnephropathy-5/NN||rate-11/NN	prep_for||evaluated-3/VBN||diabeticretinopathy-14/NN	conj_and||diabeticnephropathy-5/NN||diabeticretinopathy-14/NN	dep||diabeticretinopathy-14/NN||classified-16/VBN	prepc_according_to||classified-16/VBN||to-18/TO	det||group-22/NN||the-19/DT	amod||group-22/NN||global-20/JJ	nn||group-22/NN||diabeticretinopathy-21/NN	pobj||classified-16/VBN||group-22/NN	diabeticretinopathy-21||albumin-9||no_rel||subjects were evaluated for diabeticnephropathy (24-h urinary albumin excretion rate) and diabeticretinopathy (classified according to the global diabeticretinopathy group).
amod||therapy-2/NN||medical-1/JJ	nsubj||useful-6/JJ||therapy-2/NN	aux||useful-6/JJ||can-3/MD	cop||useful-6/JJ||be-4/VB	advmod||useful-6/JJ||also-5/RB	root||ROOT-0/null||useful-6/JJ	prep_in||useful-6/JJ||patients-8/NNS	nn||while-11/NN||cd-10/NN	prep_with||patients-8/NNS||while-11/NN	vmod||while-11/NN||waiting-12/VBG	amod||radiotherapy-15/NN||pituitary-14/JJ	prep_for||waiting-12/VBG||radiotherapy-15/NN	aux||take-17/VB||to-16/TO	xcomp||waiting-12/VBG||take-17/VB	dobj||take-17/VB||effect-18/NN	nsubj||take-22/VB||effect-18/NN	aux||take-22/VB||can-21/MD	rcmod||effect-18/NN||take-22/VB	prt||take-22/VB||up-23/RP	num||years-26/NNS||10-25/CD	prep_to||take-22/VB||years-26/NNS	cc||more-28/JJR||or-27/CC	num||years-26/NNS||more-28/JJR	cd-10||pituitary-14||no_rel||medical therapy can be also useful in patients with cd while waiting for pituitary radiotherapy to take effect, which can take up to 10 years or more.
advmod||significantly-2/RB||more-1/RBR	advmod||open-6/VB||significantly-2/RB	nsubj||open-6/VB||this-4/DT	aux||open-6/VB||would-5/MD	root||ROOT-0/null||open-6/VB	det||door-8/NN||the-7/DT	dobj||open-6/VB||door-8/NN	det||â-12/NN||a-10/DT	amod||â-12/NN||wider-11/JJR	prep_to||open-6/VB||â-12/NN	amod||â-12/NN||$-13/$	dep||$-13/$||œanti-metastaticâ-14/JJ	dobj||open-6/VB||$-15/$	nsubj||have-19/VB||$-15/$	num||$-15/$||approach-16/CD	aux||have-19/VB||could-18/MD	rcmod||$-15/$||have-19/VB	advmod||greater-21/JJR||much-20/RB	amod||impact-22/NN||greater-21/JJR	dobj||have-19/VB||impact-22/NN	prep_in||impact-22/NN||patients-24/NNS	amod||disease-27/NN||minimal-26/JJ	prep_with||patients-24/NNS||disease-27/NN	auxpass||treated-29/VBN||being-28/VBG	vmod||disease-27/NN||treated-29/VBN	amod||settings-32/NNS||adjuvant-31/JJ	prep_in||treated-29/VBN||settings-32/NNS	det||malignancies-37/NNS||the-34/DT	advmod||common-36/JJ||more-35/RBR	amod||malignancies-37/NNS||common-36/JJ	prep_for||settings-32/NNS||malignancies-37/NNS	nn||cancer-43/NN||breast-40/NN	conj_and||breast-40/NN||colon-42/NN	nn||cancer-43/NN||colon-42/NN	prep_such_as||malignancies-37/NNS||cancer-43/NN	cancer-43||adjuvant-31||no_rel||more significantly, this would open the door to a wider â€œanti-metastaticâ€? approach that could have much greater impact in patients with minimal disease being treated in adjuvant settings for the more common malignancies such as breast and colon cancer.
advmod||increased-11/VBD||however-1/RB	amod||administration-4/NN||fluoxetine-3/JJ	nsubj||increased-11/VBD||administration-4/NN	advmod||increased-11/VBD||significantly-5/RB	dep||<-8/JJ||p-7/RB	dep||significantly-5/RB||<-8/JJ	dep||<-8/JJ||0.05-9/CD	root||ROOT-0/null||increased-11/VBD	amod||ans-13/NN||key-12/JJ	nn||responses-40/NNS||ans-13/NN	dep||ans-13/NN||epinephrine-15/NN	dep||ans-13/NN||norepinephrine-17/NN	conj_and||epinephrine-15/NN||norepinephrine-17/NN	dep||ans-13/NN||msna-20/NN	conj_and||epinephrine-15/NN||msna-20/NN	conj_and||ans-13/NN||metabolic-23/NN	nn||responses-40/NNS||metabolic-23/NN	amod||production-27/NN||endogenous-25/JJ	nn||production-27/NN||glucose-26/NN	dep||metabolic-23/NN||production-27/NN	dep||metabolic-23/NN||lipolysis-29/NNS	conj_and||production-27/NN||lipolysis-29/NNS	amod||counterregulatory-39/NN||cardiovascular-33/JJ	amod||pressure-37/NN||systolic-35/JJ	nn||pressure-37/NN||blood-36/NN	appos||counterregulatory-39/NN||pressure-37/NN	conj_and||ans-13/NN||counterregulatory-39/NN	nn||responses-40/NNS||counterregulatory-39/NN	dobj||increased-11/VBD||responses-40/NNS	prep_during||increased-11/VBD||hypoglycemia-42/NN	hypoglycemia-42||glucose-26||yes||however, fluoxetine administration significantly ( p < 0.05) increased key ans (epinephrine, norepinephrine, and msna), metabolic (endogenous glucose production and lipolysis), and cardiovascular (systolic blood pressure) counterregulatory responses during hypoglycemia.
nsubjpass||known-9/VBN||macrophages-1/NNS	nsubj||refractory-12/JJ||macrophages-1/NNS	nsubj||ifn-î-14/VB||macrophages-1/NNS	vmod||macrophages-1/NNS||infected-2/VBN	prep_with||infected-2/VBN||mycobacteriumtuberculosis-4/NNS	appos||macrophages-1/NNS||m.tb-6/NN	auxpass||known-9/VBN||are-8/VBP	root||ROOT-0/null||known-9/VBN	aux||refractory-12/JJ||to-10/TO	cop||refractory-12/JJ||be-11/VB	xcomp||known-9/VBN||refractory-12/JJ	aux||ifn-î-14/VB||to-13/TO	xcomp||refractory-12/JJ||ifn-î-14/VB	amod||stimulation-16/NN||³-15/JJ	dobj||ifn-î-14/VB||stimulation-16/NN	tb--1||mycobacteriumtuberculosis-4||no||macrophages infected with mycobacteriumtuberculosis ( m.tb ) are known to be refractory to ifn-î³ stimulation.
advmod||conclude-4/VBP||therefore-1/RB	nsubj||conclude-4/VBP||we-3/PRP	root||ROOT-0/null||conclude-4/VBP	mark||counteracts-7/VBZ||that-5/IN	nsubj||counteracts-7/VBZ||p-cadherin-6/NN	ccomp||conclude-4/VBP||counteracts-7/VBZ	det||expression-9/NN||the-8/DT	dobj||counteracts-7/VBZ||expression-9/NN	dobj||counteracts-7/VBZ||function-11/NN	conj_and||expression-9/NN||function-11/NN	nn||ii-b-14/NN||myosin-13/NN	prep_of||expression-9/NN||ii-b-14/NN	vmod||counteracts-7/VBZ||resulting-16/VBG	det||suppression-19/NN||the-18/DT	prep_in||resulting-16/VBG||suppression-19/NN	det||behaviour-25/NN||the-21/DT	amod||behaviour-25/NN||invasive-22/JJ	conj_and||invasive-22/JJ||migratory-24/JJ	amod||behaviour-25/NN||migratory-24/JJ	prep_of||suppression-19/NN||behaviour-25/NN	nn||cells-29/NNS||blm-27/NN	nn||cells-29/NNS||melanoma-28/NN	prep_of||behaviour-25/NN||cells-29/NNS	melanoma-28||blm-27||yes||therefore, we conclude that p-cadherin counteracts the expression and function of myosin ii-b, resulting in the suppression of the invasive and migratory behaviour of blm melanoma cells
det||goals-2/NNS||the-1/DT	nsubj||were-6/VBD||goals-2/NNS	det||study-5/NN||this-4/DT	prep_of||goals-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||examine-8/VB||to-7/TO	ccomp||were-6/VBD||examine-8/VB	det||influence-10/NN||the-9/DT	dobj||examine-8/VB||influence-10/NN	amod||type1diabetes-13/NNS||maternal-12/JJ	prep_of||influence-10/NN||type1diabetes-13/NNS	prep_during||examine-8/VB||pregnancy-15/NN	nn||adiposity-18/NN||offspring-17/NN	prep_on||examine-8/VB||adiposity-18/NN	nn||tolerance-21/NN||glucose-20/NN	prep_on||examine-8/VB||tolerance-21/NN	conj_and||adiposity-18/NN||tolerance-21/NN	prep_at||adiposity-18/NN||age-23/NN	num||years-25/NNS||7-24/CD	dep||adiposity-18/NN||years-25/NNS	aux||assess-28/VB||to-27/TO	ccomp||were-6/VBD||assess-28/VB	conj_and||examine-8/VB||assess-28/VB	mark||predict-40/VBP||whether-29/IN	amod||factors-31/NNS||metabolic-30/JJ	nsubj||predict-40/VBP||factors-31/NNS	prep_at||factors-31/NNS||birth-33/NN	amod||leptin-36/NNS||neonatal-35/JJ	appos||birth-33/NN||leptin-36/NNS	appos||birth-33/NN||insulin-38/NN	conj_and||leptin-36/NNS||insulin-38/NN	ccomp||assess-28/VB||predict-40/VBP	amod||outcomes-42/NNS||adverse-41/JJ	dobj||predict-40/VBP||outcomes-42/NNS	type1diabetes-13||insulin-38||yes||the goals of this study were to examine the influence of maternal type1diabetes during pregnancy on offspring adiposity and glucose tolerance at age 7 years and to assess whether metabolic factors at birth (neonatal leptin and insulin) predict adverse outcomes.
det||prevalence-2/NN||the-1/DT	nsubj||%-10/NN||prevalence-2/NN	prep_of||prevalence-2/NN||tb-4/NN	amod||population-7/NN||hiv/aids-6/JJ	prep_among||tb-4/NN||population-7/NN	cop||%-10/NN||was-8/VBD	number||%-10/NN||7.2-9/CD	root||ROOT-0/null||%-10/NN	num||%-13/NN||4.2-12/CD	npadvmod||â-14/RB||%-13/NN	dep||%-18/NN||â-14/RB	dep||%-18/NN||$-15/$	num||$-15/$||12.3-17/CD	dep||%-10/NN||%-18/NN	nsubj||higher-25/JJR||this-22/DT	cop||higher-25/JJR||was-23/VBD	advmod||higher-25/JJR||much-24/RB	conj_but||%-10/NN||higher-25/JJR	advmod||restricted-30/VBN||when-26/WRB	det||analyses-28/NNS||the-27/DT	nsubjpass||restricted-30/VBN||analyses-28/NNS	auxpass||restricted-30/VBN||were-29/VBD	ccomp||higher-25/JJR||restricted-30/VBN	nn||patients-33/NNS||aids-32/NNS	prep_to||restricted-30/VBN||patients-33/NNS	num||%-36/NN||22.8-35/CD	appos||patients-33/NNS||%-36/NN	aids-32||hiv--1||no||the prevalence of tb among hiv/aids population was 7.2% (4.2%â€“12.3%), but this was much higher when the analyses were restricted to aids patients (22.8%).
prep_in||persisted-5/VBD||addition-2/NN	nsubj||persisted-5/VBD||pleuraleffusion-4/NN	root||ROOT-0/null||persisted-5/VBD	num||weeks-10/NNS||4-9/CD	prep_in_spite_of||persisted-5/VBD||weeks-10/NNS	prep_of||weeks-10/NNS||drainage-12/NN	det||tube-16/NN||the-14/DT	amod||tube-16/NN||thoracotomy-15/JJ	prep_through||persisted-5/VBD||tube-16/NN	amod||pleurodesis-19/NNS||talc-18/JJ	prep_through||persisted-5/VBD||pleurodesis-19/NNS	conj_and||tube-16/NN||pleurodesis-19/NNS	pleuraleffusion-4||talc-18||yes||in addition, pleuraleffusion persisted in spite of 4 weeks of drainage through the thoracotomy tube and talc pleurodesis.
det||results-2/NNS||the-1/DT	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||ability-9/NN||the-4/DT	amod||ability-9/NN||monitorâ-5/JJ	amod||ability-9/NN||$-6/$	number||s-8/CD||™-7/CD	num||$-6/$||s-8/CD	dobj||demonstrate-3/VBP||ability-9/NN	aux||objectively-11/VB||to-10/TO	vmod||demonstrate-3/VBP||objectively-11/VB	dobj||objectively-11/VB||measure-12/NN	mark||receiving-21/VBG||whether-13/IN	ccomp||demonstrate-3/VBP||not-15/RB	conj_or||receiving-21/VBG||not-15/RB	nsubj||receiving-21/VBG||men-16/NNS	amod||obstructivepulmonarydisease-19/NN||chronic-18/JJ	prep_with||men-16/NNS||obstructivepulmonarydisease-19/NN	aux||receiving-21/VBG||are-20/VBP	ccomp||demonstrate-3/VBP||receiving-21/VBG	poss||treatment-24/NN||their-22/PRP$	nn||treatment-24/NN||oxygen-23/NN	dobj||receiving-21/VBG||treatment-24/NN	obstructivepulmonarydisease-19||oxygen-23||yes||the results demonstrate the monitorâ€™s ability to objectively measure whether or not men with chronic obstructivepulmonarydisease are receiving their oxygen treatment.
det||level-3/NN||the-2/DT	nsubj||hiv-infected-8/VBD||level-3/NN	prep_of||level-3/NN||adherence-5/NN	prep_of||adherence-5/NN||adults-7/NNS	ccomp||documented-35/VBN||hiv-infected-8/VBD	dobj||hiv-infected-8/VBD||patients-9/NNS	vmod||patients-9/NNS||treated-10/VBN	det||centres-16/NNS||the-12/DT	amod||centres-16/NNS||hiv/aids-13/JJ	nn||centres-16/NNS||health-14/NN	nn||centres-16/NNS||care-15/NN	prep_in||treated-10/VBN||centres-16/NNS	det||togo-24/NN||the-18/DT	nn||togo-24/NN||association-19/NN	nn||togo-24/NN||espoir-22/NN	nn||togo-24/NN||vie-23/NNS	prep_of||centres-16/NNS||togo-24/NN	prep_in||treated-10/VBN||togo-28/NN	nn||africa-31/NN||west-30/NN	nsubjpass||documented-35/VBN||africa-31/NN	auxpass||documented-35/VBN||is-32/VBZ	neg||documented-35/VBN||not-33/RB	advmod||documented-35/VBN||properly-34/RB	root||ROOT-0/null||documented-35/VBN	aids--1||hiv--1||no||" the level of adherence of adults hiv-infected patients treated in the hiv/aids health care centres of the association ""espoir vie togo"" in togo, west africa is not properly documented."
amod||studies-2/NNS||forty-nine-1/JJ	nsubj||met-3/VBD||studies-2/NNS	root||ROOT-0/null||met-3/VBD	det||criteria-6/NNS||the-4/DT	nn||criteria-6/NNS||inclusion-5/NN	dobj||met-3/VBD||criteria-6/NNS	num||indicators-10/NNS||30-8/CD	amod||indicators-10/NNS||different-9/JJ	nsubjpass||extracted-12/VBN||indicators-10/NNS	nsubjpass||categorized-14/VBN||indicators-10/NNS	auxpass||extracted-12/VBN||were-11/VBD	parataxis||met-3/VBD||extracted-12/VBN	parataxis||met-3/VBD||categorized-14/VBN	conj_and||extracted-12/VBN||categorized-14/VBN	num||categories-18/NNS||four-16/CD	amod||categories-18/NNS||nonorthogonal-17/JJ	prep_into||extracted-12/VBN||categories-18/NNS	nn||zones-21/NNS||blood-19/NN	nn||zones-21/NNS||glucose-20/NN	dep||categories-18/NNS||zones-21/NNS	prep_for||zones-21/NNS||example-24/NN	dep||example-24/NN||hypoglycaemia-27/NN	nn||levels-33/NNS||blood-31/NN	nn||levels-33/NNS||glucose-32/NN	prep_into||extracted-12/VBN||levels-33/NNS	conj_and||categories-18/NNS||levels-33/NNS	prep_for||levels-33/NNS||example-36/NN	amod||level-42/NN||mean-39/JJ	nn||level-42/NN||blood-40/NN	nn||level-42/NN||glucose-41/NN	dep||example-36/NN||level-42/NN	nn||intervals-47/NNS||time-46/NN	prep_into||extracted-12/VBN||intervals-47/NNS	conj_and||categories-18/NNS||intervals-47/NNS	prep_for||intervals-47/NNS||example-50/NN	dep||example-50/NN||time-53/NN	prep_to||time-53/NN||occurrence-55/NN	det||event-58/NN||an-57/DT	prep_of||occurrence-55/NN||event-58/NN	nn||characteristics-64/NNS||protocol-63/NN	prep_into||extracted-12/VBN||characteristics-64/NNS	conj_and||categories-18/NNS||characteristics-64/NNS	prep_for||categories-18/NNS||example-67/NN	nn||glucose-71/NN||blood-70/NN	nsubj||sampling-72/VBG||glucose-71/NN	dep||example-67/NN||sampling-72/VBG	dobj||sampling-72/VBG||frequency-73/NN	hypoglycaemia-27||glucose-71||yes||forty-nine studies met the inclusion criteria; 30 different indicators were extracted and categorized into four nonorthogonal categories blood glucose zones (for example, 'hypoglycaemia'); blood glucose levels (for example, 'mean blood glucose level'); time intervals (for example, 'time to occurrence of an event'); and protocol characteristics (for example, 'blood glucose sampling frequency').
nsubj||determined-2/VBD||we-1/PRP	root||ROOT-0/null||determined-2/VBD	det||prevalence-4/NN||the-3/DT	dobj||determined-2/VBD||prevalence-4/NN	amod||infection-13/NN||hbv-6/JJ	conj_and||hbv-6/JJ||hepatitisc-8/JJ	amod||infection-13/NN||hepatitisc-8/JJ	nn||infection-13/NN||virus-9/NN	appos||infection-13/NN||hcv-11/NN	prep_of||prevalence-4/NN||infection-13/NN	det||accuracy-19/NN||the-17/DT	amod||accuracy-19/NN||diagnostic-18/JJ	dobj||determined-2/VBD||accuracy-19/NN	conj_and||prevalence-4/NN||accuracy-19/NN	det||device-24/NN||the-21/DT	amod||device-24/NN||rapid-22/JJ	nn||device-24/NN||test-23/NN	prep_of||accuracy-19/NN||device-24/NN	dep||determined-2/VBD||determine-25/VB	xcomp||determine-25/VB||hbsag-26/VBG	det||cohort-30/NN||an-28/DT	nn||cohort-30/NN||hiv-29/NN	prep_in||hbsag-26/VBG||cohort-30/NN	amod||tanzania-33/NN||rural-32/JJ	prep_in||cohort-30/NN||tanzania-33/NN	hbv-6||hbsag-26||yes||we determined the prevalence of hbv and hepatitisc virus (hcv) infection as well as the diagnostic accuracy of the rapid test device determine hbsag in an hiv cohort in rural tanzania.
num||groups-3/NNS||two-1/CD	nn||groups-3/NNS||treatment-2/NN	nsubjpass||compared-11/VBN||groups-3/NNS	amod||patients-7/NNS||resuscitated-5/JJ	nn||patients-7/NNS||trauma-6/NN	prep_of||groups-3/NNS||patients-7/NNS	prep_in||patients-7/NNS||cardiacarrest-9/NN	auxpass||compared-11/VBN||were-10/VBD	root||ROOT-0/null||compared-11/VBN	det||patients-16/NNS||the-13/DT	amod||patients-16/NNS||epinephrine-14/JJ	nn||patients-16/NNS||group-15/NN	prep_in||compared-11/VBN||patients-16/NNS	dep||patients-16/NNS||received-17/VBN	amod||mg-20/NN||epinephrine-18/JJ	amod||mg-20/NN||1â-19/JJ	nsubj||iv-21/VB||mg-20/NN	ccomp||received-17/VBN||iv-21/VB	det||min-24/NN||every-22/DT	amod||min-24/NN||3â-23/JJ	dobj||iv-21/VB||min-24/NN	advmod||iv-21/VB||only-25/RB	det||vasopressin-29/NN||the-28/DT	prep_in||iv-21/VB||vasopressin-29/NN	nn||patients-31/NNS||group-30/NN	nsubj||received-33/VBD||patients-31/NNS	advmod||received-33/VBD||first-32/RB	rcmod||vasopressin-29/NN||received-33/VBD	amod||hhs-35/NN||hypertonic-34/JJ	dobj||received-33/VBD||hhs-35/NN	nn||vasopressin-38/NN||arginine-37/NN	dobj||received-33/VBD||vasopressin-38/NN	conj_and||hhs-35/NN||vasopressin-38/NN	num||units-40/NNS||40-39/CD	npadvmod||iv-41/JJ||units-40/NNS	amod||hhs-35/NN||iv-41/JJ	advmod||received-33/VBD||only-42/RB	dep||patients-16/NNS||followed-44/VBN	conj_or||received-17/VBN||followed-44/VBN	amod||mg-48/NN||epinephrine-46/JJ	amod||mg-48/NN||1â-47/JJ	prep_by||followed-44/VBN||mg-48/NN	det||min-51/NN||every-49/DT	amod||min-51/NN||3â-50/JJ	dobj||received-17/VBN||min-51/NN	prep_until||received-17/VBN||cessation-53/NN	prep_of||cessation-53/NN||cpr-55/NN	cardiacarrest-9||epinephrine-46||yes||two treatment groups of resuscitated trauma patients in cardiacarrest were compared in the epinephrine group patients received epinephrine 1â mg iv every 3â min only; in the vasopressin group patients first received hypertonic hhs and arginine vasopressin 40 units iv only or followed by epinephrine 1â mg every 3â min until cessation of cpr.
nsubj||manifestation-6/NN||glomerulonephritis-1/NNS	cop||manifestation-6/NN||is-2/VBZ	det||manifestation-6/NN||an-3/DT	amod||manifestation-6/NN||important-4/JJ	amod||manifestation-6/NN||extrahepatic-5/JJ	root||ROOT-0/null||manifestation-6/NN	nn||infection-12/NN||chronichepatitisbvirus-8/NNP	appos||infection-12/NN||hbv-10/NN	prep_of||manifestation-6/NN||infection-12/NN	hbv-10||hepatitisbvirus--1||no||glomerulonephritis is an important extrahepatic manifestation of chronichepatitisbvirus (hbv) infection.
nsubj||disease-6/NN||leprosy-1/NNP	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||a-3/DT	amod||disease-6/NN||chronic-4/JJ	nn||disease-6/NN||granulomatous-5/NNS	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	agent||caused-7/VBN||mycobacteriumleprae-9/NN	advmod||present-12/JJ||clinically-11/RB	amod||type-20/NN||present-12/JJ	dep||present-12/JJ||either-13/CC	dep||tuberculoid-15/JJ||as-14/IN	conj||present-12/JJ||tuberculoid-15/JJ	conj||present-12/JJ||borderline-17/JJ	conj_or||tuberculoid-15/JJ||borderline-17/JJ	conj||present-12/JJ||lepromatous-19/JJ	conj_or||tuberculoid-15/JJ||lepromatous-19/JJ	appos||mycobacteriumleprae-9/NN||type-20/NN	leprosy-1||mycobacteriumleprae-9||no||leprosy is a chronic granulomatous disease caused by mycobacteriumleprae , clinically present either as tuberculoid, borderline or lepromatous type.
amod||cancer-2/NN||endometrial-1/JJ	nsubj||cancer-9/NN||cancer-2/NN	appos||cancer-2/NN||ec-4/NN	cop||cancer-9/NN||is-6/VBZ	det||cancer-9/NN||a-7/DT	amod||cancer-9/NN||hormone-dependent-8/JJ	root||ROOT-0/null||cancer-9/NN	nsubj||represents-12/VBZ||cancer-9/NN	advmod||represents-12/VBZ||currently-11/RB	rcmod||cancer-9/NN||represents-12/VBZ	det||malignancy-16/NN||the-13/DT	advmod||frequent-15/JJ||most-14/RBS	amod||malignancy-16/NN||frequent-15/JJ	dobj||represents-12/VBZ||malignancy-16/NN	det||tract-21/NN||the-18/DT	amod||tract-21/NN||female-19/JJ	amod||tract-21/NN||reproductive-20/JJ	prep_of||malignancy-16/NN||tract-21/NN	cancer-9||hormone--1||no_rel||endometrial cancer (ec) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female reproductive tract.
amod||lar-2/NN||octreotide-1/JJ	nsubj||lengthened-4/VBN||lar-2/NN	advmod||lengthened-4/VBN||significantly-3/RB	root||ROOT-0/null||lengthened-4/VBN	amod||time-6/NN||median-5/JJ	dobj||lengthened-4/VBN||time-6/NN	nn||progression-9/NN||tumor-8/NN	prep_to||lengthened-4/VBN||progression-9/NN	prepc_compared_with||lengthened-4/VBN||with-11/IN	pobj||lengthened-4/VBN||placebo-12/NN	prep_in||placebo-12/NN||patients-14/NNS	amod||tumors-18/NNS||metastatic-16/JJ	nn||tumors-18/NNS||neuroendocrine-17/NN	prep_with||patients-14/NNS||tumors-18/NNS	det||midgut-21/NN||the-20/DT	prep_of||tumors-18/NNS||midgut-21/NN	octreotide-1||tumor-8||no_rel||octreotide lar significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut.
det||viruses-3/NNS||the-1/DT	amod||viruses-3/NNS||recombinant-2/JJ	nsubj||reagents-12/NNS||viruses-3/NNS	vmod||viruses-3/NNS||expressing-4/VBG	amod||protein-7/NN||tagged-5/JJ	dep||tagged-5/JJ||l-6/NN	dobj||expressing-4/VBG||protein-7/NN	aux||reagents-12/NNS||will-8/MD	cop||reagents-12/NNS||be-9/VB	advmod||valuable-11/JJ||highly-10/RB	amod||reagents-12/NNS||valuable-11/JJ	root||ROOT-0/null||reagents-12/NNS	det||dissection-16/NN||the-14/DT	amod||dissection-16/NN||detailed-15/JJ	prep_for||reagents-12/NNS||dissection-16/NN	det||role-19/NN||the-18/DT	prep_of||dissection-16/NN||role-19/NN	det||protein-24/NN||the-21/DT	amod||protein-24/NN||bunv-22/JJ	dep||bunv-22/JJ||l-23/NN	prep_of||role-19/NN||protein-24/NN	nn||replication-27/NN||virus-26/NN	prep_in||protein-24/NN||replication-27/NN	virus-26||viruses-3||no||the recombinant viruses expressing tagged l protein will be highly valuable reagents for the detailed dissection of the role of the bunv l protein in virus replication.
det||study-3/NN||a-1/DT	nn||study-3/NN||retrospective-2/NN	nsubjpass||conducted-5/VBN||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||assess-7/VB||to-6/TO	ccomp||conducted-5/VBN||assess-7/VB	det||efficacy-9/NN||the-8/DT	dobj||assess-7/VB||efficacy-9/NN	prep_of||efficacy-9/NN||d-penicillamine-11/NN	det||management-14/NN||the-13/DT	prep_in||assess-7/VB||management-14/NN	prep_of||management-14/NN||cystinuria-16/NN	aux||define-22/VB||to-21/TO	ccomp||conducted-5/VBN||define-22/VB	conj_and||assess-7/VB||define-22/VB	det||frequency-24/NN||the-23/DT	dobj||define-22/VB||frequency-24/NN	dobj||define-22/VB||nature-26/NN	conj_and||frequency-24/NN||nature-26/NN	amod||reactions-29/NNS||untoward-28/JJ	prep_of||frequency-24/NN||reactions-29/NNS	det||drug-32/NN||this-31/DT	prep_to||define-22/VB||drug-32/NN	cystinuria-16||d-penicillamine-11||yes||a retrospective study was conducted to assess the efficacy of d-penicillamine in the management of cystinuria, as well as to define the frequency and nature of untoward reactions to this drug.
det||expression-2/NN||the-1/DT	nsubjpass||analyzed-25/VBN||expression-2/NN	nn||receptor-5/NN||estrogen-4/NN	prep_of||expression-2/NN||receptor-5/NN	appos||receptor-5/NN||er-7/NN	amod||pr-13/NN||progesterone-10/JJ	nn||pr-13/NN||receptor-11/NN	prep_of||expression-2/NN||pr-13/NN	conj_and||receptor-5/NN||pr-13/NN	prep_of||expression-2/NN||her2-16/NNS	conj_and||receptor-5/NN||her2-16/NNS	prep_of||expression-2/NN||her4-18/NNS	conj_and||receptor-5/NN||her4-18/NNS	nn||m-22/NN||cystatin-21/NN	prep_of||expression-2/NN||m-22/NN	conj_and||receptor-5/NN||m-22/NN	auxpass||analyzed-25/VBN||was-23/VBD	advmod||analyzed-25/VBN||retrospectively-24/RB	root||ROOT-0/null||analyzed-25/VBN	xcomp||analyzed-25/VBN||using-26/VBG	advmod||using-26/VBG||immunohistochemistry-27/RB	num||patients-30/NNS||117-29/CD	prep_in||using-26/VBG||patients-30/NNS	amod||carcinoma-33/NN||ductal-32/JJ	prep_with||patients-30/NNS||carcinoma-33/NN	prep_in||carcinoma-33/NN||situ-35/NN	appos||situ-35/NN||dcis-37/NNS	num||patients-42/NNS||175-41/CD	prep_in||using-26/VBG||patients-42/NNS	conj_and||patients-30/NNS||patients-42/NNS	amod||cancer-46/NN||invasive-44/JJ	nn||cancer-46/NN||breast-45/NN	prep_with||patients-42/NNS||cancer-46/NN	appos||cancer-46/NN||ibc-48/NN	estrogen-4||cancer-46||no_rel||the expression of estrogen receptor (er), progesterone receptor (pr), her2, her4, and cystatin m was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (dcis) and in 175 patients with invasive breast cancer (ibc).
amod||prionprotein-2/NN||protease-resistant-1/JJ	nsubjpass||analysed-7/VBN||prionprotein-2/NN	appos||prionprotein-2/NN||prpres-4/NNS	auxpass||analysed-7/VBN||was-6/VBD	root||ROOT-0/null||analysed-7/VBN	amod||blot-10/NN||western-9/JJ	agent||analysed-7/VBN||blot-10/NN	det||spleen-13/NN||the-12/DT	prep_in||analysed-7/VBN||spleen-13/NN	amod||mice-16/NNS||transgenic-15/JJ	prep_of||spleen-13/NN||mice-16/NNS	nsubj||express-21/VBP||mice-16/NNS	appos||mice-16/NNS||tgovprp4-18/NNP	rcmod||mice-16/NNS||express-21/VBP	det||prionprotein-24/NN||the-22/DT	amod||prionprotein-24/NN||ovine-23/JJ	dobj||express-21/VBP||prionprotein-24/NN	det||control-27/NN||the-26/DT	prep_under||express-21/VBP||control-27/NN	det||promoter-32/NN||the-29/DT	amod||promoter-32/NN||neuron-specific-30/JJ	nn||promoter-32/NN||enolase-31/NN	prep_of||control-27/NN||promoter-32/NN	prep_after||express-21/VBP||infection-35/NN	amod||route-38/NN||intra-cerebral-37/JJ	prep_by||express-21/VBP||route-38/NN	det||variety-41/NN||a-40/DT	prep_with||express-21/VBP||variety-41/NN	prep_of||variety-41/NN||transmissiblespongiformencephalopathies-43/NNS	appos||transmissiblespongiformencephalopathies-43/NNS||tses-45/NNS	prep_from||express-21/VBP||cattle-48/NNS	amod||ruminants-51/NNS||small-50/JJ	prep_from||express-21/VBP||ruminants-51/NNS	conj_and||cattle-48/NNS||ruminants-51/NNS	transmissiblespongiformencephalopathies-43||prionprotein-24||no||protease-resistant prionprotein (prpres) was analysed by western blot in the spleen of transgenic mice (tgovprp4) that express the ovine prionprotein under the control of the neuron-specific enolase promoter, after infection by intra-cerebral route with a variety of transmissiblespongiformencephalopathies (tses) from cattle and small ruminants.
det||study-2/NN||this-1/DT	nsubj||demonstrated-3/VBD||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	mark||caused-15/VBN||that-4/IN	det||incidence-6/NN||the-5/DT	nsubjpass||caused-15/VBN||incidence-6/NN	prep_of||incidence-6/NN||tb-8/NN	prep_in||tb-8/NN||jos-10/NN	appos||jos-10/NN||nigeria-12/NN	aux||caused-15/VBN||may-13/MD	auxpass||caused-15/VBN||be-14/VB	ccomp||demonstrated-3/VBD||caused-15/VBN	det||families-21/NNS||a-17/DT	amod||families-21/NNS||few-18/JJ	amod||families-21/NNS||successful-19/JJ	nn||families-21/NNS||m.tuberculosis-20/NN	agent||caused-15/VBN||families-21/NNS	vmod||families-21/NNS||dominated-23/VBN	det||family-27/NN||the-25/DT	amod||family-27/NN||lam10-26/JJ	agent||dominated-23/VBN||family-27/NN	tb-8||m.tuberculosis-20||no||this study demonstrated that the incidence of tb in jos , nigeria may be caused by a few successful m.tuberculosis families , dominated by the lam10 family .
nsubjpass||known-14/VBN||rosiglitazone-1/NN	nsubj||have-16/VB||rosiglitazone-1/NN	appos||rosiglitazone-1/NN||rsg-3/NN	vmod||rosiglitazone-1/NN||developed-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||developed-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||type2diabetesmellitus-11/CD	auxpass||known-14/VBN||is-13/VBZ	root||ROOT-0/null||known-14/VBN	aux||have-16/VB||to-15/TO	xcomp||known-14/VBN||have-16/VB	amod||effects-18/NNS||potent-17/JJ	dobj||have-16/VB||effects-18/NNS	nn||metabolism-23/NN||carbohydrate-20/NN	conj_and||carbohydrate-20/NN||lipid-22/NN	nn||metabolism-23/NN||lipid-22/NN	prep_on||have-16/VB||metabolism-23/NN	xcomp||have-16/VB||leading-24/VBG	det||improvement-27/NN||the-26/DT	prep_to||leading-24/VBG||improvement-27/NN	nn||sensitivity-30/NN||insulin-29/NN	prep_of||improvement-27/NN||sensitivity-30/NN	nn||tissues-33/NNS||target-32/NN	prep_in||sensitivity-30/NN||tissues-33/NNS	type2diabetesmellitus-11||insulin-29||yes||rosiglitazone (rsg), developed for the treatment of type2diabetesmellitus, is known to have potent effects on carbohydrate and lipid metabolism leading to the improvement of insulin sensitivity in target tissues.
det||aliskiren-3/NN||the-2/DT	prep_in||received-23/VBD||aliskiren-3/NN	det||evaluation-6/NN||the-5/DT	prep_in||aliskiren-3/NN||evaluation-6/NN	prep_of||evaluation-6/NN||proteinuria-8/NN	nn||study-14/NN||diabetes-10/NNP	appos||study-14/NN||avoid-12/NNP	prep_in||proteinuria-8/NN||study-14/NN	num||patients-18/NNS||599-16/CD	amod||patients-18/NNS||hypertensive-17/JJ	nsubj||received-23/VBD||patients-18/NNS	prep_with||patients-18/NNS||type2diabetes-20/NN	prep_with||patients-18/NNS||nephropathy-22/NN	conj_and||type2diabetes-20/NN||nephropathy-22/NN	root||ROOT-0/null||received-23/VBD	num||months-25/NNS||6-24/CD	dobj||received-23/VBD||months-25/NNS	prep_of||months-25/NNS||aliskiren-27/NN	num||mg-30/NN||150-29/CD	dep||months-25/NNS||mg-30/NN	advmod||titrated-32/VBN||daily-31/RB	vmod||mg-30/NN||titrated-32/VBN	number||mg-35/CD||300-34/CD	prep_to||titrated-32/VBN||mg-35/CD	advmod||titrated-32/VBN||daily-36/RB	num||months-39/NNS||3-38/CD	prep_after||titrated-32/VBN||months-39/NNS	nn||therapy-51/NN||placebo-42/NN	dep||therapy-51/NN||added-43/VBN	num||losartan-47/NN||100-45/CD	nn||losartan-47/NN||mg-46/NN	prep_to||added-43/VBN||losartan-47/NN	amod||antihypertensive-50/JJ||optimal-49/JJ	conj_and||added-43/VBN||antihypertensive-50/JJ	dep||therapy-51/NN||antihypertensive-50/JJ	dobj||received-23/VBD||therapy-51/NN	conj_or||months-25/NNS||therapy-51/NN	type2diabetes-20||losartan-47||no_rel||in the aliskiren in the evaluation of proteinuria in diabetes (avoid) study, 599 hypertensive patients with type2diabetes and nephropathy received 6 months of aliskiren (150 mg daily titrated to 300 mg daily after 3 months) or placebo added to 100 mg losartan and optimal antihypertensive therapy.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-15/VBN||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulfadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	auxpass||recommended-15/VBN||is-14/VBZ	root||ROOT-0/null||recommended-15/VBN	dobj||low-29/JJ||who-17/WP	advmod||high-24/JJ||where-18/WRB	nn||incidence-20/NN||malaria-19/NN	nsubj||high-24/JJ||incidence-20/NN	nsubj||sp-26/JJ||incidence-20/NN	prep_in||incidence-20/NN||infancy-22/NN	cop||high-24/JJ||is-23/VBZ	advcl||low-29/JJ||high-24/JJ	conj_and||high-24/JJ||sp-26/JJ	advcl||low-29/JJ||sp-26/JJ	nsubj||low-29/JJ||resistance-27/NN	cop||low-29/JJ||is-28/VBZ	agent||recommended-15/VBN||low-29/JJ	malaria-19||pyrimethamine--1||no||intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine (sp) is recommended by who where malaria incidence in infancy is high and sp resistance is low.
amod||women-2/NNS||postmenopausal-1/JJ	nsubj||susceptible-5/JJ||women-2/NNS	cop||susceptible-5/JJ||are-3/VBP	advmod||susceptible-5/JJ||particularly-4/RB	root||ROOT-0/null||susceptible-5/JJ	prep_to||susceptible-5/JJ||osteoporosis-7/NNS	tmod||declines-13/VBZ||osteoporosis-7/NNS	advmod||declines-13/VBZ||when-8/WRB	poss||production-10/NN||their-9/PRP$	nsubj||declines-13/VBZ||production-10/NN	prep_of||production-10/NN||estrogen-12/NN	rcmod||osteoporosis-7/NNS||declines-13/VBZ	osteoporosis-7||estrogen-12||no_rel||postmenopausal women are particularly susceptible to osteoporosis when their production of estrogen declines.
det||interview-4/NN||the-2/DT	amod||interview-4/NN||same-3/JJ	prep_in||conduct-8/VB||interview-4/NN	nsubj||conduct-8/VB||we-6/PRP	aux||conduct-8/VB||will-7/MD	root||ROOT-0/null||conduct-8/VB	amod||exercises-10/NNS||preference-elicitation-9/JJ	dobj||conduct-8/VB||exercises-10/NNS	vmod||exercises-10/NNS||using-11/VBG	det||thermometer-14/NN||the-12/DT	nn||thermometer-14/NN||feeling-13/NN	dobj||using-11/VBG||thermometer-14/NN	aux||identify-16/VB||to-15/TO	vmod||using-11/VBG||identify-16/VB	det||utilities-18/NNS||the-17/DT	dobj||identify-16/VB||utilities-18/NNS	mark||place-21/VBP||that-19/IN	nsubj||place-21/VBP||patients-20/NNS	ccomp||identify-16/VB||place-21/VBP	prepc_on||place-21/VBP||taking-23/VBG	dobj||taking-23/VBG||medication-24/NN	dep||medication-24/NN||warfarin-26/NN	dep||medication-24/NN||aspirin-28/NN	conj_and||warfarin-26/NN||aspirin-28/NN	prepc_on||place-21/VBP||having-33/VBG	conj_and||taking-23/VBG||having-33/VBG	det||stroke-36/NN||a-34/DT	amod||stroke-36/NN||mild-35/JJ	dobj||having-33/VBG||stroke-36/NN	det||stroke-40/NN||a-38/DT	amod||stroke-40/NN||severe-39/JJ	dobj||having-33/VBG||stroke-40/NN	conj_and||stroke-36/NN||stroke-40/NN	det||bleed-45/NN||a-43/DT	amod||bleed-45/NN||major-44/JJ	dobj||having-33/VBG||bleed-45/NN	conj_and||stroke-36/NN||bleed-45/NN	stroke-40||warfarin-26||yes||in the same interview, we will conduct preference-elicitation exercises using the feeling thermometer to identify the utilities that patients place on taking medication (warfarin and aspirin), and on having a mild stroke, a severe stroke, and a major bleed.
nsubj||promising-15/VBG||capecitabine-1/NN	conj_plus||capecitabine-1/NN||docetaxel-3/NN	nsubj||promising-15/VBG||docetaxel-3/NN	appos||docetaxel-3/NN||xt-5/NN	conj_and||capecitabine-1/NN||trastuzumab-8/NN	nsubj||promising-15/VBG||trastuzumab-8/NN	prep_with||trastuzumab-8/NN||xt-10/NN	appos||xt-10/NN||hxt-12/NN	aux||promising-15/VBG||are-14/VBP	root||ROOT-0/null||promising-15/VBG	amod||regimens-17/NNS||non-anthracycline-16/JJ	dobj||promising-15/VBG||regimens-17/NNS	det||treatment-21/NN||the-19/DT	amod||treatment-21/NN||preoperative-20/JJ	prep_for||promising-15/VBG||treatment-21/NN	prep_of||treatment-21/NN||women-23/NNS	amod||cancer-29/NN||her2-negative-25/JJ	conj_and||her2-negative-25/JJ||her2-positive-27/JJ	amod||cancer-29/NN||her2-positive-27/JJ	nn||cancer-29/NN||breast-28/NN	prep_with||women-23/NNS||cancer-29/NN	advmod||promising-15/VBG||respectively-31/RB	cancer-29||trastuzumab-8||no_rel||capecitabine plus docetaxel (xt) and trastuzumab with xt (hxt) are promising non-anthracycline regimens for the preoperative treatment of women with her2-negative and her2-positive breast cancer, respectively.
poss||prevalence-2/NN||its-1/PRP$	nsubjpass||affected-7/VBN||prevalence-2/NN	det||population-5/NN||the-4/DT	prep_in||prevalence-2/NN||population-5/NN	auxpass||affected-7/VBN||is-6/VBZ	root||ROOT-0/null||affected-7/VBN	amod||endocrinological-21/NN||genetic-9/JJ	amod||endocrinological-21/NN||environmental-11/JJ	amod||endocrinological-21/NN||viral-13/JJ	amod||endocrinological-21/NN||infectious-15/JJ	amod||endocrinological-21/NN||immunological-17/JJ	amod||endocrinological-21/NN||biochemical-19/JJ	agent||affected-7/VBN||endocrinological-21/NN	amod||factors-25/NNS||psychological-24/JJ	agent||affected-7/VBN||factors-25/NNS	conj_and||endocrinological-21/NN||factors-25/NNS	agent||affected-7/VBN||alcohol-30/NN	conj_and||endocrinological-21/NN||alcohol-30/NN	conj_and||endocrinological-21/NN||drugabuse-32/NN	conj_and||alcohol-30/NN||drugabuse-32/NN	drugabuse-32||alcohol-30||no_rel||its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drugabuse.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||replaced-20/VBN||that-4/IN	advmod||pathogenic-6/JJ||highly-5/RB	amod||avianinfluenzaviruses-7/NNS||pathogenic-6/JJ	nsubjpass||replaced-20/VBN||avianinfluenzaviruses-7/NNS	appos||avianinfluenzaviruses-7/NNS||h5n1-9/NNP	advmod||imported-12/VBN||initially-11/RB	vmod||avianinfluenzaviruses-7/NNS||imported-12/VBN	prep_into||imported-12/VBN||nigeria-14/NN	prep_in||nigeria-14/NN||2006-16/CD	aux||replaced-20/VBN||have-17/VBP	auxpass||replaced-20/VBN||been-18/VBN	advmod||replaced-20/VBN||gradually-19/RB	ccomp||suggest-3/VBP||replaced-20/VBN	amod||reassortments-23/NNS||various-22/JJ	agent||replaced-20/VBN||reassortments-23/NNS	h5n1-9||influenzaviruses--1||no||our results suggest that highly pathogenic avianinfluenzaviruses (h5n1) initially imported into nigeria in 2006 have been gradually replaced by various reassortments.
poss||opinion-3/NN||our-2/PRP$	prep_in||important-8/JJ||opinion-3/NN	nsubj||important-8/JJ||it-5/PRP	nsubj||investigate-10/VB||it-5/PRP	cop||important-8/JJ||is-6/VBZ	advmod||important-8/JJ||more-7/RBR	root||ROOT-0/null||important-8/JJ	aux||investigate-10/VB||to-9/TO	xcomp||important-8/JJ||investigate-10/VB	det||effect-12/NN||the-11/DT	dobj||investigate-10/VB||effect-12/NN	prep_of||effect-12/NN||melatonin-14/NN	det||sle-20/NN||the-16/DT	nn||sle-20/NN||environmental-17/JJ	amod||environmental-17/JJ||related-19/VBN	prep_on||investigate-10/VB||sle-20/NN	melatonin-14||sle-20||no_rel||in our opinion, it is more important to investigate the effect of melatonin on the environmental- related sle.
nsubj||mtb-3/VBP||m.tuberculosis-1/NNS	advmod||mtb-3/VBP||-lrb--2/RB	root||ROOT-0/null||mtb-3/VBP	amod||components-7/NNS||-rrb--4/JJ	nn||components-7/NNS||cell-5/NN	nn||components-7/NNS||wall-6/NN	nsubjpass||implicated-10/VBN||components-7/NNS	aux||implicated-10/VBN||have-8/VBP	auxpass||implicated-10/VBN||been-9/VBN	ccomp||mtb-3/VBP||implicated-10/VBN	det||pathogenicity-13/NN||the-12/DT	prep_in||implicated-10/VBN||pathogenicity-13/NN	prep_of||pathogenicity-13/NN||tb-15/NN	advmod||target-22/NN||therefore-17/RB	aux||target-22/NN||have-18/VBP	cop||target-22/NN||been-19/VBN	det||target-22/NN||a-20/DT	amod||target-22/NN||prime-21/JJ	ccomp||mtb-3/VBP||target-22/NN	conj_and||implicated-10/VBN||target-22/NN	det||identification-25/NN||the-24/DT	prep_for||target-22/NN||identification-25/NN	prep_for||target-22/NN||characterization-27/NN	conj_and||identification-25/NN||characterization-27/NN	nn||proteins-31/NNS||cell-29/NN	nn||proteins-31/NNS||wall-30/NN	prep_of||identification-25/NN||proteins-31/NNS	amod||application-34/NN||potential-33/JJ	prep_with||target-22/NN||application-34/NN	nn||development-37/NN||vaccine-36/NN	prep_in||application-34/NN||development-37/NN	tb-15||mtb-3||no||m.tuberculosis -lrb- mtb -rrb- cell wall components have been implicated in the pathogenicity of tb and therefore have been a prime target for the identification and characterization of cell wall proteins with potential application in vaccine development .
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||determine-8/VB||to-7/TO	ccomp||is-6/VBZ||determine-8/VB	det||effect-10/NN||the-9/DT	dobj||determine-8/VB||effect-10/NN	det||length-14/NN||the-12/DT	amod||length-14/NN||microsatellite-13/JJ	prep_of||effect-10/NN||length-14/NN	amod||activity-18/NN||fli1-16/JJ	nn||activity-18/NN||promoter-17/NN	prep_on||determine-8/VB||activity-18/NN	prep_in||activity-18/NN||vitro-20/NNP	aux||determine-23/VB||to-22/TO	ccomp||is-6/VBZ||determine-23/VB	conj_and||determine-8/VB||determine-23/VB	mark||associated-32/VBN||if-24/IN	det||length-26/NN||the-25/DT	nsubjpass||associated-32/VBN||length-26/NN	det||microsatellite-30/NN||the-28/DT	nn||microsatellite-30/NN||gan-29/NN	prep_of||length-26/NN||microsatellite-30/NN	auxpass||associated-32/VBN||is-31/VBZ	advcl||determine-23/VB||associated-32/VBN	amod||characteristics-38/NNS||sle-34/JJ	nn||characteristics-38/NNS||and/or-35/NNP	amod||characteristics-38/NNS||specific-36/JJ	nn||characteristics-38/NNS||disease-37/NN	prep_with||associated-32/VBN||characteristics-38/NNS	gan-29||sle-34||no_rel||the purpose of this study is to determine the effect of the microsatellite length on fli1 promoter activity in vitro and to determine if the length of the gan microsatellite is associated with sle and/or specific disease characteristics.
num||means-3/NNS||one-1/CD	amod||means-3/NNS||recommended-2/VBN	nsubj||therapy-12/NN||means-3/NNS	prepc_of||means-3/NNS||preventing-5/VBG	dobj||preventing-5/VBG||malaria-6/NN	prep_during||preventing-5/VBG||pregnancy-8/NN	cop||therapy-12/NN||is-9/VBZ	amod||therapy-12/NN||intermittent-10/JJ	nn||therapy-12/NN||preventive-11/NN	root||ROOT-0/null||therapy-12/NN	appos||therapy-12/NN||iptp-14/NN	prep_with||therapy-12/NN||sulfadoxine/pyrimethamine-17/NN	appos||sulfadoxine/pyrimethamine-17/NN||sp-19/NN	malaria-6||pyrimethamine--1||yes||one recommended means of preventing malaria during pregnancy is intermittent preventive therapy (iptp) with sulfadoxine/pyrimethamine (sp).
nsubj||consisted-2/VBD||treatment-1/NN	root||ROOT-0/null||consisted-2/VBD	amod||treatment-11/NN||antibiotics-4/JJ	conj_and||antibiotics-4/JJ||corticosteroids-6/JJ	amod||treatment-11/NN||corticosteroids-6/JJ	conj_and||antibiotics-4/JJ||immunoglobulin-8/JJ	amod||treatment-11/NN||immunoglobulin-8/JJ	conj_and||antibiotics-4/JJ||supportive-10/JJ	amod||treatment-11/NN||supportive-10/JJ	prep_of||consisted-2/VBD||treatment-11/NN	prep_for||consisted-2/VBD||haemodynamic-13/JJ	prep_for||consisted-2/VBD||respiratory-15/JJ	conj_and||haemodynamic-13/JJ||respiratory-15/JJ	prep_for||consisted-2/VBD||renalfailure-17/JJ	conj_and||haemodynamic-13/JJ||renalfailure-17/JJ	corticosteroids-6||renalfailure-17||no_rel||treatment consisted of antibiotics, corticosteroids, immunoglobulin and supportive treatment for haemodynamic, respiratory and renalfailure.
det||approval-3/NN||the-2/DT	prep_with||became-18/VBD||approval-3/NN	prep_in||approval-3/NN||2007-5/CD	det||inhibitor-10/NN||the-7/DT	amod||inhibitor-10/NN||first-8/JJ	nn||inhibitor-10/NN||integrase-9/NN	prep_of||2007-5/CD||inhibitor-10/NN	appos||inhibitor-10/NN||ini-12/NN	advmod||became-18/VBD||raltegravir-15/RB	nsubj||became-18/VBD||clinicians-17/NNS	root||ROOT-0/null||became-18/VBD	advmod||able-20/JJ||better-19/RBR	acomp||became-18/VBD||able-20/JJ	aux||suppress-22/VB||to-21/TO	xcomp||able-20/JJ||suppress-22/VB	nn||replication-24/NN||virus-23/NN	dobj||suppress-22/VB||replication-24/NN	prep_in||suppress-22/VB||patients-26/NNS	vmod||patients-26/NNS||infected-27/VBN	nn||type-30/NN||humanimmunodeficiencyvirus-29/NN	prep_with||infected-27/VBN||type-30/NN	num||type-30/NN||1-31/CD	dep||able-20/JJ||hiv-1-33/JJ	nsubj||harboring-37/VBG||who-35/WP	aux||harboring-37/VBG||were-36/VBD	ccomp||able-20/JJ||harboring-37/VBG	dobj||harboring-37/VBG||many-38/JJ	det||viruses-44/NNS||the-40/DT	advmod||drug-resistant-43/JJ||most-41/RBS	advmod||drug-resistant-43/JJ||highly-42/RB	amod||viruses-44/NNS||drug-resistant-43/JJ	prep_of||many-38/JJ||viruses-44/NNS	virus-23||viruses-44||no||with the approval in 2007 of the first integrase inhibitor (ini), raltegravir, clinicians became better able to suppress virus replication in patients infected with humanimmunodeficiencyvirus type 1 (hiv-1) who were harboring many of the most highly drug-resistant viruses.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	det||girl-8/NN||an-6/DT	amod||girl-8/NN||11-year-old-7/JJ	prep_of||case-4/NN||girl-8/NN	amod||retardation-13/NN||adhd-10/JJ	conj_and||adhd-10/JJ||mental-12/JJ	amod||retardation-13/NN||mental-12/JJ	prep_with||describe-2/VBP||retardation-13/NN	vmod||retardation-13/NN||treated-14/VBN	prep_with||treated-14/VBN||methylphenidate-16/NN	nsubj||developed-19/VBD||methylphenidate-16/NN	rcmod||methylphenidate-16/NN||developed-19/VBD	dobj||developed-19/VBD||mania-20/NN	prep_like||developed-19/VBD||symptoms-22/NNS	vmod||symptoms-22/NNS||requiring-23/VBG	amod||treatment-25/NN||inpatient-24/JJ	dobj||requiring-23/VBG||treatment-25/NN	adhd-10||methylphenidate-16||yes||we describe a case of an 11-year-old girl with adhd and mental retardation treated with methylphenidate, who developed mania like symptoms requiring inpatient treatment.
det||procedure-2/NN||this-1/DT	nsubjpass||performed-5/VBN||procedure-2/NN	aux||performed-5/VBN||has-3/VBZ	auxpass||performed-5/VBN||been-4/VBN	root||ROOT-0/null||performed-5/VBN	amod||numbers-8/NNS||small-7/JJ	prep_in||performed-5/VBN||numbers-8/NNS	advmod||obese-11/JJ||severely-10/RB	amod||patients-12/NNS||obese-11/JJ	prep_of||numbers-8/NNS||patients-12/NNS	prep_with||performed-5/VBN||type1diabetes-14/NNS	appos||type1diabetes-14/NNS||dm1-16/NNP	det||impact-21/NN||the-20/DT	nsubjpass||described-35/VBN||impact-21/NN	amod||control-24/NN||glycemic-23/JJ	prep_on||impact-21/NN||control-24/NN	nn||requirement-27/NN||insulin-26/NN	prep_on||impact-21/NN||requirement-27/NN	conj_and||control-24/NN||requirement-27/NN	det||population-30/NN||this-29/DT	prep_in||control-24/NN||population-30/NN	aux||described-35/VBN||has-31/VBZ	neg||described-35/VBN||not-32/RB	auxpass||described-35/VBN||been-33/VBN	advmod||described-35/VBN||widely-34/RB	conj_but||performed-5/VBN||described-35/VBN	type1diabetes-14||insulin-26||yes||this procedure has been performed in small numbers of severely obese patients with type1diabetes (dm1), but the impact on glycemic control and insulin requirement in this population has not been widely described.
det||study-3/NN||this-2/DT	prep_in||used-25/VBN||study-3/NN	det||time-8/NN||the-6/DT	amod||time-8/NN||first-7/JJ	prep_for||used-25/VBN||time-8/NN	amod||ectodomain-11/NN||recombinant-10/JJ	nsubjpass||used-25/VBN||ectodomain-11/NN	amod||protein-14/NN||m2-13/JJ	prep_of||ectodomain-11/NN||protein-14/NN	appos||protein-14/NN||m2e-16/NNP	prep_of||protein-14/NN||avianinfluenzavirus-19/NNS	amod||strain-22/NN||h5n1-21/JJ	appos||avianinfluenzavirus-19/NNS||strain-22/NN	auxpass||used-25/VBN||was-24/VBD	root||ROOT-0/null||used-25/VBN	det||test-30/NN||the-27/DT	nn||test-30/NN||diva-28/NN	nn||test-30/NN||serology-29/NN	prep_for||used-25/VBN||test-30/NN	h5n1-21||avianinfluenzavirus-19||no||in this study, for the first time, recombinant ectodomain of m2 protein (m2e) of avianinfluenzavirus (h5n1 strain) was used for the diva serology test.
nsubj||characterized-4/JJ||mpa-1/NN	cop||characterized-4/JJ||is-2/VBZ	advmod||characterized-4/JJ||clinically-3/RB	root||ROOT-0/null||characterized-4/JJ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||multisystemic-7/JJ	prep_by||characterized-4/JJ||disease-8/NN	prep_such_as||disease-8/NN||rpgn-11/NN	amod||hemorrhage-14/NN||pulmonary-13/JJ	prep_such_as||disease-8/NN||hemorrhage-14/NN	conj_and||rpgn-11/NN||hemorrhage-14/NN	prep_such_as||disease-8/NN||mononeuritis-16/NNS	conj_and||rpgn-11/NN||mononeuritis-16/NNS	nn||involvement-20/NN||skin-19/NN	prep_such_as||disease-8/NN||involvement-20/NN	conj_and||rpgn-11/NN||involvement-20/NN	amod||manifestations-26/NNS||other-25/JJ	prep_by||characterized-4/JJ||manifestations-26/NNS	conj_and||disease-8/NN||manifestations-26/NNS	prep_in||manifestations-26/NNS||conjunction-28/NN	amod||levels-31/NNS||high-30/JJ	prep_with||characterized-4/JJ||levels-31/NNS	amod||activity-34/NN||inflammatory-33/JJ	prep_of||levels-31/NNS||activity-34/NN	amod||esr-38/NN||high-37/JJ	prep_such_as||activity-34/NN||esr-38/NN	prep_such_as||activity-34/NN||crp-40/NN	conj_or||esr-38/NN||crp-40/NN	hemorrhage-14||mpa-1||no||mpa is clinically characterized by a multisystemic disease such as rpgn, pulmonary hemorrhage, mononeuritis, and skin involvement, as well as other manifestations in conjunction with high levels of inflammatory activity such as high esr or crp.
nsubj||important-8/JJ||adherence-1/NN	det||regimen-6/NN||the-3/DT	amod||regimen-6/NN||14-day-4/JJ	nn||regimen-6/NN||primaquine-5/NN	prep_to||adherence-1/NN||regimen-6/NN	cop||important-8/JJ||is-7/VBZ	root||ROOT-0/null||important-8/JJ	det||cure-12/NN||the-10/DT	amod||cure-12/NN||radical-11/JJ	prep_for||important-8/JJ||cure-12/NN	nn||infection-16/NN||p.-14/NN	nn||infection-16/NN||vivaxmalaria-15/NN	prep_of||cure-12/NN||infection-16/NN	vivaxmalaria-15||primaquine-5||yes||adherence to the 14-day primaquine regimen is important for the radical cure of p. vivaxmalaria infection .
nn||phagocytes-2/NNS||mononuclear-1/NN	nsubjpass||attributed-5/VBN||phagocytes-2/NNS	aux||attributed-5/VBN||have-3/VBP	auxpass||attributed-5/VBN||been-4/VBN	root||ROOT-0/null||attributed-5/VBN	det||role-8/NN||a-6/DT	amod||role-8/NN||crucial-7/JJ	dobj||attributed-5/VBN||role-8/NN	det||defense-12/NN||the-10/DT	nn||defense-12/NN||host-11/NN	prep_in||role-8/NN||defense-12/NN	prep_toward||attributed-5/VBN||influenzavirus-14/NNS	appos||influenzavirus-14/NNS||iv-16/NN	poss||contribution-21/NN||their-20/PRP$	nsubjpass||understood-28/VBN||contribution-21/NN	amod||failure-25/NN||influenza-induced-23/JJ	nn||failure-25/NN||lung-24/NN	prep_to||contribution-21/NN||failure-25/NN	auxpass||understood-28/VBN||is-26/VBZ	advmod||understood-28/VBN||incompletely-27/RB	conj_but||attributed-5/VBN||understood-28/VBN	influenza--1||influenzavirus-14||no||mononuclear phagocytes have been attributed a crucial role in the host defense toward influenzavirus (iv), but their contribution to influenza-induced lung failure is incompletely understood.
det||patients-3/NNS||all-1/DT	nn||patients-3/NNS||warfarin-2/NN	nsubj||received-14/VBD||patients-3/NNS	nsubjpass||included-19/VBN||patients-3/NNS	amod||myocardialinfarction-8/NN||suspected-5/VBN	amod||myocardialinfarction-8/NN||st-segment-6/JJ	nn||myocardialinfarction-8/NN||elevation-7/NN	prep_with||patients-3/NNS||myocardialinfarction-8/NN	appos||myocardialinfarction-8/NN||stemi-10/NNP	rcmod||patients-3/NNS||received-14/VBD	amod||fibrinolysis-16/NNS||pre-hospital-15/JJ	dobj||received-14/VBD||fibrinolysis-16/NNS	auxpass||included-19/VBN||were-18/VBD	root||ROOT-0/null||included-19/VBN	myocardialinfarction-8||warfarin-2||yes||all warfarin patients with suspected st-segment elevation myocardialinfarction (stemi), who received pre-hospital fibrinolysis, were included.
det||information-2/NN||this-1/DT	nsubj||be-4/VB||information-2/NN	nsubj||aids-23/VBZ||information-2/NN	aux||be-4/VB||may-3/MD	root||ROOT-0/null||be-4/VB	prep_of||be-4/VB||use-6/NN	det||design-9/NN||the-8/DT	prep_in||be-4/VB||design-9/NN	prep_in||be-4/VB||targeting-11/NN	conj_and||design-9/NN||targeting-11/NN	prep_in||be-4/VB||monitoring-13/NN	conj_and||design-9/NN||monitoring-13/NN	prep_in||be-4/VB||evaluation-15/NN	conj_and||design-9/NN||evaluation-15/NN	prep_of||design-9/NN||programs-17/NNS	vmod||programs-17/NNS||aimed-18/VBN	prepc_at||aimed-18/VBN||improving-20/VBG	dobj||improving-20/VBG||hiv-21/NN	conj_and||be-4/VB||aids-23/VBZ	amod||knowledge-25/NN||related-24/JJ	dobj||aids-23/VBZ||knowledge-25/NN	prep_in||aids-23/VBZ||iraq-27/NNP	aids-23||hiv-21||no||this information may be of use in the design, targeting, monitoring and evaluation of programs aimed at improving hiv and aids related knowledge in iraq.
det||respondents-2/NNS||the-1/DT	nsubj||had-9/VBD||respondents-2/NNS	quantmod||than-5/IN||less-4/JJR	num||education-8/NN||than-5/IN	amod||school-7/NN||secondary-6/JJ	dep||than-5/IN||school-7/NN	prep_with||respondents-2/NNS||education-8/NN	root||ROOT-0/null||had-9/VBD	det||attitude-12/NN||a-10/DT	amod||attitude-12/NN||discriminatory-11/JJ	dobj||had-9/VBD||attitude-12/NN	amod||people-15/NNS||hivpositive-14/JJ	prep_toward||attitude-12/NN||people-15/NNS	nsubj||deserving-21/VBG||them-20/PRP	nsubj||suffer-23/VB||them-20/PRP	nsubj||dismissing-25/VBG||them-20/PRP	nsubj||hesitating-30/VBG||them-20/PRP	nsubj||sit-32/VB||them-20/PRP	nsubj||divorcing-42/VBG||them-20/PRP	nsubj||willingness-48/VBG||them-20/PRP	nsubjpass||tested-51/VBN||them-20/PRP	prepc_with_regard_to||had-9/VBD||deserving-21/VBG	aux||suffer-23/VB||to-22/TO	xcomp||deserving-21/VBG||suffer-23/VB	prepc_with_regard_to||had-9/VBD||dismissing-25/VBG	conj_and||deserving-21/VBG||dismissing-25/VBG	det||maid-28/NN||a-26/DT	amod||maid-28/NN||hivpositive-27/JJ	dobj||dismissing-25/VBG||maid-28/NN	prepc_with_regard_to||had-9/VBD||hesitating-30/VBG	conj_and||deserving-21/VBG||hesitating-30/VBG	aux||sit-32/VB||to-31/TO	xcomp||hesitating-30/VBG||sit-32/VB	det||person-37/NN||a-35/DT	amod||person-37/NN||hivpositive-36/JJ	prep_next_to||sit-32/VB||person-37/NN	det||bus-40/NN||the-39/DT	prep_in||sit-32/VB||bus-40/NN	prepc_with_regard_to||had-9/VBD||divorcing-42/VBG	conj_and||deserving-21/VBG||divorcing-42/VBG	det||spouse-45/NN||the-43/DT	amod||spouse-45/NN||infected-44/JJ	dobj||divorcing-42/VBG||spouse-45/NN	prepc_with_regard_to||had-9/VBD||willingness-48/VBG	conj_and||deserving-21/VBG||willingness-48/VBG	aux||tested-51/VBN||to-49/TO	auxpass||tested-51/VBN||get-50/VB	xcomp||willingness-48/VBG||tested-51/VBN	prep_for||tested-51/VBN||hiv-53/NN	nsubjpass||found-57/VBN||hiv-53/NN	nsubj||significant-61/JJ||hiv-53/NN	auxpass||found-57/VBN||was-56/VBD	rcmod||hiv-53/NN||found-57/VBN	aux||significant-61/JJ||to-58/TO	cop||significant-61/JJ||be-59/VB	advmod||significant-61/JJ||statistically-60/RB	xcomp||found-57/VBN||significant-61/JJ	hivpositive-36||hiv-53||no||the respondents with less than secondary school education had a discriminatory attitude toward hivpositive people, with regard to them deserving to suffer, dismissing a hivpositive maid, hesitating to sit next to a hivpositive person in the bus, divorcing the infected spouse, and willingness to get tested for hiv, which was found to be statistically significant.
advmod||gained-5/VBN||also-1/RB	nsubj||gained-5/VBN||nicotinicacid-3/NN	aux||gained-5/VBN||has-4/VBZ	root||ROOT-0/null||gained-5/VBN	amod||interest-7/NN||more-6/JJR	dobj||gained-5/VBN||interest-7/NN	advmod||gained-5/VBN||partly-8/RB	mark||demonstrated-13/VBN||because-9/IN	amod||studies-11/NNS||recent-10/JJ	nsubj||demonstrated-13/VBN||studies-11/NNS	aux||demonstrated-13/VBN||have-12/VBP	advcl||gained-5/VBN||demonstrated-13/VBN	amod||effects-15/NNS||positive-14/JJ	dobj||demonstrated-13/VBN||effects-15/NNS	amod||development-18/NN||atherosclerosis-17/JJ	prep_on||demonstrated-13/VBN||development-18/NN	advmod||seems-27/VBZ||partly-20/RB	mark||seems-27/VBZ||because-21/IN	det||effect-24/NN||the-22/DT	nn||effect-24/NN||side-23/NN	nsubj||seems-27/VBZ||effect-24/NN	nsubj||avoidable-31/JJ||effect-24/NN	prep_of||effect-24/NN||flushing-26/NN	advcl||gained-5/VBN||seems-27/VBZ	conj_and||demonstrated-13/VBN||seems-27/VBZ	aux||avoidable-31/JJ||to-28/TO	cop||avoidable-31/JJ||be-29/VB	advmod||avoidable-31/JJ||partially-30/RB	xcomp||seems-27/VBZ||avoidable-31/JJ	det||administration-35/NN||the-33/DT	amod||administration-35/NN||concomitant-34/JJ	prep_with||avoidable-31/JJ||administration-35/NN	prep_of||administration-35/NN||laropiprant-37/NN	flushing-26||nicotinicacid-3||no||also, nicotinicacid has gained more interest partly because recent studies have demonstrated positive effects on atherosclerosis development and partly because the side effect of flushing seems to be partially avoidable with the concomitant administration of laropiprant.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||prevents-9/VBZ||that-5/IN	num||terbutaline-8/NN||2.5-6/CD	nn||terbutaline-8/NN||mg-7/NN	nsubj||prevents-9/VBZ||terbutaline-8/NN	ccomp||tested-2/VBD||prevents-9/VBZ	amod||hypoglycemia-11/NN||nocturnal-10/JJ	dobj||prevents-9/VBZ||hypoglycemia-11/NN	prepc_without||prevents-9/VBZ||causing-13/VBG	nn||hyperglycemia-15/NN||morning-14/NN	dobj||causing-13/VBG||hyperglycemia-15/NN	terbutaline-8||hypoglycemia-11||no_rel||we tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia.
advmod||differed-11/VBD||however-1/RB	det||expression-7/NN||the-3/DT	amod||expression-7/NN||serological-4/JJ	conj_and||serological-4/JJ||molecular-6/JJ	amod||expression-7/NN||molecular-6/JJ	nsubj||differed-11/VBD||expression-7/NN	nn||infection-10/NN||hbv-9/NN	prep_of||expression-7/NN||infection-10/NN	root||ROOT-0/null||differed-11/VBD	det||groups-15/NNS||the-13/DT	num||groups-15/NNS||two-14/CD	prep_in||differed-11/VBD||groups-15/NNS	det||group-17/NN||the-16/DT	nsubj||included-20/VBD||group-17/NN	prep_of||group-17/NN||patients-19/NNS	rcmod||groups-15/NNS||included-20/VBD	amod||individuals-22/NNS||more-21/JJR	dobj||included-20/VBD||individuals-22/NNS	amod||infection-26/NN||ongoing-24/JJ	nn||infection-26/NN||hbv-25/NN	prep_with||included-20/VBD||infection-26/NN	mark||defined-29/VBN||as-28/IN	advcl||included-20/VBD||defined-29/VBN	det||presence-32/NN||the-31/DT	prep_by||defined-29/VBN||presence-32/NN	amod||hbsag-35/NN||detectable-34/JJ	prep_of||presence-32/NN||hbsag-35/NN	prep_in||differed-11/VBD||or-37/CC	conj_or||groups-15/NNS||or-37/CC	nn||dna-39/NN||hbv-38/NN	prep_in||differed-11/VBD||dna-39/NN	conj_or||groups-15/NNS||dna-39/NN	num||%-42/NN||17-41/CD	dep||dna-39/NN||%-42/NN	num||%-45/NN||12-44/CD	dep||dna-39/NN||%-45/NN	conj_and||%-42/NN||%-45/NN	advmod||%-42/NN||respectively-47/RB	hbv-38||hbsag-35||yes||however, the serological and molecular expression of hbv infection differed in the two groups the group of patients included more individuals with ongoing hbv infection, as defined by the presence of detectable hbsag and or hbv dna (17% and 12%, respectively).
nn||rhythms-2/NNS||melatonin-1/NN	nsubj||displayed-3/VBD||rhythms-2/NNS	root||ROOT-0/null||displayed-3/VBD	amod||instability-5/NN||prolonged-4/JJ	dobj||displayed-3/VBD||instability-5/NN	amod||days-7/NNS||several-6/JJ	tmod||displayed-3/VBD||days-7/NNS	prep_after||displayed-3/VBD||stroke-9/NN	det||majority-13/NN||a-12/DT	prep_with||displayed-3/VBD||majority-13/NN	prep_of||majority-13/NN||rats-15/NNS	vmod||rats-15/NNS||showing-16/VBG	det||alternation-19/NN||a-17/DT	amod||alternation-19/NN||day-to-day-18/JJ	dobj||showing-16/VBG||alternation-19/NN	prep_between||alternation-19/NN||advance-21/NN	prep_between||alternation-19/NN||delay-23/NN	conj_and||advance-21/NN||delay-23/NN	nn||onset-26/NN||melatonin-25/NN	prep_in||showing-16/VBG||onset-26/NN	prep_in||showing-16/VBG||duration-28/NN	conj_and||onset-26/NN||duration-28/NN	melatonin-25||stroke-9||no_rel||melatonin rhythms displayed prolonged instability several days after stroke, with a majority of rats showing a day-to-day alternation between advance and delay in melatonin onset and duration.
nsubj||conducted-5/VBD||we-1/PRP	advmod||conducted-5/VBD||therefore-3/RB	root||ROOT-0/null||conducted-5/VBD	det||evaluation-8/NN||a-6/DT	amod||evaluation-8/NN||comprehensive-7/JJ	dobj||conducted-5/VBD||evaluation-8/NN	advmod||resistant-11/JJ||inh-10/RB	amod||levels-54/NNS||resistant-11/JJ	amod||strains-13/NNS||m.tuberculosis-12/JJ	nn||n-15/NN||strains-13/NNS	amod||n-15/NN||-lrb--14/JJ	npadvmod||resistant-11/JJ||n-15/NN	dep||-rrb--18/NNS||=-16/SYM	num||-rrb--18/NNS||224-17/CD	dep||n-15/NN||-rrb--18/NNS	npadvmod||south-21/RB||three-20/CD	advmod||countries-23/NNS||south-21/RB	amod||countries-23/NNS||american-22/JJ	prep_from||resistant-11/JJ||countries-23/NNS	amod||burden-26/NN||high-25/JJ	prep_with||resistant-11/JJ||burden-26/NN	prep_of||burden-26/NN||drug-28/NN	amod||levels-54/NNS||resistant-29/JJ	advmod||resistant-29/JJ||tb-30/RB	aux||characterize-32/VB||to-31/TO	xcomp||resistant-29/JJ||characterize-32/VB	dobj||characterize-32/VB||mutations-33/NNS	nn||g-36/NN||kat-35/NN	prep_in||characterize-32/VB||g-36/NN	xcomp||resistant-29/JJ||ahp-38/VB	conj_and||characterize-32/VB||ahp-38/VB	dep||ahp-38/VB||c-39/SYM	xcomp||resistant-29/JJ||inh-41/VB	conj_and||characterize-32/VB||inh-41/VB	det||loci-44/NN||a-42/DT	nn||loci-44/NN||gene-43/NN	dobj||inh-41/VB||loci-44/NN	conj_and||characterize-32/VB||correlate-46/VB	conj_and||inh-41/VB||correlate-46/VB	amod||concentrations-50/NNS||minimal-48/JJ	nn||concentrations-50/NNS||inhibitory-49/NN	prep_with||correlate-46/VB||concentrations-50/NNS	amod||levels-54/NNS||-lrb--51/JJ	amod||levels-54/NNS||mic-52/JJ	nn||levels-54/NNS||-rrb--53/NN	prep_of||evaluation-8/NN||levels-54/NNS	amod||family-58/NN||spoligotype-56/JJ	nn||family-58/NN||strain-57/NN	prep_of||evaluation-8/NN||family-58/NN	conj_and||levels-54/NNS||family-58/NN	tb-30||inh-41||yes||we , therefore , conducted a comprehensive evaluation of inh resistant m.tuberculosis strains -lrb- n = 224 -rrb- from three south american countries with high burden of drug resistant tb to characterize mutations in kat g , ahp c and inh a gene loci and correlate with minimal inhibitory concentrations -lrb- mic -rrb- levels and spoligotype strain family .
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||earlier-2/RB	root||ROOT-0/null||reported-3/VBD	mark||resulted-20/VBD||that-4/IN	nsubj||resulted-20/VBD||treatment-5/NN	amod||cultures-8/NNS||astrocyte-7/JJ	prep_of||treatment-5/NN||cultures-8/NNS	det||concentration-12/NN||a-10/DT	amod||concentration-12/NN||pathophysiological-11/JJ	prep_with||cultures-8/NNS||concentration-12/NN	prep_of||concentration-12/NN||ammonia-14/NN	num||nh4cl-18/NNS||5-16/CD	nn||nh4cl-18/NNS||mm-17/NNP	appos||ammonia-14/NN||nh4cl-18/NNS	ccomp||reported-3/VBD||resulted-20/VBD	det||activation-23/NN||the-22/DT	prep_in||resulted-20/VBD||activation-23/NN	amod||factor-kappab-26/NN||nuclear-25/JJ	prep_of||activation-23/NN||factor-kappab-26/NN	appos||factor-kappab-26/NN||nf-îºb-28/NNP	mark||diminished-36/VBN||that-31/IN	nsubj||diminished-36/VBN||inhibition-32/NN	amod||activation-35/NN||such-34/JJ	prep_of||inhibition-32/NN||activation-35/NN	ccomp||reported-3/VBD||diminished-36/VBN	conj_and||resulted-20/VBD||diminished-36/VBN	dobj||diminished-36/VBN||astrocyte-37/NN	amod||astrocyte-37/NN||swelling-38/VBG	vmod||diminished-36/VBN||suggesting-40/VBG	det||role-43/NN||a-41/DT	amod||role-43/NN||key-42/JJ	dobj||suggesting-40/VBG||role-43/NN	prep_of||role-43/NN||nf-îºb-45/NN	det||mechanism-48/NN||the-47/DT	prep_in||suggesting-40/VBG||mechanism-48/NN	amod||astrocyte-51/NN||ammonia-induced-50/JJ	prep_of||mechanism-48/NN||astrocyte-51/NN	amod||astrocyte-51/NN||swelling-52/VBG	ammonia-14||swelling-52||no_rel||we earlier reported that treatment of astrocyte cultures with a pathophysiological concentration of ammonia (5 mm nh4cl) resulted in the activation of nuclear factor-kappab (nf-îºb) and that inhibition of such activation diminished astrocyte swelling, suggesting a key role of nf-îºb in the mechanism of ammonia-induced astrocyte swelling.
amod||â-2/NN||objective-1/JJ	nsubj||was-10/VBD||â-2/NN	nsubj||examine-12/VB||â-2/NN	dep||â-2/NN||$-3/$	det||purpose-6/NN||the-5/DT	dep||â-2/NN||purpose-6/NN	det||study-9/NN||this-8/DT	prep_of||purpose-6/NN||study-9/NN	root||ROOT-0/null||was-10/VBD	aux||examine-12/VB||to-11/TO	xcomp||was-10/VBD||examine-12/VB	det||effect-14/NN||the-13/DT	dobj||examine-12/VB||effect-14/NN	prep_of||effect-14/NN||type-16/NN	nn||analog-19/NN||insulin-18/NN	prep_of||type-16/NN||analog-19/NN	prep_of||type-16/NN||age-21/NN	conj_and||analog-19/NN||age-21/NN	nn||site-24/NN||insertion-23/NN	prep_of||effect-14/NN||site-24/NN	det||characteristics-28/NNS||the-26/DT	amod||characteristics-28/NNS||pharmacodynamic-27/JJ	prep_on||examine-12/VB||characteristics-28/NNS	det||bolus-33/NNS||a-30/DT	amod||bolus-33/NNS||standard-31/JJ	nn||bolus-33/NNS||insulin-32/NN	prep_of||characteristics-28/NNS||bolus-33/NNS	prep_in||bolus-33/NNS||youth-35/NN	amod||therapy-41/NN||type1diabetes-37/JJ	nn||therapy-41/NN||receiving-38/NN	nn||therapy-41/NN||insulin-39/NN	nn||therapy-41/NN||pump-40/NN	prep_with||examine-12/VB||therapy-41/NN	type1diabetes-37||insulin-39||yes||objective â€”the purpose of this study was to examine the effect of type of insulin analog and age of insertion site on the pharmacodynamic characteristics of a standard insulin bolus in youth with type1diabetes receiving insulin pump therapy.
amod||practices-3/NNS||unsafe-1/JJ	nn||practices-3/NNS||injection-2/NN	nsubj||prevalent-5/JJ||practices-3/NNS	nsubj||resulted-15/VBN||practices-3/NNS	cop||prevalent-5/JJ||are-4/VBP	root||ROOT-0/null||prevalent-5/JJ	nn||users-9/NNS||injection-7/NN	nn||users-9/NNS||drug-8/NN	prep_among||prevalent-5/JJ||users-9/NNS	appos||users-9/NNS||idu-11/NN	aux||resulted-15/VBN||have-14/VBP	conj_and||prevalent-5/JJ||resulted-15/VBN	amod||forms-18/NNS||numerous-17/JJ	prep_in||resulted-15/VBN||forms-18/NNS	amod||harm-21/NN||drug-related-20/JJ	prep_of||forms-18/NNS||harm-21/NN	amod||transmission-24/NN||hiv/hcv-23/JJ	prep_including||harm-21/NN||transmission-24/NN	amod||bacterial-27/NNS||other-26/JJ	prep_including||harm-21/NN||bacterial-27/NNS	conj_and||transmission-24/NN||bacterial-27/NNS	conj_and||transmission-24/NN||viralinfections-29/NNS	conj_and||bacterial-27/NNS||viralinfections-29/NNS	viralinfections-29||idu-11||yes||unsafe injection practices are prevalent among injection drug users (idu) and have resulted in numerous forms of drug-related harm including hiv/hcv transmission and other bacterial and viralinfections.
amod||mortality-2/NN||overall-1/JJ	nsubj||%-5/NN||mortality-2/NN	cop||%-5/NN||was-3/VBD	num||%-5/NN||9-4/CD	root||ROOT-0/null||%-5/NN	num||deaths-8/NNS||21-7/CD	appos||%-5/NN||deaths-8/NNS	det||arm-15/NN||the-11/DT	amod||arm-15/NN||high-12/JJ	nn||arm-15/NN||flow-13/NN	nn||arm-15/NN||oxygen-14/NN	prep_in||%-5/NN||arm-15/NN	prep||arm-15/NN||compared-16/VBN	pcomp||compared-16/VBN||with-17/IN	num||%-19/NN||4-18/CD	pobj||with-17/IN||%-19/NN	num||deaths-22/NNS||7-21/CD	appos||%-19/NN||deaths-22/NNS	det||arm-28/NN||the-25/DT	amod||arm-28/NN||titrated-26/JJ	nn||arm-28/NN||oxygen-27/NN	prep_in||%-19/NN||arm-28/NN	nsubj||%-40/NN||mortality-30/NN	det||subgroup-33/NN||the-32/DT	prep_in||mortality-30/NN||subgroup-33/NN	amod||obstructivepulmonarydisease-37/NN||confirmed-35/JJ	amod||obstructivepulmonarydisease-37/NN||chronic-36/JJ	prep_with||subgroup-33/NN||obstructivepulmonarydisease-37/NN	cop||%-40/NN||was-38/VBD	num||%-40/NN||9-39/CD	parataxis||%-5/NN||%-40/NN	num||deaths-43/NNS||11-42/CD	appos||%-40/NN||deaths-43/NNS	det||arm-49/NN||the-46/DT	amod||arm-49/NN||high-47/JJ	nn||arm-49/NN||flow-48/NN	prep_in||%-40/NN||arm-49/NN	prepc_compared_with||arm-49/NN||with-51/IN	num||%-53/NN||2-52/CD	pobj||arm-49/NN||%-53/NN	num||deaths-56/NNS||2-55/CD	appos||%-53/NN||deaths-56/NNS	det||arm-62/NN||the-59/DT	amod||arm-62/NN||titrated-60/JJ	nn||arm-62/NN||oxygen-61/NN	prep_in||%-53/NN||arm-62/NN	obstructivepulmonarydisease-37||oxygen-61||yes||overall mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (7 deaths) in the titrated oxygen arm; mortality in the subgroup with confirmed chronic obstructivepulmonarydisease was 9% (11 deaths) in the high flow arm compared with 2% (2 deaths) in the titrated oxygen arm.
nn||profiles-3/NNS||dsp-1/NN	nn||profiles-3/NNS||toxin-2/NN	nsubj||showed-4/VBD||profiles-3/NNS	root||ROOT-0/null||showed-4/VBD	det||presence-6/NN||the-5/DT	dobj||showed-4/VBD||presence-6/NN	amod||oa-10/NN||okadaicacid-8/JJ	prep_of||presence-6/NN||oa-10/NN	prep_in||oa-10/NN||three-13/CD	dobj||showed-4/VBD||ytx-16/NN	conj_and||presence-6/NN||ytx-16/NN	prep_in||ytx-16/NN||four-18/CD	num||samples-22/NNS||nine-21/CD	prep_out_of||showed-4/VBD||samples-22/NNS	nsubjpass||analyzed-25/VBN||samples-22/NNS	auxpass||analyzed-25/VBN||were-24/VBD	rcmod||samples-22/NNS||analyzed-25/VBN	agent||analyzed-25/VBN||lc-ms/ms-27/NNS	oa-10||toxin-2||no_rel||dsp toxin profiles showed the presence of okadaicacid (oa) in three, and ytx in four out of nine samples that were analyzed by lc-ms/ms.
amod||â-2/NN||objective-1/JJ	nsubj||was-10/VBD||â-2/NN	nsubj||examine-12/VB||â-2/NN	dep||â-2/NN||$-3/$	det||purpose-6/NN||the-5/DT	dep||â-2/NN||purpose-6/NN	det||study-9/NN||this-8/DT	prep_of||purpose-6/NN||study-9/NN	root||ROOT-0/null||was-10/VBD	aux||examine-12/VB||to-11/TO	xcomp||was-10/VBD||examine-12/VB	det||effect-14/NN||the-13/DT	dobj||examine-12/VB||effect-14/NN	prep_of||effect-14/NN||type-16/NN	nn||analog-19/NN||insulin-18/NN	prep_of||type-16/NN||analog-19/NN	prep_of||type-16/NN||age-21/NN	conj_and||analog-19/NN||age-21/NN	nn||site-24/NN||insertion-23/NN	prep_of||effect-14/NN||site-24/NN	det||characteristics-28/NNS||the-26/DT	amod||characteristics-28/NNS||pharmacodynamic-27/JJ	prep_on||examine-12/VB||characteristics-28/NNS	det||bolus-33/NNS||a-30/DT	amod||bolus-33/NNS||standard-31/JJ	nn||bolus-33/NNS||insulin-32/NN	prep_of||characteristics-28/NNS||bolus-33/NNS	prep_in||bolus-33/NNS||youth-35/NN	amod||therapy-41/NN||type1diabetes-37/JJ	nn||therapy-41/NN||receiving-38/NN	nn||therapy-41/NN||insulin-39/NN	nn||therapy-41/NN||pump-40/NN	prep_with||examine-12/VB||therapy-41/NN	type1diabetes-37||insulin-39||yes||objective â€”the purpose of this study was to examine the effect of type of insulin analog and age of insertion site on the pharmacodynamic characteristics of a standard insulin bolus in youth with type1diabetes receiving insulin pump therapy.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||current-2/JJ	nsubj||relies-6/VBZ||treatment-3/NN	nsubj||relies-6/VBZ||treatment-3/NN	prep_of||treatment-3/NN||onchocerciasis-5/NNS	root||ROOT-0/null||relies-6/VBZ	conj_and||relies-6/VBZ||relies-6/VBZ	det||use-9/NN||the-8/DT	prep_on||relies-6/VBZ||use-9/NN	nsubj||microfilaricidal-15/JJ||use-9/NN	prep_of||use-9/NN||ivermectin-11/NN	cop||microfilaricidal-15/JJ||is-13/VBZ	advmod||microfilaricidal-15/JJ||only-14/RB	rcmod||use-9/NN||microfilaricidal-15/JJ	dobj||detected-28/VBN||which-18/WDT	amod||strains-21/NNS||resistant-19/JJ	nn||strains-21/NNS||parasite-20/NN	nsubjpass||detected-28/VBN||strains-21/NNS	amod||importance-24/NN||veterinary-23/JJ	prep_of||strains-21/NNS||importance-24/NN	aux||detected-28/VBN||are-25/VBP	advmod||detected-28/VBN||increasingly-26/RB	auxpass||detected-28/VBN||being-27/VBG	prepc_for||relies-6/VBZ||detected-28/VBN	onchocerciasis-5||ivermectin-11||yes||the current treatment of onchocerciasis relies on the use of ivermectin which is only microfilaricidal and for which resistant parasite strains of veterinary importance are increasingly being detected.
det||study-4/NN||this-2/DT	amod||study-4/NN||prospective-3/JJ	prep_in||associated-14/VBN||study-4/NN	prep_of||study-4/NN||women-6/NNS	nn||size-10/NN||nmr-8/NN	nn||size-10/NN||lipoprotein-9/NN	nsubjpass||associated-14/VBN||size-10/NN	nsubjpass||remained-19/VBD||size-10/NN	conj_and||size-10/NN||concentrations-12/NNS	nsubjpass||associated-14/VBN||concentrations-12/NNS	auxpass||associated-14/VBN||were-13/VBD	root||ROOT-0/null||associated-14/VBN	nn||type2diabetes-17/NNS||incident-16/NN	prep_with||associated-14/VBN||type2diabetes-17/NNS	conj_and||associated-14/VBN||remained-19/VBD	acomp||remained-19/VBD||significant-20/JJ	prep_after||significant-20/JJ||adjustment-22/NN	amod||factors-26/NNS||established-24/VBN	nn||factors-26/NNS||risk-25/NN	prep_for||adjustment-22/NN||factors-26/NNS	nn||cholesterol-30/NN||hdl-29/NN	prep_including||associated-14/VBN||cholesterol-30/NN	prep_including||associated-14/VBN||triglycerides-32/NNPS	conj_and||cholesterol-30/NN||triglycerides-32/NNPS	cholesterol-30||type2diabetes-17||no_rel||in this prospective study of women, nmr lipoprotein size and concentrations were associated with incident type2diabetes and remained significant after adjustment for established risk factors, including hdl cholesterol and triglycerides.
amod||africa-3/NN||south-2/JJ	prep_in||varies-11/VBZ||africa-3/NN	det||severity-6/NN||the-5/DT	nsubj||varies-11/VBZ||severity-6/NN	det||epidemic-10/NN||the-8/DT	amod||epidemic-10/NN||hiv/aids-9/JJ	prep_of||severity-6/NN||epidemic-10/NN	root||ROOT-0/null||varies-11/VBZ	prepc_according_to||varies-11/VBZ||to-13/TO	amod||location-15/NN||geographical-14/JJ	pobj||varies-11/VBZ||location-15/NN	advmod||enable-25/VB||hence-17/RB	amod||monitoring-20/NN||localized-19/VBN	nsubj||enable-25/VB||monitoring-20/NN	det||epidemic-23/NN||the-22/DT	prep_of||monitoring-20/NN||epidemic-23/NN	aux||enable-25/VB||would-24/MD	parataxis||varies-11/VBZ||enable-25/VB	advmod||effective-27/JJ||more-26/RBR	amod||strategies-29/NNS||effective-27/JJ	nn||strategies-29/NNS||prevention-28/NN	dobj||enable-25/VB||strategies-29/NNS	aids--1||hiv--1||no||in south africa, the severity of the hiv/aids epidemic varies according to geographical location; hence, localized monitoring of the epidemic would enable more effective prevention strategies.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	mark||index-16/NN||whether-3/IN	det||level-11/NN||the-4/DT	amod||level-11/NN||erythrocyte-5/JJ	amod||level-11/NN||phosphorylated-6/JJ	nn||level-11/NN||ribavirin-7/FW	appos||level-11/NN||rbv-9/NN	nsubj||index-16/NN||level-11/NN	aux||index-16/NN||might-12/MD	cop||index-16/NN||be-13/VB	det||index-16/NN||a-14/DT	amod||index-16/NN||useful-15/JJ	ccomp||determine-2/VB||index-16/NN	prep_of||index-16/NN||evr-18/NN	prep_of||index-16/NN||risk-20/NN	conj_and||evr-18/NN||risk-20/NN	prep_of||index-16/NN||anemia-22/NN	aux||determine-25/VB||to-24/TO	conj_and||determine-2/VB||determine-25/VB	det||dose-28/NN||the-26/DT	amod||dose-28/NN||optimal-27/JJ	dobj||determine-25/VB||dose-28/NN	prep_of||dose-28/NN||rbv-30/NN	num||patients-33/NNS||24-32/CD	prep_in||determine-25/VB||patients-33/NNS	prep_with||patients-33/NNS||hepatitisc-35/NN	amod||interferon-38/NN||pegylated-37/JJ	prep_with||determine-25/VB||interferon-38/NN	prep_with||determine-25/VB||rbv-40/NN	conj_and||interferon-38/NN||rbv-40/NN	anemia-22||ribavirin-7||no||to determine whether the erythrocyte phosphorylated ribavirin (rbv) level might be a useful index of evr and risk of anemia and to determine the optimal dose of rbv in 24 patients with hepatitisc with pegylated interferon and rbv.
det||study-14/NN||a-1/DT	amod||study-14/NN||2-week-2/JJ	amod||study-14/NN||prospective-4/JJ	amod||study-14/NN||randomized-6/JJ	amod||study-14/NN||controlled-8/JJ	amod||study-14/NN||single-center-10/JJ	amod||study-14/NN||parallel-group-12/JJ	nn||study-14/NN||pilot-13/NN	nsubj||administered-29/VBN||study-14/NN	auxpass||carried-16/VBN||was-15/VBD	rcmod||study-14/NN||carried-16/VBN	prt||carried-16/VBN||out-17/RP	aux||determine-19/VB||to-18/TO	xcomp||carried-16/VBN||determine-19/VB	det||efficacy-21/NN||the-20/DT	dobj||determine-19/VB||efficacy-21/NN	dobj||determine-19/VB||safety-23/NN	conj_and||efficacy-21/NN||safety-23/NN	nn||g-27/NN||paracetamol-25/NNP	num||g-27/NN||1-26/CD	prep_of||efficacy-21/NN||g-27/NN	advmod||administered-29/VBN||orally-28/RB	root||ROOT-0/null||administered-29/VBN	det||hours-32/NNS||every-30/DT	num||hours-32/NNS||6-31/CD	dobj||administered-29/VBN||hours-32/NNS	amod||patients-35/NNS||adult-34/JJ	prep_in||administered-29/VBN||patients-35/NNS	amod||openangleglaucoma-40/NN||primary-37/JJ	conj_or||primary-37/JJ||secondary-39/JJ	amod||openangleglaucoma-40/NN||secondary-39/JJ	prep_with||patients-35/NNS||openangleglaucoma-40/NN	prepc_as||administered-29/VBN||compared-42/VBN	pcomp||compared-42/VBN||with-43/IN	amod||levobunolol-45/NN||topical-44/JJ	pobj||with-43/IN||levobunolol-45/NN	number||%-47/NN||0.5-46/CD	amod||levobunolol-45/NN||%-47/NN	advmod||day-50/NN||twice-48/RB	det||day-50/NN||a-49/DT	tmod||with-43/IN||day-50/NN	openangleglaucoma-40||levobunolol-45||yes||a 2-week, prospective, randomized, controlled, single-center, parallel-group pilot study was carried out to determine the efficacy and safety of paracetamol 1 g orally administered every 6 hours in adult patients with primary or secondary openangleglaucoma as compared with topical levobunolol 0.5% twice a day.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	insulin-2||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	mark||emerged-9/VBD||that-3/IN	det||lineage-5/NN||this-4/DT	nsubj||emerged-9/VBD||lineage-5/NN	amod||viruses-8/NNS||defective-7/JJ	prep_of||lineage-5/NN||viruses-8/NNS	ccomp||show-2/VBP||emerged-9/VBD	prep_between||emerged-9/VBD||june-11/NNP	num||june-11/NNP||1998-12/CD	prep_between||emerged-9/VBD||february-14/NNP	conj_and||june-11/NNP||february-14/NNP	num||february-14/NNP||2001-15/CD	mark||transmitted-23/VBN||that-18/IN	det||virus-21/NN||the-19/DT	amod||virus-21/NN||defective-20/JJ	nsubjpass||transmitted-23/VBN||virus-21/NN	auxpass||transmitted-23/VBN||was-22/VBD	ccomp||show-2/VBP||transmitted-23/VBN	conj_and||emerged-9/VBD||transmitted-23/VBN	advmod||transmitted-23/VBN||primarily-24/RB	prep_through||transmitted-23/VBN||co-transmission-26/NN	det||virus-30/NN||the-28/DT	amod||virus-30/NN||functional-29/JJ	prep_with||transmitted-23/VBN||virus-30/NN	amod||individuals-33/NNS||uninfected-32/JJ	prep_to||virus-30/NN||individuals-33/NNS	virus-30||viruses-8||no||we show that this lineage of defective viruses emerged between june 1998 and february 2001, and that the defective virus was transmitted primarily through co-transmission with the functional virus to uninfected individuals.
mark||decreased-7/VBD||since-1/IN	poss||concentration-6/NN||her-2/PRP$	nn||concentration-6/NN||blood-3/NN	nn||concentration-6/NN||urea-4/NN	nn||concentration-6/NN||nitrogen-5/NN	nsubj||decreased-7/VBD||concentration-6/NN	advcl||suggested-12/VBN||decreased-7/VBD	advmod||decreased-7/VBD||greatly-8/RB	nsubjpass||suggested-12/VBN||it-10/PRP	auxpass||suggested-12/VBN||was-11/VBD	root||ROOT-0/null||suggested-12/VBN	mark||had-15/VBD||that-13/IN	nsubj||had-15/VBD||she-14/PRP	ccomp||suggested-12/VBN||had-15/VBD	amod||-rrb--28/NN||massive-16/JJ	amod||-rrb--28/NN||polyuria-17/JJ	amod||-rrb--28/NN||due-18/JJ	aux||overhydration-20/VB||to-19/TO	xcomp||due-18/JJ||overhydration-20/VB	amod||dilution-23/NN||-lrb--21/JJ	amod||dilution-23/NN||i.e.-22/JJ	dobj||overhydration-20/VB||dilution-23/NN	poss||fluids-27/NNS||her-25/PRP$	nn||fluids-27/NNS||body-26/NN	prep_of||dilution-23/NN||fluids-27/NNS	dobj||had-15/VBD||-rrb--28/NN	nitrogen-5||polyuria-17||no_rel||since her blood urea nitrogen concentration decreased greatly , it was suggested that she had massive polyuria due to overhydration -lrb- i.e. dilution of her body fluids -rrb- .
det||lack-2/NN||the-1/DT	nsubj||hindered-12/VBN||lack-2/NN	amod||trials-7/NNS||adequate-4/JJ	amod||trials-7/NNS||randomized-5/JJ	amod||trials-7/NNS||clinical-6/JJ	prep_of||lack-2/NN||trials-7/NNS	appos||trials-7/NNS||rct-9/NN	aux||hindered-12/VBN||has-11/VBZ	root||ROOT-0/null||hindered-12/VBN	dobj||hindered-12/VBN||identification-13/NN	nsubj||safe-19/JJ||identification-13/NN	nsubj||effective-21/JJ||identification-13/NN	amod||therapies-16/NNS||new-15/JJ	prep_of||identification-13/NN||therapies-16/NNS	cop||safe-19/JJ||are-18/VBP	rcmod||identification-13/NN||safe-19/JJ	rcmod||identification-13/NN||effective-21/JJ	conj_and||safe-19/JJ||effective-21/JJ	prep_for||safe-19/JJ||patients-23/NNS	amod||glomerulosclerosis-28/NNS||primary-25/JJ	amod||glomerulosclerosis-28/NNS||focal-26/JJ	amod||glomerulosclerosis-28/NNS||segmental-27/JJ	prep_with||patients-23/NNS||glomerulosclerosis-28/NNS	appos||glomerulosclerosis-28/NNS||fsgs-30/NNS	dep||safe-19/JJ||especially-33/RB	prep_in||safe-19/JJ||patients-35/NNS	nsubj||fail-37/VBP||patients-35/NNS	nsubj||respond-39/VB||patients-35/NNS	rcmod||patients-35/NNS||fail-37/VBP	aux||respond-39/VB||to-38/TO	xcomp||fail-37/VBP||respond-39/VB	prep_to||respond-39/VB||corticosteroids-41/NNS	nn||therapies-44/NNS||immunosuppressive-43/NN	prep_to||respond-39/VB||therapies-44/NNS	conj_and||corticosteroids-41/NNS||therapies-44/NNS	fsgs-30||immunosuppressive-43||no_rel||the lack of adequate randomized clinical trials (rct) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (fsgs), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies.
nsubj||worked-2/VBD||doctors-1/NNS	root||ROOT-0/null||worked-2/VBD	amod||clinics-8/NNS||urban-4/JJ	conj_and||urban-4/JJ||peri-urban-6/NN	amod||clinics-8/NNS||peri-urban-6/NN	nn||clinics-8/NNS||hiv/aids-7/NNS	prep_in||worked-2/VBD||clinics-8/NNS	prep_in||worked-2/VBD||peru-10/NN	advmod||are-24/VBP||where-12/WRB	quantmod||70-14/CD||almost-13/RB	num||%-15/NN||70-14/CD	nsubj||are-24/VBP||%-15/NN	det||nation-18/NN||the-17/DT	poss||patients-21/NNS||nation-18/NN	nn||patients-21/NNS||hiv-20/NN	prep_of||%-15/NN||patients-21/NNS	prep_in||%-15/NN||need-23/NN	advcl||worked-2/VBD||are-24/VBP	prep_on||are-24/VBP||treatment-26/NN	aids--1||hiv-20||no||doctors worked in urban and peri-urban hiv/aids clinics in peru, where almost 70% of the nation's hiv patients in need are on treatment.
nsubj||report-2/VBP||i-1/FW	root||ROOT-0/null||report-2/VBP	dobj||report-2/VBP||chorea-3/NN	det||patient-6/NN||a-5/DT	prep_in||chorea-3/NN||patient-6/NN	prep_with||report-2/VBP||celiacdisease-8/NN	nsubj||responded-11/VBD||celiacdisease-8/NN	rcmod||celiacdisease-8/NN||responded-11/VBD	det||diet-15/NN||a-13/DT	amod||diet-15/NN||gluten-restricted-14/JJ	prep_to||responded-11/VBD||diet-15/NN	celiacdisease-8||gluten--1||no||i report chorea in a patient with celiacdisease, which responded to a gluten-restricted diet.
nsubj||report-5/NN||this-1/DT	cop||report-5/NN||is-2/VBZ	det||report-5/NN||the-3/DT	amod||report-5/NN||first-4/JJ	root||ROOT-0/null||report-5/NN	aux||show-7/VB||to-6/TO	vmod||report-5/NN||show-7/VB	mark||expressed-13/VBN||that-8/IN	amod||oncogenes-10/NNS||certain-9/JJ	nsubjpass||expressed-13/VBN||oncogenes-10/NNS	auxpass||expressed-13/VBN||are-11/VBP	advmod||expressed-13/VBN||specifically-12/RB	ccomp||show-7/VB||expressed-13/VBN	det||sp-17/NN||the-15/DT	nn||sp-17/NN||myeloma-16/NN	prep_in||expressed-13/VBN||sp-17/NN	det||bortezomib-21/NN||that-20/DT	nsubj||downregulates-23/VBZ||bortezomib-21/NN	advmod||downregulates-23/VBZ||effectively-22/RB	conj_and||report-5/NN||downregulates-23/VBZ	dobj||downregulates-23/VBZ||expression-24/NN	poss||products-27/NNS||their-26/PRP$	prep_of||expression-24/NN||products-27/NNS	myeloma-16||bortezomib-21||yes||this is the first report to show that certain oncogenes are specifically expressed in the myeloma sp, and that bortezomib effectively downregulates expression of their products.
det||three-dose-4/NN||the-1/DT	advmod||three-dose-4/NN||once-2/RB	amod||three-dose-4/NN||daily-3/JJ	nsubj||superior-14/JJ||three-dose-4/NN	nsubj||six-dose-16/VB||three-dose-4/NN	amod||suspension-7/NN||artemether-lumefantrine-6/JJ	prep_of||three-dose-4/NN||suspension-7/NN	nn||®-10/NNP||co-artesianeâ-9/NNP	appos||three-dose-4/NN||®-10/NNP	cop||superior-14/JJ||was-12/VBD	neg||superior-14/JJ||not-13/RB	root||ROOT-0/null||superior-14/JJ	aux||six-dose-16/VB||to-15/TO	xcomp||superior-14/JJ||six-dose-16/VB	amod||tablets-18/NNS||artemether-lumefantrine-17/JJ	dobj||six-dose-16/VB||tablets-18/NNS	nn||®-21/NNP||coartemâ-20/NNP	appos||tablets-18/NNS||®-21/NNP	det||treatment-25/NN||the-24/DT	prep_for||six-dose-16/VB||treatment-25/NN	amod||malaria-28/NN||uncomplicated-27/JJ	prep_of||treatment-25/NN||malaria-28/NN	prep_in||malaria-28/NN||children-30/NNS	num||years-33/NNS||five-32/CD	prep_below||six-dose-16/VB||years-33/NNS	prep_of||years-33/NNS||age-35/NN	amod||kenya-38/NN||western-37/JJ	prep_in||age-35/NN||kenya-38/NN	malaria-28||artemether--1||yes||the once daily three-dose of artemether-lumefantrine suspension (co-artesianeâ®) was not superior to six-dose artemether-lumefantrine tablets (coartemâ®) for the treatment of uncomplicated malaria in children below five years of age in western kenya.
nn||fumigatus-2/NNS||a.-1/NN	nsubjpass||associated-5/VBN||fumigatus-2/NNS	aux||associated-5/VBN||has-3/VBZ	auxpass||associated-5/VBN||been-4/VBN	root||ROOT-0/null||associated-5/VBN	det||spectrum-9/NN||a-7/DT	amod||spectrum-9/NN||wide-8/JJ	prep_with||associated-5/VBN||spectrum-9/NN	prep_of||spectrum-9/NN||allergicdisorders-11/NNS	prep_such_as||allergicdisorders-11/NNS||abpa-14/NN	prep_such_as||allergicdisorders-11/NNS||safs-16/NNS	conj_or||abpa-14/NN||safs-16/NNS	abpa-14||allergicdisorders-11||no||a. fumigatus has been associated with a wide spectrum of allergicdisorders such as abpa or safs .
det||hearts-3/NNS||those-2/DT	prep_in||shorter-48/JJR||hearts-3/NNS	det||factor-6/NN||the-4/DT	nn||factor-6/NN||fibrillation-5/NN	nsubj||shorter-48/JJR||factor-6/NN	appos||factor-6/NN||ff-8/NN	det||domain-31/NN||the-11/DT	amod||domain-31/NN||interval-12/JJ	det||repolarization-16/NN||the-14/DT	amod||repolarization-16/NN||earliest-15/JJS	prep_between||interval-12/JJ||repolarization-16/NN	det||beat-20/NN||the-18/DT	amod||beat-20/NN||premature-19/JJ	prep_of||repolarization-16/NN||beat-20/NN	appos||beat-20/NN||s2-22/NNP	det||repolarizing-27/NN||the-25/DT	amod||repolarizing-27/NN||early-26/JJ	prep_in||beat-20/NN||repolarizing-27/NN	dep||repolarizing-27/NN||pinacidil-29/JJ	appos||factor-6/NN||domain-31/NN	det||domain-44/NN||the-34/DT	amod||domain-44/NN||last-35/JJ	amod||domain-44/NN||s2-activation-36/JJ	det||repolarizing-40/NN||the-38/DT	amod||repolarizing-40/NN||late-39/JJ	prep_in||s2-activation-36/JJ||repolarizing-40/NN	dep||domain-44/NN||sotalol-42/JJ	appos||factor-6/NN||domain-44/NN	conj_and||domain-31/NN||domain-44/NN	cop||shorter-48/JJR||was-46/VBD	advmod||shorter-48/JJR||significantly-47/RB	root||ROOT-0/null||shorter-48/JJR	prep||shorter-48/JJR||than-49/IN	pcomp||than-49/IN||in-50/IN	det||hearts-52/NNS||the-51/DT	pobj||in-50/IN||hearts-52/NNS	prep_without||shorter-48/JJR||vf-54/NN	num||â-57/NN||33-56/CD	nsubj||±-58/VBD||â-57/NN	parataxis||shorter-48/JJR||±-58/VBD	num||11â-64/NNS||22-59/CD	number||93-61/CD||vs-60/CD	num||11â-64/NNS||93-61/CD	amod||11â-64/NNS||â-62/JJ	num||11â-64/NNS||±-63/CD	nsubj||p-74/VBP||11â-64/NNS	num||11â-64/NNS||$-65/$	number||ms-67/CD||‰-66/CD	num||$-65/$||ms-67/CD	nn||sem-72/NNP||m-69/NN	nn||sem-72/NNP||â-70/NN	nn||sem-72/NNP||±-71/NNP	appos||11â-64/NNS||sem-72/NNP	ccomp||±-58/VBD||p-74/VBP	num||0.05-76/CD||<-75/CD	dobj||p-74/VBP||0.05-76/CD	vf-54||sotalol-42||yes||in those hearts the fibrillation factor (ff), the interval between the earliest repolarization of the premature beat (s2) in the early repolarizing (pinacidil) domain, and the last s2-activation in the late repolarizing (sotalol) domain, was significantly shorter than in the hearts without vf (33 â± 22 vs 93 â± 11â€‰ms, m â± sem, p < 0.05).
prepc_based_on||showed-20/VBD||on-2/IN	num||covariates-5/NNS||21-3/CD	amod||covariates-5/NNS||potential-4/JJ	pobj||showed-20/VBD||covariates-5/NNS	vmod||covariates-5/NNS||fitted-6/VBN	advmod||fitted-6/VBN||simultaneously-7/RB	amod||ratios-11/NNS||adjusted-9/JJ	nn||ratios-11/NNS||hazard-10/NN	nsubj||showed-20/VBD||ratios-11/NNS	dep||ratios-11/NNS||hr-13/NN	num||intervals-18/NNS||95-15/CD	nn||intervals-18/NNS||%-16/NN	nn||intervals-18/NNS||confidence-17/NN	dep||ratios-11/NNS||intervals-18/NNS	conj_and||hr-13/NN||intervals-18/NNS	root||ROOT-0/null||showed-20/VBD	mark||protectors-102/NNS||that-21/IN	nsubj||protectors-102/NNS||age-22/NN	dep||age-22/NN||hr-24/NN	num||hr-24/NN||1.03-25/CD	num||.06-28/CD||1.01-1-27/CD	dep||hr-24/NN||.06-28/CD	nn||0.01-32/NNP||p-30/NNP	nn||0.01-32/NNP||=-31/NNP	appos||.06-28/CD||0.01-32/NNP	conj_and||age-22/NN||diabetes-35/NN	nsubj||protectors-102/NNS||diabetes-35/NN	nn||1.68-38/NNS||hr-37/NN	dep||diabetes-35/NN||1.68-38/NNS	num||.79-41/CD||1.01-2-40/CD	appos||1.68-38/NNS||.79-41/CD	vmod||.79-41/CD||p-43/VBN	dep||0.05-45/CD||=-44/SYM	ccomp||p-43/VBN||0.05-45/CD	conj_and||age-22/NN||intra-48/NN	nsubj||protectors-102/NNS||intra-48/NN	amod||pump-51/NN||aortic-49/JJ	nn||pump-51/NN||balloon-50/NN	nsubj||factors-66/NNS||pump-51/NN	nn||5.12-54/NNS||hr-53/NN	dep||pump-51/NN||5.12-54/NNS	num||.10-57/CD||2.36-11-56/CD	appos||5.12-54/NNS||.10-57/CD	vmod||.10-57/CD||p-59/VBN	dep||0.0001-61/CD||=-60/SYM	ccomp||p-59/VBN||0.0001-61/CD	cop||factors-66/NNS||were-63/VBD	amod||factors-66/NNS||significant-64/JJ	nn||factors-66/NNS||risk-65/NN	rcmod||intra-48/NN||factors-66/NNS	mark||thrombolysis-68/JJ||whereas-67/IN	advcl||factors-66/NNS||thrombolysis-68/JJ	prep_by||thrombolysis-68/JJ||tenecteplase-70/NN	dep||tenecteplase-70/NN||hr-72/NN	num||hr-72/NN||0.35-73/CD	num||.98-76/CD||0.13-0-75/CD	appos||hr-72/NN||.98-76/CD	vmod||.98-76/CD||p-78/VBN	dep||0.05-80/CD||=-79/SYM	ccomp||p-78/VBN||0.05-80/CD	aux||had-84/VBN||having-83/VBG	advcl||factors-66/NNS||had-84/VBN	conj_and||thrombolysis-68/JJ||had-84/VBN	dobj||had-84/VBN||hypertension-85/NN	amod||treatment-88/NN||anti-hypertensive-87/JJ	dobj||had-84/VBN||treatment-88/NN	conj_or||hypertension-85/NN||treatment-88/NN	dep||age-22/NN||hr-90/NN	num||hr-90/NN||0.58-91/CD	num||.93-94/CD||0.36-0-93/CD	appos||hr-90/NN||.93-94/CD	vmod||.93-94/CD||p-96/VBN	dep||0.03-98/CD||=-97/SYM	ccomp||p-96/VBN||0.03-98/CD	cop||protectors-102/NNS||were-100/VBD	amod||protectors-102/NNS||significant-101/JJ	ccomp||showed-20/VBD||protectors-102/NNS	prep_for||protectors-102/NNS||events-104/NNS	hypertension-85||tenecteplase-70||no||based on 21 potential covariates fitted simultaneously, adjusted hazard ratios (hr and 95% confidence intervals) showed that age (hr 1.03, 1.01-1.06, p=0.01), diabetes (hr 1.68, 1.01-2.79, p=0.05) and intra aortic balloon pump (hr 5.12, 2.36-11.10, p=0.0001) were significant risk factors whereas thrombolysis by tenecteplase (hr 0.35, 0.13-0.98, p=0.05) and having had hypertension or anti-hypertensive treatment (hr 0.58, 0.36-0.93, p=0.03) were significant protectors for events.
prep_among||stroke-8/NN||females-2/NNS	det||causes-6/NNS||the-4/DT	amod||causes-6/NNS||leading-5/VBG	nsubj||stroke-8/NN||causes-6/NNS	cop||stroke-8/NN||are-7/VBP	root||ROOT-0/null||stroke-8/NN	number||%-11/NN||11.3-10/CD	dep||stroke-8/NN||%-11/NN	dep||stroke-8/NN||diabetes-14/NN	num||%-17/NN||8-16/CD	appos||diabetes-14/NN||%-17/NN	amod||heartdisease-21/NN||ischemic-20/JJ	conj_and||stroke-8/NN||heartdisease-21/NN	num||%-24/NN||7.5-23/CD	appos||heartdisease-21/NN||%-24/NN	dep||heartdisease-21/NN||hiv/aids-27/NNS	num||%-30/NN||5.7-29/CD	appos||hiv/aids-27/NNS||%-30/NN	conj_and||stroke-8/NN||renaldiseases-34/NNS	num||%-37/NN||4-36/CD	appos||renaldiseases-34/NNS||%-37/NN	aids--1||hiv--1||no||among females, the leading causes are stroke (11.3%); diabetes (8%); ischemic heartdisease (7.5%); hiv/aids (5.7%); and renaldiseases (4%).
advmod||assessed-3/VBN||adiposity-1/RB	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	prep_in||assessed-3/VBN||terms-5/NNS	prep_of||terms-5/NNS||bmi-7/NN	appos||bmi-7/NN||body-9/NN	num||%-11/NN||fat-10/CD	nsubjpass||assessed-3/VBN||%-11/NN	amod||mass-14/NN||fat-13/JJ	appos||%-11/NN||mass-14/NN	amod||index-18/NN||fat-16/JJ	amod||index-18/NN||mass-17/JJ	appos||%-11/NN||index-18/NN	conj_and||mass-14/NN||index-18/NN	amod||circumference-21/NN||waist-20/JJ	appos||%-11/NN||circumference-21/NN	conj_and||mass-14/NN||circumference-21/NN	adiposity-1||fat-16||no_rel||adiposity was assessed in terms of bmi, body fat %, fat mass, fat mass index and waist circumference.
nsubj||demonstrated-13/VBN||chondroitinsulfate-1/NN	conj_and||chondroitinsulfate-1/NN||diacereine-3/NN	nsubj||demonstrated-13/VBN||diacereine-3/NN	amod||sulfate-6/NN||glucosamine-5/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-6/NN	nsubj||demonstrated-13/VBN||sulfate-6/NN	nn||unsaponifiables-9/NNS||avocado/soybean-8/NN	conj_and||chondroitinsulfate-1/NN||unsaponifiables-9/NNS	nsubj||demonstrated-13/VBN||unsaponifiables-9/NNS	conj_and||chondroitinsulfate-1/NN||hyaluronicacid-11/NN	nsubj||demonstrated-13/VBN||hyaluronicacid-11/NN	aux||demonstrated-13/VBN||have-12/VBP	root||ROOT-0/null||demonstrated-13/VBN	nn||reduction-15/NN||pain-14/NN	dobj||demonstrated-13/VBN||reduction-15/NN	amod||improvement-19/NN||physical-17/JJ	nn||improvement-19/NN||function-18/NN	dobj||demonstrated-13/VBN||improvement-19/NN	conj_and||reduction-15/NN||improvement-19/NN	advmod||low-22/JJ||very-21/RB	amod||toxicity-23/NN||low-22/JJ	prep_with||demonstrated-13/VBN||toxicity-23/NN	amod||high-28/JJ||moderate-26/JJ	dep||high-28/JJ||to-27/TO	amod||evidence-30/NN||high-28/JJ	nn||evidence-30/NN||quality-29/NN	prep_with||demonstrated-13/VBN||evidence-30/NN	pain-14||hyaluronicacid-11||yes||chondroitinsulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronicacid have demonstrated pain reduction and physical function improvement with very low toxicity, with moderate to high quality evidence.
prep_in||needs-12/VBZ||order-2/NN	prep_to||order-2/NN||replicate-4/NNP	nsubj||needs-12/VBZ||hiv-6/NN	nsubj||invade-14/VB||hiv-6/NN	nsubj||hijack-19/VB||hiv-6/NN	det||viruses-10/NNS||all-9/DT	prep_like||hiv-6/NN||viruses-10/NNS	root||ROOT-0/null||needs-12/VBZ	aux||invade-14/VB||to-13/TO	xcomp||needs-12/VBZ||invade-14/VB	det||cell-17/NN||a-15/DT	nn||cell-17/NN||host-16/NN	dobj||invade-14/VB||cell-17/NN	xcomp||needs-12/VBZ||hijack-19/VB	conj_and||invade-14/VB||hijack-19/VB	dobj||hijack-19/VB||it-20/PRP	poss||use-24/NN||its-22/PRP$	amod||use-24/NN||own-23/JJ	prep_for||hijack-19/VB||use-24/NN	det||process-27/NN||a-26/DT	appos||use-24/NN||process-27/NN	nsubj||involves-29/VBZ||process-27/NN	rcmod||process-27/NN||involves-29/VBZ	amod||interactions-32/NNS||multiple-30/JJ	nn||interactions-32/NNS||protein-31/NN	dobj||involves-29/VBZ||interactions-32/NNS	prep_between||interactions-32/NNS||virus-34/NN	prep_between||interactions-32/NNS||host-36/NN	conj_and||virus-34/NN||host-36/NN	virus-34||viruses-10||no||in order to replicate, hiv, like all viruses, needs to invade a host cell and hijack it for its own use, a process that involves multiple protein interactions between virus and host.
nsubjpass||admitted-4/VBN||patients-1/NNS	nsubj||icu-6/VB||patients-1/NNS	prep_with||icu-6/VB||patients-1/NNS	nsubj||confirmed-8/VBD||patients-1/NNS	auxpass||admitted-4/VBN||were-3/VBD	rcmod||patients-1/NNS||admitted-4/VBN	aux||icu-6/VB||to-5/TO	xcomp||admitted-4/VBN||icu-6/VB	root||ROOT-0/null||confirmed-8/VBD	nsubj||included-10/VBD||h1n1-9/NNS	ccomp||confirmed-8/VBD||included-10/VBD	det||factors-14/NNS||the-11/DT	amod||factors-14/NNS||following-12/JJ	nn||factors-14/NNS||risk-13/NN	nsubj||delayed-15/VBD||factors-14/NNS	ccomp||included-10/VBD||delayed-15/VBD	dobj||delayed-15/VBD||initiation-16/NN	amod||therapy-19/NN||antiviral-18/JJ	prep_of||initiation-16/NN||therapy-19/NN	appos||therapy-19/NN||history-21/NN	nn||inhalation-24/NNS||opium-23/NN	prep_of||history-21/NN||inhalation-24/NNS	prep_of||history-21/NN||symptoms-26/NNS	conj_and||inhalation-24/NNS||symptoms-26/NNS	amod||cough-30/NN||productive-29/JJ	prep_including||delayed-15/VBD||cough-30/NN	prep_including||delayed-15/VBD||hemoptysis-32/NNS	conj_and||cough-30/NN||hemoptysis-32/NNS	nn||pain-35/NN||chest-34/NN	prep_including||delayed-15/VBD||pain-35/NN	conj_and||cough-30/NN||pain-35/NN	prep_including||delayed-15/VBD||confusion-37/NN	conj_and||cough-30/NN||confusion-37/NN	prep_including||delayed-15/VBD||loss-40/NN	conj_and||cough-30/NN||loss-40/NN	prep_of||loss-40/NN||consciousness-42/NN	pain-35||opium-23||yes||patients who were admitted to icu with confirmed h1n1 included the following risk factors delayed initiation of antiviral therapy, history of opium inhalation and symptoms including; productive cough, hemoptysis, chest pain, confusion, and loss of consciousness.
amod||weeks-3/NNS||2â-2/JJ	prep_after||developed-16/VBD||weeks-3/NNS	prep_of||weeks-3/NNS||treatment-5/NN	prep_with||treatment-5/NN||meropenem-7/NN	prep_with||treatment-5/NN||erythromycin-9/NN	conj_and||meropenem-7/NN||erythromycin-9/NN	amod||weeks-12/NNS||4â-11/JJ	prep_for||meropenem-7/NN||weeks-12/NNS	det||patient-15/NN||the-14/DT	nsubj||developed-16/VBD||patient-15/NN	root||ROOT-0/null||developed-16/VBD	det||relapse-18/NN||a-17/DT	dobj||developed-16/VBD||relapse-18/NN	nn||jejuni-31/NNS||bacteremia-20/NN	num||months-22/NNS||10â-21/CD	npadvmod||later-23/RBR||months-22/NNS	advmod||resistant-29/NN||later-23/RBR	det||erythromycin-28/NN||a-25/DT	amod||erythromycin-28/NN||high-26/JJ	nn||erythromycin-28/NN||level-27/NN	prep_with||resistant-29/NN||erythromycin-28/NN	amod||jejuni-31/NNS||resistant-29/NN	nn||jejuni-31/NNS||c.-30/NN	prep_of||relapse-18/NN||jejuni-31/NNS	meropenem-7||bacteremia-20||no_rel||after 2â weeks of treatment with meropenem and erythromycin for 4â weeks , the patient developed a relapse of bacteremia 10â months later with a high level erythromycin resistant c. jejuni .
nsubj||provides-2/VBZ||oxymorphone-1/NN	root||ROOT-0/null||provides-2/VBZ	amod||relief-5/NN||excellent-3/JJ	nn||relief-5/NN||pain-4/NN	dobj||provides-2/VBZ||relief-5/NN	amod||pain-8/NN||significant-7/JJ	prep_for||relief-5/NN||pain-8/NN	amod||effects-14/NNS||typical-11/JJ	amod||effects-14/NNS||opioid-12/JJ	nn||effects-14/NNS||side-13/NN	prep_with||provides-2/VBZ||effects-14/NNS	nsubj||mild-18/JJ||effects-14/NNS	nsubj||moderate-20/JJ||effects-14/NNS	cop||mild-18/JJ||are-16/VBP	advmod||mild-18/JJ||usually-17/RB	rcmod||effects-14/NNS||mild-18/JJ	rcmod||effects-14/NNS||moderate-20/JJ	conj_or||mild-18/JJ||moderate-20/JJ	prep_in||mild-18/JJ||intensity-22/NN	pain-8||oxymorphone-1||yes||oxymorphone provides excellent pain relief for significant pain, with typical opioid side effects that are usually mild or moderate in intensity.
amod||trends-3/NNS||google-1/JJ	nn||trends-3/NNS||flu-2/NN	nsubjpass||developed-5/VBN||trends-3/NNS	nsubj||estimate-7/VB||trends-3/NNS	auxpass||developed-5/VBN||was-4/VBD	root||ROOT-0/null||developed-5/VBN	aux||estimate-7/VB||to-6/TO	xcomp||developed-5/VBN||estimate-7/VB	nsubj||rates-14/NNS||us-8/PRP	amod||rates-14/NNS||influenza-like-9/JJ	nn||rates-14/NNS||illness-10/NN	appos||rates-14/NNS||ili-12/NN	xcomp||estimate-7/VB||rates-14/NNS	nn||searches-17/NNS||internet-16/NN	prep_from||rates-14/NNS||searches-17/NNS	advmod||correlate-24/VB||however-19/RB	nsubj||correlate-24/VB||ili-20/NN	aux||correlate-24/VB||does-21/VBZ	neg||correlate-24/VB||not-22/RB	advmod||correlate-24/VB||necessarily-23/RB	parataxis||developed-5/VBN||correlate-24/VB	amod||influenzavirusinfections-27/NNS||actual-26/JJ	prep_with||correlate-24/VB||influenzavirusinfections-27/NNS	influenza--1||influenzavirus--1||no||google flu trends was developed to estimate us influenza-like illness (ili) rates from internet searches; however ili does not necessarily correlate with actual influenzavirusinfections.
det||study-3/NN||this-2/DT	prep_in||is-13/VBZ||study-3/NN	det||prevalence-6/NN||the-5/DT	nsubj||is-13/VBZ||prevalence-6/NN	nn||abnormalities-9/NNS||glucose-8/NN	prep_of||prevalence-6/NN||abnormalities-9/NNS	amod||children-12/NNS||obese-11/JJ	prep_in||abnormalities-9/NNS||children-12/NNS	root||ROOT-0/null||is-13/VBZ	dep||than-15/IN||higher-14/JJR	advmod||is-13/VBZ||than-15/IN	amod||series-18/NN||other-17/JJ	prep_in||is-13/VBZ||series-18/NN	advmod||present-25/JJ||furthermore-20/RB	det||correlation-23/NN||a-22/DT	nsubj||present-25/JJ||correlation-23/NN	cop||present-25/JJ||is-24/VBZ	parataxis||is-13/VBZ||present-25/JJ	prep_between||present-25/JJ||markers-27/NNS	amod||inflammation-32/NN||systemic-29/JJ	conj_and||systemic-29/JJ||intestinal-31/JJ	amod||inflammation-32/NN||intestinal-31/JJ	prep_of||markers-27/NNS||inflammation-32/NN	nn||abnormalities-35/NNS||glucose-34/NN	prep_of||markers-27/NNS||abnormalities-35/NNS	conj_and||inflammation-32/NN||abnormalities-35/NNS	inflammation-32||glucose-34||no_rel||in this study, the prevalence of glucose abnormalities in obese children is higher than in other series; furthermore, a correlation is present between markers of systemic and intestinal inflammation and glucose abnormalities.
amod||melanoma-2/NN||db-1-1/JJ	nsubjpass||treated-19/VBN||melanoma-2/NN	nn||wildtype-5/NN||p53-4/NN	appos||melanoma-2/NN||wildtype-5/NN	conj_and||melanoma-2/NN||sk-9/NN	nsubjpass||treated-19/VBN||sk-9/NN	number||28-11/CD||mel-10/CD	num||lines-17/NNS||28-11/CD	num||mutant-14/NNS||p53-13/CD	appos||lines-17/NNS||mutant-14/NNS	nn||lines-17/NNS||cell-16/NN	dep||sk-9/NN||lines-17/NNS	auxpass||treated-19/VBN||were-18/VBD	root||ROOT-0/null||treated-19/VBN	prep_with||treated-19/VBN||tmz-21/NN	num||î-24/NN||400-23/CD	dep||tmz-21/NN||î-24/NN	num||m-26/NN||1/4-25/CD	dep||î-24/NN||m-26/NN	num||hrs-30/NN||48-29/CD	prep_for||treated-19/VBN||hrs-30/NN	vmod||hrs-30/NN||followed-31/VBN	agent||followed-31/VBN||qct-33/NN	num||î-36/NN||75-35/CD	dep||qct-33/NN||î-36/NN	num||m-38/NN||1/4-37/CD	dep||î-36/NN||m-38/NN	num||hrs-42/NN||24-41/CD	prep_for||qct-33/NN||hrs-42/NN	melanoma-2||tmz-21||yes||db-1 melanoma (p53 wildtype), and sk mel 28 (p53 mutant) cell lines were treated with tmz (400 î¼m) for 48 hrs followed by qct (75 î¼m) for 24 hrs.
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	cardiovasculardisease-15||estrogen-13||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
nn||manufacturers-2/NNS||indian-1/NN	nsubj||facilitated-10/VBD||manufacturers-2/NNS	amod||antiretroviral-5/JJ||generic-4/JJ	amod||medicines-9/NNS||antiretroviral-5/JJ	appos||medicines-9/NNS||arv-7/NN	prep_of||manufacturers-2/NNS||medicines-9/NNS	root||ROOT-0/null||facilitated-10/VBD	det||scale-13/NN||the-11/DT	amod||scale-13/NN||rapid-12/JJ	dobj||facilitated-10/VBD||scale-13/NN	prt||facilitated-10/VBD||up-14/RP	amod||treatment-17/NN||hiv/aids-16/JJ	prep_of||facilitated-10/VBD||treatment-17/NN	amod||countries-20/NNS||developing-19/VBG	prep_in||facilitated-10/VBD||countries-20/NNS	prep_though||countries-20/NNS||provision-22/NN	amod||medicines-27/NNS||low-priced-24/JJ	amod||medicines-27/NNS||quality-assured-26/JJ	prep_of||provision-22/NN||medicines-27/NNS	aids--1||hiv--1||no||indian manufacturers of generic antiretroviral (arv) medicines facilitated the rapid scale up of hiv/aids treatment in developing countries though provision of low-priced, quality-assured medicines.
det||results-2/NNS||the-1/DT	nsubj||show-6/VBP||results-2/NNS	det||study-5/NN||this-4/DT	prep_of||results-2/NNS||study-5/NN	root||ROOT-0/null||show-6/VBP	mark||added-9/VBD||that-7/IN	nsubj||added-9/VBD||remifentanil-8/NN	nsubj||propofol-11/VB||remifentanil-8/NN	ccomp||show-6/VBP||added-9/VBD	aux||propofol-11/VB||to-10/TO	xcomp||added-9/VBD||propofol-11/VB	nn||sensitization-15/NN||anesthesia-12/NN	nn||sensitization-15/NN||causes-13/NNS	nn||sensitization-15/NN||pain-14/NN	dobj||propofol-11/VB||sensitization-15/NN	det||period-20/NN||the-17/DT	amod||period-20/NN||immediate-18/JJ	nn||period-20/NN||postoperative-19/NN	prep_in||sensitization-15/NN||period-20/NN	pain-14||propofol-11||yes||the results of this study show that remifentanil added to propofol anesthesia causes pain sensitization in the immediate postoperative period.
amod||analyses-2/NNS||secondary-1/JJ	nsubj||compare-4/VB||analyses-2/NNS	aux||compare-4/VB||will-3/MD	ccomp||hiv-15/VBP||compare-4/VB	det||rates-6/NNS||the-5/DT	dobj||compare-4/VB||rates-6/NNS	prep_of||rates-6/NNS||change-8/NN	amod||count-11/NN||cd4-10/JJ	prep_in||compare-4/VB||count-11/NN	amod||log10-14/NNS||median-13/JJ	nsubj||hiv-15/VBP||log10-14/NNS	root||ROOT-0/null||hiv-15/VBP	amod||load-17/NN||viral-16/JJ	dobj||hiv-15/VBP||load-17/NN	amod||events-21/NNS||drug-related-19/JJ	amod||events-21/NNS||adverse-20/JJ	appos||load-17/NN||events-21/NNS	dobj||hiv-15/VBP||frequency-23/NN	conj_and||load-17/NN||frequency-23/NN	nn||reactivations-26/NNS||hsv-25/NN	prep_of||frequency-23/NN||reactivations-26/NNS	dobj||hiv-15/VBP||rate-28/NN	conj_and||load-17/NN||rate-28/NN	amod||hsv-31/NN||acyclovir-resistant-30/JJ	prep_of||rate-28/NN||hsv-31/NN	dobj||hiv-15/VBP||quality-34/NN	conj_and||load-17/NN||quality-34/NN	prep_of||quality-34/NN||life-36/NN	nn||arms-39/NNS||study-38/NN	prep_between||life-36/NN||arms-39/NNS	hsv-31||acyclovir--1||yes||secondary analyses will compare the rates of change in cd4 count, median log10 hiv viral load, drug-related adverse events, frequency of hsv reactivations, rate of acyclovir-resistant hsv, and quality of life between study arms.
nsubj||drugs-14/NNS||glatirameracetate-1/NN	appos||glatirameracetate-1/NN||ga-3/NN	conj_and||glatirameracetate-1/NN||interferon-beta-6/NN	nsubj||drugs-14/NNS||interferon-beta-6/NN	appos||interferon-beta-6/NN||infb-8/NN	cop||drugs-14/NNS||are-10/VBP	amod||drugs-14/NNS||first-line-11/JJ	nn||drugs-14/NNS||disease-12/NN	nn||drugs-14/NNS||modifying-13/NN	root||ROOT-0/null||drugs-14/NNS	prep_for||drugs-14/NNS||relapsingremittingmultiplesclerosis-16/NNS	appos||relapsingremittingmultiplesclerosis-16/NNS||rrms-18/NNS	relapsingremittingmultiplesclerosis-16||glatirameracetate-1||yes||glatirameracetate (ga) and interferon-beta (infb) are first-line disease modifying drugs for relapsingremittingmultiplesclerosis (rrms).
det||review-2/NN||this-1/DT	nsubj||seeks-3/VBZ||review-2/NN	nsubj||synthesise-5/VB||review-2/NN	root||ROOT-0/null||seeks-3/VBZ	aux||synthesise-5/VB||to-4/TO	xcomp||seeks-3/VBZ||synthesise-5/VB	poss||data-8/NNS||our-6/PRP$	amod||data-8/NNS||new-7/JJ	dobj||synthesise-5/VB||data-8/NNS	amod||nanotubes-12/NNS||multi-walled-10/JJ	nn||nanotubes-12/NNS||carbon-11/NN	prep_with||synthesise-5/VB||nanotubes-12/NNS	appos||nanotubes-12/NNS||cnt-14/NN	det||hypothesis-18/NNS||that-17/DT	prep_with||synthesise-5/VB||hypothesis-18/NNS	det||behaviour-21/NN||the-20/DT	prep_for||hypothesis-18/NNS||behaviour-21/NN	amod||fibres-24/NNS||long-23/JJ	prep_of||behaviour-21/NN||fibres-24/NNS	det||lung-27/NN||the-26/DT	prep_in||fibres-24/NNS||lung-27/NN	poss||retention-30/NN||their-29/PRP$	prep_with||synthesise-5/VB||retention-30/NN	conj_and||hypothesis-18/NNS||retention-30/NN	det||pleura-34/NN||the-32/DT	amod||pleura-34/NN||parietal-33/JJ	prep_in||retention-30/NN||pleura-34/NN	vmod||retention-30/NN||leading-35/VBG	det||initiation-38/NN||the-37/DT	prep_to||leading-35/VBG||initiation-38/NN	nn||pathology-43/NN||inflammation-40/NN	conj_and||inflammation-40/NN||pleural-42/NN	nn||pathology-43/NN||pleural-42/NN	prep_of||initiation-38/NN||pathology-43/NN	prep_such_as||retention-30/NN||mesothelioma-46/NN	carbon-11||inflammation-40||no_rel||this review seeks to synthesise our new data with multi-walled carbon nanotubes (cnt) with that hypothesis for the behaviour of long fibres in the lung and their retention in the parietal pleura leading to the initiation of inflammation and pleural pathology such as mesothelioma.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||looks-4/VBZ||study-3/NN	root||ROOT-0/null||looks-4/VBZ	det||aspects-7/NNS||some-6/DT	prep_at||looks-4/VBZ||aspects-7/NNS	prep_of||aspects-7/NNS||disability-9/NN	vmod||disability-9/NN||associated-10/VBN	num||disorders-14/NNS||7-12/CD	amod||disorders-14/NNS||psychiatric-13/JJ	prep_with||associated-10/VBN||disorders-14/NNS	nn||depression-21/NN||schizophrenia-15/NN	dep||depression-21/NN||bipolaraffectivedisorder-17/NN	dep||depression-21/NN||anxietydisorders-19/NNS	dep||disorders-14/NNS||depression-21/NN	vmod||disorders-14/NNS||obsessiveâ-23/VBG	dobj||obsessiveâ-23/VBG||$-24/$	advmod||alcohol-41/CD||compulsive-26/RB	dep||mental-32/JJ||disorder-27/JJ	conj_and||mental-32/JJ||dementia-29/JJ	amod||disorders-35/NNS||dementia-29/JJ	amod||disorders-35/NNS||mental-32/JJ	conj_and||mental-32/JJ||behavioural-34/JJ	amod||disorders-35/NNS||behavioural-34/JJ	npadvmod||alcohol-41/CD||disorders-35/NNS	det||use-39/NN||the-38/DT	prep_due_to||alcohol-41/CD||use-39/NN	prep||use-39/NN||of-40/IN	num||$-24/$||alcohol-41/CD	alcohol-41||disorder-27||no_rel||the present study looks at some aspects of disability associated with 7 psychiatric disorders schizophrenia, bipolaraffectivedisorder, anxietydisorders, depression, obsessiveâ€“compulsive disorder, dementia, and mental and behavioural disorders due to the use of alcohol.
nsubj||remains-2/VBZ||pneumocystisjirovecii-1/NNS	root||ROOT-0/null||remains-2/VBZ	det||cause-5/NN||an-3/DT	amod||cause-5/NN||important-4/JJ	xcomp||remains-2/VBZ||cause-5/NN	amod||pneumonia-8/NN||fatal-7/JJ	prep_of||cause-5/NN||pneumonia-8/NN	dep||pneumonia-8/NN||pneumocystispneumonia-10/NN	dep||pneumonia-8/NN||pcp-12/NN	conj_or||pneumocystispneumonia-10/NN||pcp-12/NN	nn||patients-17/NNS||hiv-15/NN	nn||patients-17/NNS||+-16/NN	prep_in||remains-2/VBZ||patients-17/NNS	amod||hosts-21/NNS||other-19/JJ	amod||hosts-21/NNS||immunocompromised-20/JJ	prep_in||remains-2/VBZ||hosts-21/NNS	conj_and||patients-17/NNS||hosts-21/NNS	pneumocystispneumonia-10||pneumocystisjirovecii-1||no||pneumocystisjirovecii remains an important cause of fatal pneumonia ( pneumocystispneumonia or pcp) in hiv+ patients and other immunocompromised hosts.
advmod||studied-4/VBD||here-1/RB	nsubj||studied-4/VBD||we-3/PRP	root||ROOT-0/null||studied-4/VBD	det||expression-6/NN||the-5/DT	dobj||studied-4/VBD||expression-6/NN	det||translocation-10/NN||the-8/DT	amod||translocation-10/NN||ten-eleven-9/JJ	prep_of||expression-6/NN||translocation-10/NN	appos||translocation-10/NN||tet-12/NN	nn||family-15/NN||gene-14/NN	dep||enzymes-21/NNS||family-15/NN	amod||deaminase/apolipoprotein-18/NN||activation-induced-17/JJ	conj_and||family-15/NN||deaminase/apolipoprotein-18/NN	dep||enzymes-21/NNS||deaminase/apolipoprotein-18/NN	dep||enzymes-21/NNS||b-19/SYM	amod||enzymes-21/NNS||mrna-editing-20/JJ	dep||expression-6/NN||enzymes-21/NNS	dep||enzymes-21/NNS||aid/apobec-23/JJ	det||lobule-29/NN||the-26/DT	amod||parietal-28/JJ||inferior-27/JJ	amod||lobule-29/NN||parietal-28/JJ	prep_in||enzymes-21/NNS||lobule-29/NN	appos||lobule-29/NN||ipl-31/NN	dep||lobule-29/NN||ba39-40-34/JJ	det||cerebellum-38/NN||the-37/DT	dep||expression-6/NN||cerebellum-38/NN	conj_and||enzymes-21/NNS||cerebellum-38/NN	amod||patients-50/NNS||psychotic-40/JJ	appos||patients-50/NNS||psy-42/NN	amod||patients-50/NNS||patients-44/JJ	amod||patients-50/NNS||depressed-46/JJ	appos||patients-50/NNS||dep-48/NN	prep_of||cerebellum-38/NN||patients-50/NNS	amod||subjects-56/NNS||nonpsychiatric-52/JJ	appos||subjects-56/NNS||ctr-54/NN	nsubj||obtained-57/VBD||subjects-56/NNS	conj_and||studied-4/VBD||obtained-57/VBD	det||institute-66/NN||the-59/DT	amod||institute-66/NN||stanley-60/JJ	nn||institute-66/NN||foundation-61/NN	nn||institute-66/NN||neuropathology-62/NN	nn||institute-66/NN||consortium-63/NN	amod||institute-66/NN||medical-64/JJ	nn||institute-66/NN||research-65/NN	prep_from||obtained-57/VBD||institute-66/NN	enzymes-21||psychotic-40||no_rel||here, we studied the expression of the ten-eleven translocation (tet) gene family and activation-induced deaminase/apolipoprotein b mrna-editing enzymes (aid/apobec) in the inferior parietal lobule (ipl) (ba39-40) and the cerebellum of psychotic (psy) patients, depressed (dep) patients and nonpsychiatric (ctr) subjects obtained from the stanley foundation neuropathology consortium medical research institute.
preconj||entry-5/NN||both-1/DT	nn||entry-5/NN||mv-2/NN	conj_and||mv-2/NN||ev-4/NN	nn||entry-5/NN||ev-4/NN	nsubjpass||inhibited-7/VBN||entry-5/NN	nsubjpass||depended-17/VBN||entry-5/NN	auxpass||inhibited-7/VBN||were-6/VBD	root||ROOT-0/null||inhibited-7/VBN	det||rottlerin-12/NN||the-9/DT	amod||rottlerin-12/NN||macropinocytosis-10/JJ	nn||rottlerin-12/NN||inhibitors-11/NNS	agent||inhibited-7/VBN||rottlerin-12/NN	nn||amiloride-15/NN||dimethyl-14/NN	agent||inhibited-7/VBN||amiloride-15/NN	conj_and||rottlerin-12/NN||amiloride-15/NN	conj_and||inhibited-7/VBN||depended-17/VBN	prep_on||depended-17/VBN||phosphotidylinositol-3-kinase-19/JJ	dep||phosphotidylinositol-3-kinase-19/JJ||pi-21/NN	appos||pi-21/NN||3-23/CD	dep||pi-21/NN||k-25/NN	nsubj||colocalised-30/VBD||both-29/DT	conj_and||inhibited-7/VBN||colocalised-30/VBD	prep_with||colocalised-30/VBD||dextran-32/NN	prep_with||colocalised-30/VBD||transferrin-35/NN	conj_negcc||dextran-32/NN||transferrin-35/NN	ev-4||dextran-32||no_rel||both mv and ev entry were inhibited by the macropinocytosis inhibitors rottlerin and dimethyl amiloride and depended on phosphotidylinositol-3-kinase (pi(3)k), and both colocalised with dextran but not transferrin.
csubj||influences-11/VBZ||encapsulating-1/VBG	amod||influenzavirus-4/NNS||inactivated-2/JJ	amod||influenzavirus-4/NNS||h5n1-3/JJ	dobj||encapsulating-1/VBG||influenzavirus-4/NNS	dobj||encapsulating-1/VBG||cpg-6/NN	conj_and||influenzavirus-4/NNS||cpg-6/NN	advmod||nanoparticles-9/JJ||emulsified-8/RB	prep_into||encapsulating-1/VBG||nanoparticles-9/JJ	advmod||nanoparticles-9/JJ||critically-10/RB	root||ROOT-0/null||influences-11/VBZ	det||responses-14/NNS||the-12/DT	amod||responses-14/NNS||humoral-13/JJ	dobj||influences-11/VBZ||responses-14/NNS	amod||influenza-17/NN||pandemic-16/JJ	prep_against||responses-14/NNS||influenza-17/NN	influenza-17||influenzavirus-4||no||encapsulating inactivated h5n1 influenzavirus and cpg into emulsified nanoparticles critically influences the humoral responses against pandemic influenza.
advmod||scarce-33/JJ||specifically-1/RB	nsubj||scarce-33/JJ||studies-3/NNS	det||association-6/NN||the-5/DT	prep_on||studies-3/NNS||association-6/NN	amod||behaviors-9/NNS||sexual-8/JJ	prep_between||association-6/NN||behaviors-9/NNS	amod||factors-13/NNS||other-11/JJ	nn||factors-13/NNS||risk-12/NN	prep_on||studies-3/NNS||factors-13/NNS	conj_and||association-6/NN||factors-13/NNS	prep_for||factors-13/NNS||sexuallytransmittedinfections-15/NNS	appos||sexuallytransmittedinfections-15/NNS||sti-17/NN	amod||transmission-21/NN||hiv/aids-20/JJ	prep_for||factors-13/NNS||transmission-21/NN	conj_and||sexuallytransmittedinfections-15/NNS||transmission-21/NN	det||consumption-26/NN||the-25/DT	prep_such_as||factors-13/NNS||consumption-26/NN	amod||drugs-29/NNS||illicit-28/JJ	prep_of||consumption-26/NN||drugs-29/NNS	prep_of||consumption-26/NN||alcohol-31/NN	conj_or||drugs-29/NNS||alcohol-31/NN	cop||scarce-33/JJ||are-32/VBP	root||ROOT-0/null||scarce-33/JJ	det||context-37/NN||this-35/DT	amod||context-37/NN||specific-36/JJ	prep_in||scarce-33/JJ||context-37/NN	aids--1||hiv--1||no||specifically, studies on the association between sexual behaviors and other risk factors for sexuallytransmittedinfections (sti) and hiv/aids transmission, such as the consumption of illicit drugs or alcohol are scarce in this specific context.
det||treatment-3/NN||the-1/DT	amod||treatment-3/NN||lidocaine-2/JJ	nsubj||decreased-7/VBD||treatment-3/NN	vmod||treatment-3/NN||resulted-4/VBN	prep||resulted-4/VBN||in-5/IN	pcomp||in-5/IN||significantly-6/RB	root||ROOT-0/null||decreased-7/VBD	nn||activity-9/NN||brain-8/NN	dobj||decreased-7/VBD||activity-9/NN	det||groups-13/NNS||both-11/DT	amod||groups-13/NNS||patient-12/JJ	prep_in||decreased-7/VBD||groups-13/NNS	amod||regions-17/NNS||distinct-15/JJ	nn||regions-17/NNS||brain-16/NN	prep_with||decreased-7/VBD||regions-17/NNS	vmod||regions-17/NNS||responding-18/VBG	det||group-21/NN||each-20/DT	prep_in||responding-18/VBG||group-21/NN	nsubjpass||correlated-29/VBN||sub-regions-24/NNS	det||areas-27/NNS||these-26/DT	prep_within||sub-regions-24/NNS||areas-27/NNS	auxpass||correlated-29/VBN||were-28/VBD	conj_and||decreased-7/VBD||correlated-29/VBN	nn||ratings-32/NNS||pain-31/NN	prep_with||correlated-29/VBN||ratings-32/NNS	advmod||correlated-29/VBN||specifically-33/RB	det||group-36/NN||each-35/DT	prep_for||correlated-29/VBN||group-36/NN	amod||cortex-40/NN||medial-38/JJ	amod||cortex-40/NN||prefrontal-39/JJ	dep||group-36/NN||cortex-40/NN	prep_in||cortex-40/NN||cbp-42/NN	prep_in||cortex-40/NN||thalamus-44/NNS	conj_and||cbp-42/NN||thalamus-44/NNS	prep_in||cortex-40/NN||oa-46/NN	pain-31||lidocaine-2||yes||the lidocaine treatment resulted in significantly decreased brain activity in both patient groups with distinct brain regions responding in each group, and sub-regions within these areas were correlated with pain ratings specifically for each group (medial prefrontal cortex in cbp and thalamus in oa).
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	vomiting-21||ondansetron-8||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	malaria-5||chloroquine-14||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
mark||declined-6/VBN||while-1/IN	poss||incidence-3/NN||its-2/PRP$	nsubj||declined-6/VBN||incidence-3/NN	aux||declined-6/VBN||has-4/VBZ	advmod||declined-6/VBN||steadily-5/RB	advcl||given-50/VBN||declined-6/VBN	det||cessation-9/NN||the-8/DT	prep_since||declined-6/VBN||cessation-9/NN	poss||route-12/NN||its-11/PRP$	prep_of||cessation-9/NN||route-12/NN	prep_of||route-12/NN||transmission-14/NN	nsubj||given-50/VBN||endocannibalism-16/NN	amod||guinea-21/NN||papua-19/JJ	amod||guinea-21/NN||new-20/JJ	prep_in||endocannibalism-16/NN||guinea-21/NN	det||1950s-24/NNS||the-23/DT	prep_in||guinea-21/NN||1950s-24/NNS	det||arrival-27/NN||the-26/DT	appos||endocannibalism-16/NN||arrival-27/NN	nn||disease-34/NN||variant-29/NN	amod||disease-34/NN||creutzfeldtâ-30/JJ	amod||disease-34/NN||$-31/JJ	nn||disease-34/NN||jakob-33/NN	prep_of||arrival-27/NN||disease-34/NN	dep||endocannibalism-16/NN||vcjd-36/VBN	advmod||thought-40/VBN||also-39/RB	vmod||endocannibalism-16/NN||thought-40/VBN	aux||transmitted-43/VBN||to-41/TO	auxpass||transmitted-43/VBN||be-42/VB	xcomp||thought-40/VBN||transmitted-43/VBN	amod||exposure-47/NN||dietary-45/JJ	nn||exposure-47/NN||prion-46/NN	agent||transmitted-43/VBN||exposure-47/NN	aux||given-50/VBN||has-49/VBZ	root||ROOT-0/null||given-50/VBN	iobj||given-50/VBN||kuru-51/PRP	det||relevance-55/NN||a-52/DT	amod||relevance-55/NN||new-53/JJ	amod||relevance-55/NN||global-54/JJ	dobj||given-50/VBN||relevance-55/NN	vcjd-36||prion-46||no_rel||while its incidence has steadily declined since the cessation of its route of transmission, endocannibalism, in papua new guinea in the 1950s, the arrival of variant creutzfeldtâ€“jakob disease (vcjd), also thought to be transmitted by dietary prion exposure, has given kuru a new global relevance.
nn||cancer-5/NN||stage-2/NN	nn||cancer-5/NN||iv-3/NN	amod||cancer-5/NN||colorectal-4/JJ	prep_in||supported-9/VBN||cancer-5/NN	nsubj||supported-9/VBN||data-7/NNS	aux||supported-9/VBN||have-8/VBP	root||ROOT-0/null||supported-9/VBN	det||use-12/NN||the-10/DT	amod||use-12/NN||routine-11/JJ	dobj||supported-9/VBN||use-12/NN	amod||treatment-16/NN||prophylactic-14/JJ	nn||treatment-16/NN||skin-15/NN	prep_of||use-12/NN||treatment-16/NN	prep_in||supported-9/VBN||patients-18/NNS	dep||patients-18/NNS||receiving-19/VBG	dobj||receiving-19/VBG||antibody-20/NN	amod||receptor-25/NN||epidermal-22/JJ	nn||receptor-25/NN||growth-23/NN	nn||receptor-25/NN||factor-24/NN	prep_against||antibody-20/NN||receptor-25/NN	det||use-29/NN||the-28/DT	dobj||receiving-19/VBG||use-29/NN	conj_and||antibody-20/NN||use-29/NN	amod||chemotherapy-32/NN||upfront-31/JJ	prep_of||use-29/NN||chemotherapy-32/NN	amod||management-35/NN||initial-34/JJ	prep_as||receiving-19/VBG||management-35/NN	prep_in||receiving-19/VBG||patients-37/NNS	amod||metastasis-40/NNS||synchronous-39/JJ	prep_with||patients-37/NNS||metastasis-40/NNS	prep_without||receiving-19/VBG||obstruction-42/NN	dep||patients-18/NNS||bleeding-44/VBG	conj_or||receiving-19/VBG||bleeding-44/VBG	det||site-48/NN||the-46/DT	amod||site-48/NN||primary-47/JJ	prep_from||bleeding-44/VBG||site-48/NN	bleeding-44||antibody-20||no_rel||in stage iv colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
amod||analyses-2/NNS||multivariable-1/JJ	nsubj||type-8/VBZ||analyses-2/NNS	nn||response-5/NN||treatment-4/NN	prep_of||analyses-2/NNS||response-5/NN	prep_in||response-5/NN||1,229-7/CD	root||ROOT-0/null||type-8/VBZ	num||patients-11/NNS||2-9/CD	amod||patients-11/NNS||diabetic-10/JJ	dobj||type-8/VBZ||patients-11/NNS	prep_with||type-8/VBZ||hypercholesterolemia-13/NN	nsubj||received-15/VBD||hypercholesterolemia-13/NN	rcmod||hypercholesterolemia-13/NN||received-15/VBD	dobj||received-15/VBD||ezetimibe/simvastatin-16/NN	dobj||received-15/VBD||atorvastatin-18/NN	conj_or||ezetimibe/simvastatin-16/NN||atorvastatin-18/NN	det||study-24/NN||a-20/DT	amod||study-24/NN||randomized-21/JJ	amod||study-24/NN||double-blind-22/JJ	amod||study-24/NN||6-week-23/JJ	prep_in||received-15/VBD||study-24/NN	hypercholesterolemia-13||simvastatin--1||yes||multivariable analyses of treatment response in 1,229 type 2 diabetic patients with hypercholesterolemia who received ezetimibe/simvastatin or atorvastatin in a randomized double-blind 6-week study.
det||method-2/NN||the-1/DT	nsubjpass||applied-5/VBN||method-2/NN	aux||applied-5/VBN||can-3/MD	auxpass||applied-5/VBN||be-4/VB	root||ROOT-0/null||applied-5/VBN	advmod||applied-5/VBN||rapidly-6/RB	det||influenzavirus-10/NNS||any-8/DT	amod||influenzavirus-10/NNS||emerging-9/VBG	prep_to||applied-5/VBN||influenzavirus-10/NNS	poss||entirety-13/NN||its-12/PRP$	prep_in||influenzavirus-10/NNS||entirety-13/NN	det||advantage-16/NN||an-15/DT	appos||entirety-13/NN||advantage-16/NN	nsubj||significant-19/JJ||advantage-16/NN	cop||significant-19/JJ||is-18/VBZ	rcmod||advantage-16/NN||significant-19/JJ	prepc_for||significant-19/JJ||dealing-21/VBG	amod||epidemics-24/NNS||seasonal-23/JJ	prep_with||dealing-21/VBG||epidemics-24/NNS	amod||threats-27/NNS||pandemic-26/JJ	prep_with||dealing-21/VBG||threats-27/NNS	conj_and||epidemics-24/NNS||threats-27/NNS	prep_such_as||influenzavirus-10/NNS||h5n1-31/CD	amod||influenza-35/NN||2009-h1n1-34/JJ	prep_to||applied-5/VBN||influenza-35/NN	conj_or||influenzavirus-10/NNS||influenza-35/NN	h5n1-31||influenzavirus-10||no||the method can be applied rapidly to any emerging influenzavirus in its entirety, an advantage that is significant for dealing with seasonal epidemics and pandemic threats, such as h5n1- or 2009-h1n1 influenza.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	ccomp||added-27/VBD||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	dobj||compare-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||liraglutide-19/NN||once-daily-14/JJ	amod||liraglutide-19/NN||human-15/JJ	amod||liraglutide-19/NN||glucagon-like-16/JJ	amod||liraglutide-19/NN||peptide-1-17/JJ	nn||liraglutide-19/NN||analogue-18/NN	prep_of||efficacy-10/NN||liraglutide-19/NN	amod||sitagliptin-24/NN||dipeptidyl-21/JJ	amod||sitagliptin-24/NN||peptidase-4-22/JJ	nn||sitagliptin-24/NN||inhibitor-23/NN	prep_with||liraglutide-19/NN||sitagliptin-24/NN	nsubj||added-27/VBD||each-26/DT	root||ROOT-0/null||added-27/VBD	prep_to||added-27/VBD||metformin-29/NN	num||weeks-33/NNS||52-32/CD	prep_over||added-27/VBD||weeks-33/NNS	prep_in||weeks-33/NNS||individuals-35/NNS	prep_with||individuals-35/NNS||type2diabetes-37/CD	type2diabetes-37||sitagliptin-24||yes||the aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type2diabetes.
nsubjpass||developed-15/VBN||dronedarone-1/NN	det||derivative-5/NN||a-3/DT	nn||derivative-5/NN||benzofuran-4/NN	appos||dronedarone-1/NN||derivative-5/NN	det||structure-8/NN||a-7/DT	prep_with||derivative-5/NN||structure-8/NN	amod||amiodarone-11/JJ||similar-9/JJ	dep||amiodarone-11/JJ||to-10/TO	amod||structure-8/NN||amiodarone-11/JJ	aux||developed-15/VBN||has-13/VBZ	auxpass||developed-15/VBN||been-14/VBN	root||ROOT-0/null||developed-15/VBN	det||therapy-19/NN||a-17/DT	amod||therapy-19/NN||potential-18/JJ	prep_as||developed-15/VBN||therapy-19/NN	prep_for||therapy-19/NN||patients-21/NNS	prep_with||patients-21/NNS||atrialfibrillation-23/NN	amiodarone-11||atrialfibrillation-23||no_rel||dronedarone, a benzofuran derivative with a structure similar to amiodarone, has been developed as a potential therapy for patients with atrialfibrillation.
det||assay-6/NN||the-1/DT	amod||assay-6/NN||adenosine-2/JJ	amod||assay-6/NN||triphosphate-based-3/JJ	nn||assay-6/NN||chemotherapy-4/NN	nn||assay-6/NN||response-5/NN	nsubj||test-13/NN||assay-6/NN	appos||assay-6/NN||atp-cra-8/NNP	cop||test-13/NN||is-10/VBZ	det||test-13/NN||a-11/DT	amod||test-13/NN||chemosensitivity-12/JJ	root||ROOT-0/null||test-13/NN	nsubj||offers-15/VBZ||test-13/NN	rcmod||test-13/NN||offers-15/VBZ	det||potential-17/NN||the-16/DT	dobj||offers-15/VBZ||potential-17/NN	prepc_of||potential-17/NN||selecting-19/VBG	nn||treatments-21/NNS||cancer-20/NN	dobj||selecting-19/VBG||treatments-21/NNS	prepc_based_on||selecting-19/VBG||on-23/IN	det||responsiveness-25/NNS||the-24/DT	pobj||selecting-19/VBG||responsiveness-25/NNS	amod||tumors-28/NNS||individual-27/JJ	prep_of||responsiveness-25/NNS||tumors-28/NNS	atp--1||cancer-20||no_rel||the adenosine triphosphate-based chemotherapy response assay (atp-cra) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||rif-10||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
advmod||syncytial-2/JJ||respiratory-1/RB	amod||virus-3/NN||syncytial-2/JJ	nsubj||virus-11/NN||virus-3/NN	appos||virus-3/NN||rsv-5/NN	cop||virus-11/NN||is-7/VBZ	det||virus-11/NN||a-8/DT	advmod||contagious-10/JJ||highly-9/RB	amod||virus-11/NN||contagious-10/JJ	root||ROOT-0/null||virus-11/NN	cop||cause-17/NN||is-14/VBZ	det||cause-17/NN||the-15/DT	amod||cause-17/NN||major-16/JJ	conj_and||virus-11/NN||cause-17/NN	amod||infections-22/NNS||lower-19/JJR	amod||infections-22/NNS||respiratory-20/JJ	nn||infections-22/NNS||tract-21/NN	prep_of||cause-17/NN||infections-22/NNS	prep_in||infections-22/NNS||infants-24/NNS	prep_in||infections-22/NNS||toddlers-26/NNS	conj_and||infants-24/NNS||toddlers-26/NNS	nsubj||poses-28/VBZ||worldwide.rsvinfection-27/NN	rcmod||cause-17/NN||poses-28/VBZ	amod||risks-31/NNS||serious-29/JJ	nn||risks-31/NNS||health-30/NN	dobj||poses-28/VBZ||risks-31/NNS	amod||children-34/NNS||young-33/JJ	prep_to||poses-28/VBZ||children-34/NNS	det||years-39/NNS||the-36/DT	amod||years-39/NNS||first-37/JJ	num||years-39/NNS||2-38/CD	prep_during||cause-17/NN||years-39/NNS	prep_of||years-39/NNS||life-41/NN	rsvinfection--1||rsv-5||no||respiratory syncytial virus (rsv) is a highly contagious virus, and is the major cause of lower respiratory tract infections in infants and toddlers worldwide.rsvinfection poses serious health risks to young children during the first 2 years of life.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâ€”irondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâ€”both in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
nsubj||component-8/NN||rifampicin-1/NN	appos||rifampicin-1/NN||rif-3/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||a-6/DT	amod||component-8/NN||major-7/JJ	root||ROOT-0/null||component-8/NN	amod||therapy-13/NN||fixed-10/VBN	nn||therapy-13/NN||dose-11/NN	nn||therapy-13/NN||combination-12/NN	prep_in||component-8/NN||therapy-13/NN	det||treatment-16/NN||the-15/DT	prep_for||therapy-13/NN||treatment-16/NN	prep_of||treatment-16/NN||tuberculosis-18/NNP	tuberculosis-18||rifampicin-1||yes||rifampicin (rif) is a major component in fixed dose combination therapy for the treatment of tuberculosis.
nsubj||identified-2/VBD||we-1/PRP	root||ROOT-0/null||identified-2/VBD	num||individuals-4/NNS||425-3/CD	dobj||identified-2/VBD||individuals-4/NNS	vmod||individuals-4/NNS||divided-6/VBN	num||categories-9/NNS||seven-8/CD	prep_into||divided-6/VBN||categories-9/NNS	prepc_according_to||divided-6/VBN||to-11/TO	amod||status-14/NN||carbohydrate-12/JJ	nn||status-14/NN||metabolism-13/NN	pobj||divided-6/VBN||status-14/NN	amod||-RSB--21/NNP||normal-16/JJ	nn||-RSB--21/NNP||glucose-17/NN	nn||-RSB--21/NNP||tolerance-18/NN	nn||-RSB--21/NNP||-LSB--19/NNP	nn||-RSB--21/NNP||ngt-20/FW	dep||individuals-4/NNS||-RSB--21/NNP	amod||glucose-25/NN||impaired-23/VBN	amod||glucose-25/NN||fasting-24/JJ	appos||-RSB--21/NNP||glucose-25/NN	nn||-RSB--30/FW||impairedglucosetolerance-27/FW	nn||-RSB--30/FW||-LSB--28/FW	nn||-RSB--30/FW||igt-29/FW	appos||glucose-25/NN||-RSB--30/FW	advmod||diagnosed-34/VBN||newly-33/RB	amod||type2diabetes-35/NNS||diagnosed-34/VBN	appos||-RSB--21/NNP||type2diabetes-35/NNS	conj_and||glucose-25/NN||type2diabetes-35/NNS	nn||duration-39/NN||diabetes-38/NN	dobj||identified-2/VBD||duration-39/NN	conj_and||individuals-4/NNS||duration-39/NN	dep||duration-39/NN||0â-41/VBN	dobj||0â-41/VBN||$-42/$	num||$-42/$||9-44/CD	amod||$-47/$||10â-46/JJ	appos||$-42/$||$-47/$	num||$-47/$||19-49/CD	amod||‰-53/NNS||â-52/JJ	appos||$-42/$||‰-53/NNS	conj_and||$-47/$||‰-53/NNS	dep||years-56/NNS||¥-54/SYM	num||years-56/NNS||20-55/CD	dep||0â-41/VBN||years-56/NNS	impairedglucosetolerance-27||carbohydrate-12||no_rel||we identified 425 individuals, divided into seven categories according to carbohydrate metabolism status (normal glucose tolerance [ngt], impaired fasting glucose, impairedglucosetolerance [igt], and newly diagnosed type2diabetes) and diabetes duration (0â€“9, 10â€“19, and â‰¥20 years).
amod||agents-4/NNS||recommended-1/VBN	amod||agents-4/NNS||parenteral-2/JJ	nn||agents-4/NNS||anticoagulant-3/NN	nsubj||include-16/VBP||agents-4/NNS	amod||indications-7/NNS||different-6/JJ	prep_with||agents-4/NNS||indications-7/NNS	det||prevention-10/NN||the-9/DT	prep_for||indications-7/NNS||prevention-10/NN	prep_for||indications-7/NNS||treatment-12/NN	conj_and||prevention-10/NN||treatment-12/NN	amod||thromboembolism-15/NN||venous-14/JJ	prep_of||prevention-10/NN||thromboembolism-15/NN	root||ROOT-0/null||include-16/VBP	dobj||include-16/VBP||unfractionatedheparin-17/NN	amod||heparins-20/NNS||low-molecular-weight-19/JJ	dobj||include-16/VBP||heparins-20/NNS	conj_and||unfractionatedheparin-17/NN||heparins-20/NNS	dobj||include-16/VBP||fondaparinux-22/NN	conj_and||unfractionatedheparin-17/NN||fondaparinux-22/NN	thromboembolism-15||unfractionatedheparin-17||yes||recommended parenteral anticoagulant agents with different indications for the prevention and treatment of venous thromboembolism include unfractionatedheparin, low-molecular-weight heparins and fondaparinux.
nsubjpass||involved-5/VBN||it-1/PRP	nsubjpass||had-21/VBN||it-1/PRP	auxpass||involved-5/VBN||is-2/VBZ	advmod||involved-5/VBN||now-3/RB	advmod||involved-5/VBN||widely-4/RB	root||ROOT-0/null||involved-5/VBN	quantmod||all-8/DT||nearly-7/RB	num||aspects-9/NNS||all-8/DT	prep_in||involved-5/VBN||aspects-9/NNS	amod||efforts-17/NNS||hiv/aids-related-11/JJ	nn||efforts-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||efforts-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||efforts-17/NNS||care-16/NN	prep_of||aspects-9/NNS||efforts-17/NNS	aux||had-21/VBN||has-20/VBZ	conj_and||involved-5/VBN||had-21/VBN	det||impact-24/NN||a-22/DT	amod||impact-24/NN||positive-23/JJ	dobj||had-21/VBN||impact-24/NN	prep_for||impact-24/NN||example-27/NN	amod||adherence-30/NN||increased-29/VBN	appos||example-27/NN||adherence-30/NN	amod||treatment-33/NN||anti-retroviral-32/JJ	prep_of||adherence-30/NN||treatment-33/NN	nn||testing-36/NN||hiv-35/NN	prep_of||adherence-30/NN||testing-36/NN	conj_and||treatment-33/NN||testing-36/NN	amod||groups-39/NNS||hard-to-reach-38/JJ	prep_among||treatment-33/NN||groups-39/NNS	aids--1||hiv-35||no||it is now widely involved in nearly all aspects of hiv/aids-related prevention, treatment and care efforts, and has had a positive impact; for example, increased adherence of anti-retroviral treatment and hiv testing among hard-to-reach groups.
nsubj||explore-2/VB||we-1/PRP	root||ROOT-0/null||explore-2/VB	dobj||explore-2/VB||reasons-3/NNS	prep_for||reasons-3/NNS||this-5/DT	amod||doubts-10/NNS||prevailing-9/VBG	prep_such_as||this-5/DT||doubts-10/NNS	det||efficacy-13/NN||the-12/DT	prep_about||doubts-10/NNS||efficacy-13/NN	prep_of||doubts-10/NNS||fondaparinux-15/NN	det||setting-18/NN||the-17/DT	prep_in||doubts-10/NNS||setting-18/NN	prep_of||setting-18/NN||angioplasty-20/NN	det||problem-23/NN||the-22/DT	prep_such_as||this-5/DT||problem-23/NN	conj_and||doubts-10/NNS||problem-23/NN	nn||thrombosis-26/NNS||catheter-25/NN	prep_of||problem-23/NN||thrombosis-26/NNS	det||lack-30/NN||the-29/DT	prep_such_as||this-5/DT||lack-30/NN	conj_and||doubts-10/NNS||lack-30/NN	prep_of||lack-30/NN||antidote-32/NN	amod||complications-37/NNS||bleeding-36/VBG	prep_in_case_of||antidote-32/NN||complications-37/NNS	fondaparinux-15||bleeding-36||no_rel||we explore reasons for this, such as prevailing doubts about the efficacy of fondaparinux in the setting of angioplasty, the problem of catheter thrombosis, and the lack of antidote in case of bleeding complications.
nsubj||herein-2/VBP||we-1/PRP	root||ROOT-0/null||herein-2/VBP	xcomp||herein-2/VBP||demonstrate-3/VB	mark||impregnated-8/VBD||that-4/IN	amod||filters-7/NNS||functional-5/JJ	nn||filters-7/NNS||air-6/NN	nsubj||impregnated-8/VBD||filters-7/NNS	ccomp||demonstrate-3/VB||impregnated-8/VBD	amod||antibodies-11/NNS||ostrich-10/JJ	prep_with||impregnated-8/VBD||antibodies-11/NNS	det||hemagglutinin-14/NN||the-13/DT	prep_against||antibodies-11/NNS||hemagglutinin-14/NN	det||virus-18/NN||the-16/DT	amod||virus-18/NN||h5n1-17/JJ	prep_of||hemagglutinin-14/NN||virus-18/NN	dep||impregnated-8/VBD||protect-19/VB	dobj||protect-19/VB||chickens-20/NNS	prep_from||protect-19/VB||death-22/NN	amod||transmission-25/NN||h5n1-24/JJ	prep_by||protect-19/VB||transmission-25/NN	antibodies-11||h5n1-24||no_rel||we herein demonstrate that functional air filters impregnated with ostrich antibodies against the hemagglutinin of the h5n1 virus protect chickens from death by h5n1 transmission.
nsubj||receiving-3/VBG||patients-2/NNS	prepc_in||had-17/VBD||receiving-3/VBG	dobj||receiving-3/VBG||dacarbazine-4/NN	amod||chemotherapy-7/NN||first-line-6/JJ	prep_as||receiving-3/VBG||chemotherapy-7/NN	amod||melanoma-10/NN||metastatic-9/JJ	prep_for||chemotherapy-7/NN||melanoma-10/NN	det||addition-13/NN||the-12/DT	nsubj||had-17/VBD||addition-13/NN	amod||bosentan-16/NN||high-dose-15/JJ	prep_of||addition-13/NN||bosentan-16/NN	root||ROOT-0/null||had-17/VBD	neg||effect-19/NN||no-18/DT	dobj||had-17/VBD||effect-19/NN	prep_on||effect-19/NN||time-21/NN	nn||progression-24/NN||tumor-23/NN	prep_to||had-17/VBD||progression-24/NN	amod||parameters-28/NNS||other-26/JJ	nn||parameters-28/NNS||efficacy-27/NN	prep_to||had-17/VBD||parameters-28/NNS	conj_or||progression-24/NN||parameters-28/NNS	melanoma-10||dacarbazine-4||yes||in patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.
det||atropine-4/NN||the-1/DT	amod||atropine-4/NN||muscarinic-2/JJ	nn||atropine-4/NN||antagonist-3/NN	nsubj||decreased-11/VBD||atropine-4/NN	num||mg/kg-7/NN||0.5-6/CD	dep||atropine-4/NN||mg/kg-7/NN	appos||mg/kg-7/NN||ip-9/NN	root||ROOT-0/null||decreased-11/VBD	det||number-13/NN||the-12/DT	dobj||decreased-11/VBD||number-13/NN	prep_of||number-13/NN||arrests-15/NNS	advmod||decreased-11/VBD||also-17/RB	prepc_without||decreased-11/VBD||altering-19/VBG	nn||lifetimes-21/NNS||arrest-20/NN	dobj||altering-19/VBG||lifetimes-21/NNS	arrest-20||atropine-4||yes||the muscarinic antagonist atropine (0.5 mg/kg, ip) decreased the number of arrests, also without altering arrest lifetimes.
mark||establish-4/VB||in-1/IN	dep||establish-4/VB||order-2/NN	aux||establish-4/VB||to-3/TO	advcl||examined-15/VBD||establish-4/VB	det||effect-6/NN||the-5/DT	dobj||establish-4/VB||effect-6/NN	amod||o2-9/NNS||low-8/JJ	prep_of||effect-6/NN||o2-9/NNS	amod||properties-12/NNS||cellular-11/JJ	prep_on||establish-4/VB||properties-12/NNS	nsubj||examined-15/VBD||we-14/PRP	root||ROOT-0/null||examined-15/VBD	amod||cultured-17/NN||bsmc-16/JJ	dobj||examined-15/VBD||cultured-17/NN	amod||conditions-25/NNS||hypoxic-19/JJ	num||%-22/NN||3-21/CD	npadvmod||o2-23/JJ||%-22/NN	dep||conditions-25/NNS||o2-23/JJ	prep_under||examined-15/VBD||conditions-25/NNS	o2-23||hypoxic-19||no_rel||in order to establish the effect of low o2 on cellular properties, we examined bsmc cultured under hypoxic (3% o2) conditions.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||contains-12/VBZ||compound-3/NN	nn||-RSB--10/NNP||-LSB--5/NNP	nn||-RSB--10/NNP||zni2-6/NNP	appos||-RSB--10/NNP||c10h8n2s-8/NNP	appos||compound-3/NN||-RSB--10/NNP	root||ROOT-0/null||contains-12/VBZ	det||ring-16/NN||a-13/DT	amod||ring-16/NN||six-membered-14/JJ	nn||ring-16/NN||chelate-15/NN	dobj||contains-12/VBZ||ring-16/NN	vmod||ring-16/NN||adopting-17/VBG	vmod||ring-16/NN||adopting-17/VBG	conj_and||adopting-17/VBG||adopting-17/VBG	det||conformation-20/NN||a-18/DT	nn||conformation-20/NN||boat-19/NN	dobj||adopting-17/VBG||conformation-20/NN	dobj||coordinated-27/VBN||which-22/WDT	det||atom-25/NN||the-23/DT	nn||atom-25/NN||zn-24/NN	nsubjpass||coordinated-27/VBN||atom-25/NN	auxpass||coordinated-27/VBN||is-26/VBZ	prepc_in||adopting-17/VBG||coordinated-27/VBN	num||ions-31/NNS||two-29/CD	amod||ions-31/NNS||iodide-30/JJ	agent||coordinated-27/VBN||ions-31/NNS	det||atoms-38/NNS||the-34/DT	num||atoms-38/NNS||two-35/CD	amod||atoms-38/NNS||pyridyl-36/JJ	nn||atoms-38/NNS||n-37/NN	agent||adopting-17/VBG||atoms-38/NNS	det||sulfide-43/NN||a-40/DT	amod||sulfide-43/NN||single-41/JJ	amod||sulfide-43/NN||di-2-pyridyl-42/JJ	prep_of||atoms-38/NNS||sulfide-43/NN	vmod||sulfide-43/NN||ligand-44/VBN	det||tetraâhedron-49/NN||a-46/DT	advmod||distorted-48/JJ||slightly-47/RB	amod||tetraâhedron-49/NN||distorted-48/JJ	prep_within||ligand-44/VBN||tetraâhedron-49/NN	ions-31||di--1||no_rel||the title compound, [zni2(c10h8n2s)], contains a six-membered chelate ring adopting a boat conformation in which the zn atom is coordinated by two iodide ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand within a slightly distorted tetraâ­hedron.
det||objectives-3/NNS||the-1/DT	amod||objectives-3/NNS||overall-2/JJ	nsubj||are-7/VBP||objectives-3/NNS	det||paper-6/NN||this-5/DT	prep_of||objectives-3/NNS||paper-6/NN	root||ROOT-0/null||are-7/VBP	dobj||are-7/VBP||1-9/CD	nsubj||provide-12/VB||1-9/CD	aux||provide-12/VB||to-11/TO	xcomp||are-7/VBP||provide-12/VB	det||overview-14/NN||an-13/DT	dobj||provide-12/VB||overview-14/NN	amod||studies-17/NNS||recent-16/JJ	prep_on||provide-12/VB||studies-17/NNS	nsubj||highlight-19/VB||studies-17/NNS	rcmod||studies-17/NNS||highlight-19/VB	det||risk-22/NN||the-20/DT	amod||risk-22/NN||increased-21/VBN	dobj||highlight-19/VB||risk-22/NN	amod||complications-25/NNS||respiratory-24/JJ	prep_for||risk-22/NN||complications-25/NNS	prep_following||complications-25/NNS||sedation-27/NN	prep_following||complications-25/NNS||analgesia-29/NN	conj_and||sedation-27/NN||analgesia-29/NN	prep_in||sedation-27/NN||children-31/NNS	amod||disabilities-34/NNS||developmental-33/JJ	prep_with||children-31/NNS||disabilities-34/NNS	prep_with||children-31/NNS||neurologicdisorders-36/NNS	conj_and||disabilities-34/NNS||neurologicdisorders-36/NNS	appos||disabilities-34/NNS||2-39/CD	aux||provide-42/VB||to-41/TO	vmod||risk-22/NN||provide-42/VB	det||understanding-45/NN||a-43/DT	amod||understanding-45/NN||better-44/JJR	dobj||provide-42/VB||understanding-45/NN	nsubjpass||used-54/VBN||understanding-45/NN	prep_of||understanding-45/NN||sedatives-47/NNS	amod||medications-50/NNS||analgesic-49/JJ	prep_of||understanding-45/NN||medications-50/NNS	conj_and||sedatives-47/NNS||medications-50/NNS	auxpass||used-54/VBN||are-52/VBP	advmod||used-54/VBN||commonly-53/RB	rcmod||understanding-45/NN||used-54/VBN	prep_in||used-54/VBN||children-56/NNS	amod||disabilities-59/NNS||developmental-58/JJ	prep_with||children-56/NNS||disabilities-59/NNS	prep_with||children-56/NNS||neurologicdisorders-61/NNS	conj_and||disabilities-59/NNS||neurologicdisorders-61/NNS	det||system-66/NN||the-63/DT	amod||system-66/NN||central-64/JJ	amod||system-66/NN||nervous-65/JJ	prep_on||used-54/VBN||system-66/NN	neurologicdisorders-61||analgesic-49||no_rel||the overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory complications following sedation and analgesia in children with developmental disabilities and neurologicdisorders, (2) to provide a better understanding of sedatives and analgesic medications which are commonly used in children with developmental disabilities and neurologicdisorders on the central nervous system.
det||surveillance-3/NN||this-1/DT	amod||surveillance-3/NN||post-marketing-2/JJ	nsubj||confirms-12/VBZ||surveillance-3/NN	nsubj||highlights-24/VBZ||surveillance-3/NN	prep_of||surveillance-3/NN||levofloxacin-5/NN	vmod||surveillance-3/NN||conducted-7/VBN	num||years-10/NNS||4-9/CD	prep_over||conducted-7/VBN||years-10/NNS	root||ROOT-0/null||confirms-12/VBZ	det||safety-14/NN||the-13/DT	dobj||confirms-12/VBZ||safety-14/NN	dobj||confirms-12/VBZ||efficacy-16/NN	conj_and||safety-14/NN||efficacy-16/NN	prep_of||safety-14/NN||levofloxacin-18/NN	amod||use-22/NN||regular-20/JJ	amod||use-22/NN||clinical-21/JJ	prep_in||confirms-12/VBZ||use-22/NN	conj_and||confirms-12/VBZ||highlights-24/VBZ	mark||treatment-30/NN||that-25/IN	nsubj||treatment-30/NN||levofloxacin-26/NN	cop||treatment-30/NN||is-27/VBZ	det||treatment-30/NN||a-28/DT	amod||treatment-30/NN||promising-29/JJ	ccomp||highlights-24/VBZ||treatment-30/NN	det||variety-33/NN||a-32/DT	prep_for||treatment-30/NN||variety-33/NN	amod||ocularbacterialinfections-36/NNS||external-35/JJ	prep_of||variety-33/NN||ocularbacterialinfections-36/NNS	ocularbacterialinfections-36||levofloxacin-26||yes||this post-marketing surveillance of levofloxacin, conducted over 4 years, confirms the safety and efficacy of levofloxacin in regular clinical use and highlights that levofloxacin is a promising treatment for a variety of external ocularbacterialinfections.
aux||evaluate-2/VB||to-1/TO	csubj||differing-10/VBD||evaluate-2/VB	csubj||differing-10/VBD||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	num||diets-9/NNS||two-6/CD	amod||diets-9/NNS||low-fat-7/JJ	amod||diets-9/NNS||hypocaloric-8/JJ	prep_of||effects-4/NNS||diets-9/NNS	root||ROOT-0/null||differing-10/VBD	conj_and||differing-10/VBD||differing-10/VBD	det||ratio-14/NN||the-12/DT	amod||ratio-14/NN||carbohydrate-to-protein-13/JJ	prep_in||differing-10/VBD||ratio-14/NN	nn||training-21/NN||resistance-19/NN	nn||training-21/NN||exercise-20/NN	prep_with||differing-10/VBD||training-21/NN	prep_without||differing-10/VBD||training-21/NN	appos||training-21/NN||rt-23/NN	nn||loss-28/NN||weight-27/NN	prep_on||differing-10/VBD||loss-28/NN	nn||composition-31/NN||body-30/NN	prep_on||differing-10/VBD||composition-31/NN	conj_and||loss-28/NN||composition-31/NN	amod||outcomes-39/NNS||cardiovasculardisease-34/JJ	dep||cardiovasculardisease-34/JJ||cvd-36/NN	nn||outcomes-39/NNS||risk-38/NN	prep_on||differing-10/VBD||outcomes-39/NNS	conj_and||loss-28/NN||outcomes-39/NNS	amod||patients-42/NNS||overweight/obese-41/JJ	prep_in||outcomes-39/NNS||patients-42/NNS	prep_with||patients-42/NNS||type2diabetes-44/CD	carbohydrate--1||cardiovasculardisease-34||no_rel||to evaluate the effects of two low-fat hypocaloric diets differing in the carbohydrate-to-protein ratio, with and without resistance exercise training (rt), on weight loss, body composition, and cardiovasculardisease (cvd) risk outcomes in overweight/obese patients with type2diabetes.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||study-7/NN||a-3/DT	amod||study-7/NN||double-blind-4/JJ	amod||study-7/NN||randomized-6/JJ	dobj||conducted-2/VBD||study-7/NN	aux||test-9/VB||to-8/TO	vmod||conducted-2/VBD||test-9/VB	det||effects-11/NNS||the-10/DT	dobj||test-9/VB||effects-11/NNS	nn||monotherapy-14/NN||ciprofloxacin-13/NN	prep_of||effects-11/NNS||monotherapy-14/NN	prep_as||test-9/VB||prophylaxis-16/NNS	prep_for||prophylaxis-16/NNS||sepsis-18/NN	prep_for||prophylaxis-16/NNS||death-20/NN	conj_and||sepsis-18/NN||death-20/NN	nn||treatment-23/NN||induction-22/NN	prep_in||test-9/VB||treatment-23/NN	det||childhood-27/NN||the-25/DT	nn||childhood-27/NN||indonesian-26/NN	prep_of||treatment-23/NN||childhood-27/NN	det||protocol-29/NN||all-28/DT	dep||childhood-27/NN||protocol-29/NN	ciprofloxacin-13||sepsis-18||no_rel||we conducted a double-blind, randomized study to test the effects of ciprofloxacin monotherapy as prophylaxis for sepsis and death in induction treatment of the indonesian childhood all protocol.
advmod||were-6/VBD||however-1/RB	amod||titers-5/NNS||anti-env-3/JJ	nn||titers-5/NNS||antibody-4/NN	nsubj||were-6/VBD||titers-5/NNS	root||ROOT-0/null||were-6/VBD	amod||higher-9/JJR||4-fold-8/JJ	prep_over||were-6/VBD||higher-9/JJR	prep_in||higher-9/JJR||ham/tsp-11/NN	prepc_compared_to||were-6/VBD||to-13/TO	det||htlv-i-16/NN||both-14/DT	amod||htlv-i-16/NN||asymptomatic-15/JJ	pobj||were-6/VBD||htlv-i-16/NN	appos||htlv-i-16/NN||p-18/NNP	number||0.0001-20/CD||<-19/CD	num||p-18/NNP||0.0001-20/CD	amod||patients-24/NNS||atll-23/JJ	pobj||were-6/VBD||patients-24/NNS	conj_and||htlv-i-16/NN||patients-24/NNS	appos||htlv-i-16/NN||p-26/NNP	number||0.0005-28/CD||<-27/CD	num||p-26/NNP||0.0005-28/CD	ham--1||htlv-i-16||no||however, anti-env antibody titers were over 4-fold higher in ham/tsp compared to both asymptomatic htlv-i ( p < 0.0001) and atll patients ( p < 0.0005).
amod||weeks-3/NNS||2â-2/JJ	prep_after||developed-16/VBD||weeks-3/NNS	prep_of||weeks-3/NNS||treatment-5/NN	prep_with||treatment-5/NN||meropenem-7/NN	prep_with||treatment-5/NN||erythromycin-9/NN	conj_and||meropenem-7/NN||erythromycin-9/NN	amod||weeks-12/NNS||4â-11/JJ	prep_for||meropenem-7/NN||weeks-12/NNS	det||patient-15/NN||the-14/DT	nsubj||developed-16/VBD||patient-15/NN	root||ROOT-0/null||developed-16/VBD	det||relapse-18/NN||a-17/DT	dobj||developed-16/VBD||relapse-18/NN	nn||jejuni-31/NNS||bacteremia-20/NN	num||months-22/NNS||10â-21/CD	npadvmod||later-23/RBR||months-22/NNS	advmod||resistant-29/NN||later-23/RBR	det||erythromycin-28/NN||a-25/DT	amod||erythromycin-28/NN||high-26/JJ	nn||erythromycin-28/NN||level-27/NN	prep_with||resistant-29/NN||erythromycin-28/NN	amod||jejuni-31/NNS||resistant-29/NN	nn||jejuni-31/NNS||c.-30/NN	prep_of||relapse-18/NN||jejuni-31/NNS	erythromycin-28||bacteremia-20||no_rel||after 2â weeks of treatment with meropenem and erythromycin for 4â weeks , the patient developed a relapse of bacteremia 10â months later with a high level erythromycin resistant c. jejuni .
vmod||has-26/VBZ||conclusionsâ-1/VBG	dobj||conclusionsâ-1/VBG||$-2/$	prep_in||$-2/$||contrast-5/NN	prep_to||conclusionsâ-1/VBG||animals-7/NNS	prep_in||conclusionsâ-1/VBG||humans-10/NNS	nsubj||has-26/VBZ||prevention-12/NN	amod||hypoglycemia-15/NN||portal-14/JJ	prep_of||prevention-12/NN||hypoglycemia-15/NN	amod||glucose-18/NN||oral-17/JJ	prep_with||hypoglycemia-15/NN||glucose-18/NN	det||beginning-21/NN||the-20/DT	prep_from||glucose-18/NN||beginning-21/NN	amod||hypoglycemia-25/NN||insulin-induced-23/JJ	amod||hypoglycemia-25/NN||slow-fall-24/JJ	prep_of||beginning-21/NN||hypoglycemia-25/NN	root||ROOT-0/null||has-26/VBZ	neg||effect-28/NN||no-27/DT	dobj||has-26/VBZ||effect-28/NN	amod||responses-33/NNS||sympathoadrenal-30/JJ	conj_and||sympathoadrenal-30/JJ||symptomatic-32/JJ	amod||responses-33/NNS||symptomatic-32/JJ	prep_on||effect-28/NN||responses-33/NNS	prep_to||has-26/VBZ||hypoglycemia-35/NN	hypoglycemia-35||glucose-18||yes||conclusionsâ€” in contrast to animals, in humans, prevention of portal hypoglycemia with oral glucose from the beginning of insulin-induced slow-fall hypoglycemia has no effect on sympathoadrenal and symptomatic responses to hypoglycemia.
det||rate-5/NN||the-1/DT	amod||rate-5/NN||2-year-2/JJ	amod||rate-5/NN||cardiac-3/JJ	nn||rate-5/NN||event-4/NN	nsubj||higher-22/JJR||rate-5/NN	prep_of||rate-5/NN||patients-7/NNS	det||hyperglycemia-13/NN||a-9/DT	number||h-11/CD||2-10/CD	num||hyperglycemia-13/NN||h-11/CD	amod||hyperglycemia-13/NN||post-load-12/JJ	prep_with||patients-7/NNS||hyperglycemia-13/NN	nn||mg/dl-19/NN||â-15/NNP	nn||mg/dl-19/NN||‰-16/NNP	nn||mg/dl-19/NN||¥-17/NNP	nn||mg/dl-19/NN||160-18/NNP	prep_of||hyperglycemia-13/NN||mg/dl-19/NN	cop||higher-22/JJR||was-20/VBD	advmod||higher-22/JJR||significantly-21/RB	ccomp||<-44/VBZ||higher-22/JJR	mark||mg/dl-35/VBP||than-23/IN	nsubj||mg/dl-35/VBP||that-24/DT	prep_of||that-24/DT||patients-26/NNS	num||glucose-31/NN||2-28/CD	amod||glucose-31/NN||h-29/JJ	amod||glucose-31/NN||post-load-30/JJ	prep_with||patients-26/NNS||glucose-31/NN	number||160-34/CD||<-33/CD	prep_of||glucose-31/NN||160-34/CD	ccomp||higher-22/JJR||mg/dl-35/VBP	number||32.2-37/CD||-lrb--36/CD	num||%-38/NN||32.2-37/CD	dobj||mg/dl-35/VBP||%-38/NN	num||%-41/NN||19.8-40/CD	prep_vs.||%-38/NN||%-41/NN	nsubj||<-44/VBZ||p-43/NN	nsubj||similar-49/JJ||p-43/NN	root||ROOT-0/null||<-44/VBZ	num||-rrb--46/NNS||0.05-45/CD	dobj||<-44/VBZ||-rrb--46/NNS	cop||similar-49/JJ||was-48/VBD	conj_and||<-44/VBZ||similar-49/JJ	prep_to||similar-49/JJ||that-51/DT	nn||group-54/NN||pdm-53/NN	prep_of||that-51/DT||group-54/NN	dep||<-44/VBZ||-lrb--55/VB	num||%-57/NN||37.4-56/CD	dobj||-lrb--55/VB||%-57/NN	nsubj||-rrb--62/NNS||p-59/NN	dep||-rrb--62/NNS||=-60/SYM	num||-rrb--62/NNS||0.513-61/CD	ccomp||<-44/VBZ||-rrb--62/NNS	hyperglycemia-13||glucose-31||no||the 2-year cardiac event rate of patients with a 2 h post-load hyperglycemia of â ‰ ¥ 160 mg/dl was significantly higher than that of patients with 2 h post-load glucose of < 160 mg/dl -lrb- 32.2 % vs. 19.8 % , p < 0.05 -rrb- and was similar to that of pdm group -lrb- 37.4 % , p = 0.513 -rrb- .
nsubj||pathogen-6/NN||hcmv-1/NNP	cop||pathogen-6/NN||is-2/VBZ	advmod||pathogen-6/NN||also-3/RB	det||pathogen-6/NN||an-4/DT	amod||pathogen-6/NN||opportunistic-5/JJ	root||ROOT-0/null||pathogen-6/NN	amod||individuals-9/NNS||immunocompromised-8/JJ	prep_in||pathogen-6/NN||individuals-9/NNS	prep_including||pathogen-6/NN||humanimmunodeficiencyvirus-12/NNS	appos||humanimmunodeficiencyvirus-12/NNS||hiv-14/NN	amod||patients-18/NNS||infected-17/JJ	conj_and||pathogen-6/NN||patients-18/NNS	prep_with||patients-18/NNS||aids-20/NNS	amod||organ-24/NN||solid-23/JJ	conj_and||pathogen-6/NN||organ-24/NN	amod||recipients-30/NNS||allogeneic-26/JJ	nn||recipients-30/NNS||stem-27/NN	nn||recipients-30/NNS||cell-28/NN	nn||recipients-30/NNS||transplantation-29/NN	conj_and||pathogen-6/NN||recipients-30/NNS	conj_and||organ-24/NN||recipients-30/NNS	aids-20||humanimmunodeficiencyvirus-12||no||hcmv is also an opportunistic pathogen in immunocompromised individuals, including humanimmunodeficiencyvirus (hiv)- infected patients with aids, and solid organ and allogeneic stem cell transplantation recipients.
det||fibrosis-3/NN||the-1/DT	nn||fibrosis-3/NN||owat-2/NN	nsubj||correlated-5/VBD||fibrosis-3/NN	advmod||correlated-5/VBD||negatively-4/RB	root||ROOT-0/null||correlated-5/VBD	amod||diameters-9/NNS||omental-7/JJ	nn||diameters-9/NNS||adipocyte-8/NN	prep_with||correlated-5/VBD||diameters-9/NNS	nsubj||=-12/VBZ||r-11/SYM	dep||diameters-9/NNS||=-12/VBZ	poss||0.30-15/NN||âˆ-13/NNP	dobj||=-12/VBZ||0.30-15/NN	vmod||0.30-15/NN||p-17/VBN	dep||0.02-19/CD||=-18/SYM	ccomp||p-17/VBN||0.02-19/CD	cc||correlated-5/VBD||and-22/CC	amod||levels-25/NNS||triglyceride-24/JJ	prep_with||correlated-5/VBD||levels-25/NNS	conj_and||diameters-9/NNS||levels-25/NNS	nn||0.42-31/NN||r-27/NN	nn||0.42-31/NN||=-28/NN	nn||0.42-31/NN||âˆ-29/NN	dep||levels-25/NNS||0.42-31/NN	nn||0.01-35/NNP||p-33/NNP	nn||0.01-35/NNP||<-34/NNP	appos||0.42-31/NN||0.01-35/NNP	advmod||correlated-5/VBD||positively-39/RB	prep_with||correlated-5/VBD||apoa1-41/NNS	conj_and||diameters-9/NNS||apoa1-41/NNS	dep||apoa1-41/NNS||r-43/SYM	dep||r-43/SYM||=-44/NNP	num||=-44/NNP||0.25-45/CD	num||=-44/NNP||p-47/CD	dep||0.05-49/CD||=-48/SYM	rcmod||=-44/NNP||0.05-49/CD	triglyceride-24||fibrosis-3||no_rel||the owat fibrosis negatively correlated with omental adipocyte diameters ( r = âˆ’0.30, p = 0.02), and with triglyceride levels ( r = âˆ’0.42, p < 0.01), and positively with apoa1 ( r = 0.25, p = 0.05).
nsubjpass||presented-9/VBN||graves-1/NNS	nn||gd-5/NN||disease-3/NN	dep||graves-1/NNS||gd-5/NN	auxpass||presented-9/VBN||is-7/VBZ	advmod||presented-9/VBN||generally-8/RB	root||ROOT-0/null||presented-9/VBN	agent||presented-9/VBN||thyrotoxicosis-11/NNS	prep_with||thyrotoxicosis-11/NNS||hyperthyroidism-13/NN	nsubj||disease-21/NN||it-16/PRP	cop||disease-21/NN||is-17/VBZ	det||disease-21/NN||an-18/DT	amod||disease-21/NN||organ-specific-19/JJ	amod||disease-21/NN||autoimmune-20/JJ	conj_and||presented-9/VBN||disease-21/NN	vmod||disease-21/NN||induced-22/VBN	amod||autoantibodies-27/NNS||thyroid-stimulating-24/JJ	nn||autoantibodies-27/NNS||hormone-25/NN	nn||autoantibodies-27/NNS||receptor-26/NN	agent||induced-22/VBN||autoantibodies-27/NNS	graves'disease--1||thyrotoxicosis-11||no||graves'disease (gd) is generally presented by thyrotoxicosis with hyperthyroidism, and it is an organ-specific autoimmune disease induced by thyroid-stimulating hormone receptor autoantibodies.
mark||documented-5/VBN||although-1/IN	nsubjpass||documented-5/VBN||it-2/PRP	aux||documented-5/VBN||has-3/VBZ	auxpass||documented-5/VBN||been-4/VBN	advcl||remained-32/VBD||documented-5/VBN	mark||modulated-15/JJ||that-6/IN	nn||gene-9/NN||dynamin-7/NN	num||gene-9/NN||1-8/CD	nsubj||modulated-15/JJ||gene-9/NN	appos||gene-9/NN||dnm1-11/NNP	cop||modulated-15/JJ||is-13/VBZ	advmod||modulated-15/JJ||significantly-14/RB	ccomp||documented-5/VBN||modulated-15/JJ	prep_by||modulated-15/JJ||nicotine-17/NN	nn||models-20/NNS||animal-19/NN	prep_in||nicotine-17/NN||models-20/NNS	poss||association-23/NN||its-22/PRP$	nsubj||remained-32/VBD||association-23/NN	nsubjpass||unexplored-35/VBN||association-23/NN	prep_with||association-23/NN||nicotinedependence-25/NN	appos||nicotinedependence-25/NN||nd-27/NN	amod||population-31/NN||human-30/JJ	prep_in||nicotinedependence-25/NN||population-31/NN	root||ROOT-0/null||remained-32/VBD	aux||unexplored-35/VBN||to-33/TO	auxpass||unexplored-35/VBN||be-34/VB	xcomp||remained-32/VBD||unexplored-35/VBN	nicotinedependence-25||nicotine-17||no||although it has been documented that dynamin 1 gene ( dnm1 ) is significantly modulated by nicotine in animal models, its association with nicotinedependence (nd) in human population remained to be unexplored.
num||males-3/NNS||ten-1/CD	amod||males-3/NNS||adult-2/JJ	nsubjpass||tested-28/VBN||males-3/NNS	amod||obstructivepulmonarydisease-7/NN||stable-5/JJ	amod||obstructivepulmonarydisease-7/NN||chronic-6/JJ	prep_with||males-3/NNS||obstructivepulmonarydisease-7/NN	amod||±-16/NNS||mean-9/JJ	nn||±-16/NNS||â-10/NN	nn||±-16/NNS||±-11/NN	nn||±-16/NNS||sd-12/NN	amod||±-16/NNS||fev1-13/JJ	amod||±-16/NNS||37.7-14/JJ	nn||±-16/NNS||â-15/NN	dep||obstructivepulmonarydisease-7/NN||±-16/NNS	num||%-18/NN||14.9-17/CD	dep||±-16/NNS||%-18/NN	prep_of||%-18/NN||predicted-20/NNP	amod||therapy-26/NN||long-term-23/JJ	amod||therapy-26/NN||continuous-24/JJ	nn||therapy-26/NN||oxygen-25/NN	prep_on||obstructivepulmonarydisease-7/NN||therapy-26/NN	auxpass||tested-28/VBN||were-27/VBD	root||ROOT-0/null||tested-28/VBN	det||laboratory-32/NN||a-30/DT	nn||laboratory-32/NN||sleep-31/NN	prep_in||tested-28/VBN||laboratory-32/NN	det||12â-35/NNS||a-34/DT	prep_over||tested-28/VBN||12â-35/NNS	dep||tested-28/VBN||$-36/$	num||period-40/NN||13-38/CD	nn||period-40/NN||hour-39/NNP	npadvmod||overnight-44/RB||period-40/NN	advmod||period-40/NN||that-41/RB	pobj||that-41/RB||included-42/JJ	dep||included-42/JJ||an-43/DT	dep||polysomnogram-45/CD||overnight-44/RB	num||$-36/$||polysomnogram-45/CD	obstructivepulmonarydisease-7||oxygen-25||yes||ten adult males with stable chronic obstructivepulmonarydisease (mean â± sd fev1 37.7 â± 14.9% of predicted) on long-term continuous oxygen therapy were tested in a sleep laboratory over a 12â€“13 hour period that included an overnight polysomnogram.
nsubj||demonstrated-3/VBN||quetiapine-1/NN	aux||demonstrated-3/VBN||has-2/VBZ	root||ROOT-0/null||demonstrated-3/VBN	advmod||demonstrated-3/VBN||efficacy-4/RB	prep_in||demonstrated-3/VBN||schizophrenia-6/NN	prep_in||demonstrated-3/VBN||bipolardisorder-8/NN	conj_and||schizophrenia-6/NN||bipolardisorder-8/NN	prep_in||demonstrated-3/VBN||in-10/IN	conj_and||schizophrenia-6/NN||in-10/IN	det||treatment-12/NN||the-11/DT	pobj||in-10/IN||treatment-12/NN	amod||clusters-16/NNS||specific-14/JJ	nn||clusters-16/NNS||symptom-15/NN	prep_of||treatment-12/NN||clusters-16/NNS	nn||problems-22/NNS||agitation-19/NN	conj_and||agitation-19/NN||sleep-21/NN	nn||problems-22/NNS||sleep-21/NN	prep_such_as||schizophrenia-6/NN||problems-22/NNS	nn||disorders-25/NNS||mood-24/NN	prep_in||problems-22/NNS||disorders-25/NNS	bipolardisorder-8||quetiapine-1||yes||quetiapine has demonstrated efficacy in schizophrenia, bipolardisorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||lumefantrine--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
nsubj||contribute-9/VBP||hiv-1/NN	conj_and||hiv-1/NN||aids-3/NNS	nsubj||contribute-9/VBP||aids-3/NNS	amod||settings-7/NNS||resource-limited-6/JJ	prep_in||hiv-1/NN||settings-7/NNS	root||ROOT-0/null||contribute-9/VBP	amod||maternal-12/NN||increased-11/JJ	prep_to||contribute-9/VBP||maternal-12/NN	nn||mortality-15/NN||infant-14/NN	prep_to||contribute-9/VBP||mortality-15/NN	conj_and||maternal-12/NN||mortality-15/NN	advmod||high-22/JJ||where-16/WRB	amod||indicators-19/NNS||such-17/JJ	amod||indicators-19/NNS||vital-18/JJ	nsubj||high-22/JJ||indicators-19/NNS	cop||high-22/JJ||are-20/VBP	advmod||high-22/JJ||already-21/RB	advcl||contribute-9/VBP||high-22/JJ	aids-3||hiv-1||no||hiv and aids, in resource-limited settings, contribute to increased maternal and infant mortality where such vital indicators are already high.
amod||microorganisms-2/NNS||such-1/JJ	nsubj||play-4/VB||microorganisms-2/NNS	aux||play-4/VB||may-3/MD	root||ROOT-0/null||play-4/VB	det||hitherto-6/NN||a-5/DT	dobj||play-4/VB||hitherto-6/NN	dep||play-4/VB||unappreciated-7/VBN	dobj||unappreciated-7/VBN||role-8/NN	det||digestion-11/NN||the-10/DT	prep_in||unappreciated-7/VBN||digestion-11/NN	amod||gluten-14/NN||dietary-13/JJ	prep_of||digestion-11/NN||gluten-14/NN	dep||play-4/VB||thus-16/RB	conj_and||unappreciated-7/VBN||thus-16/RB	dep||unappreciated-7/VBN||protection-17/NN	prep_from||protection-17/NN||celiacdisease-19/NN	prep_in||celiacdisease-19/NN||subjects-21/NNS	prep_at||subjects-21/NNS||risk-23/NN	celiacdisease-19||gluten-14||no||such microorganisms may play a hitherto unappreciated role in the digestion of dietary gluten and thus protection from celiacdisease in subjects at risk.
det||expression-3/NN||the-1/DT	amod||expression-3/NN||gastric-2/JJ	nsubj||necrosis-6/VBZ||expression-3/NN	prep_of||expression-3/NN||tumor-5/NN	root||ROOT-0/null||necrosis-6/VBZ	nn||±-8/NNP||factor-î-7/NNP	nsubj||increased-13/VBD||±-8/NNP	amod||chemoattractant-1-12/NN||cytokine-induced-10/JJ	amod||chemoattractant-1-12/NN||neutrophil-11/JJ	conj_and||±-8/NNP||chemoattractant-1-12/NN	nsubj||increased-13/VBD||chemoattractant-1-12/NN	ccomp||necrosis-6/VBZ||increased-13/VBD	advmod||increased-13/VBD||significantly-14/RB	prep_in||increased-13/VBD||rats-16/NNS	vmod||rats-16/NNS||treated-17/VBN	acomp||treated-17/VBN||ischemia-reperfusion-18/JJ	det||increases-22/NNS||these-21/DT	nsubj||inhibited-25/JJ||increases-22/NNS	cop||inhibited-25/JJ||were-23/VBD	advmod||inhibited-25/JJ||significantly-24/RB	conj_and||necrosis-6/VBZ||inhibited-25/JJ	prep_by||inhibited-25/JJ||treatment-27/NN	prep_with||inhibited-25/JJ||pioglitazone-29/NN	pioglitazone-29||ischemia--1||no_rel||the gastric expression of tumor necrosis factor-î± and cytokine-induced neutrophil chemoattractant-1 increased significantly in rats treated ischemia-reperfusion, and these increases were significantly inhibited by treatment with pioglitazone.
amod||factor-22/NN||present-2/JJ	det||efalizumab-7/NN||an-3/DT	amod||efalizumab-7/NN||anti-cd11a-4/JJ	nn||efalizumab-7/NN||antibody-5/NN	dep||present-2/JJ||efalizumab-7/NN	det||alefacept-16/NN||an-10/DT	amod||alefacept-16/NN||anti-lfa3-11/JJ	amod||alefacept-16/NN||/-12/JJ	amod||alefacept-16/NN||cd2-13/JJ	nn||alefacept-16/NN||receptor-14/NN	dep||present-2/JJ||alefacept-16/NN	conj_and||efalizumab-7/NN||alefacept-16/NN	num||necrosis-21/NNS||3-19/CD	nn||necrosis-21/NNS||antitumor-20/NN	dep||present-2/JJ||necrosis-21/NNS	conj_and||efalizumab-7/NN||necrosis-21/NNS	prep_at||alpha-23/NN||factor-22/NN	amod||agents-24/NNS||alpha-23/NN	nsubj||available-35/JJ||agents-24/NNS	nn||infliximab-30/NN||adalimumab-26/NN	dep||infliximab-30/NN||etanercept-28/NN	appos||agents-24/NNS||infliximab-30/NN	cop||available-35/JJ||are-32/VBP	advmod||available-35/JJ||now-33/RB	advmod||available-35/JJ||commercially-34/RB	root||ROOT-0/null||available-35/JJ	det||treatment-38/NN||the-37/DT	prep_for||available-35/JJ||treatment-38/NN	preconj||psoriasis-41/NNS||both-40/DT	prep_of||treatment-38/NN||psoriasis-41/NNS	prep_of||treatment-38/NN||psoriaticarthritis-43/NNS	conj_and||psoriasis-41/NNS||psoriaticarthritis-43/NNS	psoriasis-41||alefacept-16||yes||at present an anti-cd11a antibody (efalizumab), an anti-lfa3/cd2 receptor (alefacept) and 3 antitumor necrosis factor alpha agents (adalimumab, etanercept, infliximab) are now commercially available for the treatment of both psoriasis and psoriaticarthritis.
nn||markers-6/NNS||hbvdna-1/NN	conj_and||hbvdna-1/NN||other-3/JJ	nn||markers-6/NNS||other-3/JJ	amod||markers-6/NNS||serum-4/JJ	nn||markers-6/NNS||hbv-5/NN	nsubjpass||tested-29/VBN||markers-6/NNS	amod||antigen-10/NN||hepatitisb-8/JJ	amod||antigen-10/NN||e-9/JJ	prep_including||markers-6/NNS||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	amod||antibody-17/NN||hepatitisb-15/JJ	nn||antibody-17/NN||core-16/NN	prep_including||markers-6/NNS||antibody-17/NN	conj_and||antigen-10/NN||antibody-17/NN	dep||antibody-17/NN||anti-hbc-19/JJ	amod||antibody-24/NN||hepatitisb-22/JJ	nn||antibody-24/NN||surface-23/NN	prep_including||markers-6/NNS||antibody-24/NN	conj_and||antigen-10/NN||antibody-24/NN	appos||antibody-24/NN||anti-hbs-26/NNS	auxpass||tested-29/VBN||were-28/VBD	root||ROOT-0/null||tested-29/VBN	prepc_among||tested-29/VBN||hbsag-31/VBG	amod||women-34/NNS||positive-32/JJ	amod||women-34/NNS||pregnant-33/JJ	dobj||hbsag-31/VBG||women-34/NNS	hbv-5||hbsag-31||yes||hbvdna and other serum hbv markers including hepatitisb e antigen (hbeag), hepatitisb core antibody (anti-hbc) and hepatitisb surface antibody (anti-hbs) were tested among hbsag positive pregnant women.
nsubj||belong-9/VBP||mutations-1/NNS	nsubj||lead-23/VB||mutations-1/NNS	amod||c-8/NN||mybpc3-3/JJ	nn||c-8/NN||encoding-4/NN	nn||c-8/NN||myosin-5/NN	amod||c-8/NN||binding-6/VBG	nn||c-8/NN||protein-7/NN	prep_in||mutations-1/NNS||c-8/NN	root||ROOT-0/null||belong-9/VBP	det||causes-14/NNS||the-11/DT	advmod||causes-14/NNS||most-12/RBS	amod||causes-14/NNS||frequent-13/JJ	prep_to||belong-9/VBP||causes-14/NNS	prep_of||causes-14/NNS||hypertrophiccardiomyopathy-16/NN	appos||hypertrophiccardiomyopathy-16/NN||hcm-18/NN	aux||lead-23/VB||may-21/MD	advmod||lead-23/VB||also-22/RB	conj_and||belong-9/VBP||lead-23/VB	amod||cardiomyopathy-26/NN||dilated-25/JJ	prep_to||lead-23/VB||cardiomyopathy-26/NN	appos||cardiomyopathy-26/NN||dcm-28/NN	dcm-28||hypertrophiccardiomyopathy-16||no_rel||mutations in mybpc3 encoding myosin binding protein c belong to the most frequent causes of hypertrophiccardiomyopathy (hcm) and may also lead to dilated cardiomyopathy (dcm).
dep||expected-32/VBN||improving-1/VBG	nn||awareness-3/NN||community-2/NN	dobj||improving-1/VBG||awareness-3/NN	det||role-6/NN||the-5/DT	prep_about||improving-1/VBG||role-6/NN	prep_of||role-6/NN||primaquine-8/NN	aux||prevent-10/VB||to-9/TO	vmod||improving-1/VBG||prevent-10/VB	amod||transmission-13/NN||further-11/JJ	nn||transmission-13/NN||malaria-12/NN	dobj||prevent-10/VB||transmission-13/NN	conj_and||improving-1/VBG||fostering-15/VBG	dep||expected-32/VBN||fostering-15/VBG	det||system-18/NN||a-16/DT	amod||system-18/NN||realistic-17/JJ	dobj||fostering-15/VBG||system-18/NN	amod||observed-21/JJ||direct-20/JJ	amod||intake-23/NN||observed-21/JJ	nn||intake-23/NN||treatment-22/NN	prep_of||system-18/NN||intake-23/NN	parataxis||expected-32/VBN||organized-25/VBN	nn||level-28/NN||community-27/NN	prep_at||organized-25/VBN||level-28/NN	aux||expected-32/VBN||can-30/MD	auxpass||expected-32/VBN||be-31/VB	root||ROOT-0/null||expected-32/VBN	aux||improve-34/VB||to-33/TO	xcomp||expected-32/VBN||improve-34/VB	dobj||improve-34/VB||adherence-35/NN	det||cure-39/NN||the-37/DT	amod||cure-39/NN||radical-38/JJ	prep_to||improve-34/VB||cure-39/NN	nn||vivax-42/NN||p.-41/NN	prep_of||cure-39/NN||vivax-42/NN	det||area-45/NN||this-44/DT	prep_in||vivax-42/NN||area-45/NN	malaria-12||primaquine-8||yes||improving community awareness about the role of primaquine to prevent further malaria transmission and fostering a realistic system of direct observed treatment intake , organized at community level , can be expected to improve adherence to the radical cure of p. vivax in this area .
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	nitricoxide-50||obesity-17||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
nsubj||likely-14/JJ||women-1/NNS	nsubj||have-16/VB||women-1/NNS	det||malaria-11/NN||either-3/DT	dep||acute-7/JJ||acute-4/JJ	amod||malaria-11/NN||acute-7/JJ	conj_and||acute-7/JJ||chronic-9/JJ	amod||malaria-11/NN||chronic-9/JJ	amod||malaria-11/NN||placental-10/JJ	prep_with||women-1/NNS||malaria-11/NN	cop||likely-14/JJ||were-12/VBD	advmod||likely-14/JJ||less-13/RBR	dep||is-25/VBZ||likely-14/JJ	aux||have-16/VB||to-15/TO	xcomp||likely-14/JJ||have-16/VB	dobj||have-16/VB||irondeficiency-17/NN	prep_than||irondeficiency-17/NN||women-19/NNS	amod||infection-23/NN||placental-21/JJ	nn||infection-23/NN||malaria-22/NN	prep_without||have-16/VB||infection-23/NN	expl||is-25/VBZ||there-24/EX	root||ROOT-0/null||is-25/VBZ	det||priority-27/NN||a-26/DT	nsubj||is-25/VBZ||priority-27/NN	aux||establish-29/VB||to-28/TO	vmod||priority-27/NN||establish-29/VB	mark||enhances-43/VBZ||if-30/IN	csubj||enhances-43/VBZ||reversing-31/VBG	advmod||reversing-31/VBG||irondeficiency-32/RB	nn||programs-36/NNS||iron-34/NN	nn||programs-36/NNS||supplementation-35/NN	prep_through||reversing-31/VBG||programs-36/NNS	dep||programs-36/NNS||either-37/DT	dep||either-37/DT||prior-38/RB	prep||prior-38/RB||to-39/TO	dep||programs-36/NNS||during-41/IN	conj_or||either-37/DT||during-41/IN	pobj||during-41/IN||pregnancy-42/NN	advcl||establish-29/VB||enhances-43/VBZ	nn||risk-45/NN||malaria-44/NN	dobj||enhances-43/VBZ||risk-45/NN	irondeficiency-32||iron-34||yes||women with either acute, or acute and chronic placental malaria were less likely to have irondeficiency than women without placental malaria infection there is a priority to establish if reversing irondeficiency through iron supplementation programs either prior to or during pregnancy enhances malaria risk.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||observe-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||observe-8/VB||to-7/TO	xcomp||was-6/VBD||observe-8/VB	det||efficacy-10/NN||the-9/DT	dobj||observe-8/VB||efficacy-10/NN	amod||therapy-14/NN||clarithromycin-based-12/JJ	amod||therapy-14/NN||triple-13/JJ	prep_of||efficacy-10/NN||therapy-14/NN	nn||pylori-17/NNS||helicobacter-16/NN	prep_for||observe-8/VB||pylori-17/NNS	appos||pylori-17/NNS||hp-19/NN	amod||duodenalulcer-23/NN||infected-22/JJ	dep||pylori-17/NNS||duodenalulcer-23/NN	advmod||combined-25/VBN||when-24/WRB	rcmod||duodenalulcer-23/NN||combined-25/VBN	amod||levels-29/NNS||different-27/JJ	nn||levels-29/NNS||ph-28/NN	prep_with||combined-25/VBN||levels-29/NNS	amod||juices-32/NNS||gastric-31/JJ	prep_of||levels-29/NNS||juices-32/NNS	duodenalulcer-23||clarithromycin--1||yes||the aim of this study was to observe the efficacy of clarithromycin-based triple therapy for helicobacter pylori ( hp )-infected duodenalulcer when combined with different ph levels of gastric juices.
nsubj||nonexistent-17/JJ||data-1/NNS	det||safety-4/NN||the-3/DT	prep_regarding||data-1/NNS||safety-4/NN	prep_of||safety-4/NN||methylphenidate-6/NN	amod||attentiondeficithyperactivitydisorder-9/NN||comorbid-8/JJ	prep_in||methylphenidate-6/NN||attentiondeficithyperactivitydisorder-9/NN	dep||data-1/NNS||adhd-11/VBN	amod||retardation-15/NN||mental-14/JJ	conj_and||data-1/NNS||retardation-15/NN	nsubj||nonexistent-17/JJ||retardation-15/NN	cop||nonexistent-17/JJ||are-16/VBP	root||ROOT-0/null||nonexistent-17/JJ	attentiondeficithyperactivitydisorder-9||methylphenidate-6||yes||data regarding the safety of methylphenidate in comorbid attentiondeficithyperactivitydisorder (adhd) and mental retardation are nonexistent.
det||results-2/NNS||the-1/DT	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	amod||level-5/NN||intermediate-4/JJ	dobj||indicate-3/VBP||level-5/NN	prep_of||level-5/NN||endemicity-7/NN	nn||infection-10/NN||hbv-9/NN	prep_of||endemicity-7/NN||infection-10/NN	nn||community-13/NN||dhaka-12/NN	prep_in||infection-10/NN||community-13/NN	advmod||higher-17/JJR||much-16/RB	prep_with||indicate-3/VBP||higher-17/JJR	amod||higher-17/JJR||prevalence-18/JJ	nn||members-21/NNS||family-20/NN	prep_among||prevalence-18/JJ||members-21/NNS	amod||individuals-25/NNS||hbsag-23/JJ	amod||individuals-25/NNS||positive-24/JJ	prep_of||members-21/NNS||individuals-25/NNS	advmod||prevalence-28/JJ||low-27/RB	amod||higher-17/JJR||prevalence-28/JJ	conj_but||prevalence-18/JJ||prevalence-28/JJ	nn||infections-31/NNS||hcv-30/NN	prep_of||higher-17/JJR||infections-31/NNS	advmod||indicating-34/VBG||clearly-33/RB	vmod||higher-17/JJR||indicating-34/VBG	dobj||indicating-34/VBG||need-35/NN	amod||vaccination-39/NN||universal-37/JJ	nn||vaccination-39/NN||hepatitisb-38/NN	prep_for||higher-17/JJR||vaccination-39/NN	hepatitisb-38||hbsag-23||yes||the results indicate intermediate level of endemicity of hbv infection in dhaka community, with much higher prevalence among family members of hbsag positive individuals but low prevalence of hcv infections, clearly indicating need for universal hepatitisb vaccination.
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	vomiting-21||dexamethasone-6||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	det||progression-4/NN||the-3/DT	dobj||determine-2/VB||progression-4/NN	nn||weight-7/NN||body-6/NN	prep_of||progression-4/NN||weight-7/NN	appos||weight-7/NN||bw-9/NN	nn||composition-13/NN||body-12/NN	prep_of||progression-4/NN||composition-13/NN	conj_and||weight-7/NN||composition-13/NN	appos||weight-7/NN||bc-15/NN	prep_in||determine-2/VB||patients-18/NNS	amod||t2d-22/NNS||type2diabetesmellitus-20/JJ	prep_with||patients-18/NNS||t2d-22/NNS	nn||therapy-26/NN||insulin-25/NN	prep_on||t2d-22/NNS||therapy-26/NN	det||consequences-29/NNS||the-28/DT	prep_with||patients-18/NNS||consequences-29/NNS	conj_and||t2d-22/NNS||consequences-29/NNS	nn||strength-32/NN||muscle-31/NN	prep_on||consequences-29/NNS||strength-32/NN	appos||strength-32/NN||ms-34/NN	det||reflect-38/NN||a-37/DT	prep_as||determine-2/VB||reflect-38/NN	amod||increases-43/NNS||free-40/JJ	amod||increases-43/NNS||fat-41/JJ	nn||increases-43/NNS||mass-42/NN	prep_of||reflect-38/NN||increases-43/NNS	t2d-22||insulin-25||yes||to determine the progression of body weight (bw) and body composition (bc) in patients with type2diabetesmellitus (t2d) on insulin therapy and the consequences on muscle strength (ms) as a reflect of free fat mass increases.
det||growth-2/NN||the-1/DT	nsubj||relaxed-11/VBD||growth-2/NN	amod||wells-7/NNS||ingan/gan-4/JJ	amod||wells-7/NNS||multiple-5/JJ	nn||wells-7/NNS||quantum-6/NN	prep_of||growth-2/NN||wells-7/NNS	det||stress-10/NN||these-9/DT	prep_on||wells-7/NNS||stress-10/NN	root||ROOT-0/null||relaxed-11/VBD	amod||templates-15/NNS||low-12/JJ	nn||templates-15/NNS||defect-13/NN	nn||templates-15/NNS||density-14/NN	nsubj||improves-16/VBZ||templates-15/NNS	ccomp||relaxed-11/VBD||improves-16/VBZ	det||efficiency-20/NN||the-17/DT	amod||efficiency-20/NN||internal-18/JJ	nn||efficiency-20/NN||quantum-19/NN	dobj||improves-16/VBZ||efficiency-20/NN	num||%-23/NN||15-22/CD	prep_by||improves-16/VBZ||%-23/NN	det||wells-29/NNS||the-25/DT	amod||wells-29/NNS||cyan-green-26/JJ	amod||wells-29/NNS||multiple-27/JJ	nn||wells-29/NNS||quantum-28/NN	prep_for||%-23/NN||wells-29/NNS	gan--1||wells-29||no_rel||the growth of ingan/gan multiple quantum wells on these stress relaxed low defect density templates improves the internal quantum efficiency by 15% for the cyan-green multiple quantum wells.
aux||understand-2/VB||to-1/TO	advcl||solved-12/VBD||understand-2/VB	det||basis-5/NN||the-3/DT	amod||basis-5/NN||structural-4/JJ	dobj||understand-2/VB||basis-5/NN	nn||adhesion-9/NN||host-7/NN	nn||adhesion-9/NN||cell-8/NN	prep_for||basis-5/NN||adhesion-9/NN	nsubj||solved-12/VBD||we-11/PRP	root||ROOT-0/null||solved-12/VBD	det||ã-15/NN||a-13/DT	num||ã-15/NN||1.35-14/CD	dobj||solved-12/VBD||ã-15/NN	nn||structure-19/NN||resolution-17/NN	nn||structure-19/NN||crystal-18/NN	dep||ã-15/NN||structure-19/NN	det||domain-25/NN||a-21/DT	amod||domain-25/NN||bpaa-22/JJ	nn||domain-25/NN||taa-23/NN	nn||domain-25/NN||head-24/NN	prep_of||structure-19/NN||domain-25/NN	prep_from||solved-12/VBD||burkholderiapseudomallei-27/NNS	det||pathogen-30/NN||the-29/DT	appos||burkholderiapseudomallei-27/NNS||pathogen-30/NN	nsubj||causes-32/VBZ||pathogen-30/NN	rcmod||pathogen-30/NN||causes-32/VBZ	dobj||causes-32/VBZ||melioidosis-33/NNS	melioidosis-33||burkholderiapseudomallei-27||no||to understand the structural basis for host cell adhesion, we solved a 1.35 ã… resolution crystal structure of a bpaa taa head domain from burkholderiapseudomallei , the pathogen that causes melioidosis.
advmod||limited-19/JJ||currently-1/RB	det||use-4/NN||the-3/DT	nsubj||limited-19/JJ||use-4/NN	advmod||administered-7/VBN||orally-6/RB	amod||antidepressants-10/NNS||administered-7/VBN	nn||antidepressants-10/NNS||mao-8/NN	nn||antidepressants-10/NNS||inhibitor-9/NN	prep_of||use-4/NN||antidepressants-10/NNS	nn||tranylcypromine-16/NN||eg-12/NN	dep||tranylcypromine-16/NN||phenelzine-14/NN	appos||antidepressants-10/NNS||tranylcypromine-16/NN	cop||limited-19/JJ||is-18/VBZ	root||ROOT-0/null||limited-19/JJ	det||risk-22/NN||the-21/DT	prep_by||limited-19/JJ||risk-22/NN	amod||events-25/NNS||tyramine-provoked-24/JJ	prep_of||risk-22/NN||events-25/NNS	dep||limited-19/JJ||eg-27/NN	amod||hypertension-30/NN||acute-29/JJ	appos||eg-27/NN||hypertension-30/NN	appos||eg-27/NN||headache-32/NN	conj_and||hypertension-30/NN||headache-32/NN	advmod||known-35/VBN||also-34/RB	vmod||hypertension-30/NN||known-35/VBN	det||$-42/NN||the-37/DT	amod||$-42/NN||â-38/JJ	amod||$-42/NN||$-39/$	dep||$-39/$||œcheese-40/JJ	amod||$-42/NN||reactionâ-41/JJ	prep_as||known-35/VBN||$-42/NN	advmod||combined-45/VBN||when-44/WRB	advcl||limited-19/JJ||combined-45/VBN	amod||tyramine-48/NN||dietary-47/JJ	prep_with||combined-45/VBN||tyramine-48/NN	hypertension-30||phenelzine-14||no||currently, the use of orally administered mao inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the â€œcheese reactionâ€?) when combined with dietary tyramine.
nsubj||determined-2/VBD||we-1/PRP	nsubj||determined-2/VBD||we-1/PRP	root||ROOT-0/null||determined-2/VBD	conj_or||determined-2/VBD||determined-2/VBD	det||efficacy-4/NN||the-3/DT	dobj||determined-2/VBD||efficacy-4/NN	dobj||determined-2/VBD||safety-6/NN	conj_and||efficacy-4/NN||safety-6/NN	det||dose-11/NN||a-8/DT	advmod||high-10/JJ||relatively-9/RB	amod||dose-11/NN||high-10/JJ	prep_of||efficacy-4/NN||dose-11/NN	prep_of||dose-11/NN||terazosin-13/NN	number||mg-16/CD||5-15/CD	dep||efficacy-4/NN||mg-16/CD	nn||patients-20/NNS||korean-19/NN	prep_in||determined-2/VBD||patients-20/NNS	amod||symptoms-25/NNS||lower-22/JJR	amod||symptoms-25/NNS||urinary-23/JJ	nn||symptoms-25/NNS||tract-24/NN	prep_with||determined-2/VBD||symptoms-25/NNS	appos||symptoms-25/NNS||luts-27/NNS	amod||hypertension-34/NN||concomitant-33/JJ	prep_with||determined-2/VBD||hypertension-34/NN	prep_without||determined-2/VBD||hypertension-34/NN	hypertension-34||terazosin-13||yes||we determined the efficacy and safety of a relatively high dose of terazosin (5 mg) in korean patients with lower urinary tract symptoms (luts), with or without concomitant hypertension.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||elucidate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||elucidate-8/VB||to-7/TO	xcomp||was-6/VBD||elucidate-8/VB	mark||differentiated-20/VBD||whether-9/IN	det||stabilization-12/NN||the-10/DT	amod||stabilization-12/NN||cytoplasmic-11/JJ	nsubj||differentiated-20/VBD||stabilization-12/NN	amod||±-15/NNS||hif1î-14/JJ	prep_of||stabilization-12/NN||±-15/NNS	amod||ne-19/NN||androgen-17/JJ	amod||ne-19/NN||independent-18/JJ	prep_in||±-15/NNS||ne-19/NN	ccomp||elucidate-8/VB||differentiated-20/VBD	nn||cancer-22/NN||prostate-21/NN	nsubj||due-24/JJ||cancer-22/NN	cop||due-24/JJ||is-23/VBZ	ccomp||differentiated-20/VBD||due-24/JJ	det||presence-27/NN||the-26/DT	prep_to||due-24/JJ||presence-27/NN	amod||isoforms-32/NNS||certain-29/JJ	amod||isoforms-32/NNS||hif1î-30/JJ	nn||isoforms-32/NNS||±-31/NN	prep_of||presence-27/NN||isoforms-32/NNS	androgen-17||cancer-22||no_rel||the aim of this study was to elucidate whether the cytoplasmic stabilization of hif1î± in androgen independent ne differentiated prostate cancer is due to the presence of certain hif1î± isoforms.
amod||glucoseintolerance-2/NN||maternal-1/JJ	nsubj||impair-4/VB||glucoseintolerance-2/NN	aux||impair-4/VB||may-3/MD	root||ROOT-0/null||impair-4/VB	amod||sensitivity-7/NN||fetal-5/JJ	nn||sensitivity-7/NN||insulin-6/NN	dobj||impair-4/VB||sensitivity-7/NN	cc||²-12/NNS||not-10/RB	nn||²-12/NNS||î-11/NN	dep||sensitivity-7/NN||²-12/NNS	nn||function-15/NN||cell-14/NN	dep||²-12/NNS||function-15/NN	advmod||â-19/NN||consequently-18/RB	dobj||impair-4/VB||â-19/NN	conj_and||sensitivity-7/NN||â-19/NN	dep||sensitivity-7/NN||$-20/$	num||$-20/$||œprogramâ-21/CD	dep||$-20/$||$-22/$	quantmod||susceptibility-24/CD||the-23/DT	num||$-22/$||susceptibility-24/CD	prep_to||impair-4/VB||type2diabetes-26/CD	type2diabetes-26||insulin-6||yes||maternal glucoseintolerance may impair fetal insulin sensitivity (but not î²-cell function) and consequently â€œprogramâ€? the susceptibility to type2diabetes.
nsubj||-lsb--7/VBZ||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	root||ROOT-0/null||-lsb--7/VBZ	amod||insulinglargine-9/NN||once-daily-8/JJ	dobj||-lsb--7/VBZ||insulinglargine-9/NN	prep||insulinglargine-9/NN||plus-10/CC	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||‰-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	pobj||plus-10/CC||+-19/NNS	advmod||-rrb--21/JJ||l-20/RB	amod||+-19/NNS||-rrb--21/JJ	nn||-rrb--29/NN||insulin-23/NN	nn||-rrb--29/NN||lispro-24/NN	nn||-rrb--29/NN||mix-25/NN	num||-rrb--29/NN||50/50-26/CD	num||-rrb--29/NN||-lrb--27/CD	amod||-rrb--29/NN||lm50/50-28/JJ	prep_vs.||+-19/NNS||-rrb--29/NN	vmod||-rrb--29/NN||progression-30/VBN	advmod||up-32/RB||once-31/RB	advmod||progression-30/VBN||up-32/RB	aux||thrice-34/VB||to-33/TO	xcomp||progression-30/VBN||thrice-34/VB	amod||progression-38/NN||daily-35/JJ	amod||progression-38/NN||-lrb--36/JJ	nn||progression-38/NN||premix-37/NN	dobj||thrice-34/VB||progression-38/NN	nn||-rsb--42/NNP||pp-40/NNP	nn||-rsb--42/NNP||-rrb--41/NNP	appos||progression-38/NN||-rsb--42/NNP	prepc_of||-rsb--42/NNP||beginning-44/VBG	prepc_of||-rsb--42/NNP||advancing-46/VBG	conj_and||beginning-44/VBG||advancing-46/VBG	dobj||beginning-44/VBG||insulin-47/NN	prep_in||+-19/NNS||patients-49/NNS	prep_with||patients-49/NNS||type2diabetes-51/CD	vmod||+-19/NNS||-lrb--52/VBG	num||control-58/NN||t2d-53/CD	amod||control-58/NN||-rrb--54/JJ	conj_and||-rrb--54/JJ||inadequate-56/JJ	amod||control-58/NN||inadequate-56/JJ	amod||control-58/NN||glycaemic-57/JJ	dobj||-lrb--52/VBG||control-58/NN	amod||therapy-61/NN||oral-60/JJ	prep_on||control-58/NN||therapy-61/NN	det||aim-65/NN||the-64/DT	prep_with||-lrb--52/VBG||aim-65/NN	prepc_of||aim-65/NN||showing-67/VBG	dobj||showing-67/VBG||non-inferiority-68/NN	prep_of||non-inferiority-68/NN||pp-70/NN	aux||g-72/VB||to-71/TO	vmod||showing-67/VBG||g-72/VB	amod||l-74/NN||+-73/JJ	dobj||g-72/VB||l-74/NN	t2d-53||insulinglargine-9||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â ‰ $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulin lispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
nsubj||used-17/VBD||celecoxib-1/NN	conj_and||celecoxib-1/NN||diclofenac-3/NN	nsubj||used-17/VBD||diclofenac-3/NN	conj_and||celecoxib-1/NN||ibuprofen-5/NN	nsubj||used-17/VBD||ibuprofen-5/NN	conj_and||celecoxib-1/NN||nimesulide-8/NN	nsubj||used-17/VBD||nimesulide-8/NN	cop||anti-inflammatorydrugs-11/NNS||are-9/VBP	amod||anti-inflammatorydrugs-11/NNS||nonsteroidal-10/JJ	rcmod||celecoxib-1/NN||anti-inflammatorydrugs-11/NNS	appos||celecoxib-1/NN||nsaids-13/NNS	advmod||commonly-16/RB||very-15/RB	advmod||used-17/VBD||commonly-16/RB	root||ROOT-0/null||used-17/VBD	det||treatment-20/NN||the-19/DT	prep_for||used-17/VBD||treatment-20/NN	amod||mild-24/JJ||moderate-22/JJ	dep||mild-24/JJ||to-23/TO	amod||pain-25/NN||mild-24/JJ	prep_of||treatment-20/NN||pain-25/NN	nn||acetaminophen-31/NN||paracetamol-29/NNP	prep_together_with||used-17/VBD||acetaminophen-31/NN	det||analgesic-38/NN||a-34/DT	advmod||used-37/JJ||very-35/RB	advmod||used-37/JJ||widely-36/RB	amod||analgesic-38/NN||used-37/JJ	appos||acetaminophen-31/NN||analgesic-38/NN	det||effect-43/NN||a-40/DT	amod||effect-43/NN||lesser-41/JJR	amod||effect-43/NN||anti-inflammatory-42/JJ	prep_with||analgesic-38/NN||effect-43/NN	pain-25||ibuprofen-5||yes||celecoxib, diclofenac, ibuprofen, and nimesulide are nonsteroidal anti-inflammatorydrugs (nsaids) very commonly used for the treatment of moderate to mild pain, together with paracetamol (acetaminophen), a very widely used analgesic with a lesser anti-inflammatory effect.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
nsubj||showed-19/VBD||mining-1/NN	dep||transcriptomic-4/JJ||available-3/JJ	amod||data-7/NNS||transcriptomic-4/JJ	conj_and||transcriptomic-4/JJ||proteomic-6/JJ	amod||data-7/NNS||proteomic-6/JJ	prep_of||mining-1/NN||data-7/NNS	vmod||data-7/NNS||pertaining-8/VBG	amod||models-12/NNS||established-10/VBN	nn||models-12/NNS||rodent-11/NN	prep_to||pertaining-8/VBG||models-12/NNS	nn||patients-18/NNS||epilepsy-14/NN	conj_and||epilepsy-14/NN||human-16/JJ	nn||patients-18/NNS||human-16/JJ	amod||patients-18/NNS||epileptic-17/JJ	prep_of||models-12/NNS||patients-18/NNS	root||ROOT-0/null||showed-19/VBD	dobj||showed-19/VBD||overrepresentation-20/NN	prep_of||overrepresentation-20/NN||epilepsy-22/NN	vmod||epilepsy-22/NN||associated-23/VBN	dobj||associated-23/VBN||genes-24/NNS	poss||set-29/NN||our-26/PRP$	amod||set-29/NN||ptz-27/JJ	amod||set-29/NN||regulated-28/JJ	prep_in||genes-24/NNS||set-29/NN	epilepsy-22||ptz-27||no||mining of available transcriptomic and proteomic data pertaining to established rodent models of epilepsy and human epileptic patients showed overrepresentation of epilepsy associated genes in our ptz regulated set.
det||series-3/NN||a-2/DT	prep_following||found-12/VBN||series-3/NN	prep_of||series-3/NN||studies-5/NNS	prep_in||studies-5/NNS||patients-7/NNS	prep_with||patients-7/NNS||non-vibriocholera-9/NN	nsubjpass||found-12/VBN||it-10/PRP	auxpass||found-12/VBN||was-11/VBD	root||ROOT-0/null||found-12/VBN	mark||had-16/VBD||that-13/IN	det||patients-15/NNS||these-14/DT	nsubj||had-16/VBD||patients-15/NNS	ccomp||found-12/VBN||had-16/VBD	amod||concentrations-18/NNS||large-17/JJ	dobj||had-16/VBD||concentrations-18/NNS	nn||coli-21/NNS||escherichia-20/NN	prep_of||concentrations-18/NNS||coli-21/NNS	det||bowel-25/NN||the-23/DT	amod||bowel-25/NN||small-24/JJ	prep_in||had-16/VBD||bowel-25/NN	prep_in||had-16/VBD||stools-27/NNS	conj_and||bowel-25/NN||stools-27/NNS	nsubj||produced-29/VBD||stools-27/NNS	nsubj||had-35/VBD||stools-27/NNS	rcmod||stools-27/NNS||produced-29/VBD	amod||enterotoxins-32/NNS||cholera-30/JJ	amod||enterotoxins-32/NNS||toxin-like-31/JJ	dobj||produced-29/VBD||enterotoxins-32/NNS	rcmod||stools-27/NNS||had-35/VBD	conj_and||produced-29/VBD||had-35/VBD	amod||abnormalities-40/NNS||fluid-36/JJ	conj_and||fluid-36/JJ||electrolyte-38/JJ	amod||abnormalities-40/NNS||electrolyte-38/JJ	nn||abnormalities-40/NNS||transport-39/NN	dobj||had-35/VBD||abnormalities-40/NNS	det||bowel-44/NN||the-42/DT	amod||bowel-44/NN||small-43/JJ	prep_in||abnormalities-40/NNS||bowel-44/NN	amod||bowel-44/NN||similar-45/JJ	prep_to||similar-45/JJ||patients-47/NNS	amod||cholera-50/NN||documented-49/VBN	prep_with||patients-47/NNS||cholera-50/NN	cholera-50||vibriocholera--1||no||following a series of studies in patients with non-vibriocholera it was found that these patients had large concentrations of escherichia coli in the small bowel and stools which produced cholera toxin-like enterotoxins, and had fluid and electrolyte transport abnormalities in the small bowel similar to patients with documented cholera.
nn||diagnosis-2/NN||pbc-1/NN	nsubjpass||established-4/VBN||diagnosis-2/NN	auxpass||established-4/VBN||was-3/VBD	root||ROOT-0/null||established-4/VBN	prepc_according_to||established-4/VBN||to-6/TO	det||profile-10/NN||the-7/DT	amod||profile-10/NN||cholestatic-8/JJ	amod||profile-10/NN||biochemical-9/JJ	pobj||established-4/VBN||profile-10/NN	amod||antibodies-13/NNS||anti-mitochondrial-12/JJ	appos||profile-10/NN||antibodies-13/NNS	appos||profile-10/NN||ama-15/NN	nn||histology-20/NN||positivity-17/NN	conj_and||positivity-17/NN||liver-19/NN	nn||histology-20/NN||liver-19/NN	dep||profile-10/NN||histology-20/NN	dep||histology-20/NN||first-22/JJ	dep||profile-10/NN||ama-26/NN	conj_and||histology-20/NN||ama-26/NN	conj_and||histology-20/NN||antinuclear-28/NN	conj_and||ama-26/NN||antinuclear-28/NN	appos||ama-26/NN||ana-30/NN	amod||antibodies-33/NNS||pbc-specific-32/JJ	dep||ama-26/NN||antibodies-33/NNS	dep||ama-26/NN||second-35/JJ	antibodies-33||pbc-1||no_rel||pbc diagnosis was established according to the cholestatic biochemical profile, anti-mitochondrial antibodies (ama) positivity and liver histology (first), and ama and antinuclear (ana) pbc-specific antibodies (second).
mark||recognized-17/VBN||while-1/IN	det||role-3/NN||the-2/DT	nsubjpass||recognized-17/VBN||role-3/NN	amod||mmf-7/NN||mycophenolatemofetil-5/JJ	prep_of||role-3/NN||mmf-7/NN	det||management-11/NN||the-10/DT	prep_in||mmf-7/NN||management-11/NN	prep_of||management-11/NN||lupusnephritis-13/NNS	aux||recognized-17/VBN||has-14/VBZ	auxpass||recognized-17/VBN||been-15/VBN	advmod||recognized-17/VBN||increasingly-16/RB	advcl||available-22/JJ||recognized-17/VBN	amod||information-20/NN||limited-19/JJ	nsubj||available-22/JJ||information-20/NN	cop||available-22/JJ||is-21/VBZ	root||ROOT-0/null||available-22/JJ	xcomp||available-22/JJ||regarding-23/VBG	poss||efficacy-25/NN||its-24/PRP$	dobj||regarding-23/VBG||efficacy-25/NN	dobj||regarding-23/VBG||safety-27/NN	conj_and||efficacy-25/NN||safety-27/NN	det||treatment-32/NN||a-29/DT	amod||treatment-32/NN||long-term-30/JJ	nn||treatment-32/NN||maintenance-31/NN	prep_as||regarding-23/VBG||treatment-32/NN	lupusnephritis-13||mycophenolatemofetil-5||no_rel||while the role of mycophenolatemofetil (mmf) in the management of lupusnephritis has been increasingly recognized, limited information is available regarding its efficacy and safety as a long-term maintenance treatment.
det||variety-2/NN||a-1/DT	nsubj||are-6/VBP||variety-2/NN	nn||platforms-5/NNS||vaccine-4/NN	prep_of||variety-2/NN||platforms-5/NNS	root||ROOT-0/null||are-6/VBP	prep_under||are-6/VBP||study-8/NN	prep_for||study-8/NN||development-10/NN	amod||vaccines-13/NNS||new-12/JJ	prep_of||development-10/NN||vaccines-13/NNS	prep_for||vaccines-13/NNS||measles-15/NNS	vaccines-13||measles-15||no_rel||a variety of vaccine platforms are under study for development of new vaccines for measles.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	nonsteroidalantiinflammatorydrugs-55||pain-30||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
nsubjpass||exposed-10/VBN||neisseriameningitidis-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	appos||neisseriameningitidis-1/NNS||agent-5/NN	prep_of||agent-5/NN||meningococcaldisease-7/NN	auxpass||exposed-10/VBN||is-9/VBZ	root||ROOT-0/null||exposed-10/VBN	amod||levels-13/NNS||high-12/JJ	prep_to||exposed-10/VBN||levels-13/NNS	amod||species-17/NNS||reactive-15/JJ	nn||species-17/NNS||oxygen-16/NN	prep_of||levels-13/NNS||species-17/NNS	poss||host-22/NN||its-19/PRP$	amod||host-22/NN||exclusive-20/JJ	amod||host-22/NN||human-21/JJ	prep_inside||species-17/NNS||host-22/NN	meningococcaldisease-7||neisseriameningitidis-1||no||neisseriameningitidis , the causative agent of meningococcaldisease, is exposed to high levels of reactive oxygen species inside its exclusive human host.
nsubj||reported-2/VBD||he-1/PRP	root||ROOT-0/null||reported-2/VBD	det||history-4/NN||a-3/DT	dobj||reported-2/VBD||history-4/NN	amod||angiography-8/NN||fundus-6/JJ	nn||angiography-8/NN||fluorescein-7/NN	prep_of||history-4/NN||angiography-8/NN	det||pre-diagnosis-11/NNS||a-10/DT	prep_with||reported-2/VBD||pre-diagnosis-11/NNS	prep_of||pre-diagnosis-11/NNS||senilemaculardegeneration-13/NN	num||months-15/NNS||2-14/CD	npadvmod||reported-2/VBD||months-15/NNS	prep_prior_to||reported-2/VBD||presentation-18/NN	fluorescein-7||senilemaculardegeneration-13||no_rel||he reported a history of fundus fluorescein angiography with a pre-diagnosis of senilemaculardegeneration 2 months prior to presentation.
det||line-4/NN||the-2/DT	amod||line-4/NN||mito-r-3/JJ	prep_in||expressed-8/VBN||line-4/NN	nsubjpass||expressed-8/VBN||yfp-6/NN	auxpass||expressed-8/VBN||is-7/VBZ	root||ROOT-0/null||expressed-8/VBN	prep_in||expressed-8/VBN||most-10/JJS	det||cells-15/NNS||all-12/DT	amod||cells-15/NNS||retinal-13/JJ	nn||cells-15/NNS||ganglion-14/NN	prep_in||expressed-8/VBN||cells-15/NNS	conj_or||most-10/JJS||cells-15/NNS	dep||most-10/JJS||rgcs-17/VBZ	prep_in||expressed-8/VBN||photoreceptors-20/NNS	conj_and||most-10/JJS||photoreceptors-20/NNS	vmod||photoreceptors-20/NNS||making-21/VBG	det||line-23/NN||this-22/DT	nsubj||useful-24/JJ||line-23/NN	xcomp||making-21/VBG||useful-24/JJ	prepc_for||useful-24/JJ||studying-26/VBG	amod||transport-28/NN||axonal-27/JJ	dobj||studying-26/VBG||transport-28/NN	prep_in||studying-26/VBG||diseases-30/NNS	nn||degeneration-36/NN||glaucoma-33/NN	conj_and||glaucoma-33/NN||photoreceptor-35/NN	nn||degeneration-36/NN||photoreceptor-35/NN	prep_such_as||diseases-30/NNS||degeneration-36/NN	vmod||degeneration-36/NN||related-37/VBN	aux||transport-39/VB||to-38/TO	xcomp||related-37/VBN||transport-39/VB	prep_of||transport-39/VB||mitochondria-41/NN	det||segments-45/NNS||the-43/DT	amod||segments-45/NNS||inner-44/JJ	prep_into||transport-39/VB||segments-45/NNS	glaucoma-33||mito--1||yes||in the mito-r line, yfp is expressed in most or all retinal ganglion cells (rgcs) and photoreceptors making this line useful for studying axonal transport in diseases such as glaucoma and photoreceptor degeneration related to transport of mitochondria into the inner segments.
prep_after||subjected-16/VBN||demonstration-2/NN	mark||was-9/VBD||that-3/IN	det||expression-6/NN||the-4/DT	nn||expression-6/NN||circadian-5/NN	nsubj||was-9/VBD||expression-6/NN	prep_of||expression-6/NN||melatonin-8/NN	dep||demonstration-2/NN||was-9/VBD	amod||state-12/NN||steady-11/JJ	prep_at||was-9/VBD||state-12/NN	nsubjpass||subjected-16/VBN||rats-14/NNS	auxpass||subjected-16/VBN||were-15/VBD	root||ROOT-0/null||subjected-16/VBN	amod||stroke-19/NN||experimental-18/JJ	prep_to||subjected-16/VBN||stroke-19/NN	xcomp||subjected-16/VBN||using-20/VBG	amod||occlusion-24/NN||two-hour-21/JJ	amod||occlusion-24/NN||intralumenal-22/JJ	nn||occlusion-24/NN||filament-23/NN	dobj||using-20/VBG||occlusion-24/NN	det||artery-29/NN||the-26/DT	amod||artery-29/NN||middle-27/JJ	amod||artery-29/NN||cerebral-28/JJ	prep_of||occlusion-24/NN||artery-29/NN	melatonin-8||stroke-19||no_rel||after demonstration that the circadian expression of melatonin was at steady state, rats were subjected to experimental stroke using two-hour intralumenal filament occlusion of the middle cerebral artery.
aux||investigate-2/VB||to-1/TO	advcl||analyzed-37/VBD||investigate-2/VB	det||bases-5/NNS||the-3/DT	amod||bases-5/NNS||molecular-4/JJ	dobj||investigate-2/VB||bases-5/NNS	det||chemosensitivity-9/NN||the-7/DT	nn||chemosensitivity-9/NN||differential-8/NN	prep_of||bases-5/NNS||chemosensitivity-9/NN	nn||marrow-12/NN||bone-11/NN	prep_of||chemosensitivity-9/NN||marrow-12/NN	amod||cells-15/NNS||hematopoietic-13/JJ	nn||cells-15/NNS||stem-14/NN	dep||chemosensitivity-9/NN||cells-15/NNS	appos||cells-15/NNS||hsc-17/NN	nn||patients-22/NNS||cr-20/NN	nn||patients-22/NNS||aml-21/NN	prep_in||cells-15/NNS||patients-22/NNS	det||relationship-26/NN||the-25/DT	prep_of||bases-5/NNS||relationship-26/NN	conj_and||chemosensitivity-9/NN||relationship-26/NN	prep_between||relationship-26/NN||chemosensitivity-28/NN	vmod||investigate-2/VB||mobilizing-30/VBG	nn||rates-34/NNS||activity-31/NN	conj_and||activity-31/NN||relapse-33/NN	nn||rates-34/NNS||relapse-33/NN	dobj||mobilizing-30/VBG||rates-34/NNS	nsubj||analyzed-37/VBD||we-36/PRP	root||ROOT-0/null||analyzed-37/VBD	poss||profile-41/NN||their-38/PRP$	amod||profile-41/NN||am-39/JJ	nn||profile-41/NN||expression-40/NN	dobj||analyzed-37/VBD||profile-41/NN	prepc_by||analyzed-37/VBD||performing-43/VBG	amod||rt-pcr-46/NN||real-44/JJ	nn||rt-pcr-46/NN||time-45/NN	nsubj||genes-50/NNS||rt-pcr-46/NN	nsubj||compared-72/VBD||rt-pcr-46/NN	prep_of||rt-pcr-46/NN||84-48/CD	cop||genes-50/NNS||am-49/VBP	ccomp||performing-43/VBG||genes-50/NNS	amod||pools-54/NNS||cd34-52/JJ	amod||pools-54/NNS||+-53/JJ	prep_in||genes-50/NNS||pools-54/NNS	det||classes-59/NNS||the-56/DT	num||classes-59/NNS||two-57/CD	amod||classes-59/NNS||extreme-58/JJ	prep_from||pools-54/NNS||classes-59/NNS	prep_of||classes-59/NNS||patients-61/NNS	dep||chemosensitive-68/JJ||i.e.-63/FW	dep||chemosensitive-68/JJ||chemoresistant-65/JJ	dep||patients-61/NNS||highly-67/RB	advmod||chemosensitive-68/JJ||highly-67/RB	conj_and||chemosensitive-68/JJ||highly-67/RB	dep||patients-61/NNS||chemosensitive-68/JJ	ccomp||performing-43/VBG||compared-72/VBD	conj_and||genes-50/NNS||compared-72/VBD	dobj||compared-72/VBD||them-73/PRP	amod||controls-76/NNS||normal-75/JJ	prep_with||compared-72/VBD||controls-76/NNS	cr-20||aml-21||no_rel||to investigate the molecular bases of the differential chemosensitivity of bone marrow hematopoietic stem cells (hsc) in cr aml patients, and the relationship between chemosensitivity, mobilizing activity and relapse rates, we analyzed their am expression profile by performing real time rt-pcr of 84 am genes in cd34+ pools from the two extreme classes of patients (i.e., chemoresistant and highly chemosensitive), and compared them with normal controls.
det||fragment-4/NN||the-1/DT	amod||fragment-4/NN||casp8p43-2/JJ	nn||fragment-4/NN||cleavage-3/NN	nsubj||transactivates-6/VBZ||fragment-4/NN	advmod||transactivates-6/VBZ||also-5/RB	root||ROOT-0/null||transactivates-6/VBZ	det||ltr-9/NN||the-7/DT	nn||ltr-9/NN||hiv-8/NN	dobj||transactivates-6/VBZ||ltr-9/NN	prep_through||transactivates-6/VBZ||nf-îºb-11/NN	det||absence-15/NN||the-14/DT	nsubj||inhibits-22/VBZ||absence-15/NN	nn||hivinfection-20/NN||caspase-17/NN	num||hivinfection-20/NN||8-18/CD	nn||hivinfection-20/NN||following-19/NN	prep_of||absence-15/NN||hivinfection-20/NN	advmod||inhibits-22/VBZ||greatly-21/RB	conj_and||transactivates-6/VBZ||inhibits-22/VBZ	nn||replication-24/NN||hiv-23/NN	dobj||inhibits-22/VBZ||replication-24/NN	hivinfection-20||hiv-23||no||the casp8p43 cleavage fragment also transactivates the hiv ltr through nf-îºb, and the absence of caspase 8 following hivinfection greatly inhibits hiv replication.
nsubj||report-2/VBP||we-1/PRP	nsubj||arthralgias-16/VBZ||we-1/PRP	nsubj||elevated-19/VBD||we-1/PRP	root||ROOT-0/null||report-2/VBP	num||females-4/NNS||two-3/CD	dobj||report-2/VBP||females-4/NNS	num||years-9/NNS||42-6/CD	conj_and||42-6/CD||44-8/CD	num||years-9/NNS||44-8/CD	npadvmod||old-10/JJ||years-9/NNS	dep||females-4/NNS||old-10/JJ	amod||fever-14/NN||low-grade-13/JJ	prep_with||report-2/VBP||fever-14/NN	conj_and||report-2/VBP||arthralgias-16/VBZ	conj_and||report-2/VBP||elevated-19/VBD	amod||enzymes-21/NNS||cholestatic-20/JJ	dobj||elevated-19/VBD||enzymes-21/NNS	dep||first-24/JJ||the-23/DT	prep_in||elevated-19/VBD||first-24/JJ	prep_in||elevated-19/VBD||fatigue-26/JJ	conj_and||first-24/JJ||fatigue-26/JJ	det||second-29/NN||the-28/DT	prep_in||elevated-19/VBD||second-29/NN	enzymes-21||fatigue-26||no_rel||we report two females (42 and 44 years old) with low-grade fever, arthralgias, and elevated cholestatic enzymes in the first and fatigue in the second.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||feasibility-4/NN||the-3/DT	dobj||investigated-2/VBD||feasibility-4/NN	prepc_of||feasibility-4/NN||using-6/VBG	amod||radiation-10/NN||low-intensity-7/JJ	amod||radiation-10/NN||pulsed-9/JJ	dobj||using-6/VBG||radiation-10/NN	amod||ultrasound-13/NN||focused-12/JJ	prep_of||radiation-10/NN||ultrasound-13/NN	dep||using-6/VBG||fus-15/NN	aux||suppress-19/VB||to-17/TO	advmod||suppress-19/VB||non-invasively-18/RB	vmod||using-6/VBG||suppress-19/VB	amod||activity-21/NN||epileptic-20/JJ	dobj||suppress-19/VB||activity-21/NN	det||model-25/NN||an-23/DT	nn||model-25/NN||animal-24/NN	prep_in||activity-21/NN||model-25/NN	nsubjpass||induced-32/VBN||model-25/NN	appos||model-25/NN||rat-27/NN	auxpass||induced-32/VBN||was-31/VBD	rcmod||model-25/NN||induced-32/VBN	det||injection-36/NN||the-34/DT	amod||injection-36/NN||intraperitonial-35/JJ	agent||induced-32/VBN||injection-36/NN	prep_of||injection-36/NN||pentylenetetrazol-38/NN	appos||pentylenetetrazol-38/NN||ptz-40/NN	epileptic-20||ptz-40||no||we investigated the feasibility of using low-intensity, pulsed radiation of focused ultrasound (fus) to non-invasively suppress epileptic activity in an animal model (rat), which was induced by the intraperitonial injection of pentylenetetrazol (ptz).
nsubj||form-4/NN||neurosyphilis-1/NNS	cop||form-4/NN||is-2/VBZ	det||form-4/NN||a-3/DT	root||ROOT-0/null||form-4/NN	amod||infection-7/NN||tertiarysyphilis-6/JJ	prep_of||form-4/NN||infection-7/NN	vmod||infection-7/NN||caused-8/VBN	det||treponemapallidum-13/NN||the-10/DT	amod||treponemapallidum-13/NN||spirochete-11/JJ	nn||treponemapallidum-13/NN||bacterium-12/NN	agent||caused-8/VBN||treponemapallidum-13/NN	tertiarysyphilis-6||bacterium-12||no||neurosyphilis is a form of tertiarysyphilis infection caused by the spirochete bacterium treponemapallidum.
det||objectives-3/NNS||the-1/DT	amod||objectives-3/NNS||overall-2/JJ	nsubj||are-7/VBP||objectives-3/NNS	det||paper-6/NN||this-5/DT	prep_of||objectives-3/NNS||paper-6/NN	root||ROOT-0/null||are-7/VBP	dobj||are-7/VBP||1-9/CD	nsubj||provide-12/VB||1-9/CD	aux||provide-12/VB||to-11/TO	xcomp||are-7/VBP||provide-12/VB	det||overview-14/NN||an-13/DT	dobj||provide-12/VB||overview-14/NN	amod||studies-17/NNS||recent-16/JJ	prep_on||provide-12/VB||studies-17/NNS	nsubj||highlight-19/VB||studies-17/NNS	rcmod||studies-17/NNS||highlight-19/VB	det||risk-22/NN||the-20/DT	amod||risk-22/NN||increased-21/VBN	dobj||highlight-19/VB||risk-22/NN	amod||complications-25/NNS||respiratory-24/JJ	prep_for||risk-22/NN||complications-25/NNS	prep_following||complications-25/NNS||sedation-27/NN	prep_following||complications-25/NNS||analgesia-29/NN	conj_and||sedation-27/NN||analgesia-29/NN	prep_in||sedation-27/NN||children-31/NNS	amod||disabilities-34/NNS||developmental-33/JJ	prep_with||children-31/NNS||disabilities-34/NNS	prep_with||children-31/NNS||neurologicdisorders-36/NNS	conj_and||disabilities-34/NNS||neurologicdisorders-36/NNS	appos||disabilities-34/NNS||2-39/CD	aux||provide-42/VB||to-41/TO	vmod||risk-22/NN||provide-42/VB	det||understanding-45/NN||a-43/DT	amod||understanding-45/NN||better-44/JJR	dobj||provide-42/VB||understanding-45/NN	nsubjpass||used-54/VBN||understanding-45/NN	prep_of||understanding-45/NN||sedatives-47/NNS	amod||medications-50/NNS||analgesic-49/JJ	prep_of||understanding-45/NN||medications-50/NNS	conj_and||sedatives-47/NNS||medications-50/NNS	auxpass||used-54/VBN||are-52/VBP	advmod||used-54/VBN||commonly-53/RB	rcmod||understanding-45/NN||used-54/VBN	prep_in||used-54/VBN||children-56/NNS	amod||disabilities-59/NNS||developmental-58/JJ	prep_with||children-56/NNS||disabilities-59/NNS	prep_with||children-56/NNS||neurologicdisorders-61/NNS	conj_and||disabilities-59/NNS||neurologicdisorders-61/NNS	det||system-66/NN||the-63/DT	amod||system-66/NN||central-64/JJ	amod||system-66/NN||nervous-65/JJ	prep_on||used-54/VBN||system-66/NN	neurologicdisorders-61||analgesic-49||no_rel||the overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory complications following sedation and analgesia in children with developmental disabilities and neurologicdisorders, (2) to provide a better understanding of sedatives and analgesic medications which are commonly used in children with developmental disabilities and neurologicdisorders on the central nervous system.
nsubj||sought-2/VBD||we-1/PRP	nsubj||investigate-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||investigate-4/VB||to-3/TO	xcomp||sought-2/VBD||investigate-4/VB	det||effect-6/NN||the-5/DT	dobj||investigate-4/VB||effect-6/NN	nn||repletion-10/NN||iv-8/NN	nn||repletion-10/NN||iron-9/NN	prep_of||effect-6/NN||repletion-10/NN	amod||counts-16/NNS||platelet-12/JJ	appos||counts-16/NNS||plt-14/NN	prep_on||repletion-10/NN||counts-16/NNS	nn||patients-19/NNS||ckd-18/NN	prep_in||investigate-4/VB||patients-19/NNS	prep_with||investigate-4/VB||irondeficiencyanemia-21/NN	appos||irondeficiencyanemia-21/NN||ida-23/NN	irondeficiencyanemia-21||iron-9||yes||we sought to investigate the effect of iv iron repletion on platelet (plt) counts in ckd patients with irondeficiencyanemia (ida).
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||technology-5/NN||deep-3/JJ	nn||technology-5/NN||sequencing-4/NN	dobj||used-2/VBD||technology-5/NN	aux||profile-7/VB||to-6/TO	vmod||used-2/VBD||profile-7/VB	det||transcriptome-9/NN||the-8/DT	dobj||profile-7/VB||transcriptome-9/NN	nn||number-13/NN||gene-11/NN	nn||number-13/NN||copy-12/NN	dobj||profile-7/VB||number-13/NN	conj_and||transcriptome-9/NN||number-13/NN	nn||status-19/NN||cpg-16/NN	nn||status-19/NN||island-17/NN	nn||status-19/NN||methylation-18/NN	dobj||profile-7/VB||status-19/NN	conj_and||transcriptome-9/NN||status-19/NN	advmod||profile-7/VB||simultaneously-20/RB	prep_in||profile-7/VB||eight-22/CD	advmod||used-24/VBN||commonly-23/RB	vmod||eight-22/CD||used-24/VBN	nn||lines-27/NNS||breast-25/NN	nn||lines-27/NNS||cell-26/NN	dobj||used-24/VBN||lines-27/NNS	aux||develop-29/VB||to-28/TO	vmod||used-24/VBN||develop-29/VB	det||model-31/NN||a-30/DT	dobj||develop-29/VB||model-31/NN	advmod||integrated-38/VBN||how-33/WRB	det||features-36/NNS||these-34/DT	amod||features-36/NNS||genomic-35/JJ	nsubjpass||integrated-38/VBN||features-36/NNS	auxpass||integrated-38/VBN||are-37/VBP	prepc_for||model-31/NN||integrated-38/VBN	nn||positive-42/NN||estrogen-40/NN	nn||positive-42/NN||receptor-41/NN	prep_in||integrated-38/VBN||positive-42/NN	nn||+-45/NNP||er-44/NNP	appos||positive-42/NN||+-45/NNP	amod||cancer-50/NN||negative-48/JJ	nn||cancer-50/NN||breast-49/NN	prep_in||integrated-38/VBN||cancer-50/NN	conj_and||positive-42/NN||cancer-50/NN	estrogen-40||cancer-50||no_rel||we used deep sequencing technology to profile the transcriptome, gene copy number, and cpg island methylation status simultaneously in eight commonly used breast cell lines to develop a model for how these genomic features are integrated in estrogen receptor positive (er+) and negative breast cancer.
amod||women-3/NNS||hiv-infected-1/JJ	nn||women-3/NNS||childbearing-2/NN	nsubjpass||enrolled-12/VBN||women-3/NNS	vmod||women-3/NNS||diagnosed-5/VBN	vmod||women-3/NNS||diagnosed-5/VBN	conj_or||diagnosed-5/VBN||diagnosed-5/VBN	prep_before||diagnosed-5/VBN||pregnancy-9/NN	prep_during||diagnosed-5/VBN||pregnancy-9/NN	auxpass||enrolled-12/VBN||were-11/VBD	root||ROOT-0/null||enrolled-12/VBN	advmod||enrolled-12/VBN||prospectively-13/RB	det||study-18/NN||a-15/DT	amod||study-18/NN||post-natal-16/JJ	nn||study-18/NN||cohort-17/NN	prep_in||enrolled-12/VBN||study-18/NN	num||centres-23/NNS||four-20/CD	amod||centres-23/NNS||regional-21/JJ	nn||centres-23/NNS||hiv/aids-22/NN	prep_in||study-18/NN||centres-23/NNS	prep_in||centres-23/NNS||ukraine-25/NN	prep_from||enrolled-12/VBN||december-27/NNP	num||december-27/NNP||2007-28/CD	aids--1||hiv--1||no||hiv-infected childbearing women, diagnosed before or during pregnancy, were enrolled prospectively in a post-natal cohort study in four regional hiv/aids centres in ukraine from december 2007.
amod||evidence-2/NN||more-1/JJR	nsubjpass||needed-4/VBN||evidence-2/NN	auxpass||needed-4/VBN||is-3/VBZ	root||ROOT-0/null||needed-4/VBN	det||safety-7/NN||the-6/DT	prep_on||needed-4/VBN||safety-7/NN	prep_of||safety-7/NN||primaquine-9/NN	advmod||administered-11/VBN||when-10/WRB	advcl||needed-4/VBN||administered-11/VBN	prepc_without||administered-11/VBN||screening-13/VBG	amod||deficiency-16/NN||g6pd-15/JJ	prep_for||screening-13/VBG||deficiency-16/NN	aux||inform-18/VB||to-17/TO	xcomp||screening-13/VBG||inform-18/VB	amod||approaches-23/NNS||individual-19/JJ	conj_and||individual-19/JJ||mass-21/JJ	amod||approaches-23/NNS||mass-21/JJ	nn||approaches-23/NNS||treatment-22/NN	dobj||inform-18/VB||approaches-23/NNS	det||context-26/NN||the-25/DT	prep_in||approaches-23/NNS||context-26/NN	nn||programmes-30/NNS||malaria-28/NN	nn||programmes-30/NNS||elimination-29/NN	prep_of||context-26/NN||programmes-30/NNS	malaria-28||primaquine-9||yes||more evidence is needed on the safety of primaquine when administered without screening for g6pd deficiency to inform individual and mass treatment approaches in the context of malaria elimination programmes.
det||action-3/NN||the-1/DT	amod||action-3/NN||insulinotropic-2/JJ	nsubjpass||impaired-14/VBN||action-3/NN	det||polypeptide-9/NN||the-5/DT	amod||polypeptide-9/NN||incretin-6/JJ	amod||polypeptide-9/NN||glucose-dependent-7/JJ	amod||polypeptide-9/NN||insulinotropic-8/JJ	prep_of||action-3/NN||polypeptide-9/NN	appos||polypeptide-9/NN||gip-11/NN	auxpass||impaired-14/VBN||is-13/VBZ	root||ROOT-0/null||impaired-14/VBN	prep_in||impaired-14/VBN||type2diabetes-16/CD	mark||preserved-28/VBN||while-18/IN	det||effect-20/NN||the-19/DT	nsubjpass||preserved-28/VBN||effect-20/NN	amod||peptide-1-23/NN||glucagon-like-22/JJ	prep_of||effect-20/NN||peptide-1-23/NN	dep||peptide-1-23/NN||glp-1-25/JJ	auxpass||preserved-28/VBN||is-27/VBZ	advcl||impaired-14/VBN||preserved-28/VBN	glucose--1||type2diabetes-16||no_rel||the insulinotropic action of the incretin glucose-dependent insulinotropic polypeptide (gip) is impaired in type2diabetes, while the effect of glucagon-like peptide-1 (glp-1) is preserved.
amod||autoimmunediseases-3/NNS||other-2/JJ	prep_in||clear-20/JJ||autoimmunediseases-3/NNS	vmod||autoimmunediseases-3/NNS||characterized-4/VBN	amod||inflammation-7/NN||substantial-6/JJ	agent||characterized-4/VBN||inflammation-7/NN	nn||destruction-10/NN||tissue-9/NN	agent||characterized-4/VBN||destruction-10/NN	conj_and||inflammation-7/NN||destruction-10/NN	det||role-13/NN||the-12/DT	nsubj||clear-20/JJ||role-13/NN	nn||interferons-17/NNS||type-15/FW	nn||interferons-17/NNS||i-16/FW	prep_of||role-13/NN||interferons-17/NNS	cop||clear-20/JJ||is-18/VBZ	advmod||clear-20/JJ||less-19/RBR	root||ROOT-0/null||clear-20/JJ	autoimmunediseases-3||interferons-17||no||in other autoimmunediseases characterized by substantial inflammation and tissue destruction, the role of type i interferons is less clear.
nsubj||virus-9/NN||humancytomegalovirus-1/NNS	appos||humancytomegalovirus-1/NNS||cmv-3/NN	cop||virus-9/NN||is-5/VBZ	det||virus-9/NN||a-6/DT	amod||virus-9/NN||ubiquitous-7/JJ	nn||virus-9/NN||dna-8/NN	root||ROOT-0/null||virus-9/NN	nsubj||causes-11/VBZ||virus-9/NN	rcmod||virus-9/NN||causes-11/VBZ	amod||disease-13/NN||severe-12/JJ	dobj||causes-11/VBZ||disease-13/NN	prep_in||causes-11/VBZ||patients-15/NNS	amod||systems-21/NNS||immature-17/JJ	conj_or||immature-17/JJ||impaired-19/JJ	amod||systems-21/NNS||impaired-19/JJ	amod||systems-21/NNS||immune-20/JJ	prep_with||patients-15/NNS||systems-21/NNS	cmv-3||humancytomegalovirus-1||no||humancytomegalovirus (cmv) is a ubiquitous dna virus that causes severe disease in patients with immature or impaired immune systems.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||outcomes-5/NNS||the-3/DT	amod||outcomes-5/NNS||long-term-4/JJ	dobj||describe-2/VBP||outcomes-5/NNS	num||patients-9/NNS||510-7/CD	amod||patients-9/NNS||diabetic-8/JJ	prep_of||outcomes-5/NNS||patients-9/NNS	amod||ischemia-13/NN||critical-11/JJ	nn||ischemia-13/NN||limb-12/NN	prep_with||patients-9/NNS||ischemia-13/NN	appos||ischemia-13/NN||cli-15/NN	det||footulcer-20/NN||an-18/DT	amod||footulcer-20/NN||active-19/JJ	prep_with||patients-9/NNS||footulcer-20/NN	conj_and||ischemia-13/NN||footulcer-20/NN	conj_and||ischemia-13/NN||gangrene-22/NN	conj_or||footulcer-20/NN||gangrene-22/NN	vmod||patients-9/NNS||seen-24/VBN	det||hospital-28/NN||the-26/DT	nn||hospital-28/NN||university-27/NN	prep_at||seen-24/VBN||hospital-28/NN	amod||vergata-32/NN||rome-30/JJ	nn||vergata-32/NN||tor-31/NN	prep_of||hospital-28/NN||vergata-32/NN	det||clinic-37/NN||a-34/DT	amod||clinic-37/NN||tertiary-35/JJ	nn||clinic-37/NN||care-36/NN	appos||vergata-32/NN||clinic-37/NN	footulcer-20||tor-31||no_rel||we describe the long-term outcomes of 510 diabetic patients with critical limb ischemia (cli) and an active footulcer or gangrene, seen at the university hospital of rome tor vergata, a tertiary care clinic.
num||patient-2/NN||one-1/CD	nsubj||developed-3/VBD||patient-2/NN	root||ROOT-0/null||developed-3/VBD	nn||reactivation-5/NN||hbv-4/NN	dobj||developed-3/VBD||reactivation-5/NN	amod||withdrawal-8/NN||lamivudine-7/JJ	prep_after||developed-3/VBD||withdrawal-8/NN	num||patients-12/NNS||4-11/CD	nsubj||developed-13/VBD||patients-12/NNS	conj_and||developed-3/VBD||developed-13/VBD	det||mutation-19/NN||the-14/DT	amod||mutation-19/NN||ymdd-15/JJ	dep||ymdd-15/JJ||tyrosine-methionine-aspartate-aspartate-17/JJ	dobj||developed-13/VBD||mutation-19/NN	amod||therapy-22/NN||lamivudine-21/JJ	prep_during||developed-13/VBD||therapy-22/NN	hbv-4||lamivudine-21||yes||one patient developed hbv reactivation after lamivudine withdrawal, and 4 patients developed the ymdd (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy.
prepc_compared_with||increased-16/VBN||with-2/IN	det||controls-5/NNS||the-3/DT	amod||controls-5/NNS||healthy-4/JJ	pobj||increased-16/VBN||controls-5/NNS	det||level-10/NN||the-7/DT	amod||level-10/NN||plasma-8/JJ	amod||level-10/NN||il-21-9/JJ	nsubjpass||increased-16/VBN||level-10/NN	nsubjpass||decreased-22/VBN||level-10/NN	amod||patients-13/NNS||chronichepatitisb-12/JJ	prep_in||level-10/NN||patients-13/NNS	auxpass||increased-16/VBN||was-14/VBD	advmod||increased-16/VBN||significantly-15/RB	root||ROOT-0/null||increased-16/VBN	amod||carriers-20/NNS||chronic-18/JJ	nn||carriers-20/NNS||hbv-19/NN	prep_in||increased-16/VBN||carriers-20/NNS	conj_and||increased-16/VBN||decreased-22/VBN	amod||carriers-29/NNS||inactive-24/JJ	nn||carriers-29/NNS||hepatitisbsurfaceantigen-25/NN	nn||carriers-29/NNS||hbsag-27/NN	prep_in||decreased-22/VBN||carriers-29/NNS	dep||<-32/JJ||p-31/RB	dep||decreased-22/VBN||<-32/JJ	dep||<-32/JJ||0.05-33/CD	hbv-19||hepatitisbsurfaceantigen-25||yes||compared with the healthy controls, the plasma il-21 level in chronichepatitisb patients was significantly increased in chronic hbv carriers and decreased in inactive hepatitisbsurfaceantigen (hbsag) carriers (p<0.05).
amod||tuberculosis-2/NNS||institutional-1/JJ	nsubj||problem-12/NN||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||tb-4/NN	advmod||problem-12/NN||transmission-6/RB	cop||problem-12/NN||is-7/VBZ	det||problem-12/NN||an-8/DT	amod||problem-12/NN||important-9/JJ	amod||problem-12/NN||public-10/JJ	nn||problem-12/NN||health-11/NN	root||ROOT-0/null||problem-12/NN	vmod||problem-12/NN||highlighted-13/VBN	det||pandemic-17/NN||the-15/DT	amod||pandemic-17/NN||hiv/aids-16/JJ	agent||highlighted-13/VBN||pandemic-17/NN	det||emergence-20/NN||the-19/DT	agent||highlighted-13/VBN||emergence-20/NN	conj_and||pandemic-17/NN||emergence-20/NN	amod||tb-27/NN||multidrug-22/JJ	conj_and||multidrug-22/JJ||extensively-25/JJ	amod||tb-27/NN||extensively-25/JJ	amod||tb-27/NN||drug-resistant-26/JJ	prep_of||emergence-20/NN||tb-27/NN	aids--1||hiv--1||no||institutional tuberculosis (tb) transmission is an important public health problem highlighted by the hiv/aids pandemic and the emergence of multidrug- and extensively drug-resistant tb.
nsubj||altered-25/VBD||acgh-1/NN	dep||acgh-1/NN||performed-2/VBN	det||cohort-8/NN||a-4/DT	amod||cohort-8/NN||larger-5/JJR	amod||cohort-8/NN||independent-7/JJ	prep_in||performed-2/VBN||cohort-8/NN	prep_of||cohort-8/NN||aa-10/NN	aux||tumors-13/VB||ca-12/MD	dep||acgh-1/NN||tumors-13/VB	conj_and||performed-2/VBN||tumors-13/VB	dobj||tumors-13/VB||validated-14/NN	num||validated-14/NN||4-15/CD	det||27-18/CD||the-17/DT	prep_of||validated-14/NN||27-18/CD	num||%-21/NN||15-20/CD	appos||acgh-1/NN||%-21/NN	advmod||significantly-24/RB||most-23/RBS	advmod||altered-25/VBD||significantly-24/RB	root||ROOT-0/null||altered-25/VBD	dobj||altered-25/VBD||regions-26/NNS	det||analysis-30/NN||the-28/DT	amod||analysis-30/NN||initial-29/JJ	prep_from||altered-25/VBD||analysis-30/NN	dep||analysis-30/NN||3q26-32/NNS	appos||3q26-32/NNS||5p15-p14-34/CD	num||5p15-p14-34/CD||14q32-36/CD	appos||3q26-32/NNS||16p11-39/CD	conj_and||5p15-p14-34/CD||16p11-39/CD	ca-12||tumors-13||no_rel||acgh performed in a larger, independent cohort of aa and ca tumors validated 4 of the 27 (15%) most significantly altered regions from the initial analysis (3q26, 5p15-p14, 14q32, and 16p11).
det||group-3/NN||the-1/DT	amod||group-3/NN||whole-2/JJ	nsubj||presented-8/VBD||group-3/NN	num||patients-7/NNS||81-5/CD	amod||patients-7/NNS||acromegalic-6/JJ	prep_of||group-3/NN||patients-7/NNS	root||ROOT-0/null||presented-8/VBD	advmod||higher-11/JJR||significantly-10/RB	amod||biomarkers-32/NNS||higher-11/JJR	amod||biomarkers-32/NNS||anthropometric-12/JJ	nn||biomarkers-32/NNS||parameters-13/NNS	nn||circumference-24/NNS||weight-17/NN	conj_and||weight-17/NN||bmi-19/NN	nn||circumference-24/NNS||bmi-19/NN	conj_and||weight-17/NN||waist-21/NN	nn||circumference-24/NNS||waist-21/NN	conj_and||weight-17/NN||hip-23/NN	nn||circumference-24/NNS||hip-23/NN	prep_such_as||parameters-13/NNS||circumference-24/NNS	conj_but||parameters-13/NNS||with-27/IN	nn||biomarkers-32/NNS||with-27/IN	advmod||favourable-29/JJ||more-28/RBR	pobj||with-27/IN||favourable-29/JJ	amod||biomarkers-32/NNS||cardiovascular-30/JJ	nn||biomarkers-32/NNS||risk-31/NN	prep_with||presented-8/VBD||biomarkers-32/NNS	amod||glucose-38/NN||fasting-36/JJ	nn||glucose-38/NN||plasma-37/NN	prep_such_as||biomarkers-32/NNS||glucose-38/NN	amod||cholesterol-41/NN||total-40/JJ	prep_such_as||biomarkers-32/NNS||cholesterol-41/NN	conj_and||glucose-38/NN||cholesterol-41/NN	prep_such_as||biomarkers-32/NNS||triglycerides-43/NNPS	conj_and||glucose-38/NN||triglycerides-43/NNPS	nn||levels-46/NNS||hdl-45/NN	prep_such_as||biomarkers-32/NNS||levels-46/NNS	conj_and||glucose-38/NN||levels-46/NNS	prep_in||presented-8/VBD||comparison-49/NN	poss||controls-53/NNS||their-51/PRP$	amod||controls-53/NNS||respective-52/JJ	prep_to||presented-8/VBD||controls-53/NNS	acromegalic-6||triglycerides-43||no_rel||the whole group of 81 acromegalic patients presented with significantly higher anthropometric parameters, such as weight, bmi, waist and hip circumference, but with more favourable cardiovascular risk biomarkers, such as fasting plasma glucose, total cholesterol, triglycerides and hdl levels, in comparison to their respective controls.
nn||albumin-2/NN||serum-1/NN	nsubjpass||found-4/VBN||albumin-2/NN	nsubj||predictor-9/NN||albumin-2/NN	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	aux||predictor-9/NN||to-5/TO	cop||predictor-9/NN||be-6/VB	det||predictor-9/NN||an-7/DT	amod||predictor-9/NN||independent-8/JJ	xcomp||found-4/VBN||predictor-9/NN	dep||predictor-9/NN||p-11/VBN	dep||0.04-13/CD||=-12/SYM	ccomp||p-11/VBN||0.04-13/CD	amod||variables-27/NNS||cvd-16/JJ	amod||analysis-21/NN||multiple-18/JJ	amod||analysis-21/NN||logistic-19/JJ	nn||analysis-21/NN||regression-20/NN	prep_by||cvd-16/JJ||analysis-21/NN	vmod||analysis-21/NN||using-22/VBG	det||factor-26/NN||the-23/DT	amod||factor-26/NN||above-24/JJ	nn||factor-26/NN||risk-25/NN	dobj||using-22/VBG||factor-26/NN	prep_of||predictor-9/NN||variables-27/NNS	cvd-16||albumin-2||no_rel||serum albumin was found to be an independent predictor (p=0.04) of cvd by multiple logistic regression analysis using the above risk factor variables.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
nn||diagnoses-2/NNS||differential-1/NN	nsubjpass||hydralazine-associated-4/VBN||diagnoses-2/NNS	auxpass||hydralazine-associated-4/VBN||were-3/VBD	root||ROOT-0/null||hydralazine-associated-4/VBN	xcomp||hydralazine-associated-4/VBN||sweetâ-5/VBG	num||syndrome-9/NN||$-6/$	number||s-8/CD||™-7/CD	num||$-6/$||s-8/CD	dobj||sweetâ-5/VBG||syndrome-9/NN	amod||eruption-13/NN||streptococcal-induced-11/JJ	nn||eruption-13/NN||cutaneous-12/NNS	dobj||sweetâ-5/VBG||eruption-13/NN	conj_or||syndrome-9/NN||eruption-13/NN	det||contactdermatitis-17/NNS||an-15/DT	amod||contactdermatitis-17/NNS||unrelated-16/JJ	dobj||sweetâ-5/VBG||contactdermatitis-17/NNS	conj_or||syndrome-9/NN||contactdermatitis-17/NNS	hydralazine--1||contactdermatitis-17||no_rel||differential diagnoses were hydralazine-associated sweetâ€™s syndrome, streptococcal-induced cutaneous eruption or an unrelated contactdermatitis.
det||results-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	det||detection-8/NN||that-4/DT	amod||detection-8/NN||hrp-ld5-5/JJ	amod||detection-8/NN||improved-6/VBN	amod||detection-8/NN||anti-hcv-7/JJ	dobj||demonstrate-3/VBP||detection-8/NN	prepc_by||demonstrate-3/VBP||enhancing-10/VBG	det||detection-12/NN||the-11/DT	dobj||enhancing-10/VBG||detection-12/NN	amod||igm-15/NN||anti-hcv-14/JJ	prep_of||detection-12/NN||igm-15/NN	nsubj||have-19/VB||igm-15/NN	aux||have-19/VB||may-18/MD	rcmod||igm-15/NN||have-19/VB	amod||value-21/NN||potential-20/JJ	dobj||have-19/VB||value-21/NN	det||diagnosis-25/NN||the-23/DT	amod||diagnosis-25/NN||early-24/JJ	prep_for||value-21/NN||diagnosis-25/NN	prep_for||value-21/NN||screening-27/NN	conj_and||diagnosis-25/NN||screening-27/NN	amod||diseases-33/NNS||hepatitisc-29/JJ	conj_and||hepatitisc-29/JJ||other-31/JJ	amod||diseases-33/NNS||other-31/JJ	amod||diseases-33/NNS||infectious-32/JJ	prep_of||diagnosis-25/NN||diseases-33/NNS	hepatitisc-29||hcv--1||no||these results demonstrate that hrp-ld5 improved anti-hcv detection by enhancing the detection of anti-hcv igm, which may have potential value for the early diagnosis and screening of hepatitisc and other infectious diseases.
amod||autopsy-2/NN||verbal-1/JJ	nsubj||option-7/NN||autopsy-2/NN	cop||option-7/NN||is-3/VBZ	advmod||option-7/NN||currently-4/RB	det||option-7/NN||the-5/DT	amod||option-7/NN||only-6/JJ	root||ROOT-0/null||option-7/NN	prepc_for||option-7/NN||obtaining-9/VBG	dobj||obtaining-9/VBG||cause-10/NN	nn||information-13/NN||death-12/NN	prep_of||cause-10/NN||information-13/NN	amod||populations-16/NNS||most-15/JJS	prep_in||information-13/NN||populations-16/NNS	det||epidemic-21/NN||a-18/DT	amod||epidemic-21/NN||widespread-19/JJ	nn||epidemic-21/NN||hiv/aids-20/NNS	prep_with||obtaining-9/VBG||epidemic-21/NN	aids--1||hiv--1||no||verbal autopsy is currently the only option for obtaining cause of death information in most populations with a widespread hiv/aids epidemic.
amod||regimens-2/NNS||efavirenz-based-1/JJ	nsubjpass||associated-11/VBN||regimens-2/NNS	neg||aids-6/NNS||no-4/DT	amod||aids-6/NNS||clinical-5/JJ	conj_and||regimens-2/NNS||aids-6/NNS	nsubjpass||associated-11/VBN||aids-6/NNS	amod||initiation-9/NN||haart-8/JJ	prep_at||aids-6/NNS||initiation-9/NN	auxpass||associated-11/VBN||were-10/VBD	root||ROOT-0/null||associated-11/VBN	amod||risk-14/NN||lower-13/JJR	prep_with||associated-11/VBN||risk-14/NN	prep_of||risk-14/NN||change-16/NN	nn||ratio-19/NN||hazard-18/NN	dep||risk-14/NN||ratio-19/NN	discourse||ratio-19/NN||hr-21/UH	rcmod||ratio-19/NN||â-23/VBP	num||â-27/NN||$-24/$	number||=-26/CD||š-25/CD	num||$-24/$||=-26/CD	dobj||â-23/VBP||â-27/NN	amod||â-27/NN||$-28/$	number||.7-30/CD||š1-29/CD	num||$-28/$||.7-30/CD	num||%-33/NN||95-32/CD	dep||$-28/$||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||1.1-35/FW	dep||%-33/NN||â-36/FW	dep||â-36/FW||$-37/$	num||$-37/$||2.6-39/CD	dobj||â-23/VBP||2.1-42/CD	conj_and||â-27/NN||2.1-42/CD	num||%-45/NN||95-44/CD	dep||2.1-42/CD||%-45/NN	vmod||%-45/NN||ci-46/VBN	num||â-48/NNS||1.7-47/CD	dobj||ci-46/VBN||â-48/NNS	num||â-48/NNS||$-49/$	num||$-49/$||2.5-51/CD	vmod||2.1-42/CD||comparing-53/VBG	amod||regimens-55/NNS||neverapine-based-54/JJ	dobj||comparing-53/VBG||regimens-55/NNS	amod||regimens-58/NNS||other-57/JJ	dobj||comparing-53/VBG||regimens-58/NNS	conj_and||regimens-55/NNS||regimens-58/NNS	prep_to||comparing-53/VBG||efavirenz-60/NN	advmod||comparing-53/VBG||respectively-62/RB	nn||â-68/FW||hrâ-64/FW	nn||â-68/FW||$-65/FW	nn||â-68/FW||š-66/FW	nn||â-68/FW||=-67/FW	dobj||â-23/VBP||â-68/FW	conj_and||â-27/NN||â-68/FW	dep||â-68/FW||$-69/$	number||.3-71/CD||š1-70/CD	num||$-69/$||.3-71/CD	num||%-74/NN||95-73/CD	dep||â-27/NN||%-74/NN	vmod||%-74/NN||ci-75/VBN	num||â-77/NNS||1.1-76/CD	dobj||ci-75/VBN||â-77/NNS	num||â-77/NNS||$-78/$	num||$-78/$||1.5-80/CD	amod||aids-84/NNS||clinical-83/JJ	prep_for||ratio-19/NN||aids-84/NNS	amod||initiation-87/NN||haart-86/JJ	prep_at||aids-84/NNS||initiation-87/NN	aids-84||efavirenz-60||yes||efavirenz-based regimens and no clinical aids at haart initiation were associated with lower risk of change (hazard ratio (hr)â€š=â€š1.7 (95% ci 1.1â€“2.6) and 2.1 (95% ci 1.7â€“2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; hrâ€š=â€š1.3 (95% ci 1.1â€“1.5) for clinical aids at haart initiation).
nsubj||improved-3/VBD||lixisenatide-1/NN	advmod||improved-3/VBD||significantly-2/RB	root||ROOT-0/null||improved-3/VBD	amod||control-5/NN||glycaemic-4/JJ	dobj||improved-3/VBD||control-5/NN	advmod||hyperglycaemic-8/JJ||mildly-7/RB	amod||patients-9/NNS||hyperglycaemic-8/JJ	prep_in||improved-3/VBD||patients-9/NNS	prep_with||improved-3/VBD||type2diabetes-11/NNS	prep_on||type2diabetes-11/NNS||metformin-13/NN	type2diabetes-11||metformin-13||yes||lixisenatide significantly improved glycaemic control in mildly hyperglycaemic patients with type2diabetes on metformin.
nsubj||reported-2/VBD||we-1/PRP	root||ROOT-0/null||reported-2/VBD	mark||suggesting-24/VBG||that-3/IN	nn||magnesium-5/NN||intracellular-4/NN	nsubj||suggesting-24/VBG||magnesium-5/NN	nn||platelets-9/NNS||cord-7/NN	nn||platelets-9/NNS||blood-8/NN	prep_of||magnesium-5/NN||platelets-9/NNS	cop||suggesting-24/VBG||is-10/VBZ	acomp||suggesting-24/VBG||lower-11/JJR	nn||groups-14/NNS||sga-13/NN	prep_in||lower-11/JJR||groups-14/NNS	prep_than||suggesting-24/VBG||that-16/DT	amod||groups-22/NNS||appropriate-18/JJ	amod||age-21/NN||gestational-20/JJ	prep_for||appropriate-18/JJ||age-21/NN	prep_in||that-16/DT||groups-22/NNS	ccomp||reported-2/VBD||suggesting-24/VBG	mark||result-29/VB||that-25/IN	amod||magnesiumdeficiency-27/NN||intrauterine-26/JJ	nsubj||result-29/VB||magnesiumdeficiency-27/NN	aux||result-29/VB||may-28/MD	ccomp||suggesting-24/VBG||result-29/VB	prep_in||result-29/VB||sga-31/NN	magnesiumdeficiency-27||magnesium-5||yes||we reported that intracellular magnesium of cord blood platelets is lower in sga groups than that in appropriate for gestational age groups, suggesting that intrauterine magnesiumdeficiency may result in sga.
advmod||provided-8/VBN||moreover-1/RB	amod||information-4/NN||little-3/JJ	nsubjpass||provided-8/VBN||information-4/NN	prep_on||information-4/NN||hiv/aids-6/NNS	auxpass||provided-8/VBN||was-7/VBD	root||ROOT-0/null||provided-8/VBN	det||communities-11/NNS||the-10/DT	prep_to||provided-8/VBN||communities-11/NNS	advmod||have-15/VBP||so-12/RB	mark||have-15/VBP||that-13/IN	nsubj||have-15/VBP||we-14/PRP	advcl||provided-8/VBN||have-15/VBP	dobj||have-15/VBP||disadvantage-16/NN	amod||epidemic-20/NN||controlling-18/VBG	amod||epidemic-20/NN||hiv/aids-19/JJ	prep_of||disadvantage-16/NN||epidemic-20/NN	det||region-23/NN||the-22/DT	prep_in||epidemic-20/NN||region-23/NN	aids--1||hiv--1||no||moreover, little information on hiv/aids was provided to the communities so that we have disadvantage of controlling hiv/aids epidemic in the region.
nsubj||depleted-2/VBD||n-3pufa-1/JJ	root||ROOT-0/null||depleted-2/VBD	dobj||depleted-2/VBD||mice-3/NNS	nn||hypercholesterolemia-5/NN||exhibit-4/NN	dep||mice-3/NNS||hypercholesterolemia-5/NN	dep||hypercholesterolemia-5/NN||total-7/NN	dep||hypercholesterolemia-5/NN||hdl-9/NN	conj_and||total-7/NN||hdl-9/NN	nn||cholesterol-13/NN||ldl-12/NN	dep||hypercholesterolemia-5/NN||cholesterol-13/NN	conj_and||total-7/NN||cholesterol-13/NN	det||increase-19/NN||an-18/DT	dobj||depleted-2/VBD||increase-19/NN	conj_and||mice-3/NNS||increase-19/NN	amod||ester-23/NN||hepatic-21/JJ	amod||ester-23/NN||cholesteryl-22/JJ	prep_in||increase-19/NN||ester-23/NN	amod||content-26/NN||triglycerides-25/JJ	prep_in||increase-19/NN||content-26/NN	conj_and||ester-23/NN||content-26/NN	hypercholesterolemia-5||cholesterol-13||no||n-3pufa depleted mice exhibit hypercholesterolemia (total, hdl, and ldl cholesterol) as well as an increase in hepatic cholesteryl ester and triglycerides content.
nn||maturation-2/NN||antibody-1/NN	nsubj||provide-10/VBP||maturation-2/NN	nn||patterns-6/NNS||hiv-4/NN	nn||patterns-6/NNS||diversification-5/NN	conj_and||maturation-2/NN||patterns-6/NNS	nsubj||provide-10/VBP||patterns-6/NNS	nn||women-9/NNS||african-8/NN	prep_in||maturation-2/NN||women-9/NNS	root||ROOT-0/null||provide-10/VBP	amod||support-12/NN||additional-11/JJ	dobj||provide-10/VBP||support-12/NN	prep_for||provide-10/VBP||use-14/NN	det||maa-17/NN||the-16/DT	prep_of||use-14/NN||maa-17/NN	aux||identify-19/VB||to-18/TO	vmod||provide-10/VBP||identify-19/VB	dobj||identify-19/VB||populations-20/NNS	amod||hivinfection-23/NN||recent-22/JJ	prep_with||identify-19/VB||hivinfection-23/NN	hivinfection-23||hiv-4||no||antibody maturation and hiv diversification patterns in african women provide additional support for use of the maa to identify populations with recent hivinfection.
advmod||described-12/VBN||here-1/RB	amod||pancreatitis-4/NNS||acute-3/JJ	nsubjpass||described-12/VBN||pancreatitis-4/NNS	vmod||pancreatitis-4/NNS||associated-5/VBN	amod||treatment-10/NN||peg-ifn-7/JJ	nn||treatment-10/NN||plus-8/NN	nn||treatment-10/NN||rbv-9/NN	prep_with||associated-5/VBN||treatment-10/NN	auxpass||described-12/VBN||is-11/VBZ	root||ROOT-0/null||described-12/VBN	num||patients-15/NNS||three-14/CD	prep_in||described-12/VBN||patients-15/NNS	amod||1b-20/NNS||chronichepatitisc-17/JJ	amod||1b-20/NNS||genotype-19/JJ	prep_with||patients-15/NNS||1b-20/NNS	amod||levels-27/NNS||high-22/JJ	nn||levels-27/NNS||serum-23/NN	amod||levels-27/NNS||hepatitisc-24/JJ	nn||levels-27/NNS||virus-25/NN	nn||levels-27/NNS||rna-26/NN	prep_with||described-12/VBN||levels-27/NNS	chronichepatitisc-17||ifn--1||yes||here, acute pancreatitis associated with peg-ifn plus rbv treatment is described in three patients with chronichepatitisc, genotype 1b with high serum hepatitisc virus rna levels.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
nn||techniques-2/NNS||immobilization-1/NN	nsubj||involve-4/VB||techniques-2/NNS	aux||involve-4/VB||can-3/MD	root||ROOT-0/null||involve-4/VB	nn||bonding-10/NN||adsorption-5/NN	conj_or||adsorption-5/NN||entrapment-7/NN	nn||bonding-10/NN||entrapment-7/NN	conj_or||adsorption-5/NN||covalent-9/NN	nn||bonding-10/NN||covalent-9/NN	dobj||involve-4/VB||bonding-10/NN	det||support-17/NN||the-12/DT	amod||support-17/NN||enzyme-13/JJ	det||insoluble-16/NN||an-15/DT	prep_into||enzyme-13/JJ||insoluble-16/NN	prep_of||bonding-10/NN||support-17/NN	amod||methods-21/NNS||carrier-free-20/JJ	prep_of||bonding-10/NN||methods-21/NNS	conj_or||support-17/NN||methods-21/NNS	prep_of||bonding-10/NN||usually-23/RB	advmod||support-17/NN||usually-23/RB	conj_or||support-17/NN||usually-23/RB	prepc_based_on||involve-4/VB||on-25/IN	det||formation-27/NN||the-26/DT	pobj||involve-4/VB||formation-27/NN	amod||aggregates-31/NNS||cross-linked-29/JJ	nn||aggregates-31/NNS||enzyme-30/NN	prep_of||formation-27/NN||aggregates-31/NNS	appos||aggregates-31/NNS||cleas-33/NNS	cross--1||enzyme-30||no_rel||immobilization techniques can involve adsorption, entrapment or covalent bonding of the enzyme into an insoluble support, or carrier-free methods, usually based on the formation of cross-linked enzyme aggregates (cleas).
amod||regimens-3/NNS||heterologous-1/JJ	amod||regimens-3/NNS||prime-boost-2/JJ	nsubj||represent-11/VBP||regimens-3/NNS	vmod||regimens-3/NNS||utilizing-4/VBG	dobj||utilizing-4/VBG||bcg-5/NN	det||vaccine-9/NN||a-7/DT	amod||vaccine-9/NN||prime-8/JJ	prep_as||utilizing-4/VBG||vaccine-9/NN	advmod||represent-11/VBP||probably-10/RB	root||ROOT-0/null||represent-11/VBP	det||hope-14/NN||the-12/DT	amod||hope-14/NN||best-13/JJS	dobj||represent-11/VBP||hope-14/NN	det||development-17/NN||the-16/DT	prep_for||hope-14/NN||development-17/NN	amod||tuberculosis-20/JJ||novel-19/JJ	amod||vaccines-24/NNS||tuberculosis-20/JJ	appos||vaccines-24/NNS||tb-22/NN	prep_of||development-17/NN||vaccines-24/NNS	tuberculosis-20||bcg-5||no||heterologous prime-boost regimens utilizing bcg as a prime vaccine probably represent the best hope for the development of novel tuberculosis (tb) vaccines.
nsubj||inhibitor-5/NN||bortezomib-1/NN	cop||inhibitor-5/NN||is-2/VBZ	det||inhibitor-5/NN||a-3/DT	amod||inhibitor-5/NN||proteasome-4/JJ	root||ROOT-0/null||inhibitor-5/NN	vmod||inhibitor-5/NN||used-6/VBN	det||treatment-9/NN||the-8/DT	prep_in||used-6/VBN||treatment-9/NN	prep_of||treatment-9/NN||multiplemyeloma-11/NN	multiplemyeloma-11||bortezomib-1||yes||bortezomib is a proteasome inhibitor used in the treatment of multiplemyeloma.
det||objective-2/NN||the-1/DT	nsubj||is-6/VBZ||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||evaluate-8/VB||to-7/TO	xcomp||is-6/VBZ||evaluate-8/VB	det||benefits-11/NNS||the-9/DT	amod||benefits-11/NNS||economic-10/JJ	dobj||evaluate-8/VB||benefits-11/NNS	nn||therapy-15/NN||immunoglobulin-13/NN	nn||therapy-15/NN||replacement-14/NN	prep_of||benefits-11/NNS||therapy-15/NN	vmod||therapy-15/NN||achieved-16/VBN	advmod||achieved-16/VBN||subcutaneously-17/RB	amod||scig-22/NN||subcutaneous-19/JJ	nn||scig-22/NN||immunoglobulin-20/NN	appos||benefits-11/NNS||scig-22/NN	det||method-28/NN||the-25/DT	amod||method-28/NN||rapid-26/JJ	nn||method-28/NN||push-27/NN	prep_by||evaluate-8/VB||method-28/NN	prepc_compared_to||method-28/NN||to-30/TO	amod||therapy-33/NN||intravenous-31/JJ	nn||therapy-33/NN||infusion-32/NN	pobj||method-28/NN||therapy-33/NN	dep||therapy-33/NN||intravenousimmunoglobulin-35/NN	appos||intravenousimmunoglobulin-35/NN||ivig-37/NN	amod||patients-45/NNS||primary-40/JJ	nn||patients-45/NNS||immunedeficiency-41/NN	nn||patients-45/NNS||pid-43/NN	prep_in||therapy-33/NN||patients-45/NNS	det||perspective-50/NN||the-47/DT	nn||perspective-50/NN||healthcare-48/NN	nn||perspective-50/NN||system-49/NN	prep_from||evaluate-8/VB||perspective-50/NN	det||context-53/NN||the-52/DT	prep_in||perspective-50/NN||context-53/NN	det||program-60/NN||the-55/DT	amod||program-60/NN||adult-56/JJ	amod||program-60/NN||scig-57/JJ	nn||program-60/NN||home-58/NN	nn||program-60/NN||infusion-59/NN	prep_of||context-53/NN||program-60/NN	vmod||program-60/NN||based-61/VBN	amod||paul-64/NN||st-63/JJ	poss||hospital-66/NN||paul-64/NN	prep_at||based-61/VBN||hospital-66/NN	appos||hospital-66/NN||vancouver-68/NN	appos||vancouver-68/NN||canada-70/NN	immunedeficiency-41||immunoglobulin-20||yes||the objective of this study is to evaluate the economic benefits of immunoglobulin replacement therapy achieved subcutaneously (subcutaneous immunoglobulin, scig) by the rapid push method compared to intravenous infusion therapy (intravenousimmunoglobulin, ivig) in primary immunedeficiency (pid) patients from the healthcare system perspective in the context of the adult scig home infusion program based at st paul's hospital, vancouver, canada.
amod||children-2/NNS||forty-eight-1/JJ	nsubjpass||recruited-8/VBN||children-2/NNS	nsubjpass||treated-17/VBN||children-2/NNS	conj_and||children-2/NNS||adolescents-4/NNS	nsubjpass||recruited-8/VBN||adolescents-4/NNS	prep_with||children-2/NNS||ticdisorders-6/NNS	auxpass||recruited-8/VBN||were-7/VBD	root||ROOT-0/null||recruited-8/VBN	det||clinic-12/NN||the-10/DT	nn||clinic-12/NN||outpatient-11/NN	prep_from||recruited-8/VBN||clinic-12/NN	amod||korea-15/NN||south-14/JJ	prep_at||recruited-8/VBN||korea-15/NN	conj_and||recruited-8/VBN||treated-17/VBN	prep_with||treated-17/VBN||aripiprazole-19/NN	amod||dose-22/NN||initial-21/JJ	dep||mg/d-31/VBD||dose-22/NN	num||mg/d-26/NN||5.0-24/CD	nn||mg/d-26/NN||â-25/NN	appos||dose-22/NN||mg/d-26/NN	amod||20â-30/NNS||maximum-28/JJ	nn||20â-30/NNS||dose-29/NN	nsubj||mg/d-31/VBD||20â-30/NNS	dep||aripiprazole-19/NN||mg/d-31/VBD	prep_with||treated-17/VBN||haloperidol-34/NN	conj_or||aripiprazole-19/NN||haloperidol-34/NN	amod||dose-37/NN||initial-36/JJ	dep||haloperidol-34/NN||dose-37/NN	num||â-40/NN||0.75-39/CD	appos||dose-37/NN||â-40/NN	vmod||â-40/NN||mg/d-41/VBN	amod||dose-44/NN||maximum-43/JJ	dep||â-40/NN||dose-44/NN	num||mg/d-48/NN||4.5-46/CD	nn||mg/d-48/NN||â-47/NN	appos||dose-44/NN||mg/d-48/NN	amod||weeks-52/NNS||8â-51/JJ	prep_for||recruited-8/VBN||weeks-52/NNS	ticdisorders-6||aripiprazole-19||no_rel||forty-eight children and adolescents with ticdisorders were recruited from the outpatient clinic at south korea and treated with aripiprazole (initial dose, 5.0â mg/d; maximum dose 20â mg/d) or haloperidol (initial dose, 0.75â mg/d; maximum dose, 4.5â mg/d) for 8â weeks.
advmod||tested-5/VBN||therefore-1/RB	nsubj||tested-5/VBN||we-3/PRP	aux||tested-5/VBN||have-4/VBP	root||ROOT-0/null||tested-5/VBN	det||hypothesis-7/NNS||the-6/DT	dobj||tested-5/VBN||hypothesis-7/NNS	mark||â-19/VBP||that-8/IN	det||allele-11/NN||the-9/DT	amod||allele-11/NN||rare-10/JJ	nsubj||â-19/VBP||allele-11/NN	det||tâ-15/NN||the-13/DT	amod||tâ-15/NN||-164-14/JJ	prep_of||allele-11/NN||tâ-15/NN	num||tâ-15/NN||$-16/$	number||>-18/CD||‰-17/CD	num||$-16/$||>-18/CD	ccomp||tested-5/VBN||â-19/VBP	num||polymorphism-23/NN||$-20/$	number||c-22/CD||‰-21/CD	num||$-20/$||c-22/CD	nsubj||alters-26/VBZ||polymorphism-23/NN	prep_in||polymorphism-23/NN||mttp-25/NN	ccomp||â-19/VBP||alters-26/VBZ	det||risk-28/NN||the-27/DT	dobj||alters-26/VBZ||risk-28/NN	prep_of||risk-28/NN||cardiovasculardisease-30/NN	appos||cardiovasculardisease-30/NN||cvd-32/NN	prepc_depending_on||alters-26/VBZ||on-36/IN	det||levels-39/NNS||the-37/DT	nn||levels-39/NNS||cholesterol-38/NN	pobj||alters-26/VBZ||levels-39/NNS	cholesterol-38||cardiovasculardisease-30||no_rel||therefore, we have tested the hypothesis that the rare allele of the -164tâ€‰>â€‰c polymorphism in mttp alters the risk of cardiovasculardisease (cvd), depending on the cholesterol levels.
nsubj||has-2/VBZ||ketamine-1/NN	root||ROOT-0/null||has-2/VBZ	det||role-5/NN||a-3/DT	amod||role-5/NN||special-4/JJ	dobj||has-2/VBZ||role-5/NN	prep_in||role-5/NN||patients-7/NNS	prepc_with||patients-7/NNS||debilitating-9/VBG	nn||allodynia-11/NN||heat-10/NN	dobj||debilitating-9/VBG||allodynia-11/NN	amod||symptoms-15/NNS||positive-13/JJ	nn||symptoms-15/NNS||cognitive-14/NN	dobj||debilitating-9/VBG||symptoms-15/NNS	conj_and||allodynia-11/NN||symptoms-15/NNS	poss||action-18/NN||its-17/PRP$	prep_via||debilitating-9/VBG||action-18/NN	amod||pathway-22/NN||central-20/JJ	nn||pathway-22/NN||pain-21/NN	prep_on||action-18/NN||pathway-22/NN	pain-21||ketamine-1||yes||ketamine has a special role in patients with debilitating heat allodynia and positive cognitive symptoms via its action on central pain pathway.
nsubj||increase-31/VB||objective-1/NN	aux||investigate-3/VB||to-2/TO	vmod||objective-1/NN||investigate-3/VB	mark||iterative-19/VBP||whether-4/IN	nn||plus-6/NN||palsa-5/NN	nsubj||iterative-19/VBP||plus-6/NN	det||programme-12/NN||an-8/DT	amod||programme-12/NN||on-site-9/JJ	amod||programme-12/NN||educational-10/JJ	nn||programme-12/NN||outreach-11/NN	appos||plus-6/NN||programme-12/NN	prep_of||programme-12/NN||non-didactic-14/JJ	appos||non-didactic-14/JJ||case-16/NN	vmod||case-16/NN||based-17/VBN	ccomp||investigate-3/VB||iterative-19/VBP	amod||education-21/NN||clinical-20/JJ	dobj||iterative-19/VBP||education-21/NN	prep_of||education-21/NN||staff-23/NN	vmod||objective-1/NN||led-25/VBN	det||trainer-28/NN||a-27/DT	agent||led-25/VBN||trainer-28/NN	aux||increase-31/VB||can-30/MD	root||ROOT-0/null||increase-31/VB	dobj||increase-31/VB||access-32/NN	aux||and-34/VB||to-33/TO	vmod||increase-31/VB||and-34/VB	dobj||and-34/VB||comprehensiveness-35/NN	prep_of||comprehensiveness-35/NN||care-37/NN	prep_for||and-34/VB||patients-39/NNS	prep_with||patients-39/NNS||hiv/aids-41/NNS	aids--1||hiv--1||no||objective to investigate whether palsa plus, an on-site educational outreach programme of non-didactic, case based, iterative clinical education of staff, led by a trainer, can increase access to and comprehensiveness of care for patients with hiv/aids.
amod||proline-2/NN||foliar-applied-1/JJ	nsubj||increased-4/VBD||proline-2/NN	advmod||increased-4/VBD||significantly-3/RB	root||ROOT-0/null||increased-4/VBD	det||content-6/NN||the-5/DT	dobj||increased-4/VBD||content-6/NN	nn||sugar-9/NN||seed-8/NN	prep_of||content-6/NN||sugar-9/NN	appos||sugar-9/NN||oil-11/NN	appos||sugar-9/NN||protein-13/NN	conj_and||oil-11/NN||protein-13/NN	appos||sugar-9/NN||moisture-15/NN	conj_and||oil-11/NN||moisture-15/NN	appos||sugar-9/NN||fiber-17/NN	conj_and||oil-11/NN||fiber-17/NN	appos||sugar-9/NN||ash-19/NN	conj_and||oil-11/NN||ash-19/NN	det||cultivars-23/NNS||both-21/DT	amod||cultivars-23/NNS||maize-22/JJ	prep_in||oil-11/NN||cultivars-23/NNS	advmod||irrigated-26/JJ||well-25/RB	amod||conditions-30/NNS||irrigated-26/JJ	nn||deficit-29/NN||water-28/NN	conj_and||irrigated-26/JJ||deficit-29/NN	amod||conditions-30/NNS||deficit-29/NN	prep_under||increased-4/VBD||conditions-30/NNS	deficit-29||oil-11||no_rel||foliar-applied proline significantly increased the content of seed sugar, oil, protein, moisture, fiber and ash in both maize cultivars under well irrigated and water deficit conditions.
prep_in||shown-7/VBN||addition-2/NN	amod||studies-5/NNS||epidemiologic-4/JJ	nsubj||shown-7/VBN||studies-5/NNS	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	mark||resulted-18/VBD||that-8/IN	det||use-10/NN||the-9/DT	nsubj||resulted-18/VBD||use-10/NN	amod||agents-13/NNS||no-donating-12/JJ	prep_of||use-10/NN||agents-13/NNS	prep_with||agents-13/NNS||nsaids-15/NNS	prep_with||agents-13/NNS||aspirin-17/NN	conj_or||nsaids-15/NNS||aspirin-17/NN	ccomp||shown-7/VBN||resulted-18/VBD	amod||risk-21/NN||reduced-20/VBN	prep_in||resulted-18/VBD||risk-21/NN	prep_for||risk-21/NN||gastrointestinalbleeding-23/NN	aspirin-17||gastrointestinalbleeding-23||no_rel||in addition, epidemiologic studies have shown that the use of no-donating agents with nsaids or aspirin resulted in reduced risk for gastrointestinalbleeding.
aux||investigate-2/VB||to-1/TO	csubj||repeated-17/VBD||investigate-2/VB	mark||mediated-6/VBD||whether-3/IN	amod||support-5/NN||social-4/JJ	nsubj||mediated-6/VBD||support-5/NN	ccomp||investigate-2/VB||mediated-6/VBD	det||association-8/NN||the-7/DT	dobj||mediated-6/VBD||association-8/NN	nn||use-13/NN||religiosity-10/NN	conj_and||religiosity-10/NN||alcohol-12/NN	nn||use-13/NN||alcohol-12/NN	prep_between||association-8/NN||use-13/NN	conj_and||investigate-2/VB||alcoholabuse/dependence-15/VB	csubj||repeated-17/VBD||alcoholabuse/dependence-15/VB	dobj||alcoholabuse/dependence-15/VB||we-16/PRP	root||ROOT-0/null||repeated-17/VBD	det||models-20/NNS||the-18/DT	amod||models-20/NNS||above-19/JJ	dobj||repeated-17/VBD||models-20/NNS	vmod||repeated-17/VBD||adding-22/VBG	det||variables-26/NNS||the-23/DT	amod||variables-26/NNS||social-24/JJ	nn||variables-26/NNS||support-25/NN	dobj||adding-22/VBG||variables-26/NNS	alcoholabuse--1||alcohol-12||no||to investigate whether social support mediated the association between religiosity and alcohol use and alcoholabuse/dependence we repeated the above models, adding the social support variables.
prep_in||several-fold-37/VBN||type2diabetes-2/CD	det||ability-5/NN||the-4/DT	nsubjpass||several-fold-37/VBN||ability-5/NN	prep_of||ability-5/NN||insulin-7/NN	aux||stimulate-9/VB||to-8/TO	vmod||insulin-7/NN||stimulate-9/VB	predet||fsr-12/NN||both-10/PDT	det||fsr-12/NN||the-11/DT	dobj||stimulate-9/VB||fsr-12/NN	num||â-15/NN||4.7-14/CD	dep||insulin-7/NN||â-15/NN	number||3.2-17/CD||±-16/CD	num||%-18/NN||3.2-17/CD	dep||â-15/NN||%-18/NN	prep_per||%-18/NN||day-20/NN	det||asr-24/NN||the-23/DT	prep_of||ability-5/NN||asr-24/NN	conj_and||insulin-7/NN||asr-24/NN	num||±-28/NNS||0.03-26/CD	nn||±-28/NNS||â-27/NN	dep||asr-24/NN||±-28/NNS	num||mol-30/NN||0.04-29/CD	dep||±-28/NNS||mol-30/NN	prep_per||mol-30/NN||day-32/NN	prep_of||asr-24/NN||nox-35/NN	auxpass||several-fold-37/VBN||was-36/VBD	root||ROOT-0/null||several-fold-37/VBN	advmod||several-fold-37/VBN||lower-38/RBR	prep_than||lower-38/RBR||that-40/DT	nn||subjects-43/NNS||control-42/NN	prep_in||that-40/DT||subjects-43/NNS	num||â-46/NN||15.0-45/CD	nsubj||±-47/VBZ||â-46/NN	parataxis||several-fold-37/VBN||±-47/VBZ	num||%-49/NN||2.9-48/CD	nsubj||±-55/VB||%-49/NN	nsubj||p-61/VB||%-49/NN	nsubj||p-65/VB||%-49/NN	prep_per||%-49/NN||day-51/NN	num||â-54/NN||0.25-53/CD	prep_per||%-49/NN||â-54/NN	conj_and||day-51/NN||â-54/NN	ccomp||±-47/VBZ||±-55/VB	num||mol-57/NN||0.07-56/CD	dobj||±-55/VB||mol-57/NN	prep_per||mol-57/NN||day-59/NN	ccomp||±-47/VBZ||p-61/VB	conj_and||±-55/VB||p-61/VB	num||0.03-63/CD||<-62/CD	dobj||p-61/VB||0.03-63/CD	ccomp||±-47/VBZ||p-65/VB	conj_and||±-55/VB||p-65/VB	num||0.02-67/CD||<-66/CD	dobj||p-65/VB||0.02-67/CD	advmod||p-65/VB||respectively-69/RB	type2diabetes-2||insulin-7||yes||in type2diabetes, the ability of insulin to stimulate both the fsr (4.7 â± 3.2% per day) and the asr (0.03 â± 0.04 mol per day) of nox was several-fold lower than that in control subjects (15.0 â± 2.9% per day and 0.25 â± 0.07 mol per day, p < 0.03 and p < 0.02, respectively).
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	cataract-45||triglycerides-53||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
nsubj||disease-8/NN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	cop||disease-8/NN||is-5/VBZ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||complex-7/JJ	root||ROOT-0/null||disease-8/NN	vmod||disease-8/NN||characterized-9/VBN	amod||hyperglycemia-12/NN||chronic-11/JJ	agent||characterized-9/VBN||hyperglycemia-12/NN	det||factor-17/NN||a-14/DT	amod||factor-17/NN||known-15/VBN	nn||factor-17/NN||risk-16/NN	appos||hyperglycemia-12/NN||factor-17/NN	amod||atherosclerosis-20/NNS||accelerated-19/JJ	prep_for||factor-17/NN||atherosclerosis-20/NNS	prep_for||factor-17/NN||vasculardisease-22/NN	conj_and||atherosclerosis-20/NNS||vasculardisease-22/NN	vasculardisease-22||dm-3||no_rel||diabetesmellitus (dm) is a complex disease characterized by chronic hyperglycemia, a known risk factor for accelerated atherosclerosis and vasculardisease.
csubj||trial-6/NN||ecog-1/VBG	dobj||ecog-1/VBG||1684-2/CD	cop||trial-6/NN||was-3/VBD	det||trial-6/NN||the-4/DT	amod||trial-6/NN||pivotal-5/JJ	root||ROOT-0/null||trial-6/NN	nsubj||demonstrated-9/VBD||trial-6/NN	advmod||demonstrated-9/VBD||first-8/RB	rcmod||trial-6/NN||demonstrated-9/VBD	det||benefit-13/NN||a-10/DT	advmod||significant-12/JJ||statistically-11/RB	amod||benefit-13/NN||significant-12/JJ	dobj||demonstrated-9/VBD||benefit-13/NN	amod||survival-18/NN||relapse-free-15/JJ	conj_and||relapse-free-15/JJ||overall-17/JJ	amod||survival-18/NN||overall-17/JJ	prep_in||benefit-13/NN||survival-18/NN	amod||interferonalpha-2b-21/NN||adjuvant-20/JJ	prep_for||demonstrated-9/VBD||interferonalpha-2b-21/NN	amod||melanoma-24/NN||high-risk-23/JJ	prep_in||interferonalpha-2b-21/NN||melanoma-24/NN	melanoma-24||interferonalpha-2b-21||yes||ecog 1684 was the pivotal trial that first demonstrated a statistically significant benefit in relapse-free and overall survival for adjuvant interferonalpha-2b in high-risk melanoma.
amod||exchange-4/NN||submaximal-1/JJ	nn||exchange-4/NN||exercise-2/NN	nn||exchange-4/NN||gas-3/NN	nsubj||tool-9/NN||exchange-4/NN	aux||tool-9/NN||may-5/MD	cop||tool-9/NN||be-6/VB	det||tool-9/NN||a-7/DT	amod||tool-9/NN||useful-8/JJ	root||ROOT-0/null||tool-9/NN	aux||track-11/VB||to-10/TO	vmod||tool-9/NN||track-11/VB	dobj||track-11/VB||responses-12/NNS	prep_to||track-11/VB||therapy-14/NN	amod||patients-21/NNS||pulmonary-16/JJ	nn||patients-21/NNS||arterialhypertension-17/NN	nn||patients-21/NNS||pah-19/NN	prep_in||therapy-14/NN||patients-21/NNS	arterialhypertension-17||gas-3||no_rel||submaximal exercise gas exchange may be a useful tool to track responses to therapy in pulmonary arterialhypertension (pah) patients.
num||statements-2/NNS||three-1/CD	nsubj||addressed-3/VBD||statements-2/NNS	root||ROOT-0/null||addressed-3/VBD	det||validity-5/NN||the-4/DT	dobj||addressed-3/VBD||validity-5/NN	nn||growthhormone-8/NN||serum-7/NN	prep_of||validity-5/NN||growthhormone-8/NN	appos||growthhormone-8/NN||gh-10/NN	amod||concentrations-19/NNS||insulin-like-13/JJ	nn||concentrations-19/NNS||growth-14/NN	nn||concentrations-19/NNS||factor-i-15/NN	appos||concentrations-19/NNS||igf-i-17/NNP	prep_of||validity-5/NN||concentrations-19/NNS	conj_and||growthhormone-8/NN||concentrations-19/NNS	prep_as||addressed-3/VBD||indicators-21/NNS	prep_as||addressed-3/VBD||predictors-23/NNS	conj_or||indicators-21/NNS||predictors-23/NNS	prep_of||indicators-21/NNS||disease-25/NN	prep_in||addressed-3/VBD||acromegaly-27/NN	growthhormone-8||acromegaly-27||no_rel||three statements addressed the validity of serum growthhormone (gh) and insulin-like growth factor-i (igf-i) concentrations as indicators or predictors of disease in acromegaly.
amod||autoinjectors-2/NNS||adrenaline-1/JJ	nsubjpass||prescribed-7/VBN||autoinjectors-2/NNS	nsubj||facilitate-9/VB||autoinjectors-2/NNS	appos||autoinjectors-2/NNS||aais-4/NNS	auxpass||prescribed-7/VBN||are-6/VBP	root||ROOT-0/null||prescribed-7/VBN	aux||facilitate-9/VB||to-8/TO	xcomp||prescribed-7/VBN||facilitate-9/VB	det||administration-12/NN||the-10/DT	nn||administration-12/NN||intramuscular-11/NN	dobj||facilitate-9/VB||administration-12/NN	prep_of||administration-12/NN||adrenaline-14/NN	prep_in||facilitate-9/VB||patients-16/NNS	vmod||patients-16/NNS||diagnosed-17/VBN	amod||anaphylaxis-20/NNS||life-threatening-19/JJ	prep_with||diagnosed-17/VBN||anaphylaxis-20/NNS	anaphylaxis-20||adrenaline-14||yes||adrenaline autoinjectors (aais) are prescribed to facilitate the intramuscular administration of adrenaline in patients diagnosed with life-threatening anaphylaxis.
amod||pathogenesis-2/NNS||mitochondrial-1/JJ	nsubj||occurs-3/VBZ||pathogenesis-2/NNS	ccomp||associated-19/VBN||occurs-3/VBZ	nn||patients-6/NNS||hiv-5/NN	prep_in||occurs-3/VBZ||patients-6/NNS	prep_in||occurs-3/VBZ||genetically-8/NNS	conj_and||patients-6/NNS||genetically-8/NNS	amod||haplogroups-12/NNS||mitochondrial-10/JJ	nn||haplogroups-12/NNS||dna-11/NN	nsubjpass||associated-19/VBN||haplogroups-12/NNS	amod||differences-16/NNS||presumed-14/JJ	amod||differences-16/NNS||functional-15/JJ	prep_with||haplogroups-12/NNS||differences-16/NNS	aux||associated-19/VBN||have-17/VBP	auxpass||associated-19/VBN||been-18/VBN	root||ROOT-0/null||associated-19/VBN	nn||progression-23/NN||differential-21/NN	nn||progression-23/NN||aids-22/NNS	prep_with||associated-19/VBN||progression-23/NN	aids-22||hiv-5||no||mitochondrial pathogenesis occurs in hiv patients and genetically, mitochondrial dna haplogroups with presumed functional differences have been associated with differential aids progression.
amod||evidence-2/NN||recent-1/JJ	nsubj||suggests-3/VBZ||evidence-2/NN	root||ROOT-0/null||suggests-3/VBZ	mark||contributes-17/VBZ||that-4/IN	amod||synthesis-6/NN||reduced-5/VBN	nsubj||contributes-17/VBZ||synthesis-6/NN	prep_of||synthesis-6/NN||nitricoxide-8/NN	amod||cells-11/NNS||endothelial-10/JJ	prep_in||nitricoxide-8/NN||cells-11/NNS	amod||dysfunction-15/NN||i.e.-13/JJ	amod||dysfunction-15/NN||endothelial-14/JJ	appos||cells-11/NNS||dysfunction-15/NN	ccomp||suggests-3/VBZ||contributes-17/VBZ	det||action-21/NN||the-19/DT	amod||action-21/NN||impaired-20/VBN	prep_to||contributes-17/VBZ||action-21/NN	prep_of||action-21/NN||insulin-23/NN	det||vasculature-26/NN||the-25/DT	prep_in||insulin-23/NN||vasculature-26/NN	prep_of||vasculature-26/NN||patients-28/NNS	prep_with||patients-28/NNS||type2diabetes-30/CD	type2diabetes-30||insulin-23||yes||recent evidence suggests that reduced synthesis of nitricoxide in endothelial cells , i.e. endothelial dysfunction , contributes to the impaired action of insulin in the vasculature of patients with type2diabetes .
amod||trial-3/NN||randomized-1/JJ	amod||trial-3/NN||controlled-2/JJ	nsubj||randomized-14/VBD||trial-3/NN	nsubj||risperidone-16/VB||trial-3/NN	appos||participants-8/NNS||50-6/CD	prep_with||trial-3/NN||participants-8/NNS	det||diagnosis-11/NN||a-10/DT	prep_with||participants-8/NNS||diagnosis-11/NN	prep_of||diagnosis-11/NN||schizophrenia-13/NN	root||ROOT-0/null||randomized-14/VBD	aux||risperidone-16/VB||to-15/TO	xcomp||randomized-14/VBD||risperidone-16/VB	dobj||risperidone-16/VB||lai-17/NN	amod||medication-21/NN||oral-19/JJ	amod||medication-21/NN||atypicalantipsychotic-20/JJ	dobj||risperidone-16/VB||medication-21/NN	conj_or||lai-17/NN||medication-21/NN	schizophrenia-13||risperidone-16||yes||randomized controlled trial with (50) participants with a diagnosis of schizophrenia randomized to risperidone lai or oral atypicalantipsychotic medication.
nsubjpass||computed-10/VBN||association-1/NN	amod||survival-4/NN||overall-3/JJ	prep_between||association-1/NN||survival-4/NN	nn||levels-8/NNS||serum-6/NN	nn||levels-8/NNS||25ohd-7/NNS	prep_between||association-1/NN||levels-8/NNS	conj_and||survival-4/NN||levels-8/NNS	auxpass||computed-10/VBN||were-9/VBD	ccomp||adjuvant-49/VBD||computed-10/VBN	xcomp||computed-10/VBN||using-11/VBG	det||model-16/NN||the-12/DT	amod||model-16/NN||cox-13/JJ	amod||model-16/NN||proportional-14/JJ	nn||model-16/NN||hazard-15/NN	dobj||using-11/VBG||model-16/NN	vmod||model-16/NN||adjusted-17/VBN	prep_for||adjusted-17/VBN||month-19/NN	nn||sampling-22/NN||serum-21/NN	prep_of||month-19/NN||sampling-22/NN	dobj||using-11/VBG||age-26/NN	conj_and||model-16/NN||age-26/NN	prep_at||age-26/NN||diagnosis-28/NN	nsubj||adjuvant-49/VBD||gender-30/NN	nn||stage-33/NN||cancer-32/NN	appos||gender-30/NN||stage-33/NN	amod||tumor-36/NN||residual-35/JJ	appos||gender-30/NN||tumor-36/NN	prep_after||tumor-36/NN||surgery-38/NN	nn||period-41/NN||time-40/NN	appos||gender-30/NN||period-41/NN	prep_of||period-41/NN||surgery-43/NN	appos||gender-30/NN||location-45/NN	prep_of||location-45/NN||tumor-47/NN	root||ROOT-0/null||adjuvant-49/VBD	dobj||adjuvant-49/VBD||chemotherapy-50/NN	dobj||adjuvant-49/VBD||number-52/NN	conj_and||chemotherapy-50/NN||number-52/NN	nn||nodes-55/NNS||lymph-54/NN	prep_of||chemotherapy-50/NN||nodes-55/NNS	prep_with||adjuvant-49/VBD||metastasis-57/NNS	prep_at||metastasis-57/NNS||surgery-59/NN	metastasis-57||adjuvant-49||no_rel||association between overall survival and serum 25ohd levels were computed using the cox proportional hazard model adjusted for month of serum sampling as well as age at diagnosis, gender, cancer stage, residual tumor after surgery, time period of surgery, location of tumor, adjuvant chemotherapy and number of lymph nodes with metastasis at surgery.
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	nitricoxide-50||inflammation-47||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
nsubjpass||shown-5/VBN||anthrax-1/NN	nsubjpass||dispersed-8/VBN||anthrax-1/NN	aux||shown-5/VBN||has-2/VBZ	advmod||shown-5/VBN||clearly-3/RB	auxpass||shown-5/VBN||been-4/VBN	root||ROOT-0/null||shown-5/VBN	aux||dispersed-8/VBN||to-6/TO	auxpass||dispersed-8/VBN||be-7/VB	xcomp||shown-5/VBN||dispersed-8/VBN	amod||commerce-11/NN||human-10/JJ	agent||dispersed-8/VBN||commerce-11/NN	agent||dispersed-8/VBN||trade-13/NN	conj_and||commerce-11/NN||trade-13/NN	nn||products-16/NNS||animal-15/NN	prep_in||dispersed-8/VBN||products-16/NNS	vmod||products-16/NNS||contaminated-17/VBN	amod||spores-20/NNS||bacillusanthracis-19/JJ	prep_with||contaminated-17/VBN||spores-20/NNS	anthrax-1||bacillusanthracis-19||no||anthrax has clearly been shown to be dispersed by human commerce and trade in animal products contaminated with bacillusanthracis spores.
det||aim-2/NN||the-1/DT	nsubj||was-3/VBD||aim-2/NN	nsubj||determine-5/VB||aim-2/NN	root||ROOT-0/null||was-3/VBD	aux||determine-5/VB||to-4/TO	xcomp||was-3/VBD||determine-5/VB	amod||aspects-9/NNS||qualitative-6/JJ	conj_and||qualitative-6/JJ||quantitative-8/JJ	amod||aspects-9/NNS||quantitative-8/JJ	dobj||determine-5/VB||aspects-9/NNS	amod||block-12/NN||caudal-11/JJ	prep_of||aspects-9/NNS||block-12/NN	amod||effects-15/NNS||haemodynamic-14/JJ	prep_of||aspects-9/NNS||effects-15/NNS	conj_and||block-12/NN||effects-15/NNS	amod||relief-19/NN||post-operativepain-18/JJ	prep_of||aspects-9/NNS||relief-19/NN	conj_and||block-12/NN||relief-19/NN	nn||ropivacaine-25/NN||ropivacaine-21/NN	number||%-23/NN||0.25-22/CD	amod||ropivacaine-25/NN||%-23/NN	nn||ropivacaine-25/NN||versus-24/NNP	prep_of||relief-19/NN||ropivacaine-25/NN	number||%-27/NN||0.25-26/CD	amod||ropivacaine-25/NN||%-27/NN	prep_with||determine-5/VB||clonidine-29/NN	amod||surgeries-33/NNS||lower-31/JJR	nn||surgeries-33/NNS||abdominal-32/NN	prep_for||determine-5/VB||surgeries-33/NNS	amod||patients-36/NNS||paediatric-35/JJ	prep_in||surgeries-33/NNS||patients-36/NNS	post-operativepain-18||ropivacaine-25||yes||the aim was to determine qualitative and quantitative aspects of caudal block, haemodynamic effects, and post-operativepain relief of ropivacaine 0.25% versus ropivacaine 0.25% with clonidine for lower abdominal surgeries in paediatric patients.
nsubj||analysed-2/VBD||we-1/PRP	root||ROOT-0/null||analysed-2/VBD	dobj||analysed-2/VBD||data-3/NNS	det||study-8/NN||an-5/DT	amod||study-8/NN||observational-6/JJ	nn||study-8/NN||cohort-7/NN	prep_from||analysed-2/VBD||study-8/NN	amod||adults-11/NNS||hiv-infected-10/JJ	prep_of||study-8/NN||adults-11/NNS	nn||ssarcoma-15/NN||aids-associatedkaposi-13/NN	prep_with||analysed-2/VBD||ssarcoma-15/NN	dep||analysed-2/VBD||enrolled-17/VBN	aux||2001-20/VB||may-19/MD	prepc_between||enrolled-17/VBN||2001-20/VB	dep||analysed-2/VBD||january-22/NNP	conj_and||enrolled-17/VBN||january-22/NNP	num||january-22/NNP||2007-23/CD	num||clinics-28/NNS||three-25/CD	amod||clinics-28/NNS||primary-26/JJ	nn||clinics-28/NNS||care-27/NN	prep_in||january-22/NNP||clinics-28/NNS	aids-associatedkaposi'ssarcoma--1||hiv--1||no||we analysed data from an observational cohort study of hiv-infected adults with aids-associatedkaposi'ssarcoma, enrolled between may 2001 and january 2007 in three primary care clinics.
prep_regardless_of||similar-10/JJ||aetiology-3/NN	prep_of||aetiology-3/NN||heartdisease-5/NN	nn||benefit-8/NN||icd-7/NN	nsubj||similar-10/JJ||benefit-8/NN	cop||similar-10/JJ||was-9/VBD	root||ROOT-0/null||similar-10/JJ	nn||rr-14/FW||cad-12/FW	nn||rr-14/FW||-lrb--13/FW	prep_for||similar-10/JJ||rr-14/FW	dep||rr-14/FW||0.67-15/CD	num||%-18/NN||95-17/CD	dep||rr-14/FW||%-18/NN	nn||0.74-30/FW||ci-19/FW	nn||0.74-30/FW||0.51-20/FW	nn||0.74-30/FW||â-21/FW	nn||0.74-30/FW||$-22/FW	nn||0.74-30/FW||0.88-24/FW	nn||0.74-30/FW||-rrb--25/FW	nn||0.74-30/FW||vs.-26/FW	nn||0.74-30/FW||dcm-27/FW	nn||0.74-30/FW||-lrb--28/FW	nn||0.74-30/FW||rr-29/FW	dep||%-18/NN||0.74-30/FW	num||%-33/NN||95-32/CD	dep||rr-14/FW||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||0.59-35/FW	dep||%-33/NN||â-36/FW	dep||-rrb--40/NN||$-37/$	num||$-37/$||0.93-39/CD	amod||rr-14/FW||-rrb--40/NN	dcm-27||heartdisease-5||no_rel||regardless of aetiology of heartdisease , icd benefit was similar for cad -lrb- rr 0.67 ; 95 % ci 0.51 â $ `` 0.88 -rrb- vs. dcm -lrb- rr 0.74 ; 95 % ci 0.59 â $ `` 0.93 -rrb- .
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	enzyme--1||crohn'sdisease--1||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||™-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	uc-25||hc-5||yes||seventeen healthy controls (hc), 20 patients with crohnâ€™s disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
amod||rates-2/NNS||prevalence-1/JJ	nsubj||have-34/VBP||rates-2/NNS	amod||virus-5/NN||hepatitisc-4/JJ	prep_of||rates-2/NNS||virus-5/NN	appos||virus-5/NN||hcv-7/NN	dep||virus-5/NN||co-infection-9/NN	det||distribution-12/NN||the-11/DT	prep_of||rates-2/NNS||distribution-12/NN	conj_and||virus-5/NN||distribution-12/NN	nn||genotypes-15/NNS||hcv-14/NN	prep_of||distribution-12/NN||genotypes-15/NNS	det||frequency-19/NN||the-18/DT	prep_of||rates-2/NNS||frequency-19/NN	conj_and||virus-5/NN||frequency-19/NN	amod||resolution-22/NN||spontaneous-21/JJ	prep_of||frequency-19/NN||resolution-22/NN	prep_of||resolution-22/NN||hepatitisc-24/NN	prep_in||hepatitisc-24/NN||patients-26/NNS	vmod||patients-26/NNS||infected-27/VBN	det||humanimmunodeficiencyvirus-30/NNS||the-29/DT	prep_with||infected-27/VBN||humanimmunodeficiencyvirus-30/NNS	appos||humanimmunodeficiencyvirus-30/NNS||hiv-32/NN	root||ROOT-0/null||have-34/VBP	det||disparity-37/NN||a-35/DT	amod||disparity-37/NN||worldwide-36/JJ	dobj||have-34/VBP||disparity-37/NN	hepatitisc-24||hcv-14||no||prevalence rates of hepatitisc virus (hcv) co-infection, the distribution of hcv genotypes, and the frequency of spontaneous resolution of hepatitisc in patients infected with the humanimmunodeficiencyvirus (hiv) have a worldwide disparity.
det||result-3/NN||a-2/DT	prep_as||synthesized-12/VBN||result-3/NN	amod||duplication-7/NN||chimeric-5/JJ	nn||duplication-7/NN||gene-6/NN	prep_of||result-3/NN||duplication-7/NN	nsubjpass||synthesized-12/VBN||aldosterone-9/NN	auxpass||synthesized-12/VBN||is-10/VBZ	advmod||synthesized-12/VBN||ectopically-11/RB	root||ROOT-0/null||synthesized-12/VBN	det||fasciculata-17/NN||the-14/DT	amod||fasciculata-17/NN||adrenal-15/JJ	nn||fasciculata-17/NN||zona-16/NN	prep_in||synthesized-12/VBN||fasciculata-17/NN	det||control-20/NN||the-19/DT	prep_under||synthesized-12/VBN||control-20/NN	prep_of||control-20/NN||adrenocorticotropin-22/NN	zona-16||adrenocorticotropin-22||no||as a result of chimeric gene duplication, aldosterone is ectopically synthesized in the adrenal zona fasciculata under the control of adrenocorticotropin.
root||ROOT-0/null||hiv-1/NN	punct||hiv-1/NN||/-2/:	amod||families-4/NNS||aids-affected-3/JJ	nsubj||diverse-6/JJ||families-4/NNS	cop||diverse-6/JJ||are-5/VBP	dep||hiv-1/NN||diverse-6/JJ	nn||structure-11/NN||household-10/NN	prep_with_respect_to||diverse-6/JJ||structure-11/NN	appos||structure-11/NN||ability-13/NN	prep_to||ability-13/NN||work-15/NN	prep_to||ability-13/NN||access-17/NN	conj_and||work-15/NN||access-17/NN	prep_to||diverse-6/JJ||assets-19/NNS	vmod||diverse-6/JJ||arguing-21/VBG	det||mix-24/NN||a-23/DT	prep_for||arguing-21/VBG||mix-24/NN	prep_of||mix-24/NN||approaches-26/NNS	nn||assistance-30/NN||food-29/NN	prep_including||diverse-6/JJ||assistance-30/NN	amod||programmes-33/NNS||income-generation-32/JJ	prep_including||diverse-6/JJ||programmes-33/NNS	conj_and||assistance-30/NN||programmes-33/NNS	aids--1||hiv-1||no||hiv/ aids-affected families are diverse with respect to household structure, ability to work and access to assets, arguing for a mix of approaches, including food assistance and income-generation programmes.
det||study-4/NN||the-2/DT	amod||study-4/NN||latter-3/JJ	prep_in||were-7/VBD||study-4/NN	expl||were-7/VBD||there-6/EX	root||ROOT-0/null||were-7/VBD	num||predictions-9/NNS||25-8/CD	nsubj||were-7/VBD||predictions-9/NNS	prep_of||predictions-9/NNS||hypoglycemia-11/NN	mark||had-15/VBD||because-12/IN	det||subjects-14/NNS||some-13/DT	nsubj||had-15/VBD||subjects-14/NNS	advcl||were-7/VBD||had-15/VBD	amod||events-18/NNS||multiple-16/JJ	amod||events-18/NNS||hypoglycemic-17/JJ	dobj||had-15/VBD||events-18/NNS	det||night-21/NN||a-20/DT	prep_during||events-18/NNS||night-21/NN	nsubjpass||prevented-26/VBN||hypoglycemia-24/NN	auxpass||prevented-26/VBN||was-25/VBD	conj_and||were-7/VBD||prevented-26/VBN	num||%-29/NN||84-28/CD	prep_for||prevented-26/VBN||%-29/NN	det||events-32/NNS||these-31/DT	prep_of||%-29/NN||events-32/NNS	hypoglycemic-17||hypoglycemia-24||no_rel||in the latter study, there were 25 predictions of hypoglycemia because some subjects had multiple hypoglycemic events during a night, and hypoglycemia was prevented for 84% of these events.
num||trials-3/NNS||three-1/CD	amod||trials-3/NNS||quasi-experimental-2/JJ	nsubj||matched-4/VBD||trials-3/NNS	root||ROOT-0/null||matched-4/VBD	det||criteria-7/NNS||the-5/DT	nn||criteria-7/NNS||inclusion-6/NN	nsubj||found-10/VBD||criteria-7/NNS	num||trials-9/NNS||two-8/CD	dep||criteria-7/NNS||trials-9/NNS	ccomp||matched-4/VBD||found-10/VBD	det||reduction-12/NN||a-11/DT	dobj||found-10/VBD||reduction-12/NN	prep_in||found-10/VBD||pain-14/NN	det||use-17/NN||the-16/DT	prep_for||found-10/VBD||use-17/NN	nn||needling-22/NN||trigger-19/NN	nn||needling-22/NN||point-20/NN	amod||needling-22/NN||dry-21/JJ	prep_of||use-17/NN||needling-22/NN	advmod||found-30/VBD||when-23/WRB	csubj||found-30/VBD||combined-24/VBN	prep_with||combined-24/VBN||acupuncture-26/NN	det||third-29/JJ||the-28/DT	prep_with||combined-24/VBN||third-29/JJ	conj_and||acupuncture-26/NN||third-29/JJ	advcl||found-10/VBD||found-30/VBD	det||reduction-32/NN||a-31/DT	dobj||found-30/VBD||reduction-32/NN	prep_in||found-30/VBD||pain-34/NN	xcomp||found-30/VBD||using-35/VBG	number||%-37/NN||1-36/CD	amod||injections-39/NNS||%-37/NN	amod||injections-39/NNS||lidocaine-38/JJ	dobj||using-35/VBG||injections-39/NNS	advmod||combined-41/VBN||when-40/WRB	advcl||using-35/VBG||combined-41/VBN	amod||therapy-44/NN||physical-43/JJ	prep_with||combined-41/VBN||therapy-44/NN	pain-34||lidocaine-38||yes||three quasi-experimental trials matched the inclusion criteria  two trials found a reduction in pain for the use of trigger point dry needling when combined with acupuncture and the third found a reduction in pain using 1% lidocaine injections when combined with physical therapy.
nn||xenografts-2/NNS||tumor-1/NN	nsubjpass||established-4/VBN||xenografts-2/NNS	auxpass||established-4/VBN||were-3/VBD	root||ROOT-0/null||established-4/VBN	det||pad-9/NN||the-6/DT	advmod||fat-8/JJ||mammary-7/RB	amod||pad-9/NN||fat-8/JJ	prep_in||established-4/VBN||pad-9/NN	amod||mice-12/NNS||nu/nu-11/JJ	prep_of||pad-9/NN||mice-12/NNS	xcomp||established-4/VBN||using-13/VBG	amod||cells-17/NNS||human-14/JJ	nn||cells-17/NNS||breast-15/NN	nn||cells-17/NNS||cancer-16/NN	dobj||using-13/VBG||cells-17/NNS	nsubjpass||pre-exposed-20/VBN||cells-17/NNS	auxpass||pre-exposed-20/VBN||were-19/VBD	rcmod||cells-17/NNS||pre-exposed-20/VBN	preconj||hypoxic-23/JJ||either-22/DT	amod||conditions-26/NNS||hypoxic-23/JJ	conj_or||hypoxic-23/JJ||normoxic-25/JJ	amod||conditions-26/NNS||normoxic-25/JJ	prep_to||pre-exposed-20/VBN||conditions-26/NNS	fat-8||tumor-1||no_rel||tumor xenografts were established in the mammary fat pad of nu/nu mice using human breast cancer cells that were pre-exposed to either hypoxic or normoxic conditions.
amod||response-2/NN||t-cell-1/JJ	nsubjpass||evaluated-6/VBN||response-2/NN	prep_to||response-2/NN||rv1985c-4/CD	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	amod||elispot-10/NN||ifn-î-8/JJ	amod||elispot-10/NN||³-9/JJ	agent||evaluated-6/VBN||elispot-10/NN	number||tb-13/CD||56-12/CD	num||patients-14/NNS||tb-13/CD	prep_in||elispot-10/NN||patients-14/NNS	num||infection-19/NN||20-16/CD	nn||infection-19/NN||latent-17/NN	nn||infection-19/NN||tb-18/NN	prep_in||elispot-10/NN||infection-19/NN	conj_and||patients-14/NNS||infection-19/NN	appos||infection-19/NN||ltbi-21/NNP	num||controls-26/NNS||30-24/CD	amod||controls-26/NNS||bcg-vaccinated-25/JJ	prep_in||elispot-10/NN||controls-26/NNS	conj_and||patients-14/NNS||controls-26/NNS	prep_in||controls-26/NNS||comparison-28/NN	det||t-spot-32/NN||the-30/DT	amod||t-spot-32/NN||commercial-31/JJ	prep_with||evaluated-6/VBN||t-spot-32/NN	tb-18||bcg--1||yes||t-cell response to rv1985c was evaluated by ifn-î³ elispot in 56 tb patients, 20 latent tb infection (ltbi) and 30 bcg-vaccinated controls in comparison with the commercial t-spot.
nsubj||±-9/VBZ||mice-1/NNS	det||deletion-5/NN||a-3/DT	amod||deletion-5/NN||whole-body-4/JJ	prep_with||mice-1/NNS||deletion-5/NN	det||î-8/NN||the-7/DT	prep_of||deletion-5/NN||î-8/NN	root||ROOT-0/null||±-9/VBZ	num||subunit-12/NN||2-10/CD	amod||subunit-12/NN||catalytic-11/JJ	dobj||±-9/VBZ||subunit-12/NN	prep_of||subunit-12/NN||ampk-14/NN	dep||±-9/VBZ||ampkî-16/VBG	nn||2âˆ-18/NNP||±-17/NNP	poss||âˆ-21/NNP||2âˆ-18/NNP	nn||âˆ-21/NNP||/-20/NNP	dobj||ampkî-16/VBG||âˆ-21/NNP	poss||littermates-27/NNS||their-25/PRP$	amod||littermates-27/NNS||wild-type-26/JJ	nsubjpass||fed-29/VBN||littermates-27/NNS	auxpass||fed-29/VBN||were-28/VBD	conj_and||±-9/VBZ||fed-29/VBN	advmod||chow-34/NN||either-31/RB	det||chow-34/NN||a-32/DT	amod||chow-34/NN||low-fat-33/JJ	prep_on||fed-29/VBN||chow-34/NN	det||corn-38/NN||a-37/DT	prep_on||fed-29/VBN||corn-38/NN	conj_or||chow-34/NN||corn-38/NN	amod||diet-41/NN||oil-based-39/JJ	amod||diet-41/NN||high-fat-40/JJ	dep||corn-38/NN||diet-41/NN	appos||diet-41/NN||chf-43/NN	det||diet-49/NN||a-47/DT	nn||diet-49/NN||chf-48/NN	prep_on||fed-29/VBN||diet-49/NN	conj_or||chow-34/NN||diet-49/NN	number||%-52/NN||15-51/CD	amod||lipids-53/NNS||%-52/NN	prep_with||diet-49/NN||lipids-53/NNS	vmod||lipids-53/NNS||replaced-54/VBN	amod||concentrate-58/NN||n-3-56/JJ	amod||concentrate-58/NN||lc-pufa-57/JJ	agent||replaced-54/VBN||concentrate-58/NN	nn||f-62/NNP||chf-60/NNP	nn||f-62/NNP||+-61/NNP	appos||concentrate-58/NN||f-62/NNP	chf-60||lipids-53||no_rel||mice with a whole-body deletion of the î±2 catalytic subunit of ampk (ampkî±2âˆ’/âˆ’) and their wild-type littermates were fed on either a low-fat chow, or a corn oil-based high-fat diet (chf), or a chf diet with 15% lipids replaced by n-3 lc-pufa concentrate (chf+f).
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	tumor-56||glucose-19||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
det||data-2/NNS||these-1/DT	nsubj||indicate-3/VBP||data-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||event-10/NN||that-4/IN	amod||stress-6/NN||oxidative-5/JJ	nsubj||event-10/NN||stress-6/NN	cop||event-10/NN||is-7/VBZ	det||event-10/NN||an-8/DT	amod||event-10/NN||early-9/JJ	ccomp||indicate-3/VBP||event-10/NN	det||evolution-13/NN||the-12/DT	prep_in||event-10/NN||evolution-13/NN	prep_of||evolution-13/NN||hyperlipidemia-15/NN	amod||support-19/NN||appropriate-18/JJ	nsubj||help-29/VB||support-19/NN	prepc_for||support-19/NN||enhancing-21/VBG	amod||supply-23/NN||antioxidant-22/JJ	dobj||enhancing-21/VBG||supply-23/NN	amod||subjects-27/NNS||higher-25/JJR	nn||subjects-27/NNS||lipid-26/NN	prep_in||enhancing-21/VBG||subjects-27/NNS	aux||help-29/VB||may-28/MD	conj_and||indicate-3/VBP||help-29/VB	xcomp||help-29/VB||prevent-30/VB	det||course-32/NN||the-31/DT	dobj||prevent-30/VB||course-32/NN	det||disease-35/NN||the-34/DT	prep_of||course-32/NN||disease-35/NN	hyperlipidemia-15||lipid-26||no_rel||these data indicate that oxidative stress is an early event in the evolution of hyperlipidemia, and appropriate support for enhancing antioxidant supply in higher lipid subjects may help prevent the course of the disease.
amod||index-4/NN||left-1/JJ	nn||index-4/NN||ventricular-2/NN	nn||index-4/NN||mass-3/NN	nsubj||decreased-219/VBD||index-4/NN	dep||index-4/NN||lvmi-6/NNS	num||â-9/NN||38.5-8/CD	dep||lvmi-6/NNS||â-9/NN	num||â-29/NN||$-10/$	number||â-12/CD||‰-11/CD	num||$-10/$||â-12/CD	amod||â-29/NN||±-13/JJ	amod||â-29/NN||â-14/JJ	amod||â-29/NN||$-15/$	number||10.7-17/CD||‰-16/CD	num||$-15/$||10.7-17/CD	nn||â-29/NN||vs-18/NN	nn||â-29/NN||35.2-19/NN	amod||â-29/NN||â-20/JJ	amod||â-29/NN||$-21/$	number||â-23/CD||‰-22/CD	num||$-21/$||â-23/CD	nn||â-29/NN||±-24/NN	nn||â-29/NN||â-25/NN	amod||â-29/NN||$-26/$	number||7.5-28/CD||‰-27/CD	num||$-26/$||7.5-28/CD	dep||â-9/NN||â-29/NN	amod||â-29/NN||g/m2-30/JJ	dep||g/m2-30/JJ||.7-31/CD	nn||â-34/NN||p-33/NN	appos||â-9/NN||â-34/NN	num||â-38/NN||$-35/$	number||=-37/CD||‰-36/CD	num||$-35/$||=-37/CD	dep||â-34/NN||â-38/NN	num||â-38/NN||$-39/$	number||0.0001-41/CD||‰-40/CD	num||$-39/$||0.0001-41/CD	appos||index-4/NN||prevalence-44/NN	prep_of||prevalence-44/NN||leftventricularhypertrophy-46/NN	num||%-49/NN||46.5-48/CD	dep||prevalence-44/NN||%-49/NN	number||31.4-51/CD||vs-50/CD	num||%-52/NN||31.4-51/CD	dep||%-49/NN||%-52/NN	nn||â-55/NN||p-54/NN	dep||%-52/NN||â-55/NN	num||â-59/NN||$-56/$	number||=-58/CD||‰-57/CD	num||$-56/$||=-58/CD	dep||â-55/NN||â-59/NN	num||â-59/NN||$-60/$	number||0.0001-62/CD||‰-61/CD	num||$-60/$||0.0001-62/CD	amod||thickness-67/NN||carotid-65/JJ	amod||thickness-67/NN||intima-media-66/JJ	appos||index-4/NN||thickness-67/NN	dep||thickness-67/NN||cimt-69/VB	num||â-72/NN||0.44-71/CD	nsubj||â-75/VBP||â-72/NN	dep||â-72/NN||$-73/$	num||$-73/$||‰-74/CD	dep||cimt-69/VB||â-75/VBP	amod||mm-93/NN||±-76/JJ	amod||mm-93/NN||â-77/JJ	amod||mm-93/NN||$-78/$	number||0.05-80/CD||‰-79/CD	num||$-78/$||0.05-80/CD	nn||mm-93/NN||vs-81/NN	num||mm-93/NN||0.42-82/CD	amod||mm-93/NN||â-83/JJ	amod||mm-93/NN||$-84/$	num||$-84/$||‰-85/CD	nn||mm-93/NN||â-86/NN	num||mm-93/NN||±-87/CD	amod||mm-93/NN||â-88/JJ	amod||mm-93/NN||$-89/$	number||0.04-91/CD||‰-90/CD	num||$-89/$||0.04-91/CD	nn||mm-93/NN||â-92/NN	dobj||â-75/VBP||mm-93/NN	advmod||â-100/VBP||p-95/RB	advmod||â-100/VBP||â-96/RB	nsubj||â-100/VBP||$-97/$	number||=-99/CD||‰-98/CD	num||$-97/$||=-99/CD	parataxis||â-75/VBP||â-100/VBP	dobj||â-100/VBP||$-101/$	number||0.0001-103/CD||‰-102/CD	num||$-101/$||0.0001-103/CD	nn||area-109/NN||wall-106/NN	amod||area-109/NN||cross-107/JJ	amod||area-109/NN||sectional-108/JJ	appos||index-4/NN||area-109/NN	dep||area-109/NN||wcsa-111/NN	num||â-114/NN||7.5-113/CD	dep||p-137/VB||â-114/NN	dep||â-119/JJ||$-115/$	number||â-117/CD||‰-116/CD	num||$-115/$||â-117/CD	advmod||â-119/JJ||±-118/RB	amod||â-114/NN||â-119/JJ	num||mm2-135/NNS||$-120/$	number||1.3-122/CD||‰-121/CD	num||$-120/$||1.3-122/CD	nn||mm2-135/NNS||vs-123/NNP	num||mm2-135/NNS||6.9-124/CD	amod||mm2-135/NNS||â-125/JJ	num||mm2-135/NNS||$-126/$	number||â-128/CD||‰-127/CD	num||$-126/$||â-128/CD	amod||mm2-135/NNS||±-129/JJ	amod||mm2-135/NNS||â-130/JJ	num||mm2-135/NNS||$-131/$	number||1.2-133/CD||‰-132/CD	num||$-131/$||1.2-133/CD	nn||mm2-135/NNS||â-134/NN	dep||p-137/VB||mm2-135/NNS	dep||wcsa-111/NN||p-137/VB	acomp||p-137/VB||â-138/JJ	num||â-142/NN||$-139/$	number||=-141/CD||‰-140/CD	num||$-139/$||=-141/CD	dep||â-138/JJ||â-142/NN	num||â-142/NN||$-143/$	number||0.002-145/CD||‰-144/CD	num||$-143/$||0.002-145/CD	appos||index-4/NN||hscrp-148/NN	num||â-151/NN||1.1-150/CD	dep||hscrp-148/NN||â-151/NN	num||vs-160/NN||$-152/$	number||â-154/CD||‰-153/CD	num||$-152/$||â-154/CD	nn||vs-160/NN||±-155/NN	nn||vs-160/NN||â-156/NN	amod||vs-160/NN||$-157/$	number||1.0-159/CD||‰-158/CD	num||$-157/$||1.0-159/CD	prep||â-151/NN||vs-160/NN	number||â-162/JJ||0.7-161/CD	amod||vs-160/NN||â-162/JJ	num||â-167/NNS||$-163/$	number||â-165/CD||‰-164/CD	num||$-163/$||â-165/CD	amod||â-167/NNS||±-166/JJ	dep||vs-160/NN||â-167/NNS	num||â-171/NN||$-168/$	number||0.7-170/CD||‰-169/CD	num||$-168/$||0.7-170/CD	npadvmod||mg/l-172/JJ||â-171/NN	amod||â-167/NNS||mg/l-172/JJ	vmod||â-167/NNS||p-174/VBN	acomp||p-174/VBN||â-175/JJ	num||â-179/NN||$-176/$	number||=-178/CD||‰-177/CD	num||$-176/$||=-178/CD	dep||â-175/JJ||â-179/NN	num||â-179/NN||$-180/$	number||0.002-182/CD||‰-181/CD	num||$-180/$||0.002-182/CD	conj_and||index-4/NN||ldl-cholesterol-186/NN	nsubj||decreased-219/VBD||ldl-cholesterol-186/NN	amod||â-210/NN||115â-188/JJ	dep||115â-188/JJ||$-189/$	number||â-191/CD||‰-190/CD	num||$-189/$||â-191/CD	amod||â-210/NN||±-192/JJ	amod||â-210/NN||â-193/JJ	amod||â-210/NN||$-194/$	number||33-196/CD||‰-195/CD	num||$-194/$||33-196/CD	amod||â-210/NN||vs-197/JJ	amod||â-210/NN||107â-198/JJ	amod||â-210/NN||$-199/$	number||â-201/CD||‰-200/CD	num||$-199/$||â-201/CD	amod||â-210/NN||±-202/JJ	amod||â-210/NN||â-203/JJ	amod||â-210/NN||$-204/$	number||26â-206/CD||‰-205/CD	num||$-204/$||26â-206/CD	amod||â-210/NN||mg/dl-207/JJ	dep||â-210/NN||p-209/NN	dep||ldl-cholesterol-186/NN||â-210/NN	dep||â-210/NN||$-211/$	number||=-213/CD||‰-212/CD	num||$-211/$||=-213/CD	vmod||$-211/$||â-214/VBN	dobj||â-214/VBN||$-215/$	number||0.001-217/CD||‰-216/CD	num||$-215/$||0.001-217/CD	root||ROOT-0/null||decreased-219/VBD	cholesterol--1||leftventricularhypertrophy-46||no_rel||left ventricular mass index (lvmi; 38.5â€‰â±â€‰10.7 vs 35.2â€‰â±â€‰7.5â g/m2.7, p â€‰=â€‰0.0001), prevalence of leftventricularhypertrophy (46.5% vs 31.4%; p â€‰=â€‰0.0001), carotid intima-media thickness (cimt; 0.44â€‰â±â€‰0.05 vs 0.42â€‰â±â€‰0.04â mm, p â€‰=â€‰0.0001), wall cross sectional area (wcsa; 7.5â€‰â±â€‰1.3 vs 6.9â€‰â±â€‰1.2â mm2, p â€‰=â€‰0.002), hscrp (1.1â€‰â±â€‰1.0 vs 0.7â€‰â±â€‰0.7â mg/l, p â€‰=â€‰0.002), and ldl-cholesterol (115â€‰â±â€‰33 vs 107â€‰â±â€‰26â mg/dl, p â€‰=â€‰0.001) decreased.
nsubj||emerged-3/VBN||lamotrigine-1/NN	aux||emerged-3/VBN||has-2/VBZ	root||ROOT-0/null||emerged-3/VBN	det||place-7/NN||a-5/DT	amod||place-7/NN||distinct-6/JJ	prep_with||emerged-3/VBN||place-7/NN	det||treatment-11/NN||the-9/DT	amod||treatment-11/NN||pharmacological-10/JJ	prep_in||emerged-3/VBN||treatment-11/NN	prep_of||treatment-11/NN||bipolardisorder-13/NN	det||potential-17/NN||the-16/DT	prep_with||emerged-3/VBN||potential-17/NN	aux||treat-19/VB||to-18/TO	vmod||potential-17/NN||treat-19/VB	vmod||potential-17/NN||prevent-21/VB	conj_and||treat-19/VB||prevent-21/VB	amod||depression-23/NN||bipolar-22/JJ	dobj||treat-19/VB||depression-23/NN	nsubj||dominant-28/JJ||depression-23/NN	cop||dominant-28/JJ||is-26/VBZ	det||dominant-28/JJ||the-27/DT	rcmod||depression-23/NN||dominant-28/JJ	rcmod||depression-23/NN||arguably-30/RB	advmod||dominant-28/JJ||arguably-30/RB	conj_and||dominant-28/JJ||arguably-30/RB	advmod||disabling-32/JJ||most-31/RBS	amod||phase-35/NN||disabling-32/JJ	conj_and||disabling-32/JJ||under-treated-34/JJ	amod||phase-35/NN||under-treated-34/JJ	dep||dominant-28/JJ||phase-35/NN	det||illness-38/NN||the-37/DT	prep_of||phase-35/NN||illness-38/NN	bipolardisorder-13||lamotrigine-1||yes||lamotrigine has emerged with a distinct place in the pharmacological treatment of bipolardisorder, with the potential to treat and prevent bipolar depression, which is the dominant and arguably most disabling and under-treated phase of the illness.
nsubjpass||performed-3/VBN||cmr-1/NN	auxpass||performed-3/VBN||was-2/VBD	root||ROOT-0/null||performed-3/VBN	num||patients-6/NNS||66-5/CD	prep_in||performed-3/VBN||patients-6/NNS	prep_with||patients-6/NNS||chf-8/NN	prep_due_to||performed-3/VBN||ischemiccardiomyopathy-11/NN	appos||ischemiccardiomyopathy-11/NN||icm-13/NN	amod||cardiomyopathy-18/NN||dilated-17/JJ	prep_due_to||performed-3/VBN||cardiomyopathy-18/NN	conj_or||ischemiccardiomyopathy-11/NN||cardiomyopathy-18/NN	appos||cardiomyopathy-18/NN||dcm-20/NN	number||healthy-24/JJ||32-23/CD	amod||controls-25/NNS||healthy-24/JJ	prep_due_to||performed-3/VBN||controls-25/NNS	conj_and||ischemiccardiomyopathy-11/NN||controls-25/NNS	dcm-20||ischemiccardiomyopathy-11||no_rel||cmr was performed in 66 patients with chf due to ischemiccardiomyopathy (icm), or dilated cardiomyopathy (dcm) and 32 healthy controls.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||efficacy-13/NN||urate-lowering-9/JJ	appos||efficacy-13/NN||ul-11/NN	dobj||compare-8/VB||efficacy-13/NN	dobj||compare-8/VB||safety-15/NN	conj_and||efficacy-13/NN||safety-15/NN	amod||febuxostat-18/NN||daily-17/JJ	prep_of||safety-15/NN||febuxostat-18/NN	amod||mg/dl-35/NNS||allopurinol-20/JJ	prep_in||allopurinol-20/JJ||subjects-22/NNS	prep_with||subjects-22/NNS||gout-24/NN	prep_with||subjects-22/NNS||serum-26/NN	conj_and||gout-24/NN||serum-26/NN	amod||mg/dl-35/NNS||urate-27/JJ	appos||mg/dl-35/NNS||sua-29/NN	nn||mg/dl-35/NNS||â-31/NN	nn||mg/dl-35/NNS||‰-32/NNP	nn||mg/dl-35/NNS||¥-33/NNP	num||mg/dl-35/NNS||8.0-34/CD	dobj||compare-8/VB||mg/dl-35/NNS	conj_and||efficacy-13/NN||mg/dl-35/NNS	det||trial-39/NN||a-37/DT	amod||trial-39/NN||six-month-38/JJ	prep_in||mg/dl-35/NNS||trial-39/NN	gout-24||allopurinol-20||yes||the purpose of this study was to compare urate-lowering (ul) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sua) â‰¥ 8.0 mg/dl in a six-month trial.
amod||proteolysis-6/NNS||tg2-1/JJ	conj_and||tg2-1/JJ||gastrointestinal-5/JJ	amod||proteolysis-6/NNS||gastrointestinal-5/JJ	nsubj||play-7/VBP||proteolysis-6/NNS	root||ROOT-0/null||play-7/VBP	amod||roles-9/NNS||important-8/JJ	dobj||play-7/VBP||roles-9/NNS	det||selection-12/NN||the-11/DT	prep_in||play-7/VBP||selection-12/NN	amod||epitopes-16/NNS||gluten-14/JJ	amod||epitopes-16/NNS||t-cell-15/JJ	prep_of||selection-12/NN||epitopes-16/NNS	prep_in||epitopes-16/NNS||celiacdisease-18/NN	celiacdisease-18||gluten-14||no||tg2 as well as gastrointestinal proteolysis play important roles in the selection of gluten t-cell epitopes in celiacdisease.
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	formaldehyde-14||cancer-21||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||analyse-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||analyse-8/VB||to-7/TO	xcomp||was-6/VBD||analyse-8/VB	dobj||analyse-8/VB||de-methylation-9/NN	dobj||analyse-8/VB||re-methylation-11/NN	conj_and||de-methylation-9/NN||re-methylation-11/NN	poss||affect-14/NN||its-13/PRP$	dobj||analyse-8/VB||affect-14/NN	conj_and||de-methylation-9/NN||affect-14/NN	nn||expression-17/NN||gene-16/NN	prep_on||analyse-8/VB||expression-17/NN	amod||lines-22/NNS||colorectal-19/JJ	nn||lines-22/NNS||cancer-20/NN	nn||lines-22/NNS||cell-21/NN	prep_in||expression-17/NN||lines-22/NNS	vmod||lines-22/NNS||treated-23/VBN	amod||combination-29/NN||5-aza-dc-25/JJ	advmod||combination-29/NN||alone-26/RB	conj_and||alone-26/RB||in-28/IN	advmod||combination-29/NN||in-28/IN	prep_with||treated-23/VBN||combination-29/NN	prep_with||combination-29/NN||tsa-31/NN	aza--1||cancer-20||no_rel||the aim of this study was to analyse de-methylation and re-methylation and its affect on gene expression in colorectal cancer cell lines treated with 5-aza-dc alone and in combination with tsa.
amod||glucose-3/NN||fasting-1/JJ	nn||glucose-3/NN||blood-2/NN	nn||levels-7/NNS||glucose-3/NN	appos||levels-7/NNS||fbg-5/NN	nsubjpass||correlated-11/VBN||levels-7/NNS	auxpass||correlated-11/VBN||were-8/VBD	advmod||moderately-10/RB||only-9/RB	advmod||correlated-11/VBN||moderately-10/RB	root||ROOT-0/null||correlated-11/VBN	prep_with||correlated-11/VBN||indexes-13/NNS	prep_of||indexes-13/NNS||hyperglycemia-15/NN	prep_of||indexes-13/NNS||average-17/NN	conj_and||hyperglycemia-15/NN||average-17/NN	amod||levels-21/NNS||postprandial-19/JJ	nn||levels-21/NNS||glucose-20/NN	prep_of||indexes-13/NNS||levels-21/NNS	conj_or||hyperglycemia-15/NN||levels-21/NNS	hyperglycemia-15||glucose-20||no||fasting blood glucose (fbg) levels were only moderately correlated with indexes of hyperglycemia and average or postprandial glucose levels.
advmod||found-11/VBN||furthermore-1/RB	nn||expression-4/NN||differential-3/NN	nsubjpass||found-11/VBN||expression-4/NN	prep_in||expression-4/NN||one-6/CD	det||dnmts-9/NNS||the-8/DT	prep_of||one-6/CD||dnmts-9/NNS	auxpass||found-11/VBN||was-10/VBD	root||ROOT-0/null||found-11/VBN	det||subset-14/NN||a-13/DT	prep_in||found-11/VBN||subset-14/NN	amod||patients-17/NNS||lupus-16/JJ	prep_of||subset-14/NN||patients-17/NNS	nn||therapy-23/NN||dehydroepiandrosterone-19/NNP	appos||therapy-23/NN||dhea-21/NNP	prep_on||found-11/VBN||therapy-23/NN	lupus-16||dehydroepiandrosterone-19||yes||furthermore, differential expression in one of the dnmts was found in a subset of lupus patients on dehydroepiandrosterone (dhea) therapy.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	cutaneousinflammation-30||pimecrolimus-7||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
prep_in||reduced-16/VBD||comparison-2/NN	amod||therapy-5/NN||aspirin-based-4/JJ	prep_with||comparison-2/NN||therapy-5/NN	amod||therapy-8/NN||triple-7/JJ	nsubj||reduced-16/VBD||therapy-8/NN	vmod||therapy-8/NN||using-9/VBG	det||inhibitor-14/NN||an-10/DT	amod||inhibitor-14/NN||intravenous-11/JJ	nn||inhibitor-14/NN||gp-12/NN	nn||inhibitor-14/NN||iib/iiia-13/NN	dobj||using-9/VBG||inhibitor-14/NN	advmod||using-9/VBG||significantly-15/RB	root||ROOT-0/null||reduced-16/VBD	amod||ves-18/NN||composite-17/JJ	dobj||reduced-16/VBD||ves-18/NN	dobj||reduced-16/VBD||mi-20/NN	conj_and||ves-18/NN||mi-20/NN	prep_in||reduced-16/VBD||patients-22/NNS	amod||syndromes-28/NNS||non-st-24/JJ	advmod||acute-26/JJ||elevation-25/RB	amod||syndromes-28/NNS||acute-26/JJ	amod||syndromes-28/NNS||coronary-27/JJ	prep_with||reduced-16/VBD||syndromes-28/NNS	appos||syndromes-28/NNS||nste-acs-30/NNS	dep||syndromes-28/NNS||ve-33/NN	dep||syndromes-28/NNS||0.69-35/CD	conj_or||ve-33/NN||0.69-35/CD	number||%-38/NN||95-37/CD	amod||ci-39/NN||%-38/NN	appos||ve-33/NN||ci-39/NN	num||.86-41/CD||0.55-0-40/CD	dep||ci-39/NN||.86-41/CD	dep||ci-39/NN||mi-43/NN	dep||ci-39/NN||0.70-45/CD	conj_or||mi-43/NN||0.70-45/CD	number||%-48/NN||95-47/CD	amod||ci-49/NN||%-48/NN	appos||ve-33/NN||ci-49/NN	num||.88-51/CD||0.56-0-50/CD	dep||ci-49/NN||.88-51/CD	nn||myocardialinfarction-56/NN||st-54/NN	nn||myocardialinfarction-56/NN||elevation-55/NN	prep_with||reduced-16/VBD||myocardialinfarction-56/NN	conj_and||syndromes-28/NNS||myocardialinfarction-56/NN	appos||myocardialinfarction-56/NN||stemi-58/NNP	dep||myocardialinfarction-56/NN||ve-61/NN	dep||myocardialinfarction-56/NN||0.39-63/CD	conj_or||ve-61/NN||0.39-63/CD	number||%-66/NN||95-65/CD	amod||ci-67/NN||%-66/NN	appos||ve-61/NN||ci-67/NN	number||.51-69/CD||0.30-0-68/CD	num||ci-67/NN||.51-69/CD	dep||ci-67/NN||mi-71/CD	dep||ci-67/NN||0.26-73/CD	conj_or||mi-71/CD||0.26-73/CD	number||%-76/NN||95-75/CD	amod||ci-77/NN||%-76/NN	appos||ve-61/NN||ci-77/NN	num||.38-79/CD||0.17-0-78/CD	dep||ci-77/NN||.38-79/CD	myocardialinfarction-56||aspirin--1||yes||in comparison with aspirin-based therapy, triple therapy using an intravenous gp iib/iiia inhibitor significantly reduced composite ves and mi in patients with non-st elevation acute coronary syndromes (nste-acs) (ve or 0.69, 95% ci 0.55-0.86; mi or 0.70, 95% ci 0.56-0.88) and st elevation myocardialinfarction (stemi) (ve or 0.39, 95% ci 0.30-0.51; mi or 0.26, 95% ci 0.17-0.38).
amod||mortality-4/NN||significant-2/JJ	amod||mortality-4/NN||aids-related-3/JJ	prep_despite||neglected-25/VBN||mortality-4/NN	conj_and||mortality-4/NN||morbidity-6/NN	prep_despite||neglected-25/VBN||morbidity-6/NN	det||area-9/NN||this-8/DT	prep_in||morbidity-6/NN||area-9/NN	det||commitment-15/NN||a-12/DT	amod||commitment-15/NN||national-13/JJ	nn||commitment-15/NN||level-14/NN	conj_and||mortality-4/NN||commitment-15/NN	prep_despite||neglected-25/VBN||commitment-15/NN	amod||care-19/NN||universal-17/JJ	nn||care-19/NN||hiv-18/NN	prep_to||commitment-15/NN||care-19/NN	nsubjpass||neglected-25/VBN||hiv-21/NN	aux||neglected-25/VBN||has-22/VBZ	auxpass||neglected-25/VBN||been-23/VBN	advmod||neglected-25/VBN||largely-24/RB	root||ROOT-0/null||neglected-25/VBN	aids--1||hiv-21||no||despite significant aids-related mortality and morbidity in this area, and a national level commitment to universal hiv care, hiv has been largely neglected.
amod||types-2/NNS||high-risk-1/JJ	nsubjpass||involved-6/VBN||types-2/NNS	prep_of||types-2/NNS||hpv-4/NN	auxpass||involved-6/VBN||are-5/VBP	root||ROOT-0/null||involved-6/VBN	det||development-9/NN||the-8/DT	prep_in||involved-6/VBN||development-9/NN	amod||dysplasia-13/NN||cervical-11/JJ	nn||dysplasia-13/NN||cell-12/NN	prep_of||development-9/NN||dysplasia-13/NN	mark||cause-19/VB||whereas-15/IN	amod||types-17/NNS||low-risk-16/JJ	nsubj||cause-19/VB||types-17/NNS	aux||cause-19/VB||may-18/MD	advcl||involved-6/VBN||cause-19/VB	amod||condyloma-21/NN||genital-20/JJ	dobj||cause-19/VB||condyloma-21/NN	condyloma-21||hpv-4||no||high-risk types of hpv are involved in the development of cervical cell dysplasia, whereas low-risk types may cause genital condyloma.
amod||symptoms-2/NNS||accompanying-1/VBG	nsubj||increased-18/VBD||symptoms-2/NNS	det||presence-5/NN||the-4/DT	prep_like||symptoms-2/NNS||presence-5/NN	nn||blood-11/NN||fever-7/NN	dep||blood-11/NN||pain-9/NN	prep_of||symptoms-2/NNS||blood-11/NN	det||stool-14/NN||the-13/DT	prep_in||symptoms-2/NNS||stool-14/NN	conj_and||symptoms-2/NNS||vomiting-16/VBG	nsubj||increased-18/VBD||vomiting-16/VBG	advmod||increased-18/VBD||significantly-17/RB	root||ROOT-0/null||increased-18/VBD	amod||prescribing-20/NN||antibiotic-19/JJ	dobj||increased-18/VBD||prescribing-20/NN	pain-9||antibiotic-19||no_rel||accompanying symptoms like the presence of fever, pain, blood in the stool and vomiting significantly increased antibiotic prescribing.
nn||expression-2/NN||gene-1/NN	nsubjpass||upregulated-16/VBN||expression-2/NN	prep_of||expression-2/NN||hepcidin-4/NN	amod||protein-1-9/NN||ferritin-h-6/JJ	amod||protein-1-9/NN||iron-regulatory-8/JJ	prep_of||expression-2/NN||protein-1-9/NN	conj_and||hepcidin-4/NN||protein-1-9/NN	amod||oxygenase-1-13/NN||heme-12/JJ	prep_of||expression-2/NN||oxygenase-1-13/NN	conj_and||hepcidin-4/NN||oxygenase-1-13/NN	auxpass||upregulated-16/VBN||was-14/VBD	advmod||upregulated-16/VBN||also-15/RB	root||ROOT-0/null||upregulated-16/VBN	mark||downregulated-31/VBN||whereas-18/IN	nsubjpass||downregulated-31/VBN||that-19/DT	prep_of||that-19/DT||hemojuvelin-21/NN	prep_of||that-19/DT||ferroportin-1-23/JJ	conj_and||hemojuvelin-21/NN||ferroportin-1-23/JJ	det||gene-28/NN||the-26/DT	amod||gene-28/NN||hemochromatosis-27/JJ	prep_of||that-19/DT||gene-28/NN	conj_and||hemojuvelin-21/NN||gene-28/NN	auxpass||downregulated-31/VBN||was-29/VBD	advmod||downregulated-31/VBN||significantly-30/RB	advcl||upregulated-16/VBN||downregulated-31/VBN	det||points-36/NNS||the-33/DT	amod||points-36/NNS||same-34/JJ	nn||points-36/NNS||time-35/NN	prep_at||downregulated-31/VBN||points-36/NNS	predet||brain-40/NN||both-38/PDT	det||brain-40/NN||the-39/DT	prep_in||points-36/NNS||brain-40/NN	det||liver-43/NN||the-42/DT	prep_in||points-36/NNS||liver-43/NN	conj_and||brain-40/NN||liver-43/NN	det||level-47/NN||the-45/DT	nn||level-47/NN||rna-46/NN	prep_at||downregulated-31/VBN||level-47/NN	hemochromatosis-27||iron--1||no||gene expression of hepcidin, ferritin-h, iron-regulatory protein-1, and heme oxygenase-1 was also upregulated, whereas that of hemojuvelin, ferroportin-1, and the hemochromatosis gene was significantly downregulated at the same time points in both the brain and the liver at the rna level.
nn||aspergillosis-4/NNS||aspergilloma-1/NN	conj_and||aspergilloma-1/NN||invasive-3/NN	nn||aspergillosis-4/NNS||invasive-3/NN	nsubj||entity-20/NN||aspergillosis-4/NNS	vmod||aspergillosis-4/NNS||coexisting-5/VBG	amod||resistant-8/JJ||multidrug-7/JJ	amod||mycobacteriumtuberculosis-9/NNS||resistant-8/JJ	prep_with||coexisting-5/VBG||mycobacteriumtuberculosis-9/NNS	appos||mycobacteriumtuberculosis-9/NNS||mdr-tb-11/NNP	det||patient-16/NN||the-14/DT	amod||patient-16/NN||same-15/JJ	prep_in||coexisting-5/VBG||patient-16/NN	cop||entity-20/NN||is-17/VBZ	det||entity-20/NN||a-18/DT	amod||entity-20/NN||rare-19/JJ	root||ROOT-0/null||entity-20/NN	tb--1||mycobacteriumtuberculosis-9||no||aspergilloma and invasive aspergillosis coexisting with multidrug resistant mycobacteriumtuberculosis (mdr-tb) in the same patient is a rare entity.
poss||model-5/NN||our-2/PRP$	amod||model-5/NN||experimental-3/JJ	nn||model-5/NN||vili-4/NN	prep_in||attenuated-11/VBD||model-5/NN	det||acidosis-8/NNS||both-6/DT	amod||acidosis-8/NNS||metabolic-7/JJ	nsubj||attenuated-11/VBD||acidosis-8/NNS	conj_and||acidosis-8/NNS||hypercapnicacidosis-10/NNS	nsubj||attenuated-11/VBD||hypercapnicacidosis-10/NNS	root||ROOT-0/null||attenuated-11/VBD	amod||edema-14/NN||vili-induced-12/JJ	amod||edema-14/NN||pulmonary-13/JJ	dobj||attenuated-11/VBD||edema-14/NN	xcomp||attenuated-11/VBD||implying-15/VBG	det||mechanism-17/NN||a-16/DT	dobj||implying-15/VBG||mechanism-17/NN	dep||mechanism-17/NN||other-18/JJ	amod||effects-22/NNS||possible-20/JJ	amod||effects-22/NNS||synergistic-21/JJ	prep_than||mechanism-17/NN||effects-22/NNS	prep_of||effects-22/NNS||acidosis-24/NNS	prep_with||implying-15/VBG||co2-26/NNS	amod||attenuation-29/NN||vili-28/JJ	prep_for||co2-26/NNS||attenuation-29/NN	hypercapnicacidosis-10||co2-26||no||in our experimental vili model both metabolic acidosis and hypercapnicacidosis attenuated vili-induced pulmonary edema implying a mechanism other than possible synergistic effects of acidosis with co2 for vili attenuation.
det||study-3/NN||this-2/DT	prep_in||combined-6/VBD||study-3/NN	nsubj||combined-6/VBD||we-5/PRP	root||ROOT-0/null||combined-6/VBD	acomp||combined-6/VBD||gm-csf-7/JJ	nn||±-10/NNP||ifn-î-9/NNP	prep_with||gm-csf-7/JJ||±-10/NNP	mark||improve-14/VB||in-11/IN	dep||improve-14/VB||order-12/NN	aux||improve-14/VB||to-13/TO	advcl||combined-6/VBD||improve-14/VB	nn||tolerance-16/NN||ifn-15/NN	dobj||improve-14/VB||tolerance-16/NN	amod||patients-20/NNS||post-asct-18/JJ	nn||patients-20/NNS||myeloma-19/NN	prep_in||improve-14/VB||patients-20/NNS	myeloma-19||ifn-15||yes||in this study, we combined gm-csf with ifn-î± in order to improve ifn tolerance in post-asct myeloma patients.
det||result-2/NN||the-1/DT	nsubj||showed-3/VBD||result-2/NN	root||ROOT-0/null||showed-3/VBD	mark||weaker-9/JJR||that-4/IN	det||pressure-7/NN||the-5/DT	nn||pressure-7/NN||selection-6/NN	nsubj||weaker-9/JJR||pressure-7/NN	cop||weaker-9/JJR||was-8/VBD	ccomp||showed-3/VBD||weaker-9/JJR	prep||weaker-9/JJR||in-10/IN	det||2000s-12/NN||the-11/DT	npadvmod||than-13/IN||2000s-12/NN	pcomp||in-10/IN||than-13/IN	det||1980s-16/NNS||the-15/DT	prep_in||weaker-9/JJR||1980s-16/NNS	xcomp||weaker-9/JJR||indicating-18/VBG	mark||become-23/VBN||that-19/IN	nsubj||become-23/VBN||it-20/PRP	aux||become-23/VBN||might-21/MD	aux||become-23/VBN||have-22/VB	ccomp||indicating-18/VBG||become-23/VBN	dep||become-23/VBN||easier-24/RBR	det||hiv-27/NN||the-26/DT	prep_for||become-23/VBN||hiv-27/NN	aux||infect-29/VB||to-28/TO	dep||hiv-27/NN||infect-29/VB	det||host-32/NN||a-30/DT	amod||host-32/NN||new-31/JJ	dobj||infect-29/VB||host-32/NN	aux||develop-35/VB||to-34/TO	dep||hiv-27/NN||develop-35/VB	conj_and||infect-29/VB||develop-35/VB	prep_into||develop-35/VB||aids-37/NNS	advmod||develop-35/VB||now-38/RB	prep||now-38/RB||than-39/IN	num||years-41/NNS||20-40/CD	npadvmod||ago-42/RB||years-41/NNS	pcomp||than-39/IN||ago-42/RB	mark||becoming-49/VBG||that-44/IN	det||hiv-46/NN||the-45/DT	nsubj||becoming-49/VBG||hiv-46/NN	aux||becoming-49/VBG||may-47/MD	aux||becoming-49/VBG||be-48/VB	ccomp||indicating-18/VBG||becoming-49/VBG	conj_and||become-23/VBN||becoming-49/VBG	amod||virulent-51/NN||more-50/JJR	xcomp||becoming-49/VBG||virulent-51/NN	det||population-55/NN||the-53/DT	amod||population-55/NN||japanese-54/JJ	prep_in||becoming-49/VBG||population-55/NN	aids-37||hiv-46||no||the result showed that the selection pressure was weaker in the 2000s than in the 1980s, indicating that it might have become easier for the hiv to infect a new host and to develop into aids now than 20 years ago and that the hiv may be becoming more virulent in the japanese population.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	enterotoxin-26||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||incidence-2/NN||the-1/DT	nsubjpass||kept-17/VBN||incidence-2/NN	advmod||severe-5/JJ||potentially-4/RB	amod||consequences-8/NNS||severe-5/JJ	conj_and||severe-5/JJ||lethal-7/JJ	amod||consequences-8/NNS||lethal-7/JJ	conj_and||incidence-2/NN||consequences-8/NNS	nsubjpass||kept-17/VBN||consequences-8/NNS	amod||necrolysis-14/NNS||allopurinolhypersensitivitysyndrome-10/JJ	conj_and||allopurinolhypersensitivitysyndrome-10/JJ||toxic-12/JJ	amod||necrolysis-14/NNS||toxic-12/JJ	nn||necrolysis-14/NNS||epidermal-13/NN	prep_of||consequences-8/NNS||necrolysis-14/NNS	aux||kept-17/VBN||could-15/MD	auxpass||kept-17/VBN||be-16/VB	root||ROOT-0/null||kept-17/VBN	det||minimum-20/NN||a-19/DT	prep_to||kept-17/VBN||minimum-20/NN	advmod||adhering-23/VBG||strictly-22/RB	agent||kept-17/VBN||adhering-23/VBG	det||indications-27/NNS||the-25/DT	amod||indications-27/NNS||established-26/VBN	prep_to||adhering-23/VBG||indications-27/NNS	amod||treatment-30/NN||allopurinol-29/JJ	prep_of||indications-27/NNS||treatment-30/NN	allopurinolhypersensitivitysyndrome-10||allopurinol-29||no||the incidence and potentially severe and lethal consequences of allopurinolhypersensitivitysyndrome and toxic epidermal necrolysis could be kept to a minimum by strictly adhering to the established indications of allopurinol treatment.
det||results-2/NNS||these-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||offers-6/VBZ||that-4/IN	nsubj||offers-6/VBZ||ea-5/NN	ccomp||indicated-3/VBD||offers-6/VBZ	det||effect-9/NN||a-7/DT	amod||effect-9/NN||beneficial-8/JJ	dobj||offers-6/VBZ||effect-9/NN	prep_on||offers-6/VBZ||insulinresistance-11/NN	amod||mice-17/NNS||obese-13/JJ	conj_and||obese-13/JJ||diabetic-15/JJ	amod||mice-17/NNS||diabetic-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||insulinresistance-11/NN||mice-17/NNS	dep||mice-17/NNS||at-19/IN	pobj||at-19/IN||least-20/JJS	dep||at-19/IN||partly-21/RB	prep_via||insulinresistance-11/NN||stimulation-24/NN	amod||±-29/NNS||sirt1/pgc-26/JJ	amod||±-29/NNS||-1-27/JJ	nn||±-29/NNS||î-28/NN	prep_of||stimulation-24/NN||±-29/NNS	advmod||resulting-32/VBG||thus-31/RB	vmod||offers-6/VBZ||resulting-32/VBG	amod||signal-36/NN||improved-34/VBN	nn||signal-36/NN||insulin-35/NN	prep_in||resulting-32/VBG||signal-36/NN	insulin-35||insulinresistance-11||no_rel||these results indicated that ea offers a beneficial effect on insulinresistance in obese and diabetic db/db mice, at least partly, via stimulation of sirt1/pgc-1 î± , thus resulting in improved insulin signal.
amod||quotient-14/NN||white-1/JJ	nn||quotient-14/NN||blood-2/NN	nn||quotient-14/NN||cell-3/NN	nn||quotient-14/NN||count-4/NN	dep||quotient-14/NN||csf/serum-6/NN	nn||quotient-14/NN||glucose-7/NN	nn||quotient-14/NN||ratio-8/NN	dep||quotient-14/NN||protein-10/NN	dep||quotient-14/NN||csf/serum-12/NN	nn||quotient-14/NN||albumin-13/NN	nsubjpass||analyzed-25/VBN||quotient-14/NN	nn||indices-17/NNS||immunoglobulin-16/NN	conj_and||quotient-14/NN||indices-17/NNS	nsubjpass||analyzed-25/VBN||indices-17/NNS	prep_for||quotient-14/NN||igg-19/NN	prep_for||quotient-14/NN||iga-21/NN	conj_and||igg-19/NN||iga-21/NN	prep_for||quotient-14/NN||igm-23/NN	conj_and||igg-19/NN||igm-23/NN	auxpass||analyzed-25/VBN||were-24/VBD	root||ROOT-0/null||analyzed-25/VBN	num||patients-28/NNS||90-27/CD	prep_in||analyzed-25/VBN||patients-28/NNS	prep_with||patients-28/NNS||bacterialmeningitis-30/NNS	num||patients-33/NNS||117-32/CD	prep_in||analyzed-25/VBN||patients-33/NNS	conj_and||patients-28/NNS||patients-33/NNS	prep_with||patients-33/NNS||viralmeningoencephalitis-35/NNS	num||patients-38/NNS||36-37/CD	prep_in||analyzed-25/VBN||patients-38/NNS	conj_and||patients-28/NNS||patients-38/NNS	prep_with||patients-38/NNS||leptomeningealmetastases-40/NNS	det||total-43/NN||a-42/DT	prep_in||leptomeningealmetastases-40/NNS||total-43/NN	num||samples-47/NNS||480-45/CD	nn||samples-47/NNS||csf-46/NN	prep_of||total-43/NN||samples-47/NNS	leptomeningealmetastases-40||glucose-7||no_rel||white blood cell count, csf/serum glucose ratio, protein, csf/serum albumin quotient and immunoglobulin indices for igg, iga and igm were analyzed in 90 patients with bacterialmeningitis, 117 patients with viralmeningoencephalitis and 36 patients with leptomeningealmetastases in a total of 480 csf samples.
det||article-2/NN||this-1/DT	nsubj||focuses-3/VBZ||article-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||determination-6/NN||the-5/DT	prep_on||focuses-3/VBZ||determination-6/NN	nn||species-9/NNS||arsenic-8/NN	prep_of||determination-6/NN||species-9/NNS	nn||samples-12/NNS||saliva-11/NN	prep_in||species-9/NNS||samples-12/NNS	nn||patients-15/NNS||apl-14/NN	prep_from||focuses-3/VBZ||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	nn||treatment-18/NN||arsenic-17/NN	dobj||undergoing-16/VBG||treatment-18/NN	arsenic-17||apl-14||no_rel||this article focuses on the determination of arsenic species in saliva samples from apl patients undergoing arsenic treatment.
nsubj||component-8/NN||rifampicin-1/NN	appos||rifampicin-1/NN||rif-3/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||a-6/DT	amod||component-8/NN||major-7/JJ	root||ROOT-0/null||component-8/NN	amod||therapy-13/NN||fixed-10/VBN	nn||therapy-13/NN||dose-11/NN	nn||therapy-13/NN||combination-12/NN	prep_in||component-8/NN||therapy-13/NN	det||treatment-16/NN||the-15/DT	prep_for||therapy-13/NN||treatment-16/NN	prep_of||treatment-16/NN||tuberculosis-18/NNP	tuberculosis-18||rif-3||yes||rifampicin (rif) is a major component in fixed dose combination therapy for the treatment of tuberculosis.
nsubj||appears-6/VBZ||alogliptin-1/NN	nsubj||option-13/NN||alogliptin-1/NN	prep||alogliptin-1/NN||plus-2/CC	amod||treatment-5/NN||pioglitazone-3/JJ	nn||treatment-5/NN||combination-4/NN	pobj||plus-2/CC||treatment-5/NN	root||ROOT-0/null||appears-6/VBZ	aux||option-13/NN||to-7/TO	cop||option-13/NN||be-8/VB	det||option-13/NN||an-9/DT	amod||option-13/NN||efficacious-10/JJ	amod||option-13/NN||initial-11/JJ	amod||option-13/NN||therapeutic-12/JJ	xcomp||appears-6/VBZ||option-13/NN	prep_for||option-13/NN||type2diabetes-15/CD	type2diabetes-15||pioglitazone-3||yes||alogliptin plus pioglitazone combination treatment appears to be an efficacious initial therapeutic option for type2diabetes.
amod||levels-4/NNS||mean-1/JJ	amod||levels-4/NNS||serum-2/JJ	amod||levels-4/NNS||timp-1-3/JJ	nsubj||ng/ml-10/JJ||levels-4/NNS	nsubj||ng/ml-19/JJ||levels-4/NNS	nsubj||ng/ml-28/JJ||levels-4/NNS	cop||ng/ml-10/JJ||were-5/VBD	number||â-7/CD||414.9-6/CD	num||17.6-9/CD||â-7/CD	number||17.6-9/CD||±-8/CD	npadvmod||ng/ml-10/JJ||17.6-9/CD	root||ROOT-0/null||ng/ml-10/JJ	nn||patients-13/NNS||uc-12/NN	prep_in||ng/ml-10/JJ||patients-13/NNS	number||â-16/CD||446.1-15/CD	num||22.8-18/CD||â-16/CD	number||22.8-18/CD||±-17/CD	npadvmod||ng/ml-19/JJ||22.8-18/CD	conj_and||ng/ml-10/JJ||ng/ml-19/JJ	nn||patients-22/NNS||cd-21/NN	prep_in||ng/ml-19/JJ||patients-22/NNS	number||â-25/CD||296.5-24/CD	num||20.6-27/CD||â-25/CD	number||20.6-27/CD||±-26/CD	npadvmod||ng/ml-28/JJ||20.6-27/CD	conj_and||ng/ml-10/JJ||ng/ml-28/JJ	prep_in||ng/ml-10/JJ||hc-30/NN	uc-12||hc-30||yes||mean serum timp-1 levels were 414.9 â± 17.6 ng/ml in uc patients, 446.1 â± 22.8 ng/ml in cd patients and 296.5 â± 20.6 ng/ml in hc.
aux||investigate-2/VB||to-1/TO	advcl||studied-22/VBD||investigate-2/VB	mark||factor-14/NN||whether-3/IN	amod||density-7/NN||increased-4/VBN	amod||density-7/NN||lymphatic-5/JJ	nn||density-7/NN||vessel-6/NN	nsubj||factor-14/NN||density-7/NN	appos||density-7/NN||lvd-9/NN	cop||factor-14/NN||is-11/VBZ	det||factor-14/NN||a-12/DT	amod||factor-14/NN||prognostic-13/JJ	ccomp||investigate-2/VB||factor-14/NN	amod||metastasis-17/NNS||nodal-16/JJ	prep_for||factor-14/NN||metastasis-17/NNS	prep_for||factor-14/NN||survival-19/NN	conj_and||metastasis-17/NNS||survival-19/NN	nsubj||studied-22/VBD||we-21/PRP	root||ROOT-0/null||studied-22/VBD	amod||lvd-24/NN||peritumoral-23/JJ	dobj||studied-22/VBD||lvd-24/NN	dep||lvd-24/NN||p-lvd-26/JJ	amod||lvd-30/NN||intratumoral-29/JJ	dobj||studied-22/VBD||lvd-30/NN	conj_and||lvd-24/NN||lvd-30/NN	dep||lvd-30/NN||i-lvd-32/JJ	prep_in||lvd-24/NN||samples-35/NNS	num||patients-38/NNS||102-37/CD	prep_from||samples-35/NNS||patients-38/NNS	amod||carcinoma-41/NN||endometrial-40/JJ	prep_with||patients-38/NNS||carcinoma-41/NN	amod||tissues-45/NNS||endometrial-43/JJ	nn||tissues-45/NNS||carcinoma-44/NN	nsubjpass||analyzed-47/VBN||tissues-45/NNS	auxpass||analyzed-47/VBN||were-46/VBD	dobj||studied-22/VBD||analyzed-47/VBN	conj_and||lvd-24/NN||analyzed-47/VBN	amod||vessels-50/NNS||lymphatic-49/JJ	prep_for||analyzed-47/VBN||vessels-50/NNS	amod||staining-53/NN||immunohistochemical-52/JJ	agent||analyzed-47/VBN||staining-53/NN	det||antibody-56/NN||an-55/DT	prep_with||analyzed-47/VBN||antibody-56/NN	prep_against||antibody-56/NN||lyve-1-58/CD	i---1||metastasis-17||no_rel||to investigate whether increased lymphatic vessel density (lvd) is a prognostic factor for nodal metastasis and survival, we studied peritumoral lvd (p-lvd) and intratumoral lvd (i-lvd) in samples from 102 patients with endometrial carcinoma; endometrial carcinoma tissues were analyzed for lymphatic vessels by immunohistochemical staining with an antibody against lyve-1.
aux||characterize-3/VB||to-1/TO	advmod||characterize-3/VB||better-2/RBR	dep||tested-14/VBD||characterize-3/VB	dobj||characterize-3/VB||mutations-4/NNS	amod||oncogenes-8/NNP||established-6/VBN	amod||oncogenes-8/NNP||known-7/VBN	prep_in||mutations-4/NNS||oncogenes-8/NNP	nn||genes-12/NNS||tumor-10/NN	nn||genes-12/NNS||suppressor-11/NN	prep_in||mutations-4/NNS||genes-12/NNS	conj_and||oncogenes-8/NNP||genes-12/NNS	nsubj||tested-14/VBD||we-13/PRP	root||ROOT-0/null||tested-14/VBD	det||spectrometric-17/NN||a-15/DT	amod||spectrometric-17/NN||mass-16/JJ	dobj||tested-14/VBD||spectrometric-17/NN	vmod||spectrometric-17/NN||based-18/VBN	dobj||based-18/VBN||platform-19/NN	aux||interrogate-21/VB||to-20/TO	vmod||based-18/VBN||interrogate-21/VB	amod||cancer-23/NN||common-22/JJ	dobj||interrogate-21/VB||cancer-23/NN	vmod||cancer-23/NN||associated-24/VBN	dobj||associated-24/VBN||mutations-25/NNS	det||panel-28/NN||a-27/DT	prep_across||associated-24/VBN||panel-28/NN	num||paraffin-33/NNS||77-30/CD	nn||paraffin-33/NNS||formalin-31/NN	amod||paraffin-33/NNS||fixed-32/VBN	prep_of||panel-28/NN||paraffin-33/NNS	vmod||paraffin-33/NNS||embedded-34/VBN	amod||cases-37/NNS||archived-35/JJ	nn||cases-37/NNS||btc-36/NN	dobj||embedded-34/VBN||cases-37/NNS	cancer-23||paraffin-33||no_rel||to better characterize mutations in established known oncogenes and tumor suppressor genes we tested a mass spectrometric based platform to interrogate common cancer associated mutations across a panel of 77 formalin fixed paraffin embedded archived btc cases.
nsubj||different-12/JJ||tg-1/NN	nsubj||different-12/JJ||tg-1/NN	appos||tg-1/NN||hdl-c-3/JJ	appos||tg-1/NN||ffa-5/NN	conj_and||hdl-c-3/JJ||ffa-5/NN	appos||tg-1/NN||fibrinogen-7/NN	conj_and||hdl-c-3/JJ||fibrinogen-7/NN	appos||tg-1/NN||isi-9/NN	conj_and||hdl-c-3/JJ||isi-9/NN	cop||different-12/JJ||were-10/VBD	advmod||different-12/JJ||significantly-11/RB	root||ROOT-0/null||different-12/JJ	conj_and||different-12/JJ||different-12/JJ	prep_between||different-12/JJ||patients-14/NNS	amod||obesity-19/NN||abdominal-18/JJ	prep_with||different-12/JJ||obesity-19/NN	prep_without||different-12/JJ||obesity-19/NN	obesity-19||tg-1||no_rel||tg, hdl-c, ffa, fibrinogen and isi were significantly different between patients with and without abdominal obesity.
nsubjpass||defined-7/VBN||diabeticretinopathy-1/NN	appos||diabeticretinopathy-1/NN||dr-3/NN	auxpass||defined-7/VBN||is-5/VBZ	advmod||defined-7/VBN||classically-6/RB	root||ROOT-0/null||defined-7/VBN	det||microvasculopathy-10/NN||a-9/DT	prep_as||defined-7/VBN||microvasculopathy-10/NN	nsubj||affects-13/VBZ||microvasculopathy-10/NN	advmod||affects-13/VBZ||primarily-12/RB	rcmod||microvasculopathy-10/NN||affects-13/VBZ	det||vessels-17/NNS||the-14/DT	amod||vessels-17/NNS||small-15/JJ	nn||vessels-17/NNS||blood-16/NN	dobj||affects-13/VBZ||vessels-17/NNS	det||retina-21/NN||the-19/DT	amod||retina-21/NN||inner-20/JJ	prep_of||vessels-17/NNS||retina-21/NN	det||complication-24/NN||a-23/DT	prep_as||affects-13/VBZ||complication-24/NN	prep_of||complication-24/NN||diabetesmellitus-26/NNS	appos||diabetesmellitus-26/NNS||dm-28/NN	dr-3||diabetesmellitus-26||no||diabeticretinopathy (dr) is classically defined as a microvasculopathy that primarily affects the small blood vessels of the inner retina as a complication of diabetesmellitus (dm).
nsubj||carried-2/VBD||we-1/PRP	nsubj||confirmed-17/VBD||we-1/PRP	root||ROOT-0/null||carried-2/VBD	prt||carried-2/VBD||out-3/RP	det||review-6/NN||a-4/DT	amod||review-6/NN||systematic-5/JJ	dobj||carried-2/VBD||review-6/NN	amod||studies-11/NNS||observational-8/JJ	conj_and||observational-8/JJ||experimental-10/JJ	amod||studies-11/NNS||experimental-10/JJ	prep_of||review-6/NN||studies-11/NNS	prep_of||review-6/NN||people-13/NNS	prep_with||people-13/NNS||suspected-15/NNP	conj_or||carried-2/VBD||confirmed-17/VBD	dobj||confirmed-17/VBD||crimean-congohemorrhagicfever-18/NN	nsubj||included-20/VBD||crimean-congohemorrhagicfever-18/NN	rcmod||crimean-congohemorrhagicfever-18/NN||included-20/VBD	dobj||included-20/VBD||comparisons-21/NNS	prep_between||comparisons-21/NNS||patients-23/NNS	vmod||patients-23/NNS||given-24/VBN	dobj||given-24/VBN||ribavirin-25/NNP	det||not-28/RB||those-27/DT	dobj||given-24/VBN||not-28/RB	conj_and||ribavirin-25/NNP||not-28/RB	ribavirin-25||crimean-congohemorrhagicfever-18||no_rel||we carried out a systematic review of observational and experimental studies of people with suspected or confirmed crimean-congohemorrhagicfever that included comparisons between patients given ribavirin and those not.
amod||hyperglycemia-2/NN||transient-1/JJ	nsubj||occurred-19/VBD||hyperglycemia-2/NN	number||â-5/CD||170-4/CD	num||35.9-7/CD||â-5/CD	number||35.9-7/CD||±-6/CD	npadvmod||mg/dl-8/JJ||35.9-7/CD	dep||hyperglycemia-2/NN||mg/dl-8/JJ	conj_and||hyperglycemia-2/NN||hypokalemia-11/NN	nsubj||occurred-19/VBD||hypokalemia-11/NN	num||±-15/NN||3.67-13/CD	nn||±-15/NN||â-14/NN	dep||mmol/l-17/JJ||±-15/NN	number||mmol/l-17/JJ||0.92-16/CD	dep||hypokalemia-11/NN||mmol/l-17/JJ	root||ROOT-0/null||occurred-19/VBD	det||period-24/NN||the-21/DT	amod||period-24/NN||immediate-22/JJ	nn||period-24/NN||postoperative-23/NN	prep_in||occurred-19/VBD||period-24/NN	det||group-28/NN||the-26/DT	nn||group-28/NN||glucose-27/NN	prep_in||occurred-19/VBD||group-28/NN	hyperglycemia-2||glucose-27||no||transient hyperglycemia (170 â± 35.9 mg/dl) and hypokalemia (3.67 â± 0.92 mmol/l) occurred in the immediate postoperative period in the glucose group.
nsubj||are-6/VBP||women-1/NNS	prep_with||women-1/NNS||hiv/aids-3/NNS	prep_in||hiv/aids-3/NNS||particular-5/NN	dep||receive-18/VBP||are-6/VBP	advmod||are-6/VBP||therefore-7/RB	det||position-11/NN||a-9/DT	amod||position-11/NN||disadvantaged-10/JJ	prep_in||are-6/VBP||position-11/NN	prep_with||position-11/NN||regard-13/NN	det||care-16/NN||the-15/DT	prep_to||are-6/VBP||care-16/NN	nsubj||receive-18/VBP||they-17/PRP	root||ROOT-0/null||receive-18/VBP	aids--1||hiv--1||no||women with hiv/aids in particular are therefore in a disadvantaged position with regard to the care they receive.
amod||proteinase-3/NN||sarscoronavirus-1/JJ	amod||proteinase-3/NN||main-2/JJ	nsubj||enzyme-11/NN||proteinase-3/NN	amod||covmpro-6/NN||sars-5/JJ	appos||proteinase-3/NN||covmpro-6/NN	cop||enzyme-11/NN||is-8/VBZ	det||enzyme-11/NN||an-9/DT	amod||enzyme-11/NN||important-10/JJ	root||ROOT-0/null||enzyme-11/NN	det||replication-14/NN||the-13/DT	prep_for||enzyme-11/NN||replication-14/NN	amod||virus-17/NN||severeacuterespiratorysyndrome-16/JJ	prep_of||replication-14/NN||virus-17/NN	sars-5||sarscoronavirus-1||no||sarscoronavirus main proteinase (sars covmpro) is an important enzyme for the replication of severeacuterespiratorysyndrome virus.
det||expression-2/NN||the-1/DT	nsubjpass||analyzed-25/VBN||expression-2/NN	nn||receptor-5/NN||estrogen-4/NN	prep_of||expression-2/NN||receptor-5/NN	appos||receptor-5/NN||er-7/NN	amod||pr-13/NN||progesterone-10/JJ	nn||pr-13/NN||receptor-11/NN	prep_of||expression-2/NN||pr-13/NN	conj_and||receptor-5/NN||pr-13/NN	prep_of||expression-2/NN||her2-16/NNS	conj_and||receptor-5/NN||her2-16/NNS	prep_of||expression-2/NN||her4-18/NNS	conj_and||receptor-5/NN||her4-18/NNS	nn||m-22/NN||cystatin-21/NN	prep_of||expression-2/NN||m-22/NN	conj_and||receptor-5/NN||m-22/NN	auxpass||analyzed-25/VBN||was-23/VBD	advmod||analyzed-25/VBN||retrospectively-24/RB	root||ROOT-0/null||analyzed-25/VBN	xcomp||analyzed-25/VBN||using-26/VBG	advmod||using-26/VBG||immunohistochemistry-27/RB	num||patients-30/NNS||117-29/CD	prep_in||using-26/VBG||patients-30/NNS	amod||carcinoma-33/NN||ductal-32/JJ	prep_with||patients-30/NNS||carcinoma-33/NN	prep_in||carcinoma-33/NN||situ-35/NN	appos||situ-35/NN||dcis-37/NNS	num||patients-42/NNS||175-41/CD	prep_in||using-26/VBG||patients-42/NNS	conj_and||patients-30/NNS||patients-42/NNS	amod||cancer-46/NN||invasive-44/JJ	nn||cancer-46/NN||breast-45/NN	prep_with||patients-42/NNS||cancer-46/NN	appos||cancer-46/NN||ibc-48/NN	carcinoma-33||progesterone-10||no_rel||the expression of estrogen receptor (er), progesterone receptor (pr), her2, her4, and cystatin m was retrospectively analyzed using immunohistochemistry in 117 patients with ductal carcinoma in situ (dcis) and in 175 patients with invasive breast cancer (ibc).
det||survey-2/NN||the-1/DT	nsubj||indicated-3/VBD||survey-2/NN	root||ROOT-0/null||indicated-3/VBD	mark||exhibited-34/VBD||that-4/IN	mark||matches-11/VBZ||while-5/IN	nn||behavior-10/NN||jilin-6/NN	nn||behavior-10/NN||province-7/NNP	nn||behavior-10/NN||money-8/NN	nn||behavior-10/NN||boy-9/NN	nsubj||matches-11/VBZ||behavior-10/NN	advcl||exhibited-34/VBD||matches-11/VBZ	amod||studies-13/NNS||other-12/JJ	dobj||matches-11/VBZ||studies-13/NNS	prep_concerning||studies-13/NNS||propensity-15/NN	amod||behavior-19/NN||high-17/JJ	nn||behavior-19/NN||risk-18/NN	prep_to||propensity-15/NN||behavior-19/NN	amod||potential-23/NN||significant-21/JJ	nn||potential-23/NN||bridging-22/NN	prep_to||propensity-15/NN||potential-23/NN	conj_and||behavior-19/NN||potential-23/NN	det||boys-28/NNS||the-25/DT	amod||boys-28/NNS||jilin-26/JJ	nn||boys-28/NNS||money-27/NN	appos||behavior-19/NN||boys-28/NNS	amod||studies-32/NNS||previous-31/JJ	prep_unlike||exhibited-34/VBD||studies-32/NNS	ccomp||indicated-3/VBD||exhibited-34/VBD	det||level-37/NN||a-35/DT	amod||level-37/NN||high-36/JJ	dobj||exhibited-34/VBD||level-37/NN	amod||knowledge-42/NN||basic-39/JJ	nn||knowledge-42/NN||hiv/aids-40/NN	nn||knowledge-42/NN||transmission-41/NN	prep_of||level-37/NN||knowledge-42/NN	aids--1||hiv--1||no||the survey indicated that while jilin province money boy behavior matches other studies concerning propensity to high risk behavior and significant bridging potential, the jilin money boys, unlike previous studies, exhibited a high level of basic hiv/aids transmission knowledge.
nsubj||represent-8/VB||patients-1/NNS	nn||metabolismdisorders-6/NNS||ir-3/NN	conj_and||ir-3/NN||glucose-5/NN	nn||metabolismdisorders-6/NNS||glucose-5/NN	prep_with||patients-1/NNS||metabolismdisorders-6/NNS	aux||represent-8/VB||might-7/MD	root||ROOT-0/null||represent-8/VB	det||population-11/NN||a-9/DT	nn||population-11/NN||target-10/NN	dobj||represent-8/VB||population-11/NN	aux||prevent-13/VB||to-12/TO	vmod||represent-8/VB||prevent-13/VB	det||development-15/NN||the-14/DT	dobj||prevent-13/VB||development-15/NN	prep_of||development-15/NN||hf-17/NN	metabolismdisorders-6||glucose-5||no_rel||patients with ir and glucose metabolismdisorders might represent a target population to prevent the development of hf.
amod||expression-3/NN||lower-1/JJR	amod||expression-3/NN||tlr8-2/JJ	nsubj||have-14/VB||expression-3/NN	vmod||expression-3/NN||observed-4/VBN	prep_in||observed-4/VBN||monocytes-6/NNS	det||rsvinfection-11/NN||an-9/DT	amod||rsvinfection-11/NN||acute-10/JJ	prep_during||have-14/VB||rsvinfection-11/NN	aux||have-14/VB||might-13/MD	root||ROOT-0/null||have-14/VB	det||impact-17/NN||a-15/DT	amod||impact-17/NN||dampening-16/VBG	nsubj||necessary-23/JJ||impact-17/NN	nsubj||control-25/VB||impact-17/NN	nsubj||initiate-31/VB||impact-17/NN	amod||production-22/NN||early-19/JJ	amod||production-22/NN||anti-viral-20/JJ	nn||production-22/NN||cytokine-21/NN	prep_on||impact-17/NN||production-22/NN	xcomp||have-14/VB||necessary-23/JJ	aux||control-25/VB||to-24/TO	xcomp||necessary-23/JJ||control-25/VB	nn||replication-27/NN||rsv-26/NN	dobj||control-25/VB||replication-27/NN	advmod||initiate-31/VB||subsequently-30/RB	xcomp||necessary-23/JJ||initiate-31/VB	conj_and||control-25/VB||initiate-31/VB	det||type-35/NN||an-32/DT	amod||type-35/NN||adaptive-33/JJ	amod||type-35/NN||th1-34/JJ	dobj||initiate-31/VB||type-35/NN	amod||response-37/NN||immune-36/JJ	dobj||control-25/VB||response-37/NN	amod||response-37/NN||leading-38/VBG	amod||disease-41/NN||severe-40/JJ	prep_to||response-37/NN||disease-41/NN	amod||infants-44/NNS||infected-43/JJ	prep_in||response-37/NN||infants-44/NNS	rsvinfection-11||rsv-26||no||lower tlr8 expression observed in monocytes, during an acute rsvinfection, might have a dampening impact on early anti-viral cytokine production necessary to control rsv replication, and subsequently initiate an adaptive th1 type immune response leading to severe disease in infected infants.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||safety-4/NN||the-3/DT	dobj||investigated-2/VBD||safety-4/NN	dobj||investigated-2/VBD||efficacy-6/NN	conj_and||safety-4/NN||efficacy-6/NN	prep_of||safety-4/NN||azithromycin-8/NN	prep_of||safety-4/NN||artesunate-10/NN	conj_or||azithromycin-8/NN||artesunate-10/NN	prep||investigated-2/VBD||combined-11/VBN	pcomp||combined-11/VBN||with-12/IN	pobj||with-12/IN||sulfadoxine-pyrimethamine-13/NN	vmod||sulfadoxine-pyrimethamine-13/NN||used-14/VBN	prep_for||used-14/VBN||treatment-16/NN	prep_of||treatment-16/NN||malaria-18/NN	amod||women-21/NNS||pregnant-20/JJ	prep_in||used-14/VBN||women-21/NNS	prep_in||women-21/NNS||blantyre-23/NN	appos||blantyre-23/NN||malawi-25/NNS	malaria-18||pyrimethamine--1||no||we investigated the safety and efficacy of azithromycin or artesunate combined with sulfadoxine-pyrimethamine used for treatment of malaria in pregnant women in blantyre, malawi.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||activities-6/NNS||the-4/DT	amod||activities-6/NNS||antibacterial-5/JJ	dobj||examined-3/VBD||activities-6/NNS	det||containing-10/NN||a-8/DT	nn||containing-10/NN||triclosan-9/NN	prep_of||activities-6/NNS||containing-10/NN	appos||containing-10/NN||seal-12/NNP	appos||containing-10/NN||protect-14/NNP	conj_and||seal-12/NNP||protect-14/NNP	det||desensitizer-20/NN||a-17/DT	nn||desensitizer-20/NN||benzalconium-18/NN	nn||desensitizer-20/NN||containing-19/NN	appos||containing-10/NN||desensitizer-20/NN	amod||prime-23/NN||micro-22/JJ	appos||desensitizer-20/NN||prime-23/NN	det||fluoride-27/NN||a-26/DT	appos||containing-10/NN||fluoride-27/NN	vmod||fluoride-27/NN||containing-28/VBG	advmod||paste-30/JJ||prophilaxy-29/RB	acomp||containing-28/VBG||paste-30/JJ	nn||desensitizer-33/NN||sultan-32/NN	appos||fluoride-27/NN||desensitizer-33/NN	num||fluoride-37/NN||two-36/CD	appos||containing-10/NN||fluoride-37/NN	dep||fluoride-37/NN||containing-38/VBG	dobj||containing-38/VBG||varnishes-39/NNS	amod||shealth-42/NN||cavity-41/JJ	dep||fluoride-37/NN||shealth-42/NN	nn||ez-45/NN||ultra-44/NN	dep||fluoride-37/NN||ez-45/NN	conj_and||shealth-42/NN||ez-45/NN	det||primer-52/NN||a-49/DT	amod||primer-52/NN||dentin-50/JJ	nn||primer-52/NN||bonding-51/NN	prep_of||activities-6/NNS||primer-52/NN	conj_and||containing-10/NN||primer-52/NN	det||bond-55/NN||all-54/DT	appos||primer-52/NN||bond-55/NN	cavity-41||fluoride-37||yes||this study examined the antibacterial activities of a triclosan containing (seal & protect), a benzalconium containing desensitizer (micro prime), a fluoride containing prophilaxy paste (sultan desensitizer), two fluoride containing varnishes (cavity shealth and ultra ez), and a dentin bonding primer (all bond).
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||a-3/DT	dobj||present-2/VBP||case-4/NN	nsubj||developed-10/VBD||case-4/NN	nn||meningitis-8/NNS||candida-6/NN	nn||meningitis-8/NNS||dubliniensis-7/NNS	prep_of||case-4/NN||meningitis-8/NNS	rcmod||case-4/NN||developed-10/VBD	num||months-12/NNS||2-11/CD	tmod||developed-10/VBD||months-12/NNS	advmod||successful-15/JJ||apparently-14/RB	amod||treatment-16/NN||successful-15/JJ	prep_after||developed-10/VBD||treatment-16/NN	det||episode-19/NN||an-18/DT	prep_of||treatment-16/NN||episode-19/NN	nn||candidemia-23/NN||c.-21/NN	nn||candidemia-23/NN||dubliniensis-22/NNS	prep_of||episode-19/NN||candidemia-23/NN	det||recipient-28/NN||a-25/DT	amod||recipient-28/NN||heart-lung-26/JJ	nn||recipient-28/NN||transplant-27/NN	prep_in||developed-10/VBD||recipient-28/NN	prep_in||recipient-28/NN||australia-30/NN	candidemia-23||candida-6||no||we present a case of candida dubliniensis meningitis that developed 2 months after apparently successful treatment of an episode of c. dubliniensis candidemia in a heart-lung transplant recipient in australia .
det||glucose-4/NN||the-1/DT	amod||glucose-4/NN||postprandial-2/JJ	nn||glucose-4/NN||blood-3/NN	nsubj||was-10/VBD||glucose-4/NN	vmod||glucose-4/NN||lowering-5/VBG	dobj||lowering-5/VBG||effect-6/NN	nn||extracts-9/NNS||omija-8/NN	prep_of||effect-6/NN||extracts-9/NNS	root||ROOT-0/null||was-10/VBD	prepc_compared_to||was-10/VBD||to-12/TO	det||drug-16/NN||a-13/DT	amod||drug-16/NN||known-14/VBN	amod||drug-16/NN||type2diabetes-15/JJ	pobj||was-10/VBD||drug-16/NN	appos||drug-16/NN||acarbose-18/NN	det||±-24/NN||a-21/DT	amod||±-24/NN||strong-22/JJ	nn||±-24/NN||î-23/NN	appos||drug-16/NN||±-24/NN	amod||inhibitor-27/NN||glucosidase-26/JJ	dep||drug-16/NN||inhibitor-27/NN	det||model-35/NN||the-29/DT	amod||model-35/NN||sprague-dawley-30/JJ	appos||model-35/NN||sd-32/NN	amod||model-35/NN||rat-34/JJ	prep_in||inhibitor-27/NN||model-35/NN	type2diabetes-15||acarbose-18||yes||the postprandial blood glucose lowering effect of omija extracts was compared to a known type2diabetes drug (acarbose), a strong î±-glucosidase inhibitor in the sprague-dawley (sd) rat model.
nsubjpass||elevated-8/VBN||levels-1/NNS	nn||trypsin-4/NN||serum-3/NN	prep_of||levels-1/NNS||trypsin-4/NN	prep_of||levels-1/NNS||psti-6/NN	conj_and||trypsin-4/NN||psti-6/NN	auxpass||elevated-8/VBN||were-7/VBD	root||ROOT-0/null||elevated-8/VBN	det||weeks-12/NNS||the-10/DT	num||weeks-12/NNS||2-11/CD	prep_during||elevated-8/VBN||weeks-12/NNS	prep_after||elevated-8/VBN||administration-14/NN	prep_of||administration-14/NN||asnase-16/NN	nsubj||suggested-19/VBD||asnase-16/NN	rcmod||asnase-16/NN||suggested-19/VBD	det||presence-21/NN||the-20/DT	dobj||suggested-19/VBD||presence-21/NN	amod||pancreatitis-24/NNS||subclinical-23/JJ	prep_of||presence-21/NN||pancreatitis-24/NNS	pancreatitis-24||asnase-16||no||levels of serum trypsin and psti were elevated during the 2 weeks after administration of asnase, which suggested the presence of subclinical pancreatitis.
nsubj||microorganisms-2/VBZ||eleven-1/NNS	root||ROOT-0/null||microorganisms-2/VBZ	acomp||microorganisms-2/VBZ||responsible-3/JJ	mark||tested-8/VBN||for-4/IN	amod||infections-6/NNS||nosocomial-5/JJ	nsubjpass||tested-8/VBN||infections-6/NNS	auxpass||tested-8/VBN||were-7/VBD	advcl||microorganisms-2/VBZ||tested-8/VBN	num||staphylococcusaureus-10/NNS||two-9/CD	dobj||tested-8/VBN||staphylococcusaureus-10/NNS	dep||staphylococcusaureus-10/NNS||strains-11/NNS	det||strain-18/NN||the-13/DT	amod||strain-18/NN||hetero-vancomycin-14/JJ	amod||strain-18/NN||intermediate-15/JJ	nn||strain-18/NN||mrsa-16/NN	amod||strain-18/NN||mu50-17/JJ	dep||strains-11/NNS||strain-18/NN	det||strain-23/NN||a-20/DT	amod||strain-23/NN||st80-pvl-producing-21/JJ	nn||strain-23/NN||mrsa-22/NN	dep||strains-11/NNS||strain-23/NN	conj_and||strain-18/NN||strain-23/NN	det||van-28/NN||a-26/DT	amod||van-28/NN||vancomycin-resistant-27/JJ	dobj||tested-8/VBN||van-28/NN	conj_and||staphylococcusaureus-10/NNS||van-28/NN	det||strain-32/NN||a-29/DT	amod||strain-32/NN||enterococcus-30/JJ	nn||strain-32/NN||faecium-31/NN	dep||van-28/NN||strain-32/NN	num||strains-38/NNS||three-34/CD	amod||strains-38/NNS||extended-spectrum-35/JJ	amod||strains-38/NNS||beta-lactamase-producing-36/JJ	nn||strains-38/NNS||enterobacteriaceae-37/NN	dobj||tested-8/VBN||strains-38/NNS	conj_and||staphylococcusaureus-10/NNS||strains-38/NNS	det||strain-44/NN||a-40/DT	amod||strain-44/NN||mbl-producing-41/JJ	nn||strain-44/NN||pseudomonas-42/NNS	nn||strain-44/NN||aeruginosa-43/NN	dep||strains-38/NNS||strain-44/NN	det||acinetobacter-48/NN||a-46/DT	amod||acinetobacter-48/NN||multidrug-resistant-47/JJ	dobj||tested-8/VBN||acinetobacter-48/NN	conj_and||staphylococcusaureus-10/NNS||acinetobacter-48/NN	amod||strain-50/NN||baumannii-49/JJ	dep||acinetobacter-48/NN||strain-50/NN	det||clostridium-54/NN||a-52/DT	amod||clostridium-54/NN||toxin-producing-53/JJ	dobj||tested-8/VBN||clostridium-54/NN	conj_and||staphylococcusaureus-10/NNS||clostridium-54/NN	amod||strain-56/NN||difficile-55/JJ	dep||clostridium-54/NN||strain-56/NN	num||fungi-60/NNS||two-59/CD	dobj||tested-8/VBN||fungi-60/NNS	conj_and||staphylococcusaureus-10/NNS||fungi-60/NNS	nn||albicans-63/NNS||candida-62/NN	dep||staphylococcusaureus-10/NNS||albicans-63/NNS	amod||fumigatus-66/NNS||aspergillus-65/JJ	dep||staphylococcusaureus-10/NNS||fumigatus-66/NNS	conj_and||albicans-63/NNS||fumigatus-66/NNS	mrsa-22||staphylococcusaureus-10||no||eleven microorganisms responsible for nosocomial infections were tested two staphylococcusaureus strains (the hetero-vancomycin intermediate mrsa mu50 strain and a st80-pvl-producing mrsa strain); a vancomycin-resistant van a enterococcus faecium strain; three extended-spectrum beta-lactamase-producing enterobacteriaceae strains; a mbl-producing pseudomonas aeruginosa strain; a multidrug-resistant acinetobacter baumannii strain; a toxin-producing clostridium difficile strain; and two fungi ( candida albicans and aspergillus fumigatus ).
det||drawbacks-3/NNS||these-2/DT	prep_despite||appears-6/VBZ||drawbacks-3/NNS	nsubj||appears-6/VBZ||posaconazole-5/NN	root||ROOT-0/null||appears-6/VBZ	acomp||appears-6/VBZ||poised-7/VBN	aux||become-9/VB||to-8/TO	xcomp||poised-7/VBN||become-9/VB	det||modality-13/NN||a-10/DT	amod||modality-13/NN||prominent-11/JJ	amod||modality-13/NN||therapeutic-12/JJ	xcomp||become-9/VB||modality-13/NN	det||prophylaxis-16/NN||the-15/DT	prep_for||modality-13/NN||prophylaxis-16/NN	prep_for||modality-13/NN||management-18/NN	conj_and||prophylaxis-16/NN||management-18/NN	amod||fungalinfections-21/NNS||various-20/JJ	prep_of||prophylaxis-16/NN||fungalinfections-21/NNS	amod||patients-24/NNS||high-risk-23/JJ	prep_among||become-9/VB||patients-24/NNS	fungalinfections-21||posaconazole-5||yes||despite these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for the prophylaxis and management of various fungalinfections among high-risk patients.
amod||analysis-3/NN||phylogenetic-2/JJ	nsubj||showed-4/VBD||analysis-3/NN	root||ROOT-0/null||showed-4/VBD	mark||was-12/VBD||that-5/IN	det||hbv-7/NN||the-6/DT	nsubj||was-12/VBD||hbv-7/NN	det||donors-11/NNS||all-9/DT	num||donors-11/NNS||five-10/CD	prep_in||hbv-7/NN||donors-11/NNS	ccomp||showed-4/VBD||was-12/VBD	advmod||was-12/VBD||genotype-13/RB	dep||was-12/VBD||b-14/SYM	det||deletion-19/NN||a-16/DT	amod||deletion-19/NN||single-17/JJ	nn||deletion-19/NN||base-18/NN	nsubjpass||detected-21/VBN||deletion-19/NN	auxpass||detected-21/VBN||was-20/VBD	ccomp||showed-4/VBD||detected-21/VBN	conj_and||was-12/VBD||detected-21/VBN	det||region-25/NN||the-23/DT	amod||region-25/NN||s-24/JJ	prep_in||detected-21/VBN||region-25/NN	nn||dna-28/NN||hbv-27/NN	prep_of||region-25/NN||dna-28/NN	num||donor-31/NN||one-30/CD	prep_from||detected-21/VBN||donor-31/NN	neg||mutation-35/NN||no-34/DT	nsubjpass||observed-37/VBN||mutation-35/NN	auxpass||observed-37/VBN||was-36/VBD	ccomp||showed-4/VBD||observed-37/VBN	conj_and||was-12/VBD||observed-37/VBN	prep_in||observed-37/VBN||the-39/NN	dep||the-39/NN||a-42/SYM	dep||observed-37/VBN||determinant-45/JJ	prepc_of||determinant-45/JJ||hbsag-47/VBG	num||donors-51/NNS||four-49/CD	amod||donors-51/NNS||other-50/JJ	prep_from||hbsag-47/VBG||donors-51/NNS	hbv-27||hbsag-47||yes||" phylogenetic analysis showed that the hbv in all five donors was genotype b; a single base deletion was detected in the s region of hbv dna from one donor, and no mutation was observed in the ""a"" determinant of hbsag from four other donors."
nn||viruses-2/NNS||dna-1/NN	nsubj||vulnerable-17/JJ||viruses-2/NNS	conj_and||viruses-2/NNS||retroviruses-4/NNS	nsubj||vulnerable-17/JJ||retroviruses-4/NNS	conj_and||viruses-2/NNS||hepadnaviruses-6/NNS	nsubj||vulnerable-17/JJ||hepadnaviruses-6/NNS	amod||virus-11/NN||hepatitisb-10/JJ	prep_such_as||viruses-2/NNS||virus-11/NN	appos||virus-11/NN||hbv-13/NN	cop||vulnerable-17/JJ||are-16/VBP	root||ROOT-0/null||vulnerable-17/JJ	amod||editing-20/NN||genetic-19/JJ	prep_to||vulnerable-17/JJ||editing-20/NN	amod||dna-24/NN||single-22/JJ	amod||dna-24/NN||stranded-23/JJ	prep_of||editing-20/NN||dna-24/NN	nn||apobec3-28/NNS||host-26/NN	nn||apobec3-28/NNS||cell-27/NN	prep_by||vulnerable-17/JJ||apobec3-28/NNS	appos||apobec3-28/NNS||a3-30/NNP	amod||deaminases-33/JJ||cytidine-32/JJ	amod||apobec3-28/NNS||deaminases-33/JJ	hbv-13||viruses-2||no||dna viruses, retroviruses and hepadnaviruses, such as hepatitisb virus (hbv), are vulnerable to genetic editing of single stranded dna by host cell apobec3 (a3) cytidine deaminases.
nsubj||strategy-16/NN||inhibition-1/NN	nsubj||led-19/VBN||inhibition-1/NN	det||system-5/NN||the-3/DT	amod||system-5/NN||ubiquitin-proteasome-4/JJ	prep_of||inhibition-1/NN||system-5/NN	appos||system-5/NN||ups-7/NNS	nn||degradation-11/NN||protein-10/NN	prep_of||system-5/NN||degradation-11/NN	cop||strategy-16/NN||is-12/VBZ	det||strategy-16/NN||a-13/DT	amod||strategy-16/NN||valid-14/JJ	amod||strategy-16/NN||anti-cancer-15/JJ	root||ROOT-0/null||strategy-16/NN	aux||led-19/VBN||has-18/VBZ	conj_and||strategy-16/NN||led-19/VBN	det||approval-22/NN||the-21/DT	prep_to||led-19/VBN||approval-22/NN	prep_of||approval-22/NN||bortezomib-24/NN	det||treatment-27/NN||the-26/DT	prep_for||led-19/VBN||treatment-27/NN	prep_of||treatment-27/NN||multiplemyeloma-29/NN	multiplemyeloma-29||bortezomib-24||yes||inhibition of the ubiquitin-proteasome system (ups) of protein degradation is a valid anti-cancer strategy and has led to the approval of bortezomib for the treatment of multiplemyeloma.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	ulcerativecolitis-10||cd-21||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
det||reaction-8/NN||a-1/DT	amod||reaction-8/NN||duplex-2/JJ	amod||reaction-8/NN||real-time-3/JJ	amod||reaction-8/NN||reverse-4/JJ	amod||reaction-8/NN||transcriptase-5/JJ	nn||reaction-8/NN||polymerase-6/NN	nn||reaction-8/NN||chain-7/NN	nsubjpass||improved-14/VBN||reaction-8/NN	appos||reaction-8/NN||rt-pcr-10/NN	advmod||improved-14/VBN||assay-12/RB	auxpass||improved-14/VBN||was-13/VBD	root||ROOT-0/null||improved-14/VBN	amod||detection-17/NN||simultaneous-16/JJ	prep_for||improved-14/VBN||detection-17/NN	advmod||pathogenic-20/JJ||highly-19/RB	amod||influenzavirus-29/NNS||pathogenic-20/JJ	amod||influenzavirus-29/NNS||h5n1-21/JJ	amod||influenzavirus-29/NNS||avianinfluenzavirus-22/JJ	conj_and||avianinfluenzavirus-22/JJ||pandemic-24/JJ	amod||influenzavirus-29/NNS||pandemic-24/JJ	nn||influenzavirus-29/NNS||h1n1-25/NN	appos||influenzavirus-29/NNS||2009-27/CD	prep_of||detection-17/NN||influenzavirus-29/NNS	nsubj||suitable-33/JJ||influenzavirus-29/NNS	cop||suitable-33/JJ||is-32/VBZ	rcmod||influenzavirus-29/NNS||suitable-33/JJ	amod||diagnosis-36/NN||early-35/JJ	prep_for||suitable-33/JJ||diagnosis-36/NN	amod||patients-39/NNS||influenza-like-38/JJ	prep_of||diagnosis-36/NN||patients-39/NNS	amod||surveillance-43/NN||epidemiological-42/JJ	prep_for||suitable-33/JJ||surveillance-43/NN	conj_and||diagnosis-36/NN||surveillance-43/NN	h5n1-21||influenzavirus-29||no||a duplex real-time reverse transcriptase polymerase chain reaction (rt-pcr) assay was improved for simultaneous detection of highly pathogenic h5n1 avianinfluenzavirus and pandemic h1n1 (2009) influenzavirus, which is suitable for early diagnosis of influenza-like patients and for epidemiological surveillance.
advmod||faced-5/VBN||internally-1/RB	amod||persons-3/NNS||displaced-2/JJ	nsubjpass||faced-5/VBN||persons-3/NNS	nsubj||deserve-16/VBP||persons-3/NNS	auxpass||faced-5/VBN||are-4/VBP	root||ROOT-0/null||faced-5/VBN	amod||problems-8/NNS||several-7/JJ	prep_with||faced-5/VBN||problems-8/NNS	amod||violence-13/NN||sexual-12/JJ	prep_such_as||problems-8/NNS||violence-13/NN	conj_and||faced-5/VBN||deserve-16/VBP	amod||intervention-18/NN||appropriate-17/JJ	dobj||deserve-16/VBP||intervention-18/NN	advmod||faced-5/VBN||especially-20/RB	prep_in||faced-5/VBN||view-22/NN	det||prevalence-26/NN||the-24/DT	amod||prevalence-26/NN||increasing-25/VBG	prep_of||view-22/NN||prevalence-26/NN	prep_of||prevalence-26/NN||hiv/aids-28/NNS	amod||infections-31/NNS||other-30/JJ	prep_of||prevalence-26/NN||infections-31/NNS	conj_and||hiv/aids-28/NNS||infections-31/NNS	prep_in||infections-31/NNS||nigeria-33/NN	aids--1||hiv--1||no||internally displaced persons are faced with several problems, such as sexual violence, and deserve appropriate intervention, especially in view of the increasing prevalence of hiv/aids and other infections in nigeria.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-34/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-24/VBZ||levels-10/NNS	amod||fattyacids-13/NNS||n-3-12/JJ	prep_of||levels-10/NNS||fattyacids-13/NNS	appos||fattyacids-13/NNS||fa-15/NN	possessive||fa-15/NN||'s-16/POS	amod||levels-20/NNS||higher-19/JJR	prep_of||levels-10/NNS||levels-20/NNS	conj_and||fattyacids-13/NNS||levels-20/NNS	amod||fa-23/NN||n-6-22/JJ	prep_of||levels-20/NNS||fa-23/NN	ccomp||contained-8/VBD||'s-24/VBZ	det||diet-28/NN||the-26/DT	nn||diet-28/NN||control-27/NN	prep_than||'s-24/VBZ||diet-28/NN	appos||diet-28/NN||ctr-30/NN	nsubj||found-34/VBD||we-33/PRP	root||ROOT-0/null||found-34/VBD	amod||decreases-36/NNS||significant-35/JJ	nsubj||'s-47/VBZ||decreases-36/NNS	amod||acid-39/NN||docosahexaenoic-38/JJ	prep_in||decreases-36/NNS||acid-39/NN	appos||acid-39/NN||dha-41/NN	amod||fa-46/NN||total-44/JJ	amod||fa-46/NN||n-3-45/JJ	prep_in||decreases-36/NNS||fa-46/NN	conj_and||acid-39/NN||fa-46/NN	ccomp||found-34/VBD||'s-47/VBZ	nn||maternal-50/NN||hfd-49/NN	prep_in||'s-47/VBZ||maternal-50/NN	amod||plasma-53/NN||fetal-52/JJ	prep_in||'s-47/VBZ||plasma-53/NN	conj_and||maternal-50/NN||plasma-53/NN	dha-41||fa-46||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3 fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	dobj||examined-2/VBD||correlates-3/NNS	amod||rna-7/NN||genital-5/JJ	amod||rna-7/NN||hiv-1-6/JJ	prep_of||correlates-3/NNS||rna-7/NN	prep_in||rna-7/NN||women-9/NNS	nsubj||seropositive-12/JJ||who-10/WP	cop||seropositive-12/JJ||were-11/VBD	dep||examined-2/VBD||seropositive-12/JJ	det||-rrb--20/NNP||both-14/DT	amod||-rrb--20/NNP||herpes-15/JJ	nn||-rrb--20/NNP||simplex-16/NN	nn||-rrb--20/NNP||virus-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||hsv-19/NNP	prep_for||seropositive-12/JJ||-rrb--20/NNP	dep||seropositive-12/JJ||-2-21/CD	dep||seropositive-12/JJ||hiv-1-23/CD	conj_and||-2-21/CD||hiv-1-23/CD	dep||enrolled-27/VBN||who-25/WP	auxpass||enrolled-27/VBN||were-26/VBD	dep||examined-2/VBD||enrolled-27/VBN	conj_and||seropositive-12/JJ||enrolled-27/VBN	det||trial-32/NN||a-29/DT	amod||trial-32/NN||randomised-30/JJ	amod||trial-32/NN||controlled-31/JJ	prep_in||enrolled-27/VBN||trial-32/NN	nn||therapy-36/NN||hsv-34/NN	nn||therapy-36/NN||suppressive-35/NN	prep_of||trial-32/NN||therapy-36/NN	num||aciclovir-38/NN||-lrb--37/CD	nsubjpass||enrolled-27/VBN||aciclovir-38/NN	num||-rrb--44/NN||400-39/CD	amod||-rrb--44/NN||mg-40/JJ	amod||-rrb--44/NN||b.i.d-41/JJ	nn||-rrb--44/NN||vs.-42/FW	nn||-rrb--44/NN||placebo-43/FW	dep||enrolled-27/VBN||-rrb--44/NN	prep_in||enrolled-27/VBN||tanzania-46/NN	hsv-34||aciclovir-38||yes||we examined correlates of genital hiv-1 rna in women who were seropositive for both herpes simplex virus -lrb- hsv -rrb- -2 and hiv-1 and who were enrolled in a randomised controlled trial of hsv suppressive therapy -lrb- aciclovir 400 mg b.i.d vs. placebo -rrb- in tanzania .
det||combination-2/NN||the-1/DT	nsubj||effective-8/JJ||combination-2/NN	prep_of||combination-2/NN||remifentanil-4/NN	prep_of||combination-2/NN||lidocaine-6/NN	conj_and||remifentanil-4/NN||lidocaine-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	prepc_in||effective-8/JJ||alleviating-10/VBG	dobj||alleviating-10/VBG||pain-11/NN	vmod||pain-11/NN||associated-12/VBN	det||injection-17/NN||a-14/DT	amod||injection-17/NN||microemulsion-15/JJ	amod||injection-17/NN||propofol-16/JJ	prep_with||associated-12/VBN||injection-17/NN	prepc_compared_with||associated-12/VBN||with-19/IN	advmod||lidocaine-21/NN||just-20/RB	pobj||associated-12/VBN||lidocaine-21/NN	pain-11||lidocaine-21||yes||the combination of remifentanil and lidocaine is effective in alleviating pain associated with a microemulsion propofol injection compared with just lidocaine.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-16/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-16/VBN||irondeficiency-9/RB	amod||anemia-12/NN||irondeficiency-11/JJ	nsubjpass||evaluated-16/VBN||anemia-12/NN	conj_and||anemia-12/NN||anemia-14/NN	nsubjpass||evaluated-16/VBN||anemia-14/NN	auxpass||evaluated-16/VBN||were-15/VBD	root||ROOT-0/null||evaluated-16/VBN	prep_among||evaluated-16/VBN||them-18/PRP	irondeficiency-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiency anemia and anemia were evaluated among them.
det||matrices-3/NNS||these-1/DT	amod||matrices-3/NNS||synthetic-2/JJ	nsubjpass||validated-6/VBN||matrices-3/NNS	auxpass||validated-6/VBN||are-4/VBP	advmod||validated-6/VBN||then-5/RB	root||ROOT-0/null||validated-6/VBN	prep||validated-6/VBN||against-7/IN	pobj||against-7/IN||recently-8/RB	vmod||recently-8/RB||collected-9/VBN	amod||data-12/NNS||italian-10/JJ	amod||data-12/NNS||serological-11/JJ	dobj||collected-9/VBN||data-12/NNS	prep_for||data-12/NNS||varicella-14/NN	appos||varicella-14/NN||vzv-16/NN	prep_for||data-12/NNS||parvovirus-19/NNS	conj_and||varicella-14/NN||parvovirus-19/NNS	appos||varicella-14/NN||b19-21/NNP	varicella-14||vzv-16||no||these synthetic matrices are then validated against recently collected italian serological data for varicella (vzv) and parvovirus (b19).
det||protein-3/NN||the-1/DT	amod||protein-3/NN||x-2/JJ	nsubjpass||involved-13/VBN||protein-3/NN	appos||protein-3/NN||hbx-5/NN	prep_of||protein-3/NN||hepatitisbvirus-8/NNS	appos||hepatitisbvirus-8/NNS||hbv-10/NN	auxpass||involved-13/VBN||is-12/VBZ	root||ROOT-0/null||involved-13/VBN	det||development-16/NN||the-15/DT	prep_in||involved-13/VBN||development-16/NN	nn||carcinoma-19/NN||hepatocellular-18/NN	prep_of||development-16/NN||carcinoma-19/NN	appos||carcinoma-19/NN||hcc-21/NN	amod||2a-27/NNS||methionine-25/JJ	nn||2a-27/NNS||adenosyltransferase-26/NN	nsubj||promotes-31/VBZ||2a-27/NNS	appos||2a-27/NNS||mat2a-29/NNP	conj_and||involved-13/VBN||promotes-31/VBZ	det||growth-33/NN||the-32/DT	dobj||promotes-31/VBZ||growth-33/NN	nn||cells-37/NNS||liver-35/NN	nn||cells-37/NNS||cancer-36/NN	prep_of||growth-33/NN||cells-37/NNS	prepc_through||promotes-31/VBZ||altering-39/VBG	dobj||altering-39/VBG||s-40/PRP	nsubj||homeostasis-43/VBZ||adenosylmethionine-42/NN	parataxis||involved-13/VBN||homeostasis-43/VBZ	hbv-10||hepatitisbvirus-8||no||the x protein (hbx) of hepatitisbvirus (hbv) is involved in the development of hepatocellular carcinoma (hcc), and methionine adenosyltransferase 2a ( mat2a ) promotes the growth of liver cancer cells through altering s -adenosylmethionine homeostasis.
nsubj||disease-9/NN||type1diabetesmellitus-1/NNS	appos||type1diabetesmellitus-1/NNS||t1dm-3/NNP	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||a-6/DT	amod||disease-9/NN||multifactorial-7/JJ	amod||disease-9/NN||autoimmune-8/JJ	root||ROOT-0/null||disease-9/NN	prep_in||²-16/VBD||disease-9/NN	det||î-15/NN||the-12/DT	nn||î-15/NN||insulin-13/NN	amod||î-15/NN||producing-14/VBG	nsubj||²-16/VBD||î-15/NN	rcmod||disease-9/NN||²-16/VBD	nn||population-18/NN||cell-17/NN	nsubjpass||destroyed-20/VBN||population-18/NN	auxpass||destroyed-20/VBN||is-19/VBZ	ccomp||²-16/VBD||destroyed-20/VBN	det||lymphocytes-25/NNS||the-22/DT	amod||lymphocytes-25/NNS||infiltrated-23/JJ	nn||lymphocytes-25/NNS||t-24/NN	agent||destroyed-20/VBN||lymphocytes-25/NNS	type1diabetesmellitus-1||insulin-13||yes||type1diabetesmellitus (t1dm) is a multifactorial autoimmune disease in which the insulin producing î² cell population is destroyed by the infiltrated t lymphocytes.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	il-2-19||tumor--1||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
det||course-3/NN||the-1/DT	amod||course-3/NN||clinical-2/JJ	nsubj||unknown-19/JJ||course-3/NN	prep_of||course-3/NN||humanpapillomavirus-5/NNS	appos||humanpapillomavirus-5/NNS||hpv-7/NN	vmod||humanpapillomavirus-5/NNS||associated-9/VBN	prep_with||associated-9/VBN||bowenoidpapulosis-11/NNS	prep_with||associated-9/VBN||condylomaacuminatum-13/NN	conj_and||bowenoidpapulosis-11/NNS||condylomaacuminatum-13/NN	amod||tumors-16/NNS||anogenital-15/JJ	prep_of||bowenoidpapulosis-11/NNS||tumors-16/NNS	cop||unknown-19/JJ||are-17/VBP	advmod||unknown-19/JJ||still-18/RB	root||ROOT-0/null||unknown-19/JJ	condylomaacuminatum-13||hpv-7||no||the clinical course of humanpapillomavirus (hpv) associated with bowenoidpapulosis and condylomaacuminatum of anogenital tumors are still unknown.
amod||work-2/NN||previous-1/JJ	nsubj||indicated-4/VBN||work-2/NN	aux||indicated-4/VBN||has-3/VBZ	root||ROOT-0/null||indicated-4/VBN	mark||originated-8/VBP||that-5/IN	det||virus-7/NN||the-6/DT	nsubj||originated-8/VBP||virus-7/NN	ccomp||indicated-4/VBN||originated-8/VBP	amod||eurasia-11/NN||western-10/JJ	prep_in||originated-8/VBP||eurasia-11/NN	nsubj||viruses-20/NNS||all-14/DT	poss||relatives-18/NNS||its-16/PRP$	amod||relatives-18/NNS||closest-17/JJS	prep_of||all-14/DT||relatives-18/NNS	cop||viruses-20/NNS||being-19/VBG	prepc_with||originated-8/VBP||viruses-20/NNS	amod||plants-23/NNS||monocotyledonous-22/JJ	prep_of||viruses-20/NNS||plants-23/NNS	virus-7||viruses-20||no||previous work has indicated that the virus originated in western eurasia, with all of its closest relatives being viruses of monocotyledonous plants.
advmod||considered-18/VBN||as-1/RB	prep_with||as-1/RB||sd-nvp-3/NN	det||value-6/NN||the-5/DT	nsubjpass||considered-18/VBN||value-6/NN	prepc_of||value-6/NN||preventing-8/VBG	dobj||preventing-8/VBG||hivinfection-9/NN	det||number-13/NN||a-11/DT	amod||number-13/NN||large-12/JJ	prep_in||preventing-8/VBG||number-13/NN	prep_of||number-13/NN||infants-15/NNS	aux||considered-18/VBN||should-16/MD	auxpass||considered-18/VBN||be-17/VB	root||ROOT-0/null||considered-18/VBN	det||risk-22/NN||the-20/DT	amod||risk-22/NN||high-21/JJ	prep_alongside||considered-18/VBN||risk-22/NN	prep_of||risk-22/NN||resistance-24/NN	vmod||resistance-24/NN||associated-25/VBN	amod||prophylaxis-29/NNS||extended-27/JJ	nn||prophylaxis-29/NNS||nvp-28/NN	prep_with||associated-25/VBN||prophylaxis-29/NNS	hivinfection-9||nvp-28||yes||as with sd-nvp, the value of preventing hivinfection in a large number of infants should be considered alongside the high risk of resistance associated with extended nvp prophylaxis.
det||sensor-5/NN||a-1/DT	amod||sensor-5/NN||hypothetical-2/JJ	amod||sensor-5/NN||innate-3/JJ	nn||sensor-5/NN||immunity-4/NN	nsubj||explain-12/VB||sensor-5/NN	nsubj||due-19/JJ||sensor-5/NN	prep_for||sensor-5/NN||cpg-7/NN	prep_in||cpg-7/NN||rna-9/NN	aux||explain-12/VB||could-10/MD	advmod||explain-12/VB||partially-11/RB	ccomp||required-34/VBN||explain-12/VB	det||bias-16/NN||the-13/DT	amod||bias-16/NN||codon-14/JJ	nn||bias-16/NN||usage-15/NN	dobj||explain-12/VB||bias-16/NN	conj_but||explain-12/VB||due-19/JJ	ccomp||required-34/VBN||due-19/JJ	prep_to||due-19/JJ||dependence-21/NN	nn||translation-24/NN||virus-23/NN	prep_of||dependence-21/NN||translation-24/NN	amod||machinery-29/NN||biased-26/JJ	nn||machinery-29/NN||host-27/NN	nn||machinery-29/NN||translation-28/NN	prep_upon||due-19/JJ||machinery-29/NN	amod||studies-32/NNS||experimental-31/JJ	nsubjpass||required-34/VBN||studies-32/NNS	nsubj||explore-37/VB||studies-32/NNS	auxpass||required-34/VBN||are-33/VBP	root||ROOT-0/null||required-34/VBN	aux||explore-37/VB||to-35/TO	advmod||explore-37/VB||further-36/RBR	xcomp||required-34/VBN||explore-37/VB	det||source-39/NN||the-38/DT	dobj||explore-37/VB||source-39/NN	amod||bias-42/NN||dinucleotide-41/JJ	prep_of||source-39/NN||bias-42/NN	nn||viruses-45/NNS||rna-44/NN	prep_in||bias-42/NN||viruses-45/NNS	virus-23||viruses-45||no||a hypothetical innate immunity sensor for cpg in rna could partially explain the codon usage bias, but due to dependence of virus translation upon biased host translation machinery, experimental studies are required to further explore the source of dinucleotide bias in rna viruses.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
amod||management-4/NN||clinical-1/JJ	conj_and||clinical-1/JJ||nutritional-3/JJ	amod||management-4/NN||nutritional-3/JJ	nsubjpass||improved-25/VBN||management-4/NN	nn||individuals-10/NNS||hiv-6/NN	conj_and||hiv-6/NN||mycobacteriumtuberculosis-8/JJ	nn||individuals-10/NNS||mycobacteriumtuberculosis-8/JJ	amod||individuals-10/NNS||co-infected-9/JJ	prep_of||management-4/NN||individuals-10/NNS	advmod||management-4/NN||especially-12/RB	amod||management-4/NN||in-13/IN	dep||management-4/NN||regions-14/NNS	advmod||co-exist-20/VB||where-15/WRB	nn||insecurity-17/NN||food-16/NN	nsubj||co-exist-20/VB||insecurity-17/NN	conj_and||insecurity-17/NN||malnutrition-19/NN	nsubj||co-exist-20/VB||malnutrition-19/NN	rcmod||regions-14/NNS||co-exist-20/VB	aux||improved-25/VBN||may-22/MD	auxpass||improved-25/VBN||be-23/VB	advmod||improved-25/VBN||further-24/RBR	root||ROOT-0/null||improved-25/VBN	advmod||understood-36/VBN||when-26/WRB	det||factors-31/NNS||the-27/DT	amod||factors-31/NNS||iron-related-28/JJ	nn||factors-31/NNS||tb-29/NN	nn||factors-31/NNS||risk-30/NN	nsubjpass||understood-36/VBN||factors-31/NNS	nsubjpass||managed-38/VBN||factors-31/NNS	nsubj||favor-40/VB||factors-31/NNS	vmod||factors-31/NNS||identified-32/VBN	advmod||identified-32/VBN||here-33/RB	auxpass||understood-36/VBN||are-34/VBP	advmod||understood-36/VBN||better-35/RBR	advcl||improved-25/VBN||understood-36/VBN	advcl||improved-25/VBN||managed-38/VBN	conj_and||understood-36/VBN||managed-38/VBN	aux||favor-40/VB||to-39/TO	xcomp||understood-36/VBN||favor-40/VB	dobj||favor-40/VB||host-41/NN	nn||outcomes-45/NNS||pathogen-44/NN	dobj||favor-40/VB||outcomes-45/NNS	conj_negcc||host-41/NN||outcomes-45/NNS	tb-29||mycobacteriumtuberculosis-8||no||clinical and nutritional management of hiv and mycobacteriumtuberculosis co-infected individuals, especially in regions where food insecurity and malnutrition co-exist, may be further improved when the iron-related tb risk factors identified here are better understood and managed to favor host rather than pathogen outcomes.
det||mutation-3/NN||the-1/DT	nn||mutation-3/NN||dapax-2/NN	nsubj||rendered-4/VBD||mutation-3/NN	root||ROOT-0/null||rendered-4/VBD	amod||avirulent-6/NN||y.pestis-5/JJ	dobj||rendered-4/VBD||avirulent-6/NN	nsubjpass||complemented-17/VBN||avirulent-6/NN	nn||models-9/NNS||mouse-8/NN	prep_in||avirulent-6/NN||models-9/NNS	prep_of||models-9/NNS||bubonic-11/NN	prep_of||models-9/NNS||septicemicplague-13/NN	conj_and||bubonic-11/NN||septicemicplague-13/NN	aux||complemented-17/VBN||could-15/MD	auxpass||complemented-17/VBN||be-16/VB	rcmod||avirulent-6/NN||complemented-17/VBN	advmod||inserted-21/VBN||when-18/WRB	nsubjpass||inserted-21/VBN||dapax-19/NN	auxpass||inserted-21/VBN||was-20/VBD	advcl||complemented-17/VBN||inserted-21/VBN	prep_in||inserted-21/VBN||single-23/JJ	prep_in||inserted-21/VBN||multi-copy-25/JJ	conj_or||single-23/JJ||multi-copy-25/JJ	vmod||rendered-4/VBD||restoring-27/VBG	dobj||restoring-27/VBG||development-28/NN	nsubj||indistinguishable-33/JJ||development-28/NN	prep_of||development-28/NN||disease-30/NN	cop||indistinguishable-33/JJ||was-32/VBD	rcmod||development-28/NN||indistinguishable-33/JJ	det||strain-39/NN||the-35/DT	amod||strain-39/NN||wild-36/JJ	nn||strain-39/NN||type-37/NN	nn||strain-39/NN||parent-38/NN	prep_from||indistinguishable-33/JJ||strain-39/NN	septicemicplague-13||y.pestis-5||no||the dapax mutation rendered y.pestis avirulent in mouse models of bubonic and septicemicplague which could be complemented when dapax was inserted in single or multi-copy , restoring development of disease that was indistinguishable from the wild type parent strain .
nsubj||shown-3/VBN||studies-1/NNS	aux||shown-3/VBN||have-2/VBP	root||ROOT-0/null||shown-3/VBN	mark||is-6/VBZ||that-4/IN	expl||is-6/VBZ||there-5/EX	ccomp||shown-3/VBN||is-6/VBZ	neg||level-9/NN||no-7/DT	amod||level-9/NN||safe-8/JJ	nsubj||is-6/VBZ||level-9/NN	amod||exposure-16/NN||secondhand-11/JJ	nn||exposure-16/NN||smoke-12/NN	appos||exposure-16/NN||shs-14/NN	prep_of||level-9/NN||exposure-16/NN	expl||is-19/VBZ||there-18/EX	conj_and||shown-3/VBN||is-19/VBZ	det||link-22/NN||a-20/DT	amod||link-22/NN||close-21/JJ	nsubj||is-19/VBZ||link-22/NN	prep_between||link-22/NN||shs-24/NN	det||risk-27/NN||the-26/DT	nsubj||is-19/VBZ||risk-27/NN	conj_and||link-22/NN||risk-27/NN	prep_of||risk-27/NN||coronaryheartdisease-29/NN	prep_of||risk-27/NN||stroke-31/NN	conj_and||coronaryheartdisease-29/NN||stroke-31/NN	coronaryheartdisease-29||smoke-12||no_rel||studies have shown that there is no safe level of secondhand smoke (shs) exposure and there is a close link between shs and the risk of coronaryheartdisease and stroke.
amod||humidity-3/NN||low-1/JJ	amod||humidity-3/NN||absolute-2/JJ	nsubjpass||associated-9/VBN||humidity-3/NN	appos||humidity-3/NN||ah-5/NN	aux||associated-9/VBN||has-7/VBZ	auxpass||associated-9/VBN||been-8/VBN	root||ROOT-0/null||associated-9/VBN	amod||survival-13/NN||increased-11/VBN	amod||survival-13/NN||influenzavirus-12/JJ	prep_with||associated-9/VBN||survival-13/NN	prep_with||associated-9/VBN||transmissibility-15/NN	conj_and||survival-13/NN||transmissibility-15/NN	det||onset-18/NN||the-17/DT	prep_with||associated-9/VBN||onset-18/NN	conj_and||survival-13/NN||onset-18/NN	amod||outbreaks-22/NNS||seasonal-20/JJ	nn||outbreaks-22/NNS||influenza-21/NN	prep_of||onset-18/NN||outbreaks-22/NNS	influenza-21||influenzavirus-12||no||low absolute humidity (ah) has been associated with increased influenzavirus survival and transmissibility and the onset of seasonal influenza outbreaks.
mark||enhance-4/VB||because-1/IN	nsubj||enhance-4/VB||iron-2/NN	aux||enhance-4/VB||can-3/MD	advcl||examined-12/VBD||enhance-4/VB	det||effects-7/NNS||the-5/DT	amod||effects-7/NNS||oxidative-6/JJ	dobj||enhance-4/VB||effects-7/NNS	prep_of||effects-7/NNS||lead-9/NN	nsubj||examined-12/VBD||we-11/PRP	root||ROOT-0/null||examined-12/VBD	mark||-LSB--19/VB||whether-13/IN	nsubj||-LSB--19/VB||polymorphisms-14/NNS	nsubj||transferrin-25/VB||polymorphisms-14/NNS	nsubj||heme-32/VB||polymorphisms-14/NNS	nn||genes-18/NNS||iron-16/NN	nn||genes-18/NNS||metabolism-17/NN	prep_in||polymorphisms-14/NNS||genes-18/NNS	ccomp||examined-12/VBD||-LSB--19/VB	dobj||-LSB--19/VB||hemochromatosis-20/NNS	appos||hemochromatosis-20/NNS||hfe-22/NN	ccomp||examined-12/VBD||transferrin-25/VB	conj_and||-LSB--19/VB||transferrin-25/VB	appos||c2-29/NNS||tf-27/NN	dobj||transferrin-25/VB||c2-29/NNS	ccomp||examined-12/VBD||heme-32/VB	conj_and||-LSB--19/VB||heme-32/VB	amod||susceptibility-39/NN||oxygenase-1-33/JJ	dep||oxygenase-1-33/JJ||hmox-1-35/JJ	amod||susceptibility-39/NN||-RSB--37/JJ	nn||susceptibility-39/NN||increase-38/NN	dobj||heme-32/VB||susceptibility-39/NN	det||effects-42/NNS||the-41/DT	prep_to||heme-32/VB||effects-42/NNS	prep_of||effects-42/NNS||lead-44/NN	nn||interval-47/NN||qt-46/NN	nsubj||community-dwelling-50/VBG||interval-47/NN	prep_in||interval-47/NN||613-49/CD	prepc_on||heme-32/VB||community-dwelling-50/VBG	amod||men-52/NNS||older-51/JJR	dobj||community-dwelling-50/VBG||men-52/NNS	hemochromatosis-20||iron-16||no||because iron can enhance the oxidative effects of lead, we examined whether polymorphisms in iron metabolism genes [hemochromatosis ( hfe ), transferrin ( tf ) c2, and heme oxygenase-1 ( hmox-1 )] increase susceptibility to the effects of lead on qt interval in 613 community-dwelling older men.
nsubjpass||associated-9/VBN||access-1/NN	det||template-7/NN||a-3/DT	nn||template-7/NN||computer-4/NN	nn||template-7/NN||insulin-5/NN	nn||template-7/NN||order-6/NN	prep_to||access-1/NN||template-7/NN	auxpass||associated-9/VBN||was-8/VBD	root||ROOT-0/null||associated-9/VBN	amod||levels-14/NNS||improved-11/JJ	amod||levels-14/NNS||mean-12/JJ	nn||levels-14/NNS||glucose-13/NN	prep_with||associated-9/VBN||levels-14/NNS	amod||hypoglycemia-17/NN||increasing-16/VBG	prep_without||associated-9/VBN||hypoglycemia-17/NN	prep_in||hypoglycemia-17/NN||patients-19/NNS	prep_with||patients-19/NNS||type2diabetes-21/CD	hypoglycemia-17||glucose-13||yes||access to a computer insulin order template was associated with improved mean glucose levels without increasing hypoglycemia in patients with type2diabetes.
nn||chinaâ-2/NNS||conclusion-1/NN	nsubj||system-12/NN||chinaâ-2/NNS	dep||chinaâ-2/NNS||$-3/$	num||$-3/$||™-4/CD	cop||system-12/NN||s-5/VBZ	amod||system-12/NN||new-6/JJ	amod||system-12/NN||unified-7/JJ	amod||system-12/NN||web-based-9/JJ	amod||system-12/NN||hiv/aids-10/JJ	nn||system-12/NN||information-11/NN	root||ROOT-0/null||system-12/NN	aux||improved-14/VBN||has-13/VBZ	rcmod||system-12/NN||improved-14/VBN	det||efficiency-16/NN||the-15/DT	dobj||improved-14/VBN||efficiency-16/NN	prep_of||efficiency-16/NN||data-18/NNS	dep||data-18/NNS||collection-19/NN	dep||data-18/NNS||reporting-21/NN	conj_and||collection-19/NN||reporting-21/NN	dep||data-18/NNS||analysis-23/NN	conj_and||collection-19/NN||analysis-23/NN	dep||data-18/NNS||use-25/NN	conj_and||collection-19/NN||use-25/NN	nn||quality-31/NN||data-30/NNS	prep_of||efficiency-16/NN||quality-31/NN	conj_and||data-18/NNS||quality-31/NN	conj_and||data-18/NNS||security-33/NN	conj_and||quality-31/NN||security-33/NN	aids--1||hiv--1||no||conclusion chinaâ€™s new unified, web-based hiv/aids information system has improved the efficiency of data collection, reporting, analysis and use, as well as data quality and security.
det||target-3/NN||a-1/DT	amod||target-3/NN||uniform-2/JJ	nsubj||mtb-4/VBP||target-3/NN	root||ROOT-0/null||mtb-4/VBP	amod||pattern-7/NN||igg-epitope-5/JJ	nn||pattern-7/NN||recognition-6/NN	nsubj||exists-8/VBZ||pattern-7/NN	ccomp||mtb-4/VBP||exists-8/VBZ	prep_in||exists-8/VBZ||pulmonarytuberculosis-10/NNS	pulmonarytuberculosis-10||mtb-4||no||a uniform target mtb igg-epitope recognition pattern exists in pulmonarytuberculosis.
det||bortezomib-4/NN||the-1/DT	amod||bortezomib-4/NN||proteasome-2/JJ	nn||bortezomib-4/NN||inhibitor-3/NN	nsubjpass||prescribed-9/VBN||bortezomib-4/NN	appos||bortezomib-4/NN||velcade-6/NN	auxpass||prescribed-9/VBN||is-8/VBZ	root||ROOT-0/null||prescribed-9/VBN	det||treatment-12/NN||the-11/DT	prep_for||prescribed-9/VBN||treatment-12/NN	prep_of||treatment-12/NN||multiplemyeloma-14/NN	multiplemyeloma-14||bortezomib-4||yes||the proteasome inhibitor bortezomib (velcade) is prescribed for the treatment of multiplemyeloma.
mark||understood-13/VBN||although-1/IN	det||details-3/NNS||the-2/DT	nsubjpass||understood-13/VBN||details-3/NNS	det||mechanism-6/NN||the-5/DT	prep_of||details-3/NNS||mechanism-6/NN	nn||propagation-9/NN||prion-8/NN	prep_of||mechanism-6/NN||propagation-9/NN	auxpass||understood-13/VBN||are-10/VBP	neg||understood-13/VBN||not-11/RB	advmod||understood-13/VBN||fully-12/RB	advcl||considered-33/VBN||understood-13/VBN	amod||conversion-16/NN||conformational-15/JJ	nsubjpass||considered-33/VBN||conversion-16/NN	amod||prionprotein-19/NN||cellular-18/JJ	prep_of||conversion-16/NN||prionprotein-19/NN	dep||prionprotein-19/NN||prpc-21/JJ	amod||prionprotein-28/NN||misfolded-24/JJ	amod||prionprotein-28/NN||disease-associated-26/JJ	nn||prionprotein-28/NN||scrapie-27/NN	prep_to||prionprotein-19/NN||prionprotein-28/NN	dep||conversion-16/NN||prpsc-30/JJ	auxpass||considered-33/VBN||is-32/VBZ	root||ROOT-0/null||considered-33/VBN	det||event-37/NN||the-34/DT	amod||event-37/NN||essential-35/JJ	amod||event-37/NN||biochemical-36/JJ	dobj||considered-33/VBN||event-37/NN	nn||replication-40/NN||prion-39/NN	prep_for||event-37/NN||replication-40/NN	scrapie-27||prion-39||no_rel||although the details of the mechanism of prion propagation are not fully understood, conformational conversion of cellular prionprotein (prpc) to misfolded, disease-associated scrapie prionprotein (prpsc) is considered the essential biochemical event for prion replication.
det||bout-3/NN||a-1/DT	amod||bout-3/NN||second-2/JJ	nsubj||suggested-6/VBD||bout-3/NN	prep_of||bout-3/NN||eosinophilia-5/NN	root||ROOT-0/null||suggested-6/VBD	amod||toxocariasis-8/NNS||recurring-7/VBG	dobj||suggested-6/VBD||toxocariasis-8/NNS	prep_for||prescribed-13/VBN||toxocariasis-8/NNS	nsubj||prescribed-13/VBN||we-12/PRP	rcmod||toxocariasis-8/NNS||prescribed-13/VBN	det||round-16/NN||a-14/DT	amod||round-16/NN||second-15/JJ	dobj||prescribed-13/VBN||round-16/NN	prep_of||round-16/NN||albendazole-18/NN	toxocariasis-8||albendazole-18||yes||a second bout of eosinophilia suggested recurring toxocariasis, for which we prescribed a second round of albendazole.
det||proportion-2/NN||the-1/DT	nsubj||%-14/NN||proportion-2/NN	det||respondents-5/NNS||the-4/DT	prep_of||proportion-2/NN||respondents-5/NNS	nsubj||had-7/VBD||respondents-5/NNS	rcmod||respondents-5/NNS||had-7/VBD	amod||knowledge-9/NN||adequate-8/JJ	dobj||had-7/VBD||knowledge-9/NN	prep_on||knowledge-9/NN||hiv/aids-11/NNS	cop||%-14/NN||was-12/VBD	num||%-14/NN||9.8-13/CD	root||ROOT-0/null||%-14/NN	aids--1||hiv--1||no||the proportion of the respondents who had adequate knowledge on hiv/aids was 9.8%.
det||increase-3/NN||a-1/DT	amod||increase-3/NN||significant-2/JJ	nsubjpass||reported-10/VBN||increase-3/NN	prep_in||increase-3/NN||congestiveheartfailure-5/NN	appos||increase-3/NN||chf-7/NN	auxpass||reported-10/VBN||was-9/VBD	root||ROOT-0/null||reported-10/VBN	advmod||used-17/VBN||when-11/WRB	det||trastuzumab-15/NN||the-12/DT	amod||trastuzumab-15/NN||anti-erbb2-13/JJ	nn||trastuzumab-15/NN||antibody-14/NN	nsubjpass||used-17/VBN||trastuzumab-15/NN	auxpass||used-17/VBN||was-16/VBD	advcl||reported-10/VBN||used-17/VBN	prep_in||used-17/VBN||combination-19/NN	det||doxorubicin-24/NN||the-21/DT	amod||doxorubicin-24/NN||chemotherapy-22/JJ	nn||doxorubicin-24/NN||drug-23/NN	prep_with||used-17/VBN||doxorubicin-24/NN	appos||doxorubicin-24/NN||dox-26/NN	congestiveheartfailure-5||dox-26||no||a significant increase in congestiveheartfailure (chf) was reported when the anti-erbb2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (dox).
det||rates-3/NNS||the-1/DT	nn||rates-3/NNS||incidence-2/NN	nsubj||30.8-12/CD||rates-3/NNS	amod||thromboembolism-6/NN||venous-5/JJ	prep_for||rates-3/NNS||thromboembolism-6/NN	det||population-10/NN||the-8/DT	nn||population-10/NN||study-9/NN	prep_in||thromboembolism-6/NN||population-10/NN	cop||30.8-12/CD||were-11/VBD	root||ROOT-0/null||30.8-12/CD	num||%-15/NN||95-14/CD	dep||30.8-12/CD||%-15/NN	nn||interval-17/NN||confidence-16/NN	dep||%-15/NN||interval-17/NN	number||36.8-20/CD||25.6-18/CD	dep||36.8-20/CD||to-19/TO	dep||interval-17/NN||36.8-20/CD	prep_per||30.8-12/CD||100â-23/CD	num||years-28/NNS||$-24/$	number||000-26/CD||‰-25/CD	num||$-24/$||000-26/CD	nn||years-28/NNS||woman-27/NN	npadvmod||30.8-12/CD||years-28/NNS	prep_among||30.8-12/CD||users-30/NNS	prep_of||users-30/NNS||oralcontraceptives-32/NNS	vmod||oralcontraceptives-32/NNS||containing-33/VBG	dobj||containing-33/VBG||drospirenone-34/NN	dobj||containing-33/VBG||12.5-36/CD	conj_and||drospirenone-34/NN||12.5-36/CD	number||15.9-40/CD||9.61-38/CD	dep||15.9-40/CD||to-39/TO	dep||12.5-36/CD||15.9-40/CD	prep_per||12.5-36/CD||100â-43/CD	num||years-48/NNS||$-44/$	number||000-46/CD||‰-45/CD	num||$-44/$||000-46/CD	nn||years-48/NNS||woman-47/NN	npadvmod||containing-33/VBG||years-48/NNS	prep_among||containing-33/VBG||users-50/NNS	prep_of||users-50/NNS||oralcontraceptives-52/NNS	vmod||oralcontraceptives-52/NNS||containing-53/VBG	acomp||containing-53/VBG||levonorgestrel-54/JJ	thromboembolism-6||levonorgestrel-54||no||the incidence rates for venous thromboembolism in the study population were 30.8 (95% confidence interval 25.6 to 36.8) per 100â€‰000 woman years among users of oralcontraceptives containing drospirenone and 12.5 (9.61 to 15.9) per 100â€‰000 woman years among users of oralcontraceptives containing levonorgestrel.
advmod||suppressed-4/VBD||further-1/RB	nsubj||suppressed-4/VBD||gla-3/NN	root||ROOT-0/null||suppressed-4/VBD	dobj||suppressed-4/VBD||expression-5/NN	amod||nitricoxide-8/JJ||inducible-7/JJ	amod||dose-dependently-12/NN||nitricoxide-8/JJ	amod||dose-dependently-12/NN||synthase-9/JJ	conj_and||synthase-9/JJ||cyclooxygenase-2-11/JJ	amod||dose-dependently-12/NN||cyclooxygenase-2-11/JJ	prep_of||expression-5/NN||dose-dependently-12/NN	det||levels-18/NNS||the-14/DT	nn||levels-18/NNS||mrna-15/NN	conj_and||mrna-15/NN||protein-17/NN	nn||levels-18/NNS||protein-17/NN	prep_at||suppressed-4/VBD||levels-18/NNS	nitricoxide-8||gla-3||no_rel||further, gla suppressed expression of inducible nitricoxide synthase and cyclooxygenase-2 dose-dependently at the mrna and protein levels.
nsubj||forms-2/VBZ||this-1/DT	root||ROOT-0/null||forms-2/VBZ	det||step-5/NN||a-3/DT	amod||step-5/NN||crucial-4/JJ	dobj||forms-2/VBZ||step-5/NN	det||development-8/NN||the-7/DT	prep_in||forms-2/VBZ||development-8/NN	prep_of||development-8/NN||strategies-10/NNS	aux||modify-12/VB||to-11/TO	vmod||forms-2/VBZ||modify-12/VB	nn||genes-14/NNS||gluten-13/NN	dobj||modify-12/VB||genes-14/NNS	prep_in||modify-12/VB||wheat-16/NN	advmod||becomes-20/VBZ||so-17/RB	mark||becomes-20/VBZ||that-18/IN	nsubj||becomes-20/VBZ||it-19/PRP	advcl||modify-12/VB||becomes-20/VBZ	acomp||becomes-20/VBZ||safe-21/JJ	amod||patients-24/NNS||celiacdisease-23/JJ	prep_for||safe-21/JJ||patients-24/NNS	celiacdisease-23||gluten-13||no||this forms a crucial step in the development of strategies to modify gluten genes in wheat so that it becomes safe for celiacdisease patients.
nsubj||associated-3/VBN||sch-1/PRP	aux||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	amod||prevalence-6/NN||greater-5/JJR	prep_with||associated-3/VBN||prevalence-6/NN	amod||4.15-20/NNS||diabeticretinopathy-8/JJ	advmod||stdr-11/JJR||especially-10/RB	amod||4.15-20/NNS||stdr-11/JJR	nn||4.15-20/NNS||-LSB--12/NN	nn||4.15-20/NNS||odds-13/NNS	nn||4.15-20/NNS||ratio-14/NN	num||%-17/NN||95-16/CD	npadvmod||ci-18/JJ||%-17/NN	dep||4.15-20/NNS||ci-18/JJ	prep_of||prevalence-6/NN||4.15-20/NNS	dep||4.15-20/NNS||2.17-22/CD	dep||4.15-20/NNS||$-24/$	conj_â||2.17-22/CD||$-24/$	num||$-24/$||7.96-26/CD	dep||associated-3/VBN||p-29/VBN	dep||-RSB--32/NNS||=-30/SYM	num||-RSB--32/NNS||0.000-31/CD	ccomp||p-29/VBN||-RSB--32/NNS	det||adjustment-35/NN||an-34/DT	prep_after||p-29/VBN||adjustment-35/NN	prep_for||adjustment-35/NN||age-37/NN	appos||age-37/NN||sex-39/NN	dobj||associated-3/VBN||duration-41/NN	nn||hypertension-49/NN||diabetes-43/NN	dep||hypertension-49/NN||a1c-45/NN	dep||hypertension-49/NN||bmi-47/NN	prep_of||duration-41/NN||hypertension-49/NN	nn||cholesterol-53/NN||ldl-52/NN	prep_of||duration-41/NN||cholesterol-53/NN	conj_and||hypertension-49/NN||cholesterol-53/NN	cholesterol-53||diabeticretinopathy-8||no_rel||sch was associated with greater prevalence of diabeticretinopathy, especially stdr [odds ratio (95% ci) 4.15 (2.17â€“7.96), p = 0.000] after an adjustment for age, sex, duration of diabetes, a1c, bmi, hypertension, and ldl cholesterol.
nsubjpass||concluded-3/VBN||it-1/PRP	auxpass||concluded-3/VBN||was-2/VBD	root||ROOT-0/null||concluded-3/VBN	mark||favor-7/VBP||that-4/IN	amod||nitrates-6/NNS||organic-5/JJ	nsubj||favor-7/VBP||nitrates-6/NNS	ccomp||concluded-3/VBN||favor-7/VBP	dobj||favor-7/VBP||regression-8/NN	prep_of||regression-8/NN||lvh-10/NN	amod||patients-13/NNS||hypertensive-12/JJ	prep_in||favor-7/VBP||patients-13/NNS	amod||dialysis-17/NN||chronic-15/JJ	amod||dialysis-17/NN||peritoneal-16/JJ	prep_on||patients-13/NNS||dialysis-17/NN	nsubjpass||considered-23/VBN||nitrates-20/NNS	aux||considered-23/VBN||may-21/MD	auxpass||considered-23/VBN||be-22/VB	conj_and||concluded-3/VBN||considered-23/VBN	prep_for||considered-23/VBN||use-25/NN	prepc_before||considered-23/VBN||employing-27/VBG	det||antihypertensiveagents-31/NNS||the-28/DT	num||antihypertensiveagents-31/NNS||five-29/CD	amod||antihypertensiveagents-31/NNS||other-30/JJ	dobj||employing-27/VBG||antihypertensiveagents-31/NNS	amod||antihypertensiveagents-31/NNS||other-32/JJ	prep_than||employing-27/VBG||nitrates-34/NNS	lvh-10||nitrates-34||no_rel||it was concluded that organic nitrates favor regression of lvh in hypertensive patients on chronic peritoneal dialysis, and nitrates may be considered for use before employing the five other antihypertensiveagents other than nitrates.
det||aims-2/NNS||the-1/DT	nsubj||were-7/VBD||aims-2/NNS	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aims-2/NNS||study-6/NN	root||ROOT-0/null||were-7/VBD	aux||assess-9/VB||to-8/TO	ccomp||were-7/VBD||assess-9/VB	det||association-12/NN||a-10/DT	amod||association-12/NN||potential-11/JJ	dobj||assess-9/VB||association-12/NN	prepc_between||association-12/NN||circulating-14/VBG	dobj||circulating-14/VBG||levels-15/NNS	amod||markers-18/NNS||inflammatory-17/JJ	prep_of||levels-15/NNS||markers-18/NNS	dobj||circulating-14/VBG||hyperglycaemia-20/NN	conj_and||levels-15/NNS||hyperglycaemia-20/NN	vmod||hyperglycaemia-20/NN||measured-21/VBN	det||myocardialinfarction-26/NN||an-23/DT	amod||st-elevation-25/JJ||acute-24/JJ	amod||myocardialinfarction-26/NN||st-elevation-25/JJ	prep_during||measured-21/VBN||myocardialinfarction-26/NN	appos||myocardialinfarction-26/NN||stemi-28/NNP	prep_in||measured-21/VBN||patients-31/NNS	amod||diabetes-34/NN||known-33/JJ	prep_without||measured-21/VBN||diabetes-34/NN	aux||determine-38/VB||to-37/TO	ccomp||were-7/VBD||determine-38/VB	conj_and||assess-9/VB||determine-38/VB	mark||associated-53/VBN||whether-39/IN	dep||associated-53/VBN||circulating-40/VBG	dobj||circulating-40/VBG||levels-41/NNS	amod||markers-44/NNS||inflammatory-43/JJ	prep_of||levels-41/NNS||markers-44/NNS	vmod||markers-44/NNS||measured-45/VBN	advmod||measured-45/VBN||early-46/RB	det||stemi-50/NN||an-48/DT	amod||stemi-50/NN||acute-49/JJ	prep_after||measured-45/VBN||stemi-50/NN	auxpass||associated-53/VBN||were-52/VBD	ccomp||determine-38/VB||associated-53/VBN	det||presence-56/NN||the-55/DT	prep_with||associated-53/VBN||presence-56/NN	amod||regulation-60/NN||abnormal-58/JJ	nn||regulation-60/NN||glucose-59/NN	prep_of||presence-56/NN||regulation-60/NN	vmod||regulation-60/NN||classified-61/VBN	det||test-67/NN||an-63/DT	amod||test-67/NN||oral-64/JJ	nn||test-67/NN||glucose-65/NN	nn||test-67/NN||tolerance-66/NN	agent||classified-61/VBN||test-67/NN	appos||test-67/NN||ogtt-69/NN	amod||follow-up-73/NN||three-month-72/JJ	prep_at||classified-61/VBN||follow-up-73/NN	det||cohort-77/NN||the-75/DT	amod||cohort-77/NN||same-76/JJ	prep_in||follow-up-73/NN||cohort-77/NN	hyperglycaemia-20||glucose-65||no||the aims of the present study were to assess a potential association between circulating levels of inflammatory markers and hyperglycaemia measured during an acute st-elevation myocardialinfarction (stemi) in patients without known diabetes, and to determine whether circulating levels of inflammatory markers measured early after an acute stemi, were associated with the presence of abnormal glucose regulation classified by an oral glucose tolerance test (ogtt) at three-month follow-up in the same cohort.
amod||concentration-3/NN||endogenous-1/JJ	nn||concentration-3/NN||formaldehyde-2/NN	nsubj||increased-4/VBD||concentration-3/NN	root||ROOT-0/null||increased-4/VBD	advmod||increased-4/VBD||significantly-5/RB	det||lines-12/NNS||the-7/DT	amod||lines-12/NNS||cultured-8/JJ	nn||lines-12/NNS||breast-9/NN	nn||lines-12/NNS||cancer-10/NN	nn||lines-12/NNS||cell-11/NN	prep_in||increased-4/VBD||lines-12/NNS	prep_in||lines-12/NNS||vitro-14/NNP	det||marrow-19/NN||the-17/DT	nn||marrow-19/NN||bone-18/NN	prep_in||increased-4/VBD||marrow-19/NN	prepc_of||marrow-19/NN||breast-21/VBG	amod||model-26/NN||mrmt-1-22/JJ	nn||model-26/NN||bone-23/NN	nn||model-26/NN||cancer-24/NN	nn||model-26/NN||pain-25/NN	dobj||breast-21/VBG||model-26/NN	prep_in||breast-21/VBG||rats-28/NNS	prep_in||breast-21/VBG||tissues-31/NNS	conj_and||rats-28/NNS||tissues-31/NNS	nn||cancer-34/NN||breast-33/NN	prep_from||tissues-31/NNS||cancer-34/NN	nn||patients-38/NNS||lung-36/NN	nn||patients-38/NNS||cancer-37/NN	prep_from||tissues-31/NNS||patients-38/NNS	conj_and||cancer-34/NN||patients-38/NNS	prep_in||breast-21/VBG||vivo-40/NN	cancer-37||formaldehyde-2||no_rel||endogenous formaldehyde concentration increased significantly in the cultured breast cancer cell lines in vitro , in the bone marrow of breast mrmt-1 bone cancer pain model in rats and in tissues from breast cancer and lung cancer patients in vivo .
det||time-4/NN||the-2/DT	amod||time-4/NN||first-3/JJ	prep_for||describe-6/VBP||time-4/NN	nsubj||describe-6/VBP||we-5/PRP	root||ROOT-0/null||describe-6/VBP	det||sequence-8/NN||the-7/DT	dobj||describe-6/VBP||sequence-8/NN	det||bacterium-13/NN||an-10/DT	nn||bacterium-13/NN||anthrax-11/NN	amod||bacterium-13/NN||causing-12/VBG	prep_of||sequence-8/NN||bacterium-13/NN	vmod||bacterium-13/NN||possessing-14/VBG	det||plasmids-17/NNS||both-15/DT	nn||plasmids-17/NNS||anthrax-16/NN	dobj||possessing-14/VBG||plasmids-17/NNS	nsubj||belong-22/VB||that-18/WDT	advmod||belong-22/VB||apparently-19/RB	aux||belong-22/VB||does-20/VBZ	neg||belong-22/VB||not-21/RB	dep||possessing-14/VBG||belong-22/VB	det||group-26/NN||the-24/DT	amod||group-26/NN||monophyletic-25/JJ	prep_to||belong-22/VB||group-26/NN	dep||so-29/IN||all-28/DT	advmod||known-31/VBN||so-29/IN	advmod||so-29/IN||far-30/RB	amod||strains-33/NNS||known-31/VBN	amod||strains-33/NNS||b.anthracis-32/JJ	prep_of||group-26/NN||strains-33/NNS	nsubj||differs-36/VBZ||that-35/WDT	dep||possessing-14/VBG||differs-36/VBZ	conj_and||belong-22/VB||differs-36/VBZ	amod||features-40/NNS||important-38/JJ	amod||features-40/NNS||diagnostic-39/JJ	prep_in||differs-36/VBZ||features-40/NNS	anthrax-16||b.anthracis-32||no||for the first time we describe the sequence of an anthrax causing bacterium possessing both anthrax plasmids that apparently does not belong to the monophyletic group of all so far known b.anthracis strains and that differs in important diagnostic features .
nsubj||remains-6/VBZ||meningococcaldisease-1/NN	vmod||meningococcaldisease-1/NN||caused-2/VBN	amod||neisseriameningitidis-5/NNS||serogroupb-4/JJ	agent||caused-2/VBN||neisseriameningitidis-5/NNS	root||ROOT-0/null||remains-6/VBZ	det||problem-10/NN||an-7/DT	amod||problem-10/NN||important-8/JJ	nn||problem-10/NN||health-9/NN	xcomp||remains-6/VBZ||problem-10/NN	amod||parts-13/NNS||many-12/JJ	prep_in||remains-6/VBZ||parts-13/NNS	det||world-16/NN||the-15/DT	prep_of||parts-13/NNS||world-16/NN	expl||are-20/VBP||there-19/EX	conj_and||remains-6/VBZ||are-20/VBP	advmod||are-20/VBP||currently-21/RB	neg||vaccines-24/NNS||no-22/DT	amod||vaccines-24/NNS||comprehensive-23/JJ	nsubj||are-20/VBP||vaccines-24/NNS	meningococcaldisease-1||neisseriameningitidis-5||no||meningococcaldisease caused by serogroupb neisseriameningitidis remains an important health problem in many parts of the world, and there are currently no comprehensive vaccines.
mark||are-3/VBP||although-1/IN	expl||are-3/VBP||there-2/EX	advcl||focused-19/VBN||are-3/VBP	det||number-6/NN||an-4/DT	amod||number-6/NN||increasing-5/VBG	nsubj||are-3/VBP||number-6/NN	prep_of||number-6/NN||studies-8/NNS	amod||stigma-11/NN||hiv-related-10/JJ	prep_on||studies-8/NNS||stigma-11/NN	prep_in||stigma-11/NN||nigeria-13/NN	advmod||little-16/JJ||very-15/RB	amod||research-17/NN||little-16/JJ	nsubj||focused-19/VBN||research-17/NN	aux||focused-19/VBN||has-18/VBZ	root||ROOT-0/null||focused-19/VBN	advmod||perpetuate-27/VBP||how-21/WRB	nn||differences-23/NNS||power-22/NN	nsubj||perpetuate-27/VBP||differences-23/NNS	prepc_based_on||differences-23/NNS||on-25/IN	pobj||differences-23/NNS||gender-26/NN	prepc_on||focused-19/VBN||perpetuate-27/VBP	det||stigmatization-29/NN||the-28/DT	dobj||perpetuate-27/VBP||stigmatization-29/NN	prep_of||stigmatization-29/NN||people-31/NNS	vmod||people-31/NNS||living-32/VBG	prep_with||living-32/VBG||hiv/aids-34/NNS	appos||hiv/aids-34/NNS||plwha-36/NNP	advmod||affect-43/VBP||how-39/WRB	det||differences-42/NNS||these-40/DT	nn||differences-42/NNS||gender-41/NN	nsubj||affect-43/VBP||differences-42/NNS	prepc_on||focused-19/VBN||affect-43/VBP	conj_and||perpetuate-27/VBP||affect-43/VBP	det||care-45/NN||the-44/DT	dobj||affect-43/VBP||care-45/NN	mark||receive-48/VBP||that-46/IN	nsubj||receive-48/VBP||plwha-47/NN	dep||perpetuate-27/VBP||receive-48/VBP	nn||institutions-52/NNS||health-50/NN	nn||institutions-52/NNS||care-51/NN	prep_in||receive-48/VBP||institutions-52/NNS	aids--1||hiv--1||no||although there are an increasing number of studies on hiv-related stigma in nigeria, very little research has focused on how power differences based on gender perpetuate the stigmatization of people living with hiv/aids (plwha) and how these gender differences affect the care that plwha receive in health care institutions.
nsubj||reconstructed-2/VBD||we-1/PRP	root||ROOT-0/null||reconstructed-2/VBD	amod||patterns-4/NNS||historical-3/JJ	dobj||reconstructed-2/VBD||patterns-4/NNS	amod||transmission-7/NN||plague-6/JJ	prep_of||patterns-4/NNS||transmission-7/NN	nn||variation-10/NN||sequence-9/NN	prep_through||reconstructed-2/VBD||variation-10/NN	num||sequences-15/NNS||17-12/CD	amod||sequences-15/NNS||complete-13/JJ	nn||sequences-15/NNS||genome-14/NN	prep_in||variation-10/NN||sequences-15/NNS	num||polymorphisms-20/NNS||933-17/CD	amod||polymorphisms-20/NNS||single-18/JJ	nn||polymorphisms-20/NNS||nucleotide-19/NN	nsubj||isolates-31/VBZ||polymorphisms-20/NNS	appos||polymorphisms-20/NNS||snps-22/NNS	det||collection-27/NN||a-25/DT	amod||collection-27/NN||global-26/JJ	prep_within||polymorphisms-20/NNS||collection-27/NN	num||yersiniapestis-30/NNS||286-29/CD	prep_of||collection-27/NN||yersiniapestis-30/NNS	conj_and||reconstructed-2/VBD||isolates-31/VBZ	plague-6||yersiniapestis-30||no||we reconstructed historical patterns of plague transmission through sequence variation in 17 complete genome sequences and 933 single nucleotide polymorphisms (snps) within a global collection of 286 yersiniapestis isolates.
det||expression-2/NN||the-1/DT	nsubj||makes-11/VBZ||expression-2/NN	prep_of||expression-2/NN||cta-4/NN	nn||cells-10/NNS||mhc-6/NN	nn||cells-10/NNS||class-7/NN	nn||cells-10/NNS||i-deficient-8/NN	amod||cells-10/NNS||germline-9/JJ	prep_in||cta-4/NN||cells-10/NNS	root||ROOT-0/null||makes-11/VBZ	det||proteins-13/NNS||these-12/DT	nsubj||attractive-15/JJ||proteins-13/NNS	advmod||attractive-15/JJ||particularly-14/RB	xcomp||makes-11/VBZ||attractive-15/JJ	amod||targets-18/NNS||immunotherapeutic-17/JJ	prep_as||attractive-15/JJ||targets-18/NNS	mark||serve-21/VBP||because-19/IN	nsubj||serve-21/VBP||they-20/PRP	advcl||makes-11/VBZ||serve-21/VBP	mark||i-restricted-29/VBD||as-22/IN	advmod||tumor-specific-24/JJ||essentially-23/RB	amod||antigens-25/NNS||tumor-specific-24/JJ	nsubj||i-restricted-29/VBD||antigens-25/NNS	nn||class-28/NN||mhc-27/NN	prep_for||antigens-25/NNS||class-28/NN	advcl||serve-21/VBP||i-restricted-29/VBD	amod||cells-33/NNS||cd8-30/JJ	amod||cells-33/NNS||+-31/JJ	nn||cells-33/NNS||t-32/NN	dobj||i-restricted-29/VBD||cells-33/NNS	i---1||tumor--1||no_rel||the expression of cta in mhc class i-deficient germline cells makes these proteins particularly attractive as immunotherapeutic targets because they serve as essentially tumor-specific antigens for mhc class i-restricted cd8+ t cells.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mtb-24||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
det||association-3/NN||a-1/DT	amod||association-3/NN||significant-2/JJ	nsubjpass||observed-5/VBN||association-3/NN	auxpass||observed-5/VBN||was-4/VBD	root||ROOT-0/null||observed-5/VBN	det||sle-10/NN||the-7/DT	amod||sle-10/NN||lupus-8/JJ	nn||sle-10/NN||cohort-9/NN	prep_in||observed-5/VBN||sle-10/NN	amod||health-13/NN||gullah-12/JJ	prep_in||sle-10/NN||health-13/NN	appos||health-13/NN||sleigh-15/NN	det||allele-22/NN||the-18/DT	amod||allele-22/NN||ga26-19/JJ	nn||allele-22/NN||base-20/NN	nn||allele-22/NN||pair-21/NN	prep_between||health-13/NN||allele-22/NN	prep_in||sle-10/NN||absence-24/NN	conj_and||health-13/NN||absence-24/NN	prep_of||absence-24/NN||nephritis-26/NNS	base-20||sle-10||no_rel||a significant association was observed in the lupus cohort sle in gullah health (sleigh) between the ga26 base pair allele and absence of nephritis.
nsubj||has-2/VBZ||ketamine-1/NN	root||ROOT-0/null||has-2/VBZ	det||role-5/NN||a-3/DT	amod||role-5/NN||special-4/JJ	dobj||has-2/VBZ||role-5/NN	prep_in||role-5/NN||patients-7/NNS	prepc_with||patients-7/NNS||debilitating-9/VBG	nn||allodynia-11/NN||heat-10/NN	dobj||debilitating-9/VBG||allodynia-11/NN	amod||symptoms-15/NNS||positive-13/JJ	nn||symptoms-15/NNS||cognitive-14/NN	dobj||debilitating-9/VBG||symptoms-15/NNS	conj_and||allodynia-11/NN||symptoms-15/NNS	poss||action-18/NN||its-17/PRP$	prep_via||debilitating-9/VBG||action-18/NN	amod||pathway-22/NN||central-20/JJ	nn||pathway-22/NN||pain-21/NN	prep_on||action-18/NN||pathway-22/NN	pain-21||ketamine-1||yes||ketamine has a special role in patients with debilitating heat allodynia and positive cognitive symptoms via its action on central pain pathway.
det||cb-3/NN||the-1/DT	amod||cb-3/NN||high-fat-2/JJ	nsubj||induced-10/VBN||cb-3/NN	conj_and||cb-3/NN||oo-5/NN	nsubj||induced-10/VBN||oo-5/NN	advmod||diets-9/NNS||so-8/RB	conj_and||cb-3/NN||diets-9/NNS	nsubj||induced-10/VBN||diets-9/NNS	root||ROOT-0/null||induced-10/VBN	dobj||induced-10/VBN||hyperglycemia-11/NN	det||increase-15/NN||a-13/DT	amod||increase-15/NN||2-fold-14/JJ	dobj||induced-10/VBN||increase-15/NN	conj_and||hyperglycemia-11/NN||increase-15/NN	amod||content-19/NN||hepatic-17/JJ	amod||content-19/NN||fat-18/JJ	prep_in||induced-10/VBN||content-19/NN	amod||mice-27/NNS||male-21/JJ	neg||female-25/JJ||not-24/RB	conj_but||male-21/JJ||female-25/JJ	amod||mice-27/NNS||female-25/JJ	amod||mice-27/NNS||wild-type-26/JJ	prep_in||content-19/NN||mice-27/NNS	prep_in||content-34/NN||females-30/NNS	amod||content-34/NN||hepatic-32/JJ	amod||content-34/NN||fat-33/JJ	dep||mice-27/NNS||content-34/NN	prep_to||similar-36/JJ||content-34/NN	cop||similar-36/JJ||was-35/VBD	rcmod||content-34/NN||similar-36/JJ	prep_in||that-38/DT||males-40/NNS	vmod||males-40/NNS||fed-41/VBN	det||diet-44/NN||a-42/DT	amod||diet-44/NN||high-fat-43/JJ	dobj||fed-41/VBN||diet-44/NN	hyperglycemia-11||fat-33||no_rel||the high-fat cb, oo, and so diets induced hyperglycemia and a 2-fold increase in hepatic fat content in male, but not female wild-type mice (in females, hepatic fat content was similar to that in males fed a high-fat diet).
nsubj||aimed-3/VBD||we-1/PRP	nsubj||determine-5/VB||we-1/PRP	advmod||aimed-3/VBD||therefore-2/RB	root||ROOT-0/null||aimed-3/VBD	aux||determine-5/VB||to-4/TO	xcomp||aimed-3/VBD||determine-5/VB	mark||is-8/VBZ||whether-6/IN	expl||is-8/VBZ||there-7/EX	ccomp||determine-5/VB||is-8/VBZ	acomp||is-8/VBZ||tdp-43-9/JJ	advmod||tdp-43-9/JJ||pathology-10/RB	amod||priondiseases-13/NNS||human-12/JJ	prep_in||tdp-43-9/JJ||priondiseases-13/NNS	nsubjpass||characterised-17/VBN||priondiseases-13/NNS	auxpass||characterised-17/VBN||are-16/VBP	rcmod||priondiseases-13/NNS||characterised-17/VBN	amod||deposition-20/NN||variable-19/JJ	agent||characterised-17/VBN||deposition-20/NN	amod||aggregates-26/NNS||prionprotein-22/JJ	appos||aggregates-26/NNS||prp-24/NN	prep_of||deposition-20/NN||aggregates-26/NNS	det||brain-29/NN||the-28/DT	prep_in||characterised-17/VBN||brain-29/NN	amod||plaques-32/NNS||amyloid-31/JJ	prep_as||brain-29/NN||plaques-32/NNS	amod||deposits-36/NNS||more-34/JJR	nn||deposits-36/NNS||diffuse-35/NN	prep_as||brain-29/NN||deposits-36/NNS	conj_or||plaques-32/NNS||deposits-36/NNS	priondiseases-13||prionprotein-22||no||we therefore aimed to determine whether there is tdp-43 pathology in human priondiseases, which are characterised by variable deposition of prionprotein (prp) aggregates in the brain as amyloid plaques or more diffuse deposits.
det||basis-3/NN||that-2/DT	prep_on||used-6/VBD||basis-3/NN	nsubj||used-6/VBD||we-5/PRP	root||ROOT-0/null||used-6/VBD	det||inhibitor-10/NN||an-7/DT	nn||inhibitor-10/NN||aurora-8/NN	nn||inhibitor-10/NN||kinase-9/NN	dobj||used-6/VBD||inhibitor-10/NN	dep||inhibitor-10/NN||vx-680-12/JJ	det||inhibitor-17/NN||a-15/DT	amod||inhibitor-17/NN||proteasome-16/JJ	dobj||used-6/VBD||inhibitor-17/NN	conj_and||inhibitor-10/NN||inhibitor-17/NN	appos||inhibitor-17/NN||bortezomib-19/NN	prep_with||used-6/VBD||rpmi-22/NN	num||rpmi-22/NN||8226-23/CD	amod||cells-26/NNS||amo1-25/JJ	prep_with||used-6/VBD||cells-26/NNS	conj_and||rpmi-22/NN||cells-26/NNS	aux||determine-28/VB||to-27/TO	vmod||used-6/VBD||determine-28/VB	mark||used-34/VBN||whether-29/IN	det||agents-31/NNS||these-30/DT	nsubjpass||used-34/VBN||agents-31/NNS	nsubj||target-37/VB||agents-31/NNS	aux||used-34/VBN||could-32/MD	auxpass||used-34/VBN||be-33/VB	ccomp||determine-28/VB||used-34/VBN	aux||target-37/VB||to-35/TO	advmod||target-37/VB||selectively-36/RB	xcomp||used-34/VBN||target-37/VB	det||sp-40/NN||the-38/DT	nn||sp-40/NN||myeloma-39/NN	dobj||target-37/VB||sp-40/NN	myeloma-39||bortezomib-19||yes||on that basis, we used an aurora kinase inhibitor (vx-680) and a proteasome inhibitor (bortezomib) with rpmi 8226 and amo1 cells to determine whether these agents could be used to selectively target the myeloma sp.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||caspofungin-25||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||artemether--1||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â€“6 months after artemetherâ€“lumefantrine (al) replaced sulfadoxineâ€“pyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||lumefantrine-20||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â€“6 months after artemetherâ€“lumefantrine (al) replaced sulfadoxineâ€“pyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
advmod||modulates-6/VBZ||moreover-1/RB	amod||treatment-5/NN||lidocaine-3/JJ	nn||treatment-5/NN||patch-4/NN	nsubj||modulates-6/VBZ||treatment-5/NN	root||ROOT-0/null||modulates-6/VBZ	amod||circuitry-9/NN||distinct-7/JJ	nn||circuitry-9/NN||brain-8/NN	dobj||modulates-6/VBZ||circuitry-9/NN	det||condition-12/NN||each-11/DT	prep_in||circuitry-9/NN||condition-12/NN	prep_in||observe-18/VBP||oa-16/NN	nsubj||observe-18/VBP||we-17/PRP	conj_yet||modulates-6/VBZ||observe-18/VBP	amod||results-20/NNS||divergent-19/JJ	dobj||observe-18/VBP||results-20/NNS	prep_with||observe-18/VBP||fmri-22/NNS	prep_with||observe-18/VBP||questionnaire-25/NN	conj_and||fmri-22/NNS||questionnaire-25/NN	vmod||questionnaire-25/NN||based-26/VBN	dobj||based-26/VBN||instruments-27/NNS	lidocaine-3||oa-16||no_rel||moreover, lidocaine patch treatment modulates distinct brain circuitry in each condition, yet in oa we observe divergent results with fmri and with questionnaire based instruments.
nsubj||binds-5/VBZ||hemagglutinin-1/NN	prep_of||hemagglutinin-1/NN||avianinfluenzaviruses-3/NNS	advmod||binds-5/VBZ||preferentially-4/RB	root||ROOT-0/null||binds-5/VBZ	amod||acids-8/NNS||sialic-7/JJ	prep_to||binds-5/VBZ||acids-8/NNS	vmod||acids-8/NNS||linked-9/VBN	aux||galactose-11/VB||to-10/TO	xcomp||linked-9/VBN||galactose-11/VB	det||linkage-17/NN||an-13/DT	nn||linkage-17/NN||î-14/NNP	nn||linkage-17/NN||±-15/NNP	amod||linkage-17/NN||-2,3-16/JJ	prep_by||galactose-11/VB||linkage-17/NN	mark||binds-22/VBZ||whereas-18/IN	nsubj||binds-22/VBZ||hemagglutinin-19/NN	prep_of||hemagglutinin-19/NN||humaninfluenzaviruses-21/NNS	advcl||galactose-11/VB||binds-22/VBZ	amod||acids-25/NNS||sialic-24/JJ	prep_to||binds-22/VBZ||acids-25/NNS	det||linkage-31/NN||an-27/DT	nn||linkage-31/NN||î-28/NNP	nn||linkage-31/NN||±-29/NNP	amod||linkage-31/NN||-2,6-30/JJ	prep_with||binds-22/VBZ||linkage-31/NN	humaninfluenza--1||influenzaviruses--1||no||hemagglutinin of avianinfluenzaviruses preferentially binds to sialic acids linked to galactose by an î±-2,3 linkage whereas hemagglutinin of humaninfluenzaviruses binds to sialic acids with an î±-2,6 linkage.
det||accumulation-3/NN||the-1/DT	amod||accumulation-3/NN||high-2/JJ	nsubj||likely-17/JJ||accumulation-3/NN	nsubj||contribute-19/VB||accumulation-3/NN	prep_of||accumulation-3/NN||methamphetamine-5/NN	det||drug-10/NN||a-7/DT	amod||drug-10/NN||potent-8/JJ	nn||drug-10/NN||stimulant-9/NN	appos||methamphetamine-5/NN||drug-10/NN	amod||organs-15/NNS||most-13/JJS	nn||organs-15/NNS||body-14/NN	prep_in||methamphetamine-5/NN||organs-15/NNS	cop||likely-17/JJ||is-16/VBZ	root||ROOT-0/null||likely-17/JJ	aux||contribute-19/VB||to-18/TO	xcomp||likely-17/JJ||contribute-19/VB	det||complications-23/NNS||the-21/DT	amod||complications-23/NNS||medical-22/JJ	prep_to||contribute-19/VB||complications-23/NNS	vmod||complications-23/NNS||associated-24/VBN	prep_with||associated-24/VBN||methamphetamineabuse-26/NN	methamphetamineabuse-26||methamphetamine-5||no||the high accumulation of methamphetamine, a potent stimulant drug, in most body organs is likely to contribute to the medical complications associated with methamphetamineabuse.
advmod||appears-4/VBZ||even-1/RB	advmod||appears-4/VBZ||when-2/WRB	nsubj||appears-4/VBZ||drug-resistance-3/NN	nsubj||responsible-7/JJ||drug-resistance-3/NN	advcl||represent-20/VB||appears-4/VBZ	aux||responsible-7/JJ||to-5/TO	cop||responsible-7/JJ||be-6/VB	xcomp||appears-4/VBZ||responsible-7/JJ	det||failure-10/NN||the-9/DT	prep_for||responsible-7/JJ||failure-10/NN	aux||control-12/VB||to-11/TO	vmod||failure-10/NN||control-12/VB	amod||hypertension-14/NN||secondary-13/JJ	dobj||control-12/VB||hypertension-14/NN	prep||control-12/VB||in-15/IN	dep||in-15/IN||as-16/RB	nsubj||represent-20/VB||clonidine-18/NN	aux||represent-20/VB||may-19/MD	root||ROOT-0/null||represent-20/VB	det||option-25/NN||a-21/DT	amod||effective-24/JJ||safe-22/JJ	amod||option-25/NN||effective-24/JJ	dobj||represent-20/VB||option-25/NN	det||normalization-28/NN||the-27/DT	prep_in||option-25/NN||normalization-28/NN	prep_of||normalization-28/NN||highbloodpressure-30/NN	hypertension-14||clonidine-18||yes||even when drug-resistance appears to be responsible for the failure to control secondary hypertension in as, clonidine may represent a safe, effective option in the normalization of highbloodpressure.
det||results-2/NNS||these-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||offers-6/VBZ||that-4/IN	nsubj||offers-6/VBZ||ea-5/NN	ccomp||indicated-3/VBD||offers-6/VBZ	det||effect-9/NN||a-7/DT	amod||effect-9/NN||beneficial-8/JJ	dobj||offers-6/VBZ||effect-9/NN	prep_on||offers-6/VBZ||insulinresistance-11/NN	amod||mice-17/NNS||obese-13/JJ	conj_and||obese-13/JJ||diabetic-15/JJ	amod||mice-17/NNS||diabetic-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||insulinresistance-11/NN||mice-17/NNS	dep||mice-17/NNS||at-19/IN	pobj||at-19/IN||least-20/JJS	dep||at-19/IN||partly-21/RB	prep_via||insulinresistance-11/NN||stimulation-24/NN	amod||±-29/NNS||sirt1/pgc-26/JJ	amod||±-29/NNS||-1-27/JJ	nn||±-29/NNS||î-28/NN	prep_of||stimulation-24/NN||±-29/NNS	advmod||resulting-32/VBG||thus-31/RB	vmod||offers-6/VBZ||resulting-32/VBG	amod||signal-36/NN||improved-34/VBN	nn||signal-36/NN||insulin-35/NN	prep_in||resulting-32/VBG||signal-36/NN	ea-5||obese-13||no_rel||these results indicated that ea offers a beneficial effect on insulinresistance in obese and diabetic db/db mice, at least partly, via stimulation of sirt1/pgc-1 î± , thus resulting in improved insulin signal.
det||status-3/NN||the-1/DT	amod||status-3/NN||endemic-2/JJ	nsubj||continues-16/VBZ||status-3/NN	nsubj||devastate-18/VB||status-3/NN	nsubj||poses-24/VBZ||status-3/NN	advmod||pathogenic-6/JJ||highly-5/RB	amod||avianinfluenzavirus-7/NNS||pathogenic-6/JJ	prep_of||status-3/NN||avianinfluenzavirus-7/NNS	appos||avianinfluenzavirus-7/NNS||hpaiv-9/NNP	amod||h5n1-13/NNS||subtype-12/JJ	prep_of||status-3/NN||h5n1-13/NNS	prep_in||h5n1-13/NNS||egypt-15/NN	root||ROOT-0/null||continues-16/VBZ	aux||devastate-18/VB||to-17/TO	xcomp||continues-16/VBZ||devastate-18/VB	det||industry-22/NN||the-19/DT	amod||industry-22/NN||local-20/JJ	nn||industry-22/NN||poultry-21/NN	dobj||devastate-18/VB||industry-22/NN	conj_and||continues-16/VBZ||poses-24/VBZ	det||threat-27/NN||a-25/DT	amod||threat-27/NN||permanent-26/JJ	dobj||poses-24/VBZ||threat-27/NN	amod||health-30/NN||human-29/JJ	prep_for||threat-27/NN||health-30/NN	h5n1-13||avianinfluenzavirus-7||no||the endemic status of highly pathogenic avianinfluenzavirus (hpaiv) of subtype h5n1 in egypt continues to devastate the local poultry industry and poses a permanent threat for human health.
amod||hivinfection-2/NN||advanced-1/JJ	nsubj||result-4/VB||hivinfection-2/NN	aux||result-4/VB||can-3/MD	root||ROOT-0/null||result-4/VB	prep_in||result-4/VB||lipoatrophy-6/NN	prep_in||result-4/VB||wasting-8/NN	conj_and||lipoatrophy-6/NN||wasting-8/NN	advmod||result-4/VB||even-10/RB	det||absence-13/NN||the-12/DT	prep_in||even-10/RB||absence-13/NN	amod||infections-17/NNS||ongoing-15/JJ	amod||infections-17/NNS||opportunistic-16/JJ	prep_of||absence-13/NN||infections-17/NNS	xcomp||result-4/VB||suggesting-19/VBG	mark||affect-24/VB||that-20/IN	nsubj||affect-24/VB||hiv-21/NN	aux||affect-24/VB||may-22/MD	advmod||affect-24/VB||directly-23/RB	ccomp||suggesting-19/VBG||affect-24/VB	amod||amount-27/NN||adipose-25/JJ	nn||amount-27/NN||tissue-26/NN	dobj||affect-24/VB||amount-27/NN	dobj||affect-24/VB||distribution-29/NN	conj_and||amount-27/NN||distribution-29/NN	hivinfection-2||hiv-21||no||advanced hivinfection can result in lipoatrophy and wasting, even in the absence of ongoing opportunistic infections, suggesting that hiv may directly affect adipose tissue amount and distribution.
nsubj||shares-2/VBZ||bacillusanthracis-1/NNS	root||ROOT-0/null||shares-2/VBZ	det||ancestor-7/NN||a-3/DT	amod||ancestor-7/NN||common-4/JJ	nn||ancestor-7/NN||soil-5/NN	amod||ancestor-7/NN||bacterial-6/JJ	dobj||shares-2/VBZ||ancestor-7/NN	poss||species-13/NN||its-9/PRP$	advmod||related-11/VBN||closely-10/RB	amod||species-13/NN||related-11/VBN	nn||species-13/NN||bacillus-12/NNS	prep_with||shares-2/VBZ||species-13/NN	cop||agent-21/NN||is-15/VBZ	det||agent-21/NN||the-16/DT	amod||agent-21/NN||only-17/JJ	amod||agent-21/NN||obligate-18/JJ	amod||agent-21/NN||causative-20/JJ	conj_but||shares-2/VBZ||agent-21/NN	prep_of||agent-21/NN||inhalationanthrax-23/NN	det||bacillus-27/NNS||the-25/DT	amod||bacillus-27/NNS||genus-26/JJ	prep_within||inhalationanthrax-23/NN||bacillus-27/NNS	inhalationanthrax-23||bacillusanthracis-1||no||bacillusanthracis shares a common soil bacterial ancestor with its closely related bacillus species but is the only obligate, causative agent of inhalationanthrax within the genus bacillus.
amod||infection-2/NN||chronic-1/JJ	nsubj||occurs-8/VBZ||infection-2/NN	prep_with||infection-2/NN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	root||ROOT-0/null||occurs-8/VBZ	quantmod||6-11/CD||approximately-10/RB	num||%-12/NN||6-11/CD	prep_in||occurs-8/VBZ||%-12/NN	det||world-15/NN||the-14/DT	poss||population-17/NN||world-15/NN	prep_of||%-12/NN||population-17/NN	nsubj||are-23/VBP||carriers-19/NNS	det||virus-22/NN||the-21/DT	prep_of||carriers-19/NNS||virus-22/NN	conj_and||occurs-8/VBZ||are-23/VBP	prep_at||are-23/VBP||risk-25/NN	nn||carcinoma-28/NN||hepatocellular-27/NN	prep_for||risk-25/NN||carcinoma-28/NN	prep_for||risk-25/NN||cirrhosis-30/NNS	conj_and||carcinoma-28/NN||cirrhosis-30/NNS	hbv-6||hepatitisbvirus-4||no||chronic infection with hepatitisbvirus (hbv) occurs in approximately 6% of the world's population and carriers of the virus are at risk for hepatocellular carcinoma and cirrhosis.
csubj||occurred-5/VBD||persisting-1/VBG	conj_or||persisting-1/VBG||relapsing-3/VBG	csubj||occurred-5/VBD||relapsing-3/VBG	dobj||persisting-1/VBG||bacteraemia-4/NN	root||ROOT-0/null||occurred-5/VBD	num||%-8/NN||27-7/CD	prep_in||occurred-5/VBD||%-8/NN	prep_of||%-8/NN||daptomycin-10/NN	num||%-13/NN||21-12/CD	prep_in||occurred-5/VBD||%-13/NN	conj_and||%-8/NN||%-13/NN	nn||patients-16/NNS||vancomycin/gentamicin-15/NN	prep_of||%-13/NN||patients-16/NNS	det||patients-20/NNS||these-19/DT	prep_among||occurred-29/VBD||patients-20/NNS	nsubj||occurred-29/VBD||mics-22/NNS	nn||¥-26/NNP||â-24/NNP	nn||¥-26/NNP||‰-25/NNP	prep_of||mics-22/NNS||¥-26/NNP	number||mg/l-28/JJ||2-27/CD	amod||¥-26/NNP||mg/l-28/JJ	parataxis||occurred-5/VBD||occurred-29/VBD	num||daptomycin-32/NN||five-31/CD	prep_in||occurred-29/VBD||daptomycin-32/NN	num||patients-36/NNS||four-34/CD	nn||patients-36/NNS||vancomycin/gentamicin-35/NN	prep_in||occurred-29/VBD||patients-36/NNS	conj_and||daptomycin-32/NN||patients-36/NNS	daptomycin-32||bacteraemia-4||no_rel||persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, mics of â‰¥2 mg/l occurred in five daptomycin and four vancomycin/gentamicin patients.
aux||gain-2/VB||to-1/TO	advcl||undertook-20/VBD||gain-2/VB	dobj||gain-2/VB||insight-3/NN	nn||signatures-7/NNS||gene-5/NN	nn||signatures-7/NNS||expression-6/NN	prep_into||gain-2/VB||signatures-7/NNS	nsubj||distinguish-10/VB||signatures-7/NNS	aux||distinguish-10/VB||can-9/MD	rcmod||signatures-7/NNS||distinguish-10/VB	dobj||distinguish-10/VB||atopicdermatitis-11/NNS	amod||controls-14/NNS||non-atopic-13/JJ	prep_from||distinguish-10/VB||controls-14/NNS	nn||biopsies-17/NNS||skin-16/NN	prep_without||distinguish-10/VB||biopsies-17/NNS	nsubj||undertook-20/VBD||we-19/PRP	root||ROOT-0/null||undertook-20/VBD	det||study-23/NN||a-21/DT	amod||study-23/NN||comparative-22/JJ	dobj||undertook-20/VBD||study-23/NN	nn||expression-26/NN||gene-25/NN	prep_of||study-23/NN||expression-26/NN	prep_in||undertook-20/VBD||fdks-28/NNS	amod||donors-31/NNS||adult-30/JJ	prep_from||fdks-28/NNS||donors-31/NNS	prep_with||undertook-20/VBD||atopicdermatitis-33/NNS	amod||donors-36/NNS||non-atopic-35/JJ	prep_with||undertook-20/VBD||donors-36/NNS	conj_and||atopicdermatitis-33/NNS||donors-36/NNS	atopicdermatitis-33||atopic--1||no||to gain insight into gene expression signatures that can distinguish atopicdermatitis from non-atopic controls without skin biopsies, we undertook a comparative study of gene expression in fdks from adult donors with atopicdermatitis and non-atopic donors.
det||administration-2/NN||the-1/DT	nsubj||result-10/VB||administration-2/NN	amod||immunoglobulin-5/NN||hepatitisb-4/JJ	prep_of||administration-2/NN||immunoglobulin-5/NN	vmod||immunoglobulin-5/NN||followed-6/VBN	agent||followed-6/VBN||hepatitisbvaccine-8/NN	aux||result-10/VB||can-9/MD	root||ROOT-0/null||result-10/VB	det||efficacy-14/NN||a-12/DT	amod||efficacy-14/NN||protective-13/JJ	prep_in||result-10/VB||efficacy-14/NN	quantmod||90-17/CD||almost-16/RB	num||%-18/NN||90-17/CD	prep_of||efficacy-14/NN||%-18/NN	amod||transmission-21/NN||mother-to-child-20/JJ	prep_in||%-18/NN||transmission-21/NN	amod||virus-24/NN||hepatitisb-23/JJ	prep_of||transmission-21/NN||virus-24/NN	appos||virus-24/NN||hbv-26/NN	hbv-26||hepatitisbvaccine-8||yes||the administration of hepatitisb immunoglobulin followed by hepatitisbvaccine can result in a protective efficacy of almost 90% in mother-to-child transmission of hepatitisb virus (hbv).
nsubjpass||managed-7/VBN||type2diabetes-1/NNS	prep_in||type2diabetes-1/NNS||children-3/NNS	auxpass||managed-7/VBN||is-4/VBZ	advmod||commonly-6/RB||most-5/RBS	advmod||managed-7/VBN||commonly-6/RB	ccomp||approved-22/VBD||managed-7/VBN	nn||modification-10/NN||lifestyle-9/NN	prep_with||managed-7/VBN||modification-10/NN	prep_with||managed-7/VBN||medications-12/NNS	conj_and||modification-10/NN||medications-12/NNS	amod||insulin-16/NN||metformin-14/JJ	amod||insulin-16/NN||and/or-15/JJ	appos||modification-10/NN||insulin-16/NN	det||medications-20/NNS||the-18/DT	amod||medications-20/NNS||only-19/JJ	nsubj||approved-22/VBD||medications-20/NNS	advmod||approved-22/VBD||currently-21/RB	root||ROOT-0/null||approved-22/VBD	prep_for||approved-22/VBD||use-24/NN	prep_in||approved-22/VBD||children-26/NNS	type2diabetes-1||insulin-16||yes||type2diabetes in children is most commonly managed with lifestyle modification and medications, metformin and/or insulin, the only medications currently approved for use in children.
amod||patients-3/NNS||chinese-2/JJ	prep_in||predicts-8/VBZ||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||predicts-8/VBZ||hyperglycemia-7/NN	root||ROOT-0/null||predicts-8/VBZ	dobj||predicts-8/VBZ||cancer-9/NN	mark||associated-15/VBN||whereas-11/IN	nn||usage-13/NN||insulin-12/NN	nsubjpass||associated-15/VBN||usage-13/NN	auxpass||associated-15/VBN||was-14/VBD	advcl||predicts-8/VBZ||associated-15/VBN	det||risk-20/NN||a-17/DT	amod||risk-20/NN||reduced-18/VBN	nn||risk-20/NN||cancer-19/NN	prep_with||associated-15/VBN||risk-20/NN	insulin-12||hyperglycemia-7||no_rel||in chinese patients with type2diabetes, hyperglycemia predicts cancer, whereas insulin usage was associated with a reduced cancer risk.
nsubj||agonist-6/NN||exenatide-1/NN	cop||agonist-6/NN||is-2/VBZ	det||agonist-6/NN||a-3/DT	amod||agonist-6/NN||glp-1-4/JJ	nn||agonist-6/NN||receptor-5/NN	root||ROOT-0/null||agonist-6/NN	vmod||agonist-6/NN||approved-7/VBN	prep_for||approved-7/VBN||use-9/NN	prep_in||use-9/NN||type2diabetesmellitus-11/CD	type2diabetesmellitus-11||exenatide-1||yes||exenatide is a glp-1 receptor agonist approved for use in type2diabetesmellitus.
mark||decreased-7/VBD||since-1/IN	poss||concentration-6/NN||her-2/PRP$	nn||concentration-6/NN||blood-3/NN	nn||concentration-6/NN||urea-4/NN	nn||concentration-6/NN||nitrogen-5/NN	nsubj||decreased-7/VBD||concentration-6/NN	advcl||suggested-12/VBN||decreased-7/VBD	advmod||decreased-7/VBD||greatly-8/RB	nsubjpass||suggested-12/VBN||it-10/PRP	auxpass||suggested-12/VBN||was-11/VBD	root||ROOT-0/null||suggested-12/VBN	mark||had-15/VBD||that-13/IN	nsubj||had-15/VBD||she-14/PRP	ccomp||suggested-12/VBN||had-15/VBD	amod||-rrb--28/NN||massive-16/JJ	amod||-rrb--28/NN||polyuria-17/JJ	amod||-rrb--28/NN||due-18/JJ	aux||overhydration-20/VB||to-19/TO	xcomp||due-18/JJ||overhydration-20/VB	amod||dilution-23/NN||-lrb--21/JJ	amod||dilution-23/NN||i.e.-22/JJ	dobj||overhydration-20/VB||dilution-23/NN	poss||fluids-27/NNS||her-25/PRP$	nn||fluids-27/NNS||body-26/NN	prep_of||dilution-23/NN||fluids-27/NNS	dobj||had-15/VBD||-rrb--28/NN	urea-4||polyuria-17||no_rel||since her blood urea nitrogen concentration decreased greatly , it was suggested that she had massive polyuria due to overhydration -lrb- i.e. dilution of her body fluids -rrb- .
nsubj||included-9/VBD||determinants-1/NNS	nn||knowledge-4/NN||clinician-3/NN	prep_of||determinants-1/NNS||knowledge-4/NN	det||analysis-8/NN||the-6/DT	amod||analysis-8/NN||multivariable-7/JJ	prep_in||knowledge-4/NN||analysis-8/NN	root||ROOT-0/null||included-9/VBD	dep||age-20/NN||category-11/NN	appos||category-11/NN||aor-13/NN	num||%-16/NN||95-15/CD	npadvmod||ci-17/RB||%-16/NN	advmod||category-11/NN||ci-17/RB	amod||age-20/NN||clinician-19/JJ	dobj||included-9/VBD||age-20/NN	dep||age-20/NN||30â-22/NNS	num||years-26/NNS||$-23/$	num||$-23/$||39-25/CD	dep||30â-22/NNS||years-26/NNS	nn||â-32/FW||3.28-28/FW	nn||â-32/FW||âˆ-29/FW	nn||â-32/FW||¶-30/FW	nn||â-32/FW||1.65-31/FW	dep||years-26/NNS||â-32/FW	dep||â-32/FW||$-33/$	num||$-33/$||9.75-35/CD	appos||age-20/NN||number-38/NN	prep_of||number-38/NN||persons-40/NNS	prep_with||included-9/VBD||hiv/aids-42/NNS	vmod||hiv/aids-42/NNS||seen-43/VBN	det||year-47/NN||the-45/DT	amod||year-47/NN||past-46/JJ	prep_in||seen-43/VBN||year-47/NN	mwe||than-50/IN||less-49/JJR	quantmod||50-51/CD||than-50/IN	dep||year-47/NN||50-51/CD	dep||50-51/CD||0.34-53/CD	nn||â-57/FW||âˆ-54/FW	nn||â-57/FW||¶-55/FW	nn||â-57/FW||0.14-56/FW	dep||0.34-53/CD||â-57/FW	dep||50-51/CD||$-58/$	num||$-58/$||0.86-60/CD	amod||profession-64/NN||clinical-63/JJ	prep_in||seen-43/VBN||profession-64/NN	conj_and||year-47/NN||profession-64/NN	amod||practitioner-68/NN||clinical-66/JJ	nn||practitioner-68/NN||nurse-67/NN	dep||year-47/NN||practitioner-68/NN	nn||â-74/FW||0.31-70/FW	nn||â-74/FW||âˆ-71/FW	nn||â-74/FW||¶-72/FW	nn||â-74/FW||0.11-73/FW	dep||practitioner-68/NN||â-74/FW	dep||â-74/FW||$-75/$	num||$-75/$||0.83-77/CD	aids--1||hiv--1||no||determinants of clinician knowledge in the multivariable analysis included (category, aor, 95% ci) clinician age (30â€“39 years; 3.28âˆ¶1.65â€“9.75), number of persons with hiv/aids seen in the past year (less than 50; 0.34âˆ¶0.14â€“0.86) and clinical profession (clinical nurse practitioner; 0.31âˆ¶0.11â€“0.83).
prep_in||led-14/VBD||patients-2/NNS	amod||control-8/NN||type2diabetes-4/JJ	conj_and||type2diabetes-4/JJ||inadequate-6/JJ	amod||control-8/NN||inadequate-6/JJ	amod||control-8/NN||glycaemic-7/JJ	prep_with||patients-2/NNS||control-8/NN	nsubj||led-14/VBD||treatment-10/NN	amod||pill-13/NN||xiaoke-12/JJ	prep_with||treatment-10/NN||pill-13/NN	root||ROOT-0/null||led-14/VBD	amod||reduction-17/NN||significant-16/JJ	prep_to||led-14/VBD||reduction-17/NN	prep_in||led-14/VBD||risk-19/NN	prep_of||risk-19/NN||hypoglycemia-21/NN	amod||improvements-24/NNS||similar-23/JJ	prep_in||led-14/VBD||improvements-24/NNS	conj_and||risk-19/NN||improvements-24/NNS	amod||control-27/NN||glycemic-26/JJ	prep_in||improvements-24/NNS||control-27/NN	num||weeks-30/NNS||48-29/CD	prep_after||led-14/VBD||weeks-30/NNS	prepc_compared_to||weeks-30/NNS||to-32/TO	pobj||weeks-30/NNS||glibenclamide-33/NN	type2diabetes-4||glibenclamide-33||yes||in patients with type2diabetes and inadequate glycaemic control, treatment with xiaoke pill led to significant reduction in risk of hypoglycemia and similar improvements in glycemic control after 48 weeks compared to glibenclamide.
nsubjpass||shown-20/VBN||mycophenolatemofetil-1/NN	nsubj||cause-22/VB||mycophenolatemofetil-1/NN	nn||®-4/NNP||cellceptâ-3/NNP	appos||mycophenolatemofetil-1/NN||®-4/NNP	det||drug-11/NN||a-7/DT	advmod||used-9/VBN||commonly-8/RB	amod||drug-11/NN||used-9/VBN	amod||drug-11/NN||immunosuppressive-10/JJ	appos||mycophenolatemofetil-1/NN||drug-11/NN	amod||transplantation-15/NN||solid-13/JJ	nn||transplantation-15/NN||organ-14/NN	prep_in||drug-11/NN||transplantation-15/NN	aux||shown-20/VBN||has-17/VBZ	advmod||shown-20/VBN||recently-18/RB	auxpass||shown-20/VBN||been-19/VBN	root||ROOT-0/null||shown-20/VBN	aux||cause-22/VB||to-21/TO	xcomp||shown-20/VBN||cause-22/VB	dobj||cause-22/VB||graft-versus-hostdisease-23/NN	dep||graft-versus-hostdisease-23/NN||gvhd-25/VBN	prep_like||cause-22/VB||changes-29/NNS	det||tract-33/NN||the-31/DT	amod||tract-33/NN||gastrointestinal-32/JJ	prep_in||changes-29/NNS||tract-33/NN	graft-versus-hostdisease-23||mycophenolatemofetil-1||yes||mycophenolatemofetil (cellceptâ®), a commonly used immunosuppressive drug in solid organ transplantation, has recently been shown to cause graft-versus-hostdisease (gvhd)-like changes in the gastrointestinal tract.
nsubjpass||complicated-7/VBN||pertussis-1/NN	appos||pertussis-1/NN||whoopingcough-3/NN	auxpass||complicated-7/VBN||is-5/VBZ	advmod||complicated-7/VBN||frequently-6/RB	root||ROOT-0/null||complicated-7/VBN	amod||infections-10/NNS||concomitant-9/JJ	agent||complicated-7/VBN||infections-10/NNS	amod||viruses-13/NNS||respiratory-12/JJ	prep_with||complicated-7/VBN||viruses-13/NNS	whoopingcough-3||pertussis-1||yes||pertussis (whoopingcough) is frequently complicated by concomitant infections with respiratory viruses.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	speed-30||age-relatedmaculardegeneration-11||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
det||factors-5/NNS||the-1/DT	num||factors-5/NNS||two-2/CD	advmod||consistent-4/JJ||most-3/RBS	amod||factors-5/NNS||consistent-4/JJ	nsubj||having-14/VBG||factors-5/NNS	vmod||factors-5/NNS||associated-6/VBN	nn||testing-9/NN||hiv-8/NN	prep_with||associated-6/VBN||testing-9/NN	det||countries-12/NNS||the-11/DT	prep_across||associated-6/VBN||countries-12/NNS	aux||having-14/VBG||were-13/VBD	root||ROOT-0/null||having-14/VBG	dep||having-14/VBG||heard-15/VBN	prep_about||heard-15/VBN||hiv/aids-17/NNS	det||centre-23/NN||a-19/DT	nn||centre-23/NN||clinic-20/NN	conj_or||clinic-20/NN||health-22/NN	nn||centre-23/NN||health-22/NN	prep_from||hiv/aids-17/NNS||centre-23/NN	aux||talked-27/VBN||having-26/VBG	dep||having-14/VBG||talked-27/VBN	conj_and||heard-15/VBN||talked-27/VBN	prep_to||talked-27/VBN||someone-29/NN	prep_about||someone-29/NN||hiv-31/NN	prep_about||someone-29/NN||aids-33/NNS	conj_and||hiv-31/NN||aids-33/NNS	aids-33||hiv-31||no||the two most consistent factors associated with hiv testing across the countries were having heard about hiv/aids from a clinic or health centre, and having talked to someone about hiv and aids.
nsubj||disease-6/NN||denguehemorrhagicfever-1/NN	cop||disease-6/NN||is-2/VBZ	det||disease-6/NN||an-3/DT	amod||disease-6/NN||acute-4/JJ	amod||disease-6/NN||infectious-5/JJ	root||ROOT-0/null||disease-6/NN	vmod||disease-6/NN||caused-7/VBN	agent||caused-7/VBN||denguevirus-9/NNS	denguehemorrhagicfever-1||denguevirus-9||no||denguehemorrhagicfever is an acute infectious disease caused by denguevirus.
advmod||inhibits-11/VBZ||altogether-1/RB	nsubj||inhibits-11/VBZ||asa-3/NN	amod||asa-3/NN||likely-5/JJ	poss||moiety-9/NN||its-7/PRP$	amod||moiety-9/NN||acetyl-8/JJ	prep_via||likely-5/JJ||moiety-9/NN	root||ROOT-0/null||inhibits-11/VBZ	amod||inflammation-14/NN||th17-12/JJ	nn||inflammation-14/NN||airway-13/NN	dobj||inhibits-11/VBZ||inflammation-14/NN	prep_by||inhibits-11/VBZ||blockade-16/NN	amod||feedback-22/NN||il-6-18/JJ	conj_and||il-6-18/JJ||il-17-20/JJ	amod||feedback-22/NN||il-17-20/JJ	amod||feedback-22/NN||positive-21/JJ	prep_of||blockade-16/NN||feedback-22/NN	inflammation-14||asa-3||yes||altogether, asa, likely via its acetyl moiety, inhibits th17 airway inflammation by blockade of il-6 and il-17 positive feedback.
nn||therapy-2/NN||insulin-1/NN	nsubj||targets-4/VBZ||therapy-2/NN	nsubj||effective-11/JJ||therapy-2/NN	nsubj||reduce-13/VB||therapy-2/NN	advmod||targets-4/VBZ||primarily-3/RB	root||ROOT-0/null||targets-4/VBZ	amod||glycemia-7/NN||elevated-5/JJ	amod||glycemia-7/NN||fasting-6/VBG	dobj||targets-4/VBZ||glycemia-7/NN	cop||effective-11/JJ||is-9/VBZ	advmod||effective-11/JJ||less-10/RBR	conj_but||targets-4/VBZ||effective-11/JJ	aux||reduce-13/VB||to-12/TO	xcomp||effective-11/JJ||reduce-13/VB	amod||hyperglycemia-15/NN||postprandial-14/JJ	dobj||reduce-13/VB||hyperglycemia-15/NN	hyperglycemia-15||insulin-1||yes||insulin therapy primarily targets elevated fasting glycemia but is less effective to reduce postprandial hyperglycemia.
nn||caregivers-2/NNS||volunteer-1/NN	nsubj||source-6/NN||caregivers-2/NNS	cop||source-6/NN||are-3/VBP	det||source-6/NN||a-4/DT	amod||source-6/NN||critical-5/JJ	root||ROOT-0/null||source-6/NN	prep_of||source-6/NN||support-8/NN	det||majority-11/NN||the-10/DT	prep_for||support-8/NN||majority-11/NN	prep_of||majority-11/NN||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv-16/NN	prep_with||living-14/VBG||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	amod||africa-21/NN||southern-20/JJ	prep_in||living-14/VBG||africa-21/NN	nsubj||has-24/VBZ||africa-21/NN	rcmod||africa-21/NN||has-24/VBZ	advmod||high-26/JJ||extremely-25/RB	amod||rates-29/NNS||high-26/JJ	amod||rates-29/NNS||hiv/aids-27/JJ	nn||rates-29/NNS||prevalence-28/NN	dobj||has-24/VBZ||rates-29/NNS	aids-18||hiv-16||no||volunteer caregivers are a critical source of support for the majority of people living with hiv and aids in southern africa, which has extremely high hiv/aids prevalence rates.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||carotene-22||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â€“69 years using a 2 ã— 2 factorial design.
det||report-4/NN||this-2/DT	nn||report-4/NN||case-3/NN	prep_through||discussed-17/VBN||report-4/NN	det||points-8/NNS||the-6/DT	nn||points-8/NNS||differential-7/NN	nsubjpass||discussed-17/VBN||points-8/NNS	nsubjpass||focused-20/VBN||points-8/NNS	amod||imbalances-13/NNS||nephrocalcinosis-10/JJ	conj_and||nephrocalcinosis-10/JJ||electrolyte-12/JJ	amod||imbalances-13/NNS||electrolyte-12/JJ	prep_of||points-8/NNS||imbalances-13/NNS	prep_between||imbalances-13/NNS||them-15/PRP	auxpass||discussed-17/VBN||are-16/VBP	root||ROOT-0/null||discussed-17/VBN	conj_and||discussed-17/VBN||focused-20/VBN	advmod||focused-20/VBN||more-21/RBR	amod||tests-24/NNS||diagnostic-23/JJ	prep_on||focused-20/VBN||tests-24/NNS	prep_on||focused-20/VBN||managements-26/NNS	conj_and||tests-24/NNS||managements-26/NNS	nn||rta-30/NN||type-28/NN	num||rta-30/NN||1-29/CD	prep_of||tests-24/NNS||rta-30/NN	rta-30||electrolyte-12||no_rel||through this case report, the differential points of nephrocalcinosis and electrolyte imbalances between them are discussed, and focused more on diagnostic tests and managements of type 1 rta.
nsubj||complication-5/NN||diabeticnephropathy-1/NN	nsubjpass||associated-10/VBN||diabeticnephropathy-1/NN	cop||complication-5/NN||is-2/VBZ	det||complication-5/NN||a-3/DT	amod||complication-5/NN||serious-4/JJ	root||ROOT-0/null||complication-5/NN	prep_of||complication-5/NN||diabetesmellitus-7/NNS	auxpass||associated-10/VBN||is-9/VBZ	conj_and||complication-5/NN||associated-10/VBN	amod||morbidity-13/NN||considerable-12/JJ	prep_with||associated-10/VBN||morbidity-13/NN	amod||mortality-16/NN||high-15/JJ	prep_with||associated-10/VBN||mortality-16/NN	conj_and||morbidity-13/NN||mortality-16/NN	diabeticnephropathy-1||diabetesmellitus-7||no||diabeticnephropathy is a serious complication of diabetesmellitus and is associated with considerable morbidity and high mortality.
det||study-3/NN||a-1/DT	amod||study-3/NN||prospective-2/JJ	nsubjpass||begun-5/VBN||study-3/NN	nsubj||attempt-7/VB||study-3/NN	nsubj||assess-9/VB||study-3/NN	auxpass||begun-5/VBN||was-4/VBD	root||ROOT-0/null||begun-5/VBN	aux||attempt-7/VB||to-6/TO	xcomp||begun-5/VBN||attempt-7/VB	aux||assess-9/VB||to-8/TO	xcomp||attempt-7/VB||assess-9/VB	det||risk-11/NN||the-10/DT	dobj||assess-9/VB||risk-11/NN	amod||hivinfection-15/NN||developing-13/VBG	amod||hivinfection-15/NN||symptomatic-14/JJ	prep_of||risk-11/NN||hivinfection-15/NN	advmod||born-20/VBN||when-16/WRB	det||child-18/NN||a-17/DT	nsubjpass||born-20/VBN||child-18/NN	auxpass||born-20/VBN||is-19/VBZ	advcl||attempt-7/VB||born-20/VBN	det||mother-23/NN||a-22/DT	prep_to||born-20/VBN||mother-23/NN	prep_with||mother-23/NN||antibodies-25/NNS	prep_to||born-20/VBN||hiv-27/NN	hivinfection-15||hiv-27||no||a prospective study was begun to attempt to assess the risk of developing symptomatic hivinfection when a child is born to a mother with antibodies to hiv.
det||inhaler-3/NN||the-1/DT	nn||inhaler-3/NN||combination-2/NN	nsubj||product-11/NN||inhaler-3/NN	vmod||inhaler-3/NN||containing-4/VBG	acomp||containing-4/VBG||salmeterol-5/JJ	acomp||containing-4/VBG||fluticasone-7/JJ	conj_and||salmeterol-5/JJ||fluticasone-7/JJ	cop||product-11/NN||is-8/VBZ	num||product-11/NN||one-9/CD	amod||product-11/NN||such-10/JJ	root||ROOT-0/null||product-11/NN	nsubjpass||proven-15/VBN||product-11/NN	aux||proven-15/VBN||has-13/VBZ	auxpass||proven-15/VBN||been-14/VBN	rcmod||product-11/NN||proven-15/VBN	acomp||proven-15/VBN||safe-16/JJ	acomp||proven-15/VBN||effective-18/JJ	conj_and||safe-16/JJ||effective-18/JJ	nn||therapy-21/NN||asthma-20/NN	prep_for||proven-15/VBN||therapy-21/NN	asthma-20||salmeterol-5||no||the combination inhaler containing salmeterol and fluticasone is one such product that has been proven safe and effective for asthma therapy.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||evaluate-8/VB||effectiveness-10/NN	prep_of||effectiveness-10/NN||monotherapy-12/NN	amod||therapy-17/NN||interferonalpha-2b-14/JJ	conj_and||interferonalpha-2b-14/JJ||combination-16/NN	amod||therapy-17/NN||combination-16/NN	prep_with||evaluate-8/VB||therapy-17/NN	prep_with||therapy-17/NN||interferonalpha-2b-19/NNP	prep_with||therapy-17/NN||ribavirin-21/NNP	conj_plus||interferonalpha-2b-19/NNP||ribavirin-21/NNP	prep_on||evaluate-8/VB||chronichepatitiscinfection-23/NN	amod||patients-26/NNS||thalassaemic-25/JJ	prep_in||chronichepatitiscinfection-23/NN||patients-26/NNS	chronichepatitiscinfection-23||interferonalpha-2b-19||yes||the aim of this study was to evaluate the effectiveness of monotherapy with interferonalpha-2b and combination therapy with interferonalpha-2b plus ribavirin on chronichepatitiscinfection in thalassaemic patients.
det||analysis-2/NN||the-1/DT	nsubj||included-3/VBD||analysis-2/NN	root||ROOT-0/null||included-3/VBD	num||studies-8/NNS||three-4/CD	amod||studies-8/NNS||randomized-5/JJ	amod||studies-8/NNS||double-blind-7/JJ	dobj||included-3/VBD||studies-8/NNS	prep_in||studies-8/NNS||patients-10/NNS	prep_with||patients-10/NNS||schizophrenia-12/NN	amod||disorder-15/NN||schizoaffective-14/JJ	dobj||included-3/VBD||disorder-15/NN	conj_or||studies-8/NNS||disorder-15/NN	nn||disorder-19/NN||schizophreniform-18/NN	dobj||included-3/VBD||disorder-19/NN	conj_or||studies-8/NNS||disorder-19/NN	dep||disorder-19/NN||diagnosed-20/VBN	prepc_according_to||diagnosed-20/VBN||to-22/TO	det||manual-27/NN||the-23/DT	amod||manual-27/NN||diagnostic-24/JJ	conj_and||diagnostic-24/JJ||statistical-26/JJ	amod||manual-27/NN||statistical-26/JJ	pobj||diagnosed-20/VBN||manual-27/NN	amod||disorders-30/NNS||mental-29/JJ	npadvmod||4th-31/JJ||disorders-30/NNS	amod||edition-32/NN||4th-31/JJ	prep_of||manual-27/NN||edition-32/NN	advmod||assigned-35/VBN||randomly-34/RB	dep||disorder-19/NN||assigned-35/VBN	conj_and||diagnosed-20/VBN||assigned-35/VBN	prep_to||assigned-35/VBN||treatment-37/NN	poss||mg/day-44/NN||olanzapine-39/PRP$	amod||mg/day-44/NN||5â-40/JJ	amod||mg/day-44/NN||$-41/$	num||$-41/$||20-43/CD	prep_with||assigned-35/VBN||mg/day-44/NN	det||antipsychotic-47/NN||another-46/DT	prep_with||assigned-35/VBN||antipsychotic-47/NN	conj_or||mg/day-44/NN||antipsychotic-47/NN	amod||2â-50/NNS||haloperidol-49/JJ	dep||antipsychotic-47/NN||2â-50/NNS	num||mg/day-54/NN||$-51/$	num||$-51/$||20-53/CD	dep||2â-50/NNS||mg/day-54/NN	poss||mg/day-61/NN||risperidone-56/PRP$	amod||mg/day-61/NN||2â-57/JJ	amod||mg/day-61/NN||$-58/$	num||$-58/$||10-60/CD	dep||2â-50/NNS||mg/day-61/NN	conj_or||mg/day-54/NN||mg/day-61/NN	poss||mg/day-69/NN||ziprasidone-64/PRP$	amod||mg/day-69/NN||80â-65/JJ	amod||mg/day-69/NN||$-66/$	num||$-66/$||160-68/CD	dep||2â-50/NNS||mg/day-69/NN	conj_or||mg/day-54/NN||mg/day-69/NN	schizophrenia-12||ziprasidone-64||yes||the analysis included three randomized, double-blind studies in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder diagnosed according to the diagnostic and statistical manual of mental disorders 4th edition and randomly assigned to treatment with olanzapine 5â€“20 mg/day or another antipsychotic (haloperidol 2â€“20 mg/day, risperidone 2â€“10 mg/day, or ziprasidone 80â€“160 mg/day).
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	pain-28||hc--1||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
nsubj||had-5/VBD||they-1/PRP	advmod||had-5/VBD||also-2/RB	advmod||frequently-4/RB||more-3/RBR	advmod||had-5/VBD||frequently-4/RB	root||ROOT-0/null||had-5/VBD	dobj||had-5/VBD||parkinsonism-6/NN	nsubjpass||correlated-11/VBN||parkinsonism-6/NN	auxpass||correlated-11/VBN||was-9/VBD	advmod||correlated-11/VBN||significantly-10/RB	rcmod||parkinsonism-6/NN||correlated-11/VBN	det||treatment-15/NN||both-13/DT	amod||treatment-15/NN||haloperidol-14/JJ	prep_with||correlated-11/VBN||treatment-15/NN	num||month-18/NN||1-17/CD	prep_at||treatment-15/NN||month-18/NN	nn||â-21/NN||p-20/NN	dep||month-18/NN||â-21/NN	nsubj||â-25/VBP||$-22/$	number||<-24/CD||‰-23/CD	num||$-22/$||<-24/CD	rcmod||â-21/NN||â-25/VBP	dobj||â-25/VBP||$-26/$	number||0.001-28/CD||‰-27/CD	num||$-26/$||0.001-28/CD	num||months-32/NNS||6-31/CD	prep_at||treatment-15/NN||months-32/NNS	conj_and||month-18/NN||months-32/NNS	nn||â-35/NN||p-34/NN	dep||months-32/NNS||â-35/NN	nsubj||â-39/VBP||$-36/$	number||=-38/CD||‰-37/CD	num||$-36/$||=-38/CD	rcmod||â-35/NN||â-39/VBP	dobj||â-39/VBP||$-40/$	number||0.016-42/CD||‰-41/CD	num||$-40/$||0.016-42/CD	amod||treatment-46/NN||olanzapine-45/JJ	prep_at||treatment-15/NN||treatment-46/NN	conj_and||month-18/NN||treatment-46/NN	prep_at||treatment-46/NN||baseline-48/NN	nn||â-51/NN||p-50/NN	dep||treatment-46/NN||â-51/NN	nsubj||â-55/VBP||$-52/$	number||=-54/CD||‰-53/CD	num||$-52/$||=-54/CD	rcmod||â-51/NN||â-55/VBP	dobj||â-55/VBP||$-56/$	number||0.016-58/CD||‰-57/CD	num||$-56/$||0.016-58/CD	num||months-62/NNS||3-61/CD	prep_with||correlated-11/VBN||months-62/NNS	conj_and||treatment-15/NN||months-62/NNS	nn||â-65/NN||p-64/NN	dep||months-62/NNS||â-65/NN	dep||â-69/NN||$-66/$	num||â-69/NN||‰-67/CD	amod||â-69/NN||=-68/JJ	dep||â-65/NN||â-69/NN	dep||â-69/NN||$-70/$	number||0.019-72/CD||‰-71/CD	num||$-70/$||0.019-72/CD	num||months-77/NNS||6-76/CD	prep_with||correlated-11/VBN||months-77/NNS	conj_and||treatment-15/NN||months-77/NNS	nn||â-80/NN||p-79/NN	dep||months-77/NNS||â-80/NN	dep||â-84/NN||$-81/$	num||â-84/NN||‰-82/CD	amod||â-84/NN||=-83/JJ	dep||â-80/NN||â-84/NN	dep||â-84/NN||$-85/$	number||0.021-87/CD||‰-86/CD	num||$-85/$||0.021-87/CD	olanzapine-45||parkinsonism-6||no_rel||they also more frequently had parkinsonism, which was significantly correlated with both haloperidol treatment at 1 month ( p â€‰<â€‰0.001) and 6 months ( p â€‰=â€‰0.016) and olanzapine treatment at baseline ( p â€‰=â€‰0.016), 3 months ( p â€‰=â€‰0.019), and 6 months ( p â€‰=â€‰0.021).
aux||identify-2/VB||to-1/TO	csubj||macrophages-17/VBZ||identify-2/VB	conj_and||identify-2/VB||localize-4/VB	csubj||macrophages-17/VBZ||localize-4/VB	conj_and||identify-2/VB||determine-7/VB	csubj||macrophages-17/VBZ||determine-7/VB	amod||polarization-9/NN||m1/m2-8/JJ	dobj||identify-2/VB||polarization-9/NN	amod||tissue-13/NN||epidydimal-11/JJ	nn||tissue-13/NN||adipose-12/NN	prep_of||polarization-9/NN||tissue-13/NN	dep||macrophages-17/VBZ||eat-15/VB	root||ROOT-0/null||macrophages-17/VBZ	nn||¦-20/NNS||î-19/NN	nsubj||s-21/VBZ||¦-20/NNS	parataxis||macrophages-17/VBZ||s-21/VBZ	amod||diet-25/NN||high-fat-24/JJ	prep_during||macrophages-17/VBZ||diet-25/NN	appos||diet-25/NN||hfd-27/NN	amod||obesity-31/NN||induced-30/JJ	dep||diet-25/NN||obesity-31/NN	fat--1||obesity-31||no_rel||to identify, localize, and determine m1/m2 polarization of epidydimal adipose tissue (eat) macrophages (î¦s) during high-fat diet (hfd)-induced obesity.
det||total-2/NN||a-1/DT	nsubj||taking-11/VBG||total-2/NN	num||%-5/NN||55-4/CD	prep_of||total-2/NN||%-5/NN	nn||patients-8/NNS||ra-7/NN	prep_of||%-5/NN||patients-8/NNS	aux||taking-11/VBG||were-9/VBD	neg||taking-11/VBG||not-10/RB	root||ROOT-0/null||taking-11/VBG	amod||supplements-13/NNS||vitamind-12/JJ	dobj||taking-11/VBG||supplements-13/NNS	det||proportion-16/NN||the-15/DT	nsubj||%-35/NN||proportion-16/NN	prep_of||proportion-16/NN||these-18/DT	amod||deficiency-21/NN||vitamind-20/JJ	prep_with||these-18/DT||deficiency-21/NN	dep||deficiency-21/NN||25-23/CD	discourse||25-23/CD||oh-25/UH	amod||<-29/NNS||d-27/JJ	nn||<-29/NNS||level-28/NN	dep||25-23/CD||<-29/NNS	num||ng/ml-31/NN||20-30/CD	dep||25-23/CD||ng/ml-31/NN	cop||%-35/NN||was-33/VBD	num||%-35/NN||52-34/CD	parataxis||taking-11/VBG||%-35/NN	vitamind-20||vitaminddeficiency--1||no_rel||a total of 55% of ra patients were not taking vitamind supplements; the proportion of these with vitamind deficiency (25(oh)d level <20 ng/ml) was 52%.
det||study-2/NN||this-1/DT	nsubj||established-4/VBN||study-2/NN	aux||established-4/VBN||has-3/VBZ	root||ROOT-0/null||established-4/VBN	amod||correlation-6/NN||inverse-5/JJ	dobj||established-4/VBN||correlation-6/NN	det||increase-9/NN||the-8/DT	prep_of||correlation-6/NN||increase-9/NN	amod||immunity-12/NN||th1/th2-11/JJ	prep_of||increase-9/NN||immunity-12/NN	det||decline-15/NN||the-14/DT	prep_of||correlation-6/NN||decline-15/NN	conj_and||increase-9/NN||decline-15/NN	nn||load-19/NN||hbv-17/NN	nn||load-19/NN||dna-18/NN	prep_of||decline-15/NN||load-19/NN	amod||patients-23/NNS||chronic-21/JJ	nn||patients-23/NNS||hbv-22/NN	prep_in||load-19/NN||patients-23/NNS	amod||treatment-26/NN||adefovirdipivoxil-25/JJ	prep_during||established-4/VBN||treatment-26/NN	hbv-22||adefovirdipivoxil-25||yes||this study has established inverse correlation of the increase of th1/th2 immunity and the decline of hbv dna load in chronic hbv patients during adefovirdipivoxil treatment.
det||method-2/NN||the-1/DT	nsubjpass||optimized-5/VBN||method-2/NN	auxpass||optimized-5/VBN||was-3/VBD	advmod||optimized-5/VBN||first-4/RB	root||ROOT-0/null||optimized-5/VBN	xcomp||optimized-5/VBN||utilizing-6/VBG	amod||strains-9/NNS||borrelia-7/JJ	nn||strains-9/NNS||laboratory-8/NN	dobj||utilizing-6/VBG||strains-9/NNS	advmod||followed-25/VBD||later-12/RB	prepc_by||later-12/RB||demonstrating-14/VBG	dobj||demonstrating-14/VBG||growth-15/NN	prep_of||growth-15/NN||borrelia-17/NN	prep_from||demonstrating-14/VBG||sera-19/NN	amod||seropositive-22/NN||fifty-21/JJ	prep_from||demonstrating-14/VBG||seropositive-22/NN	amod||patients-24/NNS||lymedisease-23/JJ	nsubj||followed-25/VBD||patients-24/NNS	conj_and||optimized-5/VBN||followed-25/VBD	det||cohort-28/NN||another-27/DT	prep_by||followed-25/VBD||cohort-28/NN	num||patients-32/NNS||72-30/CD	amod||patients-32/NNS||lymedisease-31/JJ	prep_of||cohort-28/NN||patients-32/NNS	pobj||of-35/IN||patients-32/NNS	dep||of-35/IN||all-34/DT	nsubj||satisfied-37/VBD||of-35/IN	rcmod||patients-32/NNS||satisfied-37/VBD	det||definition-43/NN||the-38/DT	amod||definition-43/NN||strict-39/JJ	nn||definition-43/NN||cdc-40/NN	nn||definition-43/NN||surveillance-41/NN	nn||definition-43/NN||case-42/NN	dobj||satisfied-37/VBD||definition-43/NN	prep_for||satisfied-37/VBD||lymedisease-45/NN	lymedisease-45||borrelia-17||no||the method was first optimized utilizing borrelia laboratory strains, and later by demonstrating growth of borrelia from sera from fifty seropositive lymedisease patients followed by another cohort of 72 lymedisease patients, all of whom satisfied the strict cdc surveillance case definition for lymedisease.
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-24/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	nn||g-10/NN||penicillin-9/NN	dep||antibiotics-7/NNS||g-10/NN	appos||g-10/NN||methicillin-12/NN	appos||g-10/NN||erythromycin-14/NN	conj_and||methicillin-12/NN||erythromycin-14/NN	appos||g-10/NN||ciprofloxacin-16/NN	conj_and||methicillin-12/NN||ciprofloxacin-16/NN	appos||g-10/NN||clindamycin-18/NN	conj_and||methicillin-12/NN||clindamycin-18/NN	appos||g-10/NN||clarithromycin-20/NN	conj_and||methicillin-12/NN||clarithromycin-20/NN	auxpass||observed-24/VBN||was-23/VBD	conj_and||contained-5/VBD||observed-24/VBN	det||isolates-28/NN||the-26/DT	nn||isolates-28/NN||mrsa-27/NN	prep_in||observed-24/VBN||isolates-28/NN	predet||uk-32/NN||both-30/PDT	det||uk-32/NN||the-31/DT	prep_in||isolates-28/NN||uk-32/NN	amod||cohorts-35/NNS||maltese-34/JJ	prep_in||isolates-28/NN||cohorts-35/NNS	conj_and||uk-32/NN||cohorts-35/NNS	erythromycin-14||mrsa-27||no_rel||the largest mar profile contained six antibiotics (penicillin g, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
amod||rickets-2/NNS||hypophosphatemic-1/JJ	nsubj||represents-3/VBZ||rickets-2/NNS	root||ROOT-0/null||represents-3/VBZ	det||group-5/NN||a-4/DT	dobj||represents-3/VBZ||group-5/NN	amod||disorders-9/NNS||heritable-7/JJ	amod||disorders-9/NNS||renal-8/JJ	prep_of||group-5/NN||disorders-9/NNS	prep_of||disorders-9/NNS||phosphate-11/NN	vmod||phosphate-11/NN||characterized-12/VBN	amod||serum-19/NN||hypophosphatemia-14/JJ	conj_or||hypophosphatemia-14/JJ||normal-16/JJ	amod||serum-19/NN||normal-16/JJ	conj_or||hypophosphatemia-14/JJ||low-18/JJ	amod||serum-19/NN||low-18/JJ	agent||characterized-12/VBN||serum-19/NN	num||serum-19/NN||1,25-20/CD	discourse||serum-19/NN||oh-22/UH	num||vitamind-25/NN||2-24/CD	dep||serum-19/NN||vitamind-25/NN	nn||levels-28/NNS||calcium-27/NN	dep||serum-19/NN||levels-28/NNS	conj_and||vitamind-25/NN||levels-28/NNS	rickets-2||vitamind-25||yes||hypophosphatemic rickets represents a group of heritable renal disorders of phosphate characterized by hypophosphatemia, normal or low serum 1,25 (oh)2 vitamind and calcium levels.
amod||âˆ-3/NN||trex1-2/JJ	poss||âˆ-6/NN||âˆ-3/NN	amod||âˆ-6/NN||/-5/JJ	poss||cells-9/NNS||âˆ-6/NN	nn||cells-9/NNS||mouse-8/NN	prep_in||accumulated-29/VBN||cells-9/NNS	amod||cells-15/NNS||human-11/JJ	amod||cells-15/NNS||cd4-12/JJ	amod||cells-15/NNS||+-13/JJ	nn||cells-15/NNS||t-14/NN	conj_and||cells-9/NNS||cells-15/NNS	prep_in||accumulated-29/VBN||cells-15/NNS	conj_and||cells-9/NNS||macrophages-17/NNS	conj_and||cells-15/NNS||macrophages-17/NNS	prep_in||inhibited-22/VBN||which-19/WDT	nsubjpass||inhibited-22/VBN||trex1-20/NNS	auxpass||inhibited-22/VBN||was-21/VBD	dep||cells-9/NNS||inhibited-22/VBN	nn||interference-25/NN||rna-24/NN	agent||inhibited-22/VBN||interference-25/NN	amod||hivdna-28/NN||cytosolic-27/JJ	nsubj||accumulated-29/VBN||hivdna-28/NN	root||ROOT-0/null||accumulated-29/VBN	nsubj||induced-33/VBN||hivinfection-32/NN	nsubj||spreading-42/VBG||hivinfection-32/NN	conj_and||accumulated-29/VBN||induced-33/VBN	nn||ifn-36/NN||type-34/FW	nn||ifn-36/NN||i-35/FW	dobj||induced-33/VBN||ifn-36/NN	nsubj||inhibited-38/VBD||ifn-36/NN	rcmod||ifn-36/NN||inhibited-38/VBD	nn||replication-40/NN||hiv-39/NN	dobj||inhibited-38/VBD||replication-40/NN	conj_and||accumulated-29/VBN||spreading-42/VBG	conj_and||induced-33/VBN||spreading-42/VBG	hivdna-28||hiv-39||no||in trex1 âˆ’/âˆ’ mouse cells and human cd4+ t cells and macrophages in which trex1 was inhibited by rna interference, cytosolic hivdna accumulated, and hivinfection induced type i ifn that inhibited hiv replication and spreading.
prepc_based_on||selected-27/VBN||on-2/IN	amod||relief-5/NN||better-3/JJR	nn||relief-5/NN||pain-4/NN	pobj||selected-27/VBN||relief-5/NN	amod||consumption-15/NN||significant-7/JJ	appos||consumption-15/NN||p-9/NNP	number||.05-11/CD||<-10/CD	num||p-9/NNP||.05-11/CD	dep||analgesic-14/VBG||least-13/JJS	amod||consumption-15/NN||analgesic-14/VBG	nsubjpass||selected-27/VBN||consumption-15/NN	amod||status-19/NN||improved-17/VBN	nn||status-19/NN||knee-18/NN	conj_and||consumption-15/NN||status-19/NN	nsubjpass||selected-27/VBN||status-19/NN	dep||$-22/$||â-21/RB	dep||status-19/NN||$-22/$	num||$-22/$||œcâ-23/CD	dep||$-22/$||$-24/$	num||$-24/$||formulation-25/CD	auxpass||selected-27/VBN||was-26/VBD	root||ROOT-0/null||selected-27/VBN	amod||development-30/NN||further-29/JJ	prep_for||selected-27/VBN||development-30/NN	analgesic-14||pain-4||no_rel||based on better pain relief, significant ( p < .05) least analgesic consumption and improved knee status, â€œcâ€? formulation was selected for further development.
det||profiling-3/NN||the-1/DT	amod||profiling-3/NN||global-2/JJ	nsubj||gives-8/VBZ||profiling-3/NN	det||genome-7/NN||the-5/DT	nn||genome-7/NN||vzv-6/NN	prep_of||profiling-3/NN||genome-7/NN	root||ROOT-0/null||gives-8/VBZ	amod||insights-10/NNS||further-9/JJ	dobj||gives-8/VBZ||insights-10/NNS	det||replication-13/NN||the-12/DT	prep_into||gives-8/VBZ||replication-13/NN	prep_into||gives-8/VBZ||pathogenesis-15/NNS	conj_and||replication-13/NN||pathogenesis-15/NNS	det||virus-18/NN||this-17/DT	prep_of||replication-13/NN||virus-18/NN	nsubj||lead-22/VB||virus-18/NN	aux||lead-22/VB||can-21/MD	rcmod||virus-18/NN||lead-22/VB	amod||prevention-25/NN||improved-24/VBN	prep_to||lead-22/VB||prevention-25/NN	prep_to||lead-22/VB||therapy-27/NN	conj_and||prevention-25/NN||therapy-27/NN	prep_of||prevention-25/NN||chickenpox-29/NN	prep_of||prevention-25/NN||shingles-31/NNS	conj_and||chickenpox-29/NN||shingles-31/NNS	chickenpox-29||vzv-6||no||the global profiling of the vzv genome gives further insights into the replication and pathogenesis of this virus, which can lead to improved prevention and therapy of chickenpox and shingles.
nsubj||analyzed-2/VBD||we-1/PRP	nsubj||immunosuppressed-31/VBD||we-1/PRP	nsubj||multiplesclerosis-39/VBZ||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	det||prevalence-4/NN||the-3/DT	dobj||analyzed-2/VBD||prevalence-4/NN	det||polyomaviruses-7/NNS||these-6/DT	prep_of||prevalence-4/NN||polyomaviruses-7/NNS	amod||fluid-10/NN||cerebrospinal-9/JJ	prep_in||polyomaviruses-7/NNS||fluid-10/NN	appos||polyomaviruses-7/NNS||csf-12/NN	amod||cells-18/NNS||peripheral-15/JJ	nn||cells-18/NNS||blood-16/NN	nn||cells-18/NNS||mononuclear-17/NN	appos||polyomaviruses-7/NNS||cells-18/NNS	dep||cells-18/NNS||pbmc-20/JJ	nn||samples-26/NNS||bone-24/NN	nn||samples-26/NNS||marrow-25/NN	dobj||analyzed-2/VBD||samples-26/NNS	conj_and||prevalence-4/NN||samples-26/NNS	nn||patients-29/NNS||pml-28/NN	prep_from||samples-26/NNS||patients-29/NNS	conj_and||analyzed-2/VBD||immunosuppressed-31/VBD	conj_and||analyzed-2/VBD||immunosuppressed-31/VBD	conj_or||immunosuppressed-31/VBD||immunosuppressed-31/VBD	dobj||immunosuppressed-31/VBD||individuals-32/NNS	prep_with||immunosuppressed-31/VBD||hiv-36/NN	prep_without||immunosuppressed-31/VBD||hiv-36/NN	conj_and||analyzed-2/VBD||multiplesclerosis-39/VBZ	appos||patients-43/NNS||ms-41/NN	dobj||multiplesclerosis-39/VBZ||patients-43/NNS	pml-28||polyomaviruses-7||no||we analyzed the prevalence of these polyomaviruses in cerebrospinal fluid(csf), peripheral blood mononuclear cells(pbmc), and bone marrow samples from pml patients, immunosuppressed individuals with or without hiv, and multiplesclerosis(ms) patients.
prep||possible-37/JJ||given-1/VBN	det||associations-4/NNS||some-2/DT	amod||associations-4/NNS||recent-3/JJ	pobj||given-1/VBN||associations-4/NNS	nsubjpass||made-8/VBN||associations-4/NNS	aux||made-8/VBN||have-6/VBP	auxpass||made-8/VBN||been-7/VBN	rcmod||associations-4/NNS||made-8/VBN	amod||studies-13/NNS||prospective-10/JJ	conj_and||prospective-10/JJ||epidemiologic-12/JJ	amod||studies-13/NNS||epidemiologic-12/JJ	nsubj||and/or-17/VBG||studies-13/NNS	prep_between||studies-13/NNS||glucose-15/NN	advmod||and/or-17/VBG||variability-16/RB	prepc_in||made-8/VBN||and/or-17/VBG	dobj||and/or-17/VBG||hypoglycemia-18/NN	amod||risk-22/NN||increased-20/VBN	amod||risk-22/NN||cardiovascular-21/JJ	dobj||and/or-17/VBG||risk-22/NN	conj_and||hypoglycemia-18/NN||risk-22/NN	det||association-27/NN||the-25/DT	amod||association-27/NN||long-known-26/JJ	dobj||and/or-17/VBG||association-27/NN	conj_and||hypoglycemia-18/NN||association-27/NN	amod||weight-30/NN||excess-29/JJ	prep_between||association-27/NN||weight-30/NN	amod||risk-33/NN||cardiovascular-32/JJ	prep_between||association-27/NN||risk-33/NN	conj_and||weight-30/NN||risk-33/NN	nsubj||possible-37/JJ||it-35/PRP	cop||possible-37/JJ||is-36/VBZ	root||ROOT-0/null||possible-37/JJ	mark||carry-46/VB||that-38/IN	det||profile-41/NN||the-39/DT	amod||profile-41/NN||clinical-40/JJ	nsubj||carry-46/VB||profile-41/NN	nn||detemir-44/NN||insulin-43/NN	prep_of||profile-41/NN||detemir-44/NN	aux||carry-46/VB||may-45/MD	ccomp||possible-37/JJ||carry-46/VB	amod||value-48/NN||prognostic-47/JJ	dobj||carry-46/VB||value-48/NN	prep_with||value-48/NN||regard-50/NN	amod||safety-53/NN||cardiovascular-52/JJ	prep_to||carry-46/VB||safety-53/NN	mark||is-57/VBZ||although-55/IN	nsubj||is-57/VBZ||this-56/DT	nsubjpass||substantiated-61/VBN||this-56/DT	advcl||carry-46/VB||is-57/VBZ	advmod||is-57/VBZ||yet-58/RB	aux||substantiated-61/VBN||to-59/TO	auxpass||substantiated-61/VBN||be-60/VB	xcomp||is-57/VBZ||substantiated-61/VBN	hypoglycemia-18||glucose-15||yes||given some recent associations that have been made in prospective and epidemiologic studies between glucose variability and/or hypoglycemia and increased cardiovascular risk, and the long-known association between excess weight and cardiovascular risk, it is possible that the clinical profile of insulin detemir may carry prognostic value with regard to cardiovascular safety, although this is yet to be substantiated.
aux||identify-2/VB||to-1/TO	advcl||performed-18/VBN||identify-2/VB	amod||locations-5/NNS||new-3/JJ	amod||locations-5/NNS||genomic-4/JJ	dobj||identify-2/VB||locations-5/NNS	vmod||locations-5/NNS||associated-6/VBN	prep_with||associated-6/VBN||irondeficiency-8/NN	det||study-13/NN||a-10/DT	amod||study-13/NN||genome-wide-11/JJ	nn||study-13/NN||association-12/NN	nsubjpass||performed-18/VBN||study-13/NN	appos||study-13/NN||gwas-15/NNS	auxpass||performed-18/VBN||was-17/VBD	root||ROOT-0/null||performed-18/VBN	xcomp||performed-18/VBN||using-19/VBG	dobj||using-19/VBG||dna-20/NN	vmod||dna-20/NN||collected-21/VBN	amod||men-24/NNS||white-23/JJ	prep_from||collected-21/VBN||men-24/NNS	vmod||men-24/NNS||aged-25/VBN	number||‰-27/CD||â-26/CD	num||y-30/NN||‰-27/CD	nn||y-30/NN||¥-28/NNP	num||y-30/NN||25-29/CD	dobj||aged-25/VBN||y-30/NN	nn||‰-34/NN||women-32/NNS	nn||‰-34/NN||â-33/NN	dobj||aged-25/VBN||‰-34/NN	conj_and||y-30/NN||‰-34/NN	vmod||y-30/NN||¥-35/VBG	num||y-37/NN||50-36/CD	dobj||¥-35/VBG||y-37/NN	det||study-47/NN||the-39/DT	amod||study-47/NN||hemochromatosis-40/JJ	conj_and||hemochromatosis-40/JJ||ironoverload-42/JJ	amod||study-47/NN||ironoverload-42/JJ	nn||study-47/NN||screening-43/NN	appos||study-47/NN||heirs-45/NNS	prep_in||y-37/NN||study-47/NN	amod||controls-67/NNS||serum-49/JJ	amod||controls-67/NNS||ferritin-50/JJ	appos||controls-67/NNS||sf-52/NN	nn||controls-67/NNS||â-54/NN	amod||controls-67/NNS||‰-55/JJ	amod||controls-67/NNS||$-56/$	number||$-56/$||12-57/CD	nn||controls-67/NNS||âµg-58/NN	punct||replete-66/JJ||/-59/:	amod||cases-62/NNS||l-60/JJ	dep||replete-66/JJ||cases-62/NNS	conj_and||cases-62/NNS||iron-65/NN	dep||replete-66/JJ||iron-65/NN	dep||controls-67/NNS||replete-66/JJ	prep_with||¥-35/VBG||controls-67/NNS	dep||controls-67/NNS||sf-69/VBN	number||100-71/CD||>-70/CD	num||âµg-72/NN||100-71/CD	iobj||sf-69/VBN||âµg-72/NN	punct||l-74/NN||/-73/:	dep||âµg-72/NN||l-74/NN	prep_in||l-74/NN||men-76/NNS	advmod||50-80/CD||sf-78/RB	number||50-80/CD||>-79/CD	appos||l-74/NN||50-80/CD	dep||50-80/CD||âµg-81/NN	punct||l-74/NN||/-82/:	dobj||sf-69/VBN||l-83/NN	prep_in||sf-69/VBN||women-85/NNS	ironoverload-42||iron-65||no||to identify new genomic locations associated with irondeficiency, a genome-wide association study (gwas) was performed using dna collected from white men aged â‰¥25 y and women â‰¥50 y in the hemochromatosis and ironoverload screening (heirs) study with serum ferritin (sf) â‰¤ 12 âµg/l (cases) and iron replete controls (sf>100 âµg/l in men, sf>50 âµg/l in women).
det||aims-3/NNS||the-1/DT	amod||aims-3/NNS||primary-2/JJ	nsubj||are-4/VBP||aims-3/NNS	nsubj||examine-6/VB||aims-3/NNS	root||ROOT-0/null||are-4/VBP	aux||examine-6/VB||to-5/TO	xcomp||are-4/VBP||examine-6/VB	det||efficacy-8/NN||the-7/DT	dobj||examine-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||atomoxetine-10/NN	prepc_for||examine-6/VB||improving-12/VBG	amod||function-16/NN||cognition-13/JJ	conj_and||cognition-13/JJ||emotional-15/JJ	amod||function-16/NN||emotional-15/JJ	dep||improving-12/VBG||function-16/NN	prep_in||function-16/NN||adhd-18/NN	mark||pronounced-28/JJ||whether-20/IN	det||improvements-22/NNS||any-21/DT	nsubj||pronounced-28/JJ||improvements-22/NNS	det||outcomes-25/NNS||these-24/DT	prep_in||improvements-22/NNS||outcomes-25/NNS	cop||pronounced-28/JJ||are-26/VBP	advmod||pronounced-28/JJ||more-27/RBR	dep||improving-12/VBG||pronounced-28/JJ	conj_and||function-16/NN||pronounced-28/JJ	prep_in||pronounced-28/JJ||participants-30/NNS	amod||anxiety-33/NN||comorbid-32/JJ	prep_with||participants-30/NNS||anxiety-33/NN	aux||determine-37/VB||to-36/TO	dep||improving-12/VBG||determine-37/VB	conj_and||function-16/NN||determine-37/VB	mark||reliable-47/JJ||if-38/IN	nsubj||reliable-47/JJ||changes-39/NNS	det||outcomes-42/NNS||these-41/DT	prep_in||changes-39/NNS||outcomes-42/NNS	prep_after||outcomes-42/NNS||atomoxetine-44/NN	cop||reliable-47/JJ||are-45/VBP	advmod||reliable-47/JJ||more-46/RBR	advcl||determine-37/VB||reliable-47/JJ	prep_than||reliable-47/JJ||changes-49/NNS	amod||symptoms-52/NNS||diagnostic-51/JJ	prep_in||changes-49/NNS||symptoms-52/NNS	prep_of||symptoms-52/NNS||adhd-54/NN	adhd-54||atomoxetine-44||yes||the primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in adhd and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of adhd.
prep_from||treated-14/VBN||december-2/NNP	num||december-2/NNP||2007-3/CD	prep_to||treated-14/VBN||march-5/NN	num||march-5/NN||2009-6/CD	num||children-9/NNS||220-8/CD	nsubjpass||treated-14/VBN||children-9/NNS	amod||plasmodiumfalciparummalaria-12/NN||uncomplicated-11/JJ	prep_with||children-9/NNS||plasmodiumfalciparummalaria-12/NN	auxpass||treated-14/VBN||were-13/VBD	root||ROOT-0/null||treated-14/VBN	prep_with||treated-14/VBN||artesunate-16/NN	prep_with||treated-14/VBN||mefloquine-18/NN	conj_and||artesunate-16/NN||mefloquine-18/NN	plasmodiumfalciparummalaria-12||mefloquine-18||yes||from december 2007 to march 2009, 220 children with uncomplicated plasmodiumfalciparummalaria were treated with artesunate and mefloquine.
advmod||thereafter-2/RB||immediately-1/RB	advmod||inflicted-12/VBN||thereafter-2/RB	preconj||femur-7/NN||either-4/CC	det||femur-7/NN||a-5/DT	amod||femur-7/NN||standardized-6/JJ	nsubjpass||inflicted-12/VBN||femur-7/NN	nn||injury-10/NN||spleen-9/NN	conj_or||femur-7/NN||injury-10/NN	nsubjpass||inflicted-12/VBN||injury-10/NN	auxpass||inflicted-12/VBN||was-11/VBD	root||ROOT-0/null||inflicted-12/VBN	nn||function-16/NN||coagulation-15/NN	nsubjpass||assessed-25/VBN||function-16/NN	conj_and||function-16/NN||including-18/VBG	nsubjpass||assessed-25/VBN||including-18/VBG	nn||generation-20/NN||thrombin-19/NN	prep_including||function-16/NN||generation-20/NN	conj_and||function-16/NN||bleeding-23/VBG	nsubjpass||assessed-25/VBN||bleeding-23/VBG	auxpass||assessed-25/VBN||were-24/VBD	conj_and||inflicted-12/VBN||assessed-25/VBN	bleeding-23||thrombin-19||yes||immediately thereafter, either a standardized femur or spleen injury was inflicted, and coagulation function, including thrombin generation, and bleeding were assessed.
nsubj||causes-5/VBZ||mycobacteriumaviumsubspeciesparatuberculosis-1/NNS	appos||mycobacteriumaviumsubspeciesparatuberculosis-1/NNS||map-3/NN	root||ROOT-0/null||causes-5/VBZ	det||inflammation-9/NN||a-6/DT	amod||inflammation-9/NN||chronic-7/JJ	nn||inflammation-9/NN||granulomatous-8/NNS	dobj||causes-5/VBZ||inflammation-9/NN	det||sdisease-16/NN||the-11/DT	nn||sdisease-16/NN||intestines-12/NNS	dep||sdisease-16/NN||johne-14/NN	prep_of||inflammation-9/NN||sdisease-16/NN	nn||cows-20/NNS||dairy-19/NN	prep_in||causes-5/VBZ||cows-20/NNS	det||species-24/NN||every-22/DT	amod||species-24/NN||other-23/JJ	prep_in||causes-5/VBZ||species-24/NN	conj_and||cows-20/NNS||species-24/NN	prep_in||identified-32/VBN||species-24/NN	prep_of||species-24/NN||mammal-26/NN	nsubjpass||identified-32/VBN||it-29/PRP	aux||identified-32/VBN||has-30/VBZ	auxpass||identified-32/VBN||been-31/VBN	rcmod||species-24/NN||identified-32/VBN	johne'sdisease--1||mycobacteriumaviumsubspeciesparatuberculosis-1||no||mycobacteriumaviumsubspeciesparatuberculosis (map) causes a chronic granulomatous inflammation of the intestines, johne'sdisease, in dairy cows and every other species of mammal in which it has been identified.
det||progression-2/NN||the-1/DT	nsubj||involves-14/VBZ||progression-2/NN	amod||tuberculosis-5/NNP||human-4/JJ	prep_of||progression-2/NN||tuberculosis-5/NNP	appos||progression-2/NN||tb-7/NN	amod||disease-11/NN||active-10/JJ	prep_to||progression-2/NN||disease-11/NN	prep_to||progression-2/NN||transmission-13/NN	conj_and||disease-11/NN||transmission-13/NN	root||ROOT-0/null||involves-14/VBZ	det||development-16/NN||the-15/DT	dobj||involves-14/VBZ||development-16/NN	det||granuloma-20/NN||a-18/DT	amod||granuloma-20/NN||caseous-19/JJ	prep_of||development-16/NN||granuloma-20/NN	nsubj||cavitates-22/VBZ||granuloma-20/NN	nsubj||releases-24/VBZ||granuloma-20/NN	rcmod||granuloma-20/NN||cavitates-22/VBZ	rcmod||granuloma-20/NN||releases-24/VBZ	conj_and||cavitates-22/VBZ||releases-24/VBZ	amod||bacilli-27/NNS||infectious-25/JJ	nn||bacilli-27/NNS||mycobacteriumtuberculosis-26/NN	dobj||cavitates-22/VBZ||bacilli-27/NNS	tuberculosis-5||mycobacteriumtuberculosis-26||no||the progression of human tuberculosis (tb) to active disease and transmission involves the development of a caseous granuloma that cavitates and releases infectious mycobacteriumtuberculosis bacilli.
nsubj||led-9/VBD||over-expression-1/NN	amod||proteins-4/NNS||socs-3/JJ	prep_of||over-expression-1/NN||proteins-4/NNS	nn||lines-8/NNS||melanoma-6/NN	nn||lines-8/NNS||cell-7/NN	prep_in||proteins-4/NNS||lines-8/NNS	root||ROOT-0/null||led-9/VBD	amod||inhibition-12/NN||significant-11/JJ	prep_to||led-9/VBD||inhibition-12/NN	amod||stat1-15/NNS||tyr701-phosphorylated-14/JJ	prep_of||inhibition-12/NN||stat1-15/NNS	dep||stat1-15/NNS||p-stat1-17/JJ	nn||expression-21/NN||gene-20/NN	prep_to||led-9/VBD||expression-21/NN	conj_and||inhibition-12/NN||expression-21/NN	prep_following||expression-21/NN||stimulation-23/NN	nn||±-26/NNP||ifn-î-25/NNP	prep_with||stimulation-23/NN||±-26/NNP	dep||±-26/NNP||ifit2-28/NNP	dep||ifit2-28/NNP||oas-1-30/JJ	dep||ifit2-28/NNP||isg-15-32/JJ	nn||³-36/NNP||ifn-î-35/NNP	prep_with||stimulation-23/NN||³-36/NNP	conj_or||±-26/NNP||³-36/NNP	appos||±-26/NNP||irf1-38/NNP	melanoma-6||ifn--1||yes||over-expression of socs proteins in melanoma cell lines led to significant inhibition of tyr701-phosphorylated stat1 (p-stat1) and gene expression following stimulation with ifn-î± (ifit2, oas-1, isg-15) or ifn-î³ (irf1).
prep_in||tb-7/NN||children-2/NNS	prep_in||accompanied-24/VBN||children-2/NNS	amod||tb-7/NN||definite-4/JJ	conj_or||definite-4/JJ||probable-6/JJ	amod||tb-7/NN||probable-6/JJ	prep_with||positive-17/JJ||tb-7/NN	det||result-15/NN||the-10/DT	amod||result-15/NN||ifn-î-11/JJ	amod||result-15/NN||³-12/JJ	nn||result-15/NN||elispot-13/NN	nn||result-15/NN||assay-14/NN	nsubj||positive-17/JJ||result-15/NN	cop||positive-17/JJ||was-16/VBD	rcmod||children-2/NNS||positive-17/JJ	prep_at||positive-17/JJ||presentation-19/NN	amod||treatment-22/NN||anti-tuberculous-21/JJ	nsubjpass||accompanied-24/VBN||treatment-22/NN	auxpass||accompanied-24/VBN||was-23/VBD	root||ROOT-0/null||accompanied-24/VBN	det||decrease-28/NN||a-26/DT	amod||decrease-28/NN||significant-27/JJ	agent||accompanied-24/VBN||decrease-28/NN	preconj||magnitude-32/NN||both-30/PDT	det||magnitude-32/NN||the-31/DT	prep_in||decrease-28/NN||magnitude-32/NN	det||response-37/NN||the-34/DT	amod||response-37/NN||ifn-î-35/JJ	amod||response-37/NN||³-36/JJ	prep_of||magnitude-32/NN||response-37/NN	prep_to||response-37/NN||individual-39/NN	amod||antigens-43/NNS||combined-41/VBN	amod||antigens-43/NNS||mtb-specific-42/JJ	prep_in||decrease-28/NN||antigens-43/NNS	conj_or||magnitude-32/NN||antigens-43/NNS	advmod||esat-6-45/JJ||-lrb--44/RB	amod||antigens-43/NNS||esat-6-45/JJ	amod||-rrb--53/NN||median-46/JJ	num||sfcs/106-48/NNS||110-47/CD	npadvmod||pbmc-49/JJ||sfcs/106-48/NNS	amod||-rrb--53/NN||pbmc-49/JJ	nn||-rrb--53/NN||-lrb--50/NN	nn||-rrb--53/NN||iqr-51/NN	num||-rrb--53/NN||65-305-52/CD	dep||antigens-43/NNS||-rrb--53/NN	prep_at||-rrb--53/NN||presentation-55/NN	prep_vs.||presentation-55/NN||15-57/CD	vmod||presentation-55/NN||-lrb--58/VBG	num||-lrb--118/NNS||10-115-59/CD	conj_and||-rrb--60/JJ||-rrb--60/JJ	amod||-lrb--118/NNS||-rrb--60/JJ	amod||-lrb--118/NNS||-rrb--60/JJ	num||months-63/NNS||six-62/CD	prep_at||-rrb--60/JJ||months-63/NNS	vmod||months-63/NNS||p-65/VBN	dep||0.04-67/CD||=-66/SYM	ccomp||p-65/VBN||0.04-67/CD	amod||-rrb--73/NNS||cfp-10-69/JJ	dep||cfp-10-69/JJ||177-70/CD	amod||-rrb--73/NNS||-lrb--71/JJ	amod||-rrb--73/NNS||48-508-72/JJ	dep||months-63/NNS||-rrb--73/NNS	prep_vs.||-rrb--73/NNS||20-75/CD	amod||-rrb--73/NNS||-lrb--76/JJ	num||-rrb--78/NNS||5-165-77/CD	dep||-lrb--76/JJ||-rrb--78/NNS	vmod||-rrb--73/NNS||p-80/VBN	dep||0.004-82/CD||=-81/SYM	ccomp||p-80/VBN||0.004-82/CD	amod||iqr-92/NNS||esat-6-84/JJ	conj_or||esat-6-84/JJ||cfp-10-86/JJ	amod||iqr-92/NNS||cfp-10-86/JJ	nn||iqr-92/NNS||median-87/NN	amod||iqr-92/NNS||250-88/VBD	amod||iqr-92/NNS||sfcs/106-89/JJ	amod||iqr-92/NNS||pbmc-90/JJ	nn||iqr-92/NNS||-lrb--91/NN	appos||-rrb--73/NNS||iqr-92/NNS	num||-rrb--94/NNS||94-508-93/CD	dep||-rrb--73/NNS||-rrb--94/NNS	num||-rrb--99/NNS||25-96/CD	amod||-rrb--99/NNS||-lrb--97/VBG	num||-rrb--99/NNS||10-165-98/CD	prep_vs.||-rrb--94/NNS||-rrb--99/NNS	vmod||months-63/NNS||p-101/VBN	dep||-rrb--104/NNS||=-102/SYM	num||-rrb--104/NNS||0.004-103/CD	ccomp||p-101/VBN||-rrb--104/NNS	det||proportion-108/NN||the-107/DT	prep_in||-rrb--60/JJ||proportion-108/NN	prep_of||proportion-108/NN||children-110/NNS	det||ifn-î-114/NN||a-112/DT	amod||ifn-î-114/NN||positive-113/JJ	prep_with||children-110/NNS||ifn-î-114/NN	amod||-lrb--118/NNS||³-115/JJ	amod||-lrb--118/NNS||elispot-116/JJ	nn||-lrb--118/NNS||assay-117/NN	dobj||-lrb--58/VBG||-lrb--118/NNS	poss||vs-125/NN||fisher-119/NN	amod||vs-125/NN||exact-121/JJ	nn||vs-125/NN||test-122/NN	nn||vs-125/NN||esat-6-123/NN	num||vs-125/NN||15/0-124/CD	dep||-lrb--118/NNS||vs-125/NN	dep||-lrb--118/NNS||5/11-126/CD	vmod||5/11-126/CD||p-128/VBN	dep||0.0002-130/CD||=-129/SYM	ccomp||p-128/VBN||0.0002-130/CD	amod||-lrb--118/NNS||cfp-10-132/JJ	dep||cfp-10-132/JJ||22/0-133/CD	amod||-rrb--53/NN||vs-134/JJ	dep||vs-134/JJ||8/17-135/CD	vmod||-rrb--53/NN||p-137/VBN	dep||0.0001-139/CD||=-138/SYM	ccomp||p-137/VBN||0.0001-139/CD	amod||-rrb--53/NN||esat-6-141/JJ	amod||-rrb--53/NN||cfp-10-143/JJ	conj_or||esat-6-141/JJ||cfp-10-143/JJ	dep||-rrb--53/NN||22/0-144/CD	prep_vs.||22/0-144/CD||9/17-146/CD	vmod||22/0-144/CD||p-148/VBN	dep||-rrb--151/NNS||=-149/SYM	num||-rrb--151/NNS||0.002-150/CD	ccomp||p-148/VBN||-rrb--151/NNS	tb-7||mtb--1||no||in children with definite or probable tb in whom the ifn-î ³ elispot assay result was positive at presentation , anti-tuberculous treatment was accompanied by a significant decrease in both the magnitude of the ifn-î ³ response to individual or combined mtb-specific antigens -lrb- esat-6 median 110 sfcs/106 pbmc -lrb- iqr 65-305 -rrb- at presentation vs. 15 -lrb- 10-115 -rrb- at six months , p = 0.04 ; cfp-10 177 -lrb- 48-508 -rrb- vs. 20 -lrb- 5-165 -rrb- , p = 0.004 , esat-6 or cfp-10 median 250 sfcs/106 pbmc -lrb- iqr 94-508 -rrb- vs. 25 -lrb- 10-165 -rrb- , p = 0.004 -rrb- and in the proportion of children with a positive ifn-î ³ elispot assay -lrb- fisher 's exact test esat-6 15/0 vs 5/11 , p = 0.0002 , cfp-10 22/0 vs 8/17 , p = 0.0001 , esat-6 or cfp-10 22/0 vs. 9/17 , p = 0.002 -rrb- .
det||course-3/NN||the-1/DT	amod||course-3/NN||clinical-2/JJ	nsubj||unknown-19/JJ||course-3/NN	prep_of||course-3/NN||humanpapillomavirus-5/NNS	appos||humanpapillomavirus-5/NNS||hpv-7/NN	vmod||humanpapillomavirus-5/NNS||associated-9/VBN	prep_with||associated-9/VBN||bowenoidpapulosis-11/NNS	prep_with||associated-9/VBN||condylomaacuminatum-13/NN	conj_and||bowenoidpapulosis-11/NNS||condylomaacuminatum-13/NN	amod||tumors-16/NNS||anogenital-15/JJ	prep_of||bowenoidpapulosis-11/NNS||tumors-16/NNS	cop||unknown-19/JJ||are-17/VBP	advmod||unknown-19/JJ||still-18/RB	root||ROOT-0/null||unknown-19/JJ	bowenoidpapulosis-11||humanpapillomavirus-5||no||the clinical course of humanpapillomavirus (hpv) associated with bowenoidpapulosis and condylomaacuminatum of anogenital tumors are still unknown.
advmod||showed-10/VBD||however-1/RB	det||r5-5/NN||the-3/DT	nn||r5-5/NN||group-4/NN	nsubj||showed-10/VBD||r5-5/NN	num||ng/ml-8/NN||5-7/CD	appos||r5-5/NN||ng/ml-8/NN	root||ROOT-0/null||showed-10/VBD	advmod||intense-13/JJ||significantly-11/RB	advmod||intense-13/JJ||less-12/RBR	amod||pain-14/NN||intense-13/JJ	dobj||showed-10/VBD||pain-14/NN	vmod||pain-14/NN||induced-15/VBN	amod||r3-22/NNS||propofol-17/JJ	prep||propofol-17/JJ||than-18/IN	pcomp||than-18/IN||in-19/IN	det||group-21/NN||the-20/DT	pobj||in-19/IN||group-21/NN	agent||induced-15/VBN||r3-22/NNS	num||ng/ml-25/NN||3-24/CD	appos||r3-22/NNS||ng/ml-25/NN	pain-14||propofol-17||yes||however, the group r5 (5 ng/ml) showed significantly less intense pain induced by propofol than in the group r3 (3 ng/ml).
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
advmod||model-3/VBD||here-1/RB	nsubj||model-3/VBD||we-2/PRP	root||ROOT-0/null||model-3/VBD	det||performance-5/NN||the-4/DT	dobj||model-3/VBD||performance-5/NN	amod||systems-10/NNS||mtb-7/JJ	amod||systems-10/NNS||liquid-8/JJ	nn||systems-10/NNS||culture-9/NN	prep_of||performance-5/NN||systems-10/NNS	amod||settings-20/NNS||high-12/JJ	conj_and||high-12/JJ||low-14/JJ	amod||settings-20/NNS||low-14/JJ	amod||settings-20/NNS||tuberculosis-15/JJ	appos||settings-20/NNS||tb-17/NN	nn||settings-20/NNS||prevalence-19/NN	prep_in||model-3/VBD||settings-20/NNS	vmod||settings-20/NNS||using-21/VBG	amod||data-24/NNS||detailed-22/JJ	amod||data-24/NNS||published-23/VBN	dobj||using-21/VBG||data-24/NNS	vmod||using-21/VBG||concentrating-25/VBG	det||frequency-29/NN||the-27/DT	amod||frequency-29/NN||likely-28/JJ	prep_on||concentrating-25/VBG||frequency-29/NN	amod||events-32/NNS||cross-contamination-31/JJ	prep_of||frequency-29/NN||events-32/NNS	tb-17||mtb-7||no||here we model the performance of mtb liquid culture systems in high and low tuberculosis (tb) prevalence settings using detailed published data concentrating on the likely frequency of cross-contamination events.
det||chc-4/NN||these-1/DT	nn||chc-4/NN||qualitatively-2/NN	amod||chc-4/NN||differing-3/VBG	nsubjpass||found-7/VBN||chc-4/NN	advmod||found-7/VBN||compounds-5/RB	auxpass||found-7/VBN||were-6/VBD	root||ROOT-0/null||found-7/VBN	amod||classes-11/NNS||various-9/JJ	nn||classes-11/NNS||substance-10/NN	prep_across||found-7/VBN||classes-11/NNS	prep_including||classes-11/NNS||alkanes-13/NNS	appos||alkanes-13/NNS||alkenes-15/NNS	appos||alkanes-13/NNS||mono-17/NN	conj_and||alkenes-15/NNS||mono-17/NN	amod||alkanes-24/NNS||di-20/JJ	conj_and||di-20/JJ||trimethyl-branched-23/JJ	amod||alkanes-24/NNS||trimethyl-branched-23/JJ	appos||alkanes-13/NNS||alkanes-24/NNS	mono-17||alkanes-24||no_rel||these qualitatively differing chc compounds were found across various substance classes including alkanes, alkenes and mono-, di- and trimethyl-branched alkanes.
det||number-2/NN||a-1/DT	nsubjpass||enrolled-48/VBN||number-2/NN	prep_of||number-2/NN||subjects-4/NNS	nsubj||met-9/VBD||subjects-4/NNS	appos||subjects-4/NNS||144-6/CD	rcmod||subjects-4/NNS||met-9/VBD	det||criteria-11/NNS||the-10/DT	dobj||met-9/VBD||criteria-11/NNS	dep||age-16/NN||1-14/LS	prep_of||criteria-11/NNS||age-16/NN	num||years-21/NNS||30-18/CD	conj_and||30-18/CD||75-20/CD	num||years-21/NNS||75-20/CD	prep_between||age-16/NN||years-21/NNS	appos||years-21/NNS||2-24/CD	vmod||years-21/NNS||had-26/VBD	dobj||had-26/VBD||type2diabetes-27/NNS	mwe||than-30/IN||more-29/JJR	quantmod||one-31/CD||than-30/IN	prep_for||type2diabetes-27/NNS||one-31/CD	tmod||had-26/VBD||year-32/NN	dep||gliclazide-39/NN||3-36/LS	nn||gliclazide-39/NN||taking-38/NN	prep_of||criteria-11/NNS||gliclazide-39/NN	conj_and||age-16/NN||gliclazide-39/NN	conj_and||age-16/NN||metformin-41/NN	conj_and||gliclazide-39/NN||metformin-41/NN	mwe||than-44/IN||more-43/JJR	quantmod||6-45/CD||than-44/IN	num||months-46/NNS||6-45/CD	prep_for||gliclazide-39/NN||months-46/NNS	auxpass||enrolled-48/VBN||were-47/VBD	root||ROOT-0/null||enrolled-48/VBN	type2diabetes-27||metformin-41||yes||a number of subjects (144) who met the criteria of (1) age between 30 and 75 years, (2) had type2diabetes for more than one year, and (3) taking gliclazide and metformin for more than 6 months were enrolled.
amod||korea-3/NN||south-2/JJ	prep_in||isolated-49/VBN||korea-3/NN	advmod||avianinfluenzavirus-6/VBZ||where-5/WRB	advcl||isolated-49/VBN||avianinfluenzavirus-6/VBZ	nsubj||circulate-16/VBP||subtypes-7/NNS	nsubjpass||detected-20/VBN||subtypes-7/NNS	num||subtypes-7/NNS||h3n2-8/CD	num||subtypes-7/NNS||h5n1-10/CD	num||subtypes-7/NNS||h6n1-12/CD	conj_and||subtypes-7/NNS||h9n2-15/CD	nsubj||circulate-16/VBP||h9n2-15/CD	ccomp||avianinfluenzavirus-6/VBZ||circulate-16/VBP	aux||detected-20/VBN||have-18/VBP	auxpass||detected-20/VBN||been-19/VBN	ccomp||avianinfluenzavirus-6/VBZ||detected-20/VBN	conj_or||circulate-16/VBP||detected-20/VBN	num||influenzavirus-26/NNS||3-22/CD	advmod||similar-24/JJ||genetically-23/RB	amod||influenzavirus-26/NNS||similar-24/JJ	nn||influenzavirus-26/NNS||canine-25/NN	nsubjpass||isolated-49/VBN||influenzavirus-26/NNS	dep||isolated-49/VBN||h3n2-28/NNP	nsubjpass||isolated-49/VBN||strains-30/NNS	nn||origin-33/NN||avian-32/NN	prep_of||strains-30/NNS||origin-33/NN	dep||strains-30/NNS||a/canine/korea-35/NN	punct||01/2007-37/CD||/-36/:	dep||a/canine/korea-35/NN||01/2007-37/CD	dep||a/canine/korea-35/NN||a/canine/korea-39/NN	conj_and||01/2007-37/CD||a/canine/korea-39/NN	number||02/2007-41/CD||/-40/CD	dep||a/canine/korea-39/NN||02/2007-41/CD	dep||a/canine/korea-35/NN||a/canine/korea-44/NN	conj_and||01/2007-37/CD||a/canine/korea-44/NN	punct||01/2007-37/CD||/-45/:	dep||a/canine/korea-35/NN||03/2007-46/CD	auxpass||isolated-49/VBN||were-48/VBD	root||ROOT-0/null||isolated-49/VBN	prep_from||isolated-49/VBN||dogs-51/NNS	vmod||dogs-51/NNS||exhibiting-52/VBG	amod||disease-55/NN||severe-53/JJ	nn||disease-55/NN||respiratory-54/NN	dobj||exhibiting-52/VBG||disease-55/NN	h5n1-10||avianinfluenzavirus-6||no||in south korea, where avianinfluenzavirus subtypes h3n2, h5n1, h6n1, and h9n2 circulate or have been detected, 3 genetically similar canine influenzavirus (h3n2) strains of avian origin (a/canine/korea/01/2007, a/canine/korea/02/2007, and a/canine/korea/03/2007) were isolated from dogs exhibiting severe respiratory disease.
nn||models-2/NNS||animal-1/NN	nsubj||essential-6/JJ||models-2/NNS	prep_of||models-2/NNS||influenza-4/NN	cop||essential-6/JJ||are-5/VBP	root||ROOT-0/null||essential-6/JJ	nn||efforts-9/NNS||research-8/NN	prep_to||essential-6/JJ||efforts-9/NNS	vmod||efforts-9/NNS||aimed-10/VBN	prepc_at||aimed-10/VBN||understanding-12/VBG	det||factors-17/NNS||the-13/DT	amod||factors-17/NNS||viral-14/JJ	conj_and||viral-14/JJ||host-16/NN	amod||factors-17/NNS||host-16/NN	dobj||understanding-12/VBG||factors-17/NNS	nsubj||contribute-19/VBP||factors-17/NNS	rcmod||factors-17/NNS||contribute-19/VBP	det||outcomes-25/NNS||the-21/DT	nn||outcomes-25/NNS||disease-22/NN	conj_and||disease-22/NN||transmission-24/NN	nn||outcomes-25/NNS||transmission-24/NN	prep_to||contribute-19/VBP||outcomes-25/NNS	prep_of||outcomes-25/NNS||influenzavirusinfection-27/NN	prep_in||contribute-19/VBP||humans-29/NNS	influenza-4||influenzavirus--1||no||animal models of influenza are essential to research efforts aimed at understanding the viral and host factors that contribute to the disease and transmission outcomes of influenzavirusinfection in humans.
det||report-2/NN||this-1/DT	nsubj||demonstrates-3/VBZ||report-2/NN	root||ROOT-0/null||demonstrates-3/VBZ	mark||present-11/VB||that-4/IN	nsubj||present-11/VB||ebv-5/NN	det||adult-9/NN||an-7/DT	amod||adult-9/NN||immunocompetent-8/JJ	prep_in||ebv-5/NN||adult-9/NN	aux||present-11/VB||can-10/MD	ccomp||demonstrates-3/VBZ||present-11/VB	amod||involvement-19/NN||diffuse-13/JJ	amod||involvement-19/NN||reversible-15/JJ	nn||involvement-19/NN||brain-16/NN	amod||involvement-19/NN||white-17/JJ	nn||involvement-19/NN||matter-18/NN	prep_with||present-11/VB||involvement-19/NN	det||phase-23/NN||the-21/DT	amod||phase-23/NN||acute-22/JJ	prep_in||present-11/VB||phase-23/NN	prep_of||phase-23/NN||mononucleosis-25/NNP	mononucleosis-25||ebv-5||no||this report demonstrates that ebv in an immunocompetent adult can present with diffuse, reversible brain white matter involvement in the acute phase of mononucleosis.
num||hundred-2/CD||two-1/CD	nsubjpass||assessed-9/VBN||hundred-2/CD	num||patients-7/NNS||twenty-4/CD	num||patients-7/NNS||one-5/CD	amod||patients-7/NNS||hiv/aids-6/JJ	conj_and||hundred-2/CD||patients-7/NNS	nsubjpass||assessed-9/VBN||patients-7/NNS	auxpass||assessed-9/VBN||were-8/VBD	root||ROOT-0/null||assessed-9/VBN	det||form-14/NN||a-11/DT	amod||form-14/NN||standardized-12/JJ	nn||form-14/NN||evaluation-13/NN	prep_with||assessed-9/VBN||form-14/NN	prep_at||form-14/NN||enrolment-16/NN	aids--1||hiv--1||no||two hundred and twenty one hiv/aids patients were assessed with a standardized evaluation form at enrolment.
prep_in||fails-15/VBZ||areas-2/NNS	amod||resistance-6/NN||widespread-4/JJ	amod||resistance-6/NN||sulfadoxine-pyrimethamine-5/JJ	prep_of||areas-2/NNS||resistance-6/NN	amod||treatment-9/NN||intermittent-8/JJ	nsubj||fails-15/VBZ||treatment-9/NN	nsubj||prevent-17/VB||treatment-9/NN	nsubj||exacerbate-25/VB||treatment-9/NN	prep_in||treatment-9/NN||pregnancy-11/NN	appos||treatment-9/NN||iptp-13/NN	root||ROOT-0/null||fails-15/VBZ	aux||prevent-17/VB||to-16/TO	xcomp||fails-15/VBZ||prevent-17/VB	amod||malaria-19/NN||placental-18/JJ	dobj||prevent-17/VB||malaria-19/NN	appos||malaria-19/NN||pm-21/NN	aux||exacerbate-25/VB||may-24/MD	conj_and||fails-15/VBZ||exacerbate-25/VB	nn||infections-28/NNS||drug-26/NN	nn||infections-28/NNS||resistant-27/NN	dobj||exacerbate-25/VB||infections-28/NNS	malaria-19||pyrimethamine--1||yes||in areas of widespread sulfadoxine-pyrimethamine resistance, intermittent treatment in pregnancy (iptp) fails to prevent placental malaria (pm) and may exacerbate drug resistant infections.
prep_in||emphasize-15/VB||light-2/NN	det||problem-6/NN||the-4/DT	amod||problem-6/NN||growing-5/VBG	prep_of||light-2/NN||problem-6/NN	prep_of||problem-6/NN||obesity-8/NN	nn||children-11/NNS||malaysian-10/NN	prep_in||obesity-8/NN||children-11/NNS	det||findings-14/NNS||these-13/DT	nsubj||emphasize-15/VB||findings-14/NNS	root||ROOT-0/null||emphasize-15/VB	det||need-18/NN||the-16/DT	amod||need-18/NN||important-17/JJ	dobj||emphasize-15/VB||need-18/NN	amod||interventions-21/NNS||appropriate-20/JJ	prep_for||need-18/NN||interventions-21/NNS	aux||address-23/VB||to-22/TO	vmod||emphasize-15/VB||address-23/VB	det||problems-25/NNS||both-24/DT	dobj||address-23/VB||problems-25/NNS	amod||status-31/NN||obesity-27/JJ	conj_and||obesity-27/JJ||poor-29/JJ	amod||status-31/NN||poor-29/JJ	amod||status-31/NN||vitamind-30/JJ	prep_of||problems-25/NNS||status-31/NN	prep_in||status-31/NN||children-33/NNS	vitamind-30||obesity-27||no_rel||in light of the growing problem of obesity in malaysian children, these findings emphasize the important need for appropriate interventions to address both problems of obesity and poor vitamind status in children.
det||infection-2/NN||the-1/DT	nsubjpass||associated-9/VBN||infection-2/NN	prep_of||infection-2/NN||cells-4/NNS	nn||viruses-7/NNS||rna-6/NN	prep_by||cells-4/NNS||viruses-7/NNS	auxpass||associated-9/VBN||is-8/VBZ	root||ROOT-0/null||associated-9/VBN	det||recognition-12/NN||the-11/DT	prep_with||associated-9/VBN||recognition-12/NN	nn||pamps-15/NNS||virus-14/NN	prep_of||recognition-12/NN||pamps-15/NNS	amod||patterns-19/NNS||pathogen-associated-17/JJ	amod||patterns-19/NNS||molecular-18/JJ	appos||pamps-15/NNS||patterns-19/NNS	det||production-23/NN||the-22/DT	prep_with||associated-9/VBN||production-23/NN	conj_and||recognition-12/NN||production-23/NN	nn||interferon-27/NN||type-25/FW	nn||interferon-27/NN||i-26/FW	prep_of||production-23/NN||interferon-27/NN	appos||interferon-27/NN||ifn-29/NN	interferon-27||virus-14||no_rel||the infection of cells by rna viruses is associated with the recognition of virus pamps (pathogen-associated molecular patterns) and the production of type i interferon (ifn).
det||response-2/NN||the-1/DT	nsubj||successful-10/JJ||response-2/NN	prep_to||response-2/NN||hiv-4/NN	prep_to||response-2/NN||aids-6/NNS	conj_and||hiv-4/NN||aids-6/NNS	aux||successful-10/JJ||can-7/MD	advmod||successful-10/JJ||only-8/RB	cop||successful-10/JJ||be-9/VB	root||ROOT-0/null||successful-10/JJ	mark||adopt-13/VB||if-11/IN	nsubj||adopt-13/VB||individuals-12/NNS	advcl||successful-10/JJ||adopt-13/VB	dobj||adopt-13/VB||behaviours-14/NNS	nsubj||protect-17/VB||behaviours-14/NNS	aux||protect-17/VB||will-16/MD	rcmod||behaviours-14/NNS||protect-17/VB	prep_against||protect-17/VB||infection-19/NN	aids-6||hiv-4||no||the response to hiv and aids can only be successful if individuals adopt behaviours that will protect against infection.
poss||results-2/NNS||our-1/PRP$	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||sensitive-22/JJ||that-4/IN	det||patients-8/NNS||the-5/DT	amod||patients-8/NNS||younger-6/JJR	nn||patients-8/NNS||age-7/NN	nsubj||sensitive-22/JJ||patients-8/NNS	det||patients-11/NNS||the-10/DT	appos||patients-8/NNS||patients-11/NNS	det||site-16/NN||a-13/DT	amod||site-16/NN||peripheral-14/JJ	nn||site-16/NN||iv-15/NN	prep_with||patients-11/NNS||site-16/NN	amod||patients-19/NNS||female-18/JJ	prep_with||patients-11/NNS||patients-19/NNS	conj_and||site-16/NN||patients-19/NNS	cop||sensitive-22/JJ||are-20/VBP	advmod||sensitive-22/JJ||more-21/RBR	ccomp||showed-3/VBD||sensitive-22/JJ	prep_to||sensitive-22/JJ||pain-24/NN	det||injection-27/NN||the-26/DT	prep_on||pain-24/NN||injection-27/NN	prep_of||injection-27/NN||propofol-29/NN	pain-24||propofol-29||yes||our results showed that the younger age patients, the patients with a peripheral iv site and female patients are more sensitive to pain on the injection of propofol.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effectiveness-4/NN||the-3/DT	dobj||evaluated-2/VBN||effectiveness-4/NN	prep_of||effectiveness-4/NN||insulinglargine-6/NN	appos||insulinglargine-6/NN||glargine-8/NN	prep||insulinglargine-6/NN||based-11/VBN	npadvmod||with-15/IN||regimens-12/NNS	prep_in||regimens-12/NNS||patients-14/NNS	pcomp||based-11/VBN||with-15/IN	pobj||with-15/IN||type2diabetesmellitus-16/NNS	appos||type2diabetesmellitus-16/NNS||t2dm-18/NNP	amod||practice-22/NN||clinical-21/JJ	prep_in||insulinglargine-6/NN||practice-22/NN	prep_in||practice-22/NN||spain-24/NN	type2diabetesmellitus-16||insulinglargine-6||yes||we evaluated the effectiveness of insulinglargine (glargine)-based regimens in patients with type2diabetesmellitus (t2dm) in clinical practice in spain.
nn||bovis-2/NNS||bartonella-1/NN	nsubjpass||identified-4/VBN||bovis-2/NNS	auxpass||identified-4/VBN||was-3/VBD	root||ROOT-0/null||identified-4/VBN	agent||identified-4/VBN||pcr-6/NN	nn||analysis-10/NN||gene-8/NN	nn||analysis-10/NN||sequences-9/NN	agent||identified-4/VBN||analysis-10/NN	conj_and||pcr-6/NN||analysis-10/NN	amod||size-19/NN||specific-13/JJ	amod||size-19/NN||internal-14/JJ	amod||size-19/NN||transcribed-15/JJ	nn||size-19/NN||spacer-16/NN	nn||size-19/NN||amplicon-17/NN	nn||size-19/NN||product-18/NN	agent||identified-4/VBN||size-19/NN	conj_and||pcr-6/NN||size-19/NN	num||cases-24/NNS||2-21/CD	amod||cases-24/NNS||bovine-22/JJ	nn||cases-24/NNS||endocarditis-23/NNS	prep_in||size-19/NN||cases-24/NNS	amod||titers-28/NNS||high-26/JJ	nn||titers-28/NNS||antibody-27/NN	prep_with||identified-4/VBN||titers-28/NNS	nsubj||demonstrates-31/VBZ||titers-28/NNS	rcmod||titers-28/NNS||demonstrates-31/VBZ	mark||pathogen-37/NN||that-32/IN	nn||bovis-34/NNS||b.-33/NN	nsubj||pathogen-37/NN||bovis-34/NNS	cop||pathogen-37/NN||is-35/VBZ	det||pathogen-37/NN||a-36/DT	ccomp||demonstrates-31/VBZ||pathogen-37/NN	prep_for||pathogen-37/NN||cattle-39/NNS	endocarditis-23||antibody-27||no_rel||bartonella bovis was identified by pcr , gene sequences analysis , and specific internal transcribed spacer amplicon product size in 2 bovine endocarditis cases with high antibody titers , which demonstrates that b. bovis is a pathogen for cattle .
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	det||review-5/NN||this-4/DT	prep_of||aim-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||analyze-8/VB||to-7/TO	ccomp||is-6/VBZ||analyze-8/VB	det||results-10/NNS||the-9/DT	dobj||analyze-8/VB||results-10/NNS	dobj||analyze-8/VB||experiences-12/NNS	conj_and||results-10/NNS||experiences-12/NNS	amod||treatments-18/NNS||old-14/JJ	conj_and||old-14/JJ||new-16/JJ	amod||treatments-18/NNS||new-16/JJ	amod||treatments-18/NNS||medical-17/JJ	prep_with||analyze-8/VB||treatments-18/NNS	prep_of||treatments-18/NNS||cd-20/NN	aux||reevaluate-23/VB||to-22/TO	ccomp||is-6/VBZ||reevaluate-23/VB	conj_and||analyze-8/VB||reevaluate-23/VB	amod||therapies-25/NNS||medical-24/JJ	dobj||reevaluate-23/VB||therapies-25/NNS	prep_for||reevaluate-23/VB||complications-27/NNS	prep_of||complications-27/NNS||cd-29/NN	prep_of||complications-27/NNS||hypopituitarism-31/NN	conj_and||cd-29/NN||hypopituitarism-31/NN	prep_in||reevaluate-23/VB||patients-33/NNS	amod||cd-36/NN||cured-35/JJ	prep_with||patients-33/NNS||cd-36/NN	hypopituitarism-31||cd-36||no_rel||the aim of this review is to analyze the results and experiences with old and new medical treatments of cd and to reevaluate medical therapies for complications of cd and hypopituitarism in patients with cured cd.
amod||viruses-2/NNS||recombinant-1/JJ	nsubj||yf-8/VBP||viruses-2/NNS	nsubj||remained-14/VBD||viruses-2/NNS	vmod||viruses-2/NNS||replicated-3/VBN	advmod||replicated-3/VBN||similarly-4/RB	nn||virus-7/NN||vaccine-6/NN	prep_to||replicated-3/VBN||virus-7/NN	root||ROOT-0/null||yf-8/VBP	dobj||yf-8/VBP||17d-9/NNS	nn||culture-12/NN||cell-11/NN	prep_in||17d-9/NNS||culture-12/NN	conj_and||yf-8/VBP||remained-14/VBD	advmod||stable-16/JJ||genetically-15/RB	acomp||remained-14/VBD||stable-16/JJ	amod||passages-20/NNS||several-18/JJ	amod||passages-20/NNS||serial-19/JJ	prep_after||remained-14/VBD||passages-20/NNS	nn||cells-23/NNS||vero-22/NN	prep_in||passages-20/NNS||cells-23/NNS	virus-7||viruses-2||no||recombinant viruses replicated similarly to vaccine virus yf 17d in cell culture and remained genetically stable after several serial passages in vero cells.
prep_in||cause-5/VB||children-2/NNS	nsubj||cause-5/VB||fungi-3/NNS	aux||cause-5/VB||can-4/MD	root||ROOT-0/null||cause-5/VB	amod||infection-7/NN||superficial-6/JJ	dobj||cause-5/VB||infection-7/NN	nsubj||nails-14/VBZ||i.e.-9/NNP	prep_on||nails-14/VBZ||skin-12/NN	ccomp||cause-5/VB||nails-14/VBZ	conj_and||cause-5/VB||nails-14/VBZ	nsubj||types-33/NNS||hair-17/NN	amod||thrush-20/NN||oral-19/JJ	prep_like||hair-17/NN||thrush-20/NN	nn||rash-24/NN||candida-22/NN	nn||rash-24/NN||diaper-23/NN	appos||thrush-20/NN||rash-24/NN	nn||infections-27/NNS||tinea-26/NN	appos||thrush-20/NN||infections-27/NNS	dep||thrush-20/NN||etc.-29/FW	cop||types-33/NNS||are-31/VBP	amod||types-33/NNS||various-32/JJ	ccomp||cause-5/VB||types-33/NNS	conj_and||cause-5/VB||types-33/NNS	conj_and||nails-14/VBZ||types-33/NNS	amod||fungalinfections-36/NNS||superficial-35/JJ	prep_of||types-33/NNS||fungalinfections-36/NNS	nsubj||fungalinfection-39/VBN||subcutaneous-38/NNS	conj_and||cause-5/VB||fungalinfection-39/VBN	prep_in||fungalinfection-39/VBN||tissues-41/NNS	det||skin-44/NN||the-43/DT	prep_under||tissues-41/NNS||skin-44/NN	advmod||causes-48/VBZ||lastly-46/RB	nsubj||causes-48/VBZ||it-47/PRP	conj_and||cause-5/VB||causes-48/VBZ	amod||infection-50/NN||systemic-49/JJ	dobj||causes-48/VBZ||infection-50/NN	amod||tissues-53/NNS||deeper-52/JJR	prep_in||infection-50/NN||tissues-53/NNS	fungalinfection-39||fungi-3||no||in children fungi can cause superficial infection, i.e., on skin, nails, and hair like oral thrush, candida diaper rash, tinea infections, etc., are various types of superficial fungalinfections, subcutaneous fungalinfection in tissues under the skin and lastly it causes systemic infection in deeper tissues.
number||hundred-2/CD||two-1/CD	num||s.aureus-4/NNS||hundred-2/CD	amod||s.aureus-4/NNS||thirty-nine-3/JJ	nsubj||isolates-5/VBZ||s.aureus-4/NNS	root||ROOT-0/null||isolates-5/VBZ	number||121-7/CD||-lrb--6/CD	num||s.aureus-9/NNS||121-7/CD	amod||s.aureus-9/NNS||methicillin-resistant-8/JJ	dobj||isolates-5/VBZ||s.aureus-9/NNS	nn||-rsb--12/NNP||-lsb--10/NNP	nn||-rsb--12/NNP||mrsa-11/NNP	dep||s.aureus-9/NNS||-rsb--12/NNP	num||s.aureus-16/NNS||118-14/CD	amod||s.aureus-16/NNS||methicillin-susceptible-15/JJ	dobj||isolates-5/VBZ||s.aureus-16/NNS	conj_and||s.aureus-9/NNS||s.aureus-16/NNS	nn||-rrb--20/NNP||-lsb--17/NNP	nn||-rrb--20/NNP||mssa-18/NNP	nn||-rrb--20/NNP||-rsb--19/NNP	nsubjpass||screened-22/VBN||-rrb--20/NNP	auxpass||screened-22/VBN||were-21/VBD	rcmod||s.aureus-16/NNS||screened-22/VBN	nn||acgh-29/NN||array-24/NN	amod||acgh-29/NN||comparative-25/JJ	amod||acgh-29/NN||genomic-26/JJ	nn||acgh-29/NN||hybridization-27/NN	nn||acgh-29/NN||-lrb--28/NN	agent||screened-22/VBN||acgh-29/NN	vmod||acgh-29/NN||-rrb--30/VBN	aux||identify-32/VB||to-31/TO	xcomp||-rrb--30/VBN||identify-32/VB	dobj||identify-32/VB||genes-33/NNS	vmod||genes-33/NNS||implicated-34/VBN	amod||infections-37/NNS||complicated-36/JJ	prep_in||implicated-34/VBN||infections-37/NNS	mrsa-11||s.aureus-16||no||two hundred thirty-nine s.aureus isolates -lrb- 121 methicillin-resistant s.aureus -lsb- mrsa -rsb- and 118 methicillin-susceptible s.aureus -lsb- mssa -rsb- -rrb- were screened by array comparative genomic hybridization -lrb- acgh -rrb- to identify genes implicated in complicated infections .
det||contribution-3/NN||the-1/DT	amod||contribution-3/NN||relative-2/JJ	nsubj||unclear-16/JJ||contribution-3/NN	det||components-9/NNS||the-5/DT	amod||components-9/NNS||budesonide-6/JJ	conj_and||budesonide-6/JJ||formoterol-8/JJ	amod||components-9/NNS||formoterol-8/JJ	prep_of||contribution-3/NN||components-9/NNS	det||control-14/NN||the-11/DT	amod||control-14/NN||improved-12/JJ	nn||control-14/NN||asthma-13/NN	prep_to||components-9/NNS||control-14/NN	cop||unclear-16/JJ||is-15/VBZ	root||ROOT-0/null||unclear-16/JJ	asthma-13||formoterol-8||no||the relative contribution of the budesonide and formoterol components to the improved asthma control is unclear.
advmod||indicates-5/VBZ||thus-1/RB	poss||study-4/NN||our-3/PRP$	nsubj||indicates-5/VBZ||study-4/NN	root||ROOT-0/null||indicates-5/VBZ	mark||vaccine-13/NN||that-6/IN	nsubj||vaccine-13/NN||pcd685a-7/NNS	aux||vaccine-13/NN||may-8/MD	cop||vaccine-13/NN||be-9/VB	det||vaccine-13/NN||an-10/DT	amod||vaccine-13/NN||efficient-11/JJ	nn||vaccine-13/NN||booster-12/NN	ccomp||indicates-5/VBZ||vaccine-13/NN	prep_against||vaccine-13/NN||tb-15/NN	det||ability-19/NN||a-17/DT	amod||ability-19/NN||strong-18/JJ	prep_with||tb-15/NN||ability-19/NN	aux||enhance-21/VB||to-20/TO	vmod||ability-19/NN||enhance-21/VB	amod||immunity-24/NN||prior-22/JJ	nn||immunity-24/NN||bcg-23/NN	dobj||enhance-21/VB||immunity-24/NN	tb-15||bcg-23||no||thus, our study indicates that pcd685a may be an efficient booster vaccine against tb with a strong ability to enhance prior bcg immunity.
prep_in||improves-7/VBZ||particular-2/JJ	amod||lh/hcg-6/NN||in-4/IN	nn||lh/hcg-6/NN||ec-5/NN	nsubj||improves-7/VBZ||lh/hcg-6/NN	root||ROOT-0/null||improves-7/VBZ	nn||invasiveness-9/NNS||cell-8/NN	dobj||improves-7/VBZ||invasiveness-9/NNS	det||mechanism-13/NN||a-12/DT	prep_through||improves-7/VBZ||mechanism-13/NN	nsubj||involves-15/VBZ||mechanism-13/NN	rcmod||mechanism-13/NN||involves-15/VBZ	det||lh/hcg-r-17/NN||the-16/DT	dobj||involves-15/VBZ||lh/hcg-r-17/NN	nsubj||activate-22/VBP||lh/hcg-r-17/NN	nsubj||modulate-27/VBP||lh/hcg-r-17/NN	prep_in||activate-22/VBP||turn-21/NN	rcmod||lh/hcg-r-17/NN||activate-22/VBP	dobj||activate-22/VBP||protein-23/NN	amod||protein-23/NN||kinase-24/JJ	dep||kinase-24/JJ||a-25/DT	rcmod||lh/hcg-r-17/NN||modulate-27/VBP	conj_and||activate-22/VBP||modulate-27/VBP	amod||receptors-30/NNS||integrin-28/JJ	nn||receptors-30/NNS||adhesion-29/NN	dobj||modulate-27/VBP||receptors-30/NNS	adhesion-29||hcg--1||no_rel||in particular, in ec lh/hcg improves cell invasiveness, through a mechanism which involves the lh/hcg-r, which in turn activate protein kinase a and modulate integrin adhesion receptors.
advmod||seen-15/VBN||irondeficiency-1/RB	nn||depletion-8/NN||anemia-3/NN	conj_and||depletion-8/NN||irondeficiencyanemia-5/NN	nsubjpass||seen-15/VBN||irondeficiencyanemia-5/NN	conj_and||depletion-8/NN||iron-7/NN	nsubjpass||seen-15/VBN||iron-7/NN	nsubjpass||seen-15/VBN||depletion-8/NN	conj_and||depletion-8/NN||lack-10/NN	nsubjpass||seen-15/VBN||lack-10/NN	nn||resources-13/NNS||iron-12/NN	prep_of||depletion-8/NN||resources-13/NNS	auxpass||seen-15/VBN||were-14/VBD	root||ROOT-0/null||seen-15/VBN	prep_in||seen-15/VBN||2.3-17/CD	prep_in||seen-15/VBN||4.08-19/CD	conj_and||2.3-17/CD||4.08-19/CD	prep_in||seen-15/VBN||2.14-21/CD	conj_and||2.3-17/CD||2.14-21/CD	prep_in||seen-15/VBN||22.76-23/NNP	conj_and||2.3-17/CD||22.76-23/NNP	amod||percent-26/NN||4.66-25/JJ	prep_in||seen-15/VBN||percent-26/NN	conj_and||2.3-17/CD||percent-26/NN	advmod||seen-15/VBN||respectively-27/RB	irondeficiencyanemia-5||iron-12||yes||irondeficiency, anemia, irondeficiencyanemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	neutropenia-25||doxorubicin-13||no||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
det||practice-2/NN||the-1/DT	nsubj||explanation-14/NN||practice-2/NN	prepc_of||practice-2/NN||combining-4/VBG	dobj||combining-4/VBG||agents-5/NNS	nsubj||counteract-7/VB||agents-5/NNS	rcmod||agents-5/NNS||counteract-7/VB	amod||mechanisms-9/NNS||different-8/JJ	dobj||counteract-7/VB||mechanisms-9/NNS	cop||explanation-14/NN||is-10/VBZ	det||explanation-14/NN||the-11/DT	advmod||likely-13/JJ||most-12/RBS	amod||explanation-14/NN||likely-13/JJ	root||ROOT-0/null||explanation-14/NN	det||fact-17/NN||the-16/DT	prep_for||explanation-14/NN||fact-17/NN	mark||have-23/VBP||that-18/IN	advmod||available-20/JJ||most-19/RBS	amod||combinations-22/NNS||available-20/JJ	amod||combinations-22/NNS||two-drug-21/JJ	nsubj||have-23/VBP||combinations-22/NNS	ccomp||explanation-14/NN||have-23/VBP	det||agent-25/NN||an-24/DT	dobj||have-23/VBP||agent-25/NN	nsubj||addresses-27/VBZ||agent-25/NN	rcmod||agent-25/NN||addresses-27/VBZ	nn||secretion-29/NN||renin-28/NN	dobj||addresses-27/VBZ||secretion-29/NN	dep||secretion-29/NN||beta-blocker-31/NN	dep||secretion-29/NN||angiotensin-33/VBG	conj_or||beta-blocker-31/NN||angiotensin-33/VBG	vmod||angiotensin-33/VBG||converting-34/VBG	amod||inhibitor-36/NN||enzyme-35/JJ	dobj||converting-34/VBG||inhibitor-36/NN	dep||secretion-29/NN||angiotensiniireceptorblocker-38/NN	conj_or||beta-blocker-31/NN||angiotensiniireceptorblocker-38/NN	amod||inhibitor-42/NN||direct-40/JJ	nn||inhibitor-42/NN||renin-41/NN	dep||secretion-29/NN||inhibitor-42/NN	conj_or||beta-blocker-31/NN||inhibitor-42/NN	det||one-46/NN||another-45/DT	dobj||addresses-27/VBZ||one-46/NN	conj_and||secretion-29/NN||one-46/NN	nsubj||effective-50/JJ||one-46/NN	cop||effective-50/JJ||is-48/VBZ	advmod||effective-50/JJ||more-49/RBR	rcmod||one-46/NN||effective-50/JJ	amod||hypertension-53/NN||renin-independent-52/JJ	prep_in||effective-50/JJ||hypertension-53/NN	dep||one-46/NN||diuretic-55/NN	dep||one-46/NN||dihydropyridine-57/NN	conj_or||diuretic-55/NN||dihydropyridine-57/NN	amod||blocker-62/NN||non-dihydropyridine-59/JJ	nn||blocker-62/NN||calcium-60/NN	nn||blocker-62/NN||channel-61/NN	dep||one-46/NN||blocker-62/NN	conj_or||diuretic-55/NN||blocker-62/NN	beta-blocker-31||hypertension-53||no_rel||the practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensin converting enzyme inhibitor, angiotensiniireceptorblocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calcium channel blocker).
mark||demonstrated-5/VBN||although-1/IN	amod||studies-3/NNS||previous-2/JJ	nsubj||demonstrated-5/VBN||studies-3/NNS	aux||demonstrated-5/VBN||had-4/VBD	advcl||out-competed-30/VBD||demonstrated-5/VBN	mark||impaired-9/VBN||that-6/IN	det||mutation-8/NN||this-7/DT	nsubj||impaired-9/VBN||mutation-8/NN	ccomp||demonstrated-5/VBN||impaired-9/VBN	det||capacity-12/NN||the-10/DT	nn||capacity-12/NN||replication-11/NN	dobj||impaired-9/VBN||capacity-12/NN	det||influenzavirus-15/NNS||the-14/DT	prep_of||capacity-12/NN||influenzavirus-15/NNS	prep_in||impaired-9/VBN||vitro-17/NN	prep_in||impaired-9/VBN||in-19/IN	conj_and||vitro-17/NN||in-19/IN	pobj||in-19/IN||vivo-20/NN	det||mutant-28/NN||the-22/DT	amod||mutant-28/NN||a/brisbane/59-23/JJ	nn||mutant-28/NN||/-24/NNP	num||mutant-28/NN||2007-25/CD	amod||mutant-28/NN||h275y-26/JJ	nn||mutant-28/NN||oseltamivir-resistant-27/NN	nsubj||out-competed-30/VBD||mutant-28/NN	nsubj||was-38/VBD||mutant-28/NN	advmod||out-competed-30/VBD||completely-29/RB	root||ROOT-0/null||out-competed-30/VBD	det||strain-36/NN||the-31/DT	amod||strain-36/NN||wild-type-32/JJ	dep||strain-36/NN||wt-34/VBN	dobj||out-competed-30/VBD||strain-36/NN	conj_and||out-competed-30/VBD||was-38/VBD	det||2008â-42/NN||the-41/DT	prep_in||out-competed-30/VBD||2008â-42/NN	dep||2008â-42/NN||$-43/$	num||$-43/$||2009-45/NNS	quantmod||2009-45/NNS||influenza-46/IN	quantmod||2009-45/NNS||season-47/JJ	det||a/h1n1-51/NN||the-49/DT	amod||a/h1n1-51/NN||primary-50/JJ	appos||2008â-42/NN||a/h1n1-51/NN	vmod||a/h1n1-51/NN||circulating-52/VBG	dobj||circulating-52/VBG||strain-53/NN	influenza-46||influenzavirus-15||no||although previous studies had demonstrated that this mutation impaired the replication capacity of the influenzavirus in vitro and in vivo, the a/brisbane/59/2007 h275y oseltamivir-resistant mutant completely out-competed the wild-type (wt) strain and was, in the 2008â€“2009 influenza season, the primary a/h1n1 circulating strain.
det||questionnaire-2/NN||the-1/DT	nsubj||consisted-3/VBD||questionnaire-2/NN	nsubj||questions-21/VBZ||questionnaire-2/NN	nsubj||assess-23/VB||questionnaire-2/NN	root||ROOT-0/null||consisted-3/VBD	num||questions-6/NNS||24-5/CD	prep_of||consisted-3/VBD||questions-6/NNS	prep_regarding||questions-6/NNS||awareness-8/NN	det||modes-11/NNS||the-10/DT	prep_of||awareness-8/NN||modes-11/NNS	prep_of||modes-11/NNS||transmission-13/NN	prep_of||transmission-13/NN||hiv/aids-15/NNS	num||questions-18/NNS||nine-17/CD	appos||hiv/aids-15/NNS||questions-18/NNS	conj_and||consisted-3/VBD||questions-21/VBZ	aux||assess-23/VB||to-22/TO	xcomp||questions-21/VBZ||assess-23/VB	det||attitude-25/NN||the-24/DT	dobj||assess-23/VB||attitude-25/NN	prep_toward||assess-23/VB||people-27/NNS	vmod||people-27/NNS||living-28/VBG	prep_with||living-28/VBG||hiv/aids-30/NNS	appos||hiv/aids-30/NNS||plwha-32/NNP	num||questions-36/NNS||15-35/CD	appos||hiv/aids-30/NNS||questions-36/NNS	aids--1||hiv--1||no||the questionnaire consisted of 24 questions regarding awareness of the modes of transmission of hiv/aids (nine questions) and questions to assess the attitude toward people living with hiv/aids (plwha) (15 questions).
det||spectrum-3/NN||a-1/DT	amod||spectrum-3/NN||wide-2/JJ	nsubjpass||observed-7/VBN||spectrum-3/NN	prep_of||spectrum-3/NN||ois-5/NN	auxpass||observed-7/VBN||were-6/VBD	root||ROOT-0/null||observed-7/VBN	amod||patients-10/NNS||hiv-infected-9/JJ	prep_amongst||observed-7/VBN||patients-10/NNS	det||clinic-15/NN||the-12/DT	amod||clinic-15/NN||hiv/aids-13/JJ	nn||clinic-15/NN||apex-14/NN	prep_in||patients-10/NNS||clinic-15/NN	aids--1||hiv--1||no||a wide spectrum of ois were observed amongst hiv-infected patients in the hiv/aids apex clinic.
nn||terms-2/NNS||search-1/NN	nsubj||included-3/VBD||terms-2/NNS	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||dyslipidemia-4/NN	dobj||included-3/VBD||obesity-6/NN	conj_and||dyslipidemia-4/NN||obesity-6/NN	dobj||included-3/VBD||tobacco-8/NN	conj_and||dyslipidemia-4/NN||tobacco-8/NN	dobj||included-3/VBD||hypertension-10/NN	conj_and||dyslipidemia-4/NN||hypertension-10/NN	dobj||included-3/VBD||diabetesmellitus-13/NNS	conj_and||dyslipidemia-4/NN||diabetesmellitus-13/NNS	tobacco-8||obesity-6||no_rel||search terms included dyslipidemia, obesity, tobacco, hypertension, and diabetesmellitus.
det||area-4/NN||a-2/DT	amod||area-4/NN||geographical-3/JJ	prep_in||considered-26/VBN||area-4/NN	det||prevalence-8/NN||a-6/DT	amod||prevalence-8/NN||high-7/JJ	prep_with||area-4/NN||prevalence-8/NN	amod||disease-11/NN||tuberculous-10/JJ	prep_of||prevalence-8/NN||disease-11/NN	det||possibility-15/NN||the-13/DT	amod||possibility-15/NN||rare-14/JJ	nsubjpass||considered-26/VBN||possibility-15/NN	amod||infection-18/NN||dual-17/JJ	prep_of||possibility-15/NN||infection-18/NN	amod||anginosus-21/NNS||streptococcus-20/JJ	prep_with||infection-18/NN||anginosus-21/NNS	prep_with||infection-18/NN||mycobacteriumtuberculosis-23/NNS	conj_and||anginosus-21/NNS||mycobacteriumtuberculosis-23/NNS	aux||considered-26/VBN||should-24/MD	auxpass||considered-26/VBN||be-25/VB	root||ROOT-0/null||considered-26/VBN	tuberculous-10||mycobacteriumtuberculosis-23||no||in a geographical area with a high prevalence of tuberculous disease, the rare possibility of dual infection with streptococcus anginosus and mycobacteriumtuberculosis should be considered.
det||raloxifene-2/NN||both-1/DT	nsubjpass||indicated-6/VBN||raloxifene-2/NN	conj_and||raloxifene-2/NN||bisphosphonates-4/NNS	nsubjpass||indicated-6/VBN||bisphosphonates-4/NNS	auxpass||indicated-6/VBN||are-5/VBP	root||ROOT-0/null||indicated-6/VBN	det||prevention-9/NN||the-8/DT	prep_for||indicated-6/VBN||prevention-9/NN	prep_for||indicated-6/VBN||treatment-11/NN	conj_and||prevention-9/NN||treatment-11/NN	prep_of||prevention-9/NN||postmenopausalosteoporosis-13/NNS	advmod||have-18/VBP||however-15/RB	det||medications-17/NNS||these-16/DT	nsubj||have-18/VBP||medications-17/NNS	parataxis||indicated-6/VBN||have-18/VBP	amod||efficacy-20/NN||different-19/JJ	dobj||have-18/VBP||efficacy-20/NN	nn||profiles-23/NNS||safety-22/NN	dobj||have-18/VBP||profiles-23/NNS	conj_and||efficacy-20/NN||profiles-23/NNS	postmenopausalosteoporosis-13||raloxifene-2||yes||both raloxifene and bisphosphonates are indicated for the prevention and treatment of postmenopausalosteoporosis, however these medications have different efficacy and safety profiles.
amod||findings-2/NNS||previous-1/JJ	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||causes-15/VBZ||that-4/IN	det||administration-7/NN||a-5/DT	amod||administration-7/NN||delayed-6/JJ	nsubj||causes-15/VBZ||administration-7/NN	prep_of||administration-7/NN||phenylephrine-9/NN	vmod||phenylephrine-9/NN||replacing-10/VBG	dobj||replacing-10/VBG||norepinephrine-11/NN	nn||patients-14/NNS||septicshock-13/NN	prep_in||norepinephrine-11/NN||patients-14/NNS	ccomp||suggest-3/VBP||causes-15/VBZ	det||vasoconstriction-20/NN||a-16/DT	advmod||pronounced-18/JJ||more-17/RBR	amod||vasoconstriction-20/NN||pronounced-18/JJ	amod||vasoconstriction-20/NN||hepatosplanchnic-19/JJ	dobj||causes-15/VBZ||vasoconstriction-20/NN	prepc_as||causes-15/VBZ||compared-22/VBN	pcomp||compared-22/VBN||with-23/IN	pobj||with-23/IN||norepinephrine-24/NN	septicshock-13||phenylephrine-9||yes||previous findings suggest that a delayed administration of phenylephrine replacing norepinephrine in septicshock patients causes a more pronounced hepatosplanchnic vasoconstriction as compared with norepinephrine.
det||study-2/NN||this-1/DT	nsubjpass||carried-4/VBN||study-2/NN	nsubj||assess-7/VB||study-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	aux||assess-7/VB||to-6/TO	xcomp||carried-4/VBN||assess-7/VB	det||magnitude-9/NN||the-8/DT	dobj||assess-7/VB||magnitude-9/NN	dobj||assess-7/VB||factors-11/NNS	conj_and||magnitude-9/NN||factors-11/NNS	vmod||magnitude-9/NN||associated-12/VBN	amod||disclosure-16/NN||hivseropositive-14/JJ	nn||disclosure-16/NN||status-15/NN	prep_of||associated-12/VBN||disclosure-16/NN	amod||partners-19/NNS||sexual-18/JJ	prep_to||disclosure-16/NN||partners-19/NNS	prep_among||associated-12/VBN||peoples-21/NNS	vmod||peoples-21/NNS||living-22/VBG	prep_with||living-22/VBG||hiv/aids-24/NNS	hivseropositive-14||hiv--1||no||this study was carried out to assess the magnitude and factors associated of hivseropositive status disclosure to sexual partners among peoples living with hiv/aids.
mark||shown-5/VBN||although-1/IN	amod||studies-3/NNS||recent-2/JJ	nsubj||shown-5/VBN||studies-3/NNS	aux||shown-5/VBN||have-4/VBP	advcl||suggest-46/VBP||shown-5/VBN	det||decrease-7/NN||a-6/DT	dobj||shown-5/VBN||decrease-7/NN	amod||hepatitis-10/NN||icteric-9/JJ	prep_in||decrease-7/NN||hepatitis-10/NN	prep_after||shown-5/VBN||administration-12/NN	det||types-15/NNS||both-14/DT	prep_of||administration-12/NN||types-15/NNS	nn||³-18/NNS||î-17/NN	prep_of||types-15/NNS||³-18/NNS	parataxis||shown-5/VBN||globulin-20/NN	prep_in||globulin-20/NN||populations-22/NNS	advmod||result-35/NN||where-23/WRB	nsubj||result-35/NN||acquisition-24/NN	amod||virus-27/NN||hepatitisb-26/JJ	prep_of||acquisition-24/NN||virus-27/NN	appos||virus-27/NN||hbv-29/NN	cop||result-35/NN||is-31/VBZ	advmod||likely-33/JJ||most-32/RBS	amod||result-35/NN||likely-33/JJ	det||result-35/NN||the-34/DT	rcmod||populations-22/NNS||result-35/NN	amod||transmission-38/NN||nonparenteral-37/JJ	prep_of||result-35/NN||transmission-38/NN	det||data-41/NNS||the-40/DT	nsubj||suggest-46/VBP||data-41/NNS	nsubj||decreases-56/VBZ||data-41/NNS	vmod||data-41/NNS||pertaining-42/VBG	aux||parenteral-44/VB||to-43/TO	xcomp||pertaining-42/VBG||parenteral-44/VB	dobj||parenteral-44/VB||exposure-45/NN	root||ROOT-0/null||suggest-46/VBP	mark||hbig-48/VBG||that-47/IN	ccomp||suggest-46/VBP||hbig-48/VBG	dobj||hbig-48/VBG||delays-49/NNS	det||period-52/NN||the-50/DT	nn||period-52/NN||incubation-51/NN	dep||hbig-48/VBG||period-52/NN	prep_of||period-52/NN||hbv-54/NN	conj_and||suggest-46/VBP||decreases-56/VBZ	det||development-58/NN||the-57/DT	dobj||decreases-56/VBZ||development-58/NN	amod||immunity-61/NN||passive-active-60/JJ	prep_of||development-58/NN||immunity-61/NN	hbv-54||hbig-48||yes||although recent studies have shown a decrease in icteric hepatitis after administration of both types of î³-globulin in populations where acquisition of hepatitisb virus (hbv) is most likely the result of nonparenteral transmission, the data pertaining to parenteral exposure suggest that hbig delays the incubation period of hbv and decreases the development of passive-active immunity.
det||reaction-8/NN||a-1/DT	amod||reaction-8/NN||duplex-2/JJ	amod||reaction-8/NN||real-time-3/JJ	amod||reaction-8/NN||reverse-4/JJ	amod||reaction-8/NN||transcriptase-5/JJ	nn||reaction-8/NN||polymerase-6/NN	nn||reaction-8/NN||chain-7/NN	nsubjpass||improved-14/VBN||reaction-8/NN	appos||reaction-8/NN||rt-pcr-10/NN	advmod||improved-14/VBN||assay-12/RB	auxpass||improved-14/VBN||was-13/VBD	root||ROOT-0/null||improved-14/VBN	amod||detection-17/NN||simultaneous-16/JJ	prep_for||improved-14/VBN||detection-17/NN	advmod||pathogenic-20/JJ||highly-19/RB	amod||influenzavirus-29/NNS||pathogenic-20/JJ	amod||influenzavirus-29/NNS||h5n1-21/JJ	amod||influenzavirus-29/NNS||avianinfluenzavirus-22/JJ	conj_and||avianinfluenzavirus-22/JJ||pandemic-24/JJ	amod||influenzavirus-29/NNS||pandemic-24/JJ	nn||influenzavirus-29/NNS||h1n1-25/NN	appos||influenzavirus-29/NNS||2009-27/CD	prep_of||detection-17/NN||influenzavirus-29/NNS	nsubj||suitable-33/JJ||influenzavirus-29/NNS	cop||suitable-33/JJ||is-32/VBZ	rcmod||influenzavirus-29/NNS||suitable-33/JJ	amod||diagnosis-36/NN||early-35/JJ	prep_for||suitable-33/JJ||diagnosis-36/NN	amod||patients-39/NNS||influenza-like-38/JJ	prep_of||diagnosis-36/NN||patients-39/NNS	amod||surveillance-43/NN||epidemiological-42/JJ	prep_for||suitable-33/JJ||surveillance-43/NN	conj_and||diagnosis-36/NN||surveillance-43/NN	h5n1-21||avianinfluenzavirus-22||no||a duplex real-time reverse transcriptase polymerase chain reaction (rt-pcr) assay was improved for simultaneous detection of highly pathogenic h5n1 avianinfluenzavirus and pandemic h1n1 (2009) influenzavirus, which is suitable for early diagnosis of influenza-like patients and for epidemiological surveillance.
dep||murine-8/VB||vaccination-1/JJ	prep_by||vaccination-1/JJ||bcg-3/NN	amod||bcg-3/NN||prime-4/JJ	amod||+-7/NNS||ighsp65-6/JJ	prep_with||bcg-3/NN||+-7/NNS	dep||boost-12/NN||murine-8/VB	acomp||murine-8/VB||il-12-9/JJ	punct||boost-12/NN||/-10/:	amod||boost-12/NN||hvj-envelope-11/JJ	root||ROOT-0/null||boost-12/NN	vmod||boost-12/NN||resulted-13/VBN	amod||efficacy-17/NN||significant-15/JJ	amod||efficacy-17/NN||protective-16/JJ	prep_in||resulted-13/VBN||efficacy-17/NN	dep||efficacy-17/NN||>-19/NNP	num||>-19/NNP||10-20/CD	num||>-19/NNP||â-22/CD	npadvmod||000-fold-25/JJ||$-23/$	num||$-23/$||‰-24/CD	amod||>-19/NNP||000-fold-25/JJ	prep_versus||>-19/NNP||bcg-27/NN	advmod||bcg-27/NN||alone-28/RB	nn||infection-32/NN||tb-31/NN	prep_against||efficacy-17/NN||infection-32/NN	det||lungs-35/NNS||the-34/DT	prep_in||resulted-13/VBN||lungs-35/NNS	prep_of||lungs-35/NNS||mice-37/NNS	tb-31||bcg-27||yes||vaccination by bcg prime with ighsp65+murine il-12/hvj-envelope boost resulted in significant protective efficacy (>10,â€‰000-fold versus bcg alone) against tb infection in the lungs of mice.
amod||cells-2/NNS||sw948-1/JJ	nsubj||sensitive-4/JJ||cells-2/NNS	cop||sensitive-4/JJ||were-3/VBD	root||ROOT-0/null||sensitive-4/JJ	quantmod||three-7/CD||all-6/DT	prep_to||sensitive-4/JJ||three-7/CD	det||agents-11/NNS||the-9/DT	amod||agents-11/NNS||dr-targeting-10/JJ	prep_of||sensitive-4/JJ||agents-11/NNS	vmod||agents-11/NNS||tested-12/VBN	mark||caspase-22/VBP||although-14/IN	det||antibody-18/NN||the-15/DT	amod||antibody-18/NN||agonistic-16/JJ	amod||antibody-18/NN||dr5-17/JJ	nsubj||caspase-22/VBP||antibody-18/NN	vmod||antibody-18/NN||induced-19/VBN	advmod||weak-21/JJ||only-20/RB	acomp||induced-19/VBN||weak-21/JJ	advcl||sensitive-4/JJ||caspase-22/VBP	number||cleavage-24/JJ||8-23/CD	dobj||caspase-22/VBP||cleavage-24/JJ	amod||apoptosis-27/NNS||limited-26/JJ	dobj||caspase-22/VBP||apoptosis-27/NNS	conj_and||cleavage-24/JJ||apoptosis-27/NNS	dr--1||antibody-18||no_rel||sw948 cells were sensitive to all three of the dr-targeting agents tested, although the agonistic dr5 antibody induced only weak caspase 8 cleavage and limited apoptosis.
nsubj||point-2/VBP||we-1/PRP	root||ROOT-0/null||point-2/VBP	prt||point-2/VBP||out-3/RP	neg||only-5/JJ||not-4/RB	preconj||association-7/NN||only-5/JJ	det||association-7/NN||the-6/DT	dobj||point-2/VBP||association-7/NN	det||abscess-11/NNS||an-9/DT	amod||abscess-11/NNS||epidural-10/JJ	prep_of||association-7/NN||abscess-11/NNS	amod||jointinfection-14/NN||facet-13/JJ	prep_with||abscess-11/NNS||jointinfection-14/NN	det||indication-20/NN||the-18/DT	amod||indication-20/NN||possible-19/JJ	dobj||point-2/VBP||indication-20/NN	conj_and||association-7/NN||indication-20/NN	amod||cement-23/NN||antibiotic-bone-22/JJ	prep_of||indication-20/NN||cement-23/NN	rcmod||indication-20/NN||beads-24/VBZ	det||treatment-27/NN||the-26/DT	prep_in||beads-24/VBZ||treatment-27/NN	amod||abscesses-30/NNS||epidural-29/JJ	prep_of||treatment-27/NN||abscesses-30/NNS	abscesses-30||antibiotic--1||no_rel||we point out not only the association of an epidural abscess with facet jointinfection, but also the possible indication of antibiotic-bone cement beads in the treatment of epidural abscesses.
det||recognition-2/NN||the-1/DT	nsubj||relies-6/VBZ||recognition-2/NN	amod||intestinalperforation-5/NN||neonatal-4/JJ	prep_of||recognition-2/NN||intestinalperforation-5/NN	root||ROOT-0/null||relies-6/VBZ	prep_on||relies-6/VBZ||identification-8/NN	amod||gas-11/NN||free-10/JJ	prep_of||identification-8/NN||gas-11/NN	det||peritoneum-14/NN||the-13/DT	prep_in||relies-6/VBZ||peritoneum-14/NN	advmod||abdominal-17/JJ||plain-16/RB	amod||radiographs-18/NNS||abdominal-17/JJ	prep_on||peritoneum-14/NN||radiographs-18/NNS	det||signs-23/NNS||the-20/DT	amod||signs-23/NNS||associated-21/VBN	amod||signs-23/NNS||clinical-22/JJ	prep_on||peritoneum-14/NN||signs-23/NNS	conj_and||radiographs-18/NNS||signs-23/NNS	gas-11||intestinalperforation-5||no_rel||the recognition of neonatal intestinalperforation relies on identification of free gas in the peritoneum on plain abdominal radiographs and the associated clinical signs.
det||groups-3/NNS||the-1/DT	num||groups-3/NNS||two-2/CD	nsubj||comparable-11/JJ||groups-3/NNS	dep||groups-3/NNS||dexamethasone-6/JJ	dep||groups-3/NNS||ondansetron-8/JJ	conj_and||dexamethasone-6/JJ||ondansetron-8/JJ	cop||comparable-11/JJ||were-10/VBD	root||ROOT-0/null||comparable-11/JJ	prep_in||comparable-11/JJ||outcome-13/NN	prep_in||comparable-11/JJ||terms-16/NNS	amod||nausea-19/NN||post-operative-18/JJ	prep_of||terms-16/NNS||nausea-19/NN	prep_of||terms-16/NNS||vomiting-21/NN	conj_and||nausea-19/NN||vomiting-21/NN	prep_in||terms-16/NNS||patients-24/NNS	vmod||patients-24/NNS||undergoing-25/VBG	amod||cholecystectomy-27/NN||laparoscopic-26/JJ	dobj||undergoing-25/VBG||cholecystectomy-27/NN	nausea-19||dexamethasone-6||yes||the two groups, (dexamethasone and ondansetron) were comparable in outcome, in terms of post-operative nausea and vomiting, in patients undergoing laparoscopic cholecystectomy.
det||patient-2/NN||the-1/DT	nsubjpass||transferred-4/VBN||patient-2/NN	auxpass||transferred-4/VBN||was-3/VBD	root||ROOT-0/null||transferred-4/VBN	det||center-7/NN||the-6/DT	prep_to||transferred-4/VBN||center-7/NN	vmod||center-7/NN||treating-8/VBG	poss||hemophilia-10/NN||his-9/PRP$	dobj||treating-8/VBG||hemophilia-10/NN	advmod||pinned-15/VBN||where-11/WRB	det||hip-13/NN||the-12/DT	nsubjpass||pinned-15/VBN||hip-13/NN	auxpass||pinned-15/VBN||was-14/VBD	advcl||treating-8/VBG||pinned-15/VBN	prep_in||pinned-15/VBN||situ-17/NN	prep_under||pinned-15/VBN||cover-19/NN	prep_with||pinned-15/VBN||factorviii-21/NNS	hemophilia-10||factorviii-21||yes||the patient was transferred to the center treating his hemophilia where the hip was pinned in situ under cover with factorviii.
nn||parvum-2/NN||crystosporidium-1/NN	nsubjpass||found-4/VBN||parvum-2/NN	nsubj||higher-8/JJR||parvum-2/NN	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	aux||higher-8/JJR||to-5/TO	cop||higher-8/JJR||be-6/VB	advmod||higher-8/JJR||significantly-7/RB	xcomp||found-4/VBN||higher-8/JJR	amod||patients-11/NNS||hiv/aids-10/JJ	prep_in||higher-8/JJR||patients-11/NNS	prep||higher-8/JJR||than-12/IN	pcomp||than-12/IN||in-13/IN	pobj||in-13/IN||controls-14/NNS	dep||<-17/JJ||p-16/RB	dep||higher-8/JJR||<-17/JJ	dep||<-17/JJ||0.05-18/CD	aids--1||hiv--1||no||crystosporidium parvum was found to be significantly higher in hiv/aids patients than in controls (p<0.05).
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||study-11/NN||a-3/DT	amod||study-11/NN||prospective-4/JJ	amod||study-11/NN||randomized-6/JJ	amod||study-11/NN||open-label-8/JJ	amod||study-11/NN||multicenter-10/JJ	dobj||conducted-2/VBD||study-11/NN	aux||compare-13/VB||to-12/TO	vmod||conducted-2/VBD||compare-13/VB	dobj||compare-13/VB||busulfan-14/NN	prep||busulfan-14/NN||plus-15/CC	pobj||plus-15/CC||fludarabine-16/NN	appos||fludarabine-16/NN||buflu-18/NNP	nn||plus-22/NN||busulfan-21/NN	prep_with||compare-13/VB||plus-22/NN	advmod||conducted-2/VBD||cyclophosphamide-23/RB	dep||conducted-2/VBD||bucy-25/RB	mark||stem-34/VBP||as-27/IN	det||regimen-30/NN||the-28/DT	nn||regimen-30/NN||conditioning-29/NN	nsubj||stem-34/VBP||regimen-30/NN	amod||hematopoietic-33/NN||allogeneic-32/JJ	prep_in||regimen-30/NN||hematopoietic-33/NN	advcl||conducted-2/VBD||stem-34/VBP	nn||transplantation-36/NN||cell-35/NN	dobj||stem-34/VBP||transplantation-36/NN	appos||transplantation-36/NN||allo-hsct-38/NN	prep_for||transplantation-36/NN||acutemyeloidleukemia-41/NN	appos||acutemyeloidleukemia-41/NN||aml-43/NN	amod||remission-48/NN||first-46/JJ	amod||remission-48/NN||complete-47/JJ	prep_in||acutemyeloidleukemia-41/NN||remission-48/NN	appos||remission-48/NN||cr1-50/NNP	acutemyeloidleukemia-41||cyclophosphamide-23||yes||we conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus fludarabine (buflu) with busulfan plus cyclophosphamide (bucy) as the conditioning regimen in allogeneic hematopoietic stem cell transplantation (allo-hsct) for acutemyeloidleukemia (aml) in first complete remission (cr1).
vmod||predicted-43/VBD||using-1/VBG	det||horizon-4/NN||a-2/DT	nn||horizon-4/NN||prediction-3/NN	dobj||using-1/VBG||horizon-4/NN	num||min-7/NN||35-6/CD	prep_of||horizon-4/NN||min-7/NN	det||threshold-11/NN||a-9/DT	nn||threshold-11/NN||glucose-10/NN	dobj||using-1/VBG||threshold-11/NN	conj_and||horizon-4/NN||threshold-11/NN	num||mg/dl-14/NN||80-13/CD	prep_of||threshold-11/NN||mg/dl-14/NN	det||threshold-19/NN||a-17/DT	amod||threshold-19/NN||voting-18/VBG	dobj||using-1/VBG||threshold-19/NN	conj_and||horizon-4/NN||threshold-19/NN	prep_of||threshold-19/NN||three-21/CD	num||algorithms-24/NNS||five-23/CD	prep_of||three-21/CD||algorithms-24/NNS	aux||predict-26/VB||to-25/TO	vmod||three-21/CD||predict-26/VB	dobj||predict-26/VB||hypoglycemia-27/NN	dep||threshold-19/NN||defined-29/VBN	det||readings-35/NNS||a-31/DT	amod||readings-35/NNS||freestyle-32/JJ	nn||readings-35/NNS||plasma-33/NN	nn||readings-35/NNS||glucose-34/NN	prep_as||defined-29/VBN||readings-35/NNS	vmod||readings-35/NNS||<-36/VBG	num||mg/dl-38/NN||60-37/CD	dobj||<-36/VBG||mg/dl-38/NN	det||hpa-42/NN||the-41/DT	nsubj||predicted-43/VBD||hpa-42/NN	root||ROOT-0/null||predicted-43/VBD	num||%-45/NN||91-44/CD	dobj||predicted-43/VBD||%-45/NN	det||events-49/NNS||the-47/DT	amod||events-49/NNS||hypoglycemic-48/JJ	prep_of||%-45/NN||events-49/NNS	hypoglycemia-27||glucose-34||yes||using a prediction horizon of 35 min, a glucose threshold of 80 mg/dl, and a voting threshold of three of five algorithms to predict hypoglycemia (defined as a freestyle plasma glucose readings <60 mg/dl), the hpa predicted 91% of the hypoglycemic events.
nsubjpass||found-3/VBN||praziquantel-1/NN	nsubj||effective-7/JJ||praziquantel-1/NN	auxpass||found-3/VBN||was-2/VBD	root||ROOT-0/null||found-3/VBN	aux||effective-7/JJ||to-4/TO	cop||effective-7/JJ||be-5/VB	advmod||effective-7/JJ||very-6/RB	xcomp||found-3/VBN||effective-7/JJ	advmod||complete-11/JJ||sometimes-10/RB	amod||worms-12/NNS||complete-11/JJ	nsubjpass||recovered-16/VBN||worms-12/NNS	aux||recovered-16/VBN||could-13/MD	neg||recovered-16/VBN||not-14/RB	auxpass||recovered-16/VBN||be-15/VB	conj_but||found-3/VBN||recovered-16/VBN	det||feces-19/NNS||the-18/DT	prep_from||recovered-16/VBN||feces-19/NNS	prep_after||recovered-16/VBN||treatment-21/NN	advmod||due-24/JJ||probably-23/RB	acomp||recovered-16/VBN||due-24/JJ	det||dissolution-27/NN||the-26/DT	prep_to||due-24/JJ||dissolution-27/NN	det||proglottids-30/NNS||the-29/DT	prep_of||dissolution-27/NN||proglottids-30/NNS	worms-12||praziquantel-1||yes||praziquantel was found to be very effective, but sometimes complete worms could not be recovered from the feces after treatment, probably due to the dissolution of the proglottids.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	det||disease-10/NN||a-9/DT	conj_and||agent-5/NN||disease-10/NN	amod||morbidity-13/NN||significant-12/JJ	prep_of||disease-10/NN||morbidity-13/NN	prep_of||disease-10/NN||mortality-15/NN	conj_and||morbidity-13/NN||mortality-15/NN	det||human-18/NN||both-17/DT	prep_in||disease-10/NN||human-18/NN	conj_and||agent-5/NN||animals-20/NNS	amod||areas-23/NNS||endemic-22/JJ	prep_in||animals-20/NNS||areas-23/NNS	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the causative agent of melioidosis, a disease of significant morbidity and mortality in both human and animals in endemic areas.
det||number-2/NN||a-1/DT	nsubj||cause-6/VBP||number-2/NN	nn||viruses-5/NNS||rna-4/NN	prep_of||number-2/NN||viruses-5/NNS	root||ROOT-0/null||cause-6/VBP	prep_in||induce-20/VB||viralhemorrhagicfever-7/NN	nsubj||leading-31/VBG||viralhemorrhagicfever-7/NN	appos||viralhemorrhagicfever-7/NN||vhf-9/NN	amod||mediators-15/NNS||proinflammatory-14/JJ	nsubj||induce-20/VB||mediators-15/NNS	vmod||mediators-15/NNS||released-16/VBN	amod||cells-19/NNS||infected-18/JJ	prep_from||released-16/VBN||cells-19/NNS	rcmod||viralhemorrhagicfever-7/NN||induce-20/VB	amod||permeability-22/NN||increased-21/VBN	dobj||induce-20/VB||permeability-22/NN	det||lining-26/NN||the-24/DT	amod||lining-26/NN||endothelial-25/JJ	prep_of||permeability-22/NN||lining-26/NN	nn||vessels-29/NNS||blood-28/NN	prep_of||lining-26/NN||vessels-29/NNS	dep||cause-6/VBP||leading-31/VBG	prep_to||leading-31/VBG||loss-33/NN	nn||volume-36/NN||plasma-35/NN	prep_of||loss-33/NN||volume-36/NN	prep_of||loss-33/NN||hypotension-38/NN	conj_and||volume-36/NN||hypotension-38/NN	amod||failure-41/NN||multi-organ-40/JJ	prep_of||loss-33/NN||failure-41/NN	conj_and||volume-36/NN||failure-41/NN	prep_of||loss-33/NN||shock-43/NN	conj_and||volume-36/NN||shock-43/NN	prep_of||loss-33/NN||death-45/NN	conj_and||volume-36/NN||death-45/NN	viralhemorrhagicfever-7||viruses-5||no||a number of rna viruses cause viralhemorrhagicfever (vhf), in which proinflammatory mediators released from infected cells induce increased permeability of the endothelial lining of blood vessels, leading to loss of plasma volume, hypotension, multi-organ failure, shock and death.
nsubj||investigated-3/VBN||we-1/PRP	aux||investigated-3/VBN||have-2/VBP	root||ROOT-0/null||investigated-3/VBN	det||effect-5/NN||the-4/DT	dobj||investigated-3/VBN||effect-5/NN	amod||treatment-9/NN||intermittent-7/JJ	nn||treatment-9/NN||preventive-8/NN	prep_of||effect-5/NN||treatment-9/NN	prep_with||treatment-9/NN||sulphadoxine-pyrimethamine-11/NN	prep_with||treatment-9/NN||artesunate-13/NN	conj_or||sulphadoxine-pyrimethamine-11/NN||artesunate-13/NN	dobj||investigated-3/VBN||amodiaquine-15/NN	conj_plus||effect-5/NN||amodiaquine-15/NN	prep_on||amodiaquine-15/NN||anaemia-17/NN	prep_on||amodiaquine-15/NN||malaria-19/NN	conj_and||anaemia-17/NN||malaria-19/NN	prep_in||investigated-3/VBN||children-21/NNS	det||area-24/NN||an-23/DT	prep_in||children-21/NNS||area-24/NN	amod||transmission-32/NN||intense-26/JJ	amod||transmission-32/NN||prolonged-28/JJ	amod||transmission-32/NN||seasonal-30/JJ	nn||transmission-32/NN||malaria-31/NN	prep_of||area-24/NN||transmission-32/NN	prep_in||investigated-3/VBN||ghana-34/NN	malaria-31||pyrimethamine--1||no||we have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in ghana.
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||consequence-12/NN||that-4/IN	det||potentiation-6/NN||the-5/DT	nsubj||consequence-12/NN||potentiation-6/NN	prep_in||potentiation-6/NN||cell-8/NN	amod||cell-8/NN||swelling-9/VBG	cop||consequence-12/NN||is-10/VBZ	det||consequence-12/NN||a-11/DT	ccomp||suggest-3/VBP||consequence-12/NN	det||activation-16/NN||the-14/DT	amod||activation-16/NN||initial-15/JJ	prep_of||consequence-12/NN||activation-16/NN	prep_of||activation-16/NN||nf-îºb-18/NN	prep_by||nf-îºb-18/NN||ammonia-20/NN	swelling-9||ammonia-20||no_rel||these data suggest that the potentiation in cell swelling is a consequence of the initial activation of nf-îºb by ammonia.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||increased-2/VBN	nsubj||highlighted-19/VBN||incidence-3/NN	amod||fungalinfections-6/NNS||opportunistic-5/JJ	prep_of||incidence-3/NN||fungalinfections-6/NNS	vmod||fungalinfections-6/NNS||associated-8/VBN	amod||resistance-11/NN||greater-10/JJR	prep_with||associated-8/VBN||resistance-11/NN	det||antifungaldrugs-14/NNS||the-13/DT	prep_to||resistance-11/NN||antifungaldrugs-14/NNS	advmod||associated-8/VBN||currently-15/RB	prep_in||associated-8/VBN||use-17/NN	aux||highlighted-19/VBN||has-18/VBZ	root||ROOT-0/null||highlighted-19/VBN	det||need-21/NN||the-20/DT	dobj||highlighted-19/VBN||need-21/NN	amod||solutions-24/NNS||new-23/JJ	prep_for||need-21/NN||solutions-24/NNS	antifungaldrugs-14||fungalinfections-6||no_rel||the increased incidence of opportunistic fungalinfections, associated with greater resistance to the antifungaldrugs currently in use has highlighted the need for new solutions.
nsubj||profile-3/VB||we-1/PRP	nsubj||propose-18/VB||we-1/PRP	nsubj||enzyme-30/VB||we-1/PRP	advmod||profile-3/VB||first-2/RB	root||ROOT-0/null||profile-3/VB	det||reaction-5/NN||each-4/DT	dobj||profile-3/VB||reaction-5/NN	poss||states-9/NNS||its-7/PRP$	nn||states-9/NNS||flux-8/NN	prep_by||profile-3/VB||states-9/NNS	amod||lines-14/NNS||nci-60-11/JJ	nn||lines-14/NNS||cancer-12/NN	nn||lines-14/NNS||cell-13/NN	prep_in||profile-3/VB||lines-14/NNS	advmod||propose-18/VB||then-17/RB	conj_and||profile-3/VB||propose-18/VB	det||model-23/NN||a-19/DT	amod||model-23/NN||kernel-20/JJ	amod||model-23/NN||k-nearest-21/JJ	nn||model-23/NN||neighbor-22/NN	dobj||propose-18/VB||model-23/NN	aux||predict-25/VB||to-24/TO	vmod||propose-18/VB||predict-25/VB	amod||reactions-28/NNS||related-26/JJ	amod||reactions-28/NNS||metabolic-27/JJ	dobj||predict-25/VB||reactions-28/NNS	conj_and||profile-3/VB||enzyme-30/VB	dobj||enzyme-30/VB||targets-31/NNS	amod||cancerdrugs-34/NNS||approved-33/JJ	prep_for||targets-31/NNS||cancerdrugs-34/NNS	enzyme-30||cancer-12||no_rel||we first profile each reaction by its flux states in nci-60 cancer cell lines, and then propose a kernel k-nearest neighbor model to predict related metabolic reactions and enzyme targets for approved cancerdrugs.
nsubj||reservoirs-3/NNS||bats-1/NNS	cop||reservoirs-3/NNS||are-2/VBP	root||ROOT-0/null||reservoirs-3/NNS	amod||viruses-7/NNS||emerging-5/VBG	amod||viruses-7/NNS||zoonotic-6/JJ	prep_for||reservoirs-3/NNS||viruses-7/NNS	nsubj||have-10/VB||viruses-7/NNS	aux||have-10/VB||can-9/MD	rcmod||viruses-7/NNS||have-10/VB	det||impact-13/NN||a-11/DT	amod||impact-13/NN||profound-12/JJ	dobj||have-10/VB||impact-13/NN	nn||health-18/NN||human-15/NN	conj_and||human-15/NN||animal-17/NN	nn||health-18/NN||animal-17/NN	prep_on||impact-13/NN||health-18/NN	nn||paramyxoviruses-25/NNS||lyssaviruses-21/NNS	dep||paramyxoviruses-25/NNS||filoviruses-23/NNS	prep_including||impact-13/NN||paramyxoviruses-25/NNS	nn||coronaviruses-29/NNS||severeacuterespiratorysyndrome-28/NN	prep_including||impact-13/NN||coronaviruses-29/NNS	conj_and||paramyxoviruses-25/NNS||coronaviruses-29/NNS	appos||reservoirs-3/NNS||sars-covs-31/NNS	sars--1||coronaviruses-29||no||bats are reservoirs for emerging zoonotic viruses that can have a profound impact on human and animal health, including lyssaviruses, filoviruses, paramyxoviruses, and severeacuterespiratorysyndrome coronaviruses (sars-covs).
nsubj||safe-3/JJ||dorzolamide-1/NN	nsubj||effective-5/JJ||dorzolamide-1/NN	cop||safe-3/JJ||is-2/VBZ	root||ROOT-0/null||safe-3/JJ	conj_and||safe-3/JJ||effective-5/JJ	advmod||used-7/VBD||when-6/WRB	advcl||safe-3/JJ||used-7/VBD	num||months-10/NNS||twelve-9/CD	prep_for||used-7/VBD||months-10/NNS	amod||therapy-13/NN||add-on-12/JJ	prep_as||months-10/NNS||therapy-13/NN	aux||latanoprost-15/VB||to-14/TO	xcomp||used-7/VBD||latanoprost-15/VB	prep_for||latanoprost-15/VB||open-angleglaucoma-17/NN	open-angleglaucoma-17||dorzolamide-1||yes||dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angleglaucoma.
dep||murine-8/VB||vaccination-1/JJ	prep_by||vaccination-1/JJ||bcg-3/NN	amod||bcg-3/NN||prime-4/JJ	amod||+-7/NNS||ighsp65-6/JJ	prep_with||bcg-3/NN||+-7/NNS	dep||boost-12/NN||murine-8/VB	acomp||murine-8/VB||il-12-9/JJ	punct||boost-12/NN||/-10/:	amod||boost-12/NN||hvj-envelope-11/JJ	root||ROOT-0/null||boost-12/NN	vmod||boost-12/NN||resulted-13/VBN	amod||efficacy-17/NN||significant-15/JJ	amod||efficacy-17/NN||protective-16/JJ	prep_in||resulted-13/VBN||efficacy-17/NN	dep||efficacy-17/NN||>-19/NNP	num||>-19/NNP||10-20/CD	num||>-19/NNP||â-22/CD	npadvmod||000-fold-25/JJ||$-23/$	num||$-23/$||‰-24/CD	amod||>-19/NNP||000-fold-25/JJ	prep_versus||>-19/NNP||bcg-27/NN	advmod||bcg-27/NN||alone-28/RB	nn||infection-32/NN||tb-31/NN	prep_against||efficacy-17/NN||infection-32/NN	det||lungs-35/NNS||the-34/DT	prep_in||resulted-13/VBN||lungs-35/NNS	prep_of||lungs-35/NNS||mice-37/NNS	tb-31||bcg-27||no||vaccination by bcg prime with ighsp65+murine il-12/hvj-envelope boost resulted in significant protective efficacy (>10,â€‰000-fold versus bcg alone) against tb infection in the lungs of mice.
det||study-3/NN||this-2/DT	prep_in||investigated-7/VBN||study-3/NN	nsubj||investigated-7/VBN||we-5/PRP	aux||investigated-7/VBN||have-6/VBP	root||ROOT-0/null||investigated-7/VBN	det||effects-9/NNS||the-8/DT	dobj||investigated-7/VBN||effects-9/NNS	amod||overexpression-12/NN||pref-1-11/JJ	prep_of||effects-9/NNS||overexpression-12/NN	amod||homeostasis-16/NNS||whole-body-14/JJ	nn||homeostasis-16/NNS||glucose-15/NN	prep_on||investigated-7/VBN||homeostasis-16/NNS	poss||contribution-19/NN||its-18/PRP$	prep_on||investigated-7/VBN||contribution-19/NN	conj_and||homeostasis-16/NNS||contribution-19/NN	det||development-22/NN||the-21/DT	prep_to||investigated-7/VBN||development-22/NN	prep_of||development-22/NN||insulinresistance-24/NN	insulinresistance-24||glucose-15||no_rel||in this study, we have investigated the effects of pref-1 overexpression on whole-body glucose homeostasis and its contribution to the development of insulinresistance.
advmod||av-6/VBP||furthermore-1/RB	det||e/e-4/NN||the-3/DT	nsubj||av-6/VBP||e/e-4/NN	root||ROOT-0/null||av-6/VBP	nn||increases-8/NNS||ratio-7/NN	dobj||av-6/VBP||increases-8/NNS	det||status-13/NN||the-10/DT	nn||status-13/NN||glucose-11/NN	nn||status-13/NN||metabolism-12/NN	prep_along||increases-8/NNS||status-13/NN	amod||metabolism-17/NN||normal-15/JJ	nn||metabolism-17/NN||glucose-16/NN	prep_from||av-6/VBP||metabolism-17/NN	number||-LSB--20/CD||7.6-19/CD	num||.1-22/CD||-LSB--20/CD	number||.1-22/CD||6.2-10-21/CD	npadvmod||-RSB--23/JJ||.1-22/CD	dep||metabolism-17/NN||-RSB--23/JJ	prep_to||metabolism-17/NN||impairedglucosetolerance-26/NN	number||-LSB--29/CD||8.8-28/CD	num||.0-31/CD||-LSB--29/CD	number||.0-31/CD||7.4-11-30/CD	npadvmod||-RSB--32/JJ||.0-31/CD	dep||impairedglucosetolerance-26/NN||-RSB--32/JJ	prep_to||metabolism-17/NN||t2dm-35/NNS	conj_and||impairedglucosetolerance-26/NN||t2dm-35/NNS	number||-LSB--38/CD||10.5-37/CD	num||.2-40/CD||-LSB--38/CD	number||.2-40/CD||8.1-13-39/CD	npadvmod||-RSB--41/JJ||.2-40/CD	dep||impairedglucosetolerance-26/NN||-RSB--41/JJ	advmod||metabolism-17/NN||respectively-44/RB	appos||metabolism-17/NN||p-46/NNP	number||0.001-48/CD||<-47/CD	num||p-46/NNP||0.001-48/CD	impairedglucosetolerance-26||glucose-16||no_rel||furthermore, the e/e'av ratio increases along the glucose metabolism status from normal glucose metabolism (7.6 [6.2-10.1]) to impairedglucosetolerance (8.8 [7.4-11.0]) and t2dm (10.5 [8.1-13.2]), respectively (p < 0.001).
det||association-2/NN||this-1/DT	nsubjpass||observed-4/VBN||association-2/NN	auxpass||observed-4/VBN||was-3/VBD	root||ROOT-0/null||observed-4/VBN	xcomp||observed-4/VBN||using-5/VBG	amod||co-immunoprecipitation-7/NN||bi-directional-6/JJ	dobj||using-5/VBG||co-immunoprecipitation-7/NN	amod||systems-10/NNS||multiple-9/JJ	prep_in||using-5/VBG||systems-10/NNS	nn||conditions-13/NNS||detergent-12/NN	prep_in||using-5/VBG||conditions-13/NNS	conj_and||systems-10/NNS||conditions-13/NNS	det||î-17/NN||an-16/DT	nsubj||²-18/VBZ||î-17/NN	conj_and||observed-4/VBN||²-18/VBZ	amod||precursor-21/NN||amyloid-20/JJ	nsubjpass||isolated-26/VBN||precursor-21/NN	amod||complex-23/JJ||protein-aph-1-22/JJ	amod||precursor-21/NN||complex-23/JJ	auxpass||isolated-26/VBN||was-24/VBD	advmod||isolated-26/VBN||specifically-25/RB	parataxis||observed-4/VBN||isolated-26/VBN	prep||isolated-26/VBN||following-27/VBG	pcomp||following-27/VBG||in-28/IN	amod||cross-linking-30/NN||situ-29/JJ	pobj||in-28/IN||cross-linking-30/NN	amod||cells-33/NNS||living-32/VBG	prep_in||cross-linking-30/NN||cells-33/NNS	cross--1||detergent-12||no_rel||this association was observed using bi-directional co-immunoprecipitation in multiple systems and detergent conditions, and an î²-amyloid precursor protein-aph-1 complex was specifically isolated following in situ cross-linking in living cells.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||monitor-8/VB||aim-2/NN	poss||study-5/NN||our-4/PRP$	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||monitor-8/VB||to-7/TO	xcomp||was-6/VBD||monitor-8/VB	nn||markers-10/NNS||hbv-9/NN	dobj||monitor-8/VB||markers-10/NNS	nn||antigen-14/NN||hbv-12/NN	nn||antigen-14/NN||surface-13/NN	prep_in||monitor-8/VB||antigen-14/NN	appos||antigen-14/NN||hbsag-16/NN	amod||patients-20/NNS||negative/anti-hbcab-positive-19/JJ	dep||antigen-14/NN||patients-20/NNS	vmod||patients-20/NNS||treated-21/VBN	det||inhibitor-26/NN||a-23/DT	amod||inhibitor-26/NN||tnfî-24/JJ	amod||inhibitor-26/NN||±-25/JJ	prep_with||treated-21/VBN||inhibitor-26/NN	amod||arthritides-29/NNS||inflammatory-28/JJ	prep_for||inhibitor-26/NN||arthritides-29/NNS	hbv-12||hbsag-16||yes||the aim of our study was to monitor hbv markers in hbv surface antigen (hbsag)-negative/anti-hbcab-positive patients treated with a tnfî± inhibitor for inflammatory arthritides.
aux||summarise-2/VB||to-1/TO	root||ROOT-0/null||summarise-2/VB	dobj||summarise-2/VB||age-3/NN	amod||associations-7/NNS||intensity-stratified-6/JJ	dobj||summarise-2/VB||associations-7/NNS	conj_and||age-3/NN||associations-7/NNS	amod||hookworminfection-10/NN||human-9/JJ	prep_between||associations-7/NNS||hookworminfection-10/NN	prep_between||associations-7/NNS||anaemia-12/NN	conj_and||hookworminfection-10/NN||anaemia-12/NN	aux||quantify-15/VB||to-14/TO	conj_and||summarise-2/VB||quantify-15/VB	det||impact-17/NN||the-16/DT	dobj||quantify-15/VB||impact-17/NN	prep_of||impact-17/NN||treatment-19/NN	det||benzimidazoles-22/NNS||the-21/DT	prep_with||treatment-19/NN||benzimidazoles-22/NNS	amod||impact-17/NN||albendazole-24/JJ	amod||impact-17/NN||mebendazole-26/JJ	conj_and||albendazole-24/JJ||mebendazole-26/JJ	prep_on||quantify-15/VB||haemoglobin-29/NN	prep_on||quantify-15/VB||anaemia-31/NN	conj_and||haemoglobin-29/NN||anaemia-31/NN	amod||populations-34/NNS||non-pregnant-33/JJ	prep_in||quantify-15/VB||populations-34/NNS	hookworminfection-10||albendazole-24||yes||to summarise age- and intensity-stratified associations between human hookworminfection and anaemia and to quantify the impact of treatment with the benzimidazoles, albendazole and mebendazole, on haemoglobin and anaemia in non-pregnant populations.
nsubj||had-2/VBD||most-1/JJS	root||ROOT-0/null||had-2/VBD	det||level-5/NN||a-3/DT	amod||level-5/NN||fair-4/JJ	dobj||had-2/VBD||level-5/NN	prep_of||level-5/NN||knowledge-7/NN	prep_on||had-2/VBD||hiv/aids-9/NNS	det||score-16/NN||the-12/DT	amod||score-16/NN||highest-13/JJS	amod||score-16/NN||mean-14/JJ	nn||score-16/NN||knowledge-15/NN	prep_with||had-2/VBD||score-16/NN	det||msm-19/NN||the-18/DT	prep_among||score-16/NN||msm-19/NN	prep_from||msm-19/NN||jiamusi-21/NNS	appos||jiamusi-21/NNS||those-23/DT	nn||rmb/month-27/NN||income-25/NN	num||rmb/month-27/NN||2000-3000-26/CD	prep_with||those-23/DT||rmb/month-27/NN	appos||those-23/DT||those-29/DT	vmod||those-29/DT||searching-30/VBG	amod||partners-32/NNS||sexual-31/JJ	dobj||searching-30/VBG||partners-32/NNS	prep_via||partners-32/NNS||internet-34/NN	dobj||searching-30/VBG||those-36/DT	conj_and||partners-32/NNS||those-36/DT	vmod||those-36/DT||performed-37/VBN	nn||testing-39/NN||hiv-38/NN	dobj||performed-37/VBN||testing-39/NN	prep||performed-37/VBN||over-40/IN	num||year-42/NN||1-41/CD	npadvmod||ago-43/RB||year-42/NN	pcomp||over-40/IN||ago-43/RB	aids--1||hiv-38||no||most had a fair level of knowledge on hiv/aids, with the highest mean knowledge score among the msm from jiamusi, those with income 2000-3000 rmb/month, those searching sexual partners via internet and those performed hiv testing over 1 year ago).
det||health-4/NN||the-2/DT	amod||health-4/NN||known-3/VBN	prep_despite||are-39/VBP||health-4/NN	nn||costs-7/NNS||healthcare-6/NN	conj_and||health-4/NN||costs-7/NNS	prep_despite||are-39/VBP||costs-7/NNS	amod||chlamydiainfection-10/NN||untreated-9/JJ	prep_of||health-4/NN||chlamydiainfection-10/NN	det||efforts-13/NNS||the-12/DT	conj_and||health-4/NN||efforts-13/NNS	prep_despite||are-39/VBP||efforts-13/NNS	det||programme-19/NN||the-15/DT	amod||programme-19/NN||national-16/JJ	nn||programme-19/NN||chlamydia-17/NN	nn||programme-19/NN||screening-18/NN	prep_of||efforts-13/NNS||programme-19/NN	appos||programme-19/NN||ncsp-21/NN	aux||control-24/VB||to-23/TO	vmod||efforts-13/NNS||control-24/VB	dobj||control-24/VB||chlamydia-25/NN	advmod||detection-28/NN||early-27/RB	prep_through||control-24/VB||detection-28/NN	prep_through||control-24/VB||treatment-30/NN	conj_and||detection-28/NN||treatment-30/NN	amod||infection-33/NN||asymptomatic-32/JJ	prep_of||detection-28/NN||infection-33/NN	det||rates-36/NNS||the-35/DT	nsubj||are-39/VBP||rates-36/NNS	prep_of||rates-36/NNS||screening-38/NN	root||ROOT-0/null||are-39/VBP	advmod||are-39/VBP||well-40/RB	det||rate-45/NN||the-42/DT	amod||rate-45/NN||2010-2011-43/JJ	nn||rate-45/NN||target-44/NN	prep_below||are-39/VBP||rate-45/NN	num||%-48/NN||35-47/CD	prep_of||rate-45/NN||%-48/NN	chlamydiainfection-10||chlamydia-25||no||despite the known health and healthcare costs of untreated chlamydiainfection and the efforts of the national chlamydia screening programme (ncsp) to control chlamydia through early detection and treatment of asymptomatic infection, the rates of screening are well below the 2010-2011 target rate of 35%.
nn||cytokines-4/NNS||objectiveâ-1/NNP	nn||cytokines-4/NNS||$-2/NNP	nsubjpass||elevated-6/VBN||cytokines-4/NNS	auxpass||elevated-6/VBN||are-5/VBP	root||ROOT-0/null||elevated-6/VBN	amod||states-10/NNS||various-8/JJ	amod||states-10/NNS||insulin-resistant-9/JJ	prep_in||elevated-6/VBN||states-10/NNS	prep_including||elevated-6/VBN||type2diabetes-13/NNS	prep_including||elevated-6/VBN||obesity-15/NN	conj_and||type2diabetes-13/NNS||obesity-15/NN	mark||controversial-32/JJ||although-17/IN	det||contribution-19/NN||the-18/DT	nsubj||controversial-32/JJ||contribution-19/NN	prep_of||contribution-19/NN||interleukin-6-21/JJ	dep||interleukin-6-21/JJ||il-6-23/JJ	det||induction-27/NN||the-26/DT	prep_in||interleukin-6-21/JJ||induction-27/NN	det||diseases-30/NNS||these-29/DT	prep_of||induction-27/NN||diseases-30/NNS	cop||controversial-32/JJ||is-31/VBZ	advcl||elevated-6/VBN||controversial-32/JJ	insulin--1||type2diabetes-13||no_rel||objectiveâ€” cytokines are elevated in various insulin-resistant states, including type2diabetes and obesity, although the contribution of interleukin-6 (il-6) in the induction of these diseases is controversial.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||prevalence-2/JJ	nsubj||100,000-9/JJ||rate-3/NN	nsubj||cd-21/JJ||rate-3/NN	prep_for||rate-3/NN||uc-5/NN	cop||100,000-9/JJ||was-6/VBD	num||/-8/NNS||5.3-7/CD	npadvmod||100,000-9/JJ||/-8/NNS	root||ROOT-0/null||100,000-9/JJ	num||%-12/NN||95-11/CD	nsubj||ci-13/VBP||%-12/NN	dep||100,000-9/JJ||ci-13/VBP	num||.6-15/CD||5.0-5-14/CD	iobj||ci-13/VBP||.6-15/CD	dobj||ci-13/VBP||/-16/NNP	num||/-16/NNP||100,000-17/CD	conj_and||100,000-9/JJ||cd-21/JJ	cop||100,000-25/CD||was-22/VBD	number||/-24/CD||1.2-23/CD	num||100,000-25/CD||/-24/CD	ccomp||cd-21/JJ||100,000-25/CD	num||%-28/NN||95-27/CD	nsubj||ci-29/VBP||%-28/NN	dep||100,000-9/JJ||ci-29/VBP	num||.4-31/CD||1.0-1-30/CD	iobj||ci-29/VBP||.4-31/CD	dobj||ci-29/VBP||/-32/NNP	num||/-32/NNP||100,000-33/CD	uc-5||cd-21||no_rel||the prevalence rate for uc was 5.3/100,000 (95% ci 5.0-5.6/100,000), and cd was 1.2/100,000 (95% ci 1.0-1.4/100,000).
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||vitamine-11||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â€“69 years using a 2 ã— 2 factorial design.
amod||responses-3/NNS||ifn-î-1/JJ	amod||responses-3/NNS||³-2/JJ	nsubjpass||measured-15/VBN||responses-3/NNS	nsubjpass||measured-15/VBN||responses-3/NNS	det||mtb-6/NN||the-5/DT	prep_to||responses-3/NNS||mtb-6/NN	amod||mtb-6/NN||antigens-7/JJ	amod||mtb-6/NN||esat-6-9/JJ	conj_and||antigens-7/JJ||esat-6-9/JJ	amod||mtb-6/NN||cfp-10-11/JJ	conj_and||antigens-7/JJ||cfp-10-11/JJ	amod||mtb-6/NN||ppd-13/JJ	conj_and||antigens-7/JJ||ppd-13/JJ	auxpass||measured-15/VBN||were-14/VBD	root||ROOT-0/null||measured-15/VBN	conj_and||measured-15/VBN||measured-15/VBN	det||assay-20/NN||an-17/DT	amod||assay-20/NN||enzyme-linked-18/JJ	nn||assay-20/NN||immunospot-19/NN	agent||measured-15/VBN||assay-20/NN	amod||elispot-24/NN||ifn-î-22/JJ	amod||elispot-24/NN||³-23/JJ	appos||assay-20/NN||elispot-24/NN	prep_at||assay-20/NN||presentation-27/NN	prep_at||measured-15/VBN||one-30/CD	num||one-30/CD||two-32/CD	prep_at||measured-15/VBN||six-34/CD	conj_and||one-30/CD||six-34/CD	pobj||measured-15/VBN||months-35/NNS	prepc_after||measured-15/VBN||starting-37/VBG	amod||treatment-39/NN||anti-tuberculous-38/JJ	dobj||starting-37/VBG||treatment-39/NN	amod||children-42/NNS||hiv-infected-41/JJ	prep_in||starting-37/VBG||children-42/NNS	amod||tb-47/NN||definite-44/JJ	conj_or||definite-44/JJ||probable-46/JJ	amod||tb-47/NN||probable-46/JJ	prep_with||children-42/NNS||tb-47/NN	tb-47||mtb-6||no||ifn-î³ responses to the mtb antigens, esat-6, cfp-10 and ppd were measured by an enzyme-linked immunospot assay (ifn-î³ elispot) at presentation and at one, two and six months after starting anti-tuberculous treatment in hiv-infected children with definite or probable tb.
nn||propofol-2/NN||microemulsion-1/NN	nsubj||produces-3/VBZ||propofol-2/NN	root||ROOT-0/null||produces-3/VBZ	advmod||frequent-5/JJ||more-4/RBR	amod||pain-8/NN||frequent-5/JJ	conj_and||frequent-5/JJ||severe-7/JJ	amod||pain-8/NN||severe-7/JJ	dobj||produces-3/VBZ||pain-8/NN	prep_upon||produces-3/VBZ||injection-10/NN	nn||propofol-14/NN||lipid-12/NN	nn||propofol-14/NN||emulsion-13/NN	prep_than||injection-10/NN||propofol-14/NN	pain-8||propofol-14||yes||microemulsion propofol produces more frequent and severe pain upon injection than lipid emulsion propofol.
det||goals-2/NNS||the-1/DT	nsubj||were-6/VBD||goals-2/NNS	det||study-5/NN||this-4/DT	prep_of||goals-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||examine-8/VB||to-7/TO	ccomp||were-6/VBD||examine-8/VB	det||influence-10/NN||the-9/DT	dobj||examine-8/VB||influence-10/NN	amod||type1diabetes-13/NNS||maternal-12/JJ	prep_of||influence-10/NN||type1diabetes-13/NNS	prep_during||examine-8/VB||pregnancy-15/NN	nn||adiposity-18/NN||offspring-17/NN	prep_on||examine-8/VB||adiposity-18/NN	nn||tolerance-21/NN||glucose-20/NN	prep_on||examine-8/VB||tolerance-21/NN	conj_and||adiposity-18/NN||tolerance-21/NN	prep_at||adiposity-18/NN||age-23/NN	num||years-25/NNS||7-24/CD	dep||adiposity-18/NN||years-25/NNS	aux||assess-28/VB||to-27/TO	ccomp||were-6/VBD||assess-28/VB	conj_and||examine-8/VB||assess-28/VB	mark||predict-40/VBP||whether-29/IN	amod||factors-31/NNS||metabolic-30/JJ	nsubj||predict-40/VBP||factors-31/NNS	prep_at||factors-31/NNS||birth-33/NN	amod||leptin-36/NNS||neonatal-35/JJ	appos||birth-33/NN||leptin-36/NNS	appos||birth-33/NN||insulin-38/NN	conj_and||leptin-36/NNS||insulin-38/NN	ccomp||assess-28/VB||predict-40/VBP	amod||outcomes-42/NNS||adverse-41/JJ	dobj||predict-40/VBP||outcomes-42/NNS	glucose-20||adiposity-18||no_rel||the goals of this study were to examine the influence of maternal type1diabetes during pregnancy on offspring adiposity and glucose tolerance at age 7 years and to assess whether metabolic factors at birth (neonatal leptin and insulin) predict adverse outcomes.
poss||properties-6/NNS||its-3/PRP$	amod||properties-6/NNS||unique-4/JJ	amod||properties-6/NNS||pharmacodynamic-5/JJ	prep_due_to||aripiprazole-23/NN||properties-6/NNS	amod||activity-11/NN||dopamine-8/JJ	amod||activity-11/NN||partial-9/JJ	nn||activity-11/NN||agonist-10/NN	prep_of||properties-6/NNS||activity-11/NN	poss||association-15/NN||its-14/PRP$	prep_of||properties-6/NNS||association-15/NN	conj_and||activity-11/NN||association-15/NN	amod||effects-21/NNS||few-17/JJ	conj_and||few-17/JJ||mild-19/JJ	amod||effects-21/NNS||mild-19/JJ	nn||effects-21/NNS||side-20/NN	prep_with||association-15/NN||effects-21/NNS	nsubj||atypicalantipsychotic-27/NN||aripiprazole-23/NN	cop||atypicalantipsychotic-27/NN||is-24/VBZ	det||atypicalantipsychotic-27/NN||a-25/DT	nn||atypicalantipsychotic-27/NN||candidate-26/NN	root||ROOT-0/null||atypicalantipsychotic-27/NN	prep_for||atypicalantipsychotic-27/NN||patients-29/NNS	prep_with||patients-29/NNS||ticdisorders-31/NNS	ticdisorders-31||dopamine-8||no_rel||due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypicalantipsychotic for patients with ticdisorders.
aux||investigate-2/VB||to-1/TO	csubj||synthase-12/VBD||investigate-2/VB	csubj||synthase-12/VBD||investigate-2/VB	det||expression-4/NN||the-3/DT	dobj||investigate-2/VB||expression-4/NN	amod||prostaglandin-7/NN||microsomal-6/JJ	prep_of||expression-4/NN||prostaglandin-7/NN	dep||expression-4/NN||e-8/SYM	appos||expression-4/NN||pge-10/NN	root||ROOT-0/null||synthase-12/VBD	conj_and||synthase-12/VBD||synthase-12/VBD	dobj||synthase-12/VBD||1-13/CD	dep||1-13/CD||mpges-1-15/JJ	dobj||synthase-12/VBD||cyclooxygenase-18/NN	conj_and||1-13/CD||cyclooxygenase-18/NN	appos||cyclooxygenase-18/NN||cox-20/NN	nn||biopsies-24/NNS||muscle-23/NN	prep_in||cyclooxygenase-18/NN||biopsies-24/NNS	prep_from||synthase-12/VBD||patients-26/NNS	prep_with||patients-26/NNS||polymyositis-28/NNS	prep_with||patients-26/NNS||dermatomyositis-30/NNS	conj_or||polymyositis-28/NNS||dermatomyositis-30/NNS	amod||treatment-36/NN||conventional-34/JJ	nn||treatment-36/NN||immunosuppressive-35/NN	prep_after||synthase-12/VBD||treatment-36/NN	prep_before||synthase-12/VBD||treatment-36/NN	polymyositis-28||pge-10||no_rel||to investigate the expression of microsomal prostaglandin e (pge) synthase 1 (mpges-1) and cyclooxygenase (cox) in muscle biopsies from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive treatment.
det||choice-2/NN||the-1/DT	nsubj||important-17/JJ||choice-2/NN	det||preparation-7/NN||the-4/DT	nn||preparation-7/NN||tumor-5/NN	nn||preparation-7/NN||antigen-6/NN	prep_of||choice-2/NN||preparation-7/NN	vmod||preparation-7/NN||used-8/VBN	amod||cell-11/NN||dendritic-10/JJ	prep_for||used-8/VBN||cell-11/NN	appos||cell-11/NN||dc-13/NN	vmod||cell-11/NN||loading-15/VBG	cop||important-17/JJ||is-16/VBZ	root||ROOT-0/null||important-17/JJ	prepc_for||important-17/JJ||optimizing-19/VBG	nn||vaccines-21/NNS||dc-20/NN	dobj||optimizing-19/VBG||vaccines-21/NNS	tumor-5||vaccines-21||no_rel||the choice of the tumor antigen preparation used for dendritic cell (dc) loading is important for optimizing dc vaccines.
det||agent-3/NN||the-1/DT	amod||agent-3/NN||causative-2/JJ	nsubj||capable-10/JJ||agent-3/NN	prep_of||agent-3/NN||anthrax-5/NN	appos||agent-3/NN||bacillusanthracis-7/NNS	cop||capable-10/JJ||is-9/VBZ	root||ROOT-0/null||capable-10/JJ	prepc_of||capable-10/JJ||circumventing-12/VBG	det||defense-18/NN||the-13/DT	amod||defense-18/NN||humoral-14/JJ	conj_and||humoral-14/JJ||innate-16/JJ	amod||defense-18/NN||innate-16/JJ	amod||defense-18/NN||immune-17/JJ	dobj||circumventing-12/VBG||defense-18/NN	det||host-21/NN||the-20/DT	prep_of||defense-18/NN||host-21/NN	prepc_of||capable-10/JJ||modulating-23/VBG	conj_and||circumventing-12/VBG||modulating-23/VBG	det||chemistry-26/NN||the-24/DT	nn||chemistry-26/NN||blood-25/NN	dobj||modulating-23/VBG||chemistry-26/NN	prep_in||modulating-23/VBG||circulation-28/NN	aux||initiate-30/VB||to-29/TO	vmod||modulating-23/VBG||initiate-30/VB	det||infection-33/NN||a-31/DT	amod||infection-33/NN||productive-32/JJ	dobj||initiate-30/VB||infection-33/NN	anthrax-5||bacillusanthracis-7||no||the causative agent of anthrax, bacillusanthracis , is capable of circumventing the humoral and innate immune defense of the host and modulating the blood chemistry in circulation to initiate a productive infection.
nsubj||one-6/CD||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||problems-13/NNS||the-8/DT	amod||problems-13/NNS||major-9/JJ	amod||problems-13/NNS||global-10/JJ	nn||problems-13/NNS||public-11/NN	nn||problems-13/NNS||health-12/NN	prep_of||one-6/CD||problems-13/NNS	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) is one of the major global public health problems.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||š-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||š41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||š-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||š51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||š-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||š12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	tb--1||rifampin--1||yes||rifampin-resistant m.tb (nâ€š=â€š41), tb-iris (nâ€š=â€š51) and drug resistant bacterialinfections (nâ€š=â€š12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
nsubjpass||shown-7/VBN||clozapine-1/NN	nsubj||effective-10/JJ||clozapine-1/NN	nsubj||elevate-15/VBP||clozapine-1/NN	conj_and||clozapine-1/NN||olanzapine-3/NN	nsubjpass||shown-7/VBN||olanzapine-3/NN	nsubj||effective-10/JJ||olanzapine-3/NN	nsubj||elevate-15/VBP||olanzapine-3/NN	auxpass||shown-7/VBN||were-6/VBD	rcmod||clozapine-1/NN||shown-7/VBN	aux||effective-10/JJ||to-8/TO	cop||effective-10/JJ||be-9/VB	xcomp||shown-7/VBN||effective-10/JJ	prepc_in||effective-10/JJ||stabilizing-12/VBG	dobj||stabilizing-12/VBG||bipolardisorder-13/NN	root||ROOT-0/null||elevate-15/VBP	amod||levels-17/NNS||pregnenolone-16/JJ	dobj||elevate-15/VBP||levels-17/NNS	nn||hippocampus-20/NNS||rat-19/NN	prep_in||elevate-15/VBP||hippocampus-20/NNS	amod||cortex-23/NN||cerebral-22/JJ	prep_in||elevate-15/VBP||cortex-23/NN	conj_and||hippocampus-20/NNS||cortex-23/NN	prep_in||elevate-15/VBP||serum-26/NN	conj_and||hippocampus-20/NNS||serum-26/NN	bipolardisorder-13||olanzapine-3||yes||clozapine and olanzapine, which were shown to be effective in stabilizing bipolardisorder, elevate pregnenolone levels in rat hippocampus, cerebral cortex, and serum.
num||rhesus-2/NNS||six-1/CD	root||ROOT-0/null||rhesus-2/NNS	nsubjpass||selected-5/VBN||macaques-3/NNS	auxpass||selected-5/VBN||were-4/VBD	rcmod||rhesus-2/NNS||selected-5/VBN	prep_for||selected-5/VBN||study-7/NN	det||pool-10/NN||a-9/DT	prep_from||selected-5/VBN||pool-10/NN	prep_of||pool-10/NN||500-12/CD	prep||selected-5/VBN||including-14/VBG	num||controls-17/NNS||two-15/CD	amod||controls-17/NNS||healthy-16/JJ	npadvmod||with-22/IN||controls-17/NNS	num||animals-21/NNS||four-19/CD	amod||animals-21/NNS||gluten-sensitive-20/JJ	conj_and||controls-17/NNS||animals-21/NNS	npadvmod||with-22/IN||animals-21/NNS	pcomp||including-14/VBG||with-22/IN	amod||antibodies-27/NNS||elevated-23/JJ	amod||antibodies-27/NNS||anti-gliadin-24/JJ	conj_or||anti-gliadin-24/JJ||anti-tg2-26/JJ	amod||antibodies-27/NNS||anti-tg2-26/JJ	pobj||with-22/IN||antibodies-27/NNS	conj_and||rhesus-2/NNS||history-31/NN	amod||diarrhea-35/NN||non-infectious-33/JJ	amod||diarrhea-35/NN||chronic-34/JJ	prep_of||history-31/NN||diarrhea-35/NN	diarrhea-35||antibodies-27||no_rel||six rhesus macaques were selected for study from a pool of 500, including two healthy controls and four gluten-sensitive animals with elevated anti-gliadin or anti-tg2 antibodies as well as history of non-infectious chronic diarrhea.
prep_for||effect-17/NN||cd-2/NN	det||mode-6/NN||the-4/DT	amod||mode-6/NN||physiological-5/JJ	nsubj||effect-17/NN||mode-6/NN	prep_of||mode-6/NN||action-8/NN	advmod||action-8/NN||as-9/RB	vmod||action-8/NN||indicated-10/VBN	amod||fitting-14/NN||debtox-12/JJ	nn||fitting-14/NN||model-13/NN	agent||indicated-10/VBN||fitting-14/NN	cop||effect-17/NN||was-15/VBD	det||effect-17/NN||an-16/DT	root||ROOT-0/null||effect-17/NN	nn||assimilation-20/NN||energy-19/NN	prep_on||effect-17/NN||assimilation-20/NN	prep_from||effect-17/NN||food-22/NN	vmod||effect-17/NN||suggesting-24/VBG	mark||dominated-33/VBN||that-25/IN	det||response-28/NN||the-26/DT	amod||response-28/NN||transcriptional-27/JJ	nsubjpass||dominated-33/VBN||response-28/NN	prep_to||response-28/NN||exposure-30/NN	aux||dominated-33/VBN||should-31/MD	auxpass||dominated-33/VBN||be-32/VB	ccomp||suggesting-24/VBG||dominated-33/VBN	agent||dominated-33/VBN||changes-35/NNS	det||expression-38/NN||the-37/DT	prep_in||changes-35/NNS||expression-38/NN	prep_of||expression-38/NN||transcripts-40/NNS	vmod||transcripts-40/NNS||associated-41/VBN	nn||metabolism-44/NN||energy-43/NN	prep_with||associated-41/VBN||metabolism-44/NN	det||mitochondria-47/NN||the-46/DT	prep_with||associated-41/VBN||mitochondria-47/NN	conj_and||metabolism-44/NN||mitochondria-47/NN	cd-2||fitting-14||no_rel||for cd, the physiological mode of action as indicated by debtox model fitting was an effect on energy assimilation from food, suggesting that the transcriptional response to exposure should be dominated by changes in the expression of transcripts associated with energy metabolism and the mitochondria.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	leucine-22||type2diabetes-34||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||incidence-6/NN||a-3/DT	advmod||lower-5/JJR||significantly-4/RB	amod||incidence-6/NN||lower-5/JJR	nsubj||was-2/VBD||incidence-6/NN	prep_of||incidence-6/NN||microemulsion-8/NN	amod||pain-11/NN||propofol-9/JJ	nn||pain-11/NN||injection-10/NN	npadvmod||than-26/IN||pain-11/NN	dep||pain-11/NN||severity-13/$	num||severity-13/$||2-14/CD	dep||pain-11/NN||more-16/JJR	conj_or||severity-13/$||more-16/JJR	det||group-21/NN||the-19/DT	nn||group-21/NN||combination-20/NN	prep_in||severity-13/$||group-21/NN	num||%-24/NN||12.5-23/CD	appos||pain-11/NN||%-24/NN	advmod||was-2/VBD||than-26/IN	det||groups-32/NNS||the-28/DT	amod||groups-32/NNS||remifentanil-29/JJ	conj_and||remifentanil-29/JJ||lidocaine-31/JJ	amod||groups-32/NNS||lidocaine-31/JJ	prep_in||than-26/IN||groups-32/NNS	num||%-35/NN||90-34/CD	nsubj||p-42/VBP||%-35/NN	num||%-38/NN||65-37/CD	conj_and||%-35/NN||%-38/NN	nsubj||p-42/VBP||%-38/NN	advmod||%-38/NN||respectively-40/RB	dep||groups-32/NNS||p-42/VBP	num||0.05-44/CD||<-43/CD	dobj||p-42/VBP||0.05-44/CD	pain-11||lidocaine-31||yes||there was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, p < 0.05).
nsubjpass||postulated-10/VBN||cross-regulation-1/NN	nsubj||play-12/VB||cross-regulation-1/NN	nn||ifn-7/NN||tnf-3/NN	conj_and||tnf-3/NN||type-5/NN	nn||ifn-7/NN||type-5/NN	nn||ifn-7/NN||i-6/NNS	prep_between||cross-regulation-1/NN||ifn-7/NN	aux||postulated-10/VBN||has-8/VBZ	auxpass||postulated-10/VBN||been-9/VBN	root||ROOT-0/null||postulated-10/VBN	aux||play-12/VB||to-11/TO	xcomp||postulated-10/VBN||play-12/VB	det||role-15/NN||an-13/DT	amod||role-15/NN||important-14/JJ	dobj||play-12/VB||role-15/NN	prep_in||play-12/VB||autoimmunediseases-17/NNS	autoimmunediseases-17||ifn-7||no||cross-regulation between tnf and type i ifn has been postulated to play an important role in autoimmunediseases.
nsubjpass||induced-3/VBN||allergy-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	det||series-6/NN||a-5/DT	agent||induced-3/VBN||series-6/NN	prep_of||series-6/NN||subcutaneous-8/NNS	amod||sensitizations-11/NNS||intratracheal-10/JJ	prep_of||series-6/NN||sensitizations-11/NNS	conj_and||subcutaneous-8/NNS||sensitizations-11/NNS	amod||allergen-15/NN||ascaris-13/JJ	nn||allergen-15/NN||suum-14/NN	prep_with||induced-3/VBN||allergen-15/NN	appos||allergen-15/NN||asa-17/NN	det||frame-24/NN||a-20/DT	num||frame-24/NN||six-21/CD	nn||frame-24/NN||week-22/NN	nn||frame-24/NN||time-23/NN	prep_during||induced-3/VBN||frame-24/NN	amod||pigs-27/NNS||post-weanling-26/JJ	prep_in||induced-3/VBN||pigs-27/NNS	vmod||pigs-27/NNS||supplemented-28/VBN	vmod||pigs-27/NNS||supplemented-28/VBN	conj_or||supplemented-28/VBN||supplemented-28/VBN	advmod||supplemented-28/VBN||daily-29/RB	prep_with||supplemented-28/VBN||hn001-31/CD	prep_without||supplemented-28/VBN||supplementation-35/NN	asa-17||allergy-1||no_rel||allergy was induced by a series of subcutaneous and intratracheal sensitizations with ascaris suum allergen (asa) during a six week time frame in post-weanling pigs supplemented daily with hn001, or without supplementation.
nn||samples-6/NNS||hivseropositive-2/NN	conj_and||hivseropositive-2/NN||hiv-4/NN	nn||samples-6/NNS||hiv-4/NN	nn||samples-6/NNS||seronegative-5/NN	prep_for||similar-37/JJ||samples-6/NNS	nsubj||similar-37/JJ||sensitivities-8/NNS	nn||dot-blot-11/NN||pcr-10/NN	prep_of||sensitivities-8/NNS||dot-blot-11/NN	num||%-14/NN||72-13/CD	dep||dot-blot-11/NN||%-14/NN	dep||%-14/NN||vs-15/NN	number||%-17/NN||75-16/CD	amod||vs-15/NN||%-17/NN	dep||vs-15/NN||p-19/NN	dep||0.46-21/CD||=-20/SYM	rcmod||p-19/NN||0.46-21/CD	prep_of||sensitivities-8/NNS||pcr-ag-24/NN	conj_and||dot-blot-11/NN||pcr-ag-24/NN	num||%-27/NN||42-26/CD	dep||dot-blot-11/NN||%-27/NN	dep||%-27/NN||vs-28/NN	number||%-30/NN||43-29/CD	amod||vs-28/NN||%-30/NN	dep||vs-28/NN||p-32/NN	dep||0.54-34/CD||=-33/SYM	rcmod||p-32/NN||0.54-34/CD	cop||similar-37/JJ||were-36/VBD	root||ROOT-0/null||similar-37/JJ	hivseropositive-2||hiv-4||no||for hivseropositive and hiv seronegative samples, sensitivities of pcr dot-blot (72% vs 75%; p = 0.46) and pcr-ag (42% vs 43%; p = 0.54) were similar.
nsubj||state-8/NN||toxicity-1/NN	prep_to||toxicity-1/NN||glucose-3/NN	cop||state-8/NN||is-4/VBZ	neg||state-8/NN||not-5/RB	det||state-8/NN||a-6/DT	amod||state-8/NN||normal-7/JJ	ccomp||reported-15/VBN||state-8/NN	advmod||state-8/NN||however-10/RB	nsubjpass||reported-15/VBN||it-12/PRP	aux||reported-15/VBN||has-13/VBZ	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	mark||produce-24/VBP||that-16/IN	mark||ingest-20/VB||after-17/IN	amod||individuals-19/NNS||certain-18/JJ	nsubj||ingest-20/VB||individuals-19/NNS	advcl||produce-24/VBP||ingest-20/VB	dobj||ingest-20/VB||sugar-21/NN	nsubj||produce-24/VBP||they-23/PRP	ccomp||reported-15/VBN||produce-24/VBP	amod||tumor-26/NN||excess-25/JJ	nsubj||necrosis-27/VBZ||tumor-26/NN	ccomp||produce-24/VBP||necrosis-27/VBZ	dobj||necrosis-27/VBZ||factor-28/NN	glucose-3||tumor-26||no_rel||toxicity to glucose is not a normal state, however, it has been reported that after certain individuals ingest sugar, they produce excess tumor necrosis factor.
det||adhesion-2/NN||the-1/DT	nsubjpass||enhanced-12/VBN||adhesion-2/NN	conj_and||adhesion-2/NN||spreading-4/NN	nsubjpass||enhanced-12/VBN||spreading-4/NN	amod||cells-7/NNS||rmg-i-h-6/JJ	prep_of||adhesion-2/NN||cells-7/NNS	prep_on||cells-7/NNS||ha-9/NN	auxpass||enhanced-12/VBN||were-10/VBD	advmod||enhanced-12/VBN||significantly-11/RB	root||ROOT-0/null||enhanced-12/VBN	prep||enhanced-12/VBN||as-13/IN	prepc_compared_to||enhanced-12/VBN||to-15/TO	pobj||enhanced-12/VBN||those-16/DT	amod||cells-19/NNS||rmg-i-18/JJ	prep_of||those-16/DT||cells-19/NNS	nn||0.01-23/NNP||p-21/NNP	nn||0.01-23/NNP||<-22/NNP	appos||cells-19/NNS||0.01-23/NNP	det||enhancement-28/NN||this-27/DT	nsubjpass||inhibited-30/VBN||enhancement-28/NN	auxpass||inhibited-30/VBN||was-29/VBD	conj_and||enhanced-12/VBN||inhibited-30/VBN	amod||antibody-35/NN||lewis-32/JJ	nn||antibody-35/NN||y-33/NN	nn||antibody-35/NN||monoclonal-34/NN	agent||inhibited-30/VBN||antibody-35/NN	dep||<-38/JJ||p-37/RB	dep||inhibited-30/VBN||<-38/JJ	dep||<-38/JJ||0.01-39/CD	adhesion-2||antibody-35||no_rel||the adhesion and spreading of rmg-i-h cells on ha were significantly enhanced as compared to those of rmg-i cells ( p < 0.01), and this enhancement was inhibited by lewis y monoclonal antibody ( p < 0.01).
aux||investigate-2/VB||to-1/TO	advcl||tested-43/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-40/VBN||when-31/WRB	amod||syndrome-34/NN||acquired-32/VBN	amod||syndrome-34/NN||immunedeficiency-33/JJ	nsubjpass||recognized-40/VBN||syndrome-34/NN	appos||syndrome-34/NN||aids-36/NNS	auxpass||recognized-40/VBN||was-38/VBD	advmod||recognized-40/VBN||first-39/RB	advcl||investigate-2/VB||recognized-40/VBN	nsubj||tested-43/VBD||we-42/PRP	root||ROOT-0/null||tested-43/VBD	dobj||tested-43/VBD||sera-44/NN	amod||women-48/NNS||310-46/JJ	amod||women-48/NNS||pregnant-47/JJ	prep_from||tested-43/VBD||women-48/NNS	nsubj||participated-50/VBD||women-48/NNS	rcmod||women-48/NNS||participated-50/VBD	det||project-55/NN||the-52/DT	amod||project-55/NN||collaborative-53/JJ	amod||project-55/NN||perinatal-54/JJ	prep_in||participated-50/VBD||project-55/NN	det||1959-1964-59/NN||the-57/DT	nn||1959-1964-59/NN||period-58/NN	prep_during||participated-50/VBD||1959-1964-59/NN	nn||antibody-64/NN||hiv-61/NN	conj_and||hiv-61/NN||htlv-i-63/NN	nn||antibody-64/NN||htlv-i-63/NN	prep_for||1959-1964-59/NN||antibody-64/NN	aids-36||hiv-61||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquired immunedeficiency syndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-i antibody.
det||burden-3/NN||the-1/DT	nn||burden-3/NN||disease-2/NN	nsubj||highest-15/JJS||burden-3/NN	prep_of||burden-3/NN||humanimmunodeficiencyvirus-5/NNS	appos||humanimmunodeficiencyvirus-5/NNS||hiv-7/NN	amod||aids-12/NNS||acquiredimmunodeficiencysyndrome-10/JJ	dep||humanimmunodeficiencyvirus-5/NNS||aids-12/NNS	cop||highest-15/JJS||is-14/VBZ	root||ROOT-0/null||highest-15/JJS	amod||africa-18/NN||sub-saharan-17/JJ	prep_in||highest-15/JJS||africa-18/NN	expl||are-21/VBP||there-20/EX	conj_but||highest-15/JJS||are-21/VBP	amod||studies-23/NNS||few-22/JJ	nsubj||are-21/VBP||studies-23/NNS	det||disorders-28/NNS||the-25/DT	amod||disorders-28/NNS||associated-26/VBN	amod||disorders-28/NNS||neurocognitive-27/JJ	prep_on||studies-23/NNS||disorders-28/NNS	det||region-31/NN||this-30/DT	prep_in||disorders-28/NNS||region-31/NN	acquiredimmunodeficiencysyndrome-10||humanimmunodeficiencyvirus-5||no||the disease burden of humanimmunodeficiencyvirus (hiv) - acquiredimmunodeficiencysyndrome (aids) is highest in sub-saharan africa but there are few studies on the associated neurocognitive disorders in this region.
num||measurements-4/NNS||77-1/CD	amod||measurements-4/NNS||different-2/JJ	nn||measurements-4/NNS||alp-3/NN	nsubjpass||included-28/VBN||measurements-4/NNS	number||nutritional-7/JJ||38-6/CD	amod||rickets-8/NNS||nutritional-7/JJ	prep_from||measurements-4/NNS||rickets-8/NNS	appos||rickets-8/NNS||nr-10/NN	num||rickets-15/NNS||7-13/CD	amod||rickets-15/NNS||vitamind-dependent-14/JJ	prep_from||measurements-4/NNS||rickets-15/NNS	conj_and||rickets-8/NNS||rickets-15/NNS	appos||rickets-15/NNS||vddr-17/NN	num||patients-26/NNS||8-20/CD	amod||patients-26/NNS||hypophosphatemic-21/JJ	nn||patients-26/NNS||rickets-22/NN	appos||patients-26/NNS||hr-24/NN	prep_from||measurements-4/NNS||patients-26/NNS	conj_and||rickets-8/NNS||patients-26/NNS	auxpass||included-28/VBN||were-27/VBD	root||ROOT-0/null||included-28/VBN	rickets-22||vitamind--1||yes||77 different alp measurements from 38 nutritional rickets (nr), 7 vitamind-dependent rickets (vddr) and 8 hypophosphatemic rickets (hr) patients were included.
det||thomson-2/NN||the-1/DT	nsubj||reuters-3/VBZ||thomson-2/NN	root||ROOT-0/null||reuters-3/VBZ	nn||databases-6/NNS||marketscanâ-4/NNP	nn||databases-6/NNS||®-5/NNP	nsubjpass||used-8/VBN||databases-6/NNS	nsubj||analyze-11/VB||databases-6/NNS	auxpass||used-8/VBN||were-7/VBD	ccomp||reuters-3/VBZ||used-8/VBN	aux||analyze-11/VB||to-9/TO	advmod||analyze-11/VB||retrospectively-10/RB	xcomp||used-8/VBN||analyze-11/VB	amod||patients-15/NNS||insulin-naã-12/JJ	amod||patients-15/NNS||¯-13/JJ	nn||patients-15/NNS||ve-14/NN	dobj||analyze-11/VB||patients-15/NNS	prep_with||analyze-11/VB||type2diabetes-17/CD	prepc_by||analyze-11/VB||initiating-19/VBG	nn||therapy-21/NN||insulin-20/NN	dobj||initiating-19/VBG||therapy-21/NN	type2diabetes-17||insulin-20||yes||the thomson reuters marketscanâ® databases were used to retrospectively analyze insulin-naã¯ve patients with type2diabetes by initiating insulin therapy.
det||cause-2/NN||the-1/DT	nsubjpass||understood-9/VBN||cause-2/NN	nsubj||due-13/JJ||cause-2/NN	det||reactions-5/NNS||these-4/DT	prep_of||cause-2/NN||reactions-5/NNS	auxpass||understood-9/VBN||is-6/VBZ	neg||understood-9/VBN||not-7/RB	advmod||understood-9/VBN||well-8/RB	root||ROOT-0/null||understood-9/VBN	aux||due-13/JJ||could-11/MD	cop||due-13/JJ||be-12/VB	conj_but||understood-9/VBN||due-13/JJ	amod||wear-16/NN||excessive-15/JJ	prep_to||due-13/JJ||wear-16/NN	nn||hypersensitivity-20/NN||metal-19/NN	prep_to||due-13/JJ||hypersensitivity-20/NN	conj_or||wear-16/NN||hypersensitivity-20/NN	det||cause-25/NN||an-22/DT	advmod||cause-25/NN||as-yet-23/RB	amod||cause-25/NN||unknown-24/JJ	prep_to||due-13/JJ||cause-25/NN	conj_or||wear-16/NN||cause-25/NN	metal-19||hypersensitivity-20||no_rel||the cause of these reactions is not well understood but could be due to excessive wear, or metal hypersensitivity or an as-yet unknown cause.
det||identification-2/NN||the-1/DT	nsubj||provided-13/VBN||identification-2/NN	nsubj||tracing-21/VBG||identification-2/NN	conj_and||identification-2/NN||differentiation-4/NN	nsubj||provided-13/VBN||differentiation-4/NN	prep_of||identification-2/NN||strains-6/NNS	prep_of||strains-6/NNS||mycobacteriumtuberculosis-8/NNS	nn||fingerprinting-11/NN||dna-10/NN	prep_by||mycobacteriumtuberculosis-8/NNS||fingerprinting-11/NN	aux||provided-13/VBN||has-12/VBZ	root||ROOT-0/null||provided-13/VBN	det||understanding-16/NN||a-14/DT	amod||understanding-16/NN||better-15/JJR	dobj||provided-13/VBN||understanding-16/NN	det||epidemiology-19/NN||the-18/DT	prep_of||understanding-16/NN||epidemiology-19/NN	conj_and||provided-13/VBN||tracing-21/VBG	det||transmission-23/NN||the-22/DT	dobj||tracing-21/VBG||transmission-23/NN	prep_of||transmission-23/NN||tuberculosis-25/NNP	tuberculosis-25||mycobacteriumtuberculosis-8||no||the identification and differentiation of strains of mycobacteriumtuberculosis by dna fingerprinting has provided a better understanding of the epidemiology and tracing the transmission of tuberculosis.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	tumor--1||il-2-23||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
amod||advances-4/NNS||recent-1/JJ	amod||advances-4/NNS||basic-2/JJ	nn||advances-4/NNS||science-3/NN	nsubj||led-6/VBN||advances-4/NNS	aux||led-6/VBN||have-5/VBP	root||ROOT-0/null||led-6/VBN	prep_to||led-6/VBN||development-8/NN	nsubj||target-14/VBP||development-8/NN	amod||treatments-11/NNS||alternative-10/JJ	prep_of||development-8/NN||treatments-11/NNS	advmod||target-14/VBP||specifically-13/RB	rcmod||development-8/NN||target-14/VBP	amod||pathways-16/NNS||aberrant-15/JJ	dobj||target-14/VBP||pathways-16/NNS	nsubj||relevant-21/JJ||pathways-16/NNS	prep_of||pathways-16/NNS||fibrosis-18/NN	cop||relevant-21/JJ||are-20/VBP	rcmod||pathways-16/NNS||relevant-21/JJ	nn||progression-24/NN||disease-23/NN	prep_to||relevant-21/JJ||progression-24/NN	prep_in||progression-24/NN||fsgs-26/NNS	fsgs-26||basic-2||no_rel||recent basic science advances have led to development of alternative treatments that specifically target aberrant pathways of fibrosis which are relevant to disease progression in fsgs.
prep_after||insulin-11/NN||accounting-2/NN	prep_for||accounting-2/NN||adiposity-4/NN	amod||factors-8/NNS||other-6/JJ	nn||factors-8/NNS||risk-7/NN	nsubj||insulin-11/NN||factors-8/NNS	cop||insulin-11/NN||were-9/VBD	amod||insulin-11/NN||high-10/JJ	root||ROOT-0/null||insulin-11/NN	conj_and||insulin-11/NN||insulinresistance-13/NN	amod||triglycerides-16/NNPS||high-15/JJ	conj_and||insulin-11/NN||triglycerides-16/NNPS	conj_and||insulin-11/NN||smoking-19/NN	nsubj||amenable-22/JJ||factors-21/NNS	nsubj||lifestyle-24/VB||factors-21/NNS	xcomp||insulin-11/NN||amenable-22/JJ	aux||lifestyle-24/VB||to-23/TO	xcomp||amenable-22/JJ||lifestyle-24/VB	dobj||lifestyle-24/VB||intervention-25/NN	insulin-11||insulinresistance-13||no_rel||after accounting for adiposity, other risk factors were high insulin, insulinresistance, high triglycerides, and smoking, factors amenable to lifestyle intervention.
nsubj||choice-8/NN||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	cop||choice-8/NN||is-5/VBZ	det||choice-8/NN||the-6/DT	amod||choice-8/NN||first-7/JJ	root||ROOT-0/null||choice-8/NN	amod||drug-12/NN||conventional-9/JJ	amod||drug-12/NN||disease-modifying-10/JJ	amod||drug-12/NN||antirheumatic-11/JJ	dep||choice-8/NN||drug-12/NN	dep||choice-8/NN||dmard-14/VBN	prep_for||choice-8/NN||rheumatoidarthritis-17/NNS	rheumatoidarthritis-17||mtx-3||yes||methotrexate (mtx) is the first choice conventional disease-modifying antirheumatic drug (dmard) for rheumatoidarthritis.
nsubj||messenger-7/NN||nitricoxide-1/NN	discourse||nitricoxide-1/NN||no-3/UH	cop||messenger-7/NN||is-5/VBZ	det||messenger-7/NN||a-6/DT	root||ROOT-0/null||messenger-7/NN	vmod||messenger-7/NN||implicated-8/VBN	det||destruction-11/NN||the-10/DT	prep_in||implicated-8/VBN||destruction-11/NN	prep_in||implicated-8/VBN||inflammation-13/NN	conj_and||destruction-11/NN||inflammation-13/NN	amod||tissues-16/NNS||joint-15/JJ	prep_of||destruction-11/NN||tissues-16/NNS	nitricoxide-1||inflammation-13||no_rel||nitricoxide (no) is a messenger implicated in the destruction and inflammation of joint tissues.
amod||disease-3/NN||end-stage-1/JJ	nn||disease-3/NN||liver-2/NN	nsubj||cause-15/NN||disease-3/NN	vmod||disease-3/NN||caused-4/VBN	amod||infection-11/NN||chronichepatitisc-6/JJ	nn||infection-11/NN||virus-7/NN	appos||infection-11/NN||hcv-9/NN	agent||caused-4/VBN||infection-11/NN	cop||cause-15/NN||is-12/VBZ	det||cause-15/NN||a-13/DT	amod||cause-15/NN||leading-14/VBG	root||ROOT-0/null||cause-15/NN	nn||transplantation-18/NN||liver-17/NN	prep_for||cause-15/NN||transplantation-18/NN	appos||transplantation-18/NN||lt-20/NN	chronichepatitisc-6||hcv-9||no||end-stage liver disease caused by chronichepatitisc virus (hcv) infection is a leading cause for liver transplantation (lt).
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||endogenous-9/VBZ||that-4/IN	nn||tissues-6/NNS||cancer-5/NN	nsubj||endogenous-9/VBZ||tissues-6/NNS	advmod||secrete-8/JJ||directly-7/RB	amod||tissues-6/NNS||secrete-8/JJ	ccomp||suggest-3/VBP||endogenous-9/VBZ	dobj||endogenous-9/VBZ||formaldehyde-10/NN	det||formaldehyde-14/NN||this-13/DT	nsubj||induces-18/VBZ||formaldehyde-14/NN	amod||concentration-17/NN||low-16/JJ	prep_at||formaldehyde-14/NN||concentration-17/NN	conj_and||suggest-3/VBP||induces-18/VBZ	amod||pain-22/NN||metastatic-19/JJ	nn||pain-22/NN||bone-20/NN	nn||pain-22/NN||cancer-21/NN	dobj||induces-18/VBZ||pain-22/NN	amod||activation-25/NN||trpv1-24/JJ	prep_through||induces-18/VBZ||activation-25/NN	advmod||induces-18/VBZ||especially-26/RB	nn||environment-30/NN||tumor-28/NN	amod||environment-30/NN||acidic-29/JJ	prep_under||induces-18/VBZ||environment-30/NN	formaldehyde-14||tumor-28||no_rel||our data suggest that cancer tissues directly secrete endogenous formaldehyde, and this formaldehyde at low concentration induces metastatic bone cancer pain through trpv1 activation especially under tumor acidic environment.
det||report-3/NN||this-2/DT	prep_in||described-5/VBD||report-3/NN	nsubj||described-5/VBD||we-4/PRP	nsubj||described-5/VBD||we-4/PRP	root||ROOT-0/null||described-5/VBD	conj_and||described-5/VBD||described-5/VBD	det||differences-8/NNS||the-6/DT	amod||differences-8/NNS||main-7/JJ	dobj||described-5/VBD||differences-8/NNS	prep_between||differences-8/NNS||pml-10/NN	det||era-16/NN||the-14/DT	amod||era-16/NN||haart-15/JJ	prep_after||described-5/VBD||era-16/NN	prep_before||described-5/VBD||era-16/NN	parataxis||described-5/VBD||highlighting-18/VBG	det||patterns-21/NNS||the-19/DT	amod||patterns-21/NNS||new-20/JJ	dobj||highlighting-18/VBG||patterns-21/NNS	prep_of||patterns-21/NNS||presentation-23/NN	det||neurotropism-26/NN||the-25/DT	dobj||highlighting-18/VBG||neurotropism-26/NN	conj_and||patterns-21/NNS||neurotropism-26/NN	amod||polyomaviruses-30/NNS||other-28/JJ	amod||polyomaviruses-30/NNS||human-29/JJ	prep_of||neurotropism-26/NN||polyomaviruses-30/NNS	det||prevalence-35/NN||the-33/DT	amod||prevalence-35/NN||increased-34/VBN	dobj||highlighting-18/VBG||prevalence-35/NN	conj_and||patterns-21/NNS||prevalence-35/NN	amod||syndrome-40/NN||immune-37/JJ	amod||syndrome-40/NN||reconstitution-38/JJ	amod||syndrome-40/NN||inflammatory-39/JJ	prep_of||prevalence-35/NN||syndrome-40/NN	dep||prevalence-35/NN||iris-42/VBZ	det||complication-47/NN||a-46/DT	prep_as||highlighting-18/VBG||complication-47/NN	prep_of||complication-47/NN||pml-49/NN	prep_in||highlighting-18/VBG||patients-51/NNS	prep_under||patients-51/NNS||haart-53/NN	pml-49||polyomaviruses-30||no||in this report we described the main differences between pml before and after the haart era; highlighting the new patterns of presentation, the neurotropism of other human polyomaviruses, and the increased prevalence of immune reconstitution inflammatory syndrome (iris), as a complication of pml in patients under haart.
amod||subjects-3/NNS||663-2/JJ	prep_in||performed-12/VBN||subjects-3/NNS	amod||hyperglycemia-6/NN||fasting-5/JJ	prep_with||subjects-3/NNS||hyperglycemia-6/NN	num||ogtt-10/NN||75-8/CD	nn||ogtt-10/NN||g-9/NN	nsubjpass||performed-12/VBN||ogtt-10/NN	nsubj||confirm-14/VB||ogtt-10/NN	auxpass||performed-12/VBN||were-11/VBD	root||ROOT-0/null||performed-12/VBN	aux||confirm-14/VB||to-13/TO	xcomp||performed-12/VBN||confirm-14/VB	det||status-18/NN||the-15/DT	nn||status-18/NN||glucose-16/NN	nn||status-18/NN||tolerant-17/NN	dobj||confirm-14/VB||status-18/NN	nsubjpass||measured-30/VBN||fasting-21/NN	amod||30-minute-24/JJ||post-challenge-23/JJ	appos||fasting-21/NN||30-minute-24/JJ	amod||levels-28/NNS||120-minute-26/JJ	nn||levels-28/NNS||glucose-27/NN	appos||fasting-21/NN||levels-28/NNS	conj_and||30-minute-24/JJ||levels-28/NNS	auxpass||measured-30/VBN||were-29/VBD	conj_and||performed-12/VBN||measured-30/VBN	hyperglycemia-6||glucose-27||no||in 663 subjects with fasting hyperglycemia, 75 g ogtt were performed to confirm the glucose tolerant status, and fasting, post-challenge 30-minute and 120-minute glucose levels were measured.
nn||design-2/NN||research-1/NN	nsubj||gain-8/VB||design-2/NN	nn||$-5/NNP||methodsâ-4/NNP	conj_and||design-2/NN||$-5/NNP	nsubj||gain-8/VB||$-5/NNP	aux||gain-8/VB||to-7/TO	advcl||measured-24/VBD||gain-8/VB	dobj||gain-8/VB||insight-9/NN	det||role-12/NN||the-11/DT	prep_into||gain-8/VB||role-12/NN	prep_of||role-12/NN||pref-1-14/JJ	det||onset-17/NN||the-16/DT	prep_on||pref-1-14/JJ||onset-17/NN	prep_of||onset-17/NN||insulinresistance-19/NN	prep_of||onset-17/NN||type2diabetes-21/NNS	conj_and||insulinresistance-19/NN||type2diabetes-21/NNS	nsubj||measured-24/VBD||we-23/PRP	root||ROOT-0/null||measured-24/VBD	nn||composition-26/NN||body-25/NN	dobj||measured-24/VBD||composition-26/NN	amod||metabolism-31/NN||whole-body-28/JJ	amod||metabolism-31/NN||insulin-stimulated-29/JJ	nn||metabolism-31/NN||glucose-30/NN	dobj||measured-24/VBD||metabolism-31/NN	conj_and||composition-26/NN||metabolism-31/NN	det||clamp-35/NN||a-33/DT	amod||clamp-35/NN||hyperinsulinemic-euglycemic-34/JJ	prep_during||measured-24/VBD||clamp-35/NN	amod||transgenic-38/JJ||pref-1-37/JJ	prep_in||clamp-35/NN||transgenic-38/JJ	amod||mice-42/NNS||wild-type-40/JJ	nn||mice-42/NNS||control-41/NN	prep_in||clamp-35/NN||mice-42/NNS	conj_and||transgenic-38/JJ||mice-42/NNS	vmod||clamp-35/NN||fed-43/VBN	det||diet-46/NN||a-44/DT	amod||diet-46/NN||high-fat-45/JJ	dobj||fed-43/VBN||diet-46/NN	insulin--1||type2diabetes-21||no_rel||research design and methodsâ€” to gain insight into the role of pref-1 on the onset of insulinresistance and type2diabetes, we measured body composition and whole-body insulin-stimulated glucose metabolism during a hyperinsulinemic-euglycemic clamp in pref-1 transgenic and wild-type control mice fed a high-fat diet.
dep||alcohol-induced-10/VBN||icd-9-2/VB	dobj||icd-9-2/VB||codes-4/NNS	nsubj||icd-9-2/VB||alcoholabuse-6/NN	nsubj||icd-9-2/VB||dependence-8/NN	conj_and||alcoholabuse-6/NN||dependence-8/NN	root||ROOT-0/null||alcohol-induced-10/VBN	amod||disorder-12/NN||mental-11/JJ	dobj||alcohol-induced-10/VBN||disorder-12/NN	amod||conditions-17/NNS||alcohol-induced-15/JJ	amod||conditions-17/NNS||medical-16/JJ	dobj||alcohol-induced-10/VBN||conditions-17/NNS	conj_and||disorder-12/NN||conditions-17/NNS	alcoholabuse-6||alcohol--1||no||(icd-9) codes) alcoholabuse and dependence; alcohol-induced mental disorder; and alcohol-induced medical conditions.
nsubj||agent-10/NN||denguevirus-1/NNS	det||flavivirus-5/NNS||a-3/DT	amod||flavivirus-5/NNS||mosquito-borne-4/JJ	appos||denguevirus-1/NNS||flavivirus-5/NNS	cop||agent-10/NN||is-7/VBZ	det||agent-10/NN||the-8/DT	amod||agent-10/NN||etiological-9/JJ	root||ROOT-0/null||agent-10/NN	prep_of||agent-10/NN||denguefever-12/NN	prep_of||agent-10/NN||denguehemorrhagicfever-14/NN	conj_and||denguefever-12/NN||denguehemorrhagicfever-14/NN	prep_of||agent-10/NN||dengueshocksyndrome-17/NN	conj_and||denguefever-12/NN||dengueshocksyndrome-17/NN	denguefever-12||denguevirus-1||no||denguevirus, a mosquito-borne flavivirus, is the etiological agent of denguefever, denguehemorrhagicfever, and dengueshocksyndrome.
prep_at||made-16/VBN||6â-2/NNS	num||years-6/NNS||$-3/$	num||$-3/$||7-5/CD	npadvmod||6â-2/NNS||years-6/NNS	prep_of||6â-2/NNS||age-8/NN	det||comparison-11/NN||the-10/DT	nsubjpass||made-16/VBN||comparison-11/NN	amod||factors-14/NNS||various-13/JJ	prep_of||comparison-11/NN||factors-14/NNS	auxpass||made-16/VBN||was-15/VBD	root||ROOT-0/null||made-16/VBN	number||lga-19/NN||31-18/CD	amod||children-26/NNS||lga-19/NN	number||appropriate-for-gestational-age-22/NN||34-21/CD	conj_and||lga-19/NN||appropriate-for-gestational-age-22/NN	amod||children-26/NNS||appropriate-for-gestational-age-22/NN	discourse||children-26/NNS||aga-24/UH	prep_between||made-16/VBN||children-26/NNS	dobj||made-16/VBN||fibrinogen-27/NN	nn||iii-30/NN||antithrombin-29/NN	dobj||made-16/VBN||iii-30/NN	conj_and||fibrinogen-27/NN||iii-30/NN	nn||c-33/NN||protein-32/NN	dobj||made-16/VBN||c-33/NN	conj_and||fibrinogen-27/NN||c-33/NN	dobj||made-16/VBN||s-35/PRP	conj_and||fibrinogen-27/NN||s-35/PRP	amod||model-44/NN||fasting-37/VBG	nn||model-44/NN||insulin-38/NN	dep||model-44/NN||glucose-40/NN	dep||model-44/NN||homeostasis-42/NN	nn||model-44/NN||assessment-43/NN	dobj||made-16/VBN||model-44/NN	conj_and||fibrinogen-27/NN||model-44/NN	prep_of||model-44/NN||insulinresistance-46/NN	appos||model-44/NN||homa-ir-48/NN	nn||protein-61/NN||index-50/NN	dep||protein-61/NN||adiponectin-52/NN	dep||protein-61/NN||leptin-54/NN	dep||protein-61/NN||visfatin-56/NN	amod||protein-61/NN||igf-1-58/JJ	amod||protein-61/NN||igf-binding-60/JJ	dep||fibrinogen-27/NN||protein-61/NN	appos||protein-61/NN||igfbp-63/NN	nsubj||lipids-69/VBZ||-1-65/CD	amod||-1-65/CD||igfbp-3-67/JJ	rcmod||protein-61/NN||lipids-69/VBZ	det||factors-74/NNS||the-72/DT	amod||factors-74/NNS||genetic-73/JJ	poss||mutation-78/NN||factors-74/NNS	nn||mutation-78/NN||leiden-76/NN	amod||mutation-78/NN||g1691a-77/VBD	dobj||made-16/VBN||mutation-78/NN	conj_and||fibrinogen-27/NN||mutation-78/NN	amod||20210a/g-81/JJ||prothrombin-80/JJ	amod||polymorphism-82/NN||20210a/g-81/JJ	conj_and||fibrinogen-27/NN||polymorphism-82/NN	conj_and||mutation-78/NN||polymorphism-82/NN	conj_and||fibrinogen-27/NN||mutation-85/NN	conj_and||mutation-78/NN||mutation-85/NN	det||gene-90/NN||the-87/DT	amod||5,10-methylenetetrahydrofolate-reductase-89/JJ||enzyme-88/JJ	amod||gene-90/NN||5,10-methylenetetrahydrofolate-reductase-89/JJ	prep_in||mutation-85/NN||gene-90/NN	dep||gene-90/NN||mthfr-c677t-92/JJ	lipids-69||insulinresistance-46||no_rel||at 6â€“7 years of age, the comparison of various factors was made between 31 lga and 34 appropriate-for-gestational-age (aga) children fibrinogen, antithrombin iii, protein c and s, fasting insulin, glucose, homeostasis assessment model of insulinresistance (homa-ir) index, adiponectin, leptin, visfatin, igf-1, igf-binding protein (igfbp)-1, igfbp-3, lipids, and the genetic factors v leiden g1691a mutation, prothrombin 20210a/g polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (mthfr-c677t).
nsubj||herpesvirus-17/NNS||varicella-zostervirus-1/NNS	nsubj||first-24/JJ||varicella-zostervirus-1/NNS	appos||varicella-zostervirus-1/NNS||vzv-3/NN	det||cause-7/NN||the-6/DT	appos||varicella-zostervirus-1/NNS||cause-7/NN	prep_of||cause-7/NN||chickenpox-9/NN	prep_of||cause-7/NN||zoster-11/NN	conj_and||chickenpox-9/NN||zoster-11/NN	cop||herpesvirus-17/NNS||was-13/VBD	det||herpesvirus-17/NNS||the-14/DT	amod||herpesvirus-17/NNS||first-15/JJ	amod||herpesvirus-17/NNS||human-16/JJ	root||ROOT-0/null||herpesvirus-17/NNS	aux||sequenced-20/VBN||to-18/TO	auxpass||sequenced-20/VBN||be-19/VB	vmod||herpesvirus-17/NNS||sequenced-20/VBN	advmod||sequenced-20/VBN||fully-21/RB	det||first-24/JJ||the-23/DT	conj_and||herpesvirus-17/NNS||first-24/JJ	prep_for||licensed-30/VBN||first-24/JJ	nsubjpass||licensed-30/VBN||vaccines-27/NNS	nsubjpass||used-33/VBN||vaccines-27/NNS	aux||licensed-30/VBN||have-28/VBP	auxpass||licensed-30/VBN||been-29/VBN	rcmod||first-24/JJ||licensed-30/VBN	advmod||used-33/VBN||widely-32/RB	rcmod||first-24/JJ||used-33/VBN	conj_and||licensed-30/VBN||used-33/VBN	chickenpox-9||vzv-3||no||varicella-zostervirus (vzv), the cause of chickenpox and zoster, was the first human herpesvirus to be sequenced fully and the first for which vaccines have been licensed and widely used.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	cancer-14||adjuvant-9||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
det||initiative-7/NN||the-1/DT	amod||initiative-7/NN||womenâ-2/JJ	amod||initiative-7/NN||$-3/$	number||s-5/CD||™-4/CD	num||$-3/$||s-5/CD	nn||initiative-7/NN||health-6/NN	nsubj||found-8/VBD||initiative-7/NN	root||ROOT-0/null||found-8/VBD	mark||increases-17/VBZ||that-9/IN	nn||estrogen-11/NN||combination-10/NN	nsubj||increases-17/VBZ||estrogen-11/NN	amod||therapy-16/NN||progesterone-13/JJ	nn||therapy-16/NN||hormone-14/NN	nn||therapy-16/NN||replacement-15/NN	conj_and||estrogen-11/NN||therapy-16/NN	nsubj||increases-17/VBZ||therapy-16/NN	ccomp||found-8/VBD||increases-17/VBZ	nn||cancer-19/NN||breast-18/NN	dobj||increases-17/VBZ||cancer-19/NN	nsubj||compelled-25/VBN||cancer-19/NN	nn||risk-22/NN||cardiovasculardisease-21/NN	dobj||increases-17/VBZ||risk-22/NN	conj_and||cancer-19/NN||risk-22/NN	nsubj||compelled-25/VBN||risk-22/NN	rcmod||cancer-19/NN||compelled-25/VBN	amod||women-27/NNS||many-26/JJ	dobj||compelled-25/VBN||women-27/NNS	nsubj||seek-29/VB||women-27/NNS	aux||seek-29/VB||to-28/TO	xcomp||compelled-25/VBN||seek-29/VB	amod||alternatives-31/NNS||herbal-30/JJ	dobj||seek-29/VB||alternatives-31/NNS	prep_such_as||alternatives-31/NNS||blackcohoshextract-34/NN	appos||blackcohoshextract-34/NN||bce-36/NN	aux||relieve-39/VB||to-38/TO	vmod||blackcohoshextract-34/NN||relieve-39/VB	poss||symptoms-42/NNS||their-40/PRP$	amod||symptoms-42/NNS||menopausal-41/JJ	dobj||relieve-39/VB||symptoms-42/NNS	estrogen-11||cardiovasculardisease-21||no_rel||the womenâ€™s health initiative found that combination estrogen and progesterone hormone replacement therapy increases breast cancer and cardiovasculardisease risk, which compelled many women to seek herbal alternatives such as blackcohoshextract (bce) to relieve their menopausal symptoms.
prep_in||found-9/VBN||contrast-2/NN	nsubjpass||found-9/VBN||mutations-4/NNS	prep_in||mutations-4/NNS||pfcyt-b-6/NN	auxpass||found-9/VBN||were-7/VBD	neg||found-9/VBN||not-8/RB	root||ROOT-0/null||found-9/VBN	num||patients-12/NNS||three-11/CD	prep_in||found-9/VBN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	prep_with||treated-13/VBN||atovaquone-proguanil-15/NN	nsubj||exhibited-17/VBD||atovaquone-proguanil-15/NN	rcmod||atovaquone-proguanil-15/NN||exhibited-17/VBD	amod||clearance-19/NN||delayed-18/JJ	dobj||exhibited-17/VBD||clearance-19/NN	det||infection-23/NN||the-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||clearance-19/NN||infection-23/NN	dobj||exhibited-17/VBD||in-26/IN	conj_nor||clearance-19/NN||in-26/IN	pobj||in-26/IN||two-27/CD	xcomp||exhibited-17/VBD||returning-28/VBG	dobj||returning-28/VBG||travellers-29/NNS	prep_with||returning-28/VBG||malaria-31/NN	nsubj||used-34/VBN||malaria-31/NN	aux||used-34/VBN||had-33/VBD	rcmod||malaria-31/NN||used-34/VBN	det||combination-36/NN||the-35/DT	dobj||used-34/VBN||combination-36/NN	prep_for||combination-36/NN||prophylaxis-38/NNS	malaria-31||atovaquone--1||yes||in contrast, mutations in pfcyt-b were not found in three patients treated with atovaquone-proguanil who exhibited delayed clearance of the primary infection, nor in two returning travellers with malaria who had used the combination for prophylaxis.
amod||women-3/NNS||premenopausal-2/JJ	prep_in||causes-6/VBZ||women-3/NNS	nsubj||causes-6/VBZ||hyperprolactinemia-5/NN	root||ROOT-0/null||causes-6/VBZ	dobj||causes-6/VBZ||hypogonadism-7/NN	prepc_by||causes-6/VBZ||inhibiting-9/VBG	dobj||inhibiting-9/VBG||secretion-10/NN	prep_of||secretion-10/NN||gonadotropin-releasinghormone-12/NN	advmod||suppressing-15/VBG||thus-14/RB	prepc_by||causes-6/VBZ||suppressing-15/VBG	conj_and||inhibiting-9/VBG||suppressing-15/VBG	vmod||suppressing-15/VBG||luteinizing-16/VBG	nn||levels-18/NNS||hormone-17/NN	dobj||luteinizing-16/VBG||levels-18/NNS	nsubj||cause-22/VB||levels-18/NNS	aux||cause-22/VB||can-21/MD	rcmod||levels-18/NNS||cause-22/VB	amod||disorders-24/NNS||menstrual-23/JJ	dobj||cause-22/VB||disorders-24/NNS	vmod||disorders-24/NNS||ranging-25/VBG	nn||oligomenorrhea-29/NN||amenorrhea-27/NN	nn||cycle-33/NN||oligomenorrhea-29/NN	conj_and||oligomenorrhea-29/NN||chronic-31/JJ	nn||cycle-33/NN||chronic-31/JJ	nn||cycle-33/NN||anovulatory-32/NN	prep_from||ranging-25/VBG||cycle-33/NN	amod||phase-37/NN||short-35/JJ	amod||phase-37/NN||luteal-36/JJ	prep_to||cycle-33/NN||phase-37/NN	det||cycle-41/NN||the-39/DT	amod||cycle-41/NN||menstrual-40/JJ	prep_of||phase-37/NN||cycle-41/NN	amenorrhea-27||gonadotropin-releasinghormone-12||yes||in premenopausal women, hyperprolactinemia causes hypogonadism by inhibiting secretion of gonadotropin-releasinghormone and thus suppressing luteinizing hormone levels, which can cause menstrual disorders ranging from amenorrhea, oligomenorrhea and chronic anovulatory cycle to short luteal phase of the menstrual cycle.
advmod||obtained-11/VBN||furthermore-1/RB	det||reduction-6/NN||a-3/DT	number||%-5/NN||50-4/CD	amod||reduction-6/NN||%-5/NN	nsubjpass||obtained-11/VBN||reduction-6/NN	amod||complications-9/NNS||bleeding-8/VBG	prep_in||reduction-6/NN||complications-9/NNS	auxpass||obtained-11/VBN||was-10/VBD	root||ROOT-0/null||obtained-11/VBN	amod||enoxaparin-15/NN||fondaparinux-13/JJ	nn||enoxaparin-15/NN||vs-14/NN	prep_with||obtained-11/VBN||enoxaparin-15/NN	xcomp||obtained-11/VBN||leading-17/VBG	det||reduction-21/NN||a-19/DT	nn||reduction-21/NN||risk-20/NN	prep_to||leading-17/VBG||reduction-21/NN	prep_for||reduction-21/NN||death-23/NN	bleeding-8||fondaparinux-13||no_rel||furthermore, a 50% reduction in bleeding complications was obtained with fondaparinux vs enoxaparin, leading to a risk reduction for death.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||rif-19||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||discomfort-4/NN||ocular-3/NN	dobj||assess-2/VB||discomfort-4/NN	prep_upon||assess-2/VB||instillation-6/NN	amod||preference-9/NN||patient-8/JJ	prep_upon||assess-2/VB||preference-9/NN	conj_and||instillation-6/NN||preference-9/NN	prep_for||preference-9/NN||brinzolamide/timolol-11/NN	amod||dorzolamide/timolol-14/JJ||relative-12/JJ	dep||dorzolamide/timolol-14/JJ||to-13/TO	amod||preference-9/NN||dorzolamide/timolol-14/JJ	prep_in||preference-9/NN||patients-17/NNS	nn||hypertension-22/NN||open-angleglaucoma-19/NN	conj_or||open-angleglaucoma-19/NN||ocular-21/NN	nn||hypertension-22/NN||ocular-21/NN	prep_with||patients-17/NNS||hypertension-22/NN	open-angleglaucoma-19||timolol--1||yes||to assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angleglaucoma or ocular hypertension.
nn||units-5/NNS||hospital-2/NN	amod||units-5/NNS||intensive-3/JJ	nn||units-5/NNS||care-4/NN	prep_in||increased-14/VBN||units-5/NNS	det||proportion-8/NN||the-7/DT	nsubj||increased-14/VBN||proportion-8/NN	amod||infections-12/NNS||mrsa-related-10/JJ	nn||infections-12/NNS||s.aureus-11/NNS	prep_of||proportion-8/NN||infections-12/NNS	aux||increased-14/VBN||has-13/VBZ	root||ROOT-0/null||increased-14/VBN	dep||increased-14/VBN||strikingly-15/RB	advmod||percent-19/NN||just-17/RB	num||percent-19/NN||2-18/CD	prep_from||strikingly-15/RB||percent-19/NN	prep_in||percent-19/NN||1974-21/CD	num||percent-24/NN||64-23/CD	prep_to||increased-14/VBN||percent-24/NN	prep_in||percent-24/NN||2004-26/CD	mrsa--1||s.aureus-11||no||in hospital intensive care units , the proportion of mrsa-related s.aureus infections has increased strikingly from just 2 percent in 1974 to 64 percent in 2004 .
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||newborns-6/NNS||34-4/CD	nn||newborns-6/NNS||preterm-5/NN	dobj||included-3/VBD||newborns-6/NNS	amod||age-10/NN||mean-8/JJ	amod||age-10/NN||gestational-9/JJ	prep_with||included-3/VBD||age-10/NN	nsubj||suffered-40/VBD||age-10/NN	prep_of||age-10/NN||30.5-12/CD	appos||30.5-12/CD||1.6-14/CD	dep||30.5-12/CD||weeks-16/NNS	prep_of||age-10/NN||mean-18/NN	conj_and||30.5-12/CD||mean-18/NN	appos||mean-18/NN||ds-20/NN	nn||weight-25/NN||birth-24/NN	prep_of||age-10/NN||weight-25/NN	conj_and||30.5-12/CD||weight-25/NN	nn||g-31/NN||1430-27/NNP	appos||g-31/NN||423-29/NNP	prep_of||weight-25/NN||g-31/NN	dep||30.5-12/CD||mean-33/NN	appos||mean-33/NN||ds-35/NN	rcmod||age-10/NN||suffered-40/VBD	amod||disease-44/NN||hyaline-42/JJ	amod||disease-44/NN||membrane-43/JJ	prep_from||suffered-40/VBD||disease-44/NN	prep_under||suffered-40/VBD||treatment-47/NN	prep_under||suffered-40/VBD||treatment-47/NN	conj_or||treatment-47/NN||treatment-47/NN	amod||cpap-50/NN||nasal-49/JJ	prep_with||treatment-47/NN||cpap-50/NN	amod||pressure-55/NN||continuous-52/JJ	nn||pressure-55/NN||positive-53/NN	nn||pressure-55/NN||airways-54/NNS	appos||cpap-50/NN||pressure-55/NN	prep_from||treatment-47/NN||pneumonia-60/NN	prep_under||suffered-40/VBD||treatment-63/NN	prep_with||treatment-63/NN||oxygen-therapy-65/NN	pneumonia-60||oxygen--1||yes||the study included 34 preterm newborns with mean gestational age of 30.5 (1.6) weeks - mean (ds) - and birth weight of 1430 (423) g - mean (ds) -, who suffered from hyaline membrane disease, under treatment with nasal cpap (continuous positive airways pressure), or from pneumonia, under treatment with oxygen-therapy.
mark||differs-8/VBZ||as-1/IN	det||profile-4/NN||the-2/DT	amod||profile-4/NN||epidemiological-3/JJ	nsubj||differs-8/VBZ||profile-4/NN	nn||cases-7/NNS||egyptian-6/NN	prep_of||profile-4/NN||cases-7/NNS	advcl||is-14/VBZ||differs-8/VBZ	amod||countries-11/NNS||other-10/JJ	prep_from||differs-8/VBZ||countries-11/NNS	expl||is-14/VBZ||there-13/EX	root||ROOT-0/null||is-14/VBZ	det||need-17/NN||an-15/DT	amod||need-17/NN||urgent-16/JJ	nsubj||is-14/VBZ||need-17/NN	aux||conduct-19/VB||to-18/TO	vmod||need-17/NN||conduct-19/VB	amod||studies-21/NNS||prospective-20/JJ	dobj||conduct-19/VB||studies-21/NNS	aux||enhance-23/VB||to-22/TO	vmod||conduct-19/VB||enhance-23/VB	poss||understanding-25/NN||our-24/PRP$	dobj||enhance-23/VB||understanding-25/NN	prep_of||understanding-25/NN||incidence-27/NN	prep_of||understanding-25/NN||prevalence-29/NN	conj_and||incidence-27/NN||prevalence-29/NN	prep_of||understanding-25/NN||determinants-32/NN	conj_and||incidence-27/NN||determinants-32/NN	prep_of||incidence-27/NN||virulence-34/NN	amod||infections-37/NNS||human-36/JJ	prep_of||virulence-34/NN||infections-37/NNS	amod||influenzaviruses-41/NNS||avian-39/JJ	amod||influenzaviruses-41/NNS||h5n1-40/JJ	prep_with||enhance-23/VB||influenzaviruses-41/NNS	h5n1-40||influenzaviruses-41||no||as the epidemiological profile of egyptian cases differs from other countries, there is an urgent need to conduct prospective studies to enhance our understanding of incidence, prevalence, and determinants of virulence of human infections with avian h5n1 influenzaviruses.
poss||regression-5/NN||spline-1/NN	amod||regression-5/NN||proportional-3/JJ	nn||regression-5/NN||hazard-4/NN	nsubjpass||used-7/VBN||regression-5/NN	nsubj||obtain-9/VB||regression-5/NN	auxpass||used-7/VBN||was-6/VBD	root||ROOT-0/null||used-7/VBN	aux||obtain-9/VB||to-8/TO	xcomp||used-7/VBN||obtain-9/VB	nn||curves-12/NNS||hazard-10/NN	nn||curves-12/NNS||ratio-11/NN	dobj||obtain-9/VB||curves-12/NNS	nsubjpass||used-16/VBN||curves-12/NNS	nsubj||identify-18/VB||curves-12/NNS	nsubj||spot-24/VB||curves-12/NNS	auxpass||used-16/VBN||were-15/VBD	rcmod||curves-12/NNS||used-16/VBN	aux||identify-18/VB||to-17/TO	xcomp||used-16/VBN||identify-18/VB	nn||points-20/NNS||cutoff-19/NN	dobj||identify-18/VB||points-20/NNS	prep_of||points-20/NNS||a1c-22/CD	xcomp||used-16/VBN||spot-24/VB	conj_and||identify-18/VB||spot-24/VB	advmod||ratio-33/NN||urinary-25/RB	num||$-27/NNS||albuminâ-26/CD	pobj||urinary-25/RB||$-27/NNS	amod||ratio-33/NN||toâ-29/JJ	amod||ratio-33/NN||$-30/$	nn||ratio-33/NN||creatinine-32/NN	dobj||spot-24/VB||ratio-33/NN	amod||risk-37/NN||increased-35/VBN	nn||risk-37/NN||ischemicstroke-36/NN	prep_for||spot-24/VB||risk-37/NN	ischemicstroke-36||albumin--1||no_rel||spline cox proportional hazard regression was used to obtain hazard ratio curves, which were used to identify cutoff points of a1c and spot urinary albuminâ€“toâ€“creatinine ratio for increased ischemicstroke risk.
amod||inactivation-2/NN||mgmt-1/JJ	nsubj||sensitized-5/VBD||inactivation-2/NN	prep_by||inactivation-2/NN||o6-benzylguanine-4/CD	root||ROOT-0/null||sensitized-5/VBD	det||lines-9/NNS||all-6/DT	amod||lines-9/NNS||melanoma-7/JJ	nn||lines-9/NNS||cell-8/NN	dobj||sensitized-5/VBD||lines-9/NNS	xcomp||sensitized-5/VBD||expressing-10/VBG	dobj||expressing-10/VBG||mgmt-11/NN	nn||apoptosis-16/NNS||tmz-13/NN	conj_and||tmz-13/NN||fotemustine-induced-15/JJ	nn||apoptosis-16/NNS||fotemustine-induced-15/JJ	prep_to||expressing-10/VBG||apoptosis-16/NNS	nn||transfection-20/NN||mgmt-19/NN	nsubj||attenuated-21/VBD||transfection-20/NN	conj_and||sensitized-5/VBD||attenuated-21/VBD	det||response-24/NN||the-22/DT	amod||response-24/NN||apoptotic-23/JJ	dobj||attenuated-21/VBD||response-24/NN	melanoma-7||tmz-13||yes||mgmt inactivation by o6-benzylguanine sensitized all melanoma cell lines expressing mgmt to tmz and fotemustine-induced apoptosis, and mgmt transfection attenuated the apoptotic response.
nsubj||occur-2/VBP||bacterialinfections-1/NNS	root||ROOT-0/null||occur-2/VBP	advmod||overwhelmed-9/JJ||when-3/WRB	det||defenses-7/NNS||the-4/DT	amod||defenses-7/NNS||natural-5/JJ	nn||defenses-7/NNS||host-6/NN	nsubj||overwhelmed-9/JJ||defenses-7/NNS	aux||overwhelmed-9/JJ||are-8/VBP	advcl||occur-2/VBP||overwhelmed-9/JJ	prepc_by||overwhelmed-9/JJ||invading-11/VBG	dobj||invading-11/VBG||bacteria-12/NNS	bacterialinfections-1||bacteria-12||no||bacterialinfections occur when the natural host defenses are overwhelmed by invading bacteria.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||artemether--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	glucagon-14||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
nsubj||case-5/NN||this-1/DT	cop||case-5/NN||is-2/VBZ	advmod||case-5/NN||particularly-3/RB	det||case-5/NN||the-4/DT	root||ROOT-0/null||case-5/NN	amod||africa-8/NN||sub-saharan-7/JJ	prep_in||case-5/NN||africa-8/NN	advmod||reside-21/VB||where-9/WRB	num||%-11/NN||70-10/CD	nsubj||reside-21/VB||%-11/NN	det||people-14/NNS||all-13/DT	prep_of||%-11/NN||people-14/NNS	vmod||people-14/NNS||living-15/VBG	prep_with||living-15/VBG||hiv/aids-17/NNS	appos||hiv/aids-17/NNS||pha-19/NN	advcl||case-5/NN||reside-21/VB	aids--1||hiv--1||no||this is particularly the case in sub-saharan africa where 70% of all people living with hiv/aids (pha) reside.
prep_by||created-15/VBN||mutagenesis-2/NNS	det||domain-8/NN||the-4/DT	amod||domain-8/NN||vitamin-5/JJ	amod||domain-8/NN||k-dependent-6/JJ	nn||domain-8/NN||gla-7/NN	prep_of||mutagenesis-2/NNS||domain-8/NN	prep_of||domain-8/NN||apc-10/NN	nsubj||created-15/VBN||we-12/PRP	aux||created-15/VBN||have-13/VBP	advmod||created-15/VBN||recently-14/RB	root||ROOT-0/null||created-15/VBN	det||variant-18/NN||an-16/DT	nn||variant-18/NN||apc-17/NN	dobj||created-15/VBN||variant-18/NN	xcomp||created-15/VBN||having-19/VBG	amod||activity-22/NN||enhanced-20/JJ	nn||activity-22/NN||anticoagulant-21/NN	nsubj||due-23/JJ||activity-22/NN	xcomp||having-19/VBG||due-23/JJ	amod||affinity-26/NN||increased-25/VBN	prep_to||due-23/JJ||affinity-26/NN	advmod||charged-29/VBN||negatively-28/RB	amod||membranes-31/NNS||charged-29/VBN	amod||membranes-31/NNS||phospholipid-30/JJ	prep_for||affinity-26/NN||membranes-31/NNS	anticoagulant-21||gla-7||no_rel||by mutagenesis of the vitamin k-dependent gla domain of apc, we have recently created an apc variant having enhanced anticoagulant activity due to increased affinity for negatively charged phospholipid membranes.
amod||trials-2/NNS||clinical-1/JJ	nsubj||shown-4/VBN||trials-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	det||benefits-6/NNS||the-5/DT	dobj||shown-4/VBN||benefits-6/NNS	amod||inhibitors-9/NNS||acetylcholinesterase-8/JJ	prep_of||benefits-6/NNS||inhibitors-9/NNS	prep_such_as||benefits-6/NNS||donepezil-13/JJ	prep_such_as||benefits-6/NNS||galantamine-15/JJ	conj_and||donepezil-13/JJ||galantamine-15/JJ	det||n-19/NN||an-18/DT	prep_such_as||benefits-6/NNS||n-19/NN	conj_and||donepezil-13/JJ||n-19/NN	amod||antagonist-23/NN||methyl-d-aspartate-21/JJ	nn||antagonist-23/NN||receptor-22/NN	dep||n-19/NN||antagonist-23/NN	appos||antagonist-23/NN||memantine-25/NN	prep_in||benefits-6/NNS||patients-28/NNS	prepc_with||patients-28/NNS||alzheimerâ-30/VBG	num||disease-34/NN||$-31/$	number||s-33/CD||™-32/CD	num||$-31/$||s-33/CD	dobj||alzheimerâ-30/VBG||disease-34/NN	appos||disease-34/NN||ad-36/NN	alzheimer--1||galantamine-15||yes||clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an n -methyl-d-aspartate receptor antagonist, memantine, in patients with alzheimerâ€™s disease (ad).
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	cancer-20||estrogens-14||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||park-53/VB||that-5/IN	nsubj||park-53/VB||all-6/DT	vmod||all-6/DT||transretinoicacid-8/VBN	nn||-rrb--11/NNP||-lrb--9/NNP	nn||-rrb--11/NNP||atra-10/NNP	dobj||transretinoicacid-8/VBN||-rrb--11/NNP	rcmod||-rrb--11/NNP||triggers-12/VBZ	det||activation-14/NN||the-13/DT	dobj||triggers-12/VBZ||activation-14/NN	amod||-rrb--21/NNS||extracellular-signal-regulated-16/JJ	amod||-rrb--21/NNS||kinase-17/JJ	num||-lrb--19/NNS||2-18/CD	dep||kinase-17/JJ||-lrb--19/NNS	amod||-rrb--21/NNS||erk2-20/JJ	prep_of||activation-14/NN||-rrb--21/NNS	nsubj||phosphorylates-24/VBZ||-rrb--21/NNS	nsubj||stimulates-27/VBZ||-rrb--21/NNS	rcmod||-rrb--21/NNS||phosphorylates-24/VBZ	dobj||phosphorylates-24/VBZ||tr2-25/NNS	rcmod||-rrb--21/NNS||stimulates-27/VBZ	conj_and||phosphorylates-24/VBZ||stimulates-27/VBZ	poss||partitioning-29/NN||its-28/PRP$	dobj||stimulates-27/VBZ||partitioning-29/NN	amod||bodies-36/NNS||promyelocyticleukemia-31/JJ	nn||bodies-36/NNS||-lrb--32/NNP	nn||bodies-36/NNS||pml-33/NN	nn||bodies-36/NNS||-rrb--34/NN	amod||bodies-36/NNS||nuclear-35/JJ	prep_to||stimulates-27/VBZ||bodies-36/NNS	advmod||converting-39/VBG||thereby-38/RB	vmod||transretinoicacid-8/VBN||converting-39/VBG	det||function-42/NN||the-40/DT	nn||function-42/NN||activator-41/NN	dobj||converting-39/VBG||function-42/NN	prep_of||function-42/NN||tr2-44/CD	nn||gupta-48/NN||repression-46/NN	nn||gupta-48/NN||-lrb--47/NN	prep_into||converting-39/VBG||gupta-48/NN	prep_into||converting-39/VBG||al.-50/NN	conj_et||gupta-48/NN||al.-50/NN	num||al.-50/NN||2008-51/CD	ccomp||found-4/VBD||park-53/VB	nn||-rrb--57/NNP||et-54/NNP	nn||-rrb--57/NNP||al.-55/NNP	num||-rrb--57/NNP||2007-56/CD	dobj||park-53/VB||-rrb--57/NNP	promyelocyticleukemia-31||transretinoicacid-8||yes||recently , we found that all - transretinoicacid -lrb- atra -rrb- triggers the activation of extracellular-signal-regulated kinase 2 -lrb- erk2 -rrb- , which phosphorylates tr2 and stimulates its partitioning to promyelocyticleukemia -lrb- pml -rrb- nuclear bodies , thereby converting the activator function of tr2 into repression -lrb- gupta et al. 2008 ; park et al. 2007 -rrb- .
det||practitioner-4/NN||the-2/DT	amod||practitioner-4/NN||dental-3/JJ	prep_for||is-6/VBZ||practitioner-4/NN	nsubj||is-6/VBZ||it-5/PRP	nsubj||learn-10/VB||it-5/PRP	root||ROOT-0/null||is-6/VBZ	prep_of||is-6/VBZ||interest-8/NN	aux||learn-10/VB||to-9/TO	xcomp||is-6/VBZ||learn-10/VB	mark||generates-18/VBZ||that-11/IN	nsubj||generates-18/VBZ||use-12/NN	nsubjpass||expected-31/VBN||use-12/NN	nsubj||provide-33/VB||use-12/NN	prep_of||use-12/NN||glycine-14/NN	nn||polishing-17/NN||air-16/NN	prep_in||glycine-14/NN||polishing-17/NN	ccomp||learn-10/VB||generates-18/VBZ	det||roughening-22/NN||the-19/DT	amod||roughening-22/NN||least-20/JJS	nn||roughening-22/NN||surface-21/NN	dobj||generates-18/VBZ||roughening-22/NN	det||restorativematerial-26/NN||the-24/DT	amod||restorativematerial-26/NN||considered-25/JJ	prep_on||roughening-22/NN||restorativematerial-26/NN	advmod||expected-31/VBN||thus-29/RB	auxpass||expected-31/VBN||is-30/VBZ	ccomp||learn-10/VB||expected-31/VBN	conj_and||generates-18/VBZ||expected-31/VBN	aux||provide-33/VB||to-32/TO	xcomp||expected-31/VBN||provide-33/VB	det||rate-36/NN||the-34/DT	amod||rate-36/NN||lowest-35/JJS	dobj||provide-33/VB||rate-36/NN	amod||growth-40/NN||bacterial-38/JJ	nn||growth-40/NN||biofilm-39/NN	prep_of||rate-36/NN||growth-40/NN	prep_of||rate-36/NN||dentalplaqueformation-42/NN	conj_and||growth-40/NN||dentalplaqueformation-42/NN	glycine-14||dentalplaqueformation-42||no_rel||for the dental practitioner it is of interest to learn that use of glycine in air polishing generates the least surface roughening on the considered restorativematerial, and thus is expected to provide the lowest rate of bacterial biofilm growth and dentalplaqueformation.
amod||tests-2/NNS||serological-1/JJ	nsubj||most-12/JJS||tests-2/NNS	amod||igm-5/NN||dengue-4/JJ	prep_of||tests-2/NNS||igm-5/NN	nn||antibodies-8/NNS||igg-7/NN	prep_of||tests-2/NNS||antibodies-8/NNS	conj_and||igm-5/NN||antibodies-8/NNS	cop||most-12/JJS||are-9/VBP	advmod||most-12/JJS||still-10/RB	det||most-12/JJS||the-11/DT	root||ROOT-0/null||most-12/JJS	advmod||used-14/VBN||widely-13/RB	vmod||most-12/JJS||used-14/VBN	prep_for||used-14/VBN||diagnosis-16/NN	prep_of||diagnosis-16/NN||dengue-18/NN	antibodies-8||dengue-18||no_rel||serological tests of dengue igm and igg antibodies are still the most widely used for diagnosis of dengue.
nsubj||characterized-3/VBD||we-1/PRP	nsubj||found-13/VBD||we-1/PRP	advmod||characterized-3/VBD||previously-2/RB	root||ROOT-0/null||characterized-3/VBD	det||mutant-8/NN||a-4/DT	nn||mutant-8/NN||î-5/NN	nn||mutant-8/NN||lpp-7/NN	dobj||characterized-3/VBD||mutant-8/NN	amod||co92-11/NNS||yersiniapestis-10/JJ	prep_of||mutant-8/NN||co92-11/NNS	conj_and||characterized-3/VBD||found-13/VBD	mark||defective-18/JJ||that-14/IN	det||mutant-16/NN||this-15/DT	nsubj||defective-18/JJ||mutant-16/NN	nsubjpass||attenuated-25/VBN||mutant-16/NN	cop||defective-18/JJ||was-17/VBD	ccomp||found-13/VBD||defective-18/JJ	prepc_in||defective-18/JJ||surviving-20/VBG	prep_in||surviving-20/VBG||macrophages-22/NNS	auxpass||attenuated-25/VBN||was-24/VBD	ccomp||found-13/VBD||attenuated-25/VBN	conj_and||defective-18/JJ||attenuated-25/VBN	det||model-30/NN||a-27/DT	nn||model-30/NN||mouse-28/NN	nn||model-30/NN||inhalation-29/NN	prep_in||attenuated-25/VBN||model-30/NN	prep_of||model-30/NN||plague-32/NNP	advmod||compared-34/VBN||when-33/WRB	advcl||attenuated-25/VBN||compared-34/VBN	det||bacterium-43/NN||the-36/DT	advmod||virulent-38/JJ||highly-37/RB	amod||bacterium-43/NN||virulent-38/JJ	nn||bacterium-43/NN||wild-type-39/NN	appos||bacterium-43/NN||wt-41/NN	prep_to||compared-34/VBN||bacterium-43/NN	plague-32||yersiniapestis-10||no||we previously characterized a î” lpp mutant of yersiniapestis co92 and found that this mutant was defective in surviving in macrophages and was attenuated in a mouse inhalation model of plague when compared to the highly virulent wild-type (wt) bacterium.
advmod||increased-11/VBD||however-1/RB	amod||administration-4/NN||fluoxetine-3/JJ	nsubj||increased-11/VBD||administration-4/NN	advmod||increased-11/VBD||significantly-5/RB	dep||<-8/JJ||p-7/RB	dep||significantly-5/RB||<-8/JJ	dep||<-8/JJ||0.05-9/CD	root||ROOT-0/null||increased-11/VBD	amod||ans-13/NN||key-12/JJ	nn||responses-40/NNS||ans-13/NN	dep||ans-13/NN||epinephrine-15/NN	dep||ans-13/NN||norepinephrine-17/NN	conj_and||epinephrine-15/NN||norepinephrine-17/NN	dep||ans-13/NN||msna-20/NN	conj_and||epinephrine-15/NN||msna-20/NN	conj_and||ans-13/NN||metabolic-23/NN	nn||responses-40/NNS||metabolic-23/NN	amod||production-27/NN||endogenous-25/JJ	nn||production-27/NN||glucose-26/NN	dep||metabolic-23/NN||production-27/NN	dep||metabolic-23/NN||lipolysis-29/NNS	conj_and||production-27/NN||lipolysis-29/NNS	amod||counterregulatory-39/NN||cardiovascular-33/JJ	amod||pressure-37/NN||systolic-35/JJ	nn||pressure-37/NN||blood-36/NN	appos||counterregulatory-39/NN||pressure-37/NN	conj_and||ans-13/NN||counterregulatory-39/NN	nn||responses-40/NNS||counterregulatory-39/NN	dobj||increased-11/VBD||responses-40/NNS	prep_during||increased-11/VBD||hypoglycemia-42/NN	hypoglycemia-42||fluoxetine-3||no_rel||however, fluoxetine administration significantly ( p < 0.05) increased key ans (epinephrine, norepinephrine, and msna), metabolic (endogenous glucose production and lipolysis), and cardiovascular (systolic blood pressure) counterregulatory responses during hypoglycemia.
nn||care-2/NN||hiv-1/NN	nsubj||provide-6/VBP||care-2/NN	nn||settings-5/NNS||treatment-4/NN	conj_and||care-2/NN||settings-5/NNS	nsubj||provide-6/VBP||settings-5/NNS	root||ROOT-0/null||provide-6/VBP	det||opportunity-8/NN||an-7/DT	dobj||provide-6/VBP||opportunity-8/NN	nsubj||reach-10/VB||opportunity-8/NN	aux||reach-10/VB||to-9/TO	xcomp||provide-6/VBP||reach-10/VB	dobj||reach-10/VB||people-11/NNS	vmod||people-11/NNS||living-12/VBG	prep_with||living-12/VBG||hiv/aids-14/NNS	appos||hiv/aids-14/NNS||plhiv-16/NNP	nn||messages-20/NNS||prevention-19/NN	prep_with||hiv/aids-14/NNS||messages-20/NNS	prep_with||hiv/aids-14/NNS||services-22/NNS	conj_and||messages-20/NNS||services-22/NNS	aids--1||hiv-1||no||hiv care and treatment settings provide an opportunity to reach people living with hiv/aids (plhiv) with prevention messages and services.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||investigate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||investigate-9/VB||to-8/TO	xcomp||was-7/VBD||investigate-9/VB	nn||factors-11/NNS||risk-10/NN	dobj||investigate-9/VB||factors-11/NNS	prep_for||factors-11/NNS||atopic-13/NN	prep_for||factors-11/NNS||non-atopicasthma-15/NN	conj_and||atopic-13/NN||non-atopicasthma-15/NN	amod||children-18/NNS||school-age-17/JJ	prep_in||investigate-9/VB||children-18/NNS	atopicasthma--1||atopic-13||no||the aim of the present study was to investigate risk factors for atopic and non-atopicasthma in school-age children.
nsubj||block-9/VB||we-2/PRP	npadvmod||here-4/RB||review-3/NN	advmod||block-9/VB||here-4/RB	nsubj||agents-6/VBZ||the-5/NNP	parataxis||block-9/VB||agents-6/VBZ	nsubj||block-9/VB||that-7/DT	aux||block-9/VB||can-8/MD	root||ROOT-0/null||block-9/VB	nn||entry-12/NN||hiv-10/NN	amod||entry-12/NN||cellular-11/JJ	dep||promise-16/NN||entry-12/NN	det||show-15/NN||that-14/DT	dobj||block-9/VB||show-15/NN	conj_and||promise-16/NN||show-15/NN	dobj||block-9/VB||promise-16/NN	amod||strategies-19/NNS||topical-18/JJ	prep_as||promise-16/NN||strategies-19/NNS	dobj||block-9/VB||virustats-23/NNS	aux||prevent-27/VB||to-26/TO	vmod||virustats-23/NNS||prevent-27/VB	amod||transmission-29/NN||mucosal-28/JJ	dobj||prevent-27/VB||transmission-29/NN	prep_of||transmission-29/NN||hivinfection-31/NN	hivinfection-31||hiv-10||no||" we review here the agents that can block hiv cellular entry and that show promise as topical strategies or ""virustats"" to prevent mucosal transmission of hivinfection"
mark||recognized-3/VBN||although-1/IN	advmod||recognized-3/VBN||increasingly-2/RB	advcl||development-13/NN||recognized-3/VBN	amod||surgery-6/NN||bariatric-5/JJ	prep_following||recognized-3/VBN||surgery-6/NN	nsubj||development-13/NN||this-8/DT	cop||development-13/NN||is-9/VBZ	det||development-13/NN||the-10/DT	amod||development-13/NN||first-11/JJ	amod||development-13/NN||reported-12/VBN	root||ROOT-0/null||development-13/NN	prep_of||development-13/NN||niphs-15/NNS	amod||syndrome-20/NN||non-insulinoma-17/JJ	nn||syndrome-20/NN||pancreatogenous-18/NN	nn||syndrome-20/NN||hypoglycemia-19/NN	appos||niphs-15/NNS||syndrome-20/NN	nn||surgery-24/NN||fundoplication-23/NN	prep_following||niphs-15/NNS||surgery-24/NN	det||use-32/NN||the-29/DT	amod||use-32/NN||first-30/JJ	amod||use-32/NN||documented-31/VBN	conj_and||development-13/NN||use-32/NN	prep_of||use-32/NN||octreotide-34/NN	amod||niphs-37/NNS||post-operative-36/JJ	prep_in||use-32/NN||niphs-37/NNS	insulinoma--1||octreotide-34||no_rel||although increasingly recognized following bariatric surgery, this is the first reported development of niphs (non-insulinoma pancreatogenous hypoglycemia syndrome) following fundoplication surgery, as well as the first documented use of octreotide in post-operative niphs.
amod||analyses-2/NNS||multiallelic-1/JJ	nsubj||showed-10/VBD||analyses-2/NNS	prepc_of||analyses-2/NNS||carrying-4/VBG	nn||alleles-6/NNS||risk-5/NN	dobj||carrying-4/VBG||alleles-6/NNS	amod||genes-9/NNS||multiple-8/JJ	prep_for||carrying-4/VBG||genes-9/NNS	root||ROOT-0/null||showed-10/VBD	dobj||showed-10/VBD||correlations-11/NNS	prep_between||correlations-11/NNS||number-13/NN	nn||alleles-16/NNS||risk-15/NN	prep_of||number-13/NN||alleles-16/NNS	prep_of||number-13/NN||type2diabetes-18/NNS	conj_and||alleles-16/NNS||type2diabetes-18/NNS	amod||secretion-22/NN||impaired-20/VBN	nn||secretion-22/NN||insulin-21/NN	prep_between||correlations-11/NNS||secretion-22/NN	conj_and||number-13/NN||secretion-22/NN	amod||subjects-25/NNS||normoglycemic-24/JJ	prep_in||secretion-22/NN||subjects-25/NNS	dep||secretion-22/NN||p-27/VBN	dep||0.006-29/CD||=-28/SYM	ccomp||p-27/VBN||0.006-29/CD	ccomp||p-27/VBN||0.0001-31/CD	conj_and||0.006-29/CD||0.0001-31/CD	prep_for||p-27/VBN||type2diabetes-33/NN	prep_for||p-27/VBN||air-35/NN	conj_and||type2diabetes-33/NN||air-35/NN	advmod||p-27/VBN||respectively-37/RB	vmod||showed-10/VBD||supporting-40/VBG	det||hypothesis-42/NNS||the-41/DT	dobj||supporting-40/VBG||hypothesis-42/NNS	mark||influence-48/VBP||that-43/IN	nsubj||influence-48/VBP||many-44/JJ	det||genes-47/NNS||these-46/DT	prep_of||many-44/JJ||genes-47/NNS	ccomp||supporting-40/VBG||influence-48/VBP	nn||risk-50/NN||diabetes-49/NN	dobj||influence-48/VBP||risk-50/NN	prepc_by||influence-48/VBP||affecting-52/VBG	nn||secretion-54/NN||insulin-53/NN	dobj||affecting-52/VBG||secretion-54/NN	type2diabetes-33||insulin-53||yes||multiallelic analyses of carrying risk alleles for multiple genes showed correlations between number of risk alleles and type2diabetes and impaired insulin secretion in normoglycemic subjects ( p = 0.006 and 0.0001 for type2diabetes and air, respectively), supporting the hypothesis that many of these genes influence diabetes risk by affecting insulin secretion.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
nsubj||complication-9/NN||heparin-inducedthrombocytopenia-1/NN	dep||heparin-inducedthrombocytopenia-1/NN||hit-3/VBN	cop||complication-9/NN||is-5/VBZ	det||complication-9/NN||an-6/DT	amod||complication-9/NN||immunoglobulin-mediated-7/JJ	amod||complication-9/NN||serious-8/JJ	root||ROOT-0/null||complication-9/NN	nn||therapy-12/NN||heparin-11/NN	prep_of||complication-9/NN||therapy-12/NN	vmod||therapy-12/NN||characterized-13/VBN	nn||risk-18/NN||thrombocytopenia-15/NN	conj_and||thrombocytopenia-15/NN||high-17/JJ	nn||risk-18/NN||high-17/JJ	agent||characterized-13/VBN||risk-18/NN	amod||syndrome-26/NN||venous-20/JJ	conj_and||venous-20/JJ||arterialthrombosis-22/JJ	amod||syndrome-26/NN||arterialthrombosis-22/JJ	amod||syndrome-26/NN||hit-23/NN	conj_and||hit-23/NN||thrombosis-25/JJ	amod||syndrome-26/NN||thrombosis-25/JJ	prep_for||risk-18/NN||syndrome-26/NN	appos||syndrome-26/NN||hitts-28/NNS	hit-23||heparin-11||no||heparin-inducedthrombocytopenia (hit) is an immunoglobulin-mediated serious complication of heparin therapy characterized by thrombocytopenia and high risk for venous and arterialthrombosis hit and thrombosis syndrome (hitts).
nsubj||mild-4/JJ||uc-1/NN	nsubj||distal-6/JJ||uc-1/NN	nsubj||left-sided-8/JJ||uc-1/NN	cop||mild-4/JJ||was-2/VBD	advmod||mild-4/JJ||mainly-3/RB	root||ROOT-0/null||mild-4/JJ	conj_or||mild-4/JJ||distal-6/JJ	conj_or||mild-4/JJ||left-sided-8/JJ	mark||involved-13/VBD||while-10/IN	nsubj||involved-13/VBD||cd-11/NN	advmod||involved-13/VBD||mainly-12/RB	advcl||mild-4/JJ||involved-13/VBD	det||bowel-16/NN||the-14/DT	amod||bowel-16/NN||large-15/JJ	dobj||involved-13/VBD||bowel-16/NN	cd-11||uc-1||no_rel||uc was mainly mild, distal or left-sided, while cd mainly involved the large bowel.
prep_in||significant-20/JJ||group-2/NN	num||group-2/NN||3-3/CD	nsubj||significant-20/JJ||use-5/NN	prep_of||use-5/NN||oxygen-7/NN	amod||ventilation-10/NN||mechanical-9/JJ	prep_in||oxygen-7/NN||ventilation-10/NN	prep_in||oxygen-7/NN||sepsis-12/NN	conj_and||ventilation-10/NN||sepsis-12/NN	prep_in||oxygen-7/NN||need-15/NN	conj_and||ventilation-10/NN||need-15/NN	nn||transfusion-18/NN||blood-17/NN	prep_for||need-15/NN||transfusion-18/NN	cop||significant-20/JJ||were-19/VBD	root||ROOT-0/null||significant-20/JJ	nn||onset-23/NN||rop-22/NN	prep_for||significant-20/JJ||onset-23/NN	rop-22||oxygen-7||no||in group 3, use of oxygen in mechanical ventilation, sepsis, and need for blood transfusion were significant for rop onset.
advmod||include-10/VBP||meanwhile-1/RB	det||steps-4/NNS||the-3/DT	nsubj||include-10/VBP||steps-4/NNS	amod||treatments-7/NNS||pharmacologic-6/JJ	prep_of||steps-4/NNS||treatments-7/NNS	prep_for||treatments-7/NNS||neuropathicpain-9/NN	root||ROOT-0/null||include-10/VBP	appos||antidepressants-15/NN||1-12/CD	amod||antidepressants-15/NN||certain-14/JJ	dobj||include-10/VBP||antidepressants-15/NN	amod||antidepressants-18/NNS||tricyclic-17/JJ	dep||antidepressants-15/NN||antidepressants-18/NNS	dep||antidepressants-15/NN||serotonin-20/NN	conj_and||antidepressants-18/NNS||serotonin-20/NN	amod||inhibitors-24/NNS||norepinephrine-22/JJ	nn||inhibitors-24/NNS||reuptake-23/NN	dep||antidepressants-15/NN||inhibitors-24/NNS	conj_and||antidepressants-18/NNS||inhibitors-24/NNS	nn||î-29/NN||calcium-27/NN	nn||î-29/NN||channel-28/NN	dobj||include-10/VBP||î-29/NN	conj_and||antidepressants-15/NN||î-29/NN	amod||ligands-33/NNS||±-30/JJ	amod||ligands-33/NNS||2-î-31/JJ	amod||ligands-33/NNS||´-32/JJ	dep||î-29/NN||ligands-33/NNS	appos||ligands-33/NNS||gabapentin-35/NN	appos||ligands-33/NNS||pregabalin-37/NNS	conj_and||gabapentin-35/NN||pregabalin-37/NNS	amod||lidocaine-41/NN||topical-40/JJ	dobj||include-10/VBP||lidocaine-41/NN	conj_and||antidepressants-15/NN||lidocaine-41/NN	appos||lidocaine-41/NN||2-44/CD	amod||analgesics-47/NNS||opioid-46/JJ	dep||lidocaine-41/NN||analgesics-47/NNS	dep||lidocaine-41/NN||tramadol-49/NN	conj_and||analgesics-47/NNS||tramadol-49/NN	amod||use-53/NN||first-line-52/JJ	prep_for||tramadol-49/NN||use-53/NN	amod||circumstances-57/NNS||selected-55/JJ	amod||circumstances-57/NNS||clinical-56/JJ	prep_in||use-53/NN||circumstances-57/NNS	appos||tramadol-49/NN||3-61/CD	amod||antidepressant-65/NN||certain-63/JJ	amod||antidepressant-65/NN||other-64/JJ	conj_and||analgesics-47/NNS||antidepressant-65/NN	conj_and||tramadol-49/NN||antidepressant-65/NN	amod||medications-68/NNS||antiepileptic-67/JJ	conj_and||tramadol-49/NN||medications-68/NNS	conj_and||antidepressant-65/NN||medications-68/NNS	amod||capsaicin-71/NN||topical-70/JJ	dep||antagonists-80/VBZ||capsaicin-71/NN	conj_and||capsaicin-71/NN||mexiletine-73/NN	dep||antagonists-80/VBZ||mexiletine-73/NN	conj_and||capsaicin-71/NN||n-76/NN	dep||antagonists-80/VBZ||n-76/NN	amod||receptor-79/NN||methyl-d-aspartate-78/JJ	nsubj||antagonists-80/VBZ||receptor-79/NN	dep||tramadol-49/NN||antagonists-80/VBZ	neuropathicpain-9||capsaicin-71||yes||meanwhile, the steps of pharmacologic treatments for neuropathicpain include (1) certain antidepressants (tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors), calcium channel î±2-î´ ligands (gabapentin and pregabalin) and topical lidocaine, (2) opioid analgesics and tramadol (for first-line use in selected clinical circumstances) and (3) certain other antidepressant and antiepileptic medications (topical capsaicin, mexiletine, and n -methyl-d-aspartate receptor antagonists).
nsubjpass||suggested-4/VBN||it-1/PRP	nsubjpass||associated-18/VBN||it-1/PRP	aux||suggested-4/VBN||has-2/VBZ	auxpass||suggested-4/VBN||been-3/VBN	root||ROOT-0/null||suggested-4/VBN	mark||play-8/VB||that-5/IN	nsubj||play-8/VB||ffar1-6/NNS	aux||play-8/VB||may-7/MD	ccomp||suggested-4/VBN||play-8/VB	det||role-10/NN||a-9/DT	dobj||play-8/VB||role-10/NN	nn||sensitivity-13/NN||insulin-12/NN	prep_in||play-8/VB||sensitivity-13/NN	advmod||play-8/VB||lipotoxicity-15/RB	auxpass||associated-18/VBN||is-17/VBZ	conj_and||suggested-4/VBN||associated-18/VBN	prep_with||associated-18/VBN||type2diabetes-20/CD	type2diabetes-20||insulin-12||yes||it has been suggested that ffar1 may play a role in insulin sensitivity, lipotoxicity and is associated with type2diabetes.
det||physician-4/NN||the-2/DT	nn||physician-4/NN||family-3/NN	prep_for||contribution-17/NN||physician-4/NN	nsubj||contribution-17/NN||nsaids-6/NNS	preconj||traditional-9/JJ||both-8/DT	amod||inhibitors-12/NNS||traditional-9/JJ	conj_and||traditional-9/JJ||cyclo-oxgenase-2-11/JJ	amod||inhibitors-12/NNS||cyclo-oxgenase-2-11/JJ	appos||nsaids-6/NNS||inhibitors-12/NNS	cop||contribution-17/NN||are-14/VBP	det||contribution-17/NN||a-15/DT	amod||contribution-17/NN||valuable-16/JJ	root||ROOT-0/null||contribution-17/NN	amod||arthritis-20/NN||managing-19/VBG	prep_to||contribution-17/NN||arthritis-20/NN	amod||conditions-24/NNS||other-22/JJ	amod||conditions-24/NNS||rheumatological-23/JJ	prep_to||contribution-17/NN||conditions-24/NNS	conj_and||arthritis-20/NN||conditions-24/NNS	amod||care-27/NN||primary-26/JJ	prep_in||conditions-24/NNS||care-27/NN	arthritis-20||nsaids-6||no_rel||for the family physician, nsaids, both traditional and cyclo-oxgenase-2 inhibitors, are a valuable contribution to managing arthritis and other rheumatological conditions in primary care.
amod||priondiseases-3/NNS||fatal-1/JJ	nn||priondiseases-3/NNS||neurodegenerative-2/NN	nsubjpass||caused-5/VBN||priondiseases-3/NNS	auxpass||caused-5/VBN||are-4/VBP	root||ROOT-0/null||caused-5/VBN	det||agent-11/NN||the-7/DT	amod||agent-11/NN||transmissible-8/JJ	amod||agent-11/NN||prpsc-9/JJ	nn||agent-11/NN||prion-10/NN	agent||caused-5/VBN||agent-11/NN	poss||replication-14/NN||agent-11/NN	amod||replication-14/NN||initial-13/JJ	nsubj||takes-18/VBZ||replication-14/NN	amod||inoculation-17/NN||peripheral-16/JJ	prep_after||replication-14/NN||inoculation-17/NN	rcmod||agent-11/NN||takes-18/VBZ	nsubj||present-24/JJ||place-19/NN	amod||cells-23/NNS||follicular-21/JJ	amod||cells-23/NNS||dendritic-22/JJ	prep_in||place-19/NN||cells-23/NNS	xcomp||takes-18/VBZ||present-24/JJ	amod||centers-27/NNS||germinal-26/JJ	prep_in||present-24/JJ||centers-27/NNS	amod||organs-30/NNS||lymphoid-29/JJ	prep_of||centers-27/NNS||organs-30/NNS	priondiseases-3||prion-10||no||fatal neurodegenerative priondiseases are caused by the transmissible prpsc prion agent whose initial replication after peripheral inoculation takes place in follicular dendritic cells present in germinal centers of lymphoid organs.
aux||advance-2/VB||to-1/TO	advcl||performed-7/VBD||advance-2/VB	det||studies-4/NNS||these-3/DT	dobj||advance-2/VB||studies-4/NNS	nsubj||performed-7/VBD||we-6/PRP	nsubj||completed-19/VBD||we-6/PRP	root||ROOT-0/null||performed-7/VBD	amod||analysis-10/NN||n-linked-8/JJ	nn||analysis-10/NN||glycan-9/NN	dobj||performed-7/VBD||analysis-10/NN	det||isoforms-15/NNS||the-12/DT	num||isoforms-15/NNS||five-13/CD	amod||isoforms-15/NNS||major-14/JJ	prep_on||performed-7/VBD||isoforms-15/NNS	prep_of||isoforms-15/NNS||a1at-17/CD	conj_and||performed-7/VBD||completed-19/VBD	det||study-22/NN||a-20/DT	amod||study-22/NN||comprehensive-21/JJ	dobj||completed-19/VBD||study-22/NN	det||glycosylation-25/NN||the-24/DT	prep_of||study-22/NN||glycosylation-25/NN	prep_of||glycosylation-25/NN||a1at-27/NNS	vmod||a1at-27/NNS||found-28/VBN	amod||controls-31/NNS||healthy-30/JJ	prep_in||found-28/VBN||controls-31/NNS	appos||controls-31/NNS||patients-33/NNS	amod||livercirrhosis-41/NNS||hepatitisc-35/JJ	dep||hepatitisc-35/JJ||hcv-38/NN	vmod||hcv-38/NN||induced-40/VBN	prep_with||patients-33/NNS||livercirrhosis-41/NNS	prep_in||found-28/VBN||patients-45/NNS	conj_and||controls-31/NNS||patients-45/NNS	vmod||patients-45/NNS||infected-46/VBN	prep_with||infected-46/VBN||hcv-48/NN	det||diagnosis-51/NN||a-50/DT	prep_with||infected-46/VBN||diagnosis-51/NN	nn||carcinoma-54/NN||hepatocellular-53/NN	prep_of||diagnosis-51/NN||carcinoma-54/NN	appos||carcinoma-54/NN||hcc-56/NN	hepatitisc-35||hcv-48||no||to advance these studies, we performed n-linked glycan analysis on the five major isoforms of a1at and completed a comprehensive study of the glycosylation of a1at found in healthy controls, patients with hepatitisc- (hcv) induced livercirrhosis, and in patients infected with hcv with a diagnosis of hepatocellular carcinoma (hcc).
nsubj||one-9/CD||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||one-9/CD||nowadays-6/RB	cop||one-9/CD||is-8/VBZ	root||ROOT-0/null||one-9/CD	det||pathogens-14/NNS||the-11/DT	amod||pathogens-14/NNS||major-12/JJ	amod||pathogens-14/NNS||human-13/JJ	prep_of||one-9/CD||pathogens-14/NNS	advmod||one-9/CD||worldwide-15/RB	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv), nowadays, is one of the major human pathogens worldwide.
amod||outcomes-2/NNS||secondary-1/JJ	nsubjpass||assessed-5/VBN||outcomes-2/NNS	auxpass||assessed-5/VBN||were-3/VBD	advmod||assessed-5/VBN||nausea-4/RB	root||ROOT-0/null||assessed-5/VBN	det||scale-10/NN||a-7/DT	amod||scale-10/NN||visual-8/JJ	amod||scale-10/NN||analog-9/JJ	agent||assessed-5/VBN||scale-10/NN	discourse||scale-10/NN||vas-12/UH	nsubj||31â-22/VBG||baseline-15/NN	amod||$-18/$||0â-17/JJ	appos||baseline-15/NN||$-18/$	num||$-18/$||30-20/CD	prepc_at||assessed-5/VBN||31â-22/VBG	dobj||31â-22/VBG||$-23/$	num||$-23/$||60-25/CD	dobj||31â-22/VBG||61â-28/NNS	conj_and||$-23/$||61â-28/NNS	num||minutes-32/NNS||$-29/$	num||$-29/$||120-31/CD	dep||61â-28/NNS||minutes-32/NNS	det||administration-35/NN||the-34/DT	prep_after||31â-22/VBG||administration-35/NN	prep_of||administration-35/NN||ondansetron-37/NN	prep_of||administration-35/NN||prochlorperazine-39/NN	conj_or||ondansetron-37/NN||prochlorperazine-39/NN	det||percentage-42/NN||the-41/DT	prep_after||31â-22/VBG||percentage-42/NN	conj_and||administration-35/NN||percentage-42/NN	prep_of||percentage-42/NN||patients-44/NNS	amod||effects-47/NNS||adverse-46/JJ	prep_with||patients-44/NNS||effects-47/NNS	nn||akathisia-53/NN||sedation-49/NN	dep||akathisia-53/NN||headache-51/NN	appos||effects-47/NNS||akathisia-53/NN	dep||akathisia-53/NN||dystonia-55/NNP	det||drug-59/NN||either-58/DT	prep_to||31â-22/VBG||drug-59/NN	nausea-4||prochlorperazine-39||yes||secondary outcomes were nausea assessed by a visual analog scale (vas) at baseline, 0â€“30, 31â€“60, and 61â€“120 minutes after the administration of ondansetron or prochlorperazine and the percentage of patients with adverse effects (sedation, headache, akathisia, dystonia) to either drug.
nsubj||immunosuppressiveagent-19/NN||rapamycin-1/NN	appos||rapamycin-1/NN||rapa-3/NNP	det||inhibitor-7/NN||an-6/DT	appos||rapamycin-1/NN||inhibitor-7/NN	amod||target-10/NN||mammalian-9/JJ	prep_of||inhibitor-7/NN||target-10/NN	prep_of||target-10/NN||rapamycin-12/NN	appos||rapamycin-12/NN||mtor-14/NN	cop||immunosuppressiveagent-19/NN||is-17/VBZ	det||immunosuppressiveagent-19/NN||an-18/DT	root||ROOT-0/null||immunosuppressiveagent-19/NN	nsubj||has-21/VBZ||immunosuppressiveagent-19/NN	rcmod||immunosuppressiveagent-19/NN||has-21/VBZ	amod||effects-23/NNS||anti-proliferative-22/JJ	dobj||has-21/VBZ||effects-23/NNS	det||tumors-26/NNS||some-25/DT	prep_on||effects-23/NNS||tumors-26/NNS	rapa-3||tumors-26||no_rel||rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), is an immunosuppressiveagent that has anti-proliferative effects on some tumors.
nsubjpass||derived-3/VBN||insulinresistance-1/NN	auxpass||derived-3/VBN||was-2/VBD	root||ROOT-0/null||derived-3/VBN	nn||measures-7/NNS||blood-5/NN	nn||measures-7/NNS||chemistry-6/NN	prep_from||derived-3/VBN||measures-7/NNS	prepc_of||measures-7/NNS||fasting-9/VBG	dobj||fasting-9/VBG||insulin-10/NN	dobj||fasting-9/VBG||glucose-12/NN	conj_and||insulin-10/NN||glucose-12/NN	vmod||fasting-9/VBG||using-13/VBG	det||method-18/NN||the-14/DT	amod||method-18/NN||homeostasis-15/JJ	nn||method-18/NN||model-16/NN	nn||method-18/NN||assessment-17/NN	dobj||using-13/VBG||method-18/NN	insulin-10||insulinresistance-1||no_rel||insulinresistance was derived from blood chemistry measures of fasting insulin and glucose using the homeostasis model assessment method.
nsubjpass||obscured-8/VBN||relapsingfever-1/NN	nsubjpass||treated-13/VBN||relapsingfever-1/NN	vmod||relapsingfever-1/NN||caused-2/VBN	nn||bacteria-5/NNS||borrelia-4/NN	agent||caused-2/VBN||bacteria-5/NNS	auxpass||obscured-8/VBN||is-6/VBZ	advmod||obscured-8/VBN||often-7/RB	root||ROOT-0/null||obscured-8/VBN	agent||obscured-8/VBN||malaria-10/NN	advmod||treated-13/VBN||incorrectly-12/RB	conj_and||obscured-8/VBN||treated-13/VBN	relapsingfever-1||bacteria-5||no||relapsingfever caused by borrelia bacteria is often obscured by malaria and incorrectly treated.
det||pyogenes-4/NNS||the-1/DT	amod||pyogenes-4/NNS||gram-positivebacterium-2/JJ	nn||pyogenes-4/NNS||streptococcus-3/NNS	nsubj||pathogen-8/NN||pyogenes-4/NNS	cop||pathogen-8/NN||is-5/VBZ	det||pathogen-8/NN||a-6/DT	amod||pathogen-8/NN||common-7/JJ	root||ROOT-0/null||pathogen-8/NN	prep_of||pathogen-8/NN||humans-10/NNS	nsubj||causes-12/VBZ||humans-10/NNS	rcmod||humans-10/NNS||causes-12/VBZ	amod||infections-14/NNS||invasive-13/JJ	dobj||causes-12/VBZ||infections-14/NNS	dobj||causes-12/VBZ||toxic-shocksyndrome-16/NN	conj_and||infections-14/NNS||toxic-shocksyndrome-16/NN	dobj||causes-12/VBZ||rheumaticfever-18/NN	conj_and||infections-14/NNS||rheumaticfever-18/NN	dobj||causes-12/VBZ||necrotizingfasciitis-20/NNS	conj_and||infections-14/NNS||necrotizingfasciitis-20/NNS	amod||diseases-23/NNS||other-22/JJ	dobj||causes-12/VBZ||diseases-23/NNS	conj_and||infections-14/NNS||diseases-23/NNS	toxic-shocksyndrome-16||gram-positivebacterium-2||no||the gram-positivebacterium streptococcus pyogenes is a common pathogen of humans that causes invasive infections, toxic-shocksyndrome, rheumaticfever, necrotizingfasciitis and other diseases.
amod||disclosure-2/NN||diagnostic-1/JJ	nsubj||becoming-9/VBG||disclosure-2/NN	prep_of||disclosure-2/NN||hiv/aids-4/NNS	det||child-7/NN||a-6/DT	prep_to||hiv/aids-4/NNS||child-7/NN	aux||becoming-9/VBG||is-8/VBZ	root||ROOT-0/null||becoming-9/VBG	det||issue-13/NN||an-10/DT	advmod||common-12/JJ||increasingly-11/RB	amod||issue-13/NN||common-12/JJ	xcomp||becoming-9/VBG||issue-13/NN	amod||practice-16/NN||clinical-15/JJ	prep_in||issue-13/NN||practice-16/NN	aids--1||hiv--1||no||diagnostic disclosure of hiv/aids to a child is becoming an increasingly common issue in clinical practice.
aux||summarise-2/VB||to-1/TO	root||ROOT-0/null||summarise-2/VB	dobj||summarise-2/VB||age-3/NN	amod||associations-7/NNS||intensity-stratified-6/JJ	dobj||summarise-2/VB||associations-7/NNS	conj_and||age-3/NN||associations-7/NNS	amod||hookworminfection-10/NN||human-9/JJ	prep_between||associations-7/NNS||hookworminfection-10/NN	prep_between||associations-7/NNS||anaemia-12/NN	conj_and||hookworminfection-10/NN||anaemia-12/NN	aux||quantify-15/VB||to-14/TO	conj_and||summarise-2/VB||quantify-15/VB	det||impact-17/NN||the-16/DT	dobj||quantify-15/VB||impact-17/NN	prep_of||impact-17/NN||treatment-19/NN	det||benzimidazoles-22/NNS||the-21/DT	prep_with||treatment-19/NN||benzimidazoles-22/NNS	amod||impact-17/NN||albendazole-24/JJ	amod||impact-17/NN||mebendazole-26/JJ	conj_and||albendazole-24/JJ||mebendazole-26/JJ	prep_on||quantify-15/VB||haemoglobin-29/NN	prep_on||quantify-15/VB||anaemia-31/NN	conj_and||haemoglobin-29/NN||anaemia-31/NN	amod||populations-34/NNS||non-pregnant-33/JJ	prep_in||quantify-15/VB||populations-34/NNS	hookworminfection-10||mebendazole-26||yes||to summarise age- and intensity-stratified associations between human hookworminfection and anaemia and to quantify the impact of treatment with the benzimidazoles, albendazole and mebendazole, on haemoglobin and anaemia in non-pregnant populations.
det||search-5/NN||a-2/DT	amod||search-5/NN||computerized-3/JJ	nn||search-5/NN||medline-4/NN	prep_in||selected-10/VBN||search-5/NN	amod||studies-8/NNS||relevant-7/JJ	nsubjpass||selected-10/VBN||studies-8/NNS	auxpass||selected-10/VBN||were-9/VBD	root||ROOT-0/null||selected-10/VBN	num||authors-13/NNS||two-12/CD	agent||selected-10/VBN||authors-13/NNS	vmod||authors-13/NNS||using-14/VBG	det||keywords-16/NNS||the-15/DT	nsubj||â-17/VB||keywords-16/NNS	nsubj||â-22/VB||keywords-16/NNS	nsubj||â-32/VB||keywords-16/NNS	ccomp||using-14/VBG||â-17/VB	dobj||â-17/VB||$-18/$	number||$-20/CD||œdiabetesmellitusâ-19/CD	num||$-18/$||$-20/CD	ccomp||using-14/VBG||â-22/VB	conj_and||â-17/VB||â-22/VB	dobj||â-22/VB||$-23/$	number||$-25/CD||œcataractâ-24/CD	num||$-23/$||$-25/CD	advmod||$-23/$||â-27/RB	pobj||â-27/RB||$-28/$	number||$-30/CD||œdiabeticretinopathyâ-29/CD	num||$-28/$||$-30/CD	ccomp||using-14/VBG||â-32/VB	conj_and||â-17/VB||â-32/VB	num||$-36/NNS||$-33/$	number||maculopathyâ-35/CD||œdiabetic-34/CD	num||$-33/$||maculopathyâ-35/CD	dobj||â-32/VB||$-36/NNS	diabeticretinopathy--1||diabetesmellitus--1||no||in a computerized medline search,relevant studies were selected by two authors using the keywords â€œdiabetesmellitusâ€?, â€œcataractâ€?, â€œdiabeticretinopathyâ€? and â€œdiabetic maculopathyâ€?.
amod||-lrb--2/NNS||epstein-barrvirus-1/JJ	nsubj||ebv-3/VBP||-lrb--2/NNS	root||ROOT-0/null||ebv-3/VBP	amod||infection-5/NN||-rrb--4/JJ	nsubj||finding-10/NN||infection-5/NN	cop||finding-10/NN||is-6/VBZ	det||finding-10/NN||an-7/DT	advmod||finding-10/NN||almost-8/RB	amod||finding-10/NN||universal-9/JJ	ccomp||ebv-3/VBP||finding-10/NN	prep_among||finding-10/NN||individuals-12/NNS	amod||ebvinfection-16/NN||ms.-14/JJ	amod||ebvinfection-16/NN||symptomatic-15/JJ	prep_with||individuals-12/NNS||ebvinfection-16/NN	mark||shown-26/VBN||as-17/IN	amod||-rrb--23/NNS||manifested-18/JJ	prep_by||manifested-18/JJ||infectiousmononucleosis-20/NNS	amod||-rrb--23/NNS||-lrb--21/JJ	nn||-rrb--23/NNS||im-22/NN	nsubjpass||shown-26/VBN||-rrb--23/NNS	nsubjpass||associated-33/VBN||-rrb--23/NNS	aux||shown-26/VBN||has-24/VBZ	auxpass||shown-26/VBN||been-25/VBN	advcl||finding-10/NN||shown-26/VBN	det||meta-analysis-30/NNS||a-28/DT	amod||meta-analysis-30/NNS||previous-29/JJ	prep_in||shown-26/VBN||meta-analysis-30/NNS	aux||associated-33/VBN||to-31/TO	auxpass||associated-33/VBN||be-32/VB	xcomp||shown-26/VBN||associated-33/VBN	det||risk-36/NN||the-35/DT	prep_with||associated-33/VBN||risk-36/NN	prep_of||risk-36/NN||ms-38/NN	advmod||published-50/VBN||however-40/RB	det||number-42/NN||a-41/DT	nsubjpass||published-50/VBN||number-42/NN	advmod||larger-45/JJR||much-44/RB	amod||studies-46/NNS||larger-45/JJR	prep_of||number-42/NN||studies-46/NNS	aux||published-50/VBN||have-47/VBP	advmod||published-50/VBN||since-48/IN	auxpass||published-50/VBN||been-49/VBN	parataxis||ebv-3/VBP||published-50/VBN	ebvinfection-16||epstein-barrvirus-1||no||epstein-barrvirus -lrb- ebv -rrb- infection is an almost universal finding among individuals with ms. symptomatic ebvinfection as manifested by infectiousmononucleosis -lrb- im -rrb- has been shown in a previous meta-analysis to be associated with the risk of ms , however a number of much larger studies have since been published .
nsubj||illness-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||illness-9/NN||is-5/VBZ	det||illness-9/NN||a-6/DT	amod||illness-9/NN||severe-7/JJ	nn||illness-9/NN||respiratory-8/NN	root||ROOT-0/null||illness-9/NN	vmod||illness-9/NN||caused-10/VBN	det||virus-14/NN||a-12/DT	nn||virus-14/NN||novel-13/NN	agent||caused-10/VBN||virus-14/NN	det||sarscoronavirus-17/NNS||the-16/DT	appos||virus-14/NN||sarscoronavirus-17/NNS	appos||sarscoronavirus-17/NNS||sars-cov-19/NNP	severeacuterespiratorysyndrome-1||sarscoronavirus-17||no||severeacuterespiratorysyndrome (sars) is a severe respiratory illness caused by a novel virus, the sarscoronavirus (sars-cov).
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	cataract-45||triglycerides-53||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
nn||mice-3/NNS||rictor-1/NN	nn||mice-3/NNS||null-2/NN	nsubj||exhibited-4/VBD||mice-3/NNS	root||ROOT-0/null||exhibited-4/VBD	amod||hyperglycemia-6/NN||mild-5/JJ	dobj||exhibited-4/VBD||hyperglycemia-6/NN	dobj||exhibited-4/VBD||glucoseintolerance-8/NN	conj_and||hyperglycemia-6/NN||glucoseintolerance-8/NN	vmod||hyperglycemia-6/NN||caused-9/VBN	det||reduction-12/NN||a-11/DT	agent||caused-9/VBN||reduction-12/NN	nn||²-15/NNS||î-14/NN	prep_in||reduction-12/NN||²-15/NNS	nn||mass-18/NN||cell-17/NN	dobj||exhibited-4/VBD||mass-18/NN	conj_and||hyperglycemia-6/NN||mass-18/NN	nn||²-21/NNS||î-20/NN	appos||mass-18/NN||²-21/NNS	nn||proliferation-24/NN||cell-23/NN	dobj||exhibited-4/VBD||proliferation-24/NN	conj_and||hyperglycemia-6/NN||proliferation-24/NN	amod||content-28/NN||pancreatic-26/JJ	nn||content-28/NN||insulin-27/NN	appos||proliferation-24/NN||content-28/NN	amod||secretion-33/NN||glucose-stimulated-31/JJ	nn||secretion-33/NN||insulin-32/NN	dobj||exhibited-4/VBD||secretion-33/NN	conj_and||hyperglycemia-6/NN||secretion-33/NN	hyperglycemia-6||insulin-32||yes||rictor null mice exhibited mild hyperglycemia and glucoseintolerance caused by a reduction in î²-cell mass, î²-cell proliferation, pancreatic insulin content, and glucose-stimulated insulin secretion.
det||cohort-2/NN||a-1/DT	nsubjpass||characterized-14/VBN||cohort-2/NN	nsubjpass||genotyped-26/VBN||cohort-2/NN	num||individuals-7/NNS||1364-4/CD	amod||individuals-7/NNS||white-5/JJ	nn||individuals-7/NNS||european-6/NN	prep_of||cohort-2/NN||individuals-7/NNS	amod||risk-10/NN||increased-9/VBN	prep_at||individuals-7/NNS||risk-10/NN	prep_for||risk-10/NN||type2diabetes-12/CD	auxpass||characterized-14/VBN||was-13/VBD	root||ROOT-0/null||characterized-14/VBN	agent||characterized-14/VBN||ogtt-16/NN	prep_with||characterized-14/VBN||glucose-18/NN	prep_with||characterized-14/VBN||insulin-20/NN	conj_and||glucose-18/NN||insulin-20/NN	amod||measurements-24/NNS||c-peptide-23/JJ	prep_with||characterized-14/VBN||measurements-24/NNS	conj_and||glucose-18/NN||measurements-24/NNS	conj_and||characterized-14/VBN||genotyped-26/VBN	amod||polymorphisms-30/NNS||single-28/JJ	nn||polymorphisms-30/NNS||nucleotide-29/NN	prep_for||genotyped-26/VBN||polymorphisms-30/NNS	appos||polymorphisms-30/NNS||snps-32/NNS	vmod||polymorphisms-30/NNS||known-34/VBN	aux||affect-36/VB||to-35/TO	xcomp||known-34/VBN||affect-36/VB	amod||secretion-42/NN||glucose-37/JJ	conj_and||glucose-37/JJ||incretin-stimulated-40/JJ	amod||secretion-42/NN||incretin-stimulated-40/JJ	nn||secretion-42/NN||insulin-41/NN	dobj||affect-36/VB||secretion-42/NN	type2diabetes-12||insulin-41||yes||a cohort of 1364 white european individuals at increased risk for type2diabetes was characterized by ogtt with glucose, insulin, and c-peptide measurements and genotyped for single nucleotide polymorphisms (snps) known to affect glucose- and incretin-stimulated insulin secretion.
amod||immunization-2/NN||efficient-1/JJ	nsubj||requires-15/VBZ||immunization-2/NN	prep_against||immunization-2/NN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	amod||pathogens-10/NNS||other-9/JJ	prep_against||immunization-2/NN||pathogens-10/NNS	conj_and||hepatitisbvirus-4/NNS||pathogens-10/NNS	amod||vaccines-14/NNS||plant-based-12/JJ	amod||vaccines-14/NNS||oral-13/JJ	prep_with||pathogens-10/NNS||vaccines-14/NNS	root||ROOT-0/null||requires-15/VBZ	amod||expressors-18/NNS||appropriate-16/JJ	nn||expressors-18/NNS||plant-17/NN	dobj||requires-15/VBZ||expressors-18/NNS	det||optimization-21/NN||the-20/DT	dobj||requires-15/VBZ||optimization-21/NN	conj_and||expressors-18/NNS||optimization-21/NN	nn||compositions-24/NNS||vaccine-23/NN	prep_of||optimization-21/NN||compositions-24/NNS	nn||protocols-27/NNS||administration-26/NN	prep_of||optimization-21/NN||protocols-27/NNS	conj_and||compositions-24/NNS||protocols-27/NNS	hbv-6||hepatitisbvirus-4||no||efficient immunization against hepatitisbvirus (hbv) and other pathogens with plant-based oral vaccines requires appropriate plant expressors and the optimization of vaccine compositions and administration protocols.
det||study-2/NN||this-1/DT	nsubj||established-4/VBN||study-2/NN	aux||established-4/VBN||has-3/VBZ	root||ROOT-0/null||established-4/VBN	amod||correlation-6/NN||inverse-5/JJ	dobj||established-4/VBN||correlation-6/NN	det||increase-9/NN||the-8/DT	prep_of||correlation-6/NN||increase-9/NN	amod||immunity-12/NN||th1/th2-11/JJ	prep_of||increase-9/NN||immunity-12/NN	det||decline-15/NN||the-14/DT	prep_of||correlation-6/NN||decline-15/NN	conj_and||increase-9/NN||decline-15/NN	nn||load-19/NN||hbv-17/NN	nn||load-19/NN||dna-18/NN	prep_of||decline-15/NN||load-19/NN	amod||patients-23/NNS||chronic-21/JJ	nn||patients-23/NNS||hbv-22/NN	prep_in||load-19/NN||patients-23/NNS	amod||treatment-26/NN||adefovirdipivoxil-25/JJ	prep_during||established-4/VBN||treatment-26/NN	hbv-22||adefovirdipivoxil-25||yes||this study has established inverse correlation of the increase of th1/th2 immunity and the decline of hbv dna load in chronic hbv patients during adefovirdipivoxil treatment.
nsubj||disease-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||an-6/DT	amod||disease-9/NN||emerging-7/VBG	amod||disease-9/NN||infectious-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||coronavirussars-cov-14/NN||the-12/DT	nn||coronavirussars-cov-14/NN||novel-13/NN	agent||caused-10/VBN||coronavirussars-cov-14/NN	severeacuterespiratorysyndrome-1||coronavirussars--1||no||severeacuterespiratorysyndrome (sars) is an emerging infectious disease caused by the novel coronavirussars-cov.
amod||analysis-3/NN||multiple-1/JJ	nn||analysis-3/NN||regression-2/NN	nsubj||revealed-7/VBD||analysis-3/NN	amod||phenotypes-6/NNS||type2diabetes-related-5/JJ	prep_with||analysis-3/NN||phenotypes-6/NNS	root||ROOT-0/null||revealed-7/VBD	det||association-10/NN||a-8/DT	amod||association-10/NN||significant-9/JJ	dobj||revealed-7/VBD||association-10/NN	amod||rate-14/NN||false-12/JJ	nn||rate-14/NN||discovery-13/NN	dep||association-10/NN||rate-14/NN	appos||rate-14/NN||fdr-16/NN	rcmod||rate-14/NN||p-18/VBP	dep||0.006-20/CD||=-19/SYM	ccomp||p-18/VBP||0.006-20/CD	prep_for||p-18/VBP||rs13144140-22/NNS	dep||rs13144140-22/NNS||fdr-24/NN	vmod||fdr-24/NN||p-25/VBN	dep||0.002-27/CD||=-26/SYM	ccomp||p-25/VBN||0.002-27/CD	prep_for||rate-14/NN||rs6830266-29/CD	amod||rs13144140-34/NNS||gpm6a-32/JJ	prep_between||association-10/NN||rs13144140-34/NNS	prep_between||association-10/NN||bmi-37/NN	conj_and||rs13144140-34/NNS||bmi-37/NN	dep||$-40/$||waistâ-39/RB	dep||rs13144140-34/NNS||$-40/$	advmod||from-54/IN||hip-42/RB	npadvmod||from-54/IN||ratio-43/NN	prep||ratio-43/NN||and-45/CC	amod||neil3-47/JJ||between-46/IN	pobj||and-45/CC||neil3-47/JJ	appos||neil3-47/JJ||rs6830266-49/NNP	nn||level-53/NN||insulin-52/NN	pobj||and-45/CC||level-53/NN	conj_and||neil3-47/JJ||level-53/NN	dep||1314-55/CD||from-54/IN	num||$-40/$||1314-55/CD	amod||individuals-57/NNS||normal-56/JJ	prep_between||association-10/NN||individuals-57/NNS	conj_and||rs13144140-34/NNS||individuals-57/NNS	type2diabetes--1||insulin-52||yes||multiple regression analysis with type2diabetes-related phenotypes revealed a significant association (false discovery rate (fdr) p =0.006 for rs13144140; fdr p =0.002 for rs6830266) between gpm6a (rs13144140) and bmi and waistâ€“hip ratio, and between neil3 (rs6830266) and insulin level from 1314 normal individuals.
det||spread-5/NN||the-1/DT	nn||spread-5/NN||selection-2/NN	conj_and||selection-2/NN||soaring-4/VBG	nn||spread-5/NN||soaring-4/VBG	nsubj||problem-24/NN||spread-5/NN	amod||multidrug-resistant-8/NN||mycobacteriumtuberculosis-7/JJ	prep_of||spread-5/NN||multidrug-resistant-8/NN	appos||multidrug-resistant-8/NN||mdr-tb-10/NNP	amod||strains-15/NNS||extensively-13/JJ	amod||strains-15/NNS||drug-resistant-14/JJ	prep_of||spread-5/NN||strains-15/NNS	conj_and||multidrug-resistant-8/NN||strains-15/NNS	appos||multidrug-resistant-8/NN||xdr-tb-17/NNP	cop||problem-24/NN||is-19/VBZ	det||problem-24/NN||a-20/DT	amod||problem-24/NN||severe-21/JJ	amod||problem-24/NN||public-22/JJ	nn||problem-24/NN||health-23/NN	root||ROOT-0/null||problem-24/NN	tb--1||mycobacteriumtuberculosis-7||no||the selection and soaring spread of mycobacteriumtuberculosis multidrug-resistant (mdr-tb) and extensively drug-resistant strains (xdr-tb) is a severe public health problem.
nsubj||required-7/VBD||patients-1/NNS	prep_in||patients-1/NNS||groupb-3/NN	appos||patients-1/NNS||dyspnea-5/NNP	root||ROOT-0/null||required-7/VBD	det||dose-10/NN||a-8/DT	amod||dose-10/NN||lower-9/JJR	dobj||required-7/VBD||dose-10/NN	prep_of||dose-10/NN||morphine-12/NN	prep_for||morphine-12/NN||alleviation-14/NN	prepc_compared_with||required-7/VBD||with-16/IN	pobj||required-7/VBD||those-17/DT	prep_in||those-17/DT||groups-19/NNS	dep||those-17/DT||a-20/SYM	amod||pain-23/NN||uncontrolled-22/JJ	appos||those-17/DT||pain-23/NN	pobj||required-7/VBD||c-26/SYM	conj_and||those-17/DT||c-26/SYM	det||dyspnea-29/NN||both-28/DT	dep||c-26/SYM||dyspnea-29/NN	dep||c-26/SYM||pain-31/NN	conj_and||dyspnea-29/NN||pain-31/NN	dyspnea-29||morphine-12||yes||patients in groupb (dyspnea) required a lower dose of morphine for alleviation compared with those in groups a (uncontrolled pain) and c (both dyspnea and pain).
det||results-2/NNS||these-1/DT	nsubj||encourage-4/VB||results-2/NNS	aux||encourage-4/VB||should-3/MD	root||ROOT-0/null||encourage-4/VB	det||association-6/NN||the-5/DT	dobj||encourage-4/VB||association-6/NN	predet||the-9/DT||all-8/PDT	nsubj||involved-10/VBD||the-9/DT	conj_and||encourage-4/VB||involved-10/VBD	dobj||involved-10/VBD||actors-11/NNS	det||hiv/aids-14/NNS||the-13/DT	poss||program-16/NN||hiv/aids-14/NNS	prep_in||involved-10/VBD||program-16/NN	aux||strengthen-18/VB||to-17/TO	vmod||program-16/NN||strengthen-18/VB	nn||interventions-24/NNS||counseling-19/NN	conj_and||counseling-19/NN||education-21/NN	nn||interventions-24/NNS||education-21/NN	conj_and||counseling-19/NN||information-23/NN	nn||interventions-24/NNS||information-23/NN	dobj||strengthen-18/VB||interventions-24/NNS	amod||patients-27/NNS||hiv-infected-26/JJ	prep_for||strengthen-18/VB||patients-27/NNS	mark||overcome-31/VB||in-28/IN	dep||overcome-31/VB||order-29/NN	aux||overcome-31/VB||to-30/TO	advcl||strengthen-18/VB||overcome-31/VB	det||barriers-34/NNS||the-32/DT	amod||barriers-34/NNS||potential-33/JJ	dobj||overcome-31/VB||barriers-34/NNS	amod||adherence-37/NN||poor-36/JJ	prep_of||barriers-34/NNS||adherence-37/NN	aids--1||hiv--1||no||these results should encourage the association and all the involved actors in the hiv/aids's program to strengthen counseling, education and information interventions for hiv-infected patients in order to overcome the potential barriers of poor adherence.
det||majority-2/NN||the-1/DT	nsubj||exhibited-7/VBD||majority-2/NN	prep_of||majority-2/NN||patients-4/NNS	prep_with||patients-4/NNS||uc-6/NN	root||ROOT-0/null||exhibited-7/VBD	amod||adherence-9/NN||low-8/JJ	dobj||exhibited-7/VBD||adherence-9/NN	dobj||exhibited-7/VBD||persistence-11/NN	conj_and||adherence-9/NN||persistence-11/NN	amod||treatments-14/NNS||mesalamine-13/JJ	prep_to||exhibited-7/VBD||treatments-14/NNS	uc-6||mesalamine-13||yes||the majority of patients with uc exhibited low adherence and persistence to mesalamine treatments.
det||docetaxel/axitinib-5/NN||the-1/DT	amod||docetaxel/axitinib-5/NN||cp-868-2/JJ	dep||cp-868-2/JJ||,596-3/CD	amod||docetaxel/axitinib-5/NN||/-4/JJ	nsubj||dose-8/NN||docetaxel/axitinib-5/NN	cop||dose-8/NN||was-6/VBD	neg||dose-8/NN||not-7/RB	root||ROOT-0/null||dose-8/NN	vmod||dose-8/NN||escalated-9/VBN	amod||incidence-13/NN||increased-12/VBN	prep_because_of||escalated-9/VBN||incidence-13/NN	amod||events-17/NNS||mucositis-like-15/JJ	amod||events-17/NNS||adverse-16/JJ	prep_of||incidence-13/NN||events-17/NNS	appos||events-17/NNS||aes-19/NN	amod||neutropenia-23/NN||concurrent-22/JJ	prep_with||incidence-13/NN||neutropenia-23/NN	advmod||incidence-13/NN||relative-24/JJ	prep_to||relative-24/JJ||that-26/DT	vmod||that-26/DT||expected-27/VBN	prep_for||expected-27/VBN||docetaxel-29/NN	neutropenia-23||docetaxel-29||no||the cp-868,596/docetaxel/axitinib was not dose escalated because of increased incidence of mucositis-like adverse events (aes) with concurrent neutropenia relative to that expected for docetaxel.
det||study-3/NN||this-1/DT	nn||study-3/NN||retrospective-2/NN	nsubjpass||undertaken-5/VBN||study-3/NN	auxpass||undertaken-5/VBN||was-4/VBD	root||ROOT-0/null||undertaken-5/VBN	aux||determine-7/VB||to-6/TO	ccomp||undertaken-5/VBN||determine-7/VB	det||usefulness-9/NN||the-8/DT	dobj||determine-7/VB||usefulness-9/NN	amod||blocks-17/NNS||intravenous-11/JJ	amod||blocks-17/NNS||regional-12/JJ	nn||blocks-17/NNS||anesthetic-13/NN	appos||blocks-17/NNS||ivra-15/NNP	prep_of||usefulness-9/NN||blocks-17/NNS	vmod||blocks-17/NNS||containing-18/VBG	acomp||containing-18/VBG||ketorolac-19/JJ	acomp||containing-18/VBG||lidocaine-21/JJ	conj_and||ketorolac-19/JJ||lidocaine-21/JJ	det||management-24/NN||the-23/DT	prep_in||containing-18/VBG||management-24/NN	amod||pain-27/NN||sympathetically-mediated-26/JJ	prep_of||management-24/NN||pain-27/NN	aux||determine-31/VB||to-30/TO	ccomp||undertaken-5/VBN||determine-31/VB	conj_and||determine-7/VB||determine-31/VB	dobj||predicted-38/VBD||what-32/WP	nsubj||predicted-38/VBD||factors-33/NNS	dep||factors-33/NNS||if-35/IN	dep||if-35/IN||any-36/DT	ccomp||determine-31/VB||predicted-38/VBD	dobj||predicted-38/VBD||success-39/NN	det||technique-42/NN||this-41/DT	prep_with||predicted-38/VBD||technique-42/NN	pain-27||lidocaine-21||yes||this retrospective study was undertaken to determine the usefulness of intravenous regional anesthetic (ivra) blocks containing ketorolac and lidocaine in the management of sympathetically-mediated pain, and to determine what factors, if any, predicted success with this technique.
nsubjpass||commenced-4/VBN||she-1/PRP	nsubjpass||commenced-13/VBD||she-1/PRP	auxpass||commenced-4/VBN||was-2/VBD	advmod||commenced-4/VBN||initially-3/RB	root||ROOT-0/null||commenced-4/VBN	amod||lincomycin-7/NN||intravenous-6/JJ	prep_on||commenced-4/VBN||lincomycin-7/NN	poss||bloodstreaminfection-10/NN||her-9/PRP$	prep_for||lincomycin-7/NN||bloodstreaminfection-10/NN	advmod||commenced-13/VBD||subsequently-12/RB	conj_and||commenced-4/VBN||commenced-13/VBD	prep_on||commenced-13/VBD||immunosuppression-15/NN	prep_after||commenced-13/VBD||cessation-17/NN	prep_of||cessation-17/NN||hydralazine-19/NN	bloodstreaminfection-10||lincomycin-7||no_rel||she was initially commenced on intravenous lincomycin for her bloodstreaminfection and subsequently commenced on immunosuppression after cessation of hydralazine.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||identify-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||identify-8/VB||to-7/TO	xcomp||was-6/VBD||identify-8/VB	det||presence-10/NN||the-9/DT	dobj||identify-8/VB||presence-10/NN	iobj||identify-8/VB||presence-10/NN	amod||inh-14/NN||isoniazid-12/JJ	prep_of||presence-10/NN||inh-14/NN	prep_of||presence-10/NN||rifampicin-17/NN	conj_and||inh-14/NN||rifampicin-17/NN	appos||presence-10/NN||rif-19/NN	nn||resistance-22/NN||drug-21/NN	dep||presence-10/NN||resistance-22/NN	amod||cases-32/NNS||new-24/JJ	advmod||treated-27/JJ||previously-26/RB	conj_and||new-24/JJ||treated-27/JJ	amod||cases-32/NNS||treated-27/JJ	nn||cases-32/NNS||tuberculosis-28/NNP	appos||cases-32/NNS||tb-30/NN	prep_in||resistance-22/NN||cases-32/NNS	vmod||cases-32/NNS||using-33/VBG	nn||sequencing-35/NN||dna-34/NN	dobj||using-33/VBG||sequencing-35/NN	tb-30||rifampicin-17||yes||the aim of this study was to identify the presence of isoniazid (inh) and rifampicin(rif) drug resistance in new and previously treated tuberculosis (tb) cases using dna sequencing.
det||study-3/NN||the-2/DT	prep_in||claimed-5/VBD||study-3/NN	nsubj||claimed-5/VBD||we-4/PRP	root||ROOT-0/null||claimed-5/VBD	aux||identify-7/VB||to-6/TO	ccomp||claimed-5/VBD||identify-7/VB	nn||species-9/NNS||brucella-8/NN	dobj||identify-7/VB||species-9/NNS	amod||samples-12/NNS||clinical-11/JJ	prep_from||identify-7/VB||samples-12/NNS	prep_of||samples-12/NNS||patients-14/NNS	amod||brucellosis-17/NNS||active-16/JJ	prep_with||patients-14/NNS||brucellosis-17/NNS	nn||region-20/NN||van-19/NN	prep_from||identify-7/VB||region-20/NN	amod||anatolia-23/NN||eastern-22/JJ	prep_of||region-20/NN||anatolia-23/NN	aux||determine-26/VB||to-25/TO	ccomp||claimed-5/VBD||determine-26/VB	conj_and||identify-7/VB||determine-26/VB	npadvmod||antimicrobial-29/JJ||vitro-28/NN	amod||susceptibilities-30/NNS||antimicrobial-29/JJ	prep_in||determine-26/VB||susceptibilities-30/NNS	det||strains-33/NNS||these-32/DT	prep_of||susceptibilities-30/NNS||strains-33/NNS	advmod||used-36/VBN||commonly-35/RB	amod||agents-38/NNS||used-36/VBN	amod||agents-38/NNS||anti-brucella-37/JJ	prep_to||determine-26/VB||agents-38/NNS	det||tigecycline-44/NN||a-40/DT	amod||tigecycline-44/NN||possible-41/JJ	amod||tigecycline-44/NN||new-42/JJ	nn||tigecycline-44/NN||alternative-43/NN	prep_to||determine-26/VB||tigecycline-44/NN	conj_and||agents-38/NNS||tigecycline-44/NN	brucellosis-17||brucella-8||no||in the study we claimed to identify brucella species from clinical samples of patients with active brucellosis from van region of eastern anatolia and to determine in vitro antimicrobial susceptibilities of these strains to commonly used anti-brucella agents and a possible new alternative tigecycline.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||looks-4/VBZ||study-3/NN	root||ROOT-0/null||looks-4/VBZ	det||aspects-7/NNS||some-6/DT	prep_at||looks-4/VBZ||aspects-7/NNS	prep_of||aspects-7/NNS||disability-9/NN	vmod||disability-9/NN||associated-10/VBN	num||disorders-14/NNS||7-12/CD	amod||disorders-14/NNS||psychiatric-13/JJ	prep_with||associated-10/VBN||disorders-14/NNS	nn||depression-21/NN||schizophrenia-15/NN	dep||depression-21/NN||bipolaraffectivedisorder-17/NN	dep||depression-21/NN||anxietydisorders-19/NNS	dep||disorders-14/NNS||depression-21/NN	vmod||disorders-14/NNS||obsessiveâ-23/VBG	dobj||obsessiveâ-23/VBG||$-24/$	advmod||alcohol-41/CD||compulsive-26/RB	dep||mental-32/JJ||disorder-27/JJ	conj_and||mental-32/JJ||dementia-29/JJ	amod||disorders-35/NNS||dementia-29/JJ	amod||disorders-35/NNS||mental-32/JJ	conj_and||mental-32/JJ||behavioural-34/JJ	amod||disorders-35/NNS||behavioural-34/JJ	npadvmod||alcohol-41/CD||disorders-35/NNS	det||use-39/NN||the-38/DT	prep_due_to||alcohol-41/CD||use-39/NN	prep||use-39/NN||of-40/IN	num||$-24/$||alcohol-41/CD	alcohol-41||schizophrenia-15||no_rel||the present study looks at some aspects of disability associated with 7 psychiatric disorders schizophrenia, bipolaraffectivedisorder, anxietydisorders, depression, obsessiveâ€“compulsive disorder, dementia, and mental and behavioural disorders due to the use of alcohol.
nn||analysis-3/NN||glycan-1/NN	nn||analysis-3/NN||microarray-2/NN	nsubj||reassortantâ-11/VBD||analysis-3/NN	det||â-8/NN||a-5/DT	amod||â-8/NN||high-6/JJ	nn||â-8/NN||infectivity-7/NN	prep_with||analysis-3/NN||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||œtriple-10/JJ	root||ROOT-0/null||reassortantâ-11/VBD	nsubj||spread-24/VBN||$-12/$	nsubj||showed-51/VBD||$-12/$	num||$-12/$||virus-13/CD	amod||/-17/NN||a/swine/mn-16/JJ	dep||$-12/$||/-17/NN	num||/-17/NN||593/99-18/CD	appos||$-12/$||h3n2-20/NNP	rcmod||$-12/$||spread-24/VBN	advmod||spread-24/VBN||widely-25/RB	det||population-31/NN||the-27/DT	nn||population-31/NN||north-28/NN	nn||population-31/NN||american-29/NN	nn||population-31/NN||swine-30/NNS	prep_throughout||spread-24/VBN||population-31/NN	det||virus-37/NN||a-33/DT	dep||human-36/JJ||lower-34/JJR	advmod||human-36/JJ||infectivity-35/RB	amod||virus-37/NN||human-36/JJ	conj_and||$-12/$||virus-37/NN	nsubj||spread-24/VBN||virus-37/NN	nsubj||showed-51/VBD||virus-37/NN	vmod||virus-37/NN||isolated-38/VBN	det||pig-42/NN||a-40/DT	amod||pig-42/NN||single-41/JJ	prep_from||isolated-38/VBN||pig-42/NN	dep||virus-37/NN||a/swine/ont-44/VB	number||00130/97-46/CD||/-45/CD	dobj||a/swine/ont-44/VB||00130/97-46/CD	appos||00130/97-46/CD||h3n2-48/NNP	ccomp||reassortantâ-11/VBD||showed-51/VBD	mark||viruses-54/VBZ||that-52/IN	nsubj||viruses-54/VBZ||both-53/DT	ccomp||showed-51/VBD||viruses-54/VBZ	acomp||viruses-54/VBZ||bound-55/VBN	advmod||bound-55/VBN||exclusively-56/RB	prep_to||bound-55/VBN||glycans-58/NNS	vmod||glycans-58/NNS||containing-59/VBG	nn||±-61/NNP||neuacî-60/NNP	dobj||containing-59/VBG||±-61/NNP	vmod||±-61/NNP||2â-62/VBG	dobj||2â-62/VBG||$-63/$	npadvmod||polylactosamine-72/JJ||6-65/CD	prep_with||6-65/CD||strong-68/JJ	amod||6-65/CD||binding-69/JJ	dep||sialylated-71/CD||to-70/TO	num||6-65/CD||sialylated-71/CD	amod||n-75/NNS||polylactosamine-72/JJ	conj_and||polylactosamine-72/JJ||sialylated-74/JJ	amod||n-75/NNS||sialylated-74/JJ	npadvmod||--76/RB||n-75/NNS	num||$-63/$||glycans-77/CD	virus-37||viruses-54||no||glycan microarray analysis with a high infectivity â€œtriple reassortantâ€? virus ((a/swine/mn/593/99 (h3n2)) that spread widely throughout the north american swine population and a lower infectivity human virus isolated from a single pig (a/swine/ont/00130/97 (h3n2)) showed that both viruses bound exclusively to glycans containing neuacî±2â€“6, with strong binding to sialylated polylactosamine and sialylated n -glycans.
